{
  "dataset": [
    {
      "id": "path_fff39451d940",
      "question": "In a patient with completely resected Stage IIIA non-small cell lung cancer (T3, N1) and confirmed negative margins (R0), is sequential chemotherapy followed by radiotherapy appropriate even if preoperative systemic therapy was not administered?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "No nodal disease",
              "Operable",
              "Surgical exploration and resection + mediastinal lymph node dissection or systematic lymph node sampling after preoperative systemic therapy, if planned",
              "Adjuvant Treatment (NSCL-4)",
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
              "Sequential chemotherapy and consider RT",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "Yes, sequential chemotherapy followed by consideration of radiotherapy remains appropriate for patients with completely resected Stage IIIA (T3, N1) NSCLC and negative margins, regardless of whether preoperative systemic therapy was given. The adjuvant approach is based on pathological staging and margin status, not on receipt of neoadjuvant therapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_3223e4eadd22",
      "question": "In a postmenopausal patient with metastatic (stage IV, M1) invasive breast cancer that is ER-positive, HER2-negative, and lacking bone or visceral crisis, who experienced disease progression within 1 year of prior endocrine therapy, is it appropriate to continue using further lines of endocrine therapy as systemic treatment, or should cytotoxic chemotherapy be prioritized?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Metastatic (M1) invasive breast cancer",
              "Stage IV (M1) or Recurrent disease",
              "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
              "Stage IV (M1) or Recurrent",
              "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
              "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
              "Recurrent unresectable (local or regional) or stage IV (M1) disease",
              "Bone disease not present",
              "ER- and/or PR-positive; HER2-negative",
              "BINV-22",
              "No visceral crisis and Prior endocrine therapy within 1 y",
              "Postmenopausal",
              "Systemic therapy",
              "Continue endocrine therapy until progression or unacceptable toxicity",
              "Progression",
              "Progression or unacceptable toxicity on first-line endocrine therapy",
              "Systemic therapy",
              "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
              "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
            ]
          }
        }
      ],
      "answer": "For a postmenopausal patient with metastatic ER-positive, HER2-negative breast cancer, without bone involvement or visceral crisis, and progression on endocrine therapy within 1 year, continued endocrine therapy may be considered until there is further progression or unacceptable toxicity; cytotoxic chemotherapy is not prioritized unless endocrine options are exhausted or there is visceral crisis.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_976765c010fc",
      "question": "For a patient with stage IIB non–small cell lung cancer (T3, N0) who underwent complete surgical resection with negative margins (R0), does the recommendation for routine follow-up with history, physical examination, and low-dose non-contrast chest CT annually still apply if the primary treatment included adjuvant radiotherapy instead of chemotherapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Disseminated metastases",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, if adjuvant radiotherapy was part of the primary treatment for stage IIB non–small cell lung cancer, surveillance should include history, physical examination, and chest CT with or without contrast every 3–6 months for 3 years, then every 6 months for 2 years, and only then switch to annual low-dose non-contrast chest CT, reflecting a more intensive monitoring schedule than after surgery ± chemotherapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_56e0201f800c",
      "question": "A 65-year-old man with a history of myelodysplastic syndrome presents with progressive fatigue and pallor. Laboratory evaluation reveals anemia with a high mean corpuscular volume and the presence of ring sideroblasts on bone marrow aspirate. He is enrolled in a clinical trial testing a novel therapy that works by incorporating into DNA and RNA, inhibiting their synthesis and thereby disrupting the proliferation of abnormal erythroid precursors. Which pharmacological mechanism best explains the therapeutic action of this investigational drug in his condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Sideroblastic anemia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002896",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004475",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Inhibition of nucleic acid synthesis",
      "reasoning_path": "Sideroblastic anemia in myelodysplastic syndrome may be treated with nucleic acid synthesis inhibitors (e.g., azacitidine), which incorporate into DNA/RNA and hinder abnormal cell proliferation.",
      "umls_path": [
        "Sideroblastic anemia",
        "may_be_treated_by",
        "Azacitidine",
        "has_mechanism_of_action",
        "Nucleic Acid Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with myelodysplastic syndrome and ring sideroblasts is experiencing sideroblastic anemia, a disorder marked by ineffective erythropoiesis due to impaired heme synthesis. Some disease-modifying therapies used in clinical trials for such conditions—including azacitidine—act by incorporating into DNA and RNA, thereby inhibiting nucleic acid synthesis. This disruption of nucleic acid synthesis impairs the proliferation of abnormal hematopoietic cells in the bone marrow, reducing the burden of ineffective erythropoiesis and potentially improving anemia. By targeting rapidly dividing cells, these agents help restore more normal marrow function. Thus, the primary pharmacologic mechanism relevant to the investigational agent in this scenario is inhibition of nucleic acid synthesis.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_1fd4016b0eb3",
      "question": "For a patient with advanced non-small cell lung cancer (NSCLC) of adenocarcinoma histology presenting with diffuse brain metastases, is initiating palliative external-beam radiotherapy prior to the completion of molecular profiling justified, or should systemic therapy selection wait for molecular testing results?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Initiating palliative external-beam radiotherapy for symptomatic diffuse brain metastases in advanced NSCLC is appropriate and does not require waiting for molecular profiling results, as urgent symptom control takes priority. Systemic therapy selection, however, should be based on completed molecular testing to enable appropriate targeted treatments.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_de46fbf2e081",
      "question": "A 68-year-old man with a long-standing history of emphysema presents with persistent, nonproductive cough despite adherence to bronchodilators and inhaled corticosteroids. The cough disrupts his sleep and daily activities. His physician prescribes a medication that diminishes the cough reflex through central nervous system action. By which molecular mechanism does this prescribed therapy alleviate his symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Lungs--Diseases, Obstructive"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0600260",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0982200",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Agonism of central opioid mu-receptors",
      "reasoning_path": "COPD with refractory cough → prescribed hydrocodone → hydrocodone acts as a central mu-opioid receptor agonist → suppresses medullary cough center → reduces cough.",
      "umls_path": [
        "Lungs--Diseases, Obstructive",
        "may_be_treated_by",
        "hydrocodone resin complex",
        "has_mechanism_of_action",
        "Opioid mu-Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with chronic obstructive pulmonary disease (COPD) is experiencing a refractory cough. When standard therapies fail to control cough, centrally acting antitussive agents such as hydrocodone may be considered for symptomatic relief. Hydrocodone is an opioid that acts primarily as an agonist at central (medullary) mu-opioid receptors. Activation of these receptors suppresses the cough reflex by inhibiting the cough center within the medulla oblongata of the brainstem. This leads to decreased sensitivity to peripheral and central stimuli that would otherwise trigger cough. The antitussive effect is thus mediated by the drug's action at mu-receptors rather than local anesthetic or anti-inflammatory effects. While effective for severe, refractory cough, opioids carry potential risks including sedation, respiratory depression, and dependence, so their use for cough is typically reserved for select cases where other treatments have failed. In summary, hydrocodone alleviates refractory cough in COPD by acting as a central mu-opioid receptor agonist, thereby suppressing the cough reflex.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_13f5b98449a9",
      "question": "In a patient with ER- and/or PR-positive, HER2-negative metastatic breast cancer, who previously received endocrine therapy within the last year and has no evidence of visceral crisis, is it required to perform ovarian ablation or suppression before initiating systemic endocrine therapy if the patient is premenopausal?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Metastatic (M1) invasive breast cancer",
              "Stage IV (M1) or Recurrent disease",
              "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
              "Stage IV (M1) or Recurrent",
              "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
              "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
              "Recurrent unresectable (local or regional) or stage IV (M1) disease",
              "Bone disease present",
              "Add denosumab zoledronic acid, or pamidronate",
              "ER- and/or PR-positive; HER2-negative",
              "BINV-22",
              "No visceral crisis and Prior endocrine therapy within 1 y",
              "Premenopausal",
              "Ovarian ablation or suppression + systemic therapy",
              "Continue endocrine therapy until progression or unacceptable toxicity",
              "Progression",
              "Progression or unacceptable toxicity on first-line endocrine therapy",
              "If not endocrine therapy refractory, consider: Alternate endocrine therapy + targeted therapy (see second-line therapy options on BINV-P)",
              "No clinical benefit after up to 3 sequential endocrine therapy regimens or Symptomatic visceral disease",
              "Systemic therapy",
              "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
              "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
            ]
          }
        }
      ],
      "answer": "Yes, for premenopausal patients with ER- and/or PR-positive, HER2-negative metastatic breast cancer and prior endocrine therapy within one year, ovarian ablation or suppression is required before starting systemic endocrine therapy, in order to suppress ovarian estrogen production and maximize treatment efficacy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_66570ee9ee65",
      "question": "In patients with stage IVA or M1b squamous non-small cell lung cancer who have adequate tissue available for molecular analysis, is comprehensive molecular profiling—including testing for EGFR, ALK, KRAS, ROS1, BRAF, NTRK, METex14 skipping, RET, and ERBB2 (HER2)—still recommended, or is this approach limited to non-squamous histology?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "EGFR S768I, L861Q, and/or G719X mutation positive",
              "EGFR S768I, L861Q, and/or G719X mutations",
              "EGFR mutation discovered prior to first-line systemic therapy",
              "Preferred: Afatinib",
              "Progression",
              "Subsequent Therapy (NSCL-23)"
            ]
          }
        }
      ],
      "answer": "Comprehensive molecular profiling is recommended for squamous cell carcinoma when adequate tissue is available, although actionable mutations are less common than in non-squamous NSCLC. This strategy ensures the identification of rare, targetable mutations and should not be restricted to non-squamous histology in advanced disease.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_7cf1c006af64",
      "question": "Which diseases are associated with the target DRD2 (Ensembl ID ENSG00000149295) that have a minimum relevance score of 0.5 in OpenTargets?",
      "tool_calls": [
        {
          "tool": "opentargets.search",
          "params": {
            "target_id": "ENSG00000149295",
            "min_score": 0.5
          }
        }
      ],
      "answer": [
        {
          "disease_id": "MONDO_0002009",
          "disease_name": "major depressive disorder",
          "score": 0.7314144788855288
        },
        {
          "disease_id": "MONDO_0005090",
          "disease_name": "schizophrenia",
          "score": 0.7046993350565542
        },
        {
          "disease_id": "MONDO_0004985",
          "disease_name": "bipolar disorder",
          "score": 0.685296601041403
        },
        {
          "disease_id": "EFO_0000677",
          "disease_name": "mental or behavioural disorder",
          "score": 0.6410536194915879
        },
        {
          "disease_id": "MONDO_0005180",
          "disease_name": "Parkinson disease",
          "score": 0.6369867716515744
        },
        {
          "disease_id": "EFO_0004895",
          "disease_name": "Tourette syndrome",
          "score": 0.629013726590614
        },
        {
          "disease_id": "EFO_0003758",
          "disease_name": "autism",
          "score": 0.6156619914790857
        },
        {
          "disease_id": "EFO_0005407",
          "disease_name": "psychosis",
          "score": 0.6146936513782291
        },
        {
          "disease_id": "EFO_0005411",
          "disease_name": "schizoaffective disorder",
          "score": 0.60599516988228
        },
        {
          "disease_id": "EFO_0009963",
          "disease_name": "bipolar I disorder",
          "score": 0.6034566131877506
        },
        {
          "disease_id": "HP_0000713",
          "disease_name": "Agitation",
          "score": 0.6000567860297616
        },
        {
          "disease_id": "EFO_0003015",
          "disease_name": "aggressive behavior",
          "score": 0.5990712880211188
        },
        {
          "disease_id": "EFO_0004270",
          "disease_name": "restless legs syndrome",
          "score": 0.5930139820840447
        },
        {
          "disease_id": "MONDO_0002050",
          "disease_name": "depressive disorder",
          "score": 0.5898202991042036
        },
        {
          "disease_id": "HP_0002017",
          "disease_name": "Nausea and vomiting",
          "score": 0.575034507961785
        },
        {
          "disease_id": "EFO_0004888",
          "disease_name": "post operative nausea and vomiting",
          "score": 0.5690802573996253
        },
        {
          "disease_id": "MONDO_0005148",
          "disease_name": "type 2 diabetes mellitus",
          "score": 0.5474933312990086
        },
        {
          "disease_id": "EFO_0010282",
          "disease_name": "gastrointestinal disease",
          "score": 0.5376668258167191
        },
        {
          "disease_id": "MONDO_0002146",
          "disease_name": "hypogonadism",
          "score": 0.5261379875719714
        },
        {
          "disease_id": "EFO_0004216",
          "disease_name": "conduct disorder",
          "score": 0.5197318623889552
        },
        {
          "disease_id": "EFO_0007319",
          "disease_name": "hyperprolactinemia",
          "score": 0.5160025486503461
        },
        {
          "disease_id": "EFO_0000545",
          "disease_name": "infertility",
          "score": 0.5130459773908275
        },
        {
          "disease_id": "EFO_1001485",
          "disease_name": "acromegaly",
          "score": 0.5037649577632791
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "path_8677599bbd68",
      "question": "In a patient with advanced non-small cell lung cancer (adenocarcinoma subtype) and newly diagnosed multiple bone metastases, but normal renal function and no evidence of impending pathological fracture, should bisphosphonate therapy or denosumab be prioritized over immediate palliative external-beam radiotherapy for bone-directed management?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Distant metastases",
              "Bone metastases",
              "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Immediate palliative external-beam radiotherapy is prioritized if there is risk of fracture or symptomatic bone metastases, aiming at pain control and local stabilization, while bisphosphonates or denosumab are primarily indicated to reduce skeletal-related events but do not replace the need for timely radiotherapy for symptomatic lesions.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_89c651146801",
      "question": "In patients with stage I–II non–small cell lung cancer who have undergone primary treatment with definitive radiotherapy rather than surgery, is it appropriate to use the same surveillance imaging frequency schedule as that recommended for surgically treated stage I–II patients, particularly in the first three years following treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (T1abc, N0); Margins positive (R1, R2)",
              "Resection (preferred) or RT (category 2B)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "No, for stage I–II non–small cell lung cancer patients treated with definitive radiotherapy, closer surveillance is indicated: history and physical examination with chest CT (with or without contrast) should be performed every 3–6 months for 3 years. In contrast, patients treated primarily with surgery ± chemotherapy should have surveillance visits every 6 months for 2–3 years during the same period.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_6cea24422376",
      "question": "A 67-year-old woman with poorly controlled diabetes presents with a chronic, non-healing ulcer over her left medial malleolus. The wound has been present for several months and shows no signs of acute infection. Her physician applies a topical antiseptic solution containing a polyvinylpyrrolidone-iodine complex as part of her wound care regimen. Despite its widespread use in such settings, the precise cellular or molecular mechanism by which this agent acts is not fully established. Given the current state of scientific understanding, how is this agent's mechanism of action best classified?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Lower Extremity Ulcer"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0023223",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0032856",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "A patient with a chronic ulcer receives povidone-iodine. The literature indicates its antiseptic effect is well-established, but no specific cellular or molecular target has been identified; thus, its mechanism is best described as unknown at the cellular or molecular level.",
      "umls_path": [
        "Lower Extremity Ulcer",
        "may_be_treated_by",
        "Povidone-containing product",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Povidone-iodine is a commonly used topical antiseptic for the management of chronic wounds and ulcers, including those occurring in diabetic patients. While it is well-documented to have broad-spectrum antimicrobial activity and is effective in reducing local microbial load, the exact cellular or molecular mechanism by which it achieves these effects remains unclear. Unlike antibiotics with defined targets such as enzymes or ribosomal subunits, povidone-iodine acts through a general oxidative mechanism, releasing free iodine that disrupts proteins and nucleic acids. However, this process does not correspond to a single, well-characterized cellular or molecular target. Therefore, despite its clinical efficacy, the agent is best classified as having an unknown or nonspecific cellular or molecular mechanism of action in the context of wound care.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_f99ad791f0e4",
      "question": "A 68-year-old woman with a history of progressive central vision loss over the past year is diagnosed with neovascular age-related macular degeneration. Her ophthalmologist discusses initiating a therapy that consists of a recombinant protein capable of binding to cell surface receptors, inducing changes in gene transcription that modulate immune and inflammatory responses. Which class of pharmacologic agents does this therapy belong to, based on its primary mechanism of action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Macular Degeneration"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0024437",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021735",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Biological Response Modifiers",
      "reasoning_path": "Vision loss from neovascular AMD can be managed with interferon alfa-2b, which functions by binding to cell surface receptors, activating intracellular signaling, and modulating immune responses—mechanisms characteristic of biological response modifiers.",
      "umls_path": [
        "Macular Degeneration",
        "may_be_treated_by",
        "Recombinant Interferon Alfa-2b",
        "has_mechanism_of_action",
        "Biological Response Modifiers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In neovascular age-related macular degeneration, abnormal blood vessel growth and inflammation contribute to vision loss. Recombinant interferon alfa-2b is sometimes considered as adjunctive therapy due to its immunomodulatory properties. This medication is a type of cytokine that binds to specific cell surface receptors, activating the JAK-STAT signaling pathway and altering gene transcription. These changes can suppress angiogenesis and modulate inflammatory responses in the retina. Agents that work through these mechanisms are classified as biological response modifiers because they alter the host’s immune or cellular responses to disease. Thus, the primary mechanism of action of interferon alfa-2b in this context is its ability to modify biological responses, not direct cytotoxicity or enzyme inhibition.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_54fbe177e9bb",
      "question": "In a patient with advanced non-small cell lung cancer (NSCLC) of adenocarcinoma subtype who is positive for EGFR S768I mutation, but also has diffuse brain metastases, should palliative external-beam radiotherapy be initiated prior to starting systemic EGFR-targeted therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "EGFR S768I, L861Q, and/or G719X mutation positive"
            ]
          }
        }
      ],
      "answer": "For advanced NSCLC patients with EGFR S768I mutation and diffuse brain metastases, palliative external-beam radiotherapy should be prioritized to promptly relieve neurological symptoms before initiating systemic EGFR-targeted therapy, as urgent local control of brain metastases is essential for symptom management.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_31569021267f",
      "question": "A 45-year-old woman from a rural area presents with a several-month history of persistent diarrhea, a scaly erythematous rash over sun-exposed areas, and increasing forgetfulness and confusion. Physical examination reveals hyperpigmented lesions on the dorsal hands and neck. She is diagnosed with a nutritional deficiency affecting metabolic pathways and is started on a vitamin supplement that restores cellular redox reactions by repleting a key cofactor for multiple dehydrogenase enzymes. Which general pharmacological class best describes the mechanism of action of this therapeutic agent?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Pellagra"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0030783",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0028027",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme activators",
      "reasoning_path": "Pellagra manifests due to niacin deficiency impairing NAD/NADP-dependent enzymes; niacinamide treatment restores these cofactors, reactivating essential metabolic enzymes and reversing symptoms.",
      "umls_path": [
        "Pellagra",
        "may_be_treated_by",
        "Niacinamide",
        "has_mechanism_of_action",
        "Enzyme Activators"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s triad of dermatitis, diarrhea, and dementia is characteristic of pellagra, a disorder caused by niacin (vitamin B3) deficiency. The effective therapy is a vitamin B3 derivative such as niacinamide or nicotinamide. These compounds serve as precursors for the synthesis of NAD+ and NADP+, essential cofactors for numerous dehydrogenase and oxidoreductase enzymes in cellular metabolism. By replenishing NAD+/NADP+ levels, niacinamide restores the activity of these enzymes and thereby corrects the metabolic impairments responsible for the patient’s symptoms. Thus, the drug’s primary pharmacological action is as an enzyme activator, facilitating the normal function of multiple metabolic enzymes whose activity is compromised in niacin deficiency.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_0b68ced3a6fe",
      "question": "In a patient with localized, invasive, non-inflammatory, non-metastatic (M0) breast cancer who is HER2-positive, ER-negative, and PR-negative, and who has at least one ipsilateral lymph node metastasis greater than 2 mm, is adjuvant chemotherapy with trastuzumab appropriate even if the tumor is of metaplastic histology, rather than ductal, lobular, mixed, or micropapillary types?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
              "ER-negative and PR-negative",
              "HER2-positive",
              "BINV-9",
              "Ductal/NST, Lobular, Mixed, Micropapillary",
              "pN+ (≥1 ipsilateral metastases >2 mm)",
              "Adjuvant chemotherapy with trastuzumab (category 1)"
            ]
          }
        }
      ],
      "answer": "No, adjuvant chemotherapy with trastuzumab is not routinely indicated for metaplastic breast cancer, even if HER2 is positive and nodal metastasis is present, because the standard recommendation in this context specifically applies to ductal, lobular, mixed, and micropapillary subtypes; metaplastic histology represents an exception.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_919801a7f240",
      "question": "In the OpenTargets database, what information is available about the event 'increased cardiac output' for the target symbol GABRA5?",
      "tool_calls": [
        {
          "tool": "opentargets.safety",
          "params": {
            "symbol": "GABRA5",
            "event": "increased cardiac output"
          }
        }
      ],
      "answer": {
        "biosamples": [
          {
            "tissueLabel": "central nervous system",
            "tissueId": "UBERON_0001017"
          },
          {
            "tissueLabel": "cardiovascular",
            "tissueId": "UBERON_0004535"
          }
        ],
        "effects": [
          {
            "dosing": "acute",
            "direction": "Activation/Increase/Upregulation"
          }
        ]
      },
      "type": "retrieval"
    },
    {
      "id": "kg_2ac12625293f",
      "question": "A 38-year-old woman with a history of systemic inflammatory disease presents with recurrent, painful, erythematous nodules over her shins. After failing standard therapies, she is started on a drug known for its anti-angiogenic effects through inhibition of a specific signaling protein involved in new blood vessel formation and inflammation. Which molecular target is primarily responsible for mediating the therapeutic action of this medication in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Erythema nodosum"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0014743",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0039736",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Vascular Endothelial Growth Factor A (VEGF-A)",
      "reasoning_path": "Erythema nodosum → refractory to standard therapy → thalidomide used → thalidomide inhibits angiogenesis → main target is VEGF-A → reduced angiogenesis and inflammation → symptom improvement.",
      "umls_path": [
        "Erythema nodosum",
        "may_be_treated_by",
        "Thalidomide",
        "has_target",
        "Vascular Endothelial Growth Factor A"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has refractory erythema nodosum, a condition characterized by inflammatory nodules often associated with increased vascular permeability and immune response. When conventional treatments fail, thalidomide is occasionally used for its immunomodulatory and anti-angiogenic actions. Thalidomide exerts a significant therapeutic effect by inhibiting vascular endothelial growth factor A (VEGF-A), a key cytokine that stimulates angiogenesis and increases vascular permeability. By blocking VEGF-A signaling, thalidomide reduces new blood vessel formation and downstream inflammation within the affected subcutaneous tissue, leading to improvement of the nodular lesions. Thus, the clinical benefit in this setting is primarily mediated by antagonism of VEGF-A, addressing both the vascular and inflammatory components of erythema nodosum.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_78e4510698c9",
      "question": "In a patient with advanced squamous cell carcinoma of the lung who is found to have a ROS1 rearrangement, is ROS1-targeted therapy an appropriate initial systemic treatment option, or does squamous histology exclude its use despite the presence of the actionable alteration?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "ROS1 rearrangement positive"
            ]
          }
        }
      ],
      "answer": "ROS1-targeted therapy is generally prioritized for patients with ROS1 rearrangements; however, its use is typically restricted to non-squamous (adenocarcinoma or NSCLC not otherwise specified) histology. Squamous cell carcinoma is considered an exclusion unless there is minimal or no smoking history and confirmed molecular driver, as true ROS1 rearrangements in pure squamous histology are extremely rare and frequently reflect specimen misclassification or admixture.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_338f0153e203",
      "question": "In a patient with stage IB (T2a, N0) non-small cell lung cancer (NSCLC) who has undergone complete surgical resection with negative margins (R0), is adjuvant systemic therapy considered standard for all such cases, or does the presence of certain risk factors influence this decision?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Nodes negative",
              "Treatment (NSCL-9)",
              "T1, N0",
              "Operable",
              "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
              "Adjuvant Treatment (NSCL-4)",
              "Stage IB (T2a, N0); Margins negative (R0)",
              "Observe or Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "Adjuvant systemic therapy is not standard for all stage IB (T2a, N0) NSCLC patients with R0 resection. The decision is influenced by high-risk features such as poor tumor differentiation, vascular invasion, wedge resection, minimal margins, or visceral pleural invasion; in their absence, observation is appropriate.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_3d7e36df50e1",
      "question": "In a patient with newly diagnosed stage IIIB non-small cell lung cancer (T1–2, N3) and a history of poor pulmonary function prohibiting surgery, is concurrent chemoradiation still a feasible definitive treatment option, or does poor lung function preclude this approach?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (peripheral T1abc, N0)",
              "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Poor pulmonary function significantly increases the risk of toxicity from concurrent chemoradiation and may contraindicate its use as a definitive treatment, as adequate lung reserve is required to tolerate combined modality therapy. In such cases, alternative strategies such as sequential chemoradiation, dose-modified regimens, or best supportive care should be considered based on functional assessment.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_d0aaf7181848",
      "question": "A 62-year-old woman undergoes cataract surgery and subsequently develops persistent pupillary constriction that is not attributable to exposure to cholinergic or miotic medications. The ophthalmologist prescribes topical drops of a medication commonly used to manage postoperative ocular inflammation and to help maintain pupillary dilation. This drug works by inhibiting an enzyme responsible for converting arachidonic acid into prostaglandins, thereby reducing prostaglandin-mediated smooth muscle contraction and inflammation in the eye. Which class of drug action best explains the therapeutic effect of this medication in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Miosis (persistent), not due to miotics"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0026205",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0016377",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cyclooxygenase inhibitors",
      "reasoning_path": "Persistent miosis after eye surgery is often mediated by prostaglandins. NSAIDs like flurbiprofen inhibit cyclooxygenase, blocking prostaglandin synthesis and reducing both inflammation and constriction of the pupil.",
      "umls_path": [
        "Miosis (persistent), not due to miotics",
        "may_be_treated_by",
        "Flurbiprofen",
        "has_mechanism_of_action",
        "Cyclooxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In the context of ocular surgery, persistent miosis can hinder visualization and healing. One cause is increased local prostaglandin synthesis, which promotes constriction of the iris sphincter muscle and inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as flurbiprofen are frequently used to counteract these effects. Their primary mechanism is inhibition of the cyclooxygenase (COX) enzymes, which are crucial for the conversion of arachidonic acid to prostaglandins. By reducing prostaglandin synthesis, these agents both decrease intraocular inflammation and help maintain mydriasis (pupil dilation) after surgery. Thus, the therapeutic action in this scenario is best explained by cyclooxygenase inhibition, which directly interrupts the pathway leading to prostaglandin-mediated miosis and inflammation.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_26a7ad9cab41",
      "question": "For a patient with stage IA (T1a, N0) non-small cell lung cancer (NSCLC) who has undergone resection but is found to have positive surgical margins (R1 or R2), is adjuvant radiotherapy routinely indicated, or is re-resection preferred as the primary management strategy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (T1abc, N0); Margins positive (R1, R2)",
              "Resection (preferred) or RT (category 2B)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "For stage IA (T1a, N0) NSCLC with positive margins after surgery, re-resection is the preferred primary management; adjuvant radiotherapy is a category 2B alternative but not routinely indicated. Definitive radiotherapy may be considered only if re-resection is not feasible.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_877d6ed93fc7",
      "question": "A 64-year-old woman with progressive exertional dyspnea and dry cough undergoes high-resolution chest CT, which reveals a reticular pattern and honeycombing at the lung bases. After a multidisciplinary review, she is diagnosed with idiopathic pulmonary fibrosis. Her pulmonologist prescribes an antifibrotic agent shown to slow decline in lung function, though the precise molecular pathways by which it acts are not fully elucidated. Based on current scientific consensus, what is the best description of this medication’s mechanism of action in treating her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Pulmonary Fibrosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0034069",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0298067",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Patient diagnosed with idiopathic pulmonary fibrosis → prescribed pirfenidone → clinical benefit observed → mechanism of action not fully understood → classified as unknown cellular or molecular interaction.",
      "umls_path": [
        "Pulmonary Fibrosis",
        "may_be_treated_by",
        "Pirfenidone",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Idiopathic pulmonary fibrosis is managed with antifibrotic agents such as pirfenidone, which has demonstrated efficacy in slowing disease progression. While pirfenidone is known to have antifibrotic and anti-inflammatory properties, its exact cellular and molecular mechanisms remain unclear. Various in vitro and animal studies suggest possible modulation of transforming growth factor-beta (TGF-β) signaling and inhibition of collagen synthesis, but these effects have not been definitively mapped to a precise molecular target in humans. As a result, the current scientific consensus is that pirfenidone’s therapeutic action in pulmonary fibrosis is due to an unknown cellular or molecular interaction. This uncertainty is reflected in clinical guidelines and prescribing information, which acknowledge its benefit but do not specify a fully characterized mechanism.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_693e88983b13",
      "question": "In ClinicalTrials.gov, which interventional studies for Heart Failure, Congestive or Dilated Cardiomyopathy started in March 2007 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "conditions=Heart Failure, Congestive,Dilated Cardiomyopathy;startDateFrom=2007-03-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00454818"
      ],
      "type": "retrieval"
    },
    {
      "id": "ret_8b33291b3cef",
      "question": "What is the unique PMID for the article titled \"The State of Immunology in Allergy and Immunology Fellowship,\" authored by Tran HN and published in Immunology and Allergy Clinics of North America in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"The State of Immunology in Allergy and Immunology Fellowship.\"[ti] AND Tran HN[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40287165"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_0f7217bb043e",
      "question": "A 34-year-old woman presents with year-round nasal congestion, sneezing, and itchy, watery eyes. She is diagnosed with perennial allergic rhinitis and started on a first-generation antihistamine that also provides significant relief from motion sickness and nausea. After a week of therapy, she reports mild drowsiness but excellent control of both her allergy and nausea symptoms. This medication is known to interact with central receptors involved in antipsychotic drug action. Which neurotransmitter receptor antagonism, aside from histamine blockade, most likely accounts for its antiemetic efficacy?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Perennial Allergic Rhinitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0035457",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0772132",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Dopamine receptor antagonism",
      "reasoning_path": "Patient takes promethazine for allergic rhinitis; experiences antiemetic effect. Promethazine blocks H1 (histamine) and D2 (dopamine) receptors. Dopamine receptor antagonism at the CTZ mediates antiemetic action, a mechanism shared by antipsychotics.",
      "umls_path": [
        "Perennial Allergic Rhinitis",
        "may_be_treated_by",
        "promethazine dioxide",
        "has_mechanism_of_action",
        "Dopamine Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "First-generation antihistamines such as promethazine are commonly used for allergic rhinitis due to their H1 receptor antagonism. However, promethazine is also effective as an antiemetic, particularly for motion sickness and postoperative nausea. This antiemetic action is attributed to its ability to antagonize dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) of the brain. Dopamine antagonism in this area inhibits nausea and vomiting pathways, a mechanism shared with several antipsychotic drugs. The sedative side effects experienced by the patient are also partly related to central histamine blockade, but the antiemetic effect specifically requires dopamine receptor inhibition. Thus, the molecular mechanism responsible for promethazine’s antiemetic properties is dopamine receptor antagonism, which is a pharmacologic mechanism also leveraged by antipsychotics.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_1000c155efe1",
      "question": "A 32-year-old man presents with fever, abdominal cramps, and watery diarrhea three days after eating undercooked poultry. Stool cultures grow non-typhoidal Salmonella species. He is started on an oral antibiotic that targets bacterial enzymes essential for DNA replication and decatenation. This drug works by interfering with a specific bacterial enzyme, leading to inhibition of chromosome segregation during cell division. Which molecular mechanism is primarily responsible for the antibacterial effect of this therapy in treating his infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Salmonella infection, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0036117",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4551111",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Inhibition of bacterial topoisomerase IV",
      "reasoning_path": "Fluoroquinolones treat Salmonella by inhibiting bacterial topoisomerase IV, blocking DNA replication and cell division.",
      "umls_path": [
        "Salmonella infection, unspecified",
        "may_be_treated_by",
        "GATIFLOXACIN HEMIHYDRATE",
        "has_mechanism_of_action",
        "Topoisomerase 4 Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is being treated for a Salmonella gastrointestinal infection with a fluoroquinolone. Fluoroquinolones, such as gatifloxacin, exert their antibacterial effects by targeting bacterial topoisomerases—specifically DNA gyrase (topoisomerase II) and topoisomerase IV. In Gram-negative bacteria like Salmonella, these drugs predominantly inhibit topoisomerase IV. This enzyme is responsible for the decatenation (separation) of interlinked daughter chromosomes following DNA replication, which is essential for proper bacterial cell division. By binding to and inhibiting topoisomerase IV, fluoroquinolones prevent the relaxation and proper segregation of replicated DNA, leading to the accumulation of double-strand DNA breaks and ultimately bacterial cell death. Thus, the therapeutic effect in this context is achieved via inhibition of bacterial topoisomerase IV, which disrupts DNA replication and cell division in Salmonella species.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_6cd25f151dd1",
      "question": "A 54-year-old woman with poorly controlled type 2 diabetes mellitus is admitted for a foot infection. Her blood glucose remains elevated despite maximum oral antihyperglycemic therapy. The inpatient team initiates a rapid-acting injectable medication before meals, which leads to prompt reductions in her blood glucose levels. This agent exerts its effects by binding to a transmembrane tyrosine kinase receptor, initiating a signaling cascade that increases glucose uptake in skeletal muscle and adipose tissue. Which molecular target is directly activated by this medication to achieve glycemic control?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "TYPE 2 DIABETES MELLITUS"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011860",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0123677",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Insulin receptor",
      "reasoning_path": "Type 2 diabetes poorly controlled → rapid-acting injectable agent → mimics insulin → binds insulin receptor → receptor activation → glucose uptake → blood glucose reduction.",
      "umls_path": [
        "TYPE 2 DIABETES MELLITUS",
        "may_be_treated_by",
        "Insulin aspart",
        "has_target",
        "Insulin Receptor"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "In this scenario, the patient has type 2 diabetes mellitus that is refractory to oral agents, necessitating the addition of a rapid-acting injectable glucose-lowering agent. The most likely medication is a rapid-acting insulin analog (such as insulin aspart, lispro, or glulisine). These agents mimic endogenous insulin, binding directly to the insulin receptor, which is a transmembrane tyrosine kinase located on the surface of target cells. Upon activation, the receptor undergoes autophosphorylation and triggers downstream signaling pathways (notably the PI3K-Akt pathway), leading to translocation of glucose transporter-4 (GLUT4) to the cell membrane in skeletal muscle and adipose tissue. This increases cellular glucose uptake and lowers blood glucose levels. The direct molecular target for this therapeutic effect is the insulin receptor.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_f03c2ec6a19e",
      "question": "What is the PMID of the 2025 article titled \"HeartConnect: Integrating primary care and specialist cardiology for rapid access and better patient and healthcare practitioner experiences,\" with first author Zurynski Y, published in the Australian Journal of General Practice?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"HeartConnect\"[ti] AND Zurynski Y[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40320805"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_4b693854e03a",
      "question": "A 29-year-old woman presents with intermittent abdominal cramps and loose stools. Stool microscopy reveals oval cysts consistent with a protozoal organism commonly implicated in gastrointestinal infections. She is started on an oral medication containing a halogenated hydroxyquinoline compound. Despite clinical efficacy, her physician explains that the exact cellular or molecular basis for this drug's antiparasitic activity remains uncertain. Which statement best describes the current understanding of the therapeutic mechanism of this agent against her infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Infection caused by Blastocystis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0085313",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0012341",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The detailed cellular or molecular mechanism of action for this drug in treating the protozoal infection is unknown.",
      "reasoning_path": "Blastocystis infection—treated with iodoquinol—mechanism of action not clearly defined; remains unknown at the cellular or molecular level.",
      "umls_path": [
        "Infection caused by Blastocystis",
        "may_be_treated_by",
        "Iodoquinol-containing product",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Blastocystis species are protozoal parasites known to cause gastrointestinal symptoms. Iodoquinol is an 8-hydroxyquinoline derivative with halogen substitutions, and it is frequently prescribed for intestinal protozoal infections such as those caused by Blastocystis. Despite its clinical efficacy, the precise cellular or molecular mechanism by which iodoquinol exerts its antiparasitic effects remains unclear. Current research has not definitively identified specific molecular targets, pathways, or cellular processes impacted by the drug in Blastocystis or other protozoa. As a result, while iodoquinol remains a standard empiric therapy, its mechanism is best described as unknown at the cellular or molecular level.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_bb00926f5398",
      "question": "In a patient with a solitary pulmonary nodule in the contralateral lung and a pathological diagnosis of non-small cell lung cancer (NSCLC) staged as IVA (N0, M1a), does the determination to treat as two primary lung tumors implicitly require both lesions to be individually curable?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
              "Pathologic Diagnosis of NSCLC",
              "Initial Evaluation",
              "CT chest and upper abdomen with contrast, including adrenals"
            ]
          }
        }
      ],
      "answer": "Yes. Treating both lesions as two primary lung tumors in the setting of NSCLC staged as IVA (N0, M1a) with a solitary contralateral pulmonary nodule is contingent on both lesions being individually curable; if either is deemed incurable, this dual primary approach is not applicable.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_59ff004fc69c",
      "question": "A 55-year-old immunocompromised patient develops a severe disseminated fungal infection confirmed as Fusarium species. He is started on a triazole antifungal medication. Shortly after initiation, the clinical pharmacist recommends close monitoring and possible adjustment of his other medications, including warfarin and tacrolimus, due to the risk of elevated drug levels. Which hepatic enzyme system is most likely inhibited by this antifungal, leading to altered metabolism of co-administered drugs?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Fusarium infection"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0276758",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0393080",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cytochrome P450 enzymes (especially CYP2C19)",
      "reasoning_path": "Fusarium infection → voriconazole treatment → voriconazole inhibits hepatic CYP450 enzymes (notably CYP2C19) → decreased metabolism of other drugs → increased risk of drug interactions.",
      "umls_path": [
        "Fusarium infection",
        "may_be_treated_by",
        "Voriconazole",
        "has_mechanism_of_action",
        "Cytochrome P450 2C19 Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Voriconazole is a triazole antifungal frequently used to treat severe Fusarium infections, particularly in immunocompromised patients. Its mechanism of action involves inhibition of fungal ergosterol synthesis, but it also has significant effects on human drug metabolism. Voriconazole is a known inhibitor of hepatic cytochrome P450 enzymes, especially CYP2C19, and to a lesser extent CYP2C9 and CYP3A4. Inhibition of these enzymes can lead to decreased metabolism and increased plasma concentrations of drugs that are CYP substrates, such as warfarin and tacrolimus. This raises the risk of toxicity or adverse effects from co-administered medications. Therefore, clinicians must monitor for drug interactions and adjust doses as necessary when voriconazole is initiated.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_9bbd3f608c64",
      "question": "In a patient with resectable non-small cell lung cancer staged as T2N2M0, who has undergone FDG-PET/CT and brain MRI showing no distant metastases, does initiation of systemic therapy without prior mediastinal lymph node biopsy assume that radiographic findings alone are sufficient for N2 confirmation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "N1 or N2 nodes positive, M0",
              "Treatment (NSCL-10)",
              "Mediastinal Biopsy Findings",
              "T1–3, N2 nodes positive, M0",
              "Systemic therapy ± RT",
              "No apparent progression",
              "Consider RT",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "No, initiation of systemic therapy in T2N2M0 non-small cell lung cancer generally requires pathologic confirmation of mediastinal (N2) lymph node involvement; radiographic evidence alone is typically insufficient, as accurate staging impacts treatment selection and prognosis.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_eec158176b55",
      "question": "What is the PMID of the article titled “[Transition in gastroenterology and hepatology],” authored by Siegmund B and published in Innere Medizin (Heidelberg, Germany) in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"[Transition in gastroenterology and hepatology].\"[ti] AND Siegmund B[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40358755"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_3f75a1a8cca9",
      "question": "For a patient with Stage I non–small cell lung cancer who underwent primary treatment with definitive radiotherapy rather than surgery, is it appropriate to use the same surveillance schedule as for those who received surgical resection, or is a more intensive follow-up schedule required?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (T1abc, N0); Margins positive (R1, R2)",
              "Resection (preferred) or RT (category 2B)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Limited metastases",
              "Stage IV, M1b (NSCL-15)"
            ]
          }
        }
      ],
      "answer": "A more intensive follow-up schedule is required for patients with Stage I non–small cell lung cancer treated with definitive radiotherapy. These patients should undergo history and physical examination (H&P) and chest CT with or without contrast every 3–6 months for the first 3 years, then H&P and chest CT every 6 months for 2 years, followed by annual low-dose non–contrast chest CT. This differs from post-surgical surveillance, which recommends H&P and chest CT every 6 months for 2–3 years, then annual imaging.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_16a04d7adba0",
      "question": "Which diseases are associated with the target ANGPT1 (Ensembl ID ENSG00000154188) in OpenTargets with a minimum relevance score of 0.5?",
      "tool_calls": [
        {
          "tool": "opentargets.search",
          "params": {
            "target_id": "ENSG00000154188",
            "min_score": 0.5
          }
        }
      ],
      "answer": [
        {
          "disease_id": "EFO_0004190",
          "disease_name": "open-angle glaucoma",
          "score": 0.5479575008534797
        },
        {
          "disease_id": "EFO_0004695",
          "disease_name": "intraocular pressure measurement",
          "score": 0.5126001852068207
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_f5e0c8b143e5",
      "question": "A 7-year-old girl presents with several small, erythematous pustules clustered on her forearm after sustaining minor abrasions while playing outdoors. Swab and Gram stain reveal gram-positive cocci in clusters, and the diagnosis of a superficial skin infection is made. Her physician decides to prescribe a topical agent with a distinct purple color, widely used historically for cutaneous infections before the advent of modern antibiotics. Although effective, the agent’s precise cellular or molecular mechanism in eradicating the causative bacteria remains incompletely understood. What best describes the current knowledge about this medication’s mechanism of action in treating her infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Staphylococcal infection of skin"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0038166",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3848552",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Diagnosis of staphylococcal skin infection → Use of gentian violet (historical topical agent) → Literature review reveals unclear mechanism → Answer: mechanism remains unknown.",
      "umls_path": [
        "Staphylococcal infection of skin",
        "may_be_treated_by",
        "gentian violet cation",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The child is diagnosed with a superficial staphylococcal skin infection, commonly managed with topical antibiotics. However, gentian violet, a synthetic dye, was historically used for such infections. Despite its demonstrated antibacterial and antifungal properties, the exact mechanism by which gentian violet inhibits or kills Staphylococcus species is not fully elucidated. While some studies suggest it causes oxidative damage to microbial cells, interferes with cell wall synthesis, or binds to DNA, none of these mechanisms have been conclusively established as the primary mode of action. Therefore, the best description is that the cellular or molecular interaction responsible for gentian violet’s antimicrobial effects remains unknown.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_75163c7f02b1",
      "question": "In a patient with localized, HR-negative/HER2-positive invasive breast cancer who is found to have a pathological complete response (ypT0N0) after preoperative systemic therapy, is adjuvant trastuzumab plus pertuzumab still required, or does the nodal status at initial clinical staging alter this recommendation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
              "Preoperative systemic therapy see BINV-M 1",
              "Response to preoperative systemic therapy and tumor is operable",
              "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
              "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
              "HR-negative/ HER2-positive",
              "ypT1–4,N0 or ypN≥1",
              "If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1) and If HR-positive, adjuvant endocrine therapy (category 1) "
            ]
          }
        }
      ],
      "answer": "Even if a pathological complete response (ypT0N0) is achieved after preoperative systemic therapy, adjuvant trastuzumab plus pertuzumab remains indicated if the initial clinical staging revealed node-positive disease, as the initial nodal status determines the need for dual HER2 blockade regardless of pathological outcome.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_50517b538924",
      "question": "In a patient with recurrent, unresectable, ER- and PR-negative, HER2-positive stage IV breast cancer who has developed progression after multiple prior lines of HER2-targeted systemic therapy, does the continued use of HER2-targeted agents remain clinically indicated, or should supportive care without further HER2-targeted treatment be prioritized?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Metastatic (M1) invasive breast cancer",
              "Stage IV (M1) or Recurrent disease",
              "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
              "Stage IV (M1) or Recurrent",
              "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
              "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
              "Recurrent unresectable (local or regional) or stage IV (M1) disease",
              "Bone disease not present",
              "ER- and PR-negative; HER2-positive",
              "BINV-26",
              "Systemic therapy + HER2-targeted therapy",
              "Continue therapy until progression or unacceptable toxicity",
              "Progression",
              "Alternate systemic therapy + HER2-targeted therapy",
              "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
              "Consider no further HER2-targeted therapy and continue supportive care (NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
            ]
          }
        }
      ],
      "answer": "After progression on multiple lines of HER2-targeted systemic therapy, further HER2-targeted treatment is generally not clinically indicated. Supportive care without continuation of HER2-targeted agents should be prioritized to focus on quality of life and symptom management as per current clinical consensus.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_146c98caebc6",
      "question": "A 62-year-old man with a 20-year history of poorly controlled type 2 diabetes presents with chronic, painful cramping in his calves after walking short distances, which is relieved by rest. Physical examination reveals diminished peripheral pulses, and Doppler studies confirm peripheral arterial disease. His physician prescribes a methylxanthine derivative to help improve his walking distance and alleviate symptoms. Although this medication is used to enhance microcirculatory blood flow in such patients, its precise cellular or molecular mechanism remains incompletely understood. Which best describes the current understanding of this drug’s therapeutic mechanism in diabetic vascular disease?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Diabetic Vascular Disorder"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011875",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0030899",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "A patient with diabetic vascular disease is treated with pentoxifylline, which may improve microcirculation, but its mechanism is not clearly defined at the cellular or molecular level.",
      "umls_path": [
        "Diabetic Vascular Disorder",
        "may_be_treated_by",
        "Pentoxifylline",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Pentoxifylline is commonly prescribed for intermittent claudication in patients with peripheral arterial disease, including those with diabetic vascular complications. Although it is classified as a methylxanthine derivative, its exact cellular or molecular mechanism in improving blood flow is not fully characterized. Proposed actions include increasing erythrocyte flexibility, reducing blood viscosity, and inhibiting platelet aggregation, but these effects have not been definitively linked to a single molecular target or pathway. Because of this, guidelines and pharmacology references designate pentoxifylline’s mechanism in this context as unknown or not fully elucidated. Therefore, the most accurate description remains that its therapeutic effect is attributed to unknown cellular or molecular interactions.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_879fb41534fd",
      "question": "A 42-year-old woman presents with progressive shortness of breath and dry cough. Chest imaging reveals bilateral hilar lymphadenopathy, and biopsy confirms noncaseating granulomas. She is started on a medication to reduce granulomatous inflammation. This drug exerts part of its anti-inflammatory effect by inhibiting the synthesis of leukotrienes, thereby decreasing the recruitment of inflammatory leukocytes. Through inhibition of which enzyme class does this medication achieve this effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Sarcoidosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0036202",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0010137",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lipoxygenase inhibitors",
      "reasoning_path": "Sarcoidosis involves granulomatous inflammation. Glucocorticoids are used to treat it. They act in part by inhibiting eicosanoid pathways, including suppression of lipoxygenases, which reduces leukotriene synthesis and inflammatory cell recruitment.",
      "umls_path": [
        "Sarcoidosis",
        "may_be_treated_by",
        "Therapeutic Cortisone",
        "has_mechanism_of_action",
        "Lipoxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In sarcoidosis, granulomatous inflammation is driven by immune cell activation and release of inflammatory mediators, including leukotrienes. Glucocorticoids are first-line therapy and exert anti-inflammatory effects through multiple mechanisms. One important pathway is the suppression of eicosanoid synthesis. Corticosteroids inhibit phospholipase A2, reducing arachidonic acid availability, and also suppress the expression of enzymes such as lipoxygenases. Lipoxygenases convert arachidonic acid into leukotrienes, potent chemoattractants that enhance leukocyte recruitment and vascular permeability. By inhibiting lipoxygenase activity, corticosteroids reduce leukotriene synthesis, diminishing the inflammatory response in affected tissues. This mechanism is particularly relevant in diseases like sarcoidosis, where granuloma formation is partly mediated by leukotriene-driven cell signaling. Thus, the inhibition of lipoxygenase enzymes is a key molecular target in the anti-inflammatory action of corticosteroids for sarcoidosis.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_7aefd06b58ae",
      "question": "A 58-year-old woman with poorly controlled diabetes and peripheral vascular disease presents with multiple non-healing ulcers on her lower legs. Despite optimized wound care and antibiotics, her ulcers persist. Her dermatologist initiates a biologic agent that promotes wound healing by stimulating immune system pathways. This drug produces its effects by binding to a specific cell surface receptor complex, leading to activation of intracellular JAK-STAT signaling and modulation of gene transcription involved in immune defense and tissue repair. Which molecular complex does this biologic agent directly target to exert its therapeutic actions in chronic skin ulcers?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Skin ulcer"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0037299",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021735",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Interferon Alpha Receptor Complex",
      "reasoning_path": "Chronic skin ulcers may respond to recombinant interferon alfa-2b, which requires direct binding to the interferon alpha receptor complex to activate downstream healing and immune pathways.",
      "umls_path": [
        "Skin ulcer",
        "may_be_treated_by",
        "Recombinant Interferon Alfa-2b",
        "has_target",
        "Interferon Alpha Receptor Complex"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Patients with chronic, non-healing skin ulcers often have impaired immune and tissue repair responses. In such cases, biologic agents like recombinant interferon alfa-2b can be used to enhance wound healing. Interferon alfa-2b is a cytokine that exerts its effects by binding directly to the interferon alpha receptor complex (IFNAR), a cell surface complex composed of IFNAR1 and IFNAR2 subunits. Ligand binding activates the associated JAK-STAT pathway, resulting in increased transcription of genes involved in immune modulation, antiviral activity, and tissue repair. This immunomodulatory action can improve the local environment of chronic ulcers, promoting healing. The therapeutic effect thus depends on the drug’s specific interaction with the interferon alpha receptor complex on target cells, not simply general immune activation.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_14d83ffb9d24",
      "question": "A 34-year-old man returns from a trip to a rural area of West Africa with a painful, ulcerated lesion on his lower leg. Examination and history reveal the recent emergence of a long, thin nematode from a blister, leading to a diagnosis of Guinea worm disease. He is started on an oral medication that impairs the parasite’s survival by blocking specific metabolic pathways through the inhibition of essential enzymes. Which general pharmacological class best describes the mechanism of action of this therapy?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Dracontiasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0013100",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0039832",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme inhibitors",
      "reasoning_path": "Dracontiasis (Guinea worm disease) is treated with thiabendazole, which works by inhibiting essential metabolic enzymes in the parasite, so its pharmacologic class is enzyme inhibitors.",
      "umls_path": [
        "Dracontiasis",
        "may_be_treated_by",
        "Thiabendazole",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has dracontiasis (Guinea worm disease), caused by the nematode Dracunculus medinensis. One of the treatments used for this helminthic infection is thiabendazole, a benzimidazole derivative. Thiabendazole works by inhibiting key metabolic enzymes within the parasite, such as fumarate reductase and other enzymes involved in the electron transport chain and microtubule synthesis. By blocking these enzymes, the drug disrupts essential metabolic processes, ultimately leading to parasite death or expulsion. Agents that act in this way are collectively classified as enzyme inhibitors, as their primary pharmacological effect is to interfere with the function of critical enzymes necessary for parasite viability. Thus, the general class best describing this mechanism is enzyme inhibitors.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_2373666236c2",
      "question": "For a patient with completely resected stage IIB non-small cell lung cancer (NSCLC) who received both surgery and postoperative chemotherapy, but who has chronic kidney disease precluding the use of intravenous contrast, is low-dose non–contrast-enhanced chest CT sufficient for routine surveillance in the first two years after treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, for stage I–II NSCLC patients who have completed primary treatment with surgery ± chemotherapy and have contraindications to intravenous contrast, low-dose non–contrast-enhanced chest CT combined with history and physical examination is a sufficient routine surveillance modality in the first two years, as contrast enhancement is optional rather than mandatory in this context.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_a192f535092a",
      "question": "A 34-year-old woman presents with multiple small, erythematous papules and pustules centered around hair follicles on her forearms. She has no fever, and her past medical history is unremarkable. Her dermatologist prescribes a topical cream containing an agent often used empirically for superficial skin infections, but notes that the precise cellular or molecular details of how this drug exerts its antimicrobial effects remain unclear. Which best describes the current scientific understanding of this topical agent’s mechanism of action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Folliculitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0016436",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021978",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Patient has superficial folliculitis → treated with topical clioquinol → clioquinol has antimicrobial activity → current literature does not define its exact cellular or molecular mechanism → answer: mechanism is unknown.",
      "umls_path": [
        "Folliculitis",
        "may_be_treated_by",
        "Clioquinol-containing product",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Clioquinol is a topical antimicrobial agent sometimes used to treat superficial skin infections such as folliculitis. While it has demonstrated broad-spectrum activity against bacteria and fungi, the exact way it disrupts microbial growth at the cellular or molecular level is not fully understood. It is thought to act as a chelating agent, binding metal ions necessary for microbial metabolism, but definitive molecular targets or pathways have not been established in current literature. Thus, although it is used clinically for its antimicrobial properties, its precise mechanism of action remains undetermined.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_1bef3b99e7ad",
      "question": "For a patient with Stage IIIC (T3, N3) non-small cell lung cancer confirmed by pathological examination, who has a resectable locoregional recurrence but also reduced pulmonary function on preoperative PFTs, is surgery still the preferred local treatment option compared to external-beam radiotherapy or SABR?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "In patients with resectable locoregional recurrence of Stage IIIC NSCLC, surgery is generally preferred. However, significantly reduced pulmonary function on preoperative PFTs may contraindicate surgery due to heightened perioperative risk. In such cases, external-beam radiotherapy or SABR becomes the more appropriate local therapy choice.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_62890e8291cb",
      "question": "A 42-year-old woman with a BMI of 34 kg/m² and no significant comorbidities is seeking pharmacological assistance for weight reduction after unsuccessful attempts at dietary and lifestyle modifications. Her physician prescribes an oral medication that is known to suppress appetite by increasing levels of monoamine neurotransmitters in the synaptic cleft, specifically through the inhibition of their neuronal reuptake. Which pharmacologic class most accurately describes the mechanism of action responsible for this medication’s weight loss effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Obesity, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0028754",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0074493",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Serotonin uptake inhibitors",
      "reasoning_path": "Obesity may be managed pharmacologically with agents like sibutramine, which inhibit serotonin reuptake in the CNS, increasing satiety and reducing caloric intake.",
      "umls_path": [
        "Obesity, unspecified",
        "may_be_treated_by",
        "Sibutramine",
        "has_mechanism_of_action",
        "Serotonin Uptake Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this scenario, the patient has obesity and is prescribed a weight-loss medication that acts by inhibiting the reuptake of monoamine neurotransmitters. One such agent, sibutramine (now withdrawn in many countries), worked primarily by blocking the reuptake of serotonin and norepinephrine at central synapses. By increasing synaptic serotonin, these drugs enhance satiety and decrease appetite, which contributes to their weight loss effect. Although norepinephrine and dopamine are also involved, serotonin reuptake inhibition is particularly significant in appetite modulation. This differentiates these agents from other anti-obesity drugs that work via alternate mechanisms, such as lipase inhibition or GLP-1 agonism. Therefore, the class 'serotonin uptake inhibitors' best describes the molecular mechanism underlying the therapeutic effect in this context.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_17de39478c39",
      "question": "A 23-year-old woman with a history of easy bruising and frequent nosebleeds is diagnosed with a congenital bleeding disorder characterized by impaired platelet adhesion and reduced activity of a clotting factor. She is started on a recombinant medication that supplements this deficient clotting factor, thereby enhancing the coagulation cascade and promoting hemostasis. Which general pharmacologic class most accurately describes the mechanism by which this therapy corrects her bleeding tendency?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "von Willebrand disorder"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0042974",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4257011",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme Activators",
      "reasoning_path": "Von Willebrand disease impairs coagulation due to deficient vWF and often low factor VIII. Lonoctocog Alfa is a recombinant factor VIII product that acts as an enzyme activator in the coagulation cascade, restoring hemostasis.",
      "umls_path": [
        "von Willebrand disorder",
        "may_be_treated_by",
        "Lonoctocog Alfa",
        "has_mechanism_of_action",
        "Enzyme Activators"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has von Willebrand disease, a hereditary disorder that leads to defective primary hemostasis due to abnormal or deficient von Willebrand factor (vWF) and, often, reduced factor VIII activity. Lonoctocog Alfa is a recombinant factor VIII product given to patients with vWF deficiency who require additional support for secondary hemostasis. Factor VIII serves as a critical cofactor in the intrinsic pathway of the coagulation cascade, accelerating the activation of factor X to Xa by factor IXa. By supplementing factor VIII, Lonoctocog Alfa enhances the activity of this enzymatic cascade, thus promoting thrombin generation and fibrin clot formation. Pharmacologically, agents that augment the function of enzymes involved in physiological processes—such as the coagulation cascade—are classified as enzyme activators. Therefore, Lonoctocog Alfa is best described as an enzyme activator, as it restores coagulation by directly increasing the activity of a key enzyme complex in clot formation.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_2286dad272ae",
      "question": "A 42-year-old woman with a decade-long history of scaly, erythematous plaques on her elbows and knees is started on a biologic therapy after topical corticosteroids and phototherapy provide insufficient control. The new medication is a fusion protein that selectively binds a glycoprotein present on the surface of memory-effector T cells, thereby inhibiting their activation and proliferation. Which molecular target is most directly responsible for the therapeutic effect of this treatment in her skin disease?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Psoriasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0033860",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0962603",
            "rela": "has_target"
          }
        }
      ],
      "answer": "T-Cell Surface Antigen CD2",
      "reasoning_path": "Moderate plaque psoriasis is mediated by activated T cells; alefacept, a biologic agent, binds CD2 on T cells, blocking their activation and reducing disease activity.",
      "umls_path": [
        "Psoriasis",
        "may_be_treated_by",
        "Alefacept",
        "has_target",
        "T-Cell Surface Antigen CD2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient’s chronic, plaque-type skin disorder is consistent with moderate plaque psoriasis. Psoriasis is an immune-mediated disease where activated T cells play a central pathogenic role by releasing cytokines that promote keratinocyte proliferation and inflammation. When topical and phototherapy approaches fail, biologic agents may be used. One such agent is a fusion protein that binds specifically to CD2, a surface glycoprotein present on T cells. By binding CD2, this drug—alefacept—prevents the interaction with its ligand LFA-3, thereby inhibiting T-cell activation and proliferation in psoriatic lesions. This leads to reduced immune-mediated skin inflammation and improvement in plaque burden. Thus, the therapeutic benefit is directly mediated by targeting the CD2 molecule on T cells, resulting in decreased pathogenic immune responses in psoriasis.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_015880f59105",
      "question": "A 47-year-old woman is diagnosed with chronic gastritis after presenting with intermittent epigastric pain and a positive urea breath test for Helicobacter pylori. She is started on a quadruple therapy that includes a medication known to coat the gastric mucosa and alter the local environment to inhibit bacterial survival. Which molecular mechanism best explains how this agent contributes to the eradication of her infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Helicobacter infections"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0079487",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0053790",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Acid-base activity—bismuth compounds act by modulating gastric acidity and protecting the mucosa, thereby creating unfavorable conditions for Helicobacter pylori.",
      "reasoning_path": "Patient with H. pylori gastritis receives bismuth; bismuth alters gastric acidity and protects mucosa, creating hostile conditions for bacterial survival via acid-base activity.",
      "umls_path": [
        "Helicobacter infections",
        "may_be_treated_by",
        "Bismuth subgallate-containing product",
        "has_mechanism_of_action",
        "Acid-Base Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Bismuth compounds, such as bismuth subgallate, are included in multi-drug regimens for Helicobacter pylori-associated gastritis. Their primary therapeutic effect is achieved through acid-base activity: they interact with gastric acid to form a protective barrier over ulcerated or inflamed mucosa. This coating reduces further mucosal damage from acid and pepsin, but importantly, it also alters the local gastric pH and disrupts the microenvironment that supports H. pylori survival. By interfering with the acid-base balance, bismuth limits the bacteria’s ability to colonize the stomach lining and enhances the effectiveness of accompanying antibiotics. This mechanism is distinct from direct antimicrobial activity; rather, it exploits the bacteria’s dependence on a specific pH environment and mucosal integrity to persist. Thus, the acid-base modulating and mucosal-protective properties of bismuth are central to its therapeutic role in Helicobacter eradication regimens.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_22f645bd9b3d",
      "question": "A 7-year-old child presents with lifelong thick, scaly skin, particularly affecting the flexural surfaces and trunk. On examination, there are widespread hyperkeratotic plaques with a corrugated appearance and superficial blistering. Genetic testing confirms a keratin mutation consistent with a congenital disorder of cornification. The dermatologist prescribes a topical cream that works by disrupting hydrogen bonds in the stratum corneum, thereby increasing water content and softening keratin. Which mechanistic class best describes the action of this topical therapy?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Epidermolytic Ichthyosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0079153",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0041942",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Physiochemical activity",
      "reasoning_path": "Epidermolytic ichthyosis causes abnormal keratinization. Urea-based topicals treat it by altering the skin’s physical and chemical environment, classifying their action as physiochemical activity.",
      "umls_path": [
        "Epidermolytic Ichthyosis",
        "may_be_treated_by",
        "urea",
        "has_mechanism_of_action",
        "Physiochemical Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Epidermolytic ichthyosis is a hereditary skin disorder characterized by abnormal keratinization, leading to thickened, scaly skin and superficial blistering. The underlying defect involves keratin mutations that compromise structural integrity of the epidermis. Management often includes topical agents to improve skin pliability and hydration. Urea is a commonly used agent in this context; it acts not via immunomodulation or metabolic pathways, but by direct physical and chemical modification of the skin. Urea disrupts hydrogen bonding within the stratum corneum, increasing water retention and softening the keratin layer. This physiochemical mechanism facilitates desquamation and improves skin texture, addressing the primary symptoms of the disorder. Thus, the therapeutic effect is best described as physiochemical activity, rather than a pharmacologic effect on receptors or enzymes.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_5312df554a6a",
      "question": "A 45-year-old woman reports difficulty seeing in low-light conditions, particularly at night, which has progressively worsened over several months. She does not wear corrective lenses and has no other significant ocular history. On examination, her pupils are normal and there is evidence of mild xerosis of the conjunctiva. Laboratory work-up suggests a micronutrient deficiency affecting photoreceptor function. Her clinician recommends a supplement with known antioxidative properties that acts by neutralizing free radicals in ocular tissues. Which mechanism best explains how this therapy improves her night vision?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Night blindness, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0028077",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4291322",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Free radical scavenging activity (antioxidant effect)",
      "reasoning_path": "Night blindness → vitamin A deficiency → vitamin A supplementation → antioxidant/free radical scavenging activity → reduced retinal oxidative stress → improved photoreceptor function → better night vision.",
      "umls_path": [
        "Night blindness, unspecified",
        "may_be_treated_by",
        "VITAMIN A MYRISTATE",
        "has_mechanism_of_action",
        "Free Radical Scavenging Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s progressive night blindness is consistent with impaired rod photoreceptor function, most commonly caused by vitamin A deficiency. Vitamin A and its derivatives are essential for the synthesis of rhodopsin, the photopigment required for low-light vision. Additionally, vitamin A compounds possess antioxidative properties—they neutralize reactive oxygen species and prevent oxidative damage to retinal cells. This antioxidant (free radical scavenging) activity protects photoreceptors from oxidative stress, which can otherwise worsen visual dysfunction. Thus, supplementation with vitamin A not only restores the visual cycle but also reduces ongoing retinal injury via its free radical scavenging mechanism, supporting the recovery of night vision.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_592fe3c89172",
      "question": "A 67-year-old man presents with progressive exertional dyspnea and a persistent dry cough. High-resolution chest CT reveals bilateral reticular opacities and subpleural honeycombing. Pulmonary function tests show a restrictive pattern with reduced diffusion capacity. After multidisciplinary discussion, he is started on an oral antifibrotic medication that inhibits several receptor tyrosine kinases involved in fibroblast proliferation and migration. Which receptor family does this therapy target to reduce fibrotic progression in his lung disease?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Idiopathic Pulmonary Fibrosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1800706",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3529778",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Fibroblast Growth Factor Receptor Family",
      "reasoning_path": "IPF involves fibroblast-driven fibrosis; nintedanib inhibits FGFR (among other RTKs), reducing fibroblast activity and fibrotic progression.",
      "umls_path": [
        "Idiopathic Pulmonary Fibrosis",
        "may_be_treated_by",
        "Nintedanib esilate",
        "has_target",
        "Fibroblast Growth Factor Receptor Family"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has idiopathic pulmonary fibrosis (IPF), a progressive interstitial lung disease characterized by excessive fibroblast activation and extracellular matrix deposition. Nintedanib is a tyrosine kinase inhibitor used to slow disease progression in IPF. It achieves its antifibrotic effects by targeting multiple receptor tyrosine kinases, most notably the fibroblast growth factor receptor (FGFR) family, along with platelet-derived and vascular endothelial growth factor receptors. Inhibition of FGFR signaling disrupts key pathways responsible for fibroblast proliferation, migration, and differentiation into myofibroblasts, thereby reducing the deposition of fibrotic tissue in the lungs. Understanding the molecular mechanism of nintedanib is crucial for recognizing its role in attenuating the progression of fibrosis in IPF.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_8fc762be7760",
      "question": "For a patient with stage I non-small cell lung cancer who underwent definitive radiotherapy as the primary treatment, is a low-dose non–contrast-enhanced chest CT scan every 6 months during the first 2–3 years after treatment an appropriate surveillance strategy, or should more frequent imaging be considered?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
              "Sequential chemotherapy and consider RT",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "For stage I non-small cell lung cancer patients treated with definitive radiotherapy, surveillance with chest CT (with or without contrast) every 3–6 months for the first 3 years is recommended; a low-dose non–contrast-enhanced chest CT every 6 months is insufficiently frequent during this period. More frequent imaging is preferred early after radiotherapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_1efacb709f17",
      "question": "A 42-year-old woman with a BMI of 34 kg/m² has struggled with weight loss despite lifestyle modifications. Her physician prescribes a medication that suppresses appetite by stimulating receptors in the hypothalamus, increasing sympathetic nervous system activity and resulting in decreased hunger. Which pharmacologic class does this agent primarily belong to, and what is the molecular mechanism underlying its appetite-suppressing effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Obesity, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0028754",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011782",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Adrenergic alpha-Agonists—these drugs reduce appetite by activating central alpha-adrenergic receptors, leading to decreased hunger signals.",
      "reasoning_path": "Obese patient prescribed an appetite suppressant; drugs like phenylpropanolamine act by stimulating central adrenergic alpha receptors, reducing hunger.",
      "umls_path": [
        "Obesity, unspecified",
        "may_be_treated_by",
        "Phenylpropanolamine hydrochloride",
        "has_mechanism_of_action",
        "Adrenergic alpha-Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient meets criteria for obesity and is prescribed an appetite suppressant. Many anti-obesity drugs function by influencing neurotransmitter pathways in the brain that regulate hunger. Agents such as phentermine or phenylpropanolamine are sympathomimetic amines that act primarily by stimulating central adrenergic alpha receptors, particularly in the hypothalamus. Activation of these receptors increases sympathetic tone and suppresses signals that promote appetite, thereby reducing caloric intake. The molecular mechanism involves agonism at alpha-adrenergic receptors, which modulates neurotransmitter release and neuronal activity in appetite-regulating centers. This mechanism is distinct from other weight-loss drugs acting via serotonergic or dopaminergic pathways, and it explains both the therapeutic effects (appetite suppression) and potential side effects (increased heart rate, insomnia) due to enhanced sympathetic output. Thus, the primary drug class for this appetite-suppressing effect is adrenergic alpha-agonists.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_7b44633aa7e8",
      "question": "A 54-year-old woman with a long-standing history of joint pain, swelling, and morning stiffness is diagnosed with rheumatoid arthritis. After beginning a new medication regimen that includes a widely available over-the-counter agent, she notes significant reduction in her joint inflammation and discomfort. This medication acts by irreversibly acetylating a specific enzyme, leading to decreased synthesis of inflammatory mediators. Which molecular target is most directly inhibited by this medication to achieve its anti-inflammatory effects in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Rheumatoid arthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003873",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004057",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 2 (COX-2)",
      "reasoning_path": "Rheumatoid arthritis involves inflammation → Aspirin started → Aspirin irreversibly inhibits COX-2 → Decreased prostaglandin synthesis → Reduced inflammation and symptom relief.",
      "umls_path": [
        "Rheumatoid arthritis",
        "may_be_treated_by",
        "Aspirin-containing product",
        "has_target",
        "Prostaglandin G/H Synthase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "The patient with rheumatoid arthritis experiences relief from joint inflammation after starting aspirin, a nonsteroidal anti-inflammatory drug (NSAID). Aspirin exerts its anti-inflammatory effect by irreversibly inhibiting cyclooxygenase enzymes, specifically Prostaglandin G/H Synthase 2 (COX-2) in inflamed tissues. COX-2 catalyzes the conversion of arachidonic acid to prostaglandin H2, a precursor for pro-inflammatory prostaglandins. By blocking COX-2, aspirin reduces the production of these mediators, thereby decreasing inflammation, pain, and swelling characteristic of rheumatoid arthritis. The selectivity for COX-2 during inflammation is crucial, as COX-1 is constitutively expressed and involved in protective functions such as maintaining gastric mucosa. Thus, the primary molecular target responsible for aspirin’s anti-inflammatory action in this clinical context is COX-2 (Prostaglandin G/H Synthase 2).",
      "type": "kg_reasoning"
    },
    {
      "id": "path_ef1cf930bc18",
      "question": "In a patient with non-small cell lung cancer presenting with a separate pulmonary nodule and mediastinal lymph node involvement, would the indication for perioperative therapy implicitly assume that the patient has Stage IIIA or higher disease, and thereby exclude Stage IIB cases?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, the indication for perioperative therapy in the setting of a separate pulmonary nodule encompasses both Stage IIB and higher stages, such as IIIA and IV, and does not exclude Stage IIB patients. The presence of a separate nodule necessitates evaluation for advanced locoregional treatment regardless of whether the disease is classified as Stage IIB or above.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_3fd8328d7d1e",
      "question": "A 42-year-old woman presents with multiple reddish-brown plaques on her face and neck, which have gradually enlarged over several months. Skin biopsy confirms granulomatous inflammation with acid-fast bacilli, consistent with a diagnosis of cutaneous tuberculosis (lupus vulgaris). She is started on a regimen including a steroidal compound sometimes used as adjunctive therapy in this condition. However, there is limited scientific literature detailing the exact cellular or molecular pathways affected by this agent in cutaneous tuberculosis. Based on available evidence, how is the mechanism of action of this adjunctive therapy best classified?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Lupus vulgaris"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0024131",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2698868",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Lupus vulgaris (cutaneous TB) is sometimes treated with sodium prasterone sulfate dihydrate, but its precise mechanism in this context is undefined, so it is classified as an unknown cellular or molecular interaction.",
      "umls_path": [
        "Lupus vulgaris",
        "may_be_treated_by",
        "Sodium Prasterone Sulfate Dihydrate",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this case, the patient has lupus vulgaris, a form of cutaneous tuberculosis. Sodium prasterone sulfate dihydrate (prasterone, also known as dehydroepiandrosterone sulfate or DHEA-S), sometimes used as adjunctive therapy, is a steroidal compound. While some clinical reports suggest benefit in cutaneous TB, the underlying cellular or molecular mechanisms by which prasterone exerts therapeutic effects in this context remain undetermined. There are no well-characterized receptor targets, signaling pathways, or specific immunomodulatory actions defined for prasterone in the treatment of lupus vulgaris. As such, the classification of its mechanism of action in this indication remains unknown at the cellular or molecular level.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_c1dcedc85aaf",
      "question": "A 63-year-old man with a history of hypertension presents to the emergency department with severe, tearing chest pain radiating to his back. Imaging confirms a rapidly enlarging thoracic aortic aneurysm. To urgently lower his blood pressure prior to surgical intervention, he receives an intravenous agent that produces profound hypotension by blocking transmission at autonomic ganglia without directly affecting vascular smooth muscle or adrenergic receptors. Through what molecular mechanism does this drug achieve its rapid antihypertensive effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Aortic Aneurysm"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003486",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0077158",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Noncompetitive antagonism of nicotinic acetylcholine receptors at autonomic ganglia",
      "reasoning_path": "Acute aortic aneurysm needs rapid blood pressure control; a ganglionic blocker like trimethaphan acts by noncompetitively inhibiting nicotinic acetylcholine receptors at autonomic ganglia, suppressing sympathetic outflow and causing hypotension.",
      "umls_path": [
        "Aortic Aneurysm",
        "may_be_treated_by",
        "Trimethaphan camsylate",
        "has_mechanism_of_action",
        "Noncompetitive Cholinergic Nicotinic Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this scenario, the patient requires immediate blood pressure reduction to minimize the risk of aneurysm rupture. The agent used acts at the level of autonomic ganglia, where sympathetic preganglionic neurons synapse with postganglionic neurons via nicotinic acetylcholine receptors. By noncompetitively antagonizing these nicotinic receptors, the drug (such as trimethaphan) inhibits synaptic transmission in both sympathetic and parasympathetic ganglia. The predominant acute effect is loss of sympathetic vascular tone, leading to rapid vasodilation and decreased blood pressure. This mechanism is distinct from drugs that block adrenergic receptors or directly relax smooth muscle. The noncompetitive nature of the antagonism means that increasing acetylcholine concentrations will not overcome the blockade, ensuring a predictable and profound effect suitable for emergent blood pressure control.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_735b711ec4d7",
      "question": "In a patient with newly diagnosed stage IVA (M1b) non-small cell lung cancer (adenocarcinoma subtype) and confirmed ALK rearrangement, if the brain MRI shows asymptomatic small brain metastasis but no neurological symptoms, should alectinib or crizotinib be prioritized as first-line therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "ALK rearrangement positive",
              "ALK rearrangement",
              "ALK rearrangement discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by alectinib (preferred) or brigatinib (preferred) or lorlatinib (preferred) or ceritinib or crizotinib",
              "Progression",
              "Subsequent Therapy (NSCL-28)"
            ]
          }
        }
      ],
      "answer": "Alectinib should be prioritized over crizotinib as first-line therapy for advanced ALK-rearranged non-small cell lung cancer, especially in the presence of brain metastases, due to superior central nervous system efficacy and overall survival benefit demonstrated in clinical trials.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_a93e91d7f81b",
      "question": "In a patient with stage I non-small cell lung cancer who has completed primary treatment with definitive radiotherapy (without surgery), is it appropriate to use the same surveillance imaging frequency as in stage I patients treated with surgery alone?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
              "Sequential chemotherapy and consider RT",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No. Following definitive radiotherapy for stage I non-small cell lung cancer, surveillance should be more frequent: history and physical examination plus chest CT every 3–6 months for 3 years, then every 6 months for 2 years, and then annually; this is more intensive than the post-surgical protocol.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_22b34b1ece73",
      "question": "For a patient with non-small cell lung cancer, T3 tumor invading the chest wall, and single brain metastasis, should priority be given to systemic therapy or local treatment (such as surgery or radiotherapy) for the thoracic lesion?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "In cases of non-small cell lung cancer with a T3 chest wall-invading tumor and limited brain metastasis (oligometastatic disease), priority is generally given to systemic therapy as initial treatment, followed by consideration of local therapies for both primary and metastatic sites if good functional status and response are achieved. Local treatment alone is not standard in the presence of distant metastasis.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_37c0be1d9051",
      "question": "A 9-year-old girl with a three-year history of polyarticular joint swelling, morning stiffness, and persistent low-grade fevers does not respond to methotrexate or NSAIDs. Her rheumatologist initiates a biologic agent, a fully human monoclonal antibody, that selectively binds and neutralizes a pro-inflammatory cytokine implicated in her disease's pathogenesis. This results in reduced synovial inflammation and improved joint mobility within several weeks. Which molecular target is directly inhibited by this therapy to achieve clinical benefit in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Juvenile idiopathic arthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3495559",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2718773",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Interleukin-1 Beta",
      "reasoning_path": "Refractory JIA → need for cytokine inhibition → canakinumab prescribed → canakinumab targets and neutralizes interleukin-1 beta → decreased inflammation and symptom relief.",
      "umls_path": [
        "Juvenile idiopathic arthritis",
        "may_be_treated_by",
        "Canakinumab-containing product",
        "has_target",
        "Interleukin-1 Beta"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "In cases of juvenile idiopathic arthritis (JIA) unresponsive to standard therapies, targeted biologic agents are considered. Canakinumab is a fully human monoclonal antibody that specifically binds to interleukin-1 beta (IL-1β), a cytokine central to the inflammatory cascade in JIA. IL-1β drives synovial inflammation, cartilage destruction, and systemic symptoms in affected children. By neutralizing IL-1β, canakinumab interrupts the downstream activation of inflammatory pathways, leading to decreased leukocyte recruitment, diminished synovial pannus formation, and improvement in symptoms such as joint swelling and pain. Therefore, the clinical efficacy of canakinumab in refractory JIA is most directly attributed to its inhibition of IL-1β, not to effects on other cytokines (such as TNF-α or IL-6).",
      "type": "kg_reasoning"
    },
    {
      "id": "path_f15e06aa3494",
      "question": "In a patient with metastatic stage IV squamous cell carcinoma of the lung whose tumor harbors a BRAF V600E mutation, is it reasonable to choose first-line BRAF and MEK inhibitor therapy (such as dabrafenib plus trametinib) over standard platinum-based chemotherapy, and what should guide this choice?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "BRAF V600E mutation positive",
              "BRAF V600E MUTATION",
              "BRAF V600E mutation discovered prior to first-line systemic therapy",
              "FIRST-LINE THERAPY",
              "Other Recommended: Systemic Therapy for Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
              "Progression",
              "Dabrafenib + trametinib or Encorafenib + binimetinib",
              "Progression",
              "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
            ]
          }
        }
      ],
      "answer": "For advanced squamous cell lung carcinoma with a confirmed BRAF V600E mutation, BRAF and MEK inhibitor therapy (such as dabrafenib plus trametinib) is a guideline-recommended, prioritized option for first-line systemic treatment. The presence of the BRAF V600E mutation specifically guides the use of targeted therapy over standard chemotherapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_8cbc64f6bca9",
      "question": "A 57-year-old man with a history of hypertension presents for evaluation after noticing intermittent palpitations. Ambulatory ECG monitoring reveals frequent, isolated premature ventricular contractions without evidence of structural heart disease. His cardiologist prescribes a medication known to suppress ventricular ectopy, but whose precise molecular mechanism—specifically, the cellular interactions underlying its antiarrhythmic effect in this setting—remains incompletely understood. What is the current understanding of the drug’s exact cellular or molecular mechanism of action for reducing these arrhythmias?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Premature ventricular contraction"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0151636",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0033216",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Premature ventricular contractions are treated with procainamide, but the precise cellular or molecular mechanism by which procainamide exerts its antiarrhythmic effect in this context remains incompletely characterized.",
      "umls_path": [
        "Premature ventricular contraction",
        "may_be_treated_by",
        "Procainamide-containing product",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Procainamide is a class Ia antiarrhythmic commonly used to treat various arrhythmias, including premature ventricular contractions (PVCs). It is known to block fast sodium channels and prolong action potential duration, which helps suppress abnormal automaticity and conduction in cardiac tissue. However, despite this general electrophysiological characterization, the precise molecular interactions and downstream pathways by which procainamide specifically suppresses PVCs have not been fully elucidated. The exact cellular targets and their contribution to the drug’s antiarrhythmic effect in this context are not completely characterized. This incomplete understanding limits the mechanistic precision of procainamide’s action for PVCs, and ongoing research continues to investigate its detailed molecular interactions in cardiac myocytes.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_9c2d09957799",
      "question": "In a patient with stage IB (T2a, N0) non–small cell lung cancer who has undergone complete surgical resection with negative margins (R0), and is currently free of clinical or radiographic evidence of disease, does the recommendation for routine brain MRI during surveillance implicitly assume a high risk of CNS relapse, or is brain MRI not routinely indicated in this scenario?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (T2a, N0); Margins negative (R0)",
              "Observe or Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Routine brain MRI is not indicated for surveillance in stage IB (T2a, N0) non–small cell lung cancer patients after complete resection when there is no clinical or radiographic evidence of recurrence; such imaging is not routinely recommended in the absence of symptoms or higher-stage disease, as the assumed risk of CNS relapse in this context is low.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_0a6f79e37fbd",
      "question": "A 58-year-old woman with a history of recurrent Clostridioides difficile infection presents with profuse watery diarrhea and abdominal cramping. She reports failing multiple courses of oral vancomycin and metronidazole. Her physician prescribes a narrowly targeted oral antibiotic that acts locally in the gut and selectively inhibits a bacterial enzyme critical for transcription initiation. Which bacterial enzyme is the molecular target of this drug, whose inhibition is essential to its therapeutic efficacy in this scenario?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Bacterial Infection"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004623",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0065023",
            "rela": "has_target"
          }
        }
      ],
      "answer": "DNA-directed RNA polymerase",
      "reasoning_path": "Recurrent C. difficile infection → fidaxomicin prescribed → acts locally in gut → inhibits bacterial DNA-directed RNA polymerase → blocks transcription → bactericidal effect → clinical improvement.",
      "umls_path": [
        "Bacterial Infection",
        "may_be_treated_by",
        "Fidaxomicin-containing product",
        "has_target",
        "DNA-directed RNA Polymerase"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has recurrent C. difficile infection unresponsive to standard therapy, prompting the use of fidaxomicin. Fidaxomicin is a macrocyclic antibiotic with minimal systemic absorption, making it ideal for gastrointestinal infections. Its antibacterial action relies on the inhibition of bacterial DNA-directed RNA polymerase. Specifically, fidaxomicin binds to the sigma subunit of the enzyme, blocking the initiation of RNA synthesis. This halts transcription, preventing the bacteria from producing essential proteins and leading to cell death. By targeting this enzyme, fidaxomicin exhibits potent bactericidal activity against C. difficile while sparing much of the normal gut flora. Thus, the clinical benefit in this patient arises directly from inhibition of bacterial DNA-directed RNA polymerase, which is the drug's primary molecular target.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_bd5caad93235",
      "question": "For a patient with stage IIB non-small cell lung cancer who underwent surgery with negative margins (R0) and completed adjuvant systemic therapy, but presents with residual radiographic abnormalities on post-treatment imaging, does this situation warrant more frequent imaging surveillance compared to patients without such findings?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Bone metastases",
              "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes. The presence of residual or new radiographic abnormalities after primary treatment indicates a need for more frequent imaging surveillance than the standard schedule recommended for patients with no evidence of disease on imaging.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_6010c50cdd2e",
      "question": "In a patient with multiple primary lung cancers staged as N0–1, where the dominant pulmonary nodule demonstrates documented growth and definitive local therapy is not feasible, if mediastinal lymph node recurrence arises without prior thoracic radiotherapy, can concurrent chemoradiation be appropriately considered, or does the initial multifocality or prior ineligibility for local therapy preclude this approach?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Multiple lung cancers (suspected or confirmed) (N0–1)",
              "Multidisciplinary evaluation",
              "Dominant nodule with evidence of growth",
              "Definitive local therapy not possible",
              "Palliative chemotherapy ± local palliative therapy or Observe",
              "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Concurrent chemoradiation remains an appropriate option for mediastinal lymph node recurrence in the absence of prior thoracic radiotherapy, regardless of initial multifocality or inability to pursue definitive local therapy for the primary disease. The recurrence location and radiotherapy history are the key determinants; initial unresectability or tumor multiplicity does not preclude concurrent chemoradiation for nodal recurrence.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_40ba96328dae",
      "question": "In a patient diagnosed with stage IVA non-small cell lung cancer (NSCLC) presenting as a solitary nodule in the contralateral lung (N0, M1a), can these lesions be managed as two curable primary lung tumors if both are deemed technically resectable, or does the presence of M1a disease status exclude this approach?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
              "Pathologic Diagnosis of NSCLC",
              "Initial Evaluation",
              "H&P (include performance status + weight loss)"
            ]
          }
        }
      ],
      "answer": "If both the primary tumor and the contralateral solitary lung nodule in a stage IVA (N0, M1a) NSCLC patient are technically resectable and considered curable, they can be managed as two primary lung tumors. The M1a designation due to a single contralateral nodule does not preclude the curative intent multimodal management in this specific scenario.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_3d863626ef35",
      "question": "In a patient with newly diagnosed stage IV, M1b non-small cell lung cancer (NSCLC) of adenocarcinoma subtype, is broad molecular profiling for EGFR, ALK, ROS1, BRAF, NTRK, MET exon 14 skipping, RET, and ERBB2 (HER2) still indicated if the patient is a never-smoker and presents with limited brain metastases but has not been tested previously?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Limited metastases",
              "Stage IV, M1b (NSCL-15)",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Yes, comprehensive molecular profiling remains indicated regardless of smoking status and number or location of metastases, as actionable mutations may be present even in never-smokers with limited metastatic disease; this guides targeted therapy selection and is standard in advanced adenocarcinoma NSCLC.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_ee2e402077ad",
      "question": "For a patient with stage III non-small cell lung cancer who has undergone curative-intent surgery and achieved R0 resection, but who also has a history of severe chronic kidney disease precluding the use of contrast agents, which imaging modality and schedule is most appropriate for routine surveillance during the first two years post-treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "For surveillance in a post-surgical stage III NSCLC patient with contraindication to contrast agents, the most appropriate imaging is a non–contrast-enhanced chest CT every 3–6 months for the first three years, combined with clinical examination. Use of contrast is not mandatory, and low-dose chest CT without contrast is acceptable in such cases.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_806edc19efb3",
      "question": "A 60-year-old man with a history of smoking and intermittent claudication presents for evaluation of worsening calf pain during ambulation. Noninvasive vascular studies confirm significant peripheral arterial occlusive disease. His clinician considers an older vasodilator agent, sometimes used for symptomatic relief in such cases, but notes that while the drug is effective at increasing blood flow, the precise cellular or molecular mechanism underlying its action in vascular smooth muscle is not fully characterized according to current scientific literature. Based on this, what is the most accurate statement regarding the drug's mechanism of action in this context?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "arterial occlusive disease"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003838",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0700461",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The precise cellular or molecular mechanism of action for papaverine hydrochloride in treating arterial occlusive disease remains unknown.",
      "reasoning_path": "Papaverine is used in arterial occlusive disease as a vasodilator, but its exact molecular mechanism in this setting is not fully understood; current evidence does not provide a definitive cellular target or pathway.",
      "umls_path": [
        "arterial occlusive disease",
        "may_be_treated_by",
        "Papaverine hydrochloride",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In patients with peripheral arterial occlusive disease, vasodilators such as papaverine hydrochloride have historically been used to relieve symptoms by increasing blood flow to ischemic limbs. While papaverine is known to induce vasodilation in smooth muscle, its detailed mechanism—whether through phosphodiesterase inhibition, direct calcium channel blockade, or other pathways—has not been fully elucidated or conclusively established for its clinical effect in this context. Thus, when asked for the best description of its cellular or molecular action in the treatment of arterial occlusive disease, the most accurate and evidence-based answer is that its precise mechanism remains unidentified. This highlights the importance of recognizing current gaps in mechanistic pharmacology knowledge, especially for older therapeutic agents.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_474ba465454f",
      "question": "A 54-year-old woman with chronic hepatitis C develops laboratory evidence of reduced platelet count on routine screening. Her physician initiates a biologic therapy that triggers the JAK-STAT pathway after binding to a specific cell-surface receptor complex. Which molecular complex is directly responsible for mediating the cellular immunomodulatory effects of this therapy in her case?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Thrombocytopenia, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0040034",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021735",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Interferon alpha receptor complex",
      "reasoning_path": "Recombinant interferon alfa-2b binds to the interferon alpha receptor complex, activating the JAK-STAT pathway and modulating immune and hematopoietic cell function.",
      "umls_path": [
        "Thrombocytopenia, unspecified",
        "may_be_treated_by",
        "Recombinant Interferon Alfa-2b",
        "has_target",
        "Interferon Alpha Receptor Complex"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "In this scenario, the patient is treated with recombinant interferon alfa-2b, a biologic agent used in various hematologic and viral conditions. Interferon alfa-2b binds to the interferon alpha receptor complex (IFNAR) on cell membranes. This binding triggers intracellular signaling primarily via the JAK-STAT pathway, leading to the transcription of genes associated with antiviral activity, immune modulation, and inhibition of cellular proliferation. These effects can modulate immune responses and influence hematopoietic cell lines, including platelets. The primary molecular complex that mediates these actions is the interferon alpha receptor complex, not downstream kinases or transcription factors. Understanding this pathway is essential for recognizing how recombinant interferon therapies can alter immune and blood cell profiles, including potential effects on platelet counts in thrombocytopenic patients.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_6c74e23e8ba9",
      "question": "In a patient with NSCLC staged as T2a N0, who has a newly identified separate pulmonary nodule in the contralateral lung but no evidence of extrathoracic metastasis, does this scenario meet criteria for stage IVA disease and therefore require biomarker testing and brain MRI with contrast as part of the diagnostic evaluation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 0–2",
              "Limited progression confirmed",
              "Other site",
              "Treatment of Thoracic Disease (NSCL-16)"
            ]
          }
        }
      ],
      "answer": "Yes, the presence of a separate pulmonary nodule in the contralateral lung without extrathoracic metastasis is classified as stage IVA (M1b) NSCLC. This stage mandates biomarker testing and brain MRI with contrast to assess for additional metastatic disease and guide therapeutic decisions.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_a46b095e7fa1",
      "question": "A 27-year-old man returns from a research trip to Central America with multiple painless, ulcerated skin lesions on his forearm. Biopsy confirms an intracellular protozoan infection. He is prescribed an oral medication that, unlike classic antiparasitic agents, acts by interacting with specific membrane-bound receptors, ultimately disrupting parasite cell signaling and membrane integrity. Which molecular pathway is primarily targeted by this therapy to achieve clinical benefit in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Cutaneous Leishmaniasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0023283",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0068006",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lysophospholipid receptor interactions",
      "reasoning_path": "Cutaneous leishmaniasis is treated with miltefosine, which acts primarily by modulating lysophospholipid receptors in the parasite, disrupting cell signaling and membrane stability rather than direct toxicity.",
      "umls_path": [
        "Cutaneous Leishmaniasis",
        "may_be_treated_by",
        "Miltefosine",
        "has_mechanism_of_action",
        "Lysophospholipid Receptor Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has cutaneous leishmaniasis, confirmed by clinical history and biopsy. Miltefosine is an oral agent often used for this condition. Unlike many antiparasitic drugs that act directly on parasite metabolism or DNA, miltefosine’s primary mechanism involves modulation of lysophospholipid membrane receptors. By interacting with these receptors, miltefosine disrupts intracellular signaling pathways vital for parasite survival, impairs membrane integrity, and induces apoptosis-like death in the protozoan. This receptor-mediated mechanism distinguishes miltefosine from agents such as pentavalent antimonials, which exert direct cytotoxic effects. The effectiveness of miltefosine in treating cutaneous leishmaniasis is thus attributed to its interference with parasite cell signaling via lysophospholipid receptor interactions.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_3a9190fa1d17",
      "question": "A wildlife rehabilitator brings in a songbird exhibiting lethargy, anemia, and splenomegaly. Blood smears confirm intraerythrocytic protozoal organisms consistent with Plasmodium species. The attending veterinarian prescribes an oral agent known to accumulate in the parasite’s food vacuole, thereby interfering with heme detoxification and ultimately disrupting the synthesis of nucleic acids needed for replication. Which pharmacological action accounts for this medication’s antiprotozoal efficacy in this case?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Avian malaria"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0024533",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0700447",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Inhibition of nucleic acid synthesis",
      "reasoning_path": "Plasmodium infects erythrocytes → chloroquine accumulates in parasite → heme detoxification blocked → toxic metabolites interfere with nucleic acid synthesis → parasite replication inhibited.",
      "umls_path": [
        "Avian malaria",
        "may_be_treated_by",
        "Chloroquine sulfate",
        "has_mechanism_of_action",
        "Nucleic Acid Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this clinical scenario, the bird is suffering from avian malaria caused by Plasmodium species, which invade red blood cells. The veterinarian prescribes chloroquine sulfate, a classic antimalarial agent. Chloroquine acts by entering the parasite’s food vacuole and preventing the biocrystallization of heme, which accumulates to toxic levels. This action not only disrupts the parasite’s ability to detoxify heme but also impedes the synthesis of nucleic acids. Specifically, the accumulation of toxic heme and related metabolites damages the parasite’s DNA and RNA synthesis machinery, inhibiting replication and survival. Thus, the primary pharmacological action responsible for chloroquine’s efficacy in treating Plasmodium infection is inhibition of nucleic acid synthesis. This mechanism is crucial in both avian and human malaria treatment, directly targeting the parasite’s ability to multiply inside host erythrocytes.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_2282759c3b2f",
      "question": "In patients with advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma subtype who are confirmed to have an ERBB2 (HER2) mutation, does the use of fam-trastuzumab deruxtecan-nxki as a preferred systemic therapy option implicitly require positive ERBB2 (HER2) mutation status, or can it reasonably be considered for patients lacking this molecular alteration?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "ERBB2 (HER2) mutation positive",
              "ERBB2 (HER2) mutation",
              "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
              "Tumor response evaluation",
              "Response or stable disease",
              "4–6 cycles (total)",
              "Tumor response evaluation",
              "Response or stable disease",
              "Maintenance therapy",
              "Progression",
              "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
              "Progression",
              "PS 3–4",
              "Best supportive care: NCCN Guidelines for Palliative Care"
            ]
          }
        }
      ],
      "answer": "The use of fam-trastuzumab deruxtecan-nxki as a preferred systemic therapy requires confirmed ERBB2 (HER2) mutation positivity; it is not indicated for patients without this mutation. The selection of this agent is specifically predicated on the presence of the ERBB2 (HER2) genetic alteration.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_66c55daa66f2",
      "question": "In ClinicalTrials.gov, which completed interventional phase 3 studies for relapsing-remitting multiple sclerosis involving Fingolimod 1.25 mg, Fingolimod 0.5 mg, or Placebo started in January 2006 in Australia?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "overallStatus=COMPLETED;phases=PHASE3;conditions=Relapsing-remitting Multiple Sclerosis;interventions.name=Fingolimod 1.25 mg,Fingolimod 0.5 mg,Placebo;startDateFrom=2006-01-01;locations.country=Australia",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00289978"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_683f88394ba4",
      "question": "In a patient with a separate pulmonary nodule located in an ipsilateral non-primary lobe (classified as T4, N0–1), is surgical resection appropriate as an initial treatment in the absence of planned preoperative systemic therapy, or should induction systemic therapy be prioritized before surgery?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treatment",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
              "Surgery after preoperative systemic therapy, if planned",
              "N2",
              "Margins positive",
              "R1",
              "Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "For a separate pulmonary nodule in an ipsilateral non-primary lobe (T4, N0–1), surgical resection may be considered; however, induction systemic therapy prior to surgery is generally preferred to optimize disease control. Proceeding directly to surgery without preoperative systemic therapy is less favored in this clinical context.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_4afe92a42dc6",
      "question": "In ClinicalTrials.gov, which completed interventional studies for gout with the main interventions pegloticase or placebo started in May 2006 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "overallStatus=COMPLETED;conditions=Gout;interventions.name=pegloticase,placebo;startDateFrom=2006-05-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00325195"
      ],
      "type": "retrieval"
    },
    {
      "id": "ret_8b35d8bcf123",
      "question": "What is the unique PMID for the article titled “[Comments of the German Society for Orthopaedic Rheumatology on the article \"Rheumatological care in Germany\" : Memorandum of the German Society for Rheumatology and Clinical Immunology 2024],” authored by Carl HD and published in Zeitschrift fur Rheumatologie in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"[Comments of the German Society for Orthopaedic Rheumatology on the article \"Rheumatological care in Germany\" \"[ti] AND Carl HD[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40167622"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_107a55685bbe",
      "question": "A 34-year-old woman presents with fatigue and pallor. Laboratory studies reveal a hemoglobin of 9.2 g/dL and mean corpuscular volume of 74 fL. Peripheral blood smear shows hypochromic, microcytic red blood cells. After dietary history and evaluation, she is started on an oral supplement containing ferric ions. At the cellular level, which fundamental process does this therapy most directly enhance to address her underlying hematologic abnormality?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Hypochromic Anemia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002884",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0060228",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Electrolyte activity facilitating iron transport and utilization for erythropoiesis",
      "reasoning_path": "Iron deficiency anemia → ferric supplement given → iron acts as an electrolyte → supports transport and utilization for hemoglobin synthesis in erythroid cells.",
      "umls_path": [
        "Hypochromic Anemia",
        "may_be_treated_by",
        "Ferric ammonium citrate",
        "has_mechanism_of_action",
        "Electrolyte Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient exhibits features of iron deficiency anemia: microcytic, hypochromic red blood cells and low hemoglobin. Treatment involves oral iron supplementation, often in the form of ferric compounds like ferric ammonium citrate. The therapeutic effect relies on restoring bioavailable iron, a critical electrolyte in the body, which is absorbed in the duodenum and transported via transferrin to the bone marrow. There, iron is incorporated into hemoglobin during erythropoiesis, enabling efficient oxygen-carrying red cell production. The cellular mechanism involves the compound’s dissociation and release of ferric ions, which participate as electrolytes in red cell precursors. This electrolyte activity of iron underlies its transport, cellular uptake, and incorporation into heme, directly correcting the deficit causing hypochromia and anemia.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_c88b06ac825a",
      "question": "In a patient with multiple lung cancers (N0–1) where definitive local therapy is not feasible and a dominant nodule shows progression, does the recommendation of palliative chemotherapy ± local palliative therapy implicitly exclude the option of observation if the patient remains asymptomatic?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Multiple lung cancers (suspected or confirmed) (N0–1)",
              "Multidisciplinary evaluation",
              "Dominant nodule with evidence of growth",
              "Definitive local therapy not possible",
              "Palliative chemotherapy ± local palliative therapy or Observe",
              "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "No, the presence of multiple lung cancers with N0–1 status and tumor progression does not automatically exclude observation, especially in asymptomatic patients. Both palliative chemotherapy ± local palliative therapy and observation remain valid options, with choice depending on symptom burden, disease dynamics, and patient preference.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_53812c268bc6",
      "question": "For a patient with non-small cell lung cancer (NSCLC) staged as T1–3, N2, M0 who has a confirmed EGFR exon 19 deletion or L858R mutation after receiving definitive concurrent chemoradiation, is it appropriate to choose osimertinib instead of durvalumab for adjuvant therapy, and which agent has a higher priority usage according to current clinical standards?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "N1 or N2 nodes positive, M0",
              "Treatment (NSCL-10)",
              "Mediastinal Biopsy Findings",
              "T1–3, N2 nodes positive, M0",
              "Definitive concurrent chemoradiationm,s (category 1) or Systemic",
              "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "For EGFR-mutant (exon 19 deletion or L858R) NSCLC (T1–3, N2, M0) after definitive concurrent chemoradiation, osimertinib is preferred over durvalumab as adjuvant therapy due to demonstrated efficacy in this molecular subgroup, while durvalumab is not recommended for EGFR-mutated patients. Thus, osimertinib holds priority in this context.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_2215b19f0054",
      "question": "In a patient with advanced stage IVA (M1b) squamous cell carcinoma of the lung who harbors a BRAF V600E mutation, is administration of dabrafenib plus trametinib contingent upon the completion or interruption of the current first-line systemic therapy, or can it be initiated immediately upon discovery of the mutation regardless of ongoing treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "BRAF V600E mutation positive",
              "BRAF V600E MUTATION",
              "BRAF V600E mutation discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by dabrafenib + trametinib (preferred) or encorafenib + binimetinib (preferred)",
              "Progression",
              "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
            ]
          }
        }
      ],
      "answer": "Initiation of dabrafenib plus trametinib in a patient with BRAF V600E-mutated advanced squamous cell lung carcinoma is recommended only after completion or interruption of the ongoing first-line systemic therapy; immediate switch is not supported if current treatment is still ongoing and effective.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_dca8fef6a8c9",
      "question": "A 37-year-old man with advanced HIV presents with new-onset headache, confusion, and low-grade fever. Neuroimaging reveals multiple ring-enhancing lesions in the brain, and serologic testing supports a diagnosis of a protozoal CNS infection. He is started on an antimicrobial regimen that includes a drug structurally similar to para-aminobenzoic acid (PABA), which competes with PABA to inhibit dihydropteroate synthase and thereby block folic acid synthesis in the pathogen. Through which class of enzymatic inhibition does this agent exert its antiparasitic effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Toxoplasmosis, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0040558",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0038675",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Para-aminobenzoic acid (PABA) inhibitors",
      "reasoning_path": "Toxoplasma infection is treated with sulfadiazine, which is a sulfonamide. Sulfadiazine inhibits folic acid synthesis by acting as a competitive inhibitor at the PABA binding site of dihydropteroate synthase, thereby blocking protozoal DNA synthesis.",
      "umls_path": [
        "Toxoplasmosis, unspecified",
        "may_be_treated_by",
        "Sulfadiazine",
        "has_mechanism_of_action",
        "Para-Aminobenzoic Acid Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has toxoplasmic encephalitis, a common opportunistic infection in immunocompromised hosts. Sulfadiazine, prescribed here, is a sulfonamide that acts as a structural analog of para-aminobenzoic acid (PABA). It competes with PABA for the active site of dihydropteroate synthase, a crucial enzyme in the folic acid synthesis pathway of Toxoplasma gondii. By inhibiting this enzyme, sulfadiazine prevents the formation of dihydrofolic acid, an essential precursor for nucleotide synthesis and DNA replication in the pathogen. This mechanism selectively targets the protozoan because mammalian cells acquire folate from the diet and do not synthesize it de novo. Therefore, the therapeutic effect of sulfadiazine in toxoplasmosis relies on its function as a PABA inhibitor, which disrupts folate metabolism and nucleic acid synthesis in the microorganism.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_05e96f2c7984",
      "question": "A 9-year-old girl with progressive lower limb weakness and difficulty with fine hand movements is evaluated for distal muscle wasting and absent deep tendon reflexes. Genetic testing confirms a diagnosis of an autosomal recessive motor neuron disorder characterized by defective splicing of a survival motor neuron gene. She is started on an oral medication that promotes exon 7 inclusion in the SMN2 transcript, thereby increasing functional SMN protein levels. Which molecular target class is primarily engaged by this therapy to exert its disease-modifying effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "NEURONOPATHY, DISTAL HEREDITARY MOTOR, AUTOSOMAL RECESSIVE 2"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1854023",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C5139676",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Pre-mRNA splicing machinery (spliceosome components)",
      "reasoning_path": "Distal hereditary motor neuronopathy due to SMN2 splicing defects is treated with risdiplam, which modulates pre-mRNA splicing by targeting spliceosome components to restore functional SMN protein.",
      "umls_path": [
        "NEURONOPATHY, DISTAL HEREDITARY MOTOR, AUTOSOMAL RECESSIVE 2",
        "may_be_treated_by",
        "Risdiplam",
        "has_mechanism_of_action",
        "Multidrug and Toxin Extrusion Transporter 1 Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient presents with clinical and genetic features of a hereditary motor neuronopathy associated with impaired SMN protein production due to aberrant splicing of the SMN2 gene. The prescribed drug, risdiplam, is an orally administered small molecule that enhances the inclusion of exon 7 in SMN2 pre-mRNA. This correction increases the amount of full-length, functional SMN protein, which is crucial for motor neuron survival. Risdiplam exerts its effect by modulating pre-mRNA splicing, directly interacting with spliceosomal proteins and regulatory elements involved in alternative splicing. Thus, the pharmacological action of risdiplam relies on targeting the pre-mRNA splicing machinery rather than membrane transporters or other protein classes. The effective restoration of SMN protein levels in motor neurons underlies the clinical benefit observed in patients with this genetic motor disorder.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_8e79c446c0d5",
      "question": "A 32-year-old woman presents with recurrent episodes of limb numbness and visual disturbances that resolve spontaneously over several weeks. Brain MRI reveals multifocal white matter lesions in the periventricular areas. She is diagnosed with relapsing-remitting demyelinating disease of the central nervous system and is started on a subcutaneous medication consisting of a mixture of synthetic polypeptides. This agent is designed to shift immune responses away from proinflammatory pathways that target myelin. Which pharmacologic class best describes the mechanism by which this therapy exerts its clinical benefit?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Relapsing-Remitting Multiple Sclerosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0751967",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0289884",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Immunologic adjuvant",
      "reasoning_path": "Relapsing-remitting MS is treated with glatiramer acetate, which modulates immune responses as an immunologic adjuvant, reducing autoimmune myelin damage.",
      "umls_path": [
        "Relapsing-Remitting Multiple Sclerosis",
        "may_be_treated_by",
        "Glatiramer Acetate",
        "has_mechanism_of_action",
        "Immunologic Adjuvants"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s presentation is classic for relapsing-remitting multiple sclerosis (MS), an autoimmune demyelinating disease. Glatiramer acetate is a commonly prescribed first-line therapy for this condition. It consists of synthetic polypeptides that resemble myelin basic protein and acts as an immunologic adjuvant. Mechanistically, glatiramer acetate modulates immune function by promoting anti-inflammatory Th2 cell responses and suppressing proinflammatory Th1 responses directed at myelin antigens. This immunomodulatory effect decreases the frequency of relapses by reducing the immune system’s attack on central nervous system myelin. Thus, the primary pharmacologic class for glatiramer acetate is immunologic adjuvant, as its clinical benefit hinges on adjusting immune activity rather than directly suppressing overall immune function or acting as an immunosuppressant. Recognition of this mechanism is important in understanding both the therapeutic benefits and the side effect profile of the drug.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_149ae23e6028",
      "question": "What diseases are associated with the target ENSG00000082175 (PGR) in OpenTargets with a minimum relevance score of 0.5?",
      "tool_calls": [
        {
          "tool": "opentargets.search",
          "params": {
            "target_id": "ENSG00000082175",
            "min_score": 0.5
          }
        }
      ],
      "answer": [
        {
          "disease_id": "EFO_0001065",
          "disease_name": "endometriosis",
          "score": 0.6566512362652481
        },
        {
          "disease_id": "EFO_0000731",
          "disease_name": "uterine fibroid",
          "score": 0.6511812563339188
        },
        {
          "disease_id": "EFO_0003894",
          "disease_name": "acne",
          "score": 0.597566968669269
        },
        {
          "disease_id": "MP_0001914",
          "disease_name": "hemorrhage",
          "score": 0.5756685311929337
        },
        {
          "disease_id": "HP_0000132",
          "disease_name": "Menorrhagia",
          "score": 0.5599706832186602
        },
        {
          "disease_id": "EFO_0003917",
          "disease_name": "premature birth",
          "score": 0.5521983150374191
        },
        {
          "disease_id": "HP_0002039",
          "disease_name": "Anorexia",
          "score": 0.5454401037889884
        },
        {
          "disease_id": "EFO_0010269",
          "disease_name": "amenorrhea",
          "score": 0.5381963603479111
        },
        {
          "disease_id": "MONDO_0001572",
          "disease_name": "leiomyoma",
          "score": 0.5296392317173237
        },
        {
          "disease_id": "HP_0004326",
          "disease_name": "Cachexia",
          "score": 0.5259320368933119
        },
        {
          "disease_id": "EFO_0000616",
          "disease_name": "neoplasm",
          "score": 0.5247245552352772
        },
        {
          "disease_id": "EFO_0003099",
          "disease_name": "Cushing syndrome",
          "score": 0.5109723808960552
        },
        {
          "disease_id": "MONDO_0003778",
          "disease_name": "inborn error of immunity",
          "score": 0.5039631962908891
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_00a94a802fbc",
      "question": "A term newborn develops persistent vomiting, dehydration, and hypotension within the first week of life. Laboratory evaluation reveals hyponatremia, hyperkalemia, and hypoglycemia. Further testing confirms markedly elevated 17-hydroxyprogesterone levels. The infant is started on a medication that compensates for the absent endogenous hormone by binding to a cytosolic receptor, translocating to the nucleus, and regulating gene transcription involved in glucose metabolism and stress response. Which pharmacological class best describes this medication's primary mechanism of action in restoring homeostasis for this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Congenital Adrenal Hyperplasia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001627",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0612688",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Glucocorticoid receptor agonists",
      "reasoning_path": "Congenital adrenal hyperplasia causes cortisol deficiency; hydrocortisone cypionate binds and activates glucocorticoid receptors, replacing deficient hormone and restoring metabolic balance.",
      "umls_path": [
        "Congenital Adrenal Hyperplasia",
        "may_be_treated_by",
        "Hydrocortisone cypionate",
        "has_mechanism_of_action",
        "Glucocorticoid Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This clinical vignette describes an infant with classic congenital adrenal hyperplasia (CAH), most commonly due to 21-hydroxylase deficiency, leading to impaired cortisol synthesis. The resultant cortisol deficiency triggers increased ACTH release and adrenal hyperplasia, causing salt-wasting and metabolic instability. Hydrocortisone cypionate, a synthetic glucocorticoid, is used as first-line therapy. Its molecular action involves binding to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription to restore deficient glucocorticoid activity. This negative feedback suppresses excess ACTH, reduces adrenal androgen production, and helps normalize electrolytes and glucose. Thus, hydrocortisone cypionate acts as a glucocorticoid receptor agonist, directly replacing the missing hormone and correcting the metabolic and hormonal derangements seen in CAH.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_117837ecca97",
      "question": "In a patient with metastatic non-small cell lung cancer (NSCLC) harboring an ERBB2 (HER2) mutation, who has demonstrated progression after initial platinum-based chemotherapy and exhibits an Eastern Cooperative Oncology Group (ECOG) performance status of 2, is fam-trastuzumab deruxtecan-nxki still an appropriate subsequent systemic therapy option?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "ERBB2 (HER2) mutation positive",
              "ERBB2 (HER2) mutation",
              "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
              "Tumor response evaluation",
              "Response or stable disease",
              "4–6 cycles (total)",
              "Tumor response evaluation",
              "Response or stable disease",
              "Maintenance therapy",
              "Progression",
              "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
              "Progression",
              "PS 0–2",
              "Systemic Therapy, Subsequent"
            ]
          }
        }
      ],
      "answer": "Yes, fam-trastuzumab deruxtecan-nxki remains an appropriate subsequent systemic therapy for advanced NSCLC with ERBB2 (HER2) mutation after progression on platinum-based chemotherapy, provided the patient has an ECOG performance status of 0–2, as current evidence supports its use in this population regardless of performance status within this range.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_9729e96312d3",
      "question": "A 68-year-old woman with a long-standing history of knee pain and morning stiffness is diagnosed with osteoarthritis. She is started on a nonsteroidal anti-inflammatory drug (NSAID) that is also known to influence an enzyme regulating intracellular levels of cyclic guanosine monophosphate (cGMP). This enzyme hydrolyzes cGMP and thereby impacts inflammatory signaling pathways as well as smooth muscle tone. What is the primary molecular target modulated by this medication, and how does its inhibition contribute to the therapeutic effect in osteoarthritis?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Osteoarthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0029408",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0038792",
            "rela": "has_target"
          }
        }
      ],
      "answer": "cGMP-specific 3',5'-cyclic phosphodiesterase (PDE)",
      "reasoning_path": "Osteoarthritis pain is treated with sulindac, which inhibits cGMP-specific 3',5'-cyclic phosphodiesterase, increasing cGMP, thereby modulating inflammation and contributing to symptom relief.",
      "umls_path": [
        "Osteoarthritis",
        "may_be_treated_by",
        "Sulindac",
        "has_target",
        "cGMP-Specific 3',5'-Cyclic Phosphodiesterase"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Sulindac, an NSAID prescribed for osteoarthritis, exerts its primary anti-inflammatory effect via cyclooxygenase (COX) inhibition but also modulates other pathways. Research has shown that sulindac can inhibit cGMP-specific 3',5'-cyclic phosphodiesterase (PDE), the enzyme responsible for breaking down cGMP within cells. Inhibition of this enzyme leads to increased intracellular cGMP concentrations. Elevated cGMP influences signaling pathways that can reduce inflammatory mediator release and modulate vascular and smooth muscle function—factors implicated in pain and tissue response in osteoarthritis. Thus, beyond COX inhibition and prostaglandin reduction, sulindac’s action on cGMP-specific PDE may contribute to its therapeutic benefits in inflammatory joint disease by enhancing anti-inflammatory signaling and improving microvascular dynamics in affected tissues.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_2510ca2306b6",
      "question": "A 54-year-old man presents with fever, fatigue, and hemolytic anemia two weeks after returning from a hiking trip in the northeastern United States. Blood smear reveals intraerythrocytic protozoa arranged in a Maltese cross pattern. He is started on a medication that acts by disrupting the pathogen’s ability to replicate its genetic material, thereby impairing survival. Which class of drug mechanisms best describes the primary pharmacological action of the prescribed agent in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Babesiosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004576",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0034417",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Nucleic Acid Synthesis Inhibitors",
      "reasoning_path": "Babesiosis is treated with quinine; quinine’s mechanism disrupts nucleic acid synthesis in Babesia, inhibiting replication and survival.",
      "umls_path": [
        "Babesiosis",
        "may_be_treated_by",
        "Quinine",
        "has_mechanism_of_action",
        "Nucleic Acid Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s clinical presentation and blood smear findings are classic for babesiosis, a tick-borne protozoal infection. Quinine is one therapeutic option for this disease. Its primary mechanism of action involves interfering with the synthesis of nucleic acids in the causative organism, Babesia microti. By disrupting the synthesis and replication of DNA and RNA, quinine impairs the pathogen’s ability to replicate and survive within red blood cells. This is distinct from other antiparasitic drugs that may target metabolic pathways or structural components. Therefore, quinine’s effectiveness in treating babesiosis is attributed to its role as a nucleic acid synthesis inhibitor, which ultimately leads to clearance of the infection.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_ae104372548f",
      "question": "A 29-year-old woman presents with sudden onset of right-sided weakness and numbness. MRI of the brain reveals a single demyelinating lesion in the periventricular white matter. After excluding other causes, her neurologist prescribes a monoclonal antibody therapy to prevent further neurologic attacks. This medication is known to bind a surface antigen on B lymphocytes, leading to their depletion and thereby reducing their role in antigen presentation and autoantibody production. Which immunological pathway is most directly inhibited by this therapy to achieve disease control?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Clinically Isolated Syndrome, CNS Demyelinating"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2350037",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4083151",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "B cell-mediated immune responses via CD20-directed antibody-dependent cytotoxicity",
      "reasoning_path": "Clinically isolated syndrome is treated with ublituximab, which binds CD20 on B cells, promoting their depletion and thus suppressing B cell-driven immune mechanisms involved in CNS demyelination.",
      "umls_path": [
        "Clinically Isolated Syndrome, CNS Demyelinating",
        "may_be_treated_by",
        "Ublituximab",
        "has_mechanism_of_action",
        "B Lymphocyte Stimulator-directed Antibody Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has experienced a clinically isolated syndrome suggestive of early multiple sclerosis. Ublituximab is a monoclonal antibody targeting the CD20 antigen on B lymphocytes. By binding to CD20, ublituximab triggers antibody-dependent cellular cytotoxicity and complement-mediated lysis, leading to selective depletion of circulating B cells. B cells play a central role in autoimmune demyelination by presenting antigens to T cells and producing pathogenic autoantibodies. By depleting B cells, ublituximab interrupts these inflammatory processes, thereby reducing disease activity and the likelihood of further demyelinating events. The most direct immunological mechanism targeted is the B cell-mediated immune response, specifically through CD20-directed antibody actions that eliminate pathogenic B cells from circulation.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_bb0f784b8c8d",
      "question": "A 3-week-old infant is admitted to the hospital with severe cough, wheezing, and hypoxemia. PCR testing of nasopharyngeal secretions confirms a viral etiology. Given the progressive respiratory distress, the medical team initiates supportive care and administers an intravenous preparation of pooled human immunoglobulins. Which molecular process best explains how this treatment helps manage the infant’s infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Respiratory Syncytial Virus Infection"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0035235",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0085297",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Antibody-receptor interactions—neutralization of viral particles and modulation of immune responses via Fc receptor engagement",
      "reasoning_path": "Severe viral infection in a neonate → administration of IGIV → antibodies bind viral antigens and engage Fc receptors → neutralization of virus and enhanced immune clearance.",
      "umls_path": [
        "Respiratory Syncytial Virus Infection",
        "may_be_treated_by",
        "IGIV",
        "has_mechanism_of_action",
        "Antibody-Receptor Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In neonates with severe respiratory viral infections such as those caused by respiratory syncytial virus (RSV), the immune system is often immature, limiting the effectiveness of endogenous antibody responses. Intravenous immunoglobulin (IGIV) provides passive immunity by supplying a broad spectrum of polyclonal antibodies capable of binding viral antigens. These antibodies neutralize viral particles by attaching to viral surface proteins, preventing viral entry into host cells. Additionally, the Fc region of these administered antibodies can interact with Fc receptors on immune cells, enhancing phagocytosis and promoting antibody-dependent cellular cytotoxicity. This dual action both directly inhibits viral propagation and modulates the host immune response, facilitating viral clearance and reducing disease severity. Therefore, the primary mechanism by which IGIV benefits a neonate with severe RSV infection is through antibody-receptor interactions that neutralize the virus and support immune function.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_aa294a369042",
      "question": "In a patient with stage IIIC (T3, N3) non-small cell lung cancer who develops a resectable isolated locoregional recurrence after initial definitive therapy and has no evidence of disseminated disease, is surgical resection preferred over external-beam radiation therapy or stereotactic ablative body radiotherapy (SABR)?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, for a patient with stage IIIC (T3, N3) non-small cell lung cancer and a resectable isolated locoregional recurrence without evidence of disseminated disease, surgical resection is the preferred treatment option compared to external-beam radiation therapy or SABR. Resection should be prioritized when the recurrence is deemed technically operable and the patient is fit for surgery.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_8166df2370f5",
      "question": "For a patient with stage IIIB (T1–2, N3) non–small cell lung cancer who develops superior vena cava (SVC) obstruction with significant clinical symptoms, but has not previously received chemoradiotherapy, should immediate SVC stenting take precedence over initiating concurrent chemoradiation when selecting the first-line intervention?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Immediate SVC stenting is prioritized as the first-line intervention in the presence of symptomatic SVC obstruction to rapidly relieve life-threatening symptoms before or in parallel with initiating concurrent chemoradiation, regardless of prior systemic treatment history.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_85494f985b90",
      "question": "In a postmenopausal woman with ER- and/or PR-positive, HER2-negative, unresectable locally recurrent or stage IV (M1) breast cancer, who has bone metastases but no evidence of visceral crisis, and experienced progression on endocrine therapy within the last year, should cytotoxic chemotherapy or further endocrine therapy be prioritized as the next line of systemic treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Metastatic (M1) invasive breast cancer",
              "Stage IV (M1) or Recurrent disease",
              "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
              "Stage IV (M1) or Recurrent",
              "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
              "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
              "Recurrent unresectable (local or regional) or stage IV (M1) disease",
              "Bone disease present",
              "Add denosumab zoledronic acid, or pamidronate",
              "ER- and/or PR-positive; HER2-negative",
              "BINV-22",
              "No visceral crisis and Prior endocrine therapy within 1 y",
              "Postmenopausal",
              "Systemic therapy",
              "Continue endocrine therapy until progression or unacceptable toxicity",
              "Progression",
              "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy",
              "Alternate systemic therapy",
              "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
              "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
            ]
          }
        }
      ],
      "answer": "In this clinical scenario, cytotoxic chemotherapy should be prioritized over further endocrine therapy as the next line of systemic treatment, since the patient experienced progression on endocrine therapy within the last year, which suggests endocrine resistance. This, combined with her postmenopausal status and absence of visceral crisis, supports initiation of chemotherapy rather than continuing ineffective endocrine therapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_12ab243ddac9",
      "question": "A 34-year-old woman presents with multiple, persistent rough papules on her hands, which have recurred despite prior cryotherapy. Her dermatologist prescribes an injectable medication that enhances antiviral immune responses by increasing expression of major histocompatibility complex molecules and activating natural killer cells. This agent is structurally analogous to endogenous cytokines and is used to treat certain refractory viral skin lesions. Which pharmacological class most accurately describes the mechanism by which this agent exerts its therapeutic effects?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Verruca vulgaris"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3665596",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0164613",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Biological Response Modifiers",
      "reasoning_path": "Refractory verruca vulgaris can be treated with interferons, which modulate immune responses as biological response modifiers to enhance viral clearance.",
      "umls_path": [
        "Verruca vulgaris",
        "may_be_treated_by",
        "Interferon Alfacon-1",
        "has_mechanism_of_action",
        "Biological Response Modifiers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has recurrent viral warts, commonly caused by human papillomavirus (HPV). When physical modalities like cryotherapy fail, immunomodulatory therapy may be considered. The prescribed agent works similarly to endogenous interferons—cytokines that play a key role in antiviral defense. Interferons stimulate immune cell activity (such as natural killer cells and cytotoxic T lymphocytes), upregulate antigen presentation, and induce antiviral gene expression in infected cells, thereby limiting viral replication. Pharmacologically, such agents are classified as biological response modifiers because they modulate the host's immune system rather than acting directly on the virus. This class includes interferons and other therapies that enhance or restore immune function, making them effective for recalcitrant viral infections like verruca vulgaris. Thus, the agent’s therapeutic mechanism is best described as a biological response modifier.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_fb0a1416f050",
      "question": "A 48-year-old woman with a history of methotrexate therapy for rheumatoid arthritis develops fatigue, glossitis, and laboratory findings of macrocytic anemia with low serum folate levels. Her physician initiates a rescue agent that is structurally similar to folic acid and can bypass the inhibited dihydrofolate reductase step, thereby restoring folate-dependent DNA synthesis. Through what key pharmacological mechanism does this agent facilitate cellular folate utilization in this clinical context?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Reduced blood folate concentration"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0016412",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0731033",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Phosphate chelating activity",
      "reasoning_path": "Methotrexate causes folate deficiency; leucovorin (a folate analog) is used as rescue therapy. Its phosphate chelating activity facilitates folate metabolism and cellular uptake, restoring folate-dependent processes.",
      "umls_path": [
        "Reduced blood folate concentration",
        "may_be_treated_by",
        "Leucovorin Calcium",
        "has_mechanism_of_action",
        "Phosphate Chelating Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s macrocytic anemia and low serum folate are consequences of methotrexate-induced folate deficiency, as methotrexate inhibits dihydrofolate reductase, disrupting folate metabolism and DNA synthesis. The clinician prescribes leucovorin (folinic acid), a reduced folate analog that can enter folate metabolic pathways without requiring dihydrofolate reductase. One of leucovorin’s pharmacological mechanisms involves phosphate chelating activity, which enhances its cellular uptake and utilization by modulating folate transport and stabilizing its active forms. This chelation helps maintain intracellular pools of tetrahydrofolate derivatives necessary for nucleotide biosynthesis, thereby reversing the effects of folate deficiency. Thus, phosphate chelating activity is a critical molecular mechanism by which leucovorin restores effective folate function in cells affected by antifolate drugs like methotrexate.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_3cc5f4f8bf3c",
      "question": "In a patient with pure tubular breast carcinoma that is ER-positive, HER2-negative, tumor size 2.7 cm, and axillary staging showing pN1mi (axillary node metastasis ≤2 mm), does considering adjuvant endocrine therapy implicitly require the presence of invasive disease features beyond the favorable histology and hormone receptor expression?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "Favorable histologic type: • Pure tubular • Pure mucinous • Pure cribriform • Adenoid cystic (conventional), secretory carcinoma, and other salivary carcinomas • Rare low-grade forms of metaplastic carcinoma • Other rare forms",
              "ER-positive and/or PR-positive or ER-negative and PR-negative",
              "Favorable Histologies (BINV-11)",
              "Pure tubular • Pure mucinous • Pure cribriform",
              "ER-positive and/or PR-positive, HER2-negative",
              "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
              "1–2.9 cm",
              "Consider adjuvant endocrine therapy",
              "Follow-Up (BINV-17)"
            ]
          }
        }
      ],
      "answer": "No; recommending adjuvant endocrine therapy in this scenario relies on the presence of hormone receptor positivity and acceptable nodal status, not on any disease features beyond the specified favorable histology, ER-positivity, HER2-negativity, tumor size, and pN1mi involvement.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_62e2a2fdb703",
      "question": "In a patient with stage IIIB squamous cell carcinoma of the lung and biopsy-confirmed N2 mediastinal lymph node involvement, is broad molecular profiling for EGFR, ALK, ROS1, and other mutations still recommended, or is such molecular testing primarily reserved for nonsquamous histologies?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
              "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Broad molecular profiling, including EGFR, ALK, ROS1, and other driver mutations, is primarily emphasized for nonsquamous NSCLC; however, it should still be considered for squamous cell carcinoma, especially in never-smokers or younger patients, as actionable mutations can occasionally be present.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_7e82a8276ccb",
      "question": "In women with ER-positive ductal carcinoma in situ (DCIS) treated with breast-conserving surgery and whole breast radiation therapy, does the recommendation for 5-year endocrine therapy implicitly assume that patients are free from significant thromboembolic risk factors?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "DCIS Tis,N0,M0, Encapsulated or solid papillary carcinoma (SPC)",
              "History and physical exam • Diagnostic bilateral mammogram • Pathology review • Determination of tumor estrogen receptor (ER) status • Genetic counseling for patients at risk of hereditary breast cancer • Breast MRI as indicated",
              "Breast-conserving surgery (BCS) without lymph node surgery",
              "Whole breast radiation therapy (WBRT) (category 1) with or without boost to tumor bed or Accelerated partial breast irradiation/partial breast irradiation (APBI/PBI) or No RT (category 2B)",
              "Postsurgical Treatment (DCIS-2)",
              "Risk reduction therapy for ipsilateral breast following BCS: • Consider endocrine therapy for 5 years for patients with ER-positive DCIS, if ➤ Treated with BCS and RT (category 1) ➤ Treated with excision alone • Endocrine therapy ➤ Tamoxifen for premenopausal patients ➤ Tamoxifen or aromatase inhibitor for postmenopausal patients with some advantage for aromatase inhibitor therapy in patients <60 years or with concerns for thromboembolism Risk reduction therapy for contralateral breast: • Counseling regarding risk reduction",
              "Interval history and physical exam every 6–12 mo for 5 y, then annually"
            ]
          }
        }
      ],
      "answer": "The recommendation for 5-year endocrine therapy in ER-positive DCIS after breast-conserving surgery and whole breast radiation does not universally assume the absence of thromboembolic risk. Instead, in postmenopausal women with elevated thromboembolic risk, aromatase inhibitors are preferred over tamoxifen due to a more favorable risk profile.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_2ca605b7374c",
      "question": "In a patient with stage IVA, M1b squamous cell carcinoma of the lung who has an EGFR exon 19 deletion, is first-line treatment with osimertinib combined with pemetrexed and platinum chemotherapy appropriate, or is this regimen restricted to nonsquamous histology only?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "EGFR exon 19 deletion or exon 21 L858R mutation positive",
              "EGFR exon 19 deletion or exon 21 L858R mutations",
              "EGFR mutation discovered prior to first-line systemic therapy",
              "Other Recommended: Osimertinib + pemetrexed + (cisplatin or carboplatin) (nonsquamous) (category 1)",
              "Progression, Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
            ]
          }
        }
      ],
      "answer": "The combination of osimertinib with pemetrexed and platinum chemotherapy is indicated specifically for EGFR-mutant nonsquamous non-small cell lung cancer. For squamous histology, this regimen is not recommended; EGFR-TKI monotherapy, such as osimertinib alone, is typically preferred if an EGFR mutation is present.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_01d13b744925",
      "question": "In a patient diagnosed with advanced or metastatic squamous cell carcinoma of the lung and confirmed RET rearrangement, should RET-targeted therapy be prioritized over conventional chemotherapy as first-line systemic treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "RET rearrangement positive"
            ]
          }
        }
      ],
      "answer": "In advanced or metastatic squamous cell lung cancer with a confirmed RET rearrangement, RET-targeted therapy is preferred as first-line systemic treatment over conventional chemotherapy, reflecting current recommendations to use targeted therapy when actionable mutations such as RET fusions are present.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_11b042dff7cf",
      "question": "A 58-year-old woman with a 10-year history of seropositive rheumatoid arthritis continues to experience joint swelling and morning stiffness despite trials of methotrexate, sulfasalazine, and a TNF-alpha inhibitor. Her rheumatologist initiates an oral small-molecule agent that blocks intracellular signaling pathways essential for cytokine-mediated immune activation. This medication specifically inhibits a cytoplasmic tyrosine kinase, disrupting the signal transduction of multiple interleukins and interferons. Which molecular target is directly inhibited by the drug, accounting for its therapeutic benefit in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Rheumatoid arthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003873",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4044947",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Tyrosine-Protein Kinase JAK1",
      "reasoning_path": "Baricitinib inhibits JAK1, blocking cytokine receptor signaling necessary for the inflammatory cascade in rheumatoid arthritis.",
      "umls_path": [
        "Rheumatoid arthritis",
        "may_be_treated_by",
        "Baricitinib",
        "has_target",
        "Tyrosine-Protein Kinase JAK1"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has refractory rheumatoid arthritis unresponsive to conventional and biologic DMARDs. The introduction of an oral small-molecule inhibitor points to a Janus kinase (JAK) inhibitor, such as baricitinib or tofacitinib. These agents act intracellularly to block the JAK-STAT pathway, which is critical for transducing signals from cytokine receptors to the nucleus. Specifically, baricitinib is a selective inhibitor of JAK1 and JAK2, but JAK1 is particularly crucial in mediating the signaling of pro-inflammatory cytokines (e.g., IL-6, interferons) that drive synovial inflammation and joint destruction in rheumatoid arthritis. By inhibiting JAK1, these drugs reduce cytokine-induced immune activation, leading to decreased inflammation, pain, and joint damage. The direct inhibition of tyrosine-protein kinase JAK1 is therefore the molecular mechanism underlying the therapeutic effect in this clinical scenario.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_e86103babce6",
      "question": "For a patient with pathologically confirmed stage IIA (T2b, N0) non–small cell lung cancer who has undergone complete surgical resection with negative margins (R0), is adjuvant systemic therapy routinely required, or is observation alone an appropriate initial management option?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Nodes negative",
              "Treatment (NSCL-9)",
              "T1, N0",
              "Operable",
              "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
              "Adjuvant Treatment (NSCL-4)",
              "Stage IIA (T2b, N0); Margins negative (R0)",
              "Observe or Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "Observation alone is an appropriate management option for patients with stage IIA (T2b, N0) non–small cell lung cancer who have undergone complete surgical resection with negative margins (R0); adjuvant systemic therapy is not routinely required in this setting and may be considered based on individual risk factors.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_9d64cc719c30",
      "question": "A 27-year-old woman presents with sore throat, fever, and difficulty swallowing for two days. Physical examination reveals erythematous pharyngeal mucosa with tonsillar exudates and tender anterior cervical lymphadenopathy. Rapid streptococcal antigen test is positive. She is prescribed an oral antibiotic that targets a critical bacterial enzyme involved in synthesizing the peptidoglycan layer of the cell wall. Which pharmacological class describes the primary mechanism through which this medication exerts its antimicrobial effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Pharyngitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0031350",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0007538",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme Inhibitors",
      "reasoning_path": "Patient with streptococcal pharyngitis is treated with a first-generation cephalosporin; these drugs inhibit bacterial enzymes (PBPs) essential for peptidoglycan synthesis, classifying them as enzyme inhibitors.",
      "umls_path": [
        "Pharyngitis",
        "may_be_treated_by",
        "Cefadroxil",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has acute streptococcal pharyngitis and is prescribed a first-generation cephalosporin, such as cefadroxil or cephalexin. These antibiotics belong to the beta-lactam class and act by binding to and inhibiting penicillin-binding proteins (PBPs), which are crucial bacterial enzymes necessary for cross-linking the peptidoglycan chains in the cell wall. This inhibition disrupts cell wall synthesis, leading to bacterial lysis and death. Thus, the primary mechanism of action is enzyme inhibition—specifically, inhibition of transpeptidase enzymes responsible for cell wall formation. This is the defining feature of the beta-lactam antibiotics and distinguishes them from other antimicrobial classes, such as protein synthesis or nucleic acid synthesis inhibitors. Therefore, the best description of this drug’s mechanism of action is 'enzyme inhibitors.'",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_e28a9151dfb2",
      "question": "A 12-year-old girl is brought to clinic after her teachers observed frequent brief episodes of staring and unresponsiveness during class, each lasting around 10 seconds and occurring multiple times daily. EEG reveals generalized 3-Hz spike-and-wave discharges. She is started on an anti-epileptic medication known to increase inhibitory neurotransmission by elevating brain GABA levels. Which molecular target is primarily responsible for mediating the drug's therapeutic effect in this form of epilepsy?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Absence Epilepsy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0014553",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0037567",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "GABA B receptor",
      "reasoning_path": "Absence epilepsy presents with generalized spike-and-wave activity; valproate is used to treat this by enhancing GABAergic neurotransmission, primarily via GABA B receptor activation.",
      "umls_path": [
        "Absence Epilepsy",
        "may_be_treated_by",
        "Valproate sodium",
        "has_mechanism_of_action",
        "GABA B Receptor Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Absence seizures are characterized by sudden, brief episodes of impaired awareness, often confirmed by characteristic EEG findings. One first-line medication for this condition is valproate sodium, which exerts its anti-epileptic effects through multiple mechanisms. A central mechanism involves enhancement of gamma-aminobutyric acid (GABA)–mediated inhibitory neurotransmission. Valproate increases GABA levels in the brain by inhibiting GABA transaminase and possibly by stimulating glutamic acid decarboxylase. The increased GABA then acts on GABA receptors, particularly the GABA B subtype, producing inhibitory postsynaptic potentials that dampen neuronal excitability and help prevent the abnormal synchronized firing responsible for absence seizures. Thus, the GABA B receptor is a key molecular mediator of valproate’s anti-epileptic action in this context.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_f5a7c759b4fe",
      "question": "A 60-year-old woman with a history of chronic knee pain and stiffness is diagnosed with osteoarthritis after radiographs reveal joint space narrowing and osteophyte formation. Her physician recommends a supplement that is a major component of the extracellular matrix in cartilage, aiming to slow progression of joint degeneration and alleviate symptoms. This agent is thought to act by interacting with large molecular structures in connective tissue, modifying cartilage metabolism and function. Which category best describes the principal molecular mechanism by which this therapy exerts its effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Cartilage disorder"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0007302",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0086999",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Biological macromolecular activity",
      "reasoning_path": "Osteoarthritis → loss of cartilage → sodium chondroitin sulfate supplementation → interacts with cartilage extracellular macromolecules → modifies matrix metabolism → classified as biological macromolecular activity.",
      "umls_path": [
        "Cartilage disorder",
        "may_be_treated_by",
        "Sodium chondroitin sulfate",
        "has_mechanism_of_action",
        "Biological Macromolecular Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Osteoarthritis is marked by the progressive loss of articular cartilage. Sodium chondroitin sulfate, a glycosaminoglycan naturally found in cartilage, is used as a supplement to support joint health. Its therapeutic effect is primarily achieved through interaction with biological macromolecules—specifically, it binds to components of the cartilage matrix, such as proteoglycans and collagen, enhancing water retention and inhibiting degradative enzymes like metalloproteinases. By modifying the molecular environment of the cartilage, it helps maintain structural integrity and reduce cartilage breakdown. This mechanism does not work via classic receptor-ligand pharmacology or enzyme inhibition, but rather by altering the activity and stability of macromolecular assemblies within the extracellular matrix. Thus, its principal molecular mechanism is classified as biological macromolecular activity, reflecting its role in modulating the function and metabolism of large biomolecules essential for cartilage health.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_fcbe11ad4078",
      "question": "What is the PMID for the 2025 article titled \"The challenges of indexing and impact factor in Latin American cardiology journals,\" authored by Piskorz DL and published in Archivos de cardiologia de Mexico?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"The challenges of indexing and impact factor in Latin American cardiology journals.\"[ti] AND Piskorz DL[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40445929"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_b31f3969aef0",
      "question": "In a patient with stage IIIB non-small cell lung cancer (T1–2, N3) and confirmed N3 disease through EBUS biopsy, does the presence of N3 lymph node involvement alone always exclude the possibility of surgical resection as initial therapy, regardless of pulmonary function test (PFT) results and absence of distant metastases?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "N3 nodes positive, M0",
              "Stage IIIB or Stage IIIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 3–4",
              "Systemic Therapy for Metastatic Disease (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, for stage IIIB non-small cell lung cancer (T1–2, N3) with pathologically confirmed N3 involvement, surgery is generally excluded as an initial treatment option, independent of pulmonary function and lacking distant metastases, as N3 disease denotes unresectable status by current oncologic standards.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_a780fbb744be",
      "question": "A 9-year-old boy diagnosed with a progressive neuromuscular disorder characterized by proximal muscle weakness is started on a new medication after his parents express concern about long-term corticosteroid side effects. The prescribed drug is reported to maintain anti-inflammatory efficacy while reducing risks such as growth suppression and bone demineralization. It achieves its effect by modulating a nuclear receptor that regulates transcription of inflammatory mediators. Which class of receptor modulators is primarily responsible for the therapeutic action of this medication in managing his condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Duchenne muscular dystrophy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0013264",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4726940",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Glucocorticoid receptor agonists",
      "reasoning_path": "Duchenne muscular dystrophy → steroid-sparing therapy → vamorolone → glucocorticoid receptor agonism → anti-inflammatory gene modulation.",
      "umls_path": [
        "Duchenne muscular dystrophy",
        "may_be_treated_by",
        "Vamorolone",
        "has_mechanism_of_action",
        "Glucocorticoid Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This vignette describes a child with Duchenne muscular dystrophy who is prescribed a novel anti-inflammatory agent in place of traditional corticosteroids. Agents like vamorolone are designed as steroid-sparing alternatives that retain the anti-inflammatory benefits of glucocorticoids but with a reduced side effect profile. These drugs achieve their clinical effect by agonizing the glucocorticoid receptor, a nuclear hormone receptor that, once activated, translocates to the nucleus and alters gene transcription—downregulating pro-inflammatory cytokines and upregulating anti-inflammatory mediators. This mechanism is central to their efficacy in reducing muscle inflammation and slowing disease progression in muscular dystrophies. Importantly, selective modulation of the glucocorticoid receptor can minimize adverse effects such as osteoporosis and growth inhibition, which are common with traditional corticosteroids. Therefore, glucocorticoid receptor agonism is the key mechanistic pathway for these newer agents.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_3c1185222b77",
      "question": "A 38-year-old woman presents with severe pain during and after defecation for the past two months. Examination reveals a linear tear in the posterior midline of the anal canal consistent with a chronic anal fissure. Conservative treatments with stool softeners and topical anesthetics have failed. Her colorectal surgeon recommends an injectable agent that locally reduces internal anal sphincter tone by inhibiting presynaptic neurotransmitter release at the neuromuscular junction. Which pharmacological class best describes the mechanism of action of this therapy?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Anal fissure"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0016167",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2719767",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Acetylcholine release inhibitors",
      "reasoning_path": "Anal fissures cause painful sphincter spasm; botulinum toxin A is injected to inhibit acetylcholine release at neuromuscular junctions, relaxing the sphincter. This places it in the acetylcholine release inhibitor class.",
      "umls_path": [
        "Anal fissure",
        "may_be_treated_by",
        "OnabotulinumtoxinA-containing product",
        "has_mechanism_of_action",
        "Acetylcholine Release Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Chronic anal fissures are often maintained by increased resting tone of the internal anal sphincter, which impairs blood flow and healing. When conservative measures fail, treatment may involve local injection of agents that reduce sphincter spasm. Botulinum toxin A is commonly used for this purpose. It acts by inhibiting the presynaptic release of acetylcholine at neuromuscular junctions, leading to temporary chemical denervation and relaxation of the internal anal sphincter. This reduction in sphincter pressure facilitates improved blood flow and promotes healing of the fissure. The primary pharmacological class for this mechanism is acetylcholine release inhibitors, which work by blocking neurotransmitter exocytosis, thus reducing muscle contraction.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_90c063fccd15",
      "question": "A 7-year-old girl is brought to the emergency department with recurrent severe nosebleeds and bruising. Laboratory testing reveals an undetectable fibrinogen level, prolonged thrombin time, and no family history of liver disease or anticoagulant use. She is diagnosed with a rare inherited disorder and receives intravenous plasma-derived concentrate containing the missing protein. This therapy enables thrombin to catalyze its substrate, ultimately forming a stable blood clot. Which pharmacological class best describes the mechanism by which this replacement therapy restores hemostasis in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Afibrinogenemia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001733",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0016006",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme activators",
      "reasoning_path": "Congenital afibrinogenemia lacks fibrinogen, preventing thrombin from forming fibrin. Fibrinogen replacement therapy supplies the substrate, allowing thrombin to catalyze clot formation—an enzyme activation mechanism.",
      "umls_path": [
        "Afibrinogenemia",
        "may_be_treated_by",
        "Fibrinogen",
        "has_mechanism_of_action",
        "Enzyme Activators"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In congenital afibrinogenemia, the absence of functional fibrinogen impairs the final step of the coagulation cascade, where thrombin normally converts fibrinogen into fibrin to form a stable clot. Plasma-derived fibrinogen replacement reintroduces the missing substrate, allowing thrombin (an enzyme) to catalyze fibrin formation. By providing the necessary substrate for thrombin's enzymatic activity, this therapy effectively 'activates' the enzyme's physiological function. Therefore, the pharmacological action is best described as enzyme activation, since the replacement enables the coagulation enzyme (thrombin) to perform its natural role and restore hemostasis.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_f06330a0bed3",
      "question": "A 34-year-old traveler returning from sub-Saharan Africa develops fever, chills, and confusion. Blood smear reveals ring-shaped trophozoites within erythrocytes, consistent with Plasmodium falciparum infection. He is started on an intravenous medication that targets the parasite’s ability to replicate by disrupting the formation of key nucleic acids. Through which drug class mechanism does this therapy exert its primary antimalarial effect at the molecular level?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Falciparum malaria [malignant tertian]"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0024535",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0034421",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Nucleic Acid Synthesis Inhibitors",
      "reasoning_path": "Severe falciparum malaria—treated with quinine hydrochloride—inhibits parasite nucleic acid synthesis, classifying it as a nucleic acid synthesis inhibitor.",
      "umls_path": [
        "Falciparum malaria [malignant tertian]",
        "may_be_treated_by",
        "Quinine hydrochloride",
        "has_mechanism_of_action",
        "Nucleic Acid Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient is diagnosed with severe falciparum malaria, a potentially life-threatening infection requiring immediate treatment. Quinine hydrochloride is used for severe cases when resistance or intolerance to other agents occurs. Quinine acts by inhibiting the parasite’s nucleic acid synthesis, interfering with DNA and RNA formation necessary for parasite replication and survival. By disrupting nucleic acid synthesis, quinine impedes the growth and division of Plasmodium falciparum within red blood cells, thereby reducing parasitemia and resolving infection. Although quinine also interferes with heme polymerization, its main nucleic-targeted action is inhibition of nucleic acid synthesis, which underlies its clinical efficacy in this scenario.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_f945af2d5646",
      "question": "In a patient with newly diagnosed stage IVA non-small cell lung cancer (NSCLC) of adenocarcinoma histology, who has an ECOG performance status of 1, comprehensive molecular profiling shows no actionable alterations and PD-L1 expression is 3%. If the patient also has advanced heart failure (NYHA class III), is immune checkpoint inhibitor monotherapy still an appropriate first-line treatment option?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "PD-L1 ≥1% and negative for actionable molecular biomarkers above",
              "PD-L1 POSITIVE (≥1%)",
              "PS 0–2",
              "Biomarker-directed therapy (NSCL-J 2 of 6)",
              "Progression",
              "Systemic Therapy (NSCL-K 1 of 5) or Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
            ]
          }
        }
      ],
      "answer": "Immune checkpoint inhibitor monotherapy remains an appropriate first-line treatment in cases with PD-L1 ≥1% and no actionable mutations, irrespective of advanced heart failure status, provided the patient has performance status 0–2 and no absolute contraindication to immunotherapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_8a25bc203b5d",
      "question": "A 27-year-old woman with a history of seasonal allergies presents with several weeks of bilateral eye itching, redness, and watery discharge. Slit-lamp examination reveals conjunctival injection and papillary hypertrophy, consistent with a diagnosis of atopic conjunctivitis. To manage her symptoms, her ophthalmologist prescribes a topical nonsteroidal anti-inflammatory drug that exerts its effect by blocking the conversion of arachidonic acid to pro-inflammatory mediators. Which specific enzyme is directly inhibited by this therapy, leading to reduced ocular inflammation?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Atopic Conjunctivitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0009766",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0064326",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 1 (COX-1)",
      "reasoning_path": "Atopic conjunctivitis causes ocular inflammation. Topical NSAIDs like ketorolac block COX enzymes. The primary target is Prostaglandin G/H Synthase 1 (COX-1), which catalyzes prostaglandin production. Inhibition of this enzyme reduces inflammatory mediators and symptoms.",
      "umls_path": [
        "Atopic Conjunctivitis",
        "may_be_treated_by",
        "Ketorolac Tromethamine",
        "has_target",
        "Prostaglandin G/H Synthase 1"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient’s atopic conjunctivitis is characterized by immune-mediated inflammation of the conjunctiva, with symptoms such as itching, redness, and discharge. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as topical ketorolac, are often used to reduce inflammation by inhibiting cyclooxygenase (COX) enzymes. The main molecular target of these drugs is Prostaglandin G/H Synthase 1, also known as cyclooxygenase-1 (COX-1). By inhibiting COX-1 activity, ketorolac blocks the conversion of arachidonic acid to prostaglandins, which are critical mediators of inflammation, vasodilation, and pain. Reduction in prostaglandin synthesis leads to decreased conjunctival inflammation, alleviating the patient’s ocular symptoms. Thus, the therapeutic effect of topical NSAIDs in atopic conjunctivitis is achieved primarily through direct inhibition of Prostaglandin G/H Synthase 1.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_fe7828d3f3ed",
      "question": "In a premenopausal woman with ER-positive, HER2-negative metastatic breast cancer who has developed disease progression after first-line endocrine therapy, is it necessary to continue ovarian suppression if switching to subsequent lines of systemic therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Metastatic (M1) invasive breast cancer",
              "Stage IV (M1) or Recurrent disease",
              "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
              "Stage IV (M1) or Recurrent",
              "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
              "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
              "Recurrent unresectable (local or regional) or stage IV (M1) disease",
              "Bone disease present",
              "Add denosumab zoledronic acid, or pamidronate",
              "ER- and/or PR-positive; HER2-negative",
              "BINV-22",
              "No visceral crisis and Prior endocrine therapy within 1 y",
              "Premenopausal",
              "Ovarian ablation or suppression + systemic therapy",
              "Continue endocrine therapy until progression or unacceptable toxicity",
              "Progression",
              "Progression or unacceptable toxicity on first-line endocrine therapy",
              "Systemic therapy",
              "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
              "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
            ]
          }
        }
      ],
      "answer": "Yes; ovarian ablation or suppression must be maintained in premenopausal women with ER-positive, HER2-negative metastatic breast cancer throughout all lines of systemic therapy, as ongoing ovarian estrogen production would otherwise diminish the efficacy of endocrine-based and most systemic treatments.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_313d70db8c42",
      "question": "For a patient with non-small cell lung cancer who has no evidence of disease after initial surgery and chemotherapy for stage II disease, is routine use of FDG-PET/CT appropriate during the first three years of surveillance if there is no clinical or radiographic suspicion of recurrence?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Disseminated metastases",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "No, routine use of FDG-PET/CT is not appropriate in this scenario. In asymptomatic patients with no evidence of recurrence on regular assessment following curative-intent treatment for stage I–II disease, standard surveillance includes history, physical examination, and chest CT imaging only. FDG-PET/CT should be reserved for evaluation when recurrence is suspected.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_405ab28a6fb4",
      "question": "In a patient with Stage II non-small cell lung cancer who underwent definitive radiotherapy as primary treatment, is routine use of FDG-PET/CT and brain MRI with contrast indicated during scheduled surveillance imaging when there is no evidence of clinical or radiographic disease?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
              "R2; Resection + systemic therapy or Concurrent chemoradiation",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, for Stage II non-small cell lung cancer patients treated with definitive radiotherapy and without clinical or radiographic evidence of disease, routine surveillance does not include FDG-PET/CT or brain MRI with contrast; scheduled follow-up consists of physical examination and chest CT at defined intervals.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_85a4bdf0e110",
      "question": "In a patient with clinically operable, non-metastatic invasive breast cancer (M0), presenting with a single suspicious axillary lymph node on imaging that is confirmed malignant by core biopsy and marked with a clip, is axillary lymph node dissection (ALND) always mandated after preoperative systemic therapy, or is sentinel lymph node biopsy (SLNB) alone sufficient if only the marked node remains positive?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS possible",
              "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
              "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
              "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
              "FNA or core biopsy positive",
              "Consider preoperative chemotherapy",
              "No preoperative chemotherapy",
              "ALND level I/II"
            ]
          }
        }
      ],
      "answer": "ALND is generally mandated if axillary lymph node metastasis is confirmed by biopsy before preoperative systemic therapy, regardless of the number of suspicious nodes; SLNB alone is not sufficient in this situation, as removal of the marked node along with SLNs does not replace the need for ALND when residual nodal disease is present.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_d573534ae961",
      "question": "A 28-year-old woman presents to her primary care clinic with a three-day history of sore throat, difficulty swallowing, and low-grade fever. Physical examination reveals erythematous tonsils with exudates and tender anterior cervical lymphadenopathy. Her physician diagnoses her with acute bacterial pharyngitis and prescribes a second-generation cephalosporin. This antibiotic works by binding to and inhibiting bacterial penicillin-binding proteins, thereby disrupting transpeptidation and ultimately compromising the integrity of the bacterial cell wall. Which general class of molecular mechanism underlies the therapeutic action of this medication in treating her infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Pharyngitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0031350",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0701852",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme inhibition (specifically inhibition of bacterial penicillin-binding proteins)",
      "reasoning_path": "Acute pharyngitis (bacterial) → treated with cefuroxime → cefuroxime binds/inhibits PBPs → disrupts cell wall synthesis → bacterial death → enzyme inhibition is key mechanism.",
      "umls_path": [
        "Pharyngitis",
        "may_be_treated_by",
        "Cefuroxime Sodium",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In cases of acute bacterial pharyngitis, second-generation cephalosporins like cefuroxime are prescribed due to their efficacy against common pathogens such as Streptococcus pyogenes. Cefuroxime functions by targeting and binding to bacterial penicillin-binding proteins (PBPs), which are critical enzymes involved in the final stages of bacterial cell wall synthesis. By inhibiting these enzymes, cefuroxime disrupts the cross-linking of the peptidoglycan layer, leading to weakened cell walls, bacterial lysis, and death. This action classifies cefuroxime as an enzyme inhibitor—more specifically, a bacterial cell wall synthesis inhibitor via PBP inhibition. Thus, the drug’s molecular therapeutic mechanism is best described as enzyme inhibition, which underpins its clinical utility in eradicating the causative bacteria in pharyngitis.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_519d6c406938",
      "question": "In a patient with stage IIB NSCLC who underwent surgical resection with positive margins (R1), is concurrent chemoradiation preferred over sequential chemoradiation, or are both considered equally appropriate options?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
              "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "For stage IIB NSCLC with positive surgical margins (R1), both concurrent and sequential chemoradiation are considered acceptable post-operative options. Current evidence does not establish superiority of one approach over the other; selection should be based on patient tolerance and comorbidities rather than a clear inherent preference for concurrent therapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_bdf07bd9a308",
      "question": "A 59-year-old man presents to the emergency department with chest pain that began at rest and has persisted for the past hour. His ECG shows no ST-segment elevation, but laboratory tests reveal mild cardiac enzyme elevation. He is diagnosed with an acute coronary syndrome without ST elevation and is started on an intravenous medication to reduce the risk of further thrombus formation. This agent works by potentiating the activity of antithrombin III, leading to inhibition of a central serine protease in the coagulation cascade, thereby limiting conversion of fibrinogen to fibrin. Which class of medications is responsible for this therapeutic effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Intermediate coronary syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002965",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0019134",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Thrombin inhibitors",
      "reasoning_path": "Acute coronary syndrome without ST elevation is treated with heparin, which potentiates antithrombin III to inhibit thrombin and thus suppresses clot formation.",
      "umls_path": [
        "Intermediate coronary syndrome",
        "may_be_treated_by",
        "Heparin",
        "has_mechanism_of_action",
        "Thrombin Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has non–ST-elevation acute coronary syndrome (a clinical scenario that includes intermediate coronary syndrome). In this setting, rapid anticoagulation is required to prevent progression of intravascular thrombosis. The primary anticoagulant used acutely is heparin, which exerts its effect by enhancing the activity of antithrombin III. Antithrombin III inactivates several enzymes of the coagulation cascade, most notably thrombin (factor IIa), a central serine protease. By inhibiting thrombin, heparin blocks the conversion of fibrinogen to fibrin, thereby preventing further clot formation and propagation. The key molecular target in this context is thrombin, and agents that inhibit it (thrombin inhibitors) are the relevant class for this mechanism.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_1faac1922877",
      "question": "In a patient with localized, non-inflammatory, non-metastatic (M0) breast cancer, clinical stage cT2, ER-negative, PR-negative, and HER2-positive, who undergoes total mastectomy and has a pT2 tumor with pN1mi (≤2 mm axillary node metastasis), does eligibility for adjuvant chemotherapy combined with trastuzumab require the tumor to be ductal/NST, lobular, mixed, or micropapillary subtype, or is metaplastic carcinoma also included?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
              "ER-negative and PR-negative",
              "HER2-positive",
              "BINV-9",
              "Ductal/NST, Lobular, Mixed, Micropapillary",
              "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
              "Tumor ≤0.5 cm",
              "pN0 Consider adjuvant chemotherapy with trastuzumab (category 2B)"
            ]
          }
        }
      ],
      "answer": "Eligibility for adjuvant chemotherapy with trastuzumab in this clinical context requires the tumor to be ductal/NST, lobular, mixed, or micropapillary subtype; metaplastic carcinoma is not included among the specified eligible histologic subtypes.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_004b741d67c7",
      "question": "A 34-year-old woman is brought to the emergency department after suddenly developing palpitations and lightheadedness. ECG reveals a narrow QRS complex tachycardia at 180 bpm with no visible P waves. A rapid intravenous bolus of a short-acting agent is administered, which abruptly restores normal sinus rhythm within seconds. This medication acts by binding to specific cell-surface receptors, triggering conformational changes in intracellular signaling complexes, and ultimately slowing conduction through the atrioventricular node. Which general category of biological targets is directly responsible for mediating this drug’s therapeutic effect in acute supraventricular tachycardia?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Re-entrant atrioventricular node tachycardia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0039232",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3256589",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Structural macromolecules (purinergic receptors)",
      "reasoning_path": "SVT → adenosine IV → binds purinergic (A1) receptors (structural macromolecules) → AV nodal conduction blocked → sinus rhythm restored.",
      "umls_path": [
        "Re-entrant atrioventricular node tachycardia",
        "may_be_treated_by",
        "ADENOSINE PHOSPHATE DISODIUM",
        "has_mechanism_of_action",
        "Structural Macromolecules"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient experienced paroxysmal supraventricular tachycardia (PSVT), most commonly due to AV nodal reentrant tachycardia. The first-line therapy for acute termination is a rapid IV push of adenosine, which acts on A1-type purinergic receptors (structural macromolecules) on cardiac cells. Binding of adenosine to these G protein-coupled receptors activates intracellular pathways that increase potassium efflux and decrease calcium influx, hyperpolarizing the AV node and transiently blocking conduction. This effectively interrupts the reentrant circuit and restores normal sinus rhythm. Thus, the drug’s therapeutic effect is mediated by direct interaction with structural macromolecules—specifically, purinergic receptors—rather than enzymes, ion channels, or nucleic acids.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_36aefb952d97",
      "question": "In a patient with advanced squamous cell carcinoma of the lung who is found to harbor an EGFR exon 20 insertion mutation, is the use of amivantamab-vmjw as systemic therapy predicated upon the completion of broad molecular profiling for other actionable genetic alterations?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "EGFR exon 20 insertion mutation positive",
              "EGFR exon 20 insertion mutation",
              "Systemic therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
              "Tumor response evaluation",
              "Progression",
              "Amivantamab-vmjw",
              "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
            ]
          }
        }
      ],
      "answer": "The use of amivantamab-vmjw specifically targets tumors with EGFR exon 20 insertion mutations and is not contingent on identification of other actionable mutations. However, comprehensive molecular profiling is recommended to exclude the presence of additional targetable alterations, which may influence therapy selection.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_237de4f3a388",
      "question": "In ClinicalTrials.gov, which interventional studies for Hepatitis C involving Pegylated Interferon Alfa 2a were started in March 2008 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "conditions=Hepatitis C;interventions.name=Pegylated Interferon Alfa 2a;startDateFrom=2008-03-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00627926"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_d3dadf5d56c8",
      "question": "A 64-year-old woman with a longstanding history of progressive central vision loss is enrolled in a clinical trial investigating a novel treatment for her condition. She receives subcutaneous injections of a recombinant cytokine known to modulate immune cell signaling and gene expression, ultimately altering the activity of multiple immune system pathways. Which drug class mechanism best explains the pharmacological action of this therapy in her disease?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Macular Degeneration"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0024437",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0244714",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Biological response modifier—modulation of immune responses",
      "reasoning_path": "Interferon beta 1b is a recombinant cytokine that acts as a biological response modifier, modulating immune responses through gene regulation and immune cell signaling.",
      "umls_path": [
        "Macular Degeneration",
        "may_be_treated_by",
        "Interferon beta 1b (recombinant)",
        "has_mechanism_of_action",
        "Biological Response Modifiers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with age-related macular degeneration is receiving interferon beta 1b, a recombinant form of a naturally occurring cytokine. Interferon beta 1b acts as a biological response modifier: it binds to cell-surface interferon receptors, initiating a cascade of intracellular signaling events that lead to the transcriptional regulation of numerous genes involved in immunity and inflammation. Through these actions, it modulates the function and activity of various immune cells—such as T cells, B cells, and macrophages—thereby altering the overall immune response. In the context of macular degeneration, the rationale for using interferon beta 1b lies in its potential to reduce pathological inflammation and immune-mediated tissue damage within the retina. The key pharmacological mechanism is not direct suppression of a single immune effector, but rather a broad modulation of immune system activity, fitting the definition of a biological response modifier.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_b0fcdd778253",
      "question": "In a patient with advanced non-squamous non-small cell lung cancer showing a KRAS G12C mutation, is it appropriate to prioritize targeted therapy against KRAS G12C over immunotherapy if programmed death ligand 1 (PD-L1) expression is high (≥50%)?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "KRAS G12C mutation positive"
            ]
          }
        }
      ],
      "answer": "For advanced NSCLC with a confirmed KRAS G12C mutation, current evidence supports prioritizing KRAS G12C-targeted therapy (such as sotorasib) after progression on first-line therapy. In cases of high PD-L1 expression (≥50%), first-line immunotherapy with or without chemotherapy remains the preferred initial option, as targeted KRAS therapy is typically reserved for subsequent lines.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_95946b601511",
      "question": "In the OpenTargets platform, what tractability information is available for the target with Ensembl ID ENSG00000140443 and approved symbol IGF1R, where the value is True?",
      "tool_calls": [
        {
          "tool": "opentargets.tractability",
          "params": {
            "target_id": "ENSG00000140443",
            "value": true
          }
        }
      ],
      "answer": [
        {
          "modality": "SM",
          "label": "Approved Drug"
        },
        {
          "modality": "SM",
          "label": "Structure with Ligand"
        },
        {
          "modality": "SM",
          "label": "High-Quality Ligand"
        },
        {
          "modality": "SM",
          "label": "High-Quality Pocket"
        },
        {
          "modality": "SM",
          "label": "Druggable Family"
        },
        {
          "modality": "AB",
          "label": "Approved Drug"
        },
        {
          "modality": "AB",
          "label": "UniProt loc high conf"
        },
        {
          "modality": "AB",
          "label": "GO CC high conf"
        },
        {
          "modality": "AB",
          "label": "UniProt SigP or TMHMM"
        },
        {
          "modality": "PR",
          "label": "Literature"
        },
        {
          "modality": "PR",
          "label": "UniProt Ubiquitination"
        },
        {
          "modality": "PR",
          "label": "Database Ubiquitination"
        },
        {
          "modality": "PR",
          "label": "Half-life Data"
        },
        {
          "modality": "PR",
          "label": "Small Molecule Binder"
        },
        {
          "modality": "OC",
          "label": "Approved Drug"
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "path_df3b7f09cff8",
      "question": "For a patient with stage IIIA (T2, N2) non-small cell lung cancer who is a non-smoker and has squamous cell carcinoma histology, is it necessary to perform molecular testing for EGFR, ALK, and ROS1 mutations as part of initial diagnostic workup?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Yes. Current practice supports broad molecular profiling—including EGFR, ALK, and ROS1 testing—for all patients with advanced or metastatic non-small cell lung cancer, regardless of smoking history or squamous histology, provided sufficient tissue is available, as actionable targets may be present even in non-typical populations.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_2e3340f9d123",
      "question": "A 32-year-old immunocompetent woman presents with multiple, persistent, flesh-colored papules on her hands and fingers that have not responded to cryotherapy or topical salicylic acid. After referral, she is enrolled in a clinical trial testing an oral agent that antagonizes a chemokine receptor critical for T-cell and dendritic cell migration. Blocking this receptor is hypothesized to disrupt the local immune environment supporting viral persistence. Which molecular target does this experimental therapy most directly affect to exert its action in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Verruca vulgaris"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3665596",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2930725",
            "rela": "has_target"
          }
        }
      ],
      "answer": "C-X-C Chemokine Receptor Type 4 (CXCR4)",
      "reasoning_path": "The patient has recalcitrant HPV warts; a drug (Mavorixafor) targeting CXCR4 is used to alter immune trafficking, promoting clearance of verruca vulgaris by antagonizing this chemokine receptor.",
      "umls_path": [
        "Verruca vulgaris",
        "may_be_treated_by",
        "Mavorixafor",
        "has_target",
        "C-X-C Chemokine Receptor Type 4"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Verruca vulgaris, or common warts, result from human papillomavirus (HPV) infection of the skin. Persistence is partly due to local immune evasion. CXCR4 is a chemokine receptor that mediates trafficking of various immune cells, including T lymphocytes and dendritic cells, to sites of inflammation or infection. Novel therapies such as Mavorixafor inhibit CXCR4, thereby altering immune cell migration and the local immune milieu. In the context of persistent verruca vulgaris, antagonizing CXCR4 may enhance viral clearance by modulating immune surveillance and breaking HPV-induced immune tolerance. Thus, the primary molecular target of this therapeutic approach is CXCR4.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_c73b031364a7",
      "question": "In a patient with advanced squamous cell carcinoma of the lung who has experienced mediastinal lymph node recurrence after prior radiotherapy and whose tumor is positive only for an EGFR G719X mutation (without other classical activating EGFR mutations), is it appropriate to consider EGFR-targeted therapy as the primary systemic treatment option over conventional chemotherapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "EGFR S768I, L861Q, and/or G719X mutation positive"
            ]
          }
        }
      ],
      "answer": "EGFR-targeted therapy can be considered in squamous cell carcinoma harboring an EGFR G719X mutation; however, the evidence for efficacy is limited compared to classical EGFR mutations, and platinum-based chemotherapy remains the preferred standard first-line systemic treatment for this histologic subtype, particularly post-radiotherapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_320f04de8ea2",
      "question": "A 28-year-old woman with a history of narcolepsy experiences frequent episodes of sudden muscle weakness triggered by laughter or surprise, but remains fully conscious during these spells. Her neurologist prescribes an oral medication taken nightly that is effective for her symptoms, though the drug's precise mode of action at the cellular level is not fully delineated in current scientific literature. Which best describes the mechanism by which this therapy alleviates her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Cataplexy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0007384",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C5398274",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Cataplexy is treated with potassium oxybate, but the exact cellular or molecular target and mechanism for its therapeutic benefit are not clearly established.",
      "umls_path": [
        "Cataplexy",
        "may_be_treated_by",
        "Potassium oxybate",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has narcolepsy with cataplexy, characterized by sudden, reversible loss of muscle tone. The mainstay pharmacologic therapy is potassium oxybate (also known as sodium oxybate), which is effective at reducing episodes of cataplexy. While its clinical efficacy is well established, the drug’s precise cellular or molecular mechanism of action remains unclear. Potassium oxybate is known to influence sleep architecture and may affect GABAergic neurotransmission, dopamine, and other neurotransmitter systems, but no definitive molecular pathway has been identified. Thus, its therapeutic effect is best described as involving an unknown cellular or molecular interaction.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_1d90a65b3c20",
      "question": "In patients with non-small cell lung cancer (NSCLC) and confirmed stage IIIA disease due to positive mediastinal lymph nodes, does the presence of separate pulmonary nodule(s) in the same lobe alter the indication for perioperative therapy, or is systemic therapy for metastatic disease required instead?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "For stage IIIA NSCLC with positive mediastinal nodes, separate pulmonary nodules confined to the same lobe do not change the indication for perioperative therapy; management remains surgical or multimodal with curative intent. Systemic therapy for metastatic disease is considered only if nodules are in a different lobe or lung, which would upstage the disease to stage IV.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_0e53f4c7f578",
      "question": "For a patient with stage IIIA non-small cell lung cancer (T1–2, N2; T3, N1) who has undergone complete (R0) surgical resection followed by sequential chemotherapy, is routine FDG-PET/CT or brain MRI with contrast indicated during surveillance if there is no clinical or radiographic evidence of disease recurrence?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
              "Sequential chemotherapy and consider RT",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, in the absence of clinical or radiographic evidence of recurrence, routine use of FDG-PET/CT or brain MRI with contrast is not indicated for post-treatment surveillance in stage IIIA non-small cell lung cancer; follow-up should focus on history, physical examination, and chest CT at recommended intervals.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_95ca7742f78a",
      "question": "For a patient with stage IIA (T2b, N0) non-small cell lung cancer who underwent complete surgical resection (R0), if follow-up chest imaging reveals equivocal small pulmonary nodules but no clear radiographic evidence of recurrence, does the recommended surveillance protocol mandate the use of routine FDG-PET/CT or brain MRI with contrast for further assessment at this stage?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIA (T2b, N0); Margins negative (R0)",
              "Observe or Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, in the absence of clinical or definitive radiographic evidence of disease recurrence after R0 resection for stage IIA (T2b, N0) NSCLC, routine FDG-PET/CT and brain MRI with contrast are not indicated during surveillance; these modalities are reserved for evaluating suspected recurrence, not for routine follow-up in asymptomatic patients.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_6228c555007b",
      "question": "For a patient with operable non-small cell lung cancer staged as T1, N0 who undergoes complete surgical resection with negative margins, is postoperative adjuvant therapy routinely indicated, or is surveillance considered sufficient in the absence of high-risk pathological features?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Nodes negative",
              "Treatment (NSCL-9)",
              "T1, N0",
              "Operable",
              "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
              "Adjuvant Treatment (NSCL-4)",
              "Stage IIA (T2b, N0); Margins positive (R1, R2)",
              "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "In operable non-small cell lung cancer patients with T1, N0 staging and complete resection with negative margins, adjuvant therapy is not routinely indicated; surveillance alone is considered sufficient unless additional high-risk pathological features are identified.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_3ee9afb9d79f",
      "question": "In a patient with advanced non–small cell lung cancer (adenocarcinoma subtype) who is negative for all actionable molecular biomarkers and has a PD-L1 tumor proportion score less than 1%, but whose performance status deteriorates to ECOG 3, is initial systemic therapy still considered appropriate, or should best supportive care take precedence?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "PD-L1 <1% and negative for actionable molecular biomarkers above",
              "PD-L1 <1%",
              "INITIAL SYSTEMIC THERAPY",
              "PS 0–2",
              "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
              "Tumor response evaluation",
              "Progression",
              "PS 3–4",
              "Best supportive care NCCN Guidelines for Palliative Care"
            ]
          }
        }
      ],
      "answer": "For advanced non–small cell lung cancer patients with adenocarcinoma histology, no actionable molecular alterations, and PD-L1 <1%, initial systemic therapy is indicated only for those with ECOG performance status 0–2. If performance status is ECOG 3–4, systemic therapy is not recommended, and best supportive care becomes the primary approach.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_2c8659e83107",
      "question": "A 32-year-old veterinarian presents with a five-day history of fever, malaise, and tender, erythematous papules on her forearms. She reports frequent contact with stray cats. Blood cultures grow a fastidious Gram-negative bacillus. She is started on an antibiotic that exerts its effect by binding to the 30S subunit of the bacterial ribosome, disrupting aminoacyl-tRNA attachment and halting polypeptide elongation. Which pharmacological class best describes the drug’s mechanism of action responsible for treating her infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Bartonellosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004771",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0039644",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Protein synthesis inhibitors",
      "reasoning_path": "Bartonellosis (cat scratch disease) → treated with tetracyclines → tetracyclines bind 30S ribosomal subunit → inhibit protein synthesis → protein synthesis inhibitors.",
      "umls_path": [
        "Bartonellosis",
        "may_be_treated_by",
        "Tetracycline",
        "has_mechanism_of_action",
        "Protein Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s presentation and occupational exposure suggest cat scratch disease, a form of bartonellosis caused by Bartonella henselae, a Gram-negative organism. The typical first-line treatment involves antibiotics that target bacterial protein synthesis. Tetracyclines, commonly used in this setting, function by binding to the 30S ribosomal subunit. This binding prevents the attachment of aminoacyl-tRNA to the mRNA-ribosome complex, effectively blocking translation and subsequent protein synthesis. Without the ability to synthesize essential proteins, the bacteria cannot grow or replicate, leading to resolution of the infection. Therefore, the primary pharmacological class responsible for the therapeutic effect in this scenario is protein synthesis inhibitors.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_8598e3d42ef3",
      "question": "A 42-year-old woman with a history of ulcerative colitis presents with multiple rapidly enlarging, painful ulcerations on her lower legs, exhibiting violaceous undermined borders and purulent bases. After excluding infection and vasculitis, her dermatologist diagnoses her with a neutrophilic dermatosis and initiates an oral medication that belongs to the sulfonamide class. This drug exerts both antimicrobial and anti-inflammatory actions by competitively inhibiting an enzyme involved in bacterial folate synthesis, as well as suppressing neutrophil chemotaxis. Through which molecular mechanism does this medication most directly achieve its therapeutic effects in this patient’s condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Pyoderma gangrenosum"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0085652",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0038710",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Inhibition of para-aminobenzoic acid (PABA) utilization in folate synthesis",
      "reasoning_path": "Patient has pyoderma gangrenosum → treated with sulfapyridine (a sulfonamide) → sulfonamides inhibit PABA utilization in folate synthesis → mechanism underlies both antimicrobial and anti-inflammatory effects.",
      "umls_path": [
        "Pyoderma gangrenosum",
        "may_be_treated_by",
        "Sulfapyridine",
        "has_mechanism_of_action",
        "Para-Aminobenzoic Acid Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient exhibits classic features of pyoderma gangrenosum, a neutrophilic dermatosis often associated with inflammatory bowel disease. Sulfapyridine, a sulfonamide, is sometimes used off-label for this disorder because of its dual antimicrobial and anti-inflammatory properties. At the molecular level, sulfonamides act as structural analogues of para-aminobenzoic acid (PABA), competitively inhibiting dihydropteroate synthase in the bacterial folate synthesis pathway. This blocks tetrahydrofolate production, which is essential for DNA synthesis in microbes. Although pyoderma gangrenosum is not caused by infection, the immunomodulatory (anti-inflammatory) effects of sulfonamides, including inhibition of neutrophil function, also contribute to improvement. However, the primary and most direct molecular mechanism is the inhibition of PABA utilization, disrupting folate synthesis. This effect underpins both the antimicrobial and, in part, the anti-inflammatory actions relevant to treatment.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_f91e7bdb5bfa",
      "question": "A 58-year-old woman with a long-standing history of symmetric polyarthritis and morning stiffness is started on a disease-modifying agent after inadequate response to NSAIDs and methotrexate. The medication, administered intramuscularly, contains a gold compound and is noted to reduce joint swelling and slow radiographic progression, though its exact intracellular target remains uncertain. What is the current understanding of the cellular or molecular mechanism by which this agent exerts its therapeutic effects in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Rheumatoid arthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003873",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0018033",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The precise cellular or molecular mechanism of action of gold compounds such as aurothioglucose in rheumatoid arthritis remains undetermined.",
      "reasoning_path": "Aurothioglucose has been used to treat rheumatoid arthritis, but the specific cellular or molecular mechanism mediating its therapeutic effects remains undetermined.",
      "umls_path": [
        "Rheumatoid arthritis",
        "may_be_treated_by",
        "Aurothioglucose-containing product",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Aurothioglucose is a gold-based disease-modifying antirheumatic drug (DMARD) historically used to treat rheumatoid arthritis by decreasing inflammation and joint damage. Despite evidence of clinical benefit, the specific molecular interactions involved in its anti-inflammatory effects have not been clearly elucidated. While some studies suggest gold compounds may interfere with immune cell function, cytokine production, or lysosomal enzyme activity, no definitive cellular target or pathway has been established. As a result, the mechanistic basis for gold’s therapeutic action in rheumatoid arthritis is still considered unknown according to current scientific understanding.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_e3e2c9354a8a",
      "question": "A 50-year-old individual presents with chronic blistering lesions on the dorsal hands and forearms, accompanied by increased skin fragility and hyperpigmentation. Laboratory analysis reveals elevated urinary uroporphyrins, and a diagnosis of a hepatic porphyrin metabolism disorder is made. The patient is initiated on a medication that increases porphyrin excretion by altering lysosomal pH and interfering with heme synthesis enzyme activity. Which drug class characterizes the mechanism by which this therapy reduces the toxic metabolite buildup in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Porphyria Cutanea Tarda"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0162566",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020336",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme Inhibitors",
      "reasoning_path": "Porphyria cutanea tarda results from impaired heme synthesis enzyme activity; hydroxychloroquine treats this by inhibiting enzymes in the pathway, classifying it as an enzyme inhibitor.",
      "umls_path": [
        "Porphyria Cutanea Tarda",
        "may_be_treated_by",
        "Hydroxychloroquine",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has porphyria cutanea tarda (PCT), a disorder characterized by deficient activity of the hepatic enzyme uroporphyrinogen decarboxylase, leading to the accumulation of uroporphyrins that cause photosensitivity and skin lesions. Hydroxychloroquine is used off-label in low doses to treat PCT by increasing the excretion of porphyrins and, critically, by interfering with the activity of key enzymes in the heme synthesis pathway. It raises lysosomal pH, which impairs the function of enzymes responsible for porphyrin processing, thereby reducing the buildup of toxic intermediates. The primary pharmacological action relevant here is enzyme inhibition, as hydroxychloroquine's therapeutic effect in PCT is based on inhibiting enzymes involved in heme metabolism, decreasing porphyrin accumulation and photosensitivity.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_b912bcbf0dec",
      "question": "In a patient with stage II non-small cell lung cancer who has undergone complete surgical resection but with microscopically positive margins (R1), is concurrent chemoradiation preferred over sequential chemoradiation as the postoperative treatment of choice?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
              "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Both concurrent and sequential chemoradiation are considered postoperative options for stage II non-small cell lung cancer with R1 resection margins; neither approach is universally preferred over the other. The choice depends on patient tolerance and comorbidities, as both strategies are recognized, without a default priority.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_14bd8645a3d1",
      "question": "In a newly diagnosed metastatic non-small cell lung cancer (NSCLC) patient with adenocarcinoma histology and confirmed EGFR S768I mutation detected before any systemic therapy, both afatinib and first-generation EGFR tyrosine kinase inhibitors (TKIs) like gefitinib or erlotinib are potentially active options. Which agent should be prioritized according to optimal first-line therapy selection for this specific EGFR mutation, and what is the rationale?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "EGFR S768I, L861Q, and/or G719X mutation positive",
              "EGFR S768I, L861Q, and/or G719X mutations",
              "EGFR mutation discovered prior to first-line systemic therapy",
              "Preferred: Afatinib",
              "Progression",
              "Subsequent Therapy (NSCL-23)"
            ]
          }
        }
      ],
      "answer": "Afatinib should be prioritized as first-line therapy for NSCLC patients harboring EGFR S768I mutation, as clinical evidence demonstrates superior activity of afatinib against rare EGFR mutations like S768I compared to first-generation TKIs. This recommendation aligns with the preferred regimen for these specific non-classical mutations.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_866efa00f370",
      "question": "What is the PMID of the article titled “Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics,” authored by Rosenbloom M and published in the Journal of Neurology in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"Monoclonal antibody administration in an academic institution and private neurological practice\"[ti] AND Rosenbloom M[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40355750"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_d01a45dcecc7",
      "question": "A 32-year-old woman presents with vulvar itching, erythema, and a malodorous vaginal discharge. Microscopy reveals numerous clue cells and a paucity of lactobacilli, suggesting a bacterial etiology. Her clinician initiates treatment with a topical antimicrobial that exerts its effect by inhibiting an essential step in bacterial folate biosynthesis, ultimately preventing microbial DNA replication and cell division. Which antimicrobial mechanism is primarily responsible for the therapeutic action of this drug in managing her infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Vaginitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0042267",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0075504",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Inhibition of para-aminobenzoic acid (PABA) utilization—disruption of bacterial folate synthesis",
      "reasoning_path": "Sulfabenzamide treats bacterial vaginitis by acting as a PABA analog, competitively inhibiting bacterial folate synthesis and thereby stopping DNA replication and bacterial growth.",
      "umls_path": [
        "Vaginitis",
        "may_be_treated_by",
        "Sulfabenzamide",
        "has_mechanism_of_action",
        "Para-Aminobenzoic Acid Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s presentation is consistent with bacterial vaginitis. A sulfonamide such as sulfabenzamide is sometimes used as a topical agent for this condition. Sulfabenzamide, like other sulfonamides, is a structural analog of para-aminobenzoic acid (PABA). It competitively inhibits the enzyme dihydropteroate synthase in bacteria, blocking the incorporation of PABA into dihydropteroic acid, a precursor of folic acid. Since bacteria must synthesize folate de novo for DNA, RNA, and protein synthesis, inhibition of this pathway blocks bacterial growth (bacteriostatic effect). Humans are unaffected because they obtain folate from their diet rather than synthesizing it. Thus, the primary antimicrobial mechanism is inhibition of PABA utilization, leading to disruption of bacterial folate synthesis, which is necessary for microbial proliferation.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_2d9767412328",
      "question": "In a patient with completely resected stage IA (T1a-c, N0) non-small cell lung cancer (NSCLC) who has positive surgical margins (R1 or R2) and is not a candidate for further resection due to comorbidities, is adjuvant radiotherapy considered an acceptable alternative to re-excision, and what is its recommended category of evidence?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (T1abc, N0); Margins positive (R1, R2)",
              "Resection (preferred) or RT (category 2B)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Adjuvant radiotherapy is considered an acceptable alternative to re-excision when complete resection is not feasible for stage IA NSCLC with positive margins; however, it is supported as a category 2B recommendation, reflecting lower-level evidence or less uniform consensus compared to re-excision.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_a2a72e96a64c",
      "question": "For a patient with non-small cell lung cancer who presents with a separate pulmonary nodule in the contralateral lung and has no evidence of nodal involvement (N0) but confirmed M1a disease, is the clinical management based on the assumption that both lesions are potentially resectable primary tumors rather than one being a metastasis?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
              "Pathologic Diagnosis of NSCLC",
              "Initial Evaluation",
              "Pathology review"
            ]
          }
        }
      ],
      "answer": "Yes, in the context of stage IVA (N0, M1a) disease with a solitary nodule in the contralateral lung, management presumes both lesions may represent distinct primary tumors amenable to curative treatment, rather than assuming metastatic spread. The approach involves evaluating each lesion for its resectability and curability.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_1e5c98a41a08",
      "question": "For a patient with non–small cell lung cancer presenting with stage IIIC disease (T3, N3, M0) and confirmed mediastinal lymph node involvement via EBUS biopsy, does the selection of perioperative therapy implicitly require the absence of distant metastases on brain MRI and FDG-PET/CT imaging?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "N3 nodes positive, M0",
              "Stage IIIB or Stage IIIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 0–2",
              "Limited progression confirmed",
              "Brain",
              "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
              "Treatment of Thoracic Disease (NSCL-16)"
            ]
          }
        }
      ],
      "answer": "Yes. The use of perioperative therapy in stage IIIC (T3, N3, M0) non–small cell lung cancer is contingent on confirming M0 status, which by definition excludes distant metastases. Negative findings on brain MRI and FDG-PET/CT are necessary prerequisites before considering perioperative interventions in this population.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_0306f46115ac",
      "question": "In a patient with localized, invasive, non-inflammatory, non-metastatic (M0), HER2-positive breast cancer with a tumor size of 0.6 cm (greater than 0.5 cm but less than 1 cm), and no axillary lymph node involvement (pN0), is adjuvant chemotherapy with trastuzumab routinely indicated, or does the small tumor size fall outside the typical recommendation boundary?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
              "ER-negative and PR-negative",
              "HER2-positive",
              "BINV-9",
              "Ductal/NST, Lobular, Mixed, Micropapillary",
              "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
              "Tumor ≤0.5 cm",
              "pN0 Consider adjuvant chemotherapy with trastuzumab (category 2B)"
            ]
          }
        }
      ],
      "answer": "For HER2-positive breast cancer with tumor size greater than 0.5 cm but less than 1 cm (T1b), and pN0 status, adjuvant chemotherapy with trastuzumab may be considered but is not routinely indicated; standard recommendations generally apply for tumors larger than 1 cm, while smaller tumors are evaluated case-by-case considering risk factors.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_8d36c0c5df47",
      "question": "A 27-year-old woman presents with a sore throat, fever, and difficulty swallowing for two days. Physical examination reveals erythematous oropharyngeal mucosa with tonsillar exudates. A rapid antigen detection test confirms a bacterial etiology. She is started on an oral medication that acts by binding to and inhibiting transpeptidase enzymes, thereby preventing the cross-linking of peptidoglycan chains essential for bacterial cell wall synthesis. Which pharmacological class best describes the mechanism by which this drug treats her infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Pharyngitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0031350",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0701889",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme Inhibitors",
      "reasoning_path": "A patient with bacterial pharyngitis is treated with cefadroxil, which inhibits bacterial transpeptidase enzymes (penicillin-binding proteins), thereby preventing peptidoglycan cross-linking and exerting its therapeutic effect as an enzyme inhibitor.",
      "umls_path": [
        "Pharyngitis",
        "may_be_treated_by",
        "Cefadroxil monohydrate",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient has acute bacterial pharyngitis, commonly due to Streptococcus pyogenes. The prescribed drug, cefadroxil monohydrate, is a first-generation cephalosporin antibiotic. Its therapeutic action is based on its ability to bind to and inhibit penicillin-binding proteins (transpeptidases) involved in the final step of bacterial cell wall synthesis. By blocking these enzymes, cefadroxil disrupts cross-linking of the peptidoglycan matrix, leading to bacterial cell lysis and death. Therefore, the central pharmacological mechanism is inhibition of a bacterial enzyme, classifying cefadroxil as an enzyme inhibitor. This distinguishes it from other antibacterial classes that may target nucleic acid synthesis or protein synthesis.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_107c6447e2ec",
      "question": "For a patient with Stage IIIA non-small cell lung cancer (T1–2, N2) who underwent complete resection (R0) and adjuvant systemic therapy, if a new suspicious lung nodule appears on imaging during routine surveillance, should FDG-PET/CT or brain MRI be included in the initial evaluation along with chest CT, or are these modalities reserved only for confirmed recurrence?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "FDG-PET/CT and brain MRI are not routinely included in surveillance for Stage IIIA NSCLC following R0 resection and adjuvant therapy; these modalities are specifically reserved for cases of confirmed recurrence or when distant metastases are clinically suspected after new findings on standard chest imaging.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_7826e8a7c2bc",
      "question": "For an adult patient with an incidentally detected solitary pure ground-glass pulmonary nodule measuring 5 mm in diameter on chest CT, but with a history of immunosuppression due to organ transplantation, is routine imaging follow-up still unnecessary according to standard nodule management boundaries?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Incidental finding of nodule suspicious for lung cancer",
              "Multidisciplinary evaluation, Smoking cessation counseling",
              "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
              "Subsolid nodules Follow-up (DIAG-3)",
              "Incidental finding: subsolid nodule(s) on chest CT",
              "Solitary pure ground-glass nodules",
              "<6 mm No routine follow-up"
            ]
          }
        }
      ],
      "answer": "No, in immunosuppressed patients, even pure ground-glass nodules smaller than 6 mm may warrant individualized evaluation and potentially closer surveillance, since immunosuppression increases the risk of both infection and malignancy, and standard management thresholds may not apply.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_8cf4c1464287",
      "question": "In a patient with stage IA (peripheral T1abc, N0) non-small cell lung cancer and severely impaired pulmonary function as demonstrated by pulmonary function tests, is surgical resection still the preferred primary treatment modality over external-beam radiotherapy or stereotactic ablative radiotherapy (SABR)?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (peripheral T1abc, N0)",
              "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "No, in patients with stage IA (peripheral T1abc, N0) non-small cell lung cancer who have severely impaired pulmonary function, surgical resection is not preferred. Instead, external-beam radiotherapy or stereotactic ablative radiotherapy (SABR) becomes the primary local treatment modality due to the increased perioperative risk associated with surgery.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_dea69352440a",
      "question": "For a patient with stage I–II non–small cell lung cancer who underwent primary treatment that included radiotherapy (without surgery), does the recommended follow-up imaging frequency during the first three years differ from a patient who underwent surgery with or without chemotherapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Limited metastases",
              "Stage IV, M1b (NSCL-15)",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 3–4",
              "Systemic Therapy for Metastatic Disease (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, the follow-up imaging frequency is higher for stage I–II patients treated with radiotherapy. They require chest CT every 3–6 months for 3 years, while those treated with surgery ± chemotherapy undergo chest CT every 6 months for 2–3 years. This reflects a more intensive surveillance strategy after radiotherapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_e14f607d925c",
      "question": "A 44-year-old woman presents with anal discomfort and swelling. On examination, she has tender, inflamed perianal tissue consistent with symptomatic hemorrhoids. Her clinician prescribes a topical medication that exerts anti-inflammatory effects by modulating eicosanoid pathways. Specifically, this agent inhibits an enzyme pathway responsible for leukotriene synthesis, thereby reducing local inflammation and edema. Which enzyme class is primarily inhibited by this medication to achieve its therapeutic effect in hemorrhoidal tissue?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Hemorrhoid"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0019112",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0082944",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lipoxygenase inhibitors",
      "reasoning_path": "Topical corticosteroids for hemorrhoids reduce inflammation by inhibiting lipoxygenase, which lowers leukotriene-mediated effects.",
      "umls_path": [
        "Hemorrhoid",
        "may_be_treated_by",
        "Hydrocortisone aceponate",
        "has_mechanism_of_action",
        "Lipoxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Corticosteroids, such as topical hydrocortisone, are commonly prescribed to reduce inflammation in patients with symptomatic hemorrhoids. Their anti-inflammatory action is mediated through multiple mechanisms, including the inhibition of phospholipase A2, which decreases synthesis of arachidonic acid derivatives. Importantly, corticosteroids also downregulate the activity of lipoxygenase enzymes, which are responsible for converting arachidonic acid into leukotrienes. Leukotrienes are potent mediators of inflammation, contributing to vasodilation, edema, and leukocyte recruitment in affected tissues. By inhibiting lipoxygenase activity, corticosteroids reduce leukotriene production, leading to diminished inflammatory responses in hemorrhoidal tissue. Therefore, the clinical benefit in this scenario is primarily due to inhibition of the lipoxygenase pathway, which plays a central role in propagating local inflammation.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_074817c07fdf",
      "question": "In a patient with stage I non-small cell lung cancer (NSCLC) who has undergone complete surgical resection (R0) without adjuvant chemotherapy, if a new, asymptomatic radiographic abnormality is detected on annual surveillance chest CT, should FDG-PET/CT or brain MRI with contrast be performed immediately as standard follow-up?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (T2a, N0); Margins negative (R0)",
              "Observe or Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, for stage I NSCLC patients post-R0 resection without signs or symptoms of recurrence, immediate use of FDG-PET/CT or brain MRI with contrast is not standard. These modalities are reserved for suspected recurrence or evaluation of distant metastases, not for routine surveillance of asymptomatic findings.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_edb35d7f4bbd",
      "question": "A 62-year-old woman with a history of small cell lung cancer presents with confusion and weakness. Laboratory tests reveal a serum sodium of 122 mmol/L. She is diagnosed with chronic hyponatremia due to excessive antidiuretic hormone secretion. After attempts at fluid restriction fail to correct her sodium, her physician prescribes a medication that is structurally related to tetracyclines and is known to interfere with bacterial ribosomal function. What is the broad pharmacological class of this drug, based on its primary mechanism of action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Syndrome of Inappropriate Antidiuretic Hormone Secretion"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021141",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011276",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Protein synthesis inhibitors",
      "reasoning_path": "SIADH leads to hyponatremia; demeclocycline is used off-label to treat SIADH, but its main mechanism is inhibition of bacterial protein synthesis, categorizing it as a protein synthesis inhibitor.",
      "umls_path": [
        "Syndrome of Inappropriate Antidiuretic Hormone Secretion",
        "may_be_treated_by",
        "Demeclocycline-containing product",
        "has_mechanism_of_action",
        "Protein Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has chronic hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH). When fluid restriction is ineffective, demeclocycline is sometimes used to induce nephrogenic diabetes insipidus, thereby reducing the kidney’s response to ADH and promoting free water excretion. However, demeclocycline’s primary pharmacological classification is not based on its off-label use in SIADH, but on its original and principal mechanism: inhibition of bacterial protein synthesis. Demeclocycline, like other tetracyclines, binds to the 30S ribosomal subunit in bacteria, blocking the attachment of aminoacyl-tRNA and halting translation. Thus, it is classified as a protein synthesis inhibitor. Its side effect of inducing renal resistance to ADH is exploited therapeutically in SIADH, but this is not the basis for its drug class.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_fbcfad682434",
      "question": "A 25-year-old man presents to the clinic with acute onset of unilateral scrotal pain and swelling. He reports dysuria, but no fever or urinary frequency. Physical examination reveals a tender, swollen epididymis on the right side. He is empirically started on a parenteral antibiotic that is highly effective against Neisseria gonorrhoeae. This antibiotic exerts its bactericidal activity by binding to and inactivating specific transpeptidase enzymes required for cross-linking of peptidoglycan in the bacterial cell wall. Which drug class best describes the primary mechanism by which this agent eliminates susceptible bacteria?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Epididymitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0014534",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0700527",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme Inhibitors",
      "reasoning_path": "Acute epididymitis in young men is treated with third-generation cephalosporins (e.g., ceftriaxone), which exert their effect by inhibiting bacterial transpeptidase enzymes (penicillin-binding proteins), disrupting cell wall synthesis and classifying them as enzyme inhibitors.",
      "umls_path": [
        "Epididymitis",
        "may_be_treated_by",
        "Ceftriaxone sodium",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is being treated empirically for acute epididymitis, likely caused by a sexually transmitted pathogen such as Neisseria gonorrhoeae. The treatment of choice in this age group is a third-generation cephalosporin, such as ceftriaxone. Third-generation cephalosporins act by binding to and inhibiting penicillin-binding proteins—bacterial transpeptidases that catalyze the final steps of peptidoglycan cross-linking in cell wall synthesis. By irreversibly inhibiting these enzymes, cephalosporins disrupt the structural integrity of the bacterial cell wall, ultimately leading to cell lysis and death. Thus, their antimicrobial effect is best described as enzyme inhibition, specifically targeting the enzymes involved in cell wall biosynthesis. Recognizing this mechanistic pathway is essential for understanding both the drug’s efficacy and the basis for resistance among some bacterial species.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_6b3144e166aa",
      "question": "For a patient diagnosed with non-small cell lung cancer presenting with a separate pulmonary nodule in the same lobe as the primary tumor (classified as T3, N0–1), after completion of preoperative systemic therapy and subsequent surgical resection, is adjuvant systemic therapy indicated regardless of pathological nodal (N0 or N1) status?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treatment",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
              "Surgery after preoperative systemic therapy, if planned",
              "N0–1",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "Yes, adjuvant systemic therapy is indicated for patients with T3, N0–1 non-small cell lung cancer after preoperative systemic therapy and surgical resection, irrespective of whether the final pathological nodal status is N0 or N1, as both fall within the recommended scope for adjuvant systemic treatment.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_3ceb63a658cc",
      "question": "In a patient with advanced non-small cell lung cancer (NSCLC) of adenocarcinoma histology, whose initial molecular testing identifies a RET rearrangement during the course of first-line systemic therapy, is it appropriate to interrupt ongoing therapy and switch to selpercatinib, or should the planned systemic therapy, including maintenance, be completed before initiating selpercatinib?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "RET rearrangement positive",
              "RET rearrangement",
              "RET rearrangement discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by selpercatinib (preferred), pralsetinib (preferred), cabozantinib",
              "Progression",
              "Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma"
            ]
          }
        }
      ],
      "answer": "For advanced NSCLC with RET rearrangement detected during first-line systemic therapy, it is clinically appropriate to either complete the planned systemic therapy (including maintenance) or interrupt the ongoing regimen to initiate selpercatinib. Both approaches are acceptable, and the choice should be individualized based on clinical circumstances and patient preference.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_bff3701ad0c2",
      "question": "A 42-year-old business executive presents with complaints of insomnia, daytime fatigue, and impaired concentration after returning from an overseas trip that involved crossing six time zones. He reports difficulty falling asleep at night and waking up early in the morning. His physician prescribes a medication that mimics the action of an endogenous hormone by binding to specific G protein-coupled receptors in the suprachiasmatic nucleus, thereby promoting sleep and helping reset his circadian rhythm. Which general class of pharmacologic agents describes the mechanism of this medication's action in treating his symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Circadian rhythm sleep disorder, jet lag type"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0231311",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0025219",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Hormone receptor agonists",
      "reasoning_path": "Jet lag → circadian misalignment → melatonin regulates circadian rhythm via receptor activation → exogenous melatonin or agonists treat jet lag → these are hormone receptor agonists.",
      "umls_path": [
        "Circadian rhythm sleep disorder, jet lag type",
        "may_be_treated_by",
        "Melatonin",
        "has_mechanism_of_action",
        "Hormone Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is exhibiting classic symptoms of jet lag, a circadian rhythm sleep disorder caused by rapid travel across multiple time zones. The body's internal clock, regulated primarily by the suprachiasmatic nucleus (SCN) in the hypothalamus, becomes misaligned with the external environment. Melatonin, an endogenous hormone secreted by the pineal gland, plays a key role in signaling night and promoting sleep by binding to melatonin receptors (MT1 and MT2) in the SCN. Pharmacologic agents such as exogenous melatonin or synthetic melatonin receptor agonists (e.g., ramelteon) are used to treat jet lag by acting as agonists at these receptors. By activating melatonin receptors, these drugs help realign the sleep-wake cycle with the new local time, thereby alleviating symptoms of jet lag. Thus, the general pharmacological class relevant here is hormone receptor agonists.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_a4cf950a5a2b",
      "question": "For a patient with completely resected Stage IIB (T3, N0) non-small cell lung cancer who has negative surgical margins and no evidence of disease on post-operative imaging, is routine surveillance with brain MRI indicated during follow-up in the absence of neurological symptoms?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Routine surveillance with brain MRI is not indicated for asymptomatic patients with resected Stage IIB non-small cell lung cancer and no evidence of disease; brain MRI is reserved for evaluation upon recurrence or the development of neurological symptoms.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_299694d9546b",
      "question": "In a patient with stage IIIA (T2, N2) non-small cell lung cancer who demonstrates no evidence of disseminated disease on FDG-PET/CT and brain MRI, but has a history of prior chest radiotherapy, is observation still an appropriate management option?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Yes; in patients with stage IIIA (T2, N2) non-small cell lung cancer, absence of disseminated disease confirmed by FDG-PET/CT and brain MRI allows consideration of observation, even with prior chest radiotherapy, as long as there is no active locoregional or symptomatic local recurrence.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_acb15f211161",
      "question": "In a patient with stage II non-small cell lung cancer who previously underwent primary surgery with negative margins but develops locoregional recurrence causing symptomatic superior vena cava (SVC) obstruction, is concurrent chemoradiation an appropriate initial management even if the patient previously did not receive chemoradiation during initial therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
              "R2; Resection + systemic therapy or Concurrent chemoradiation",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, for patients with locoregional recurrence and symptomatic SVC obstruction who did not receive prior chemoradiation, concurrent chemoradiation is an appropriate initial management. This approach targets both the local recurrence and relieves SVC obstruction, provided there is no prior definitive chemoradiation.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_5c8369dd5eab",
      "question": "A 42-year-old woman diagnosed with idiopathic inflammatory myopathy reports persistent muscle aches and spasms that interfere with her daily activities. Her physician prescribes a centrally acting muscle relaxant, frequently used off-label for relief of muscle spasm, in addition to her standard immunosuppressive regimen. Despite its widespread clinical use, the precise cellular or molecular mechanism by which this muscle relaxant alleviates muscle symptoms in patients with inflammatory muscle diseases is not fully elucidated. What is currently understood about the drug’s mechanistic action in this context?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Myositis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0027121",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0056732",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown Cellular or Molecular Interaction",
      "reasoning_path": "A patient with myositis is treated with cyclobenzaprine for muscle spasms. Despite its use, there is no definitive knowledge about its molecular or cellular target in this context.",
      "umls_path": [
        "Myositis",
        "may_be_treated_by",
        "Cyclobenzaprine",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Cyclobenzaprine is often prescribed to reduce muscle spasms in patients with conditions such as myositis, despite limited evidence for its effectiveness in inflammatory myopathies. The drug is structurally related to tricyclic antidepressants and is known to act centrally, primarily at the level of the brainstem, to reduce tonic somatic motor activity. However, unlike other muscle relaxants that have well-characterized mechanisms (such as GABAergic or direct muscle effects), cyclobenzaprine’s precise cellular or molecular target in the context of muscle inflammation remains unknown. No direct binding target or downstream signaling pathway has been conclusively identified in skeletal muscle or neural tissue for its antispasmodic actions in myositis. Therefore, while cyclobenzaprine is widely used for symptomatic relief, its exact cellular or molecular mechanism in muscle diseases like myositis is not clearly defined.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_a2d299f91afc",
      "question": "For a patient with Stage IVA non-small cell lung cancer (NSCLC), proven metastatic disease, and an ECOG performance status of 3–4, does the recommendation of systemic therapy implicitly assume that the patient is free of severe comorbidities such as uncontrolled infections or organ failure?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 3–4",
              "Systemic Therapy for Metastatic Disease (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, the use of systemic therapy in Stage IVA NSCLC patients with ECOG 3–4 does not automatically assume the absence of severe comorbidities; however, severe uncontrolled infections or organ failure are absolute contraindications to systemic therapy regardless of performance status, and these should be specifically evaluated before treatment is initiated.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_1a034d3d16fb",
      "question": "If a patient presents with clinical signs suggestive of Paget disease of the nipple, but both diagnostic mammogram and ultrasound are negative for a breast lesion, is it still necessary to perform a core biopsy of the breast and a full-thickness biopsy of the affected nipple-areolar complex?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Clinical suspicion of Paget disease",
              "Clinical breast exam, Diagnostic bilateral mammogram, ultrasound as necessary",
              "Examination and imaging negative for breast lesion",
              "Examination or imaging positive for breast lesion",
              "Core biopsy of breast lesion and full-thickness skin biopsy of involved NAC",
              "Breast and NAC biopsy negative",
              "Clinical follow-up Re-biopsy if not healing",
              "Appropriate systemic adjuvant therapy as clinically indicated, See NCCN Guidelines for DCIS or Invasive Breast Cancer"
            ]
          }
        }
      ],
      "answer": "Yes. Even when imaging fails to identify a breast lesion in the presence of clinical signs suggestive of Paget disease, a core biopsy of the breast and a full-thickness biopsy of the affected nipple-areolar complex are necessary to rule out underlying malignancy, as Paget disease may exist without clear radiological findings.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_3ea394d30a67",
      "question": "In a patient with localized, non-inflammatory, non-metastatic breast cancer (M0), presenting as cT1–T2, cN0, who undergoes mastectomy after not receiving preoperative chemotherapy and is found to have 1–2 positive sentinel lymph nodes, does the planned inclusion of undissected axilla in adjuvant radiotherapy allow for omission of further axillary surgery, or does this apply only if breast-conserving surgery is performed?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS not possible",
              "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
              "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
              "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
              "FNA or core biopsy negative",
              "SLN mapping and excision",
              "SLN positive",
              "Mastectomy",
              "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • Adjuvant RT planned with intentional inclusion of undissected axilla at risk",
              "Yes to all",
              "Consider no further axillary surgery"
            ]
          }
        }
      ],
      "answer": "Omission of further axillary surgery is allowable for patients with cT1–T2, cN0 disease, 1–2 positive sentinel lymph nodes after mastectomy without preoperative chemotherapy, provided that adjuvant radiotherapy intentionally covers the undissected axilla; this approach is not restricted only to those undergoing breast-conserving surgery.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_a7133c4ee945",
      "question": "A 54-year-old woman with Wilson disease is enrolled in a clinical trial evaluating a supplement shown to influence intracellular protein turnover. Researchers hypothesize that the compound acts by modulating a large, ATP-dependent protein complex responsible for targeted degradation of ubiquitinated proteins within the cytoplasm and nucleus. Which molecular complex should investigators focus on to best understand the direct intracellular mechanism of action of this supplement in metabolic disease?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "nutritional and metabolic diseases"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0028715",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0009975",
            "rela": "has_target"
          }
        }
      ],
      "answer": "26S ATP-Dependent Proteasome",
      "reasoning_path": "Copper gluconate delivers copper ions that can modulate the 26S ATP-Dependent Proteasome, the main cellular complex for regulated protein degradation, thus influencing metabolic disease processes.",
      "umls_path": [
        "nutritional and metabolic diseases",
        "may_be_treated_by",
        "copper gluconate",
        "has_target",
        "26S ATP-Dependent Proteasome"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Copper gluconate is investigated as a therapeutic agent in metabolic diseases involving copper imbalance, such as Wilson disease. Mechanistically, copper ions derived from copper gluconate can influence the activity of proteolytic pathways inside the cell. The 26S ATP-dependent proteasome is a multi-subunit protease complex that degrades polyubiquitinated proteins, thus regulating protein homeostasis, cell cycle, and stress responses. Copper ions have been shown to interact directly with this proteasome, potentially modulating its activity. By affecting proteasome function, copper gluconate may alter the degradation of misfolded or regulatory proteins, impacting metabolic processes. Therefore, to elucidate the drug's mechanism of action and its effect on cellular metabolism, researchers should focus on the 26S ATP-dependent proteasome as the primary molecular target. Understanding this interaction provides insight into how copper gluconate exerts its therapeutic effects in metabolic diseases marked by abnormal protein or metal handling.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_0bbb7b41eb12",
      "question": "A 57-year-old woman with a history of myeloproliferative neoplasm presents with sustained elevations in white blood cell count despite previous management. Her hematologist initiates a medication that acts by inhibiting ribonucleotide reductase, thereby decreasing the availability of deoxyribonucleotides and impairing DNA synthesis in rapidly dividing cells. Which pharmacological class best describes the primary mechanism by which this drug lowers her leukocyte count?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Leukocytosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0023518",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020402",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Nucleic acid synthesis inhibitors",
      "reasoning_path": "Leukocytosis in myeloproliferative neoplasms is managed with hydroxyurea, which inhibits ribonucleotide reductase and DNA synthesis, thus acting as a nucleic acid synthesis inhibitor.",
      "umls_path": [
        "Leukocytosis",
        "may_be_treated_by",
        "Hydroxyurea",
        "has_mechanism_of_action",
        "Nucleic Acid Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient's persistent leukocytosis in the setting of a myeloproliferative disorder is managed with hydroxyurea. Hydroxyurea's mechanism centers on the inhibition of ribonucleotide reductase, a crucial enzyme for converting ribonucleotides to deoxyribonucleotides required for DNA synthesis. By limiting the pool of deoxyribonucleotides, the drug impairs DNA replication and thus selectively suppresses proliferation of rapidly dividing hematopoietic cells, including leukocyte precursors. This pharmacological effect leads to a decrease in white blood cell production, providing therapeutic benefit in disorders characterized by excessive leukocyte counts. Based on this mechanism, hydroxyurea is classified as a nucleic acid synthesis inhibitor.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_633c8352da2f",
      "question": "In a premenopausal woman diagnosed with ER- and/or PR-positive, HER2-negative unresectable stage IV breast cancer, who presents without bone metastases or visceral crisis and has not received endocrine therapy in the past year, does the initiation of selective estrogen receptor modulators as first-line systemic therapy implicitly require confirmation of hormone receptor status on a biopsy of metastatic or recurrent lesion, rather than relying solely on the original primary tumor?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Metastatic (M1) invasive breast cancer",
              "Stage IV (M1) or Recurrent disease",
              "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
              "Stage IV (M1) or Recurrent",
              "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
              "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
              "Recurrent unresectable (local or regional) or stage IV (M1) disease",
              "Bone disease not present",
              "ER- and/or PR-positive; HER2-negative",
              "BINV-22",
              "No visceral crisis and No prior endocrine therapy within 1 y",
              "Premenopausal",
              "Selective ER modulators",
              "Continue endocrine therapy until progression or unacceptable toxicity",
              "Progression",
              "Progression or unacceptable toxicity on first-line endocrine therapy",
              "If not endocrine therapy refractory, consider: Alternate endocrine therapy + targeted therapy (see second-line therapy options on BINV-P)",
              "No clinical benefit after up to 3 sequential endocrine therapy regimens or Symptomatic visceral disease",
              "Systemic therapy",
              "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
              "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
            ]
          }
        }
      ],
      "answer": "Yes, initiating selective estrogen receptor modulators as first-line therapy in this metastatic setting presumes that hormone receptor status (ER/PR) has been confirmed on a biopsy of the recurrent or metastatic lesion, as receptor status may change compared to the primary tumor, and this assessment guides systemic therapy selection.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_178960303c0f",
      "question": "A 42-year-old woman presents with a long-standing history of severe, throbbing headaches accompanied by photophobia and occasional visual aura. She has tried several over-the-counter analgesics without benefit. Her neurologist initiates therapy with a medication known to modulate neurotransmitter activity at the level of cranial blood vessels and the trigeminal system. This agent is effective in preventing headache attacks by acting predominantly at specific receptors involved in vascular tone regulation and neurogenic inflammation. Which molecular target and pharmacological mechanism most directly account for this drug's prophylactic benefit in her clinical scenario?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Vascular Headache"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0042376",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0025842",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Serotonin receptor antagonism (mainly 5-HT2 receptors) by methysergide",
      "reasoning_path": "Methysergide prevents vascular headaches by blocking 5-HT2 serotonin receptors, thereby reducing serotonin-mediated vasoconstriction and inflammation in cranial vessels.",
      "umls_path": [
        "Vascular Headache",
        "may_be_treated_by",
        "Methysergide-containing product",
        "has_mechanism_of_action",
        "Serotonin Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Methysergide is used in the prophylaxis of migraine and other vascular headaches. Its therapeutic effect stems from its action as a serotonin receptor antagonist, particularly at 5-HT2 receptors. By blocking these receptors, methysergide prevents serotonin-induced vasoconstriction and neurogenic inflammation, both of which are central to the pathophysiology of migraines. The drug thereby reduces the frequency and severity of headache episodes. Although historically described as an 'antagonist', methysergide may display partial agonist activity at some serotonin receptor subtypes, but its clinical benefit in vascular headaches is most directly related to antagonism at 5-HT2 receptors regulating cranial vasculature and pain pathways.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_e29196cd89df",
      "question": "In a patient with newly diagnosed stage II non-small cell lung cancer (clinical T2b, N0) who also presents with moderate chronic obstructive pulmonary disease and decreased pulmonary function on preoperative testing, is definitive surgical resection still appropriate as the first-line treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "For stage II non-small cell lung cancer, definitive surgical resection is generally the preferred first-line treatment. However, in patients with moderate chronic obstructive pulmonary disease and reduced pulmonary function, surgical risk is significantly increased. In such scenarios, surgery may not be appropriate, and non-surgical options like definitive radiotherapy or chemoradiotherapy should be considered instead.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_a150e98119f5",
      "question": "In a patient with oligometastatic stage IV non-small cell lung cancer (NSCLC) who has received definitive therapy to all metastatic sites and now shows no evidence of disease on follow-up imaging, should surveillance be conducted with the same frequency and imaging modalities as for stage III NSCLC, or are there distinctions in the recommended surveillance protocols for these two clinical scenarios?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
              "R2; Concurrent chemoradiation",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "For patients with oligometastatic stage IV NSCLC who have received definitive treatment to all sites and have no evidence of disease, surveillance should follow the same protocol as for stage III: history and physical examination plus chest CT every 3–6 months for 3 years, then every 6 months for 2 years, then annual low-dose chest CT. There is no distinction in surveillance frequency or imaging modality between these groups.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_1e626c194f79",
      "question": "In a premenopausal woman with ER-positive, HER2-negative metastatic breast cancer without bone disease, and no history of endocrine therapy in the past year, should initial systemic treatment always involve selective estrogen receptor modulators, or are there circumstances in which another option would take precedence?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Metastatic (M1) invasive breast cancer",
              "Stage IV (M1) or Recurrent disease",
              "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
              "Stage IV (M1) or Recurrent",
              "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
              "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
              "Recurrent unresectable (local or regional) or stage IV (M1) disease",
              "Bone disease not present",
              "ER- and/or PR-positive; HER2-negative",
              "BINV-22",
              "No visceral crisis and No prior endocrine therapy within 1 y",
              "Premenopausal",
              "Selective ER modulators",
              "Continue endocrine therapy until progression or unacceptable toxicity",
              "Progression",
              "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy",
              "Alternate systemic therapy",
              "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
              "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
            ]
          }
        }
      ],
      "answer": "While selective estrogen receptor modulators are the recommended initial systemic therapy in this setting, the presence of a visceral crisis would take precedence and necessitate cytotoxic chemotherapy instead, as timely disease control becomes paramount to prevent life-threatening organ dysfunction.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_609b69b3308e",
      "question": "A 55-year-old man with advanced HIV presents with persistent fever, night sweats, weight loss, and diarrhea. Blood cultures grow a non-tuberculous mycobacterium identified as Mycobacterium avium complex. He is started on a regimen including a medication known to selectively inhibit the bacterial DNA-dependent RNA polymerase, thereby interrupting the transcription of bacterial genes. Which drug class best describes the mechanism of action responsible for this agent’s effect against his infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Mycobacterium Avium Infection"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0026916",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0140575",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Nucleic acid synthesis inhibitors (specifically, rifamycins inhibit bacterial DNA-dependent RNA polymerase)",
      "reasoning_path": "Disseminated MAC infection → rifabutin prescribed → rifabutin inhibits bacterial DNA-dependent RNA polymerase → blocks RNA synthesis → nucleic acid synthesis inhibitor.",
      "umls_path": [
        "Mycobacterium Avium Infection",
        "may_be_treated_by",
        "Rifabutin",
        "has_mechanism_of_action",
        "Nucleic Acid Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Patients with immunosuppression, especially advanced HIV, are at high risk for disseminated Mycobacterium avium complex (MAC) infection. Rifabutin is often used in the treatment of MAC due to its activity against these organisms. The drug exerts its antimicrobial effect by binding to the beta subunit of bacterial DNA-dependent RNA polymerase, thus inhibiting transcription of bacterial RNA. This blockade prevents the synthesis of essential proteins, ultimately leading to bacterial death or growth arrest. The underlying mechanism falls under the broader category of nucleic acid synthesis inhibitors, as the primary interruption is at the transcriptional level. This mechanistic distinction is important, as other antibiotic classes target cell wall synthesis or protein translation, whereas rifamycins directly interfere with nucleic acid (RNA) synthesis. Therefore, the therapeutic effect of rifabutin in disseminated MAC infection is due to its role as a nucleic acid synthesis inhibitor, specifically via inhibition of bacterial RNA polymerase.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_94b4ff3b7084",
      "question": "In a patient with non-squamous non-small cell lung cancer and newly identified distant metastases, if molecular profiling is negative for actionable mutations but PD-L1 testing shows tumor proportion score ≥50%, should first-line systemic therapy prioritize immune checkpoint inhibitor monotherapy over platinum-based chemotherapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Distant metastases",
              "Disseminated metastases",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Yes; for metastatic non-squamous NSCLC lacking actionable mutations and with PD-L1 TPS ≥50%, first-line immune checkpoint inhibitor monotherapy is prioritized over platinum-based chemotherapy, consistent with current evidence and international treatment guidelines.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_12f79283fee9",
      "question": "A 58-year-old man presents to the emergency department with crushing substernal chest pain radiating to his left arm. Electrocardiogram reveals ST-segment elevations in the anterior leads. Emergent coronary angiography confirms an occlusive thrombus in the left anterior descending artery. The patient is promptly started on an intravenous anticoagulant known to accelerate the activity of a natural plasma inhibitor, thereby preventing the conversion of fibrinogen to fibrin and further clot propagation. Which class of molecular targets is primarily responsible for the therapeutic effect of this agent in the acute setting?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Coronary artery thrombosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0010072",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0019134",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Thrombin inhibitors",
      "reasoning_path": "Acute coronary thrombosis is treated with heparin, which enhances antithrombin III activity, leading to inhibition of thrombin and thereby preventing further clot formation.",
      "umls_path": [
        "Coronary artery thrombosis",
        "may_be_treated_by",
        "Heparin",
        "has_mechanism_of_action",
        "Thrombin Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient's presentation is consistent with an acute ST-elevation myocardial infarction due to coronary artery thrombosis. Rapid anticoagulation is critical to prevent further thrombus extension and facilitate reperfusion. The most commonly used intravenous anticoagulant in this setting is unfractionated heparin. Heparin's primary mechanism is to potentiate the activity of antithrombin III, a physiological serine protease inhibitor. When activated, antithrombin III most potently inhibits thrombin (factor IIa) and factor Xa, but inhibition of thrombin is particularly important in the context of acute thrombosis. By inhibiting thrombin, heparin prevents the conversion of fibrinogen to fibrin, which is a crucial step in forming the insoluble fibrin mesh of a thrombus. Thus, the primary molecular targets relevant to its therapeutic effect are thrombin (factor IIa) molecules, and the class of agents is referred to as thrombin inhibitors.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_0e0176dd95ed",
      "question": "What is the PMID of the 2025 PLoS Medicine article titled “The cardiology community begins to embrace obesity as an important target for cardiovascular health,” authored by Sattar N?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"The cardiology community begins to embrace obesity as an important target for cardiovascular health.\"[ti] AND Sattar N[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40273224"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_73527e360aaa",
      "question": "A 34-year-old woman returns from a vacation in Southeast Asia and presents with cyclical fevers and chills every 48 hours. Blood smear confirms infection with Plasmodium vivax. She is started on a well-tolerated oral antimalarial agent with proven clinical efficacy for this species, but when asked how the drug works at the cellular or molecular level, her physician explains that the mechanism is not fully elucidated. Which best describes the current understanding of the pharmacologic action of this therapy?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Vivax malaria [benign tertian]"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0024537",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0282398",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Diagnosis: P. vivax malaria → Drug: mefloquine → Clinical efficacy recognized → Mechanism not clearly defined → Answer: unknown cellular or molecular interaction.",
      "umls_path": [
        "Vivax malaria [benign tertian]",
        "may_be_treated_by",
        "Mefloquine Hydrochloride",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is being treated for Plasmodium vivax malaria, the causative agent of benign tertian malaria. Mefloquine is a commonly used antimalarial agent with activity against blood schizonts of P. vivax and P. falciparum. Despite its clinical efficacy, the precise cellular or molecular mechanism by which mefloquine exerts its antimalarial effects has not been conclusively determined. Several hypotheses exist, including interference with heme polymerization in the parasite’s food vacuole, but definitive evidence for a singular mechanism is lacking. Thus, the best current description of mefloquine’s pharmacologic action is that it acts via unknown cellular or molecular interactions.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_4a938d5d565d",
      "question": "For a patient with stage IIB (T3, N0) non-small cell lung cancer who underwent complete surgical resection with positive margins (R1) and no evidence of distant metastasis, is concurrent chemoradiation an appropriate initial postoperative management approach, or should re-resection always be prioritized, assuming both options are technically feasible?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
              "R2; Resection + systemic therapy or Concurrent chemoradiation",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "In resected stage IIB (T3, N0) non-small cell lung cancer with positive surgical margins (R1), both re-resection and postoperative chemoradiation are acceptable strategies when technically feasible. However, if a complete re-resection can be safely performed, re-resection to achieve negative margins is generally preferred over immediate chemoradiation, as it offers improved local control and potentially better outcomes.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_f239207910ff",
      "question": "In a patient with advanced non-small cell lung cancer (NSCLC), histologically confirmed adenocarcinoma, and diffuse brain metastases, who tests positive for NTRK1 gene fusion, should an NTRK inhibitor be prioritized over conventional palliative external-beam radiotherapy for management of brain lesions?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "NTRK1/2/3 gene fusion positive"
            ]
          }
        }
      ],
      "answer": "For advanced NSCLC with diffuse brain metastases and confirmed NTRK1 gene fusion, an NTRK inhibitor is generally prioritized due to its systemic efficacy, including intracranial activity. However, if brain lesions are causing severe neurological symptoms or mass effect, urgent palliative radiotherapy may be necessary before initiating targeted therapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_44bb3d2180ca",
      "question": "A 9-year-old boy with a history of recurrent fever episodes, joint pain, and a diagnosis of an inherited autoinflammatory disorder is evaluated for initiation of a biologic therapy. His condition is thought to be driven by excessive activity of a pro-inflammatory cytokine implicated in innate immune responses. The selected therapy is a fusion protein that binds and neutralizes this cytokine, thereby preventing downstream signaling and inflammation. What is the principal drug class responsible for this mechanism of action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "inborn genetic disease"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0950123",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2343589",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Interleukin 1 Receptor Antagonists",
      "reasoning_path": "Inherited autoinflammatory syndromes are driven by IL-1 hyperactivity; Rilonacept binds and neutralizes IL-1, acting as an interleukin 1 receptor antagonist to control inflammation.",
      "umls_path": [
        "inborn genetic disease",
        "may_be_treated_by",
        "Rilonacept-containing product",
        "has_mechanism_of_action",
        "Interleukin 1 Receptor Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s clinical scenario describes a classic autoinflammatory syndrome, such as familial Mediterranean fever or a related periodic fever disorder, which are frequently caused by dysregulated interleukin-1 (IL-1) activity. Rilonacept is a biologic agent designed as a decoy receptor fusion protein. It binds with high affinity to IL-1β (and, to a lesser extent, IL-1α), thereby sequestering the cytokine and preventing it from interacting with its cell surface receptor. By neutralizing IL-1, Rilonacept blocks the cascade of inflammatory gene expression and cellular activation that underlies periodic fever syndromes. The drug is thus classified as an interleukin 1 receptor antagonist. Its use is indicated for specific autoinflammatory conditions, where targeting IL-1 signaling directly addresses the molecular defect and alleviates symptoms.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_e97840e91b9f",
      "question": "For a patient with non-small cell lung cancer (NSCLC) presenting with a single extrathoracic metastatic lesion and no prior history of chest radiotherapy, is it appropriate to consider local therapy directed at the metastatic site instead of immediate systemic therapy as the initial treatment approach?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Yes, in cases of oligometastatic NSCLC with a limited number of extrathoracic metastatic lesions and no prior chest radiotherapy, local therapy targeting the metastatic site can be appropriate and may be considered over immediate systemic therapy, provided there is careful staging confirming absence of disseminated disease.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_b852a8af41b9",
      "question": "For a patient with advanced squamous cell carcinoma of the lung who is found to harbor a BRAF V600E mutation prior to any systemic therapy, does the recommendation to use BRAF inhibitors such as vemurafenib or dabrafenib necessarily imply that broad molecular profiling including other actionable mutations has already been completed?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "BRAF V600E mutation positive",
              "BRAF V600E MUTATION",
              "BRAF V600E mutation discovered prior to first-line systemic therapy",
              "FIRST-LINE THERAPY",
              "Useful in Certain Circumstances: Vemurafenib or dabrafenib",
              "Progression",
              "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
            ]
          }
        }
      ],
      "answer": "Yes, the use of BRAF inhibitors in advanced squamous cell carcinoma with a confirmed BRAF V600E mutation implies that comprehensive molecular profiling has been performed to identify this targetable alteration, as such mutations are rare in squamous subtype and require explicit testing beyond standard panels.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_ac35e023f107",
      "question": "For a patient with resectable non-small cell lung cancer classified as stage IIIA (T4, N0–1), if intraoperative pathology reveals positive surgical margins (R1), is surgery alone an adequate definitive treatment in this context?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
              "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Contralateral mediastinal node negative",
              "Ipsilateral mediastinal node negative (T4, N0–1)",
              "Treatment for Stage IIIA (NSCL-7)",
              "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
              "Surgery (preferred)",
              "Margins positive",
              "R1",
              "Resection + chemotherapy or Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "No, surgery alone is insufficient when positive margins (R1) are detected in resectable stage IIIA (T4, N0–1) non-small cell lung cancer. Additional treatment with chemotherapy or chemoradiation is required post-resection to address microscopic residual disease and reduce recurrence risk.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_3b0b2fb27273",
      "question": "In a patient with non-inflammatory, non-metastatic (M0), clinical stage cT2N0M0, ER-negative and PR-negative, HER2-positive invasive ductal carcinoma of the breast who has undergone breast-conserving surgery with surgical axillary staging, is the administration of adjuvant chemotherapy combined with trastuzumab and pertuzumab contingent upon the confirmation of at least one ipsilateral lymph node metastasis (pN+; >2 mm) on final pathology?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
              "ER-negative and PR-negative",
              "HER2-positive",
              "BINV-9",
              "Ductal/NST, Lobular, Mixed, Micropapillary",
              "pN+ (≥1 ipsilateral metastases >2 mm)",
              "or Adjuvant chemotherapy with trastuzumab + pertuzumab (category 1, preferred)"
            ]
          }
        }
      ],
      "answer": "Yes, initiation of adjuvant chemotherapy with trastuzumab plus pertuzumab is primarily indicated when at least one ipsilateral lymph node metastasis larger than 2 mm is confirmed (pN+). In the absence of nodal involvement, the benefit and indication for dual anti-HER2 therapy with chemotherapy should be carefully reconsidered.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_a35b222e8df0",
      "question": "In ClinicalTrials.gov, which completed interventional studies for metastatic breast cancer with Eribulin Mesylate as a main intervention have been conducted in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "overallStatus=COMPLETED;conditions=Metastatic Breast Cancer;interventions.name=Eribulin Mesylate;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00337103"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_b3887baaeadc",
      "question": "In a patient with non-small cell lung cancer who presents with separate pulmonary nodules located in the contralateral lung (M1a), and is otherwise a candidate for surgery, does the outlined approach of surgery after preoperative systemic therapy still apply, or does this site of disease represent a boundary beyond which surgical resection is not indicated?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
              "Surgery after preoperative systemic therapy, if planned",
              "N0–1",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "For non-small cell lung cancer with separate pulmonary nodules in the contralateral lung (M1a), this finding classifies the disease as metastatic. Surgical resection is generally not indicated for M1a disease, and the described strategy of surgery after preoperative systemic therapy applies only to cases with nodules in the same or ipsilateral lung, not in the contralateral lung.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_524966218b1c",
      "question": "A 52-year-old man reports persistent excessive daytime sleepiness despite adherence to his prescribed continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea. To improve his alertness and ability to function during the day, his sleep specialist prescribes a medication that enhances wakefulness by increasing extracellular concentrations of certain monoamines in the brain. Which class of pharmacologic agents best describes the primary mechanism by which this medication promotes wakefulness in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Obstructive Sleep Apnea Syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0520679",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0066677",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Dopamine uptake inhibitors",
      "reasoning_path": "Patient with sleepiness due to OSA → modafinil prescribed for wakefulness → modafinil acts by inhibiting dopamine reuptake → increases synaptic dopamine → CNS stimulation and increased alertness.",
      "umls_path": [
        "Obstructive Sleep Apnea Syndrome",
        "may_be_treated_by",
        "Modafinil",
        "has_mechanism_of_action",
        "Dopamine Uptake Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has residual excessive daytime sleepiness despite adequate treatment for obstructive sleep apnea, for which modafinil is often prescribed as adjunctive therapy. Modafinil’s primary wake-promoting effect is mediated by inhibition of dopamine reuptake transporters in the central nervous system. By blocking these transporters, modafinil increases synaptic dopamine concentrations, particularly in wake-promoting regions of the brain such as the hypothalamus. This dopaminergic stimulation enhances alertness and reduces the propensity to fall asleep during the day. Although modafinil is a relatively selective and atypical stimulant compared to amphetamines, its main pharmacologic action relevant to wakefulness is through dopamine uptake inhibition.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_558bfecfca30",
      "question": "In a patient with stage IIA non-small cell lung cancer (NSCLC) who underwent definitive radiotherapy as primary treatment and is now three years post-treatment with no evidence of disease, what is the recommended frequency of chest imaging during the subsequent two years—should it be every six months or annually?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
              "R2; Concurrent chemoradiation",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "For a patient with stage I–II NSCLC treated primarily with radiotherapy, the recommended chest imaging frequency during years 4 and 5 post-treatment is every six months with chest CT (with or without contrast), along with history and physical examination, rather than annual imaging.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_f62b6500b1ce",
      "question": "A 72-year-old woman presents with new-onset temporal headaches, jaw claudication, and visual disturbances. Laboratory studies reveal an elevated erythrocyte sedimentation rate and C-reactive protein. Temporal artery biopsy confirms a granulomatous vasculitis with multinucleated giant cells. She is started on high-dose corticosteroids, but due to persistent symptoms, an immunomodulatory agent is added. This biologic therapy acts by binding to a specific cytokine receptor subunit, blocking downstream signaling involved in the acute-phase inflammatory response that drives her disease. Which molecular target does this added medication primarily inhibit to achieve its therapeutic effect in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Giant cell arteritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0039483",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1609165",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Soluble Interleukin-6 Receptor Subunit Alpha",
      "reasoning_path": "Giant cell arteritis involves IL-6–driven inflammation. Tocilizumab is added for refractory disease. It binds soluble/membrane IL-6 receptor alpha, blocking IL-6 signaling and inflammation.",
      "umls_path": [
        "Giant cell arteritis",
        "may_be_treated_by",
        "Tocilizumab-containing product",
        "has_target",
        "Soluble Interleukin-6 Receptor Subunit Alpha"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has classic giant cell arteritis, a large-vessel vasculitis driven by pro-inflammatory cytokines, especially interleukin-6 (IL-6). Tocilizumab is a monoclonal antibody used when steroids alone are insufficient or to reduce steroid exposure. Tocilizumab binds to both soluble and membrane-bound IL-6 receptor subunit alpha (IL-6Rα), thereby inhibiting IL-6 from engaging its receptor. This blocks the JAK/STAT signaling pathway, reducing hepatic production of acute-phase reactants and suppressing the vascular inflammation central to giant cell arteritis. By specifically targeting the IL-6 receptor alpha subunit, tocilizumab interrupts a key driver of systemic and vascular inflammation, leading to clinical improvement and decreased risk of complications such as vision loss.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_df9afc43307b",
      "question": "In the OpenTargets database, what information is available regarding heart disease for the target JAK2?",
      "tool_calls": [
        {
          "tool": "opentargets.safety",
          "params": {
            "symbol": "JAK2",
            "event": "heart disease"
          }
        }
      ],
      "answer": {
        "biosamples": [
          {
            "tissueLabel": "cardiovascular system",
            "tissueId": "UBERON_0004535"
          }
        ],
        "effects": "absence"
      },
      "type": "retrieval"
    },
    {
      "id": "path_2e42bd873b58",
      "question": "For a patient with advanced squamous cell carcinoma of the lung whose tumor tests positive for an uncommon EGFR mutation (specifically S768I, L861Q, or G719X) prior to initiation of first-line systemic therapy, is the use of osimertinib an appropriate first-line treatment regardless of smoking history or the presence of other common squamous-associated mutations (e.g., KRAS)?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "EGFR S768I, L861Q, and/or G719X mutation positive",
              "EGFR S768I, L861Q, and/or G719X mutations",
              "EGFR mutation discovered prior to first-line systemic therapy",
              "Preferred: Osimertinib",
              "Progression",
              "Subsequent Therapy (NSCL-22)"
            ]
          }
        }
      ],
      "answer": "Yes, when a squamous cell lung carcinoma harbors a sensitizing uncommon EGFR mutation such as S768I, L861Q, or G719X, first-line treatment with osimertinib is appropriate, independent of the patient's smoking history or coexistence of other common squamous mutations. The presence of these specific EGFR mutations supersedes typical histologic and molecular expectations for squamous carcinoma.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_1df1a811eb41",
      "question": "A 27-year-old recent traveler to Southeast Asia presents with abdominal discomfort and intermittent diarrhea. Stool examination reveals the presence of ova suggestive of a nematode infection. He is started on an oral medication that acts by blocking the function of critical metabolic enzymes required for the parasite’s energy production and survival. Which general class of drug mechanism underlies the efficacy of this therapy in eradicating the helminthic infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Helminth infection, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0018889",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0039832",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme inhibitors",
      "reasoning_path": "Patient with helminth infection is treated with a drug (e.g., thiabendazole) that inhibits parasite metabolic enzymes, classifying it as an enzyme inhibitor.",
      "umls_path": [
        "Helminth infection, unspecified",
        "may_be_treated_by",
        "Thiabendazole",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s symptoms and stool findings are consistent with a helminthic (parasitic nematode) infection. Standard treatment often involves antihelminthic agents such as thiabendazole. Thiabendazole exerts its therapeutic effect by inhibiting essential metabolic enzymes within the parasite—specifically, it blocks fumarate reductase and other key enzymes involved in the electron transport chain. This disruption impairs the parasite’s energy metabolism, ultimately leading to its death. Drugs that work by blocking enzymatic activity in pathogens are classified as enzyme inhibitors. This mechanistic class is distinct from agents that, for example, disrupt cell membranes or microtubule formation. Understanding the pharmacological class is crucial for anticipating the spectrum of activity, potential side effects, and resistance mechanisms. Thus, the principal mechanism for this treatment is inhibition of parasite enzymes, placing these drugs in the enzyme inhibitor category.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_242de63bfddd",
      "question": "A 42-year-old woman with a history of systemic sclerosis develops rapidly worsening skin discoloration with multiple non-blanching, purpuric lesions on her extremities. Laboratory tests reveal thrombocytopenia and elevated D-dimer. She is admitted for management of suspected microvascular occlusion. As part of her treatment, she receives a continuous intravenous medication that acts by binding to specific G protein-coupled receptors on vascular smooth muscle, resulting in vasodilation and inhibition of platelet aggregation. Which drug class mediates these therapeutic effects through this mechanism?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Purpuric disorder"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0034150",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0354594",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Prostaglandin receptor agonists",
      "reasoning_path": "Severe purpuric disorder → risk of microvascular thrombosis → treatment requires vasodilation and inhibition of platelet aggregation → prostaglandin receptor agonists (e.g., epoprostenol) bind IP receptors → increase cAMP → vasodilation and antiplatelet effects → clinical improvement.",
      "umls_path": [
        "Purpuric disorder",
        "may_be_treated_by",
        "Epoprostenol sodium",
        "has_mechanism_of_action",
        "Prostaglandin Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient presents with purpuric lesions, thrombocytopenia, and evidence of microvascular occlusion, all features consistent with a severe purpuric disorder such as thrombotic microangiopathy. In such settings, improving vascular perfusion and inhibiting further platelet aggregation are key therapeutic goals. Epoprostenol sodium is a synthetic analog of prostacyclin (PGI2) and acts as a prostaglandin receptor agonist. By binding to IP (prostacyclin) receptors on vascular smooth muscle and platelets, it activates adenylate cyclase, increases cAMP, and causes vasodilation while also inhibiting platelet aggregation. These effects help restore blood flow and limit further microvascular thrombosis, addressing both the vascular and hematologic aspects of the purpuric disorder. Thus, prostaglandin receptor agonists are the drug class mediating these therapeutic benefits.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_ec885b68f7c5",
      "question": "In a patient with advanced or metastatic squamous cell lung carcinoma who is confirmed to have a RET rearrangement prior to any systemic therapy, does this molecular finding justify the consideration of cabozantinib as a first-line therapy, or is it preferable to prioritize established RET inhibitors such as selpercatinib or pralsetinib if available?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "RET rearrangement positive",
              "RET rearrangement",
              "RET rearrangement discovered prior to first-line systemic therapy",
              "First-Line Therapy",
              "Useful in Certain Circumstances Cabozantinib",
              "Progression",
              "Subsequent Therapy",
              "Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma"
            ]
          }
        }
      ],
      "answer": "For advanced or metastatic squamous cell lung carcinoma with confirmed RET rearrangement before systemic therapy, established RET inhibitors like selpercatinib or pralsetinib are the preferred first-line options if available, due to superior efficacy and safety profiles; cabozantinib is considered only when these agents are inaccessible.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_9a5ffb313e6f",
      "question": "In a patient with stage IIIA non-small cell lung cancer (T1–2, N2) who has previously undergone thoracic radiation therapy for another malignancy, is perioperative therapy with chemoradiation still an appropriate option, or should alternative systemic therapy be prioritized due to prior radiation exposure?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "For stage IIIA (T1–2, N2) non-small cell lung cancer patients with prior thoracic radiation, concurrent chemoradiation carries increased risk of cumulative toxicity, particularly pulmonary and cardiac complications. Systemic therapy should be prioritized, as repeat radiation in previously treated fields is generally not recommended except in highly selected cases.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_3c79c3124da2",
      "question": "For a patient with completely resected stage IA non-small cell lung cancer (T1abc, N0), who has positive surgical margins (R1 or R2), is resection always preferred over radiotherapy, or are there clinical circumstances where radiotherapy may be considered appropriate as a primary approach?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (T1abc, N0); Margins positive (R1, R2)",
              "Resection (preferred) or RT (category 2B)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Severe hemoptysis",
              "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "In completely resected stage IA non-small cell lung cancer with positive margins, re-resection is the preferred option if technically feasible and medically suitable. However, radiotherapy is considered a category 2B alternative when re-resection is not feasible due to patient comorbidities, anatomical limitations, or surgical risk, making it an acceptable primary local treatment in select circumstances.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_4c59ca457a18",
      "question": "A 54-year-old woman is diagnosed with pruritus and fatigue. Laboratory studies reveal elevated alkaline phosphatase and positive anti-mitochondrial antibodies. She is diagnosed with an autoimmune destruction of intrahepatic bile ducts. Her hepatologist prescribes a bile acid medication that is the standard first-line treatment for her condition, though the precise mechanism by which it benefits hepatobiliary function at the cellular or molecular level remains unclear. Which best describes the current understanding of this drug’s mechanism of action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Biliary cirrhosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0023892",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0042105",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Primary biliary cholangitis is treated with ursodiol, but despite clinical benefit, its detailed molecular mechanism remains undetermined.",
      "umls_path": [
        "Biliary cirrhosis",
        "may_be_treated_by",
        "Ursodiol",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has primary biliary cholangitis, an autoimmune disease leading to progressive intrahepatic bile duct destruction. Ursodiol (ursodeoxycholic acid) is the first-line therapy for this condition, improving liver biochemistry and delaying disease progression. However, despite widespread clinical use, ursodiol’s exact molecular mechanism in this context is not fully understood. It is thought to alter bile acid composition, reduce cytotoxicity, and improve bile flow, but the detailed cellular targets and pathways responsible for its beneficial effects remain unresolved. Thus, its mechanism is best described as unknown at the cellular or molecular level.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_0cbe72d130ce",
      "question": "A 65-year-old woman is admitted with fever, hypotension, and severe muscle pain following a traumatic wound contaminated with soil. Blood cultures are positive for an anaerobic, Gram-positive rod, and she is diagnosed with a rapidly progressing soft tissue infection. She is started on intravenous antibiotics, including a third-generation cephalosporin that acts by binding to penicillin-binding proteins, thereby inhibiting the cross-linking of peptidoglycan chains in the bacterial cell wall. This disrupts cell wall synthesis and leads to bacterial lysis. Which class of pharmacological agents best characterizes the primary mechanism of action of this antibiotic?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Clostridial infection"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0009062",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0007554",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme Inhibitors",
      "reasoning_path": "Severe clostridial infection → cefotaxime treatment → binds PBPs → inhibits cell wall synthesis enzymes → classified as enzyme inhibitors.",
      "umls_path": [
        "Clostridial infection",
        "may_be_treated_by",
        "Cefotaxime",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s presentation is consistent with a severe clostridial infection, such as gas gangrene, for which broad-spectrum antibiotics like cefotaxime are frequently administered. Cefotaxime is a third-generation cephalosporin that exerts its antibacterial effect by targeting and binding to bacterial penicillin-binding proteins (PBPs), which are essential enzymes involved in the final stages of bacterial cell wall synthesis. Specifically, PBPs catalyze the cross-linking of peptidoglycan strands, a critical step for maintaining cell wall integrity. By inhibiting these enzymes, cefotaxime disrupts peptidoglycan synthesis, resulting in a weakened cell wall and subsequent osmotic lysis of the bacterium. Therefore, cefotaxime and other beta-lactam antibiotics are classified as enzyme inhibitors, as their primary mechanism involves inhibition of bacterial enzymes essential for cell wall construction.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_6f9b95592444",
      "question": "A 20-year-old woman presents to the clinic with a history of severe lower abdominal pain beginning a few hours before the onset of menstruation and lasting for the first two days of her period. She describes the pain as cramping, sometimes accompanied by nausea and headache, and notes that over-the-counter acetaminophen provides little relief. Her physician prescribes a nonsteroidal anti-inflammatory drug that inhibits the first committed enzyme in the synthesis of a class of lipid mediators responsible for increased uterine contractions. Which molecular target is primarily inhibited by this therapy to achieve symptom relief in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Dysmenorrhea"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0013390",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0025041",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 1 (Cyclooxygenase-1, COX-1)",
      "reasoning_path": "Patient has primary dysmenorrhea → Prostaglandin-mediated uterine contractions → Meclofenamate sodium prescribed → NSAID mechanism: inhibits prostaglandin G/H synthase 1 (COX-1) → Decreases prostaglandin synthesis → Relieves cramping and pain.",
      "umls_path": [
        "Dysmenorrhea",
        "may_be_treated_by",
        "Meclofenamate Sodium",
        "has_target",
        "Prostaglandin G/H Synthase 1"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Primary dysmenorrhea is caused by increased production of uterine prostaglandins, particularly prostaglandin F2α, which promotes myometrial contractions and pain. Meclofenamate sodium, a nonsteroidal anti-inflammatory drug (NSAID), alleviates symptoms by inhibiting prostaglandin synthesis. The drug achieves this by blocking the activity of prostaglandin G/H synthase 1 (COX-1), an enzyme that catalyzes the conversion of arachidonic acid to prostaglandin H2, the precursor for all prostaglandins. By reducing prostaglandin levels, the drug decreases uterine contractility and associated pain. Thus, the primary molecular target responsible for symptom improvement is prostaglandin G/H synthase 1 (COX-1).",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_11acaa56cc93",
      "question": "A 54-year-old woman presents with chronic, pruritic, erythematous plaques on the dorsal surface of both hands. She has a history of atopic dermatitis and works as a florist, frequently exposed to irritants. After failing topical emollients, her dermatologist prescribes a medication that acts as a high-potency anti-inflammatory agent by modulating gene transcription to suppress the synthesis of pro-inflammatory mediators such as prostaglandins and leukotrienes. Which class of drugs exerts anti-inflammatory effects via a similar mechanism of inhibiting the production of leukotrienes?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Dermatoses, Hand"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0018567",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0700603",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lipoxygenase inhibitors",
      "reasoning_path": "Betamethasone (a corticosteroid) suppresses inflammation by reducing leukotriene synthesis via upstream inhibition of phospholipase A2; lipoxygenase inhibitors reduce leukotrienes directly by blocking lipoxygenase—both decrease leukotriene-mediated inflammation.",
      "umls_path": [
        "Dermatoses, Hand",
        "may_be_treated_by",
        "Betamethasone sodium phosphate",
        "has_mechanism_of_action",
        "Lipoxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s chronic hand dermatitis was treated with betamethasone sodium phosphate, a potent topical corticosteroid. Corticosteroids exert their anti-inflammatory effects primarily through regulation of gene transcription: they induce lipocortin-1, which suppresses phospholipase A2, thereby reducing the release of arachidonic acid from membrane phospholipids. This results in decreased synthesis of both prostaglandins (via cyclooxygenase) and leukotrienes (via lipoxygenase). Lipoxygenase inhibitors, such as zileuton, directly block the lipoxygenase pathway, thereby reducing leukotriene synthesis. Thus, both corticosteroids and lipoxygenase inhibitors decrease leukotriene-mediated inflammation, although corticosteroids do so indirectly (upstream) and lipoxygenase inhibitors act directly on the lipoxygenase enzyme. This shared impact on leukotriene pathways underlies their similar anti-inflammatory effects.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_6c5eda641bb2",
      "question": "A 27-year-old schoolteacher presents with a two-day history of sore throat, nasal congestion, sneezing, and mild cough. She has no fever and her physical exam is unremarkable except for erythematous nasal mucosa. She requests advice on over-the-counter remedies. Her clinician recommends a lozenge containing a metal salt known to alter local pH and potentially interfere with viral processes in the oropharynx. By which molecular mechanism does this supplement most likely provide symptomatic benefit in her self-limited illness?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Acute nasopharyngitis [common cold]"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0009443",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0770983",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Acid-base activity",
      "reasoning_path": "Acute nasopharyngitis (common cold) is treated with zinc acetate; its efficacy is attributed to acid-base activity, which alters mucosal pH and disrupts viral replication.",
      "umls_path": [
        "Acute nasopharyngitis [common cold]",
        "may_be_treated_by",
        "Zinc acetate anhydrous",
        "has_mechanism_of_action",
        "Acid-Base Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient has symptoms consistent with acute nasopharyngitis, commonly caused by rhinoviruses. Zinc acetate lozenges are sometimes recommended to reduce the duration or severity of the common cold. The proposed mechanism involves the acid-base activity of zinc ions: when zinc acetate dissolves in the oral cavity, it releases free zinc ions that can alter the local mucosal environment, particularly by modulating pH. This acid-base activity may disrupt viral adherence to mucosal cells and interfere with viral replication or protein function, which are sensitive to pH shifts. Additionally, zinc may have direct antiviral effects by inhibiting viral uncoating or polymerase activity. Thus, the primary pharmacological action underlying zinc's efficacy in this context is its acid-base activity at the mucosal surface, contributing to both symptomatic relief and possible shortening of the illness.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_0ceebc3bc785",
      "question": "A 34-year-old woman presents with episodic numbness and blanching of her fingers in response to cold exposure. She describes her fingers turning white, then blue, and finally red upon rewarming, often accompanied by pain and tingling. After ruling out secondary causes, her physician prescribes a medication that improves her symptoms by blocking a specific class of G protein-coupled receptors on vascular smooth muscle, thereby decreasing peripheral vascular resistance and promoting vasodilation. Which drug class is most likely responsible for this effect, and what is the precise molecular mechanism by which it alleviates her symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Raynaud's disease"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0034734",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0700578",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Adrenergic alpha-antagonists—blockade of alpha-adrenergic receptors on vascular smooth muscle",
      "reasoning_path": "Raynaud's phenomenon involves excessive alpha-adrenergic–mediated vasoconstriction; alpha-antagonists block these receptors, promoting vasodilation and reducing symptoms.",
      "umls_path": [
        "Raynaud's disease",
        "may_be_treated_by",
        "Prazosin Hydrochloride",
        "has_mechanism_of_action",
        "Adrenergic alpha-Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient’s symptoms are classic for Raynaud’s phenomenon, characterized by episodic vasospasm of digital arteries in response to cold or stress. The underlying pathophysiology involves exaggerated sympathetic-mediated vasoconstriction. Adrenergic alpha-antagonists, such as prazosin or doxazosin, exert their therapeutic effect by competitively inhibiting alpha-1 adrenergic receptors located on vascular smooth muscle cells. These G protein-coupled receptors, when activated by norepinephrine, cause vasoconstriction. By blocking these receptors, alpha-antagonists reduce smooth muscle contraction, leading to vasodilation, decreased peripheral vascular resistance, and improved blood flow to the extremities. This mechanism directly targets the abnormal vasoconstrictive response in Raynaud’s disease, thereby reducing the frequency and severity of episodes. Beta blockers, in contrast, may worsen symptoms by allowing unopposed alpha-mediated vasoconstriction. Thus, alpha-antagonists are a rational pharmacologic choice for vasospastic disorders like Raynaud’s disease.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_d464eecfbb10",
      "question": "A 54-year-old woman is admitted with profuse watery diarrhea, abdominal pain, and fever two weeks after completing a course of clindamycin for a dental infection. Stool studies confirm the presence of a toxin-producing bacterial pathogen. She is started on an oral antimicrobial agent that is commonly used in this setting, but the precise details of its cellular or molecular action in treating her condition remain unclear. What is the current understanding of the molecular mechanism by which this drug exerts its therapeutic effect in this context?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "pseudomembranous enterocolitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0014358",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0282239",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The precise cellular or molecular mechanism by which metronidazole treats pseudomembranous enterocolitis is not clearly defined.",
      "reasoning_path": "Pseudomembranous enterocolitis (often C. difficile) is treated with metronidazole, but the detailed cellular or molecular mechanism responsible for its benefit is not conclusively established.",
      "umls_path": [
        "pseudomembranous enterocolitis",
        "may_be_treated_by",
        "Metronidazole hydrochloride",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has pseudomembranous enterocolitis (most commonly due to Clostridioides difficile) following antibiotic use. Metronidazole is a standard therapy for this infection, acting as an antimicrobial agent against anaerobic bacteria, including C. difficile. While it is believed to enter microbial cells and disrupt DNA synthesis via nitroreductive activation, the specific molecular interactions responsible for its therapeutic effect in pseudomembranous enterocolitis remain incompletely understood. No definitive cellular target or pathway uniquely explains its clinical efficacy in this context. Thus, the exact mechanism of action for metronidazole in this syndrome is considered undefined at the molecular level.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_e57b7c4586f2",
      "question": "For a patient with newly diagnosed advanced non-small cell lung cancer (NSCLC) of adenocarcinoma histology and confirmed distant metastases, if comprehensive molecular profiling reveals no actionable driver mutations but PD-L1 expression is found to be 70%, which should take priority as the initial systemic therapy: PD-1/PD-L1 inhibitor monotherapy or platinum-based chemotherapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Disseminated metastases",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "In this clinical setting—advanced NSCLC, adenocarcinoma subtype, no actionable mutations, and high PD-L1 expression (≥50%)—PD-1/PD-L1 inhibitor monotherapy is prioritized as first-line systemic therapy over platinum-based chemotherapy, according to current evidence and guideline consensus.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_60fd9e2f124f",
      "question": "A 7-year-old boy presents with frequent episodes of spontaneous bruising and prolonged bleeding after minor injuries. Laboratory studies reveal a markedly prolonged prothrombin time and reduced activity of a specific coagulation protein. He is diagnosed with a rare inherited bleeding disorder and started on intravenous therapy with a recombinant protein that directly enhances the activity of serine proteases within the coagulation cascade, leading to increased generation of activated clotting factors and improved hemostasis. Which general pharmacological class best describes the mechanism of action of this recombinant therapy?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Factor VII deficiency"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0015503",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1307126",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme activators",
      "reasoning_path": "Bleeding disorder (factor VII deficiency) → recombinant coagulation factor administered → increases enzymatic activity of clotting cascade → mechanism class: enzyme activator.",
      "umls_path": [
        "Factor VII deficiency",
        "may_be_treated_by",
        "Coagulation Factor VIII",
        "has_mechanism_of_action",
        "Enzyme Activators"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This vignette describes a patient with a rare bleeding disorder, likely congenital factor VII deficiency, manifesting as easy bruising and prolonged bleeding. The therapy provided is a recombinant form of a coagulation factor that directly increases the activity of the clotting cascade by acting as a co-factor or enzyme activator. Such recombinant factor proteins (e.g., recombinant factor VIIa) function by accelerating the conversion of inactive clotting factors to their active forms, ultimately resulting in enhanced thrombin generation and fibrin clot formation. This mechanistic action places these agents in the general pharmacological class of 'enzyme activators,' as they promote enzymatic processes within a physiological pathway—in this case, blood coagulation.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_4eae2f37ea2f",
      "question": "What is the unique PMID for the 2025 BMC Gastroenterology article titled “Challenges and needs in the management of non-alcoholic fatty liver disease from the perspective of gastroenterology and hepatology specialists: a qualitative study,” authored by Salmanizadeh F?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"Challenges and needs in the management of non-alcoholic fatty liver disease from the perspective of gastroenterology and hepatology specialists\"[ti] AND Salmanizadeh F[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40405078"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_2689cec14175",
      "question": "A 35-year-old man presents with pruritic, scaling lesions between the toes and on the plantar surface of his feet. He reports that the symptoms began after using shared showers at his gym. Examination reveals erythematous, macerated plaques with central clearing. He is prescribed a topical medication that targets fungal cell growth by interfering with ribosomal function and ultimately blocking the synthesis of essential fungal proteins. Which broad pharmacological mechanism underlies the therapeutic effect of this agent in this patient’s condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Dermatophytosis of foot"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0040259",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0055711",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Protein synthesis inhibition",
      "reasoning_path": "Patient with tinea pedis is treated with ciclopirox, a topical antifungal. Ciclopirox works by inhibiting fungal protein synthesis, which disrupts cell growth and survival.",
      "umls_path": [
        "Dermatophytosis of foot",
        "may_be_treated_by",
        "Ciclopirox-containing product",
        "has_mechanism_of_action",
        "Protein Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has classic findings of tinea pedis, a dermatophyte infection. Ciclopirox is a topical antifungal agent often used for superficial mycoses such as tinea pedis. Its primary mechanism is inhibition of fungal protein synthesis. Ciclopirox chelates polyvalent cations (such as Fe3+ and Al3+), which disrupts the metal-dependent enzymes necessary for energy production and macromolecule synthesis, including proteins. By interfering with ribosomal function and enzyme activity, ciclopirox impairs the synthesis of essential proteins required for fungal cell growth, division, and survival, leading to cell death. Unlike azoles or allylamines, which target ergosterol synthesis, ciclopirox’s main antifungal action is through protein synthesis inhibition. This mechanistic distinction is important when considering resistance patterns and alternative treatments for superficial fungal infections.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_32957d6176f2",
      "question": "In a patient with advanced non-small cell lung cancer (NSCLC) histologically classified as adenocarcinoma, large cell carcinoma, or NSCLC not otherwise specified, with confirmed BRAF V600E mutation, should BRAF-targeted therapy be considered if the patient has a significant history of prior thoracic radiotherapy and ongoing palliative care needs?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "BRAF V600E mutation positive"
            ]
          }
        }
      ],
      "answer": "Yes. The presence of a BRAF V600E mutation in advanced NSCLC indicates eligibility for BRAF-targeted therapy, such as a BRAF inhibitor (± MEK inhibitor), regardless of prior thoracic radiotherapy or concurrent palliative care requirements, provided overall clinical status permits systemic treatment.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_e8f0e79d1ced",
      "question": "In a patient with stage II non-small cell lung cancer (defined as T2b, N0), if a brain MRI with contrast is omitted from the preoperative workup, does this omission compromise the adequacy of distant metastasis evaluation compared to a patient with stage IIIA (T3, N1) disease?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, omission of brain MRI with contrast in preoperative evaluation for stage II (T2b, N0) non-small cell lung cancer may compromise the thoroughness of distant metastasis assessment, as brain MRI is routinely required for stage II and above to exclude occult brain involvement, which directly impacts surgical candidacy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_54ab5f77e13e",
      "question": "An 8-year-old girl presents with persistent joint pain and morning stiffness affecting her wrists and knees for several weeks. She has mild swelling and limited range of motion in the affected joints. Her pediatrician initiates a medication that provides significant relief from pain and swelling within days. This drug exerts its effect by blocking a key enzyme involved in the synthesis of pro-inflammatory mediators derived from arachidonic acid. Which enzyme inhibition is primarily responsible for the reduction in joint inflammation observed in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Juvenile idiopathic arthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3495559",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020740",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 2 (COX-2)",
      "reasoning_path": "Juvenile idiopathic arthritis → treatment with NSAIDs (e.g., ibuprofen) → inhibition of COX-2 → decreased prostaglandin synthesis → reduced inflammation and pain.",
      "umls_path": [
        "Juvenile idiopathic arthritis",
        "may_be_treated_by",
        "Ibuprofen",
        "has_target",
        "Prostaglandin G/H Synthase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This child has juvenile idiopathic arthritis (JIA), an autoimmune condition causing chronic joint inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, are often used as first-line therapy to manage pain and swelling in JIA. NSAIDs work by inhibiting the enzyme prostaglandin G/H synthase 2, also known as cyclooxygenase-2 (COX-2). COX-2 catalyzes the conversion of arachidonic acid to prostaglandins, which are potent mediators of inflammation, pain, and fever. By blocking COX-2, NSAIDs decrease prostaglandin production, leading to reduced vasodilation, edema, and leukocyte infiltration in the joints. This mechanistic pathway explains the clinical improvement in joint symptoms observed in children with JIA who are treated with NSAIDs. COX-2 inhibition thus underlies the anti-inflammatory and analgesic effects seen in this context.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_4b08124a8be1",
      "question": "A 58-year-old man with relapsed diffuse large B-cell lymphoma receives CAR-T cell therapy. Within 24 hours, he develops high fevers, hypotension, and hypoxia. Laboratory studies reveal elevated C-reactive protein and markedly increased serum interleukin-6 levels. The intensive care team administers an IV monoclonal antibody that rapidly improves his hemodynamics and oxygenation by directly interfering with a cytokine signaling pathway. Which molecular target is inhibited by this therapy to attenuate his life-threatening inflammatory response?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "cytokine release syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0948245",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1609165",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Interleukin-6 receptor (IL-6R), specifically the alpha subunit (IL-6Rα)",
      "reasoning_path": "CAR-T therapy induces CRS via IL-6; tocilizumab blocks the IL-6Rα, halting IL-6-driven inflammation and resolving symptoms.",
      "umls_path": [
        "cytokine release syndrome",
        "may_be_treated_by",
        "Tocilizumab-containing product",
        "has_target",
        "Interleukin-6 Receptor Subunit Alpha"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "CAR-T cell therapy can trigger cytokine release syndrome (CRS), a severe inflammatory state characterized by excessive cytokine production, notably interleukin-6 (IL-6). IL-6 exerts its pro-inflammatory effects by binding to its receptor, which consists of the IL-6 receptor alpha subunit (IL-6Rα) and a signal-transducing component (gp130). Tocilizumab, an anti-IL-6R monoclonal antibody, is used to treat severe CRS. It binds specifically to both soluble and membrane-bound IL-6Rα, blocking IL-6 from activating its downstream signaling pathways (such as JAK-STAT). This inhibition curtails the inflammatory cascade responsible for the clinical manifestations of CRS (fever, hypotension, hypoxia). Tocilizumab's rapid effect in CRS is due to its targeted blockade of IL-6Rα, not general cytokine suppression or direct action on CAR-T cells themselves. Thus, the alpha subunit of the IL-6 receptor is the key molecular target mediating tocilizumab's therapeutic benefits in CRS.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_01f560e8bb15",
      "question": "In a patient with biopsy-proven synchronous pulmonary nodules located in the same lobe, classified as T3N0–1, how would the discovery of a positive mediastinal lymph node impact the initial management strategy compared to cases with confirmed N0–1 status?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
              "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "No disease outside of chest",
              "Pathologic mediastinal lymph node evaluation",
              "N0–1",
              "Initial Treatment (NSCL-12)"
            ]
          }
        }
      ],
      "answer": "The presence of a positive mediastinal lymph node would upstage the disease from T3N0–1 to at least stage IIIA, which necessitates additional mediastinal evaluation and consideration of multimodal perioperative therapy, rather than proceeding directly to surgical management as might be considered for T3N0–1 without mediastinal involvement.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_a2c1e016474e",
      "question": "In a patient with stage IIIA (T4, N1) non-small cell lung cancer that is deemed resectable and shows invasion into the mediastinum, if both concurrent chemoradiation and primary surgical resection are technically feasible, which treatment should be prioritized as initial management and why?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Stage IIIA (T4, N0–1)",
              "Treatment (NSCL-7)",
              "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
              "Systemic therapy or Concurrent chemoradiation",
              "Surgical reevaluation including chest CT ± PET/CT",
              "Surgery",
              "Margins negative (R0)",
              "Observe or Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "For resectable stage IIIA (T4, N1) non-small cell lung cancer with mediastinal invasion, initial systemic therapy or concurrent chemoradiation is generally prioritized over immediate surgical resection. This approach increases the likelihood of margin-negative (R0) resection, addresses micrometastatic disease, and allows for surgical reevaluation based on treatment response. Direct surgery is typically reserved for select cases without bulky disease or major invasion precluding complete resection.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_d2fcb6a08bb6",
      "question": "A 54-year-old woman who recently underwent allogeneic stem cell transplantation develops persistent diarrhea, skin rash, and elevated liver enzymes despite high-dose corticosteroids. Her medical team decides to initiate an immunomodulatory agent that is known to suppress the production of certain pro-inflammatory cytokines implicated in tissue injury. This medication is most effective in this setting by directly inhibiting which molecular target to attenuate the ongoing immune-mediated damage?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Graft Versus Host Disease"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0018133",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0039736",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Tumor Necrosis Factor",
      "reasoning_path": "GVHD refractory to steroids is managed with thalidomide, which inhibits TNF production, thereby attenuating cytokine-driven inflammation and tissue injury characteristic of this disease.",
      "umls_path": [
        "Graft Versus Host Disease",
        "may_be_treated_by",
        "Thalidomide",
        "has_target",
        "Tumor Necrosis Factor"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient is experiencing steroid-refractory graft-versus-host disease (GVHD), a serious complication of allogeneic stem cell transplantation characterized by immune-mediated attack on host tissues. In such cases, thalidomide or its analogs may be used for their immunomodulatory properties. The central mechanism involves inhibition of tumor necrosis factor (TNF), a cytokine that promotes inflammation and tissue destruction in GVHD. By suppressing TNF synthesis and release, thalidomide reduces leukocyte recruitment, cytokine cascades, and subsequent tissue damage. This targeted cytokine blockade is especially important in refractory cases where broad immunosuppression has failed, as TNF is a key driver of the inflammatory process in GVHD. Therefore, the primary molecular target responsible for the drug’s therapeutic effect in this context is TNF.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_efb6527c38ce",
      "question": "In a patient with a biopsy-proven synchronous lung lesion in a different lobe of the ipsilateral lung and no evidence of distant metastasis, does the presence of such a lesion automatically upstage the disease to stage IV non-small cell lung cancer (NSCLC)?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (peripheral T1abc, N0)",
              "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
              "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Disease outside of chest",
              "Systemic therapy for metastatic disease (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No; a synchronous nodule in a different lobe of the ipsilateral lung corresponds to T4 disease (stage IIIA or IIIB, depending on nodal status) rather than stage IV. Stage IV is reserved for distant metastases, including disease outside of the chest.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_74b58b1e42f5",
      "question": "Which diseases are associated with the target RAF1 (Ensembl ID ENSG00000132155) with a minimum relevance score of 0.5 in OpenTargets?",
      "tool_calls": [
        {
          "tool": "opentargets.search",
          "params": {
            "target_id": "ENSG00000132155",
            "min_score": 0.5
          }
        }
      ],
      "answer": [
        {
          "disease_id": "MONDO_0018997",
          "disease_name": "Noonan syndrome",
          "score": 0.8743368084331032
        },
        {
          "disease_id": "MONDO_0007893",
          "disease_name": "Noonan syndrome with multiple lentigines",
          "score": 0.8055526401002233
        },
        {
          "disease_id": "EFO_0000407",
          "disease_name": "dilated cardiomyopathy",
          "score": 0.7532212410305463
        },
        {
          "disease_id": "EFO_1001502",
          "disease_name": "rasopathy",
          "score": 0.6750036782937922
        },
        {
          "disease_id": "MONDO_0004992",
          "disease_name": "cancer",
          "score": 0.63228885118352
        },
        {
          "disease_id": "EFO_0000538",
          "disease_name": "hypertrophic cardiomyopathy",
          "score": 0.5688937395310645
        },
        {
          "disease_id": "MONDO_0009026",
          "disease_name": "Costello syndrome",
          "score": 0.5612499326656918
        },
        {
          "disease_id": "EFO_0000681",
          "disease_name": "renal cell carcinoma",
          "score": 0.5283197189339974
        },
        {
          "disease_id": "HP_0001626",
          "disease_name": "Abnormality of the cardiovascular system",
          "score": 0.5281170330281758
        },
        {
          "disease_id": "EFO_0000616",
          "disease_name": "neoplasm",
          "score": 0.5216825458299084
        },
        {
          "disease_id": "MONDO_0020297",
          "disease_name": "Noonan syndrome and Noonan-related syndrome",
          "score": 0.5146735424695826
        },
        {
          "disease_id": "EFO_0000182",
          "disease_name": "hepatocellular carcinoma",
          "score": 0.5089592119094807
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_d88925def306",
      "question": "A 58-year-old man in the intensive care unit develops acute onset dyspnea, tachycardia, and jugular venous distension following massive pulmonary embolism. Echocardiography shows dilated right ventricle with poor contractility and elevated pulmonary artery pressures. To rapidly lower his pulmonary vascular resistance and improve right heart function, the team initiates a continuous intravenous infusion of a medication that mimics the effects of endogenous prostacyclin. Through activation of which receptor class does this agent primarily exert its beneficial hemodynamic effects in this scenario?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Lung, Shock"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0852283",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0354594",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Prostaglandin (prostacyclin/IP) receptor agonists",
      "reasoning_path": "Acute pulmonary hypertension with right heart failure → prostacyclin analog (epoprostenol) infusion → IP (prostacyclin) receptor agonism → increased cAMP in pulmonary vascular smooth muscle → pulmonary vasodilation → reduced right ventricular afterload and improved hemodynamics.",
      "umls_path": [
        "Lung, Shock",
        "may_be_treated_by",
        "Epoprostenol sodium",
        "has_mechanism_of_action",
        "Prostaglandin Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has acute right heart failure due to severe pulmonary hypertension, likely from a massive pulmonary embolism. The drug initiated is a prostacyclin analog, such as epoprostenol, which is used in acute settings for rapid pulmonary vasodilation. Epoprostenol mimics endogenous prostacyclin (PGI2) and acts as an agonist at IP (prostacyclin) receptors on vascular smooth muscle cells. Activation of these Gs-protein-coupled receptors increases intracellular cAMP, leading to smooth muscle relaxation and vasodilation, specifically within the pulmonary circulation. This reduces pulmonary vascular resistance, decreases right ventricular afterload, and improves cardiac output. Thus, the therapeutic effect in acute pulmonary vascular compromise is mediated primarily via agonism of prostacyclin (IP) receptors.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_5fd21da92fd7",
      "question": "A 54-year-old woman presents with progressive numbness, tingling, and weakness in her lower limbs. She has a family history of similar symptoms and genetic testing reveals a pathogenic transthyretin (TTR) gene variant. Neurological examination confirms a length-dependent sensorimotor polyneuropathy. Her physician prescribes a recently approved RNA interference (RNAi) therapeutic that targets hepatic synthesis of mutant and wild-type TTR protein by engaging the RNA-induced silencing complex (RISC) to degrade specific mRNA transcripts. Which molecular process is disrupted by this therapy to achieve the observed clinical benefit?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "familial polyneuropathy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0751448",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C5678686",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Degradation of transthyretin (TTR) mRNA via RNA interference (gene silencing)",
      "reasoning_path": "Familial TTR polyneuropathy → mutant TTR gene → misfolded TTR protein → amyloid neuropathy. Vutrisiran is a siRNA → binds TTR mRNA in liver → RISC-mediated mRNA cleavage → reduced TTR protein synthesis → decreased amyloid deposition → symptom improvement.",
      "umls_path": [
        "familial polyneuropathy",
        "may_be_treated_by",
        "vutrisiran sodium",
        "has_mechanism_of_action",
        "RNA Synthetase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has hereditary transthyretin-mediated (hATTR) amyloidosis, a form of familial polyneuropathy caused by pathogenic TTR variants leading to misfolded TTR protein deposition in nerves. Vutrisiran sodium is a small interfering RNA (siRNA) drug designed to treat this condition. It operates by binding to TTR mRNA in hepatocytes and recruiting the RNA-induced silencing complex (RISC), which cleaves and degrades the targeted mRNA. This post-transcriptional gene silencing reduces both mutant and wild-type TTR protein synthesis, thereby lowering circulating amyloidogenic TTR that contributes to neuropathy. This mechanism is distinct from traditional inhibitors or enzyme blockers; it relies on sequence-specific mRNA degradation, not inhibition of RNA synthetases. The clinical benefit arises from reduced deposition of TTR amyloid in peripheral nerves, stabilizing or improving neurological function.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_9d9be514a77d",
      "question": "A 68-year-old woman with poorly controlled diabetes presents with a chronic, non-healing ulcer on her lower leg. Despite standard wound care, the lesion persists. Her clinician adds a topical agent containing a metallic salt, which is known to enhance the local wound environment by creating mildly acidic conditions and exerting antimicrobial effects. Through which primary pharmacological mechanism does this agent promote healing in chronic skin ulcers?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Skin ulcer"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0037299",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0772384",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Acid-base activity",
      "reasoning_path": "Chronic skin ulcers are treated with topical zinc sulfate heptahydrate, which acts by acidifying the wound environment; this acid-base activity inhibits microbes and supports tissue repair, driving its therapeutic effect.",
      "umls_path": [
        "Skin ulcer",
        "may_be_treated_by",
        "Zinc Sulfate Heptahydrate",
        "has_mechanism_of_action",
        "Acid-Base Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has a chronic skin ulcer, a common complication in individuals with diabetes due to impaired circulation and immune response. Topical zinc sulfate heptahydrate can be used as an adjunct to promote wound healing. The therapeutic effect of this compound is mainly due to its acid-base activity: when applied to the ulcer, it creates a mildly acidic environment at the wound surface. This acidity inhibits growth of pathogenic bacteria and fungi, reduces protease activity that could degrade new tissue, and favors the migration and proliferation of epithelial and fibroblast cells necessary for tissue repair. By optimizing the local pH, zinc sulfate also facilitates enzymatic activity involved in matrix remodeling and overall wound closure. Thus, the direct modulation of the acid-base environment at the wound site is the primary mechanism through which this agent supports healing in chronic ulcers.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_221e696a9618",
      "question": "A poultry farmer reports increased mortality and lethargy among young chickens. Laboratory analysis confirms infection with a Plasmodium species responsible for avian malaria. A veterinary pharmacologist recommends a drug that accumulates within the parasite's food vacuole, leading to inhibition of DNA and RNA synthesis, thereby impairing the organism’s proliferation and survival. Which drug mechanism best explains the therapeutic effect observed in this scenario?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Avian malaria"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0024533",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1383389",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Inhibition of nucleic acid synthesis",
      "reasoning_path": "Avian malaria is treated with chloroquine hydrochloride, which exerts its effect by accumulating in the parasite’s food vacuole and inhibiting nucleic acid synthesis, thereby disrupting parasite replication and survival.",
      "umls_path": [
        "Avian malaria",
        "may_be_treated_by",
        "Chloroquine hydrochloride",
        "has_mechanism_of_action",
        "Nucleic Acid Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this case, the chickens are affected by avian malaria, a disease caused by Plasmodium species similar to those infecting humans. Chloroquine hydrochloride is used as a treatment, functioning by accumulating within the acidic food vacuole of the parasite. Once inside, it interferes with the detoxification of heme—a process essential for parasite survival—and, crucially, it also disrupts nucleic acid synthesis by inhibiting DNA and RNA polymerase activity. This inhibition of nucleic acid synthesis prevents replication and transcription, effectively stopping the parasite from multiplying within the host. The ultimate result is parasite death and clinical improvement in the infected birds. Thus, the primary pharmacologic mechanism underlying chloroquine's efficacy in treating avian malaria is inhibition of nucleic acid synthesis in the malaria parasite.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_1c400834170e",
      "question": "A 42-year-old man returns from a trip to Central America and develops abdominal pain, loose stools, and mild fever. Stool studies reveal trophozoites with ingested red blood cells, and he is diagnosed with an intestinal protozoal infection. He is started on a nitroimidazole antibiotic, which leads to symptom resolution. Despite the clinical efficacy of this medication, what is the best current description of its precise cellular or molecular target within the protozoal organism?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Amebiasis, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002438",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0025872",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The exact cellular or molecular target remains unknown; the precise mechanism by which nitroimidazoles act against protozoa has not been fully established.",
      "reasoning_path": "Amebiasis is treated with nitroimidazoles; these drugs are activated inside protozoa, causing cytotoxic effects, but the specific molecular target is not fully defined.",
      "umls_path": [
        "Amebiasis, unspecified",
        "may_be_treated_by",
        "Metronidazole",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Nitroimidazole antibiotics, such as metronidazole, are the standard treatment for protozoal infections like those caused by Entamoeba histolytica. These drugs are known to enter protozoal cells and undergo reductive activation by intracellular electron transport proteins. The resulting reactive intermediates are believed to interact with various cellular components, leading to DNA damage and cell death. However, despite decades of clinical use, the exact molecular target or pathway leading to protozoal killing has not been fully characterized. While nucleic acids are suspected to be involved, no single protein or enzyme target has been definitively identified in protozoa. Thus, although nitroimidazoles are highly effective, their mechanism of action at the cellular and molecular level remains incompletely understood.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_04f80cbb7017",
      "question": "A 57-year-old woman with a several-year history of symmetric joint pain and morning stiffness is diagnosed with rheumatoid arthritis. She is started on a nonsteroidal anti-inflammatory drug (NSAID) that, in addition to cyclooxygenase inhibition, is known to reduce inflammation by altering cyclic nucleotide signaling. This effect is mediated through inhibition of a specific enzyme responsible for the degradation of cGMP in immune cells. Which molecular target is most directly involved in this additional anti-inflammatory mechanism?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Rheumatoid arthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003873",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0038792",
            "rela": "has_target"
          }
        }
      ],
      "answer": "cGMP-specific 3',5'-cyclic phosphodiesterase",
      "reasoning_path": "Patient with rheumatoid arthritis is treated with sulindac; sulindac inhibits cGMP-specific PDE, raising cGMP; increased cGMP dampens inflammatory signaling, reducing symptoms.",
      "umls_path": [
        "Rheumatoid arthritis",
        "may_be_treated_by",
        "Sulindac",
        "has_target",
        "cGMP-Specific 3',5'-Cyclic Phosphodiesterase"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "In rheumatoid arthritis, NSAIDs are commonly used for symptomatic control of inflammation. While most NSAIDs primarily act by inhibiting cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, certain agents such as sulindac also inhibit cGMP-specific 3',5'-cyclic phosphodiesterase. Phosphodiesterases (PDEs) hydrolyze cyclic nucleotides like cAMP and cGMP, thus regulating their intracellular concentrations. Inhibition of cGMP-specific PDE increases cGMP levels, which can reduce immune cell activation and inflammatory mediator release. This mechanism provides an adjunct anti-inflammatory effect beyond COX inhibition. Therefore, the therapeutic benefit of sulindac in rheumatoid arthritis involves not only COX enzyme blockade but also suppression of cGMP breakdown through direct inhibition of cGMP-specific 3',5'-cyclic phosphodiesterase.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_9947a8e3a756",
      "question": "For a patient with stage IIIA non-small cell lung cancer (T1–2, N2) and an R1 resection margin after surgery, if consolidation chemoradiation is considered, does this implicitly require the absence of distant metastases at the time of initiation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
              "R1; Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, consolidation chemoradiation after an R1 resection in stage IIIA non-small cell lung cancer is indicated only in the absence of distant metastases, as its intent is local-regional control; the presence of distant metastases would shift management toward systemic or palliative therapies.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_e0d423c28da4",
      "question": "A 54-year-old woman presents with epigastric discomfort and nausea. Upper endoscopy reveals erythematous and edematous mucosa in the proximal duodenum consistent with duodenitis. She is prescribed a medication that acts by competitively inhibiting acetylcholine at specific G protein-coupled receptors in the gastrointestinal tract, leading to decreased smooth muscle contractions and reduced glandular secretions. Which molecular target is responsible for mediating the primary therapeutic action of this agent in her gastrointestinal symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Duodenitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0013298",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0022233",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Muscarinic acetylcholine receptors",
      "reasoning_path": "Isopropamide iodide blocks muscarinic acetylcholine receptors, reducing GI motility and secretions to relieve duodenitis symptoms.",
      "umls_path": [
        "Duodenitis",
        "may_be_treated_by",
        "Isopropamide iodide",
        "has_mechanism_of_action",
        "Cholinergic Muscarinic Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this case, the patient’s duodenitis is managed with isopropamide iodide, a synthetic antimuscarinic agent. Isopropamide iodide exerts its effect by competitively antagonizing muscarinic acetylcholine receptors (primarily M3 subtype) located on smooth muscle and glandular cells in the GI tract. Activation of these receptors by acetylcholine normally increases intestinal motility and stimulates secretions. By blocking these receptors, isopropamide iodide decreases gastrointestinal smooth muscle contractions and reduces acid and mucus secretions, thereby alleviating symptoms such as pain and nausea associated with duodenal inflammation. This pharmacologic action targets the pathophysiological processes that contribute to the discomfort in duodenitis, providing symptomatic relief. Notably, muscarinic antagonists do not address the underlying cause of inflammation but are useful for symptomatic management.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_5fee96758e0b",
      "question": "In a patient diagnosed with metastatic squamous cell carcinoma of the lung (stage M1b) who has an ERBB2 (HER2) mutation identified on broad molecular profiling and an Eastern Cooperative Oncology Group (ECOG) performance status of 2, is fam-trastuzumab deruxtecan-nxki still considered an appropriate treatment option, or is the ECOG performance status of 2 an exclusion criterion?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "ERBB2 (HER2) mutation positive",
              "ERBB2 (HER2) mutation",
              "Progression",
              "Preferred: Fam-trastuzumab deruxtecan-nxki or Other Recommended: Ado-trastuzumab emtansine",
              "Progression",
              "PS 0–2",
              "Systemic Therapy, Subsequent"
            ]
          }
        }
      ],
      "answer": "Fam-trastuzumab deruxtecan-nxki remains an appropriate treatment option for metastatic squamous cell lung carcinoma with an ERBB2 (HER2) mutation when the patient has an ECOG performance status of 0–2; ECOG 2 is not an exclusion criterion.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_38d33a1d4868",
      "question": "In a patient with advanced non-small cell lung cancer (NSCLC) of adenocarcinoma subtype whose tumor harbors an EGFR exon 19 deletion mutation, is it appropriate to consider first-line treatment with amivantamab-vmjw plus lazertinib even if KRAS mutation coexists?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "EGFR exon 19 deletion or exon 21 L858R mutation positive",
              "EGFR exon 19 deletion or exon 21 L858R mutations",
              "EGFR mutation discovered prior to first-line systemic therapy",
              "Other Recommended: Amivantamab-vmjw + lazertinib (category 1)",
              "Progression: Subsequent Therapy (NSCL-22)"
            ]
          }
        }
      ],
      "answer": "The presence of an actionable EGFR exon 19 deletion remains the primary driver for first-line therapy selection in advanced NSCLC, and EGFR-targeted therapy with amivantamab-vmjw plus lazertinib is indicated regardless of concurrent KRAS mutation status, as KRAS mutations do not currently negate the benefit of EGFR inhibition.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_553aa752a2b5",
      "question": "In a patient with advanced squamous cell lung carcinoma who is positive for MET exon 14 skipping mutation and has not received prior systemic therapy, is MET-targeted therapy with crizotinib preferred over standard platinum-based chemotherapy as first-line treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "METex14 skipping mutation positive",
              "METex14 skipping mutation",
              "METex14 skipping mutation discovered prior to first-line systemic therapy",
              "Useful in Certain Circumstances: Crizotinib",
              "Progression",
              "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
            ]
          }
        }
      ],
      "answer": "For advanced squamous cell lung carcinoma with MET exon 14 skipping mutation detected prior to initiation of systemic therapy, MET-targeted therapy such as crizotinib is considered a preferred first-line option over standard platinum-based chemotherapy, given its mutation-specific efficacy demonstrated in clinical evidence.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_b881f0b00752",
      "question": "In a patient diagnosed with stage IVA non-small cell lung cancer presenting with malignant pleural effusion, whose tumor is squamous cell carcinoma, broad molecular testing including EGFR, ALK, KRAS, and other actionable mutations yields negative results, and PD-L1 expression is below 1%. Is immunotherapy with a PD-1/PD-L1 inhibitor as monotherapy considered appropriate first-line systemic treatment in this setting?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1a: pleural or pericardial effusion",
              "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
              "Positive",
              "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "PD-L1 <1% and negative for actionable molecular biomarkers above"
            ]
          }
        }
      ],
      "answer": "No, in patients with squamous cell carcinoma of the lung, stage IV disease, negative for actionable molecular alterations and with PD-L1 expression less than 1%, first-line monotherapy with a PD-1/PD-L1 inhibitor is not indicated. Standard care favors platinum-based doublet chemotherapy; immunotherapy may be added in combination but not as monotherapy in this scenario.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_cb2857e4e4d4",
      "question": "A 34-year-old man recently returned from a trip to South America and presents with a three-week history of persistent fever, weight loss, and multiple non-healing skin ulcers. A biopsy confirms the diagnosis of cutaneous leishmaniasis. His physician initiates an oral antifungal agent that is also active against this protozoal infection. After several weeks, his lesions improve. Further research into resistance patterns reveals that the efficacy of this drug can be compromised by increased activity of an ATP-binding cassette (ABC) transporter that effluxes xenobiotics from cells. Which transporter is most relevant to the mechanism of action and resistance profile of this therapy?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Leishmaniasis, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0023281",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0064113",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Breast cancer resistance protein (BCRP; ABCG2)",
      "reasoning_path": "Leishmaniasis is treated with itraconazole, which is subject to efflux by breast cancer resistance protein (BCRP/ABCG2); BCRP inhibitors can overcome resistance by increasing intracellular drug concentration.",
      "umls_path": [
        "Leishmaniasis, unspecified",
        "may_be_treated_by",
        "Itraconazole",
        "has_mechanism_of_action",
        "Breast Cancer Resistance Protein Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Itraconazole, an azole antifungal agent, is sometimes used off-label for cutaneous leishmaniasis due to its ability to inhibit ergosterol synthesis in the parasite. However, drug resistance is a concern. The ABCG2 transporter, also known as breast cancer resistance protein (BCRP), is an efflux pump that can actively transport azole compounds out of cells, reducing intracellular concentrations and thus therapeutic efficacy. Overexpression of BCRP in Leishmania or host cells can lead to decreased drug accumulation and clinical resistance. Inhibiting BCRP enhances itraconazole’s efficacy by preventing drug efflux, leading to increased intracellular drug levels and improved parasite clearance. Understanding this mechanism is clinically relevant, as BCRP-mediated resistance can limit the effectiveness of azole therapy in leishmaniasis and other infections.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_4294259be65a",
      "question": "A 58-year-old woman with metastatic small intestinal neuroendocrine tumors presents with persistent diarrhea and flushing despite optimized therapy with somatostatin analogues. Laboratory results show elevated 24-hour urinary 5-HIAA levels, indicating ongoing excess serotonin production. Her oncologist initiates an oral agent that specifically inhibits the rate-limiting enzyme responsible for serotonin biosynthesis in enterochromaffin cells. Which enzyme is directly inhibited by this medication, thereby reducing serotonin-mediated symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Carcinoid syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0024586",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2825840",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Tryptophan 5-hydroxylase 1",
      "reasoning_path": "Carcinoid syndrome → excess serotonin → symptoms; telotristat etiprate inhibits TPH1 in enterochromaffin cells → decreased serotonin synthesis → symptom relief.",
      "umls_path": [
        "Carcinoid syndrome",
        "may_be_treated_by",
        "telotristat etiprate",
        "has_target",
        "Tryptophan 5-Hydroxylase 1"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has carcinoid syndrome, caused by serotonin-secreting neuroendocrine tumors. The cardinal symptoms (diarrhea, flushing) are driven by serotonin overproduction. Somatostatin analogues reduce hormone secretion but may be insufficient in refractory cases. Telotristat etiprate is then added; it selectively inhibits tryptophan 5-hydroxylase 1 (TPH1), the rate-limiting enzyme in serotonin biosynthesis in peripheral tissues, notably enterochromaffin cells. By blocking TPH1, telotristat decreases serotonin synthesis, leading to lower circulating serotonin and relief of carcinoid syndrome symptoms. Therefore, the therapeutic effect depends on inhibition of tryptophan 5-hydroxylase 1, not other enzymes in the serotonin pathway.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_90e17081019f",
      "question": "A 42-year-old man presents with pruritic, scaling lesions between the toes and along the lateral aspect of his feet. Physical examination reveals erythematous, macerated plaques with fine scaling. He is diagnosed with a superficial fungal infection and is prescribed a topical ointment that contains an agent historically used to manage various skin infections, including fungal etiologies. Although effective, the precise cellular or molecular target of this agent’s antifungal activity remains incompletely characterized. Which aspect best describes the current understanding of this drug’s mechanism of action in treating this patient’s condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Dermatophytosis of foot"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0040259",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021978",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction—clioquinol’s precise mechanism against dermatophytes is not fully elucidated.",
      "reasoning_path": "Tinea pedis is treated with clioquinol, but the detailed molecular mechanism of clioquinol’s antifungal activity remains undefined.",
      "umls_path": [
        "Dermatophytosis of foot",
        "may_be_treated_by",
        "Clioquinol-containing product",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has tinea pedis (dermatophytosis of the foot), a common superficial fungal infection. Clioquinol, an 8-hydroxyquinoline derivative, is occasionally used topically for such infections due to its antimicrobial and antifungal properties. However, despite its clinical effectiveness, the exact cellular or molecular mechanism by which clioquinol exerts antifungal action is not well established. It is known to chelate metal ions, which may disrupt critical enzymatic processes in microorganisms, but no definitive molecular target (such as a specific fungal enzyme or cellular structure) has been identified. Therefore, the most accurate way to describe clioquinol’s mechanism in this context is that it acts via an unknown or incompletely characterized cellular or molecular interaction.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_4d112054db3d",
      "question": "A 67-year-old woman presents with chronic knee pain and stiffness that worsens with activity and improves with rest. Radiographs reveal joint space narrowing and osteophyte formation consistent with a degenerative joint disease. She is prescribed an oral medication to alleviate her symptoms. This drug primarily inhibits an enzyme responsible for converting arachidonic acid to prostaglandins, thereby reducing local inflammation and pain. Which molecular target does this medication act upon to exert its therapeutic effect in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Osteoarthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0029408",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021246",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 1 (Cyclooxygenase-1, COX-1)",
      "reasoning_path": "Osteoarthritis causes pain via prostaglandin-mediated inflammation. Indomethacin, an NSAID, inhibits prostaglandin G/H synthase 1 (COX-1), reducing prostaglandin synthesis and thus inflammation and pain.",
      "umls_path": [
        "Osteoarthritis",
        "may_be_treated_by",
        "Indomethacin",
        "has_target",
        "Prostaglandin G/H Synthase 1"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has osteoarthritis, a common degenerative joint disease characterized by cartilage breakdown, subchondral bone changes, and secondary synovial inflammation. Nonsteroidal anti-inflammatory drugs (NSAIDs) like indomethacin are often prescribed for symptomatic relief. Indomethacin acts primarily by inhibiting the enzyme prostaglandin G/H synthase 1 (COX-1), as well as COX-2, which are cyclooxygenase isoforms responsible for converting arachidonic acid into prostaglandins. Prostaglandins mediate inflammation, pain, and swelling in affected joints. By inhibiting COX-1 and reducing prostaglandin synthesis, indomethacin alleviates both pain and inflammation. The main therapeutic effect in osteoarthritis is thus achieved through the reduction of local prostaglandin-mediated inflammatory processes in synovial tissues. However, COX-1 inhibition is also associated with gastrointestinal side effects, but for symptom control, its effect on prostaglandin synthesis is most relevant.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_29cb6c8db71e",
      "question": "What diseases are associated with the target MTOR (Ensembl ID ENSG00000198793) in OpenTargets with a minimum relevance score of 0.5?",
      "tool_calls": [
        {
          "tool": "opentargets.search",
          "params": {
            "target_id": "ENSG00000198793",
            "min_score": 0.5
          }
        }
      ],
      "answer": [
        {
          "disease_id": "EFO_0009050",
          "disease_name": "Macrocephaly-intellectual disability-neurodevelopmental disorder-small thorax syndrome",
          "score": 0.8290637055715058
        },
        {
          "disease_id": "MONDO_0011818",
          "disease_name": "isolated focal cortical dysplasia type II",
          "score": 0.8171797250275835
        },
        {
          "disease_id": "MONDO_0100283",
          "disease_name": "overgrowth syndrome and/or cerebral malformations due to abnormalities in MTOR pathway genes",
          "score": 0.6531008507541695
        },
        {
          "disease_id": "EFO_0005772",
          "disease_name": "neurodegenerative disease",
          "score": 0.5602790851398625
        },
        {
          "disease_id": "EFO_0000349",
          "disease_name": "clear cell renal carcinoma",
          "score": 0.5435334415095743
        },
        {
          "disease_id": "MONDO_0032908",
          "disease_name": "CEBALID syndrome",
          "score": 0.5241279996927086
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_22f50fa8a47b",
      "question": "A 57-year-old man with relapsed acute lymphoblastic leukemia is admitted for induction chemotherapy. Within 48 hours, he develops acute kidney injury, hyperkalemia, hyperphosphatemia, and marked hyperuricemia. To prevent further renal damage, he is started on an intravenous medication that rapidly reduces serum uric acid by converting it to allantoin, a more soluble compound. Which general pharmacologic mechanism best describes how this agent achieves its therapeutic effect in this scenario?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Tumor Lysis Syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0041364",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0937932",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme activation (enzyme activator)",
      "reasoning_path": "Tumor lysis syndrome causes hyperuricemia; recombinant urate oxidase is given to convert uric acid to allantoin. This is accomplished by providing an active enzyme that catalyzes uric acid oxidation, so its mechanism is classified as enzyme activation (enzyme activator).",
      "umls_path": [
        "Tumor Lysis Syndrome",
        "may_be_treated_by",
        "Recombinant urate oxidase",
        "has_mechanism_of_action",
        "Enzyme Activators"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient exhibits classic laboratory features of tumor lysis syndrome (TLS): hyperuricemia, hyperkalemia, hyperphosphatemia, and acute renal dysfunction following cytotoxic therapy for hematologic malignancy. TLS leads to massive cell lysis, releasing nucleic acids that are metabolized to uric acid, which can precipitate in renal tubules and worsen kidney injury. Recombinant urate oxidase (rasburicase) is administered in this setting to catalyze the enzymatic oxidation of uric acid to allantoin, a compound much more water-soluble and easily excreted by the kidneys. The drug’s mechanism is not receptor antagonism, inhibition, or mimicking of endogenous substances, but rather direct activation of a metabolic pathway by providing an exogenous enzyme that accelerates substrate conversion. Thus, recombinant urate oxidase functions as an enzyme activator, rapidly reducing uric acid burden and preventing or mitigating renal complications of TLS.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_89c83a1e61bc",
      "question": "A 52-year-old woman presents with acute onset pain, swelling, and warmth localized over her right elbow after a week of increased gardening activity. Examination reveals a fluctuant, tender mass over the olecranon process. She is diagnosed with olecranon bursitis and started on a nonsteroidal anti-inflammatory drug (NSAID). After several days, her symptoms improve markedly. The prescribed medication achieves its therapeutic effect by inhibiting which enzyme, thereby reducing inflammation and pain in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Bursitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0006444",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021246",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 2 (COX-2)",
      "reasoning_path": "Bursitis causes inflammation and pain. Indomethacin, an NSAID, is prescribed. NSAIDs inhibit COX enzymes. COX-2 (prostaglandin G/H synthase 2) mediates inflammation. Indomethacin's inhibition of COX-2 decreases prostaglandin synthesis, relieving symptoms.",
      "umls_path": [
        "Bursitis",
        "may_be_treated_by",
        "Indomethacin",
        "has_target",
        "Prostaglandin G/H Synthase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Olecranon bursitis is an acute inflammatory disorder involving the synovial-lined sac over the elbow. Indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), is often prescribed to reduce pain and swelling in such cases. NSAIDs like indomethacin exert their primary anti-inflammatory effect by inhibiting cyclooxygenase enzymes, specifically prostaglandin G/H synthase 1 and 2 (COX-1 and COX-2). Among these, COX-2 (prostaglandin G/H synthase 2) is the key inducible isoform responsible for upregulating prostaglandin synthesis during inflammation. By blocking COX-2, indomethacin reduces the production of pro-inflammatory prostaglandins, leading to decreased vasodilation, vascular permeability, and recruitment of inflammatory cells, which in turn alleviates the pain and swelling characteristic of bursitis. Therefore, the inhibition of prostaglandin G/H synthase 2 is directly responsible for the therapeutic benefit seen with indomethacin in this scenario.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_5a932a311466",
      "question": "For a patient with stage IIA (T2b, N0) non-small cell lung cancer who undergoes surgical resection with positive margins (R1 or R2), is adjuvant radiotherapy always indicated, or are there situations where surveillance without immediate radiotherapy is acceptable within standard management boundaries?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIA (T2b, N0); Margins positive (R1, R2)",
              "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Adjuvant radiotherapy is not always mandatory after positive-margin resection for stage IIA (T2b, N0) non-small cell lung cancer; surveillance without immediate radiotherapy may be acceptable if further surgery is performed to achieve negative margins or if systemic therapy is administered based on individual risk assessment and clinical judgment.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_6d7d605c28b0",
      "question": "In ClinicalTrials.gov, which completed interventional studies for Multiple Sclerosis involving Laquinimod started in November 2007 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "overallStatus=COMPLETED;conditions=Multiple Sclerosis;interventions.name=Laquinimod;startDateFrom=2007-11-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00509145"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_e9ba9f7b2d0e",
      "question": "A 5-month-old infant is brought to the clinic with a two-day history of erythematous, mildly eroded skin in the diaper area. The lesions are not vesicular or purulent; there is no fever. The pediatrician recommends a non-prescription topical ointment containing a quaternary ammonium compound with documented antimicrobial properties. This compound exerts its effect by interfering with essential microbial metabolic processes. Which general class of pharmacological action best describes the mechanism by which this agent treats the patient’s skin condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Diaper or napkin rash"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011974",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4048241",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme interactions",
      "reasoning_path": "Diaper dermatitis can be complicated by infection. Methylbenzethonium chloride is a topical antimicrobial that acts via enzyme interactions, disrupting microbial metabolism and aiding in rash resolution.",
      "umls_path": [
        "Diaper or napkin rash",
        "may_be_treated_by",
        "Methylbenzethonium Chloride",
        "has_mechanism_of_action",
        "Enzyme Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this clinical scenario, the infant has diaper dermatitis, a common condition often complicated by secondary infection with bacteria or yeast. The pediatrician selects a topical agent with antimicrobial properties. Many such agents, including quaternary ammonium compounds like methylbenzethonium chloride, act by disrupting microbial cell membranes and interfering with key microbial enzymes. This disrupts essential metabolic processes, leading to microbial death or inhibition. Thus, the pharmacological action most relevant to this drug’s therapeutic effect is interaction with microbial enzymes. This is distinct from anti-inflammatory or purely barrier-creators, which act by different mechanisms. Therefore, enzyme interactions constitute the principal pharmacological basis for the antimicrobial effect in this context.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_c6336e294164",
      "question": "For a patient with stage IVA non-small cell lung cancer presenting with pleural effusion and histologically confirmed squamous cell carcinoma, who tests positive for an NTRK1 gene fusion, does the recommendation for NTRK-targeted therapy presume that comprehensive molecular profiling was performed regardless of smoking status?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1a: pleural or pericardial effusion",
              "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
              "Positive",
              "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "NTRK1/2/3 gene fusion positive"
            ]
          }
        }
      ],
      "answer": "Yes; the use of NTRK-targeted therapy in squamous cell carcinoma with NTRK1 gene fusion positivity presumes that broad molecular profiling—including NTRK1/2/3 fusion testing—has been performed regardless of the patient's smoking history, as recommended for advanced non-small cell lung cancer.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_7e0d7e23c528",
      "question": "What is the unique PMID of the article titled “Next-generation sequencing and immuno-informatics for designing a multi-epitope vaccine against HSV-1-induced uveitis,” authored by Cao H and published in Frontiers in Immunology in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"Next-generation sequencing and immuno-informatics for designing a multi-epitope vaccine against HSV-1-induced uveitis.\"[ti] AND Cao H[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "39958333"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_1069e613ed54",
      "question": "A 34-year-old woman presents with chronic, itchy, flaky patches on her scalp that worsen during periods of stress. Examination reveals greasy, yellowish scales and erythema along her hairline and behind the ears. She is started on a medicated shampoo that works by modifying the local chemical environment of the scalp, leading to decreased shedding and improved symptoms. By which primary mechanism does this topical agent exert its therapeutic benefit in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Seborrhea capitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0221244",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0074281",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Physiochemical alteration of the scalp environment (as seen with selenium sulfide)",
      "reasoning_path": "Seborrheic dermatitis → treated with selenium sulfide → selenium sulfide alters scalp environment physiochemically → reduces cell turnover and fungal proliferation → clinical improvement.",
      "umls_path": [
        "Seborrhea capitis",
        "may_be_treated_by",
        "Selenium Sulfide",
        "has_mechanism_of_action",
        "Physiochemical Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Seborrheic dermatitis of the scalp is driven by excessive sebum production and proliferation of Malassezia species, along with increased epidermal turnover. Selenium sulfide, a commonly prescribed topical agent for this condition, acts primarily through physiochemical mechanisms: it changes the scalp’s chemical environment, making it less hospitable to Malassezia and slowing down the rate of epidermal cell turnover. By altering local pH and ionic composition, selenium sulfide reduces flakiness and inhibits fungal growth, thereby relieving the signs and symptoms of seborrheic dermatitis. Unlike agents that act directly on cellular signaling or immune pathways, selenium sulfide works by non-specific chemical interactions at the scalp surface. This physiochemical activity is the principal basis for its therapeutic effect in seborrheic dermatitis.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_9cf9e5bdcc79",
      "question": "In a patient with stage IVB metastatic squamous non-small cell lung cancer who is found to have an NTRK1 gene fusion during first-line systemic therapy, and who also has significant hepatic impairment (Child-Pugh class B), is initiation of larotrectinib or entrectinib still considered appropriate in the context of disease control?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "NTRK1/2/3 gene fusion positive",
              "NTRK1/2/3 gene fusion",
              "NTRK1/2/3 gene fusion discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by larotrectinib, entrectinib, or repotrectinib",
              "Progression",
              "Repotrectinib (if not previously given) or Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
              "Progression",
              "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
            ]
          }
        }
      ],
      "answer": "Initiation of larotrectinib or entrectinib in a patient with significant hepatic impairment (Child-Pugh class B) requires caution, as both agents are metabolized hepatically and dose adjustments or alternative therapies may be needed. Use in this scenario is not routinely appropriate without careful risk assessment and monitoring.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_23a7101ab132",
      "question": "A 54-year-old woman is admitted to the ICU with severe community-acquired pneumonia complicated by sepsis-induced acute respiratory distress syndrome. She develops worsening hypoxemia despite mechanical ventilation and is started on supportive therapies. As an adjunct, she receives an intravenous medication that is known to replenish cellular glutathione stores and neutralize reactive oxygen species. Which pharmacological property of this agent is most directly responsible for its potential benefit in reducing tissue damage in her current condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Lung, Shock"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0852283",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0772506",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Free radical scavenging activity",
      "reasoning_path": "Acute lung injury increases ROS → oxidative cellular damage → sodium acetylcysteine administered → replenishes glutathione and scavenges free radicals → reduces oxidative tissue injury.",
      "umls_path": [
        "Lung, Shock",
        "may_be_treated_by",
        "Sodium, Acetylcysteine",
        "has_mechanism_of_action",
        "Free Radical Scavenging Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Acute lung injury and ARDS are characterized by increased oxidative stress, leading to tissue injury from the accumulation of reactive oxygen species (ROS). In the setting of critical illness and shock, the balance between oxidants and antioxidants in the lung is disrupted, further promoting cellular and endothelial damage. Sodium acetylcysteine acts as a precursor to glutathione, a key intracellular antioxidant, and also possesses direct free radical scavenging properties. By neutralizing ROS, sodium acetylcysteine may help limit oxidative injury and reduce further lung tissue damage. This mechanism underlies its adjunctive use in conditions of acute lung injury associated with high oxidative stress, aiming to protect cells and support recovery.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_6f08c02cef8f",
      "question": "In a patient with pathologically confirmed non-small cell lung cancer presenting with a solitary nodule in the contralateral lung (M1a, N0, Stage IVA), does treating both lesions as separate primary lung tumors implicitly require that both lesions are potentially curable?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
              "Pathologic Diagnosis of NSCLC",
              "Clinical Stage",
              "Stage IVA (M1b)",
              "Pretreatment Evaluation (NSCL-15)"
            ]
          }
        }
      ],
      "answer": "Yes. The approach of treating both lesions as separate primary lung tumors in a patient with a solitary contralateral lung nodule (Stage IVA, M1a, N0) is predicated on the clinical judgment that both lesions are potentially curable; if either lesion is not amenable to curative therapy, this strategy would not apply.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_89a5ed6922d4",
      "question": "In a woman with newly diagnosed, non-metastatic, invasive breast cancer who is in the late third trimester of pregnancy, is it appropriate to proceed with adjuvant chemotherapy prior to delivery, or should chemotherapy be deferred until after childbirth?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Workup • History and physical exam • Imaging: ▸ Diagnostic bilateral mammogram ▸ Ultrasound as necessary ▸ Breast MRI (optional), with special consideration for mammographically occult tumors • Pathology review • Determination of tumor estrogen/ progesterone receptor (ER/PR) status and HER2 status • Genetic counseling and testing if patient is at risk for hereditary breast cancer, has triple-negative breast cancer (TNBC) (at any age), or is a candidate for adjuvant olaparib • Address fertility and sexual health concerns as appropriate • Pregnancy test in all patients of childbearing potential (If pregnant, see PREG-1) • Assess for distress • Consider additional imaging studies only in the presence of signs and symptoms of metastatic disease and for patients who are clinically high risk (BINV-18)",
              "If indicated: • Chest x-ray (with abdominal shielding) • Abdominal ultrasound to assess liver metastases • Consider non-contrast MRI of spine if indicated to assess for bone metastases",
              "If pregnant with confirmed breast cancer; No distant metastases on staging",
              "Late third trimester",
              "Mastectomy or BCS + axillary staging",
              "Adjuvant chemotherapy ± RT postpartum ± Adjuvant endocrine therapy postpartum"
            ]
          }
        }
      ],
      "answer": "For women diagnosed with non-metastatic, invasive breast cancer in the late third trimester of pregnancy, adjuvant chemotherapy should be deferred until after delivery. Surgery with either mastectomy or breast-conserving surgery with axillary staging is performed during pregnancy, but systemic therapies—including chemotherapy, radiotherapy, and endocrine therapy—are initiated postpartum to avoid fetal exposure.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_4650dc685969",
      "question": "A 62-year-old woman with a longstanding history of knee discomfort presents with worsening joint pain and stiffness, particularly after activity. She is diagnosed with osteoarthritis and started on a medication commonly used for symptomatic relief. This drug works by directly inhibiting an enzyme responsible for converting arachidonic acid into prostaglandins, thus reducing inflammation and pain. What is the primary molecular target of this medication in the management of her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Osteoarthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0029408",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020740",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 1 (COX-1)",
      "reasoning_path": "Osteoarthritis causes pain → NSAID (ibuprofen) prescribed → NSAID inhibits COX-1 (prostaglandin G/H synthase 1) → Decreased prostaglandin synthesis → Reduced pain and inflammation.",
      "umls_path": [
        "Osteoarthritis",
        "may_be_treated_by",
        "Ibuprofen",
        "has_target",
        "Prostaglandin G/H Synthase 1"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Osteoarthritis leads to joint pain largely due to local inflammation and prostaglandin-mediated sensitization of nociceptors. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, are frequently prescribed to relieve these symptoms. The principal mechanism involves direct, reversible inhibition of cyclooxygenase enzymes (COX-1 and COX-2), also known as prostaglandin G/H synthases. By blocking COX-1, NSAIDs prevent the conversion of arachidonic acid into prostaglandin H2, a precursor for various prostaglandins responsible for pain, inflammation, and swelling. This inhibition decreases local prostaglandin concentrations, resulting in reduced pain and improved function for patients with osteoarthritis. Although both COX-1 and COX-2 are inhibited, COX-1 is a key constitutive enzyme affected by nonselective NSAIDs such as ibuprofen. Thus, the primary molecular target responsible for the therapeutic effect in this scenario is prostaglandin G/H synthase 1 (COX-1).",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_8ae9770631af",
      "question": "What is the unique PMID of the article titled “Complexity of neuro-oncological in-hospital consultations: a multicentre study” by first author Jauregui Larrañaga C, published in Neurologia in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"Complexity of neuro-oncological in-hospital consultations\"[ti] AND Jauregui Larrañaga C[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40306462"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_bb773184f733",
      "question": "In a patient with localized, non-metastatic, HR-positive/HER2-negative breast cancer who, after preoperative systemic therapy and mastectomy, is found to have residual disease (ypT2N1), a CPS+EG score of 3, and a confirmed germline BRCA1 mutation, but also has stage 3 chronic kidney disease (eGFR 35 mL/min/1.73 m²), is adjuvant olaparib administration still appropriate?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS not possible",
              "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
              "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
              "HR-positive/ HER2-negative",
              "ypT1–4,N0 or ypN≥1",
              "Adjuvant endocrine therapy (category 1) + adjuvant olaparib if germline BRCA1/2 mutation CPS+EG score ≥3, and residual disease (category 1). Select patients may be eligible for adjuvant abemaciclib, see BINV-K for eligibility criteria."
            ]
          }
        }
      ],
      "answer": "Adjuvant olaparib is not recommended in this patient due to stage 3 chronic kidney disease; olaparib is contraindicated when moderate renal impairment is present (eGFR < 40 mL/min/1.73 m²), regardless of BRCA mutation status or residual disease. Renal function must be adequate prior to olaparib initiation.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_4c432d8b8944",
      "question": "A 42-year-old woman with a history of focal seizures is started on a prodrug that is metabolized to an agent structurally related to GABA but does not bind to GABA receptors. Although this medication is effective in controlling her seizures, the exact way it reduces neuronal hyperexcitability at the cellular or molecular level has not been fully determined. Which statement best describes the current scientific understanding of this drug’s mechanism of action in the treatment of her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Focal epilepsy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0014547",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2700226",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The precise cellular or molecular mechanism by which gabapentin enacarbil exerts its antiepileptic effects is unknown.",
      "reasoning_path": "Patient with focal epilepsy is treated with gabapentin enacarbil → drug is a gabapentin prodrug → does not bind GABA receptors → possible action on voltage-gated calcium channels → precise antiepileptic mechanism remains unknown.",
      "umls_path": [
        "Focal epilepsy",
        "may_be_treated_by",
        "Gabapentin Enacarbil",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Gabapentin enacarbil is a prodrug of gabapentin, commonly used for focal epilepsy. Although gabapentin is structurally similar to gamma-aminobutyric acid (GABA), it does not act directly on GABA receptors or participate in GABA metabolism. While some studies suggest it may modulate voltage-gated calcium channels (specifically the α2δ subunit), the exact cellular or molecular mechanism underlying its antiepileptic action remains unclear. Clinical efficacy is established, but the full details of how it decreases neuronal excitability and seizure activity are not completely understood. As of now, the prevailing view is that the mechanism of action in epilepsy is incompletely characterized.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_04d90fc0f7b8",
      "question": "A 68-year-old woman with a history of chronic knee pain and morning stiffness presents for evaluation. Examination reveals crepitus and decreased range of motion in the affected joint, and radiographs show narrowing of the joint space consistent with a degenerative process. She is started on a medication that irreversibly acetylates a key enzyme, leading to decreased synthesis of prostaglandins and improvement of her symptoms. Which molecular target is most directly inhibited to achieve this anti-inflammatory effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Osteoarthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0029408",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004057",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 2 (COX-2)",
      "reasoning_path": "Osteoarthritis causes joint inflammation; aspirin is prescribed for symptom relief and acts by irreversibly inhibiting COX-2 (prostaglandin G/H synthase 2), reducing prostaglandin-mediated inflammation.",
      "umls_path": [
        "Osteoarthritis",
        "may_be_treated_by",
        "Aspirin-containing product",
        "has_target",
        "Prostaglandin G/H Synthase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient’s presentation is consistent with osteoarthritis, a degenerative joint disease characterized by cartilage breakdown and inflammation. Aspirin, an NSAID sometimes used for symptomatic relief, exerts its anti-inflammatory and analgesic effects by irreversibly inhibiting cyclooxygenase enzymes (COX-1 and COX-2). Of these, COX-2 (also known as prostaglandin G/H synthase 2) is the inducible isoform upregulated during inflammation and primarily responsible for the synthesis of pro-inflammatory prostaglandins in affected tissues. By acetylating a serine residue in the active site of COX-2, aspirin prevents the conversion of arachidonic acid to prostaglandin H2, the precursor for various inflammatory mediators. This reduction in prostaglandin synthesis leads to decreased pain, swelling, and stiffness in osteoarthritic joints, directly addressing the patient’s symptoms.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_beb8bb44cab2",
      "question": "In ClinicalTrials.gov, which completed interventional phase 3 studies for leukemia started in July 2001 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "overallStatus=COMPLETED;phases=PHASE3;conditions=Leukemia;startDateFrom=2001-07-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00024440"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_7117dc7e2236",
      "question": "For a patient with advanced or metastatic squamous cell carcinoma of the lung who tests positive for an EGFR S768I mutation, is EGFR-targeted therapy prioritized over standard platinum-based chemotherapy as the preferred initial systemic treatment approach?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Disseminated metastases",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "EGFR S768I, L861Q, and/or G719X mutation positive"
            ]
          }
        }
      ],
      "answer": "Yes, for advanced or metastatic squamous cell lung cancer with an EGFR S768I mutation, EGFR-targeted therapy is prioritized over standard platinum-based chemotherapy, as EGFR mutations predict sensitivity to EGFR tyrosine kinase inhibitors, which offer superior efficacy in this molecular subgroup.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_e9ea390bc8a6",
      "question": "For a patient with squamous cell carcinoma of the lung and confirmed stage IV disease with diffuse brain metastases, is broad molecular profiling (including EGFR, ALK, ROS1, BRAF, NTRK, METex14, RET, ERBB2) and PD-L1 testing routinely indicated prior to initiating systemic therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "For stage IV squamous cell carcinoma of the lung with diffuse brain metastases, broad molecular profiling is generally not routinely indicated due to the low prevalence of actionable oncogenic drivers in this subtype; however, PD-L1 testing remains standard to guide immunotherapy selection. Molecular testing may be considered in never-smokers or younger patients.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_3054f4abe65b",
      "question": "In patients with stage IIIA non-small cell lung cancer (T1–2, N2), if a contrast-enhanced brain MRI has not been previously performed, is omitting this imaging step acceptable prior to perioperative therapy initiation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Distant metastases",
              "Limited metastases",
              "Stage IV, M1b (NSCL-15)"
            ]
          }
        }
      ],
      "answer": "No, omission of a contrast-enhanced brain MRI prior to perioperative therapy in stage IIIA (T1–2, N2) non-small cell lung cancer is not acceptable, as occult brain metastases must be excluded to inform accurate staging and appropriate treatment planning.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_52c0de9304ae",
      "question": "A 20-year-old woman presents to her primary care clinic with severe lower abdominal pain that occurs monthly and coincides with the onset of her menstrual periods. She reports that the pain is crampy, begins a few hours before her menses, and lasts for 1–2 days, often interfering with her daily activities. On examination, there are no abnormal pelvic findings. She is prescribed a medication that reduces pain by blocking the synthesis of signaling molecules responsible for stimulating uterine contractions. Which enzyme is the primary molecular target responsible for mediating this drug’s therapeutic effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Dysmenorrhea"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0013390",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0025041",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 2 (COX-2)",
      "reasoning_path": "Dysmenorrhea involves increased uterine prostaglandin synthesis → Prostaglandins trigger painful contractions → NSAIDs inhibit COX enzymes → COX-2 (prostaglandin G/H synthase 2) is the key isoform mediating prostaglandin production in this setting → Inhibition of COX-2 reduces prostaglandin synthesis and relieves symptoms.",
      "umls_path": [
        "Dysmenorrhea",
        "may_be_treated_by",
        "Meclofenamate Sodium",
        "has_target",
        "Prostaglandin G/H Synthase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Primary dysmenorrhea is caused by excessive production of prostaglandins in the endometrium during menstruation, leading to increased uterine contractions and pain. NSAIDs, such as meclofenamate sodium, provide symptomatic relief by inhibiting the cyclooxygenase (COX) enzymes involved in prostaglandin synthesis. Of the two main isoforms, COX-2 (prostaglandin G/H synthase 2) is particularly induced during inflammation and is the primary source of prostaglandins mediating pain and uterine muscle contractions in dysmenorrhea. By selectively or non-selectively inhibiting COX-2, NSAIDs decrease prostaglandin levels in the uterus, resulting in reduced myometrial contractions and relief of menstrual pain. Thus, the principal therapeutic effect in primary dysmenorrhea is mediated by inhibition of prostaglandin G/H synthase 2 (COX-2).",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_22cf0062f028",
      "question": "A 62-year-old woman with a history of diabetes presents with fever, abdominal pain, and leukocytosis. CT imaging reveals a localized fluid collection in the left lower quadrant consistent with an intra-abdominal abscess. She is started on broad-spectrum intravenous antibiotics, including a beta-lactam agent that exerts its antibacterial effect by binding to and inhibiting the activity of specific bacterial enzymes involved in peptidoglycan cross-linking. Which general pharmacological class best describes the primary mechanism of action of this antibiotic?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Abdominal abscess"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0243001",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1120106",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme Inhibitors",
      "reasoning_path": "Intra-abdominal abscess is treated with ertapenem, which inhibits PBPs (bacterial enzymes) needed for cell wall synthesis—placing it in the enzyme inhibitor class.",
      "umls_path": [
        "Abdominal abscess",
        "may_be_treated_by",
        "Ertapenem",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient has an intra-abdominal abscess, a serious infection often requiring empiric broad-spectrum antibiotics. Ertapenem is a carbapenem beta-lactam antibiotic commonly used in such cases. Its antibacterial activity arises from its ability to bind irreversibly to penicillin-binding proteins (PBPs), a group of bacterial enzymes (transpeptidases) that catalyze the final steps of peptidoglycan cross-linking in the cell wall. By inhibiting these key enzymes, ertapenem disrupts cell wall synthesis, leading to bacterial cell lysis and death. Thus, the core pharmacological mechanism of ertapenem falls under the class of enzyme inhibitors, specifically those targeting bacterial cell wall enzymes. This distinguishes it from antibiotics that act through other mechanisms, such as protein synthesis inhibition or DNA gyrase inhibition.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_d787e5030431",
      "question": "For a patient newly diagnosed with stage IVA (M1b) non-small cell lung cancer (NSCLC) of adenocarcinoma subtype, is broad molecular profiling including EGFR, ALK, ROS1, BRAF, KRAS, NTRK, METex14, RET, and HER2 testing appropriate if the individual has a known history of large cell histology and insufficient tissue for initial molecular analysis?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Yes, broad molecular profiling is still appropriate for advanced or metastatic non-squamous NSCLC such as adenocarcinoma or large cell histology, even if the initial tissue sample is insufficient. In this scenario, re-biopsy or plasma-based testing should be considered to ensure adequate molecular testing and guide targeted therapy decisions.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_76bb150ad12a",
      "question": "A 68-year-old man with progressive shortness of breath and dry cough is diagnosed with idiopathic pulmonary fibrosis after high-resolution CT imaging shows bilateral, basilar-predominant reticulation and honeycombing. His pulmonologist initiates a medication that targets multiple receptor tyrosine kinases, including those for platelet-derived growth factor, fibroblast growth factor, and vascular endothelial growth factor, in order to slow the progression of his disease. Which drug class most directly accounts for this medication’s ability to inhibit fibrotic remodeling in the lungs?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Idiopathic Pulmonary Fibrosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1800706",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2930789",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Protein kinase inhibitors",
      "reasoning_path": "Idiopathic pulmonary fibrosis involves aberrant fibrotic signaling; nintedanib inhibits multiple growth factor receptor tyrosine kinases, classifying it as a protein kinase inhibitor, which interferes with fibrogenesis.",
      "umls_path": [
        "Idiopathic Pulmonary Fibrosis",
        "may_be_treated_by",
        "Nintedanib-containing product",
        "has_mechanism_of_action",
        "Protein Kinase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Idiopathic pulmonary fibrosis is characterized by unregulated proliferation and activation of fibroblasts, leading to excessive deposition of extracellular matrix and progressive lung scarring. Key growth factor signaling pathways—such as those mediated by PDGF, FGF, and VEGF—are implicated in driving this fibroproliferative response. Nintedanib, a medication frequently used in this setting, is a multi-targeted tyrosine kinase inhibitor that antagonizes the activity of these growth factor receptors. By blocking their intracellular kinase domains, nintedanib disrupts downstream signaling cascades necessary for fibroblast recruitment, proliferation, and transformation into collagen-producing myofibroblasts. Thus, the primary pharmacological action responsible for slowing disease progression in idiopathic pulmonary fibrosis involves inhibition of protein kinases—enzymes that phosphorylate target proteins in these fibrogenic pathways. This mechanism underlies the clinical benefit of reduced lung function decline observed with this class of drugs.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_531db03b4b65",
      "question": "For a patient with non-small cell lung cancer staged as T1–2, N3, M0 (stage IIIB) who has already undergone an FDG-PET/CT scan but has compromised renal function precluding use of intravenous contrast, is brain MRI with contrast still a mandatory part of the staging workup?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (peripheral T1abc, N0)",
              "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "N3 nodes positive, M0",
              "Stage IIIB or Stage IIIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)"
            ]
          }
        }
      ],
      "answer": "No, brain MRI with contrast is not mandatory if intravenous contrast is contraindicated due to impaired renal function. In such cases, a non-contrast brain MRI or, if not available, a brain CT may be considered to evaluate for brain metastases, acknowledging reduced sensitivity compared to contrast-enhanced MRI.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_5e1f31cdd69c",
      "question": "A 24-year-old woman presents with acute onset of red, swollen eyes producing yellow-green discharge and crusting of the eyelids. She is diagnosed with a bacterial eye infection and is prescribed an ophthalmic solution from a drug class that targets bacterial enzymes responsible for DNA replication and segregation. Which molecular target is inhibited by this medication to exert its antibacterial effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Purulent conjunctivitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0009768",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0028365",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Topoisomerase IV",
      "reasoning_path": "Bacterial conjunctivitis is treated with topical fluoroquinolones, which inhibit bacterial topoisomerase IV and thereby block DNA replication in the pathogens causing infection.",
      "umls_path": [
        "Purulent conjunctivitis",
        "may_be_treated_by",
        "Norfloxacin-containing product",
        "has_mechanism_of_action",
        "Topoisomerase 4 Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has classic bacterial (purulent) conjunctivitis, which is often treated with topical fluoroquinolone antibiotics. These drugs, such as norfloxacin or moxifloxacin, exert their antibacterial activity by inhibiting bacterial DNA topoisomerases: DNA gyrase (topoisomerase II) and, more importantly in Gram-positive organisms, topoisomerase IV. Topoisomerase IV is essential for separating replicated chromosomal DNA during bacterial cell division. Inhibition of this enzyme disrupts DNA replication and segregation, resulting in bacterial cell death. Thus, the primary molecular mechanism responsible for the clinical effect of fluoroquinolone eye drops in conjunctivitis is inhibition of bacterial topoisomerase IV.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_ac5a95818372",
      "question": "A 10-year-old child is evaluated for recurrent episodes of high fever, rash, abdominal pain, and joint swelling since early childhood. Laboratory studies reveal elevated inflammatory markers during attacks. Genetic testing confirms a rare autosomal recessive disorder affecting the mevalonate pathway, leading to impaired cholesterol precursor synthesis and increased systemic inflammation. The patient is started on a biologic medication that provides partial symptom relief by selectively binding and neutralizing a key proinflammatory cytokine, thereby decreasing downstream inflammatory signaling. Which molecular pathway is directly inhibited by this therapy to achieve its anti-inflammatory effect in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Deficiency of mevalonate kinase"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0342731",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2718773",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Interleukin-1 signaling via antagonism of the interleukin-1 receptor",
      "reasoning_path": "Mevalonate kinase deficiency causes excess IL-1 production; canakinumab neutralizes IL-1β, preventing activation of the interleukin-1 receptor and reducing inflammation.",
      "umls_path": [
        "Deficiency of mevalonate kinase",
        "may_be_treated_by",
        "Canakinumab-containing product",
        "has_mechanism_of_action",
        "Interleukin 1 Receptor Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has mevalonate kinase deficiency, a hereditary autoinflammatory disorder characterized by recurrent fever episodes and systemic symptoms due to dysregulation of innate immunity. The pathophysiology involves accumulation of mevalonic acid and upregulation of inflammatory cytokines, particularly interleukin-1 (IL-1). Canakinumab, the therapy described, is a monoclonal antibody that binds to IL-1β and prevents its interaction with the interleukin-1 receptor on immune cells. By blocking this receptor, the drug interrupts the downstream signaling cascade responsible for recruiting inflammatory mediators and driving the clinical features of the disease. Thus, the primary molecular target affected is the interleukin-1 receptor pathway, and the therapeutic effect directly results from antagonizing this proinflammatory signal.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_bda4efb242c4",
      "question": "In a patient with recurrent or symptomatic local disease of non-small cell lung cancer (NSCLC) who has previously received thoracic radiotherapy, is it mandatory to perform broad molecular profiling, including EGFR, ALK, KRAS, and other driver mutations, before initiation of further systemic therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Yes; obtaining histologic subtype and performing comprehensive molecular profiling, including analysis of EGFR, ALK, KRAS, ROS1, BRAF, NTRK, MET exon 14 skipping, RET, and ERBB2 (HER2) mutations, is required with adequate tissue prior to subsequent systemic therapy, regardless of prior radiotherapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_11ee7f063191",
      "question": "If a patient with non-small cell lung cancer has a solitary pulmonary nodule in the contralateral lung (stage IVA, N0, M1a), but both the primary tumor and the contralateral nodule are deemed potentially resectable and the patient is medically operable, should the approach be to treat as metastatic disease or as two separate primary lung cancers?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
              "Pathologic Diagnosis of NSCLC",
              "Initial Evaluation",
              "Use the 5 A's Framework: Ask, Advise, Assess, Assist, Arrange"
            ]
          }
        }
      ],
      "answer": "If both the primary tumor and the contralateral pulmonary nodule are potentially curable and the patient is medically fit for surgery, these lesions should be treated as two separate primary lung cancers, not as metastatic disease, and curative-intent local therapy can be pursued for each lesion.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_90d4cc3f5fbb",
      "question": "A 28-year-old man of Mediterranean descent presents with a history of intermittent high fevers, abdominal pain, and episodes of chest discomfort over the past year. He reports that these episodes last 1–3 days and resolve spontaneously. Family history reveals similar symptoms in his brother. Laboratory tests during attacks show elevated inflammatory markers, but infectious and autoimmune workups are negative. He is started on a prophylactic medication that reduces the frequency and severity of his symptoms by binding a cytoskeletal protein, thereby inhibiting the assembly of key cellular structures involved in leukocyte motility and inflammatory mediator release. Which molecular structure is the principal pharmacologic target of this therapy in controlling his disease?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Familial Mediterranean fever"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0031069",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0009262",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Tubulin",
      "reasoning_path": "The clinical scenario is FMF, treated with colchicine. Colchicine binds tubulin, preventing microtubule polymerization. This inhibits leukocyte function and inflammation, controlling FMF attacks.",
      "umls_path": [
        "Familial Mediterranean fever",
        "may_be_treated_by",
        "Colchicine",
        "has_mechanism_of_action",
        "Tubulin Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient's recurrent fevers, serositis, and family history are classic for familial Mediterranean fever (FMF), a hereditary autoinflammatory disorder. Prophylactic treatment aims to prevent inflammatory flares and amyloidosis. The mainstay of therapy is colchicine, which exerts its effect by binding to tubulin, a cytoskeletal protein. By inhibiting tubulin polymerization, colchicine disrupts microtubule formation necessary for leukocyte chemotaxis, phagocytosis, and degranulation. This disruption reduces migration of inflammatory cells and the release of proinflammatory cytokines, ameliorating the clinical manifestations of FMF. Thus, the core molecular target responsible for colchicine’s effects in FMF is tubulin.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_619d385f7508",
      "question": "For a patient with stage IA peripheral non-small cell lung cancer (T1abc, N0), if pulmonary function tests indicate marginal operability, is surgical resection with mediastinal lymph node dissection still prioritized over non-surgical options?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (peripheral T1abc, N0)",
              "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
              "Negative mediastinal nodes",
              "Operable",
              "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
              "Adjuvant Treatment (NSCL-4)",
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
              "R1; Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "Yes, in patients with stage IA peripheral non-small cell lung cancer who are deemed marginally operable based on pulmonary function tests, surgical resection with mediastinal lymph node dissection remains the standard primary approach, provided surgery is not contraindicated by comorbidities; non-surgical modalities are considered only if operative risk is unacceptable.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_ee5e18b242b5",
      "question": "A 34-year-old woman presents to the ophthalmology clinic with a two-day history of unilateral eye pain, redness, and watery discharge. Slit-lamp examination reveals dendritic corneal ulcers. She is diagnosed with a viral ocular infection and is prescribed an older topical antiviral agent that, after phosphorylation, is incorporated into viral DNA and inhibits the enzyme responsible for DNA chain elongation. Which class of pharmacological agents best describes the molecular mechanism by which this drug limits viral replication in the affected tissue?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Ophthalmic herpes simplex"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0019357",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2700247",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "DNA polymerase inhibitors",
      "reasoning_path": "Herpes simplex keratitis is treated with vidarabine, which is phosphorylated intracellularly and inhibits viral DNA polymerase, preventing viral DNA replication.",
      "umls_path": [
        "Ophthalmic herpes simplex",
        "may_be_treated_by",
        "Vidarabine Anhydrous",
        "has_mechanism_of_action",
        "DNA Polymerase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s clinical presentation is consistent with herpes simplex keratitis, which is characterized by dendritic corneal ulcers. Vidarabine is an older antiviral agent used topically for ocular herpes simplex infections. Upon entering infected cells, vidarabine is phosphorylated to its active triphosphate form. The active metabolite then acts as a competitive inhibitor of viral DNA polymerase, the enzyme responsible for synthesis and elongation of viral DNA. By inhibiting this enzyme, vidarabine prevents viral DNA replication, effectively limiting viral proliferation and the progression of herpetic ocular disease. Because human (host) DNA polymerase is less sensitive to inhibition by vidarabine, the drug exhibits selective antiviral activity. The primary pharmacological class associated with this mechanism is DNA polymerase inhibitors, which also includes other antivirals such as acyclovir and ganciclovir. Understanding this molecular target explains both the drug’s antiviral efficacy and its selective action against viral, rather than host, DNA synthesis.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_73b723595dc6",
      "question": "For a patient with stage IIIA non-small cell lung cancer (defined as T1-2, N2) who underwent surgical resection with positive margins (R1 resection), is adjuvant chemoradiation implicitly based on the assumption of no evidence of distant metastases on postoperative imaging?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
              "R1; Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Limited metastases",
              "Stage IV, M1b (NSCL-15)"
            ]
          }
        }
      ],
      "answer": "Yes, the use of adjuvant chemoradiation after R1 resection in stage IIIA non-small cell lung cancer is predicated on the absence of distant metastases on postoperative imaging. The therapeutic intent is curative local control; the presence of metastases would instead shift management toward systemic therapy for advanced disease.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_27b656167b5d",
      "question": "A 34-year-old woman presents with fatigue, pallor, and jaundice. Laboratory workup reveals anemia with elevated lactate dehydrogenase, indirect hyperbilirubinemia, and a positive direct antiglobulin (Coombs) test. She is diagnosed with autoimmune hemolytic anemia. Due to inadequate response to corticosteroids, she is started on high-dose intravenous immunoglobulin (IVIG) therapy. Considering the pathogenesis of her condition and the pharmacological properties of IVIG, which key immunological mechanism explains its therapeutic effect in reducing hemolysis in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Autoimmune hemolytic anemias"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002880",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0085297",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Neutralization of pathogenic autoantibodies (antigen neutralization)",
      "reasoning_path": "Autoimmune hemolytic anemia involves pathogenic autoantibodies against RBCs. IVIG neutralizes these autoantibodies and saturates Fc receptors, thereby reducing antibody-mediated red cell destruction.",
      "umls_path": [
        "Autoimmune hemolytic anemias",
        "may_be_treated_by",
        "IGIV",
        "has_mechanism_of_action",
        "Antigen Neutralization"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In autoimmune hemolytic anemia, the patient's immune system produces autoantibodies that bind to antigens on red blood cell membranes, leading to their destruction. IVIG is administered in high doses as an immunomodulatory therapy when first-line treatments are insufficient. The primary mechanism by which IVIG exerts its therapeutic effect is by saturating Fc receptors on phagocytic cells and neutralizing pathogenic autoantibodies. By competing with autoantibodies for Fc receptor binding and directly neutralizing circulating autoantibodies, IVIG reduces their ability to mediate red blood cell destruction. This decreases the clearance of antibody-coated erythrocytes by the reticuloendothelial system, thus ameliorating hemolysis. The net result is an improvement in anemia and a reduction in related symptoms. Other mechanisms, such as modulation of complement activation and cytokine production, may contribute, but the principal effect in this context is antigen (autoantibody) neutralization.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_71f4af765961",
      "question": "In a patient with resectable non-small cell lung cancer involving T4 extension to the chest wall and with N1 nodal status, if postoperative pathology reveals an R1 margin, is a sequential or concurrent chemoradiation approach still preferred over systemic chemotherapy alone, or are both considered acceptable first-line adjuvant strategies in this scenario?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Chest wall",
              "Treatment (NSCL-7)",
              "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
              "Surgery (preferred)",
              "Margins positive",
              "R1",
              "Resection + chemotherapy or Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "In the setting of R1 resection margin following surgery for resectable T4N1 non-small cell lung cancer, both sequential or concurrent chemoradiation and chemotherapy alone are considered acceptable adjuvant approaches, though chemoradiation is generally preferred due to the increased risk of local recurrence associated with positive margins.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_e50b5e1864cf",
      "question": "In a patient with non-small cell lung cancer presenting with a separate pulmonary nodule located in the contralateral lung and classified as clinical stage IVA (N0, M1a), is it appropriate to treat both lesions as distinct primary tumors if each lesion is deemed potentially curable?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
              "Pathologic Diagnosis of NSCLC",
              "Clinical Stage",
              "Stage IIIB (T1–2, N3); Stage IIIC (T3, N3)",
              "Pretreatment Evaluation (NSCL-13)"
            ]
          }
        }
      ],
      "answer": "Yes, when a solitary contralateral pulmonary nodule is present in non-small cell lung cancer classified as stage IVA (N0, M1a), and both lesions are potentially curable, current practice supports treating them as two separate primary lung tumors, which may allow for individualized curative treatment approaches for each lesion.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_06c8acc3052e",
      "question": "In a patient diagnosed with a solitary nodule in the contralateral lung, staged as IVA (N0, M1a) non-small cell lung cancer, does classifying and treating these lesions as two primary lung tumors implicitly require that both lesions are independently considered curable?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
              "Pathologic Diagnosis of NSCLC",
              "Initial Evaluation",
              "Smoking cessation advice, counseling, and pharmacotherapy"
            ]
          }
        }
      ],
      "answer": "Yes, treating a solitary contralateral lung nodule in stage IVA (N0, M1a) as two primary lung tumors implicitly presumes that both tumors are amenable to curative intent therapy, with no evidence of unresectable disease or widespread metastasis.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_ccae5157ff5d",
      "question": "A 48-year-old woman presents to the emergency department with recurrent episodes of chest pain at rest, often occurring in the early morning hours and resolving spontaneously within 10–15 minutes. Her ECG during an episode shows transient ST-segment elevation in the absence of troponin elevation. She is diagnosed with a coronary vasospastic disorder and started on a medication that reduces the frequency of her symptoms by promoting relaxation of vascular smooth muscle in the coronary arteries through inhibition of calcium entry. Which drug class best describes the mechanism underlying this therapeutic effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Prinzmetal angina"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002963",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0354468",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "L-type calcium channel blockers",
      "reasoning_path": "Coronary vasospasm (Prinzmetal angina) is treated by vasodilators; amlodipine achieves this by blocking L-type calcium channels in vascular smooth muscle, preventing calcium influx and thereby relaxing coronary arteries.",
      "umls_path": [
        "Prinzmetal angina",
        "may_be_treated_by",
        "Amlodipine Besylate",
        "has_mechanism_of_action",
        "L-Calcium Channel Receptor Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient's episodic chest pain at rest that resolves spontaneously, along with transient ST-segment elevation and a diagnosis of coronary vasospastic (Prinzmetal) angina, points to episodic coronary artery spasm as the underlying pathophysiology. The mainstay of therapy in this condition is a medication that relaxes vascular smooth muscle, thereby preventing or reversing coronary spasm. Amlodipine besylate is a dihydropyridine calcium channel blocker that acts primarily on vascular smooth muscle by inhibiting the influx of calcium through L-type calcium channels. This results in vasodilation, especially of coronary arteries, directly counteracting the vasospasm responsible for the patient's symptoms. By reducing vascular tone and preventing calcium-mediated contraction, these agents restore myocardial oxygen supply and reduce angina episodes. Thus, the therapeutic effect in Prinzmetal angina is primarily mediated by L-type calcium channel blockade.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_cb5dbbee129d",
      "question": "A 28-year-old woman reports excessive daytime sleepiness and episodes of sudden muscle weakness triggered by laughter. She is diagnosed with a chronic neurologic disorder characterized by impaired regulation of sleep-wake cycles. To help her remain alert during the day, her physician prescribes a medication that increases synaptic concentrations of a key catecholamine neurotransmitter by blocking its reuptake into presynaptic neurons. Through which pharmacologic mechanism does this therapy primarily promote wakefulness in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Narcolepsy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0027404",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0700545",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Dopamine reuptake inhibition",
      "reasoning_path": "Narcolepsy causes daytime sleepiness. Methylphenidate is prescribed to promote wakefulness. Its main action is dopamine reuptake inhibition, increasing synaptic dopamine and improving alertness.",
      "umls_path": [
        "Narcolepsy",
        "may_be_treated_by",
        "Methylphenidate Hydrochloride",
        "has_mechanism_of_action",
        "Dopamine Uptake Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient's symptoms suggest narcolepsy, a disorder of excessive daytime sleepiness and cataplexy. A common first-line treatment is a central nervous system stimulant, such as methylphenidate. Methylphenidate works by inhibiting the dopamine transporter (DAT), reducing reuptake of dopamine into presynaptic neurons. This increases extracellular dopamine levels in the synaptic cleft, particularly in wake-promoting regions of the brain like the striatum and prefrontal cortex. Enhanced dopaminergic signaling is associated with increased alertness, attention, and arousal, counteracting the hypersomnolence seen in narcolepsy. By directly targeting dopamine reuptake, these medications improve wakefulness and reduce episodes of sleep attacks, making dopamine reuptake inhibition the key pharmacologic mechanism in this context.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_7e5e2be061ee",
      "question": "What is the PMID of the article titled “[Exploring screening practices for sexual disorders in breast cancer patients],” authored by Jacquet C and published in Soins; la revue de reference infirmiere in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"[Exploring screening practices for sexual disorders in breast cancer patients].\"[ti] AND Jacquet C[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40483090"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_a1a9e0511435",
      "question": "A 47-year-old man with a 15-year history of heavy tobacco use presents with severe pain in his fingers and toes, worsened by cold exposure. Examination reveals diminished peripheral pulses and multiple areas of superficial ulceration on the digits. Angiography demonstrates segmental vascular occlusions in the distal extremities without evidence of atherosclerosis. After counseling on smoking cessation, his physician prescribes a medication that promotes vasodilation by inhibiting a specific G-protein coupled receptor pathway in vascular smooth muscle. Which drug class is most likely responsible for this effect, and what is the molecular mechanism underlying its therapeutic benefit in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Thromboangiitis obliterans [Buerger's disease]"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0040021",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0040373",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Adrenergic alpha-antagonists—blockade of alpha-adrenergic receptors on vascular smooth muscle",
      "reasoning_path": "Buerger’s disease causes distal ischemia. Alpha-adrenergic antagonists block vasoconstrictive signaling in vascular smooth muscle, promoting vasodilation and improving blood flow to ischemic tissues.",
      "umls_path": [
        "Thromboangiitis obliterans [Buerger's disease]",
        "may_be_treated_by",
        "Tolazoline-containing product",
        "has_mechanism_of_action",
        "Adrenergic alpha-Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s presentation is consistent with Buerger’s disease (thromboangiitis obliterans), a non-atherosclerotic inflammatory vasculopathy commonly associated with tobacco use. The vascular compromise is due in part to intense vasoconstriction and inflammation of small and medium arteries. Vasodilator therapy can help restore perfusion. Adrenergic alpha-antagonists (such as tolazoline or phentolamine) exert their effect by competitively blocking alpha-adrenergic receptors on vascular smooth muscle. Normally, activation of these receptors by endogenous catecholamines (like norepinephrine) leads to vasoconstriction via increased intracellular calcium. By inhibiting this pathway, alpha-antagonists reduce smooth muscle tone, leading to vasodilation and improved peripheral blood flow. This mechanism addresses the pathophysiology of digital ischemia in Buerger’s disease by counteracting excessive vasoconstriction, thereby alleviating pain and reducing the risk of tissue loss.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_a6bc918713fc",
      "question": "A 34-year-old hiker returns from a camping trip in the mountains with a several-day history of foul-smelling, greasy diarrhea, abdominal cramps, and bloating. Stool microscopy reveals flagellated protozoa, and he is started on an oral antimicrobial that is the standard of care for this infection. When discussing the pharmacology of this drug, his medical student asks about its precise cellular or molecular mechanism of action against the pathogen. What is the most accurate classification of the molecular target for this medication in this context?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Giardiasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0017536",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0353490",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Giardiasis diagnosed → treated with metronidazole derivative → general mechanism involves production of reactive intermediates → precise molecular target not fully characterized → mechanism classified as unknown cellular or molecular interaction.",
      "umls_path": [
        "Giardiasis",
        "may_be_treated_by",
        "Metronidazole benzoate",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient is treated for protozoal infection (giardiasis) with metronidazole or its derivative, which is considered first-line therapy. Metronidazole is known to exert its antiparasitic effects by entering the microorganism and—after intracellular reduction—forming reactive intermediates that damage DNA and other macromolecules, leading to cell death. However, despite this general understanding, the precise cellular or molecular targets and pathways by which metronidazole benzoate acts against Giardia lamblia have not been fully elucidated. As such, the pharmacodynamic mechanism is officially classified as an 'unknown cellular or molecular interaction' because the exact molecular target (such as a specific enzyme, receptor, or structural protein) has not been definitively identified. This classification is important for documentation and regulatory purposes, reflecting gaps in current scientific knowledge.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_9efb6680d534",
      "question": "A 42-year-old woman with a history of chronic viral hepatitis C is found to have a persistently low platelet count during routine follow-up. Her hepatologist initiates treatment with a long-acting biologic agent known to enhance host antiviral defenses by upregulating proteins that inhibit viral genome replication at the transcriptional level. Which class of pharmacologic agents shares the most similar mechanism of action to this therapy's antiviral effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Thrombocytopenia, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0040034",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0391001",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "RNA replicase inhibitors",
      "reasoning_path": "Chronic hepatitis C therapy uses interferon to upregulate proteins that inhibit viral RNA replication, mechanistically similar to RNA replicase inhibitors that directly block viral RNA polymerase.",
      "umls_path": [
        "Thrombocytopenia, unspecified",
        "may_be_treated_by",
        "PEG-interferon alfa-2a",
        "has_mechanism_of_action",
        "RNA Replicase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this scenario, the patient is being treated for chronic hepatitis C with a long-acting formulation of interferon, such as pegylated interferon alfa-2a. Interferons exert their antiviral effects primarily by inducing the expression of host cell enzymes that disrupt viral RNA synthesis and inhibit viral replication. These enzymes interfere with viral RNA-dependent RNA polymerase (RNA replicase), thus preventing the transcription and replication of viral genomes inside host cells. The class of pharmacologic agents that most closely mimics this mechanism is the RNA replicase inhibitors, which directly target and inhibit the viral RNA polymerase necessary for RNA virus replication. While interferons act indirectly via host-mediated pathways and RNA replicase inhibitors act directly on the viral enzyme, both ultimately suppress viral RNA synthesis, leading to reduced viral load.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_fb7b1a1fdb41",
      "question": "In ClinicalTrials.gov, which interventional studies for Breast Cancer started in January 2007 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "conditions=Breast Cancer;startDateFrom=2007-01-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00524277"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_04ba76944667",
      "question": "For a patient with stage IVb squamous cell lung carcinoma harboring a RET rearrangement, is first-line therapy with selpercatinib or pralsetinib still appropriate if the RET rearrangement was only identified after initial systemic chemotherapy, rather than prior to starting treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "RET rearrangement positive",
              "RET rearrangement",
              "RET rearrangement discovered prior to first-line systemic therapy",
              "First-Line Therapy",
              "Preferred Selpercatinib or Pralsetinib",
              "Progression",
              "Subsequent Therapy",
              "Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma"
            ]
          }
        }
      ],
      "answer": "First-line use of selpercatinib or pralsetinib specifically applies when the RET rearrangement is identified before initiation of systemic therapy. If the RET rearrangement is discovered after initial chemotherapy, these agents would be used as subsequent-line therapy rather than as first-line options.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_5214ff153d12",
      "question": "A 10-year-old girl is brought to clinic with a two-month history of morning joint stiffness and swelling in her knees and wrists, accompanied by intermittent low-grade fever. Laboratory evaluation shows mild anemia and elevated inflammatory markers. She is diagnosed with a chronic inflammatory disorder affecting multiple joints. For symptom relief, her physician prescribes a commonly used over-the-counter nonsteroidal anti-inflammatory drug. This medication provides benefit by inhibiting an enzyme critical for the synthesis of pro-inflammatory lipid mediators. What is the principal molecular target inhibited by this drug to reduce joint inflammation in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Juvenile idiopathic arthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3495559",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020740",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 1 (Cyclooxygenase-1)",
      "reasoning_path": "Juvenile idiopathic arthritis causes inflammation; ibuprofen (an NSAID) is prescribed; ibuprofen inhibits cyclooxygenase enzymes (COX-1/Prostaglandin G/H Synthase 1); this reduces prostaglandin synthesis and inflammation.",
      "umls_path": [
        "Juvenile idiopathic arthritis",
        "may_be_treated_by",
        "Ibuprofen",
        "has_target",
        "Prostaglandin G/H Synthase 1"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has juvenile idiopathic arthritis, a chronic inflammatory condition managed with nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. Ibuprofen exerts its anti-inflammatory effects by inhibiting the enzyme prostaglandin G/H synthase, better known as cyclooxygenase (COX). There are two major COX isoforms: COX-1 and COX-2. Ibuprofen is a non-selective inhibitor, but COX-1 is a principal molecular target in this context. COX enzymes catalyze the conversion of arachidonic acid to prostaglandins, which are key mediators of inflammation, pain, and fever. By inhibiting COX-1, ibuprofen reduces prostaglandin synthesis, thereby decreasing inflammation and improving joint symptoms. This mechanism explains the drug’s utility in relieving pain and swelling in patients with juvenile idiopathic arthritis.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_0efeaa2a035f",
      "question": "For a patient with newly diagnosed non-small cell lung cancer staged as T1–2, N3, is pathological confirmation of N3 status mandatory before proceeding to initial stage IIIB/IIIC treatment, or can imaging findings (e.g., FDG-PET/CT) alone suffice as evidence of N3 disease?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Nodes negative",
              "Treatment (NSCL-9)",
              "T1, N0",
              "Operable",
              "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
              "Adjuvant Treatment (NSCL-4)"
            ]
          }
        }
      ],
      "answer": "Pathological confirmation of N3 status is mandatory prior to initiating stage IIIB/IIIC therapy; imaging findings alone, such as FDG-PET/CT results, are insufficient for definitive staging, as histological proof is required to establish N3 disease and guide appropriate management.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_f9067fdb1a00",
      "question": "A 14-year-old boy is brought to clinic by his parents because of frequent, involuntary motor and vocal tics that have caused social difficulties at school. After a thorough evaluation, he is started on a medication that directly stimulates postsynaptic receptors associated with a key neurotransmitter involved in movement regulation. Within weeks, his tics markedly improve. Which class of drugs most likely accounts for this effect, and what is the primary molecular mechanism responsible for symptom reduction in this scenario?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Tourette's disorder"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0040517",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0031007",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Dopamine agonists—direct stimulation of dopamine receptors",
      "reasoning_path": "Tourette's disorder involves dopaminergic dysregulation; pergolide is a dopamine agonist that stimulates dopamine receptors to reduce tics.",
      "umls_path": [
        "Tourette's disorder",
        "may_be_treated_by",
        "Pergolide-containing product",
        "has_mechanism_of_action",
        "Dopamine Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Tourette's disorder is characterized by motor and vocal tics, which are thought to result from dysregulation of dopaminergic neurotransmission within basal ganglia circuits. Pergolide, the medication described, is a dopamine agonist that directly stimulates dopamine D2 (and D1) receptors. By activating these receptors, pergolide modulates dopaminergic signaling in motor pathways, which can help normalize abnormal neuronal firing patterns underlying tics. While some treatments for Tourette's involve dopamine antagonists, certain cases may benefit from agonist activity, particularly if symptoms are linked to underactivity of specific dopaminergic circuits. Thus, the clinical improvement observed in this patient is due to the drug’s ability to mimic dopamine at its receptor, restoring neurotransmitter balance and reducing tic severity.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_6d721f71ce6f",
      "question": "For a patient with stage II non-small cell lung cancer who completed definitive radiotherapy as primary treatment and now presents with completely resected oligometastatic disease, is the follow-up imaging schedule identical to a stage I–II patient who received only surgery and chemotherapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "No, the follow-up imaging schedule differs. Patients with stage II non-small cell lung cancer treated with definitive radiotherapy or those with oligometastatic disease treated definitively require more frequent imaging—specifically, chest CT every 3–6 months for 3 years—compared to surgery±chemotherapy alone, which is followed by chest CT every 6 months for 2–3 years.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_95f1b96ce908",
      "question": "A 68-year-old woman is evaluated for difficulty initiating urination and a sensation of incomplete bladder emptying following abdominal surgery. Neurological exam is unremarkable and imaging excludes mechanical obstruction. Her clinician considers a medication that increases acetylcholine levels at neuromuscular junctions, thereby enhancing detrusor muscle contractility. Which class of pharmacologic agent is most appropriate for improving her voiding symptoms in this scenario, and through which molecular mechanism does it act?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Unspecified disorder of bladder"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0005686",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0282261",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cholinesterase inhibitors—inhibit acetylcholinesterase, increasing acetylcholine and stimulating detrusor muscle contraction",
      "reasoning_path": "Bladder emptying depends on detrusor contraction mediated by acetylcholine. Neostigmine, a cholinesterase inhibitor, prevents breakdown of acetylcholine, increasing its availability and stimulating muscarinic receptors in the bladder wall to restore contractility.",
      "umls_path": [
        "Unspecified disorder of bladder",
        "may_be_treated_by",
        "Neostigmine bromide",
        "has_mechanism_of_action",
        "Cholinesterase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is experiencing postoperative urinary retention, a functional bladder disorder often due to impaired detrusor muscle activity. The detrusor muscle contracts in response to acetylcholine released from parasympathetic nerve terminals acting on muscarinic receptors. Neostigmine is a cholinesterase inhibitor, which blocks the enzyme acetylcholinesterase that normally degrades acetylcholine in the synaptic cleft. By inhibiting this enzyme, neostigmine increases the concentration and duration of action of acetylcholine at neuromuscular junctions, including those supplying the detrusor muscle. The resulting increase in acetylcholine levels enhances muscarinic receptor activation, thereby improving bladder contractility and facilitating urination. Thus, cholinesterase inhibitors are effective in treating certain types of bladder dysfunction characterized by underactive detrusor muscle, such as postoperative urinary retention, by targeting this specific molecular pathway.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_8e8bb080d2af",
      "question": "A 54-year-old man returns from a hiking trip in the northeastern United States and presents with several days of fever, chills, fatigue, and myalgias. Laboratory evaluation reveals hemolytic anemia and intraerythrocytic ring forms on peripheral blood smear. He is diagnosed with a tick-borne protozoal infection and is started on a medication that targets the pathogen by disrupting synthesis of its DNA and RNA, thereby halting its cellular replication. By what general pharmacologic mechanism does this therapy exert its antiparasitic effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Babesiosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004576",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0771588",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Inhibition of nucleic acid synthesis",
      "reasoning_path": "Babesiosis is diagnosed; treatment involves drugs that target DNA/RNA synthesis in the parasite, thereby inhibiting its replication and survival.",
      "umls_path": [
        "Babesiosis",
        "may_be_treated_by",
        "Quinine Ascorbate",
        "has_mechanism_of_action",
        "Nucleic Acid Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient's clinical and laboratory findings are consistent with a diagnosis of Babesiosis, a tick-borne infection caused by Babesia species. The standard treatment for moderate to severe cases often includes drugs such as atovaquone plus azithromycin, or clindamycin plus quinine. These agents exert their antiparasitic activity by interfering with the synthesis of nucleic acids (DNA and RNA) within the Babesia organisms. Disruption of nucleic acid synthesis prevents the parasite from replicating and transcribing essential genes, leading to its death. This mechanism is effective because Babesia, as a protozoan parasite, relies on rapid DNA replication for proliferation within red blood cells. By targeting this process, nucleic acid synthesis inhibitors directly impede the survival and propagation of the pathogen, thereby treating the infection.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_7c4292a6319c",
      "question": "A 42-year-old woman with a positive interferon-gamma release assay but no symptoms or radiographic evidence of active lung disease is started on a medication as part of a regimen to prevent progression to active tuberculosis. This drug acts by binding to the beta subunit of a key bacterial enzyme, thereby suppressing transcription of essential genes. Which drug class best describes the primary molecular action responsible for this medication’s efficacy in latent tuberculosis infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Inactive tuberculosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1609538",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0073372",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Nucleic Acid Synthesis Inhibitors",
      "reasoning_path": "Latent TB is treated with rifapentine, which binds bacterial RNA polymerase, inhibiting RNA synthesis; this places it in the nucleic acid synthesis inhibitor class.",
      "umls_path": [
        "Inactive tuberculosis",
        "may_be_treated_by",
        "Rifapentine",
        "has_mechanism_of_action",
        "Nucleic Acid Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Latent tuberculosis infection is treated to prevent progression to active disease. Rifapentine, the drug described in this scenario, is a rifamycin antibiotic that targets Mycobacterium tuberculosis. Its primary mechanism involves binding to the beta subunit of bacterial DNA-dependent RNA polymerase. This action prevents the enzyme from synthesizing RNA, thereby halting bacterial mRNA production and inhibiting protein synthesis necessary for bacterial survival. Because this blockade disrupts nucleic acid (RNA) synthesis at the transcriptional level, rifapentine—and related agents like rifampin—are classified as nucleic acid synthesis inhibitors. This mechanism is key to their bactericidal activity, making them effective in eradicating dormant or slowly replicating mycobacteria present in latent infection. Thus, the therapeutic effect of rifapentine in latent tuberculosis is most directly attributable to its role as a nucleic acid synthesis inhibitor.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_75d9d3db6036",
      "question": "A 7-year-old girl presents with a two-week history of persistent, foul-smelling discharge from her right ear following an episode of acute otitis media. Otoscopic examination reveals a perforated tympanic membrane with purulent drainage. Her physician prescribes a topical antibiotic that acts by interfering with bacterial DNA replication and segregation through inhibition of a specific bacterial enzyme complex. Which molecular target is most directly responsible for this drug's antimicrobial effect in her case?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Unspecified suppurative otitis media"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0029888",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0028902",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Topoisomerase IV",
      "reasoning_path": "Suppurative otitis media treated with topical fluoroquinolone; fluoroquinolones act by inhibiting bacterial topoisomerase IV, blocking DNA replication and segregation, leading to bacterial death.",
      "umls_path": [
        "Unspecified suppurative otitis media",
        "may_be_treated_by",
        "Ofloxacin",
        "has_mechanism_of_action",
        "Topoisomerase 4 Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this case of chronic suppurative otitis media with tympanic membrane perforation, topical fluoroquinolones such as ofloxacin are often used because of their efficacy and safety profile. Fluoroquinolones exert their bactericidal effect by targeting bacterial enzymes involved in DNA replication. Specifically, in gram-positive bacteria commonly implicated in otitis media, the primary target is topoisomerase IV, an enzyme essential for decatenation (separation) of replicated DNA. By inhibiting topoisomerase IV, fluoroquinolones prevent proper DNA segregation during bacterial cell division, resulting in bacterial cell death. In gram-negative bacteria, these drugs may also target DNA gyrase, but topoisomerase IV inhibition is critical for activity against key pathogens in otic infections. Thus, the therapeutic effect in this patient is primarily mediated by inhibition of bacterial topoisomerase IV.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_c38b8a372d12",
      "question": "A 55-year-old man with poorly controlled diabetes mellitus is admitted to the hospital with fever, facial swelling, and black nasal discharge. Imaging and biopsy confirm invasive mucormycosis. He is started on an intravenous antifungal that is effective against Mucorales species but is also known to inhibit a specific renal transporter involved in drug elimination. Which class of drugs does this antifungal belong to based on its transporter-inhibiting mechanism, and what is the clinical significance of this property?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Mucormycosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0026718",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1832021",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Organic Cation Transporter 2 (OCT2) inhibitors—Isavuconazole inhibits renal OCT2, potentially affecting the excretion and plasma levels of co-administered drugs that are OCT2 substrates.",
      "reasoning_path": "Isavuconazole treats mucormycosis and inhibits OCT2, affecting renal drug clearance and interaction risk.",
      "umls_path": [
        "Mucormycosis",
        "may_be_treated_by",
        "Isavuconazole",
        "has_mechanism_of_action",
        "Organic Cation Transporter 2 Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s invasive mucormycosis is being treated with isavuconazole, a broad-spectrum triazole antifungal. Besides its primary antifungal mechanism (inhibition of ergosterol synthesis), isavuconazole is also a clinically significant inhibitor of the renal Organic Cation Transporter 2 (OCT2). OCT2 is responsible for the tubular secretion of many cationic drugs, including certain chemotherapeutics and metformin. Inhibition of OCT2 by isavuconazole can reduce renal clearance of these drugs, increasing their plasma concentrations and risk of toxicity or drug-drug interactions. Recognizing isavuconazole as an OCT2 inhibitor is important for anticipating and managing such pharmacokinetic interactions in patients receiving concomitant therapies.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_c6e63f4de89a",
      "question": "A 54-year-old woman with a long-standing history of upper abdominal discomfort, described as burning epigastric pain worsened by meals, is diagnosed with chronic gastritis. Her physician prescribes a medication containing bismuth, formic acid, and iodide. This combination is chosen for its ability to interact with the gastric environment, providing symptomatic relief. Through which primary pharmacological mechanism does this therapy exert its protective effect on the gastric mucosa?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Stomach Disorder"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0038354",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0772488",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Acid-base activity—modulation of gastric pH and mucosal protection",
      "reasoning_path": "Chronic gastritis exposes the stomach lining to acid; bismuth-based therapies act via acid-base activity, buffering acid and protecting the mucosa to alleviate symptoms.",
      "umls_path": [
        "Stomach Disorder",
        "may_be_treated_by",
        "BISMUTH/FORMIC/IODIDE",
        "has_mechanism_of_action",
        "Acid-Base Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In chronic gastritis, the gastric mucosa is vulnerable to acidic injury, resulting in persistent pain and inflammation. Medications containing bismuth, formic acid, and iodide are used for their ability to alter the local gastric environment. The primary therapeutic mechanism involves acid-base activity: bismuth compounds can buffer gastric acid, coat the mucosal lining, and form a barrier that shields epithelial cells from further acid-mediated damage. This not only protects the mucosa but may also enhance healing of superficial lesions and promote symptom relief. Modulation of pH and mucosal protection are thus central to this therapy’s effectiveness. While other components such as formic acid and iodide may have minor roles, the dominant action relates to the buffering and physical protection provided by bismuth, highlighting the importance of acid-base modulation in the management of chronic gastric disorders.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_554faa1d9578",
      "question": "A 68-year-old woman with a long-standing history of severe chronic obstructive pulmonary disease presents with a persistent, nonproductive cough that has not improved despite inhaled bronchodilators and corticosteroids. The cough significantly disrupts her sleep and quality of life. Her physician prescribes a medication that acts on specific central nervous system receptors to suppress the cough reflex. Which pharmacologic class best describes the molecular mechanism by which this agent exerts its antitussive action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Lungs--Diseases, Obstructive"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0600260",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020264",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Full opioid agonists—hydrocodone suppresses cough via μ-opioid receptor activation in the medullary cough center.",
      "reasoning_path": "Chronic cough unresponsive to standard therapy → hydrocodone prescribed → acts as a full opioid agonist → activates μ-opioid receptors in medullary cough center → suppresses cough reflex.",
      "umls_path": [
        "Lungs--Diseases, Obstructive",
        "may_be_treated_by",
        "Hydrocodone-containing product",
        "has_mechanism_of_action",
        "Full Opioid Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In patients with chronic obstructive pulmonary disease, persistent cough may remain refractory to standard inhaled therapies. Hydrocodone is sometimes used as an antitussive in these cases. Its primary mechanism involves binding to and activating μ-opioid receptors in the medullary cough center of the brainstem. This activation leads to suppression of the cough reflex by decreasing the excitability of neurons involved in cough generation. Hydrocodone is classified pharmacologically as a full opioid agonist because it fully activates the opioid receptor, as opposed to partial agonists or antagonists. The antitussive effect is thus a direct consequence of opioid receptor-mediated inhibition of the neuronal pathways responsible for coughing. While opioid agonists like hydrocodone are effective, their use is limited by the risk of side effects such as sedation, constipation, and respiratory depression, especially in patients with underlying pulmonary disease. Nonetheless, the main pharmacological class mediating the antitussive effect in this scenario is full opioid agonists.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_48f6c91d41be",
      "question": "For a patient with completely resected stage IIB non-small cell lung cancer who underwent surgery followed by adjuvant chemotherapy, is routine FDG-PET/CT or brain MRI indicated during scheduled surveillance in the absence of symptoms or suspicious findings on chest CT?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
              "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "No, for patients with stage IIB non-small cell lung cancer treated with surgery and adjuvant chemotherapy, routine FDG-PET/CT or brain MRI is not indicated during surveillance if there are no symptoms or radiographic suspicion on chest CT; surveillance should be performed with history, physical examination, and chest CT.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_c5916d55ddf7",
      "question": "For a patient with stage IIIC (T3, N3) non-small cell lung cancer, if pathological confirmation of N3 disease is inconclusive or not feasible due to inaccessible lymph nodes, is it acceptable to proceed with initial treatment as if N3 disease is present, or must alternative diagnostic strategies always be exhausted first?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 0–2",
              "Multiple lesions",
              "Systemic Therapy for Metastatic Disease (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Definitive pathological confirmation of N3 disease is essential before classifying as stage IIIC non-small cell lung cancer and proceeding with corresponding therapy. If N3 lymph nodes are inaccessible by standard techniques, additional diagnostic modalities—such as EUS, EBUS, or advanced biopsy—should be fully pursued before initiating stage-specific treatment. Empiric treatment based solely on imaging without tissue confirmation is not considered adequate.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_56ccc6321871",
      "question": "A 58-year-old woman presents with gradual, painless loss of peripheral vision in both eyes over several months. On examination, intraocular pressures are elevated and cupping of the optic discs is noted. Her ophthalmologist initiates therapy with a medication that inhibits the enzyme responsible for acetylcholine breakdown at synaptic junctions. Which class of agents is responsible for mediating the beneficial effect of this drug on her eye condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Unspecified glaucoma"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0017601",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0071002",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cholinesterase inhibitors",
      "reasoning_path": "Patient with glaucoma receives physostigmine salicylate → physostigmine inhibits acetylcholinesterase → increased acetylcholine at muscarinic receptors in the eye → enhanced trabecular meshwork outflow of aqueous humor → decreased intraocular pressure → cholinesterase inhibitors mediate this effect.",
      "umls_path": [
        "Unspecified glaucoma",
        "may_be_treated_by",
        "Physostigmine salicylate",
        "has_mechanism_of_action",
        "Cholinesterase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has clinical findings consistent with open-angle glaucoma, characterized by elevated intraocular pressure and optic disc cupping. The prescribed medication, physostigmine salicylate, is a reversible cholinesterase inhibitor. By inhibiting acetylcholinesterase, physostigmine increases the concentration of acetylcholine at muscarinic synapses, including those in the eye. Enhanced cholinergic stimulation of the iris sphincter and ciliary muscle facilitates trabecular meshwork outflow of aqueous humor, thereby lowering intraocular pressure. Thus, the therapeutic benefit in glaucoma is mediated by the cholinesterase inhibitor class, which augments endogenous acetylcholine and promotes aqueous humor drainage to protect optic nerve function.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_9a1de65c2e51",
      "question": "A 28-year-old woman presents with several weeks of intense ocular itching, watery discharge, and redness, especially after exposure to pollen. She has a history of seasonal allergies and eczema. On examination, her conjunctivae are hyperemic with mild chemosis. The ophthalmologist prescribes a topical medication that rapidly reduces her symptoms by blocking the production of inflammatory mediators. This agent exerts its effect by directly inhibiting an enzyme that catalyzes the conversion of arachidonic acid to prostaglandin precursors. Which molecular target is most directly responsible for mediating the therapeutic action of this drug in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Atopic Conjunctivitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0009766",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0064326",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 2 (COX-2)",
      "reasoning_path": "Topical NSAIDs treat atopic conjunctivitis by inhibiting COX-2, blocking prostaglandin synthesis and reducing inflammation.",
      "umls_path": [
        "Atopic Conjunctivitis",
        "may_be_treated_by",
        "Ketorolac Tromethamine",
        "has_target",
        "Prostaglandin G/H Synthase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Atopic conjunctivitis is an allergic, immune-mediated inflammation of the ocular surface. Prostaglandins, synthesized via the cyclooxygenase pathway, play a major role in mediating ocular pain, redness, and edema. Topical NSAIDs such as ketorolac inhibit cyclooxygenase enzymes, particularly COX-2 (prostaglandin G/H synthase 2), which is upregulated during inflammation. By directly inhibiting this enzyme, the drug reduces the synthesis of prostaglandin intermediates (PGG2 and PGH2), leading to diminished inflammation and symptomatic relief. This mechanism is distinct from antihistamines, which block histamine receptors, and corticosteroids, which broadly suppress multiple inflammatory genes. Therefore, the most direct molecular target responsible for alleviating the patient’s conjunctival inflammation with topical NSAID therapy is prostaglandin G/H synthase 2 (COX-2).",
      "type": "kg_reasoning"
    },
    {
      "id": "path_f677d6988fcb",
      "question": "For a patient with stage IIIC (T3, N3) non-small cell lung cancer who also presents with a separate pulmonary nodule in the contralateral lung, should management be aligned with limited stage disease protocols or primarily follow the approach for metastatic (stage IV) disease?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Presence of a separate pulmonary nodule in the contralateral lung is classified as stage IV disease, indicating metastatic involvement. In this situation, management should primarily follow treatment protocols for metastatic (stage IV) non-small cell lung cancer rather than limited stage (stage IIIC) protocols.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_a7a3b7967a5f",
      "question": "For a patient with stage I non-small cell lung cancer who underwent surgical resection but has positive surgical margins (R1, R2), is re-excision required as the only preferred option, or can radiotherapy serve as an acceptable alternative definitive treatment in this setting?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (T1abc, N0); Margins positive (R1, R2)",
              "Resection (preferred) or RT (category 2B)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Re-excision is the preferred approach for stage I NSCLC patients with positive surgical margins, but definitive radiotherapy is an acceptable alternative option when resection is not feasible or contraindicated. Both strategies are recognized as appropriate for achieving local disease control in this context.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_a6456c93f08f",
      "question": "A 38-year-old man from an endemic region presents with multiple, asymmetrical, hypopigmented skin lesions and peripheral nerve thickening. Skin biopsy confirms granulomatous inflammation with acid-fast bacilli. He is diagnosed with a form of leprosy intermediate between tuberculoid and lepromatous types, and is started on combination therapy including a red-colored oral agent known to bind mycobacterial DNA, disrupt template function, and inhibit growth. Which broad pharmacological class best describes the mechanism by which this medication exerts its antimicrobial effect in this setting?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Borderline leprosy [group B]"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0023346",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0008996",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Nucleic acid synthesis inhibitors",
      "reasoning_path": "Borderline leprosy is treated with clofazimine, which binds mycobacterial DNA and inhibits nucleic acid synthesis, placing it in the nucleic acid synthesis inhibitor class.",
      "umls_path": [
        "Borderline leprosy [group B]",
        "may_be_treated_by",
        "Clofazimine-containing product",
        "has_mechanism_of_action",
        "Nucleic Acid Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Leprosy (Hansen’s disease) is treated with multidrug regimens to prevent resistance. In borderline forms, therapy often includes clofazimine, a phenazine dye with antimycobacterial activity. Clofazimine acts by binding to mycobacterial DNA, interfering with the template function and thereby inhibiting DNA replication and transcription. This leads to disruption of nucleic acid synthesis, which is essential for bacterial survival and proliferation. Unlike cell wall inhibitors (like dapsone or rifampin), clofazimine’s principal effect is on nucleic acid processes rather than cell wall formation or protein synthesis. This mechanism places clofazimine within the pharmacological class of nucleic acid synthesis inhibitors. Its unique action also contributes to its anti-inflammatory effects, useful in lepra reactions. Understanding this distinction is critical for selecting appropriate therapy and anticipating possible side effects, such as skin discoloration, which is related to the drug’s deposition rather than its molecular target.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_51a1a62c74a5",
      "question": "In a patient with newly diagnosed non-small cell lung cancer presenting with a T3N1 lesion (classified as stage IIIA), if pulmonary function tests (PFTs) reveal significant impairment and bronchoscopy shows central tumor involvement, is concurrent chemoradiation still an appropriate initial treatment option?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Concurrent chemoradiation is generally not appropriate for patients with significant pulmonary dysfunction, especially when there is central tumor involvement, due to increased risk of severe toxicity. Adequate pulmonary function is a prerequisite for this modality; alternative treatment strategies should be considered in cases of compromised respiratory function.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_82bc1dc629ee",
      "question": "What is the unique PMID for the 2025 Neurogastroenterology and Motility article titled \"Trainees' Exposure to the Field of Neurogastroenterology and Motility in Internal Medicine and General Surgery Residency Programs,\" authored by Cohen DL?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"Trainees' Exposure to the Field of Neurogastroenterology and Motility in Internal Medicine and General Surgery Residency Programs.\"[ti] AND Cohen DL[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40145420"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_a127e2fd99bb",
      "question": "A 34-year-old contact lens wearer presents with severe ocular pain, photophobia, and blurred vision. Slit-lamp examination reveals a ring-shaped stromal infiltrate with perineural radial keratoneuritis in the cornea. Microbiological analysis confirms an infection caused by a free-living protozoan. The ophthalmologist prescribes a systemic agent that both treats the infection and is known to inhibit a specific cytochrome P450 enzyme involved in steroidogenesis and xenobiotic metabolism. Which class of enzyme inhibition most directly accounts for the therapeutic and pharmacological profile of this agent in this setting?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Acanthamoeba keratitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0000880",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4550366",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cytochrome P450 17A1 inhibitors",
      "reasoning_path": "Acanthamoeba keratitis → treated with levoketoconazole → inhibits CYP17A1 → blocks protozoan steroidogenesis/metabolism → therapeutic effect via cytochrome P450 17A1 inhibition.",
      "umls_path": [
        "Acanthamoeba keratitis",
        "may_be_treated_by",
        "Levoketoconazole",
        "has_mechanism_of_action",
        "Cytochrome P450 17A1 Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Acanthamoeba keratitis is a rare but serious corneal infection often seen in contact lens users. Effective therapy may involve agents such as levoketoconazole, an azole antifungal with anti-protozoal activity. Levoketoconazole's mechanism centers on inhibiting the cytochrome P450 17A1 enzyme (also known as CYP17A1), which is involved in steroid biosynthesis and the metabolism of certain xenobiotics. By blocking CYP17A1, levoketoconazole disrupts important biochemical pathways in the protozoan, impairing its growth and survival. The therapeutic benefit in keratitis arises specifically from this enzyme inhibition, which is distinct from the antifungal's more common role of inhibiting CYP51 in fungal pathogens. Therefore, the relevant mechanistic class is cytochrome P450 17A1 inhibitors, which accounts for both the clinical efficacy and the unique pharmacological effects of the drug in treating Acanthamoeba keratitis.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_6f7a04df3594",
      "question": "A 32-year-old man presents with chronic scalp scaling and itching. Examination reveals greasy, yellowish scales and erythematous plaques over the scalp and hairline. The dermatologist prescribes a topical medication that exerts both antifungal and anti-proliferative effects. Notably, the molecular action of this agent involves inhibition of a membrane-bound proton pump, a mechanism it shares with a widely used class of drugs for peptic ulcer disease. Which drug class shares this primary molecular target with the prescribed topical agent?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Seborrhea capitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0221244",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0078792",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Proton Pump Inhibitors",
      "reasoning_path": "Zinc pyrithione treats seborrhea capitis by inhibiting proton pumps; this is the same primary molecular target as proton pump inhibitors used for gastric acid suppression.",
      "umls_path": [
        "Seborrhea capitis",
        "may_be_treated_by",
        "Zinc pyrithione",
        "has_mechanism_of_action",
        "Proton Pump Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has clinical features of seborrheic dermatitis (seborrhea capitis), commonly managed with topical agents such as zinc pyrithione. Zinc pyrithione has antifungal and anti-proliferative properties, and its molecular mechanism includes inhibition of membrane-bound proton pumps (H+/ATPases) in fungal and epidermal cells. Interestingly, this mechanism is shared with proton pump inhibitors (PPIs), such as omeprazole and pantoprazole, which irreversibly inhibit the gastric H+/K+-ATPase to suppress gastric acid secretion in peptic ulcer and GERD management. While the clinical contexts differ—topical versus systemic, dermatologic versus gastrointestinal—the underlying molecular action (proton pump inhibition) is analogous. Understanding this connection highlights how drugs with seemingly disparate indications can share fundamental mechanisms at the cellular level.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_dbb4bb38de9c",
      "question": "For a patient with stage III (T3, N2) non–small cell lung cancer (NSCLC) who has completed concurrent chemoradiation and is found to have residual radiographic abnormalities on follow-up imaging, does the presence of such abnormalities necessitate more frequent surveillance imaging even in the absence of symptoms or clinical progression?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
              "R2; Concurrent chemoradiation",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Limited metastases",
              "Stage IV, M1b (NSCL-15)"
            ]
          }
        }
      ],
      "answer": "Yes; in patients with stage III NSCLC who demonstrate residual or new radiographic abnormalities after concurrent chemoradiation, closer or more frequent imaging surveillance is warranted regardless of clinical symptoms, as these findings may indicate incomplete response or risk of recurrence.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_208b4f5c41a9",
      "question": "In a patient with stage IVA NSCLC presenting with malignant pleural effusion and confirmed BRAF V600E mutation, does the recommendation to perform broad molecular profiling and PD-L1 testing implicitly require that the histologic subtype is non-small cell lung cancer (NSCLC) of adenocarcinoma, large cell, or not otherwise specified (NOS), rather than squamous cell carcinoma?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1a: pleural or pericardial effusion",
              "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
              "Positive",
              "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "BRAF V600E mutation positive"
            ]
          }
        }
      ],
      "answer": "Yes, conducting broad molecular profiling and PD-L1 testing is primarily indicated for advanced-stage NSCLC with adenocarcinoma, large cell, or NOS histology, rather than squamous cell carcinoma, due to the higher prevalence of actionable molecular alterations in these subtypes.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_d33bb5fa5be1",
      "question": "What diseases are associated with the target IL13, which has the Ensembl ID ENSG00000169194, with a minimum relevance score of 0.5 in OpenTargets?",
      "tool_calls": [
        {
          "tool": "opentargets.search",
          "params": {
            "target_id": "ENSG00000169194",
            "min_score": 0.5
          }
        }
      ],
      "answer": [
        {
          "disease_id": "EFO_0000274",
          "disease_name": "atopic eczema",
          "score": 0.6993140228020157
        },
        {
          "disease_id": "MONDO_0004979",
          "disease_name": "asthma",
          "score": 0.6780711161785388
        },
        {
          "disease_id": "HP_0000964",
          "disease_name": "Eczematoid dermatitis",
          "score": 0.6148607200185839
        },
        {
          "disease_id": "EFO_0005854",
          "disease_name": "allergic rhinitis",
          "score": 0.5666922121972621
        },
        {
          "disease_id": "EFO_0000676",
          "disease_name": "psoriasis",
          "score": 0.5492499302524128
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_fc831cbaf0cf",
      "question": "A 54-year-old woman presents with progressive numbness in her feet, orthostatic hypotension, and a family history of early-onset neuropathy. Genetic testing reveals a pathogenic mutation in the TTR gene. She is started on a recently approved therapy that uses small interfering RNA (siRNA) to target and degrade the mutant transthyretin mRNA in hepatocytes, leading to reduced production of the pathogenic protein. Which class of molecular mechanism underlies the therapeutic effect of this agent in treating her disease?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "AMYLOIDOSIS, HEREDITARY SYSTEMIC 1"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2751492",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C5678686",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Nucleic acid synthesis inhibition",
      "reasoning_path": "Hereditary TTR amyloidosis → mutant TTR protein production → vutrisiran siRNA binds TTR mRNA in hepatocytes → mRNA degradation → reduced TTR synthesis → nucleic acid synthesis inhibition is the primary mechanism.",
      "umls_path": [
        "AMYLOIDOSIS, HEREDITARY SYSTEMIC 1",
        "may_be_treated_by",
        "vutrisiran sodium",
        "has_mechanism_of_action",
        "Nucleic Acid Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has hereditary transthyretin-mediated amyloidosis, characterized by accumulation of misfolded transthyretin (TTR) protein and subsequent amyloid deposition. Vutrisiran is an siRNA-based drug that specifically binds to TTR mRNA in the liver, promoting its degradation and thereby inhibiting translation of both mutant and wild-type TTR proteins. By reducing hepatic production of TTR at the mRNA level, the drug decreases circulating amyloidogenic protein, thus slowing or preventing further amyloid deposition. The fundamental mechanism is inhibition of nucleic acid synthesis—specifically, post-transcriptional gene silencing via RNA interference. This reduces the protein burden driving amyloid formation and addresses the root cause of hereditary systemic amyloidosis at the molecular level.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_517732e1b37c",
      "question": "A 9-year-old girl is brought to the neurology clinic by her parents due to frequent episodes of brief, sudden staring spells during which she becomes unresponsive for several seconds and then resumes activity without confusion. EEG shows 3 Hz spike-and-wave discharges consistent with a specific type of generalized epilepsy. She is started on an oral medication containing a succinimide derivative, but her family asks about how this medicine works at the cellular level. Given current scientific understanding, what best describes the knowledge of this drug’s mechanism of action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Absence Epilepsy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0014553",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0070592",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The precise cellular or molecular mechanism of phensuximide in absence epilepsy remains unknown.",
      "reasoning_path": "Absence epilepsy is treated with phensuximide. Unlike ethosuximide, the exact cellular or molecular mechanism of phensuximide is not defined, so its therapeutic action cannot be attributed to a specific molecular target or pathway.",
      "umls_path": [
        "Absence Epilepsy",
        "may_be_treated_by",
        "Phensuximide-containing product",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Absence epilepsy is characterized by abnormal thalamocortical rhythmicity, typically managed with drugs like ethosuximide, and less commonly phensuximide. While ethosuximide’s mechanism—blockade of T-type calcium channels in thalamic neurons—is well described, the specific molecular targets and mechanisms for phensuximide have not been clearly identified or characterized. Although phensuximide is structurally related to ethosuximide and is clinically effective in some patients with absence seizures, direct evidence for its action on ion channels or other cellular components is lacking. Therefore, clinicians must counsel patients and families that, while phensuximide is used for absence epilepsy, its detailed molecular and cellular mechanisms remain unknown, reflecting a limitation in current neuropharmacological understanding.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_5d12e194b824",
      "question": "A 32-year-old pregnant woman is admitted to the hospital after experiencing new-onset tonic-clonic seizures, hypertension (BP 180/110 mmHg), and proteinuria at 35 weeks’ gestation. In addition to magnesium sulfate, she is given an intravenous medication that rapidly lowers her blood pressure and is also used to relieve chest pain in patients with angina. This drug exerts its primary antihypertensive action by increasing cyclic GMP in vascular smooth muscle. Through which pharmacological class does this medication achieve its therapeutic vasodilatory effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Eclampsia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0013537",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0017887",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Nitric oxide donors",
      "reasoning_path": "Eclampsia is treated acutely with nitroglycerin, which acts as a nitric oxide donor, promoting vasodilation and rapid reduction in blood pressure via increased cGMP in vascular smooth muscle.",
      "umls_path": [
        "Eclampsia",
        "may_be_treated_by",
        "Nitroglycerin",
        "has_mechanism_of_action",
        "Nitric Oxide Donors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with eclampsia requires urgent blood pressure control. Nitroglycerin, a drug used both for angina and hypertensive emergencies such as eclampsia, is administered intravenously. Nitroglycerin is a nitric oxide donor; it releases nitric oxide (NO), which diffuses into vascular smooth muscle cells. There, NO activates guanylate cyclase, increasing intracellular cyclic GMP. Elevated cyclic GMP causes dephosphorylation of myosin light chains, leading to smooth muscle relaxation and vasodilation. This process reduces systemic vascular resistance and lowers blood pressure. The same vasodilatory mechanism also relieves angina by decreasing myocardial oxygen demand. Thus, the medication's antihypertensive and antianginal effects are mediated via the nitric oxide donor class, which distinguishes it mechanistically from other antihypertensives such as beta-blockers or calcium channel blockers.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_81ca17be9580",
      "question": "A 42-year-old woman presents with violaceous, flat-topped papules on her wrists and lower legs. A skin biopsy confirms a diagnosis of lichenoid dermatitis. Her dermatologist prescribes a topical cream containing an agent with both antimicrobial and anti-inflammatory properties. During a follow-up appointment, she inquires about how this medication works at the cellular or molecular level to improve her skin lesions. Based on current scientific understanding, what is the best description of the drug's mechanism of action in this dermatologic context?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "lichenoid dermatitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0162848",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021978",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The precise cellular or molecular mechanism of action of clioquinol in lichenoid dermatitis is unknown.",
      "reasoning_path": "Lichenoid dermatitis → treated with clioquinol-containing topical → mechanism in skin disease not established → classified as unknown cellular or molecular interaction.",
      "umls_path": [
        "lichenoid dermatitis",
        "may_be_treated_by",
        "Clioquinol-containing product",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Clioquinol is often included in topical preparations for inflammatory skin conditions such as lichenoid dermatitis due to its antimicrobial and mild anti-inflammatory properties. However, despite its clinical use, the exact molecular or cellular pathways through which clioquinol exerts a therapeutic effect in these dermatologic conditions have not been clearly elucidated. No specific receptor, enzyme, or signaling pathway has been definitively linked to its activity in the treatment of lichenoid eruptions. Thus, although clioquinol may provide symptomatic relief, its precise mechanism of action at the cellular or molecular level in this context remains undetermined.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_8068dac52471",
      "question": "For a patient with squamous cell carcinoma presenting with locoregional recurrence and symptomatic superior vena cava (SVC) obstruction, but no evidence of disseminated disease on chest CT, brain MRI, and FDG-PET/CT, should concurrent chemoradiation be prioritized over immediate SVC stent placement if the patient is clinically stable?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "In a clinically stable patient with squamous cell carcinoma, locoregional recurrence, and symptomatic SVC obstruction without disseminated disease, immediate SVC stent placement provides rapid symptom relief and is prioritized for severe obstruction, whereas concurrent chemoradiation is indicated if not previously given but typically follows after hemodynamic stabilization by stenting.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_802e808ffc2b",
      "question": "A 54-year-old woman with a history of dry, gritty eyes and decreased tearing presents for evaluation. Slit-lamp examination reveals punctate staining on the corneal epithelium, and Schirmer's test confirms reduced tear production. She is started on an ophthalmic medication derived from vitamin A. This agent is known to enhance mucin production and epithelial cell differentiation through its action on specific intracellular enzymes. Which molecular mechanism best explains how this medication improves her ocular surface symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Tear film insufficiency, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0043349",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0073109",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme interactions—modulation of epithelial and mucin-related enzymes by retinoids",
      "reasoning_path": "Tear film insufficiency → vitamin A derivative prescribed → retinoid acts via enzyme interactions → promotes epithelial differentiation & mucin production → improves tear film stability and ocular surface.",
      "umls_path": [
        "Tear film insufficiency, unspecified",
        "may_be_treated_by",
        "Retinyl Acetate",
        "has_mechanism_of_action",
        "Enzyme Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s symptoms and exam findings are consistent with tear film insufficiency, leading to dry eye and epithelial damage. Topical vitamin A derivatives, such as retinyl acetate, are sometimes prescribed to improve ocular surface health. Their therapeutic effect is primarily due to their role as cofactors or modulators of enzymes involved in cellular differentiation and mucin synthesis. Retinoids promote the differentiation of conjunctival and corneal epithelial cells and increase the expression of mucin genes, both of which are crucial for maintaining a stable and healthy tear film. These molecular actions are mediated through interactions with intracellular enzymes, including retinol dehydrogenases and other retinoid-activated transcription regulators. Enhanced mucin production and improved epithelial integrity restore the ocular surface and alleviate symptoms of dry eye. Thus, the key pharmacological mechanism is the interaction of vitamin A derivatives with enzymes that regulate epithelial and mucin gene expression.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_2cfc6709af8d",
      "question": "In a patient diagnosed with stage IVA non-small cell lung cancer presenting with pleural effusion, who is found to have a ROS1 rearrangement on molecular profiling, does the use of a ROS1-targeted tyrosine kinase inhibitor implicitly require confirmation of non-squamous histology prior to initiation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1a: pleural or pericardial effusion",
              "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
              "Positive",
              "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "ROS1 rearrangement positive"
            ]
          }
        }
      ],
      "answer": "Yes, initiation of a ROS1-targeted tyrosine kinase inhibitor is predicated on confirmation of non-squamous histology—specifically adenocarcinoma, large cell, or NSCLC not otherwise specified—since ROS1 rearrangements are exceedingly rare in squamous cell carcinoma, and routine molecular testing is not recommended for pure squamous histology in the absence of mixed features or clinical suspicion.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_4f6d2be4a8c1",
      "question": "A 32-year-old laboratory worker is exposed to variola virus during a containment breach and develops fever, malaise, and a vesiculopustular rash. In addition to supportive care, she is started on an antiviral medication that is known to interfere with the metabolism of several oral medications, including proton pump inhibitors and certain antiepileptics. This agent works by inhibiting a specific hepatic enzyme involved in the oxidative metabolism of many drugs. Which enzyme is most likely inhibited by this antiviral, and what is the clinical significance of this interaction?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Smallpox, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0037354",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2713595",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cytochrome P450 2C19; inhibition of this enzyme by the antiviral can increase levels of co-administered drugs metabolized by CYP2C19, potentially leading to adverse effects or toxicity.",
      "reasoning_path": "Tecovirimat is used for smallpox and acts as a CYP2C19 inhibitor, which can alter the metabolism of other drugs processed by this enzyme, necessitating monitoring for interactions.",
      "umls_path": [
        "Smallpox, unspecified",
        "may_be_treated_by",
        "Tecovirimat",
        "has_mechanism_of_action",
        "Cytochrome P450 2C19 Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is being treated for smallpox with an antiviral agent that can affect drug metabolism. Tecovirimat is approved for the treatment of smallpox and is known to inhibit the enzyme cytochrome P450 2C19 (CYP2C19) in the liver. Inhibition of CYP2C19 slows the metabolism of drugs that are substrates of this enzyme, such as certain proton pump inhibitors (e.g., omeprazole), selective serotonin reuptake inhibitors, and some antiepileptics. This can lead to higher plasma concentrations of these co-administered drugs, increasing the risk of side effects or toxicity. Therefore, clinicians must monitor for drug-drug interactions and adjust dosages as necessary when prescribing Tecovirimat with other medications metabolized by CYP2C19.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_f6b9885550b4",
      "question": "What diseases are associated with the target NR3C1, which has the Ensembl ID ENSG00000113580, and have a minimum relevance score of 0.5 in OpenTargets?",
      "tool_calls": [
        {
          "tool": "opentargets.search",
          "params": {
            "target_id": "ENSG00000113580",
            "min_score": 0.5
          }
        }
      ],
      "answer": [
        {
          "disease_id": "MONDO_0014421",
          "disease_name": "glucocorticoid resistance",
          "score": 0.7915382113548423
        },
        {
          "disease_id": "EFO_0000341",
          "disease_name": "chronic obstructive pulmonary disease",
          "score": 0.7045546959776285
        },
        {
          "disease_id": "MONDO_0005301",
          "disease_name": "multiple sclerosis",
          "score": 0.6841166085552951
        },
        {
          "disease_id": "EFO_1000941",
          "disease_name": "frozen shoulder",
          "score": 0.6436439828322041
        },
        {
          "disease_id": "EFO_0000685",
          "disease_name": "rheumatoid arthritis",
          "score": 0.6318120426084437
        },
        {
          "disease_id": "EFO_0000729",
          "disease_name": "ulcerative colitis",
          "score": 0.6182720106116167
        },
        {
          "disease_id": "EFO_0007160",
          "disease_name": "autoimmune thrombocytopenic purpura",
          "score": 0.6174774224880838
        },
        {
          "disease_id": "EFO_0000544",
          "disease_name": "infection",
          "score": 0.6143127801552344
        },
        {
          "disease_id": "MONDO_0019338",
          "disease_name": "sarcoidosis",
          "score": 0.6122412480921858
        },
        {
          "disease_id": "EFO_0004255",
          "disease_name": "nephrotic syndrome",
          "score": 0.6103523986733679
        },
        {
          "disease_id": "EFO_0000384",
          "disease_name": "Crohn's disease",
          "score": 0.6096175194680566
        },
        {
          "disease_id": "MONDO_0004979",
          "disease_name": "asthma",
          "score": 0.6093000298135062
        },
        {
          "disease_id": "MONDO_0004992",
          "disease_name": "cancer",
          "score": 0.6087147865226739
        },
        {
          "disease_id": "EFO_0000574",
          "disease_name": "lymphoma",
          "score": 0.6085338062641863
        },
        {
          "disease_id": "MONDO_0005178",
          "disease_name": "osteoarthritis",
          "score": 0.6082930297131999
        },
        {
          "disease_id": "EFO_0000274",
          "disease_name": "atopic eczema",
          "score": 0.607514053015777
        },
        {
          "disease_id": "EFO_0000565",
          "disease_name": "leukemia",
          "score": 0.6072230111709825
        },
        {
          "disease_id": "MP_0001845",
          "disease_name": "inflammation",
          "score": 0.6070319539806248
        },
        {
          "disease_id": "EFO_0005854",
          "disease_name": "allergic rhinitis",
          "score": 0.6070273813562097
        },
        {
          "disease_id": "EFO_0000676",
          "disease_name": "psoriasis",
          "score": 0.6060952673715753
        },
        {
          "disease_id": "EFO_0003106",
          "disease_name": "pneumonia",
          "score": 0.6049059903156613
        },
        {
          "disease_id": "EFO_0000701",
          "disease_name": "skin disease",
          "score": 0.6041967898956461
        },
        {
          "disease_id": "EFO_0002609",
          "disease_name": "juvenile idiopathic arthritis",
          "score": 0.6036867766632718
        },
        {
          "disease_id": "EFO_0003956",
          "disease_name": "seasonal allergic rhinitis",
          "score": 0.6011694655297128
        },
        {
          "disease_id": "EFO_1001494",
          "disease_name": "psoriasis vulgaris",
          "score": 0.6004211328376824
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "path_ece872cd6aea",
      "question": "In a patient with localized, non-inflammatory, non-metastatic (M0) breast cancer, clinical stage cT2, HR-negative, and HER2-positive disease who, after preoperative systemic therapy, is found to have ypT2, ypN1 disease, is the use of adjuvant ado-trastuzumab emtansine for 14 cycles appropriate even if axillary lymph node involvement (ypN≥1) persists after therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS possible",
              "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
              "Adjuvant systemic therapy (BINV-16), no RT",
              "HR-negative/ HER2-positive",
              "ypT1–4,N0 or ypN≥1",
              "Ado-trastuzumab emtansine (category 1) alone for 14 cycles"
            ]
          }
        }
      ],
      "answer": "Yes, in HR-negative, HER2-positive breast cancer patients with residual invasive disease in the breast or persistent axillary lymph node involvement (ypN≥1) after preoperative systemic therapy, adjuvant ado-trastuzumab emtansine for 14 cycles is indicated regardless of nodal status, provided M0 disease is present.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_609368109391",
      "question": "In a patient with stage IIIC (T3, N3) non-small cell lung cancer who has developed mediastinal lymph node recurrence after prior chest radiotherapy, is repeat radiotherapy generally considered an appropriate option for managing the recurrence, or does prior RT serve as an absolute contraindication requiring exclusive use of systemic therapy or observation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Prior chest radiotherapy is generally considered a contraindication to repeat mediastinal radiotherapy due to increased risk of severe toxicity; therefore, management of mediastinal lymph node recurrence after prior RT typically prioritizes systemic therapy or observation rather than repeat radiotherapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_e6155c75e9a6",
      "question": "A 72-year-old woman with a history of hypertension and intermittent claudication complains of leg pain while walking short distances, relieved by rest. On examination, her lower extremities are cool with diminished peripheral pulses. Her physician initiates a medication to improve her walking distance by enhancing peripheral blood flow. This agent works by stimulating specific G protein-coupled receptors on vascular smooth muscle, leading to increased intracellular cAMP and subsequent vasodilation. Which pharmacological class does this medication belong to, and how does this mechanism address her symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Arteriosclerosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003850",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0028735",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Adrenergic beta-agonists; stimulation of beta-adrenergic receptors in vascular smooth muscle causes vasodilation, improving peripheral circulation in arteriosclerosis.",
      "reasoning_path": "Arteriosclerosis reduces blood flow. Nylidrin stimulates beta-adrenergic receptors on vascular smooth muscle, leading to increased cAMP, smooth muscle relaxation, and vasodilation. This improves peripheral circulation, alleviating claudication. Thus, the drug is classified as an adrenergic beta-agonist.",
      "umls_path": [
        "Arteriosclerosis",
        "may_be_treated_by",
        "Nylidrin",
        "has_mechanism_of_action",
        "Adrenergic beta-Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This case describes a patient with peripheral arterial disease secondary to arteriosclerosis, manifesting as intermittent claudication. The therapeutic goal is to increase peripheral blood flow to alleviate symptoms. Nylidrin, the drug described, is a beta-adrenergic agonist. By activating beta-adrenergic receptors (mainly beta-2) on vascular smooth muscle, the drug increases intracellular cAMP, which results in relaxation of smooth muscle fibers and subsequent vasodilation. This vasodilatory action lowers vascular resistance and enhances blood flow to ischemic peripheral tissues, thereby improving the patient's exercise tolerance and reducing claudication symptoms. The pharmacological class responsible for this mechanism is adrenergic beta-agonists, which directly address the patient's symptoms by counteracting the effects of arterial narrowing and improving tissue perfusion.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_73e39a32cfcb",
      "question": "For a patient with stage IIIA NSCLC (T1–2, N2; or T3, N1) who has undergone complete surgical resection (R0) followed by adjuvant systemic therapy and currently shows no clinical or radiographic evidence of disease, is routine use of FDG-PET/CT or brain MRI indicated during surveillance, even if the patient has a prior history of isolated brain metastasis that was definitively treated?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Routine use of FDG-PET/CT or brain MRI is not indicated during surveillance for resected stage IIIA NSCLC patients without evidence of disease, even if they had a prior isolated brain metastasis that was definitively treated. These modalities are reserved for cases with symptoms or suspicion of recurrence rather than routine follow-up.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_597380310eb1",
      "question": "In ClinicalTrials.gov, which completed interventional phase 3 studies for Type 2 Diabetes Mellitus involving Exenatide Once Weekly were conducted in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "overallStatus=COMPLETED;phases=PHASE3;conditions=Type 2 Diabetes Mellitus;interventions.name=Exenatide Once Weekly;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00641056"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_c16dbdabfb89",
      "question": "In a patient with localized, non-inflammatory, non-metastatic invasive breast cancer (clinical stages T1–T4, N0, M0) who is HER2-positive and ER/PR-positive, if axillary staging reveals at least one ipsilateral lymph node metastasis >2 mm (pN+), is adjuvant chemotherapy with both trastuzumab and pertuzumab plus endocrine therapy appropriate, or should adjuvant chemotherapy with trastuzumab plus endocrine therapy alone be prioritized?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
              "ER-positive and/or PR-positive",
              "HER2-positive",
              "BINV-5",
              "Ductal/NST • Lobular • Mixed • Micropapillary",
              "pN+ (≥1 ipsilateral metastases >2 mm)",
              "Adjuvant chemotherapy with trastuzumab (category 1) and endocrine therapy or Adjuvant chemotherapy with trastuzumab + pertuzumab (category 1, preferred) and endocrine therapy",
              "Follow-Up (BINV-17)"
            ]
          }
        }
      ],
      "answer": "For HER2-positive, ER/PR-positive breast cancer with pN+ (≥1 ipsilateral node metastasis >2 mm), adjuvant chemotherapy combined with trastuzumab and pertuzumab plus endocrine therapy is preferred over chemotherapy with trastuzumab plus endocrine therapy, as dual HER2 blockade improves disease-free survival in this higher-risk subgroup.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_8c32a09e41c8",
      "question": "A 54-year-old woman undergoes abdominal surgery and, during recovery, develops diffuse abdominal discomfort without signs of infection or obstruction. Imaging reveals mild peritoneal irritation, but no clear etiology is found. To manage her symptoms, her physician recommends an agent that forms a protective, soothing barrier on mucosal surfaces. Which pharmacological property of this agent is responsible for alleviating her symptoms in this setting?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Unspecified disorder of peritoneum"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0031142",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0982057",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Demulcent activity—soothing and protecting irritated peritoneal surfaces",
      "reasoning_path": "Peritoneal irritation → agent selection for mucosal protection → Carboxymethylcellulose Calcium forms a protective barrier → demulcent activity reduces irritation and discomfort.",
      "umls_path": [
        "Unspecified disorder of peritoneum",
        "may_be_treated_by",
        "Carboxymethylcellulose Calcium",
        "has_mechanism_of_action",
        "Demulcent Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In patients with non-specific peritoneal irritation, management focuses on symptom control and mucosal protection. Carboxymethylcellulose Calcium is a pharmacological agent with demulcent properties. Demulcents are substances that form a soothing, protective film over mucous membranes, reducing irritation, discomfort, and further injury. In the context of peritoneal irritation, applying a demulcent like Carboxymethylcellulose Calcium helps to coat the peritoneal surfaces, minimizing friction and mechanical irritation. This protective barrier decreases local inflammation and promotes comfort, even when the underlying cause of irritation is not clearly identified. Unlike agents that modify peritoneal fluid dynamics or directly address infection or inflammation, demulcents act primarily by physical means—protecting tissues from further insult. Thus, the beneficial effect in this patient is due to the demulcent activity of Carboxymethylcellulose Calcium, which soothes and shields the peritoneal lining, facilitating recovery and symptom relief.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_bfeac14da10a",
      "question": "A 34-year-old contact lens wearer presents with redness, pain, and photophobia in her right eye. Slit-lamp examination reveals conjunctival injection and a superficial corneal infiltrate. Corneal scrapings are sent for analysis, and PCR confirms a microsporidial infection. She is started on an ophthalmic medication that targets a key component of fungal cell membranes, leading to loss of membrane integrity and organism death. Through inhibition of which molecular process does this drug exert its therapeutic effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Infection by Microspora"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0085407",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0027444",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Ergosterol synthesis inhibition",
      "reasoning_path": "Microsporidial keratitis responds to natamycin, which binds to ergosterol in the pathogen’s cell membrane, inhibiting ergosterol function and disrupting membrane integrity to cause pathogen death.",
      "umls_path": [
        "Infection by Microspora",
        "may_be_treated_by",
        "Natamycin",
        "has_mechanism_of_action",
        "Ergosterol Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Microsporidial keratitis, although caused by a protozoan-like organism, often responds to antifungal agents due to similarities in membrane composition. Natamycin, a polyene antifungal, is commonly used for ophthalmic fungal infections, including those caused by Microspora. Its mechanism involves binding to ergosterol, a critical component of fungal cell membranes, thereby disrupting membrane integrity and causing cell death. Inhibition of ergosterol synthesis or function leads to increased membrane permeability and loss of essential intracellular contents. Human cells lack ergosterol, so the drug selectively targets the pathogen. Therefore, the therapeutic benefit observed in this patient is due to natamycin’s ability to inhibit ergosterol synthesis or function, compromising the structural and functional integrity of the microsporidial cell membrane.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_d24f85998599",
      "question": "A 68-year-old man with progressive shortness of breath and dry cough is diagnosed with a restrictive lung disease after high-resolution CT reveals subpleural reticulation and honeycombing, and pulmonary function tests show reduced FVC and DLCO. He is started on a medication that acts as a tyrosine kinase inhibitor, aiming to slow disease progression by blocking signaling pathways that promote fibroblast activation and extracellular matrix deposition. Which receptor family is the principal molecular target of this therapy, mediating its antifibrotic effects?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Idiopathic Pulmonary Fibrosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1800706",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2930789",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Fibroblast Growth Factor Receptor Family",
      "reasoning_path": "Patient with IPF → Treated with nintedanib (a tyrosine kinase inhibitor) → Nintedanib inhibits FGFR family → Disrupts fibroblast activation and fibrogenesis → Slows disease progression.",
      "umls_path": [
        "Idiopathic Pulmonary Fibrosis",
        "may_be_treated_by",
        "Nintedanib-containing product",
        "has_target",
        "Fibroblast Growth Factor Receptor Family"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient with idiopathic pulmonary fibrosis (IPF) is being treated with a tyrosine kinase inhibitor, such as nintedanib. IPF is characterized by aberrant fibroblast proliferation and excessive extracellular matrix production, largely driven by growth factor signaling. Nintedanib exerts its antifibrotic effects by inhibiting several receptor tyrosine kinases, most notably the fibroblast growth factor receptor (FGFR) family, along with platelet-derived growth factor receptors (PDGFR) and vascular endothelial growth factor receptors (VEGFR). By directly blocking FGFR activity, the drug disrupts key intracellular signaling cascades (such as the MAPK and PI3K pathways) that mediate fibroblast proliferation, migration, and differentiation into collagen-secreting myofibroblasts. This targeted inhibition ultimately slows the progression of fibrosis in the lungs, making the FGFR family the principal molecular target in this context.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_3525ee4d925c",
      "question": "A 62-year-old woman with type 1 diabetes is brought to the emergency department after being found confused and diaphoretic. Her blood glucose is measured at 38 mg/dL. She is immediately given an oral glucose gel. At the cellular level, the administered agent is rapidly transported into cells and directly replenishes which class of biological macromolecules, thereby correcting her acute symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Hypoglycemia, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020615",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0017734",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Structural macromolecules—specifically, glycogen (a polysaccharide) in the form of stored glucose within cells.",
      "reasoning_path": "Exogenous glucose is absorbed, enters cells, and is converted to glycogen (a structural macromolecule), directly addressing the cellular deficit caused by hypoglycemia.",
      "umls_path": [
        "Hypoglycemia, unspecified",
        "may_be_treated_by",
        "Glucose monohydrate",
        "has_mechanism_of_action",
        "Structural Macromolecules"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this scenario, the patient’s severe hypoglycemia is rapidly corrected by oral glucose, a simple carbohydrate. Once absorbed, glucose enters cells via facilitated diffusion and is promptly utilized for ATP production through glycolysis and oxidative phosphorylation. Additionally, excess glucose is enzymatically converted to glycogen, a structural macromolecule, via glycogenesis within hepatocytes and myocytes. Glycogen serves as the primary intracellular storage form of glucose and is essential for maintaining glucose homeostasis. The pharmacological effect of exogenous glucose administration in hypoglycemia is to directly increase the availability of glucose for both immediate energy needs and replenishment of cellular glycogen stores. Thus, the class of biological molecules most directly impacted at the cellular level are structural macromolecules—specifically, glycogen. This restoration is critical for preventing neuroglycopenic symptoms and reversing the acute effects of hypoglycemia.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_327a05558d30",
      "question": "A 58-year-old man with hypertension and type 2 diabetes presents with ongoing difficulty achieving an erection. After other therapies fail, his urologist administers an intracavernosal injection of a medication historically used for this indication. The drug is thought to induce smooth muscle relaxation and increase blood flow, but current pharmacological references state that its precise cellular or molecular mechanism remains unclear. Based on this information, what best describes the molecular mechanism of this agent in the treatment of his condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Erectile Dysfunction"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0242350",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0030350",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction—current evidence does not define papaverine’s exact mechanism of action in erectile dysfunction.",
      "reasoning_path": "Papaverine is used for erectile dysfunction, but its pharmacological mechanism is not fully defined and is officially listed as unknown at the cellular or molecular level.",
      "umls_path": [
        "Erectile Dysfunction",
        "may_be_treated_by",
        "Papaverine",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Papaverine is sometimes used as an intracavernosal injection for erectile dysfunction when first-line therapies are ineffective. It is known to cause relaxation of penile smooth muscle and facilitate increased blood flow, leading to an erection. However, unlike agents such as phosphodiesterase type 5 inhibitors, papaverine's exact mechanism has not been fully elucidated at the molecular or cellular level. While it is believed to inhibit phosphodiesterases non-selectively and affect intracellular cyclic nucleotide concentrations, the pharmacological literature acknowledges ambiguity and lacks consensus about its primary mechanism. Thus, papaverine’s precise cellular target and pathway remain officially classified as unknown, highlighting the incomplete understanding of its action in this context.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_91ab6ac62c77",
      "question": "A 47-year-old bird handler presents with a week of fever, dry cough, and headache. Chest radiograph reveals patchy infiltrates, and serologic testing confirms infection with Chlamydia psittaci. He is prescribed an oral antibiotic that binds the 30S ribosomal subunit of bacteria, blocking the addition of aminoacyl-tRNA to the mRNA-ribosome complex and thereby inhibiting microbial protein synthesis. To which broad pharmacologic class does this drug belong?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Ornithosis, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0029291",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0282125",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Protein synthesis inhibitors",
      "reasoning_path": "Chlamydia psittaci infection (ornithosis) is treated with demeclocycline, which inhibits bacterial protein synthesis by binding the 30S ribosomal subunit; therefore, it is classified as a protein synthesis inhibitor.",
      "umls_path": [
        "Ornithosis, unspecified",
        "may_be_treated_by",
        "Demeclocycline Hydrochloride",
        "has_mechanism_of_action",
        "Protein Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s diagnosis is psittacosis (ornithosis), a zoonotic infection caused by Chlamydia psittaci, commonly contracted from birds. The standard therapy involves tetracycline-class antibiotics, such as demeclocycline, which are effective due to their mechanism of action. Demeclocycline binds reversibly to the 30S subunit of the bacterial ribosome, preventing the attachment of aminoacyl-tRNA to the acceptor site on the mRNA-ribosome complex. This action halts bacterial protein synthesis, ultimately inhibiting cell growth and replication. Because this mechanism targets a fundamental process in bacteria, demeclocycline is categorized as a protein synthesis inhibitor. This class encompasses antibiotics that interfere with various steps of ribosomal function, and it is particularly effective against intracellular organisms like Chlamydia. Thus, the therapeutic benefit in ornithosis is directly related to the drug’s ability to inhibit bacterial protein synthesis.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_8546f3c85598",
      "question": "For a patient with stage IIA (T2b, N0) non–small cell lung cancer who underwent complete surgical resection with negative margins (R0), does the recommendation for adjuvant systemic therapy implicitly require the presence of high-risk recurrence features, or can it be routinely considered for all such patients regardless of additional risk factors?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIA (T2b, N0); Margins negative (R0)",
              "Observe or Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Adjuvant systemic therapy after R0 resection in stage IIA (T2b, N0) non–small cell lung cancer is not routinely required for all patients; it is typically considered in the presence of high-risk recurrence features. In the absence of such factors, observation is an accepted option.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_62b098f46dac",
      "question": "A 48-year-old woman presents with acute-onset pain and swelling over her right elbow after several days of repetitive activity. Physical exam reveals localized tenderness, erythema, and fluctuant swelling over the olecranon process. She is diagnosed with an inflammatory periarticular condition and is started on an oral medication known to reduce pain and swelling by inhibiting the conversion of arachidonic acid to prostaglandins. Which molecular target is most directly responsible for mediating the anti-inflammatory effect of this therapy in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Bursitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0006444",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021246",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase (Cyclooxygenase, COX-1/COX-2)",
      "reasoning_path": "NSAIDs inhibit COX enzymes (Prostaglandin G/H Synthases), blocking prostaglandin synthesis and reducing inflammation in bursitis.",
      "umls_path": [
        "Bursitis",
        "may_be_treated_by",
        "Indomethacin",
        "has_target",
        "Prostaglandin G/H Synthase 1"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "The patient has acute bursitis, an inflammation of the bursal sac, commonly managed with NSAIDs. NSAIDs like indomethacin or ibuprofen exert their anti-inflammatory effects by inhibiting cyclooxygenase (COX) enzymes (also known as Prostaglandin G/H Synthase 1 and 2, or COX-1 and COX-2). These enzymes catalyze the conversion of arachidonic acid to prostaglandin H2, a precursor for various prostaglandins that mediate inflammation, pain, and swelling. By blocking COX activity, NSAIDs decrease prostaglandin synthesis, thereby reducing the inflammatory response in the affected bursal tissue. This molecular mechanism underpins the therapeutic effect in bursitis and similar inflammatory conditions. The most direct molecular target responsible for this effect is the COX enzyme family, with both COX-1 and COX-2 playing roles in inflammatory prostaglandin production.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_f2e2aef5fb6c",
      "question": "In patients with inflammatory breast cancer who are HER2-positive and have completed preoperative chemotherapy but have not finished the full planned HER2-targeted therapy course prior to surgery, is it appropriate to continue HER2-targeted therapy postoperatively concurrently with radiation and endocrine therapy if indicated?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Clinical pathologic diagnosis of IBC",
              "History and physical exam by multidisciplinary team and obtain medical photography, CBC, Comprehensive metabolic panel, including LFTs and alkaline phosphatase, Pathology review, Determination of tumor ER/PR status and HER2 status, Fertility counseling if premenopausal, Genetic counseling if patient is at risk for hereditary breast cancer, Imaging: Bilateral diagnostic mammogram, ultrasound as necessary, Chest diagnostic CT ± contrast, Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast, Bone scan or FDG-PET/CT, Breast MRI (optional)",
              "Preoperative/Adjuvant Therapy Regimens (BINV-L)",
              "Response to preoperative therapy",
              "No response",
              "Consider additional systemic chemotherapy, and/or preoperative radiation.",
              "Patients may be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
              "Response",
              "Total mastectomy + level I/II axillary dissection + RT to chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk ± delayed breast reconstruction",
              "Complete planned chemotherapy regimen course if not completed preoperatively plus endocrine treatment if ER-positive and/or PR-positive (sequential chemotherapy followed by endocrine therapy). Complete up to one year of HER2-targeted therapy if HER2-positive (category 1). May be administered concurrently with RT and with endocrine therapy if indicated."
            ]
          }
        }
      ],
      "answer": "Yes, for HER2-positive inflammatory breast cancer patients, it is standard to complete up to one year of HER2-targeted therapy. If the full course was not finished preoperatively, continuation postoperatively is appropriate and may be given concurrently with radiation and endocrine therapy if endocrine therapy is also indicated.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_9590c95f6641",
      "question": "A 45-year-old man presents with coarsened facial features, enlarged hands and feet, and newly diagnosed diabetes mellitus. Laboratory studies reveal elevated serum insulin-like growth factor 1 (IGF-1) and growth hormone (GH) levels that fail to suppress after oral glucose administration. MRI of the pituitary shows a 1.5-cm macroadenoma. He is started on a medication that acts on pituitary cells to inhibit secretion of the hormone responsible for his symptoms. Which general pharmacologic mechanism underlies the therapeutic effect of this agent?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Acromegaly"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001206",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0546852",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Dopamine agonism (stimulation of dopamine D2 receptors)",
      "reasoning_path": "Acromegaly is due to excessive GH; bromocriptine is used to lower GH; it acts by dopamine D2 receptor agonism on pituitary somatotrophs, inhibiting GH release.",
      "umls_path": [
        "Acromegaly",
        "may_be_treated_by",
        "Bromocriptine Mesylate",
        "has_mechanism_of_action",
        "Dopamine Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has acromegaly, caused by excess secretion of growth hormone (GH), most commonly due to a pituitary adenoma. Bromocriptine is a medication used when surgery is not feasible or as adjunctive therapy. It acts as a dopamine agonist, specifically stimulating D2 receptors on pituitary somatotrophs. In normal physiology, dopamine inhibits prolactin release; in acromegaly, dopamine agonists can paradoxically suppress GH secretion in some pituitary adenomas. By activating dopamine D2 receptors, bromocriptine reduces intracellular cyclic AMP and decreases GH synthesis and release, leading to symptomatic improvement and decreased IGF-1 levels. The general pharmacologic mechanism, therefore, is dopamine agonism at the D2 receptor, which results in suppression of growth hormone secretion from the pituitary.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_eed9dd6b0f0d",
      "question": "For a patient with advanced or metastatic squamous cell lung carcinoma, is broad molecular profiling for mutations such as EGFR, ALK, and ROS1 still indicated, or is its use limited by the histologic subtype?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Broad molecular profiling—including EGFR, ALK, ROS1, and other actionable mutations—remains indicated in advanced squamous cell lung carcinoma, as rare actionable mutations can be present regardless of histology; testing should not be limited purely based on squamous subtype.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_a1e836666e44",
      "question": "A 45-year-old swimmer presents with severe right ear pain and purulent discharge after frequent use of public pools. Physical examination reveals erythema and edema of the external auditory canal, consistent with a diagnosis of otitis externa. He is prescribed topical drops containing an antibiotic known to interfere with bacterial DNA replication by targeting enzymes essential for decatenation of daughter chromosomes during cell division. Which specific bacterial enzyme is the principal target of this antibiotic, leading to its therapeutic effect in this case?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Otitis externa"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0029878",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0008809",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Bacterial topoisomerase IV",
      "reasoning_path": "Otitis externa → treat with fluoroquinolone (e.g., ciprofloxacin) → inhibits bacterial topoisomerase IV → blocks DNA replication → bacterial death.",
      "umls_path": [
        "Otitis externa",
        "may_be_treated_by",
        "Ciprofloxacin",
        "has_mechanism_of_action",
        "Topoisomerase 4 Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this vignette, the patient has otitis externa, commonly caused by Pseudomonas aeruginosa or Staphylococcus species. Fluoroquinolones, such as ciprofloxacin, are preferred topical agents due to their activity against these pathogens and favorable safety profile in the ear. The antibacterial effect of fluoroquinolones depends on inhibition of bacterial topoisomerases—enzymes critical for DNA manipulation during replication. Specifically, ciprofloxacin inhibits both DNA gyrase (topoisomerase II) and topoisomerase IV. However, in many gram-negative organisms (like Pseudomonas), topoisomerase IV is the primary target for inhibition. Blocking topoisomerase IV prevents the decatenation (separation) of replicated DNA, resulting in failure of cell division and subsequent bacterial death. Thus, the principal molecular target responsible for ciprofloxacin's therapeutic effect in this setting is bacterial topoisomerase IV.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_f3cf320713a4",
      "question": "In a patient with advanced squamous cell carcinoma of the lung and confirmed RET rearrangement, is RET-targeted therapy a valid first-line systemic treatment option, or should standard chemotherapy or immunotherapy be preferred given the histologic subtype?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Disseminated metastases",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "RET rearrangement positive"
            ]
          }
        }
      ],
      "answer": "For advanced squamous cell carcinoma of the lung with RET rearrangement, RET-targeted therapy is not currently standard first-line treatment due to limited supporting data in squamous histology. Standard platinum-based chemotherapy, with or without immunotherapy based on PD-L1 status, remains the recommended initial approach, reserving RET inhibitors primarily for non-squamous subtypes.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_7798cec906ee",
      "question": "A 58-year-old woman with chronic kidney disease presents with fatigue and pallor. Laboratory studies reveal a normocytic, normochromic anemia with a low reticulocyte count. After secondary causes are excluded, she is started on a long-acting injectable medication designed to increase her hemoglobin over time. This biologic agent acts by binding to a specific cell-surface receptor on erythroid progenitor cells in the bone marrow, initiating JAK2-mediated signaling cascades that promote proliferation and differentiation. Which molecular pathway is directly responsible for the therapeutic effect of this drug in improving her anemia?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Anemia, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002871",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1328071",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Erythropoietin receptor activation on erythroid progenitor cells",
      "reasoning_path": "CKD-induced anemia is treated with erythropoiesis-stimulating agents, which act by binding the erythropoietin receptor on bone marrow progenitor cells, thereby activating JAK2 signaling and stimulating erythropoiesis.",
      "umls_path": [
        "Anemia, unspecified",
        "may_be_treated_by",
        "Methoxy polyethylene glycol-epoetin beta-containing product",
        "has_mechanism_of_action",
        "Receptor Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Patients with chronic kidney disease often develop anemia due to decreased endogenous erythropoietin production. Long-acting erythropoiesis-stimulating agents (such as darbepoetin alfa or methoxy polyethylene glycol-epoetin beta) are synthetic analogs that mimic the function of natural erythropoietin. They exert their effects by binding to the erythropoietin receptor (EPO-R), which is a transmembrane receptor expressed on the surface of erythroid progenitor cells in the bone marrow. Upon ligand binding, the EPO-R dimerizes and activates intracellular JAK2 tyrosine kinase pathways, resulting in transcription of genes that drive proliferation, survival, and differentiation of erythroid precursors into mature red blood cells. This targeted receptor-mediated mechanism increases erythropoiesis and gradually corrects the anemia. Thus, the therapeutic effect hinges on receptor interaction and downstream signaling, not direct iron supplementation or general bone marrow stimulation.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_778659dac5b2",
      "question": "A 62-year-old man presents to dermatology with multiple rough, scaly, erythematous plaques on his scalp and dorsal hands. He has a history of chronic sun exposure and was recently diagnosed with actinic keratosis. The dermatologist prescribes a topical medication that is known to inhibit cellular proliferation by acting on a specific receptor tyrosine kinase implicated in skin lesion pathogenesis. Which molecular target is most directly responsible for the therapeutic effects of this topical agent in treating his condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Keratosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0022593",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0733397",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Receptor Tyrosine-Protein Kinase erbB-2 (HER2/neu)",
      "reasoning_path": "Actinic keratosis leads to abnormal keratinocyte proliferation; masoprocol acts by inhibiting erbB-2 (HER2/neu) receptor tyrosine kinase, thereby blocking proliferative signaling and treating the lesion.",
      "umls_path": [
        "Keratosis",
        "may_be_treated_by",
        "Masoprocol-containing product",
        "has_target",
        "Receptor Tyrosine-Protein Kinase erbB-2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Actinic keratosis, a premalignant skin lesion, develops due to UV-induced DNA damage and abnormal proliferation of keratinocytes. Topical agents such as masoprocol (nordihydroguaiaretic acid) are sometimes used for their antiproliferative properties. The therapeutic effect of such agents is achieved by inhibiting receptor tyrosine kinases, specifically the erbB-2 (HER2/neu) receptor. erbB-2 is involved in regulating cell growth and differentiation; its upregulation can drive uncontrolled keratinocyte proliferation. By inhibiting this receptor, the topical agent reduces downstream signaling through pathways such as MAPK and PI3K/AKT, leading to decreased cellular proliferation and promoting normalization of skin cell turnover. This mechanism directly targets the pathophysiology of keratosis, helping resolve the plaques and reducing the risk of malignant transformation.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_4f462c492124",
      "question": "A 9-year-old boy is brought to the clinic with joint pain, fever, and a new heart murmur two weeks after recovering from streptococcal pharyngitis. He is diagnosed with acute rheumatic fever and started on a medication to reduce inflammation and relieve his joint symptoms. This drug works by irreversibly inhibiting a key enzyme responsible for the conversion of arachidonic acid to prostaglandins, thereby decreasing inflammation. Which enzyme is the primary pharmacological target of this therapy in managing his condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Rheumatic Fever"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0035436",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004057",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 2 (COX-2)",
      "reasoning_path": "Aspirin is given for inflammation in rheumatic fever; it exerts its effect by irreversibly inhibiting COX-2 (prostaglandin G/H synthase 2), thus suppressing prostaglandin-mediated inflammatory responses.",
      "umls_path": [
        "Rheumatic Fever",
        "may_be_treated_by",
        "Aspirin-containing product",
        "has_target",
        "Prostaglandin G/H Synthase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Acute rheumatic fever is an inflammatory sequela of streptococcal infection, often presenting with arthritis, carditis, and fever. Aspirin is commonly used for its anti-inflammatory effects. Its mechanism involves irreversible inhibition of cyclooxygenase enzymes, specifically prostaglandin G/H synthase 1 and 2 (COX-1 and COX-2). In the context of inflammation, COX-2 is the principal isoenzyme induced at sites of tissue injury and responsible for the synthesis of pro-inflammatory prostaglandins. By inhibiting COX-2, aspirin decreases the production of prostaglandins that mediate pain, fever, and inflammation, leading to symptomatic relief. Although aspirin also affects COX-1, its anti-inflammatory action in rheumatic fever is primarily attributed to its effect on COX-2. Understanding this mechanism is crucial for selecting appropriate anti-inflammatory agents in pediatric rheumatic conditions.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_87efe1b70784",
      "question": "In a patient with advanced squamous cell carcinoma of the lung who is confirmed to have an EGFR exon 19 deletion mutation before first-line systemic therapy, is it appropriate to recommend osimertinib-based therapy given that squamous histology is present, or is this strategy restricted to nonsquamous subtypes?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "EGFR exon 19 deletion or exon 21 L858R mutation positive",
              "EGFR exon 19 deletion or exon 21 L858R mutations",
              "EGFR mutation discovered prior to first-line systemic therapy",
              "Other Recommended: Osimertinib + pemetrexed + (cisplatin or carboplatin) (nonsquamous) (category 1)",
              "Progression, Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
            ]
          }
        }
      ],
      "answer": "Osimertinib-based therapy is generally reserved for nonsquamous histology; in advanced squamous cell carcinoma, EGFR mutation–targeted therapy is typically not recommended due to limited clinical benefit except in rare cases with mixed or ambiguous histology confirmed by expert pathology. Standard first-line options for classic squamous histology exclude EGFR TKIs, prioritizing platinum-doublet chemotherapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_e7e1a5cbdc36",
      "question": "In a patient diagnosed with breast ductal carcinoma in situ (DCIS) concomitant with Paget disease of the nipple-areola complex (NAC), if imaging and clinical examination do not identify an underlying invasive breast lesion, is systemic adjuvant therapy routinely indicated?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Clinical suspicion of Paget disease",
              "Clinical breast exam, Diagnostic bilateral mammogram, ultrasound as necessary",
              "Examination and imaging negative for breast lesion",
              "Examination or imaging positive for breast lesion",
              "Core biopsy of breast lesion and full-thickness skin biopsy of involved NAC",
              "Breast DCIS and NAC Paget",
              "See NCCN Guidelines for Noninvasive Breast Cancer for DCIS (DCIS-1)",
              "Appropriate systemic adjuvant therapy as clinically indicated, See NCCN Guidelines for DCIS or Invasive Breast Cancer"
            ]
          }
        }
      ],
      "answer": "Systemic adjuvant therapy is not routinely indicated for pure DCIS with associated Paget disease of the NAC in the absence of invasive carcinoma, as current evidence supports local therapy alone unless additional high-risk features or invasive disease are present.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_9ea06e2cdb5b",
      "question": "In a patient with stage IVA non-small cell lung cancer presenting with malignant pleural effusion and confirmed ERBB2 (HER2) mutation, is local therapy such as pleurodesis sufficient as the sole treatment, or is it necessary to initiate systemic therapy targeting stage IV disease concurrently?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1a: pleural or pericardial effusion",
              "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
              "Positive",
              "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "ERBB2 (HER2) mutation positive"
            ]
          }
        }
      ],
      "answer": "Local therapy such as pleurodesis addresses symptoms from pleural effusion but is not sufficient as the sole treatment for stage IVA disease. Systemic therapy targeting stage IV non-small cell lung cancer, guided by molecular findings such as ERBB2 (HER2) mutation, is necessary and should be initiated concurrently with any local measures.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_47828e13a261",
      "question": "In a patient with advanced squamous cell carcinoma of the lung and confirmed ALK rearrangement detected during ongoing first-line systemic therapy, is it appropriate to initiate alectinib immediately upon detection of the ALK rearrangement, or should the completion of the planned systemic therapy take precedence before switching to ALK inhibitor therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "ALK rearrangement positive",
              "ALK rearrangement",
              "ALK rearrangement discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by alectinib (preferred) or brigatinib (preferred) or lorlatinib (preferred) or ceritinib or crizotinib",
              "Progression",
              "Subsequent Therapy (NSCL-28)"
            ]
          }
        }
      ],
      "answer": "In this context, the preferred approach is to complete the planned first-line systemic therapy, including maintenance if applicable, before initiating alectinib or another ALK inhibitor. Immediate interruption is not routinely recommended unless clinically indicated; therapy sequence prioritizes finishing current systemic therapy prior to targeted ALK inhibition.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_a04763dee953",
      "question": "A 28-year-old woman presents with secondary amenorrhea, fatigue, and decreased libido. Laboratory evaluation reveals low serum estrogen and progesterone levels with elevated gonadotropins, confirming a diagnosis of primary hypogonadism. Her endocrinologist prescribes a synthetic agent that structurally resembles a naturally occurring steroid hormone and acts primarily as an agonist at a specific intracellular receptor, influencing gene transcription involved in reproductive tissue maintenance. Which receptor pathway does this medication most directly target to exert its therapeutic effect in restoring hormonal balance?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Hypogonadism"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020619",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0015117",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Progestational hormone receptor agonists",
      "reasoning_path": "Hypogonadism leads to hormone deficiency; ethynodiol diacetate, a synthetic progestin, acts as an agonist at progestational hormone receptors to restore reproductive hormonal activity.",
      "umls_path": [
        "Hypogonadism",
        "may_be_treated_by",
        "Ethynodiol diacetate",
        "has_mechanism_of_action",
        "Progestational Hormone Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Ethynodiol diacetate is a synthetic progestin structurally related to endogenous progesterone. In the context of hypogonadism—where endogenous sex hormone production is deficient—replacement therapy aims to restore normal hormonal function and secondary sexual characteristics. Ethynodiol diacetate binds to and activates intracellular progesterone (progestational) receptors. This receptor is a nuclear hormone receptor that, upon ligand binding, translocates to the nucleus and modulates the transcription of genes essential for the development and maintenance of female reproductive tissues and secondary sexual characteristics. The drug's agonist activity at the progestational hormone receptor counteracts the clinical and biochemical effects of progesterone deficiency, helping to regulate the menstrual cycle and alleviate symptoms of hypogonadism. While it may also have weak estrogenic or androgenic effects, its primary mechanism of action is mediated through progestational receptor agonism.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_9d1b259a1d72",
      "question": "In a patient with multiple primary lung cancers staged as N0–1, who presents with a dominant nodule showing documented growth but is not a candidate for definitive local therapy, does the use of palliative chemotherapy implicitly assume that there is no evidence of disseminated metastatic disease on imaging such as FDG-PET/CT and brain MRI?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Multiple lung cancers (suspected or confirmed) (N0–1)",
              "Multidisciplinary evaluation",
              "Dominant nodule with evidence of growth",
              "Definitive local therapy not possible",
              "Palliative chemotherapy ± local palliative therapy or Observe",
              "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, the use of palliative chemotherapy in this context does not implicitly exclude the presence of disseminated metastatic disease. In cases where definitive local therapy is not feasible and disseminated disease is present, systemic therapy—including palliative chemotherapy—is indicated regardless of metastasis status, as confirmed by advanced imaging.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_398a1e921cd7",
      "question": "A 52-year-old woman with a history of episodic ear pain, redness, and swelling affecting her auricles and nose is diagnosed with a rare autoimmune cartilage disorder. Her symptoms persist despite corticosteroids, so her physician initiates a second-line agent that acts as a structural analog of para-aminobenzoic acid (PABA) and competitively inhibits an enzyme required for bacterial folate synthesis. What general molecular mechanism underlies this medication's therapeutic action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Relapsing Polychondritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0032453",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0010980",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Inhibition of folate synthesis via antagonism of para-aminobenzoic acid (PABA)",
      "reasoning_path": "Relapsing polychondritis may be treated with dapsone. Dapsone works by competitively inhibiting PABA, blocking bacterial folate synthesis via inhibition of dihydropteroate synthase.",
      "umls_path": [
        "Relapsing Polychondritis",
        "may_be_treated_by",
        "Dapsone",
        "has_mechanism_of_action",
        "Para-Aminobenzoic Acid Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has relapsing polychondritis, an autoimmune disease affecting cartilage. When corticosteroids prove insufficient, dapsone is sometimes used as a steroid-sparing agent. Dapsone exerts its effect by acting as a structural analog of para-aminobenzoic acid (PABA), thereby competitively inhibiting dihydropteroate synthase, an enzyme essential for bacterial folate synthesis. Although dapsone is mainly used as an antimicrobial, its anti-inflammatory properties are exploited in autoimmune diseases. The general class of mechanism targeted by dapsone is the inhibition of folate synthesis via PABA antagonism. This mechanism deprives bacteria of tetrahydrofolate, but in humans, it also reduces neutrophil-mediated inflammation, likely by similar molecular interference. Thus, the drug's primary action is competitive inhibition at the PABA site, preventing the formation of dihydropteroic acid and downstream folate derivatives.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_9af44dcfda80",
      "question": "A 29-year-old woman with no significant past medical history presents to the emergency department with sudden-onset palpitations and dizziness. Her ECG reveals a narrow-complex tachycardia at 180 bpm consistent with an AV nodal re-entrant tachycardia (AVNRT). She is administered a rapid intravenous bolus of a medication that transiently blocks AV nodal conduction by activating a specific G protein–coupled receptor, resulting in temporary asystole and termination of her arrhythmia. Which class of drugs shares this primary molecular target with the medication used in this scenario?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Re-entrant atrioventricular node tachycardia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0039232",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3256589",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Adenosine receptor agonists",
      "reasoning_path": "AVNRT is terminated by adenosine, which acts as an adenosine receptor agonist, so drugs in this class share the primary molecular target (adenosine receptors).",
      "umls_path": [
        "Re-entrant atrioventricular node tachycardia",
        "may_be_treated_by",
        "ADENOSINE PHOSPHATE DISODIUM",
        "has_mechanism_of_action",
        "Adenosine Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this case, the patient has AV nodal re-entrant tachycardia (AVNRT), a common form of supraventricular tachycardia characterized by a re-entry circuit that involves the AV node. The mainstay of acute termination for AVNRT is intravenous adenosine. Adenosine acts as an agonist at the adenosine (A1) receptor, a G protein–coupled receptor present in cardiac tissue. Activation of these receptors increases potassium efflux and inhibits calcium influx in AV nodal cells, causing hyperpolarization and transient AV nodal block. This interrupts the re-entry circuit and restores sinus rhythm. Therefore, the class of drugs that shares this mechanism—agonism at adenosine receptors—are adenosine receptor agonists. Other antiarrhythmic drug classes (e.g., beta-blockers, calcium channel blockers) act via different primary molecular targets.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_2fd907bd9403",
      "question": "A 7-year-old boy presents with abdominal pain and intermittent diarrhea. Stool studies reveal the presence of eggs consistent with a cestode infection. He is started on a benzimidazole anthelmintic that disrupts parasite microtubule formation and undergoes hepatic metabolism before exerting its effect. A pharmacology researcher wants to investigate how concurrent administration of certain medications may alter the efficacy of this anthelmintic by increasing its metabolic clearance. Which class of hepatic enzymes, if induced, would most likely reduce the therapeutic levels and efficacy of this medication?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Hymenolepiasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020413",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001911",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cytochrome P450 1A inducers",
      "reasoning_path": "Albendazole is metabolized in the liver via CYP1A; inducers of this enzyme increase metabolism, decreasing drug levels and efficacy.",
      "umls_path": [
        "Hymenolepiasis",
        "may_be_treated_by",
        "Albendazole",
        "has_mechanism_of_action",
        "Cytochrome P450 1A Inducers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The child’s cestode infection is being treated with albendazole, a benzimidazole anthelmintic that must be metabolized in the liver to its active form, albendazole sulfoxide. This metabolic process is primarily mediated by hepatic cytochrome P450 enzymes, notably the CYP1A subfamily. Drugs or substances that induce CYP1A enzymes can accelerate the hepatic metabolism of albendazole, leading to reduced plasma concentrations of its active metabolite. As a result, concurrent use of CYP1A inducers (such as certain anticonvulsants or rifampin) can decrease the therapeutic efficacy of albendazole by lowering its bioavailability. Understanding this interaction is crucial in managing potential drug-drug interactions and ensuring optimal anthelmintic treatment effectiveness.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_67ec8fa93a07",
      "question": "A 45-year-old renal transplant recipient presents with fever, malaise, and visual disturbances. Fundoscopic examination reveals findings consistent with viral retinitis. PCR testing confirms cytomegalovirus infection. Given his impaired renal function, his clinician chooses an antiviral agent that does not require activation by viral kinases. This drug is known to act as a nucleotide analogue, exerting its effect by directly inhibiting a specific viral enzyme crucial for DNA replication. Which viral enzyme is the principal target responsible for the antiviral efficacy of this medication in cytomegaloviral retinitis?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Cytomegaloviral disease"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0010823",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0286079",
            "rela": "has_target"
          }
        }
      ],
      "answer": "DNA-directed DNA polymerase",
      "reasoning_path": "CMV retinitis is treated with cidofovir, a nucleotide analogue that is activated by host enzymes and inhibits viral DNA-directed DNA polymerase, blocking viral DNA synthesis and replication.",
      "umls_path": [
        "Cytomegaloviral disease",
        "may_be_treated_by",
        "Cidofovir",
        "has_target",
        "DNA-directed DNA Polymerase"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Cidofovir is an antiviral nucleotide analogue used in the treatment of cytomegalovirus (CMV) infections, particularly in immunocompromised patients such as transplant recipients. Unlike some other antivirals, cidofovir does not require initial phosphorylation by viral kinases for activation. Instead, it is converted to its active diphosphate form by host cell enzymes. The active form directly inhibits viral DNA-directed DNA polymerase, the enzyme responsible for viral DNA synthesis. By incorporating into viral DNA or competing with endogenous nucleotides, cidofovir halts DNA chain elongation, thereby preventing viral replication. DNA-directed DNA polymerase is essential for CMV and other DNA viruses to replicate their genomes within host cells. Inhibiting this enzyme leads to the cessation of viral proliferation and resolution of infection-related symptoms. The drug's mechanism of action specifically targets the viral, rather than human, DNA polymerase, thereby maximizing antiviral activity while minimizing host toxicity.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_504ec2c0c528",
      "question": "A 55-year-old woman with a long history of irritable bowel syndrome reports frequent abdominal cramping and urgency. Her physician prescribes a medication that decreases smooth muscle contractions via anticholinergic properties and is also known to attenuate the effects of neurotransmitters involved in emesis. Which class of pharmacologic agents operates through a similar molecular mechanism by inhibiting the relevant neurotransmitter receptors?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Disorder of colon"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0009373",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0036442",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Serotonin antagonists",
      "reasoning_path": "Anticholinergic agents and serotonin antagonists both reduce GI motility and emetic signaling by inhibiting neurotransmitter receptors, specifically targeting acetylcholine and serotonin pathways, respectively.",
      "umls_path": [
        "Disorder of colon",
        "may_be_treated_by",
        "Scopolamine",
        "has_mechanism_of_action",
        "Serotonin Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with a functional colon disorder, such as irritable bowel syndrome, is prescribed an anticholinergic agent that relaxes gastrointestinal smooth muscle and reduces motility. Many anticholinergic drugs (e.g., scopolamine) also have activity affecting neurotransmitter systems involved in nausea and vomiting. Serotonin (5-HT3) antagonists, such as ondansetron, share a similar mechanism by blocking serotonin receptors. In the gut and central nervous system, serotonin signaling increases motility and can trigger nausea; blocking these receptors reduces both gastrointestinal activity and emesis. Thus, agents that antagonize serotonin receptors are effective for both GI disorders and as antiemetics, paralleling the action of certain anticholinergics.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_0df9136333db",
      "question": "A 22-year-old woman with a lifelong history of frequent nosebleeds and menorrhagia is found to have a mild inherited deficiency of a clotting factor after a family member was diagnosed with a similar disorder. During dental extraction, her hematologist prescribes an oral medication to reduce perioperative mucosal bleeding. This agent acts by reversibly binding to lysine sites on a specific enzyme, thereby preventing the breakdown of fibrin clots. Which class of pharmacologic agents best describes the mechanism by which this medication exerts its therapeutic effect in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "INHERITED COAG DIS"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0852077",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0040613",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Plasmin inhibitors",
      "reasoning_path": "Tranexamic acid is used for bleeding in inherited coagulopathies. It exerts its effect by inhibiting plasminogen activation and plasmin activity, thereby reducing fibrinolysis and stabilizing clots—making it a plasmin inhibitor.",
      "umls_path": [
        "INHERITED COAG DIS",
        "may_be_treated_by",
        "Tranexamic Acid",
        "has_mechanism_of_action",
        "Plasmin Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Tranexamic acid is often used as adjunct therapy to control mucosal bleeding in patients with hereditary coagulation disorders such as mild hemophilia or von Willebrand disease. Its primary mechanism involves inhibition of fibrinolysis: tranexamic acid competitively binds to lysine-binding sites on plasminogen and plasmin, preventing their interaction with fibrin. This blocks the conversion of plasminogen to plasmin and the subsequent degradation of fibrin clots, thereby stabilizing formed clots and reducing bleeding. Thus, the therapeutic effect in this context is due to tranexamic acid acting as a plasmin inhibitor, preserving hemostatic plugs at sites of vascular injury, especially in mucosal tissues where fibrinolytic activity is high. This is distinctly different from agents that promote clotting factor activity or platelet function; the central action here is on the inhibition of the fibrinolytic pathway.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_70e35e438769",
      "question": "In a premenopausal woman with ER-positive, HER2-negative, invasive ductal carcinoma of the breast, clinical stage pT2pN0, tumor size 0.8 cm, who is not considered for preoperative systemic therapy, if the genomic recurrence score is 24, is it appropriate to recommend adjuvant chemotherapy followed by endocrine therapy as opposed to endocrine therapy alone?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
              "ER-positive and/or PR-positive",
              "HER2-negative",
              "Premenopausal",
              "pT1-3 AND pN0",
              "Ductal/NST, Lobular, Mixed, Micropapillary",
              "Tumor >0.5 cm and pN0",
              "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
              "Recurrence score 16–25",
              "Adjuvant chemotherapy followed by endocrine therapy ± ovarian suppression/ablation",
              "Follow-Up (BINV-17)"
            ]
          }
        }
      ],
      "answer": "Yes, for a premenopausal patient with ER-positive, HER2-negative, pT2pN0 breast cancer greater than 0.5 cm and a genomic recurrence score between 16 and 25, adjuvant chemotherapy followed by endocrine therapy is indicated. Endocrine therapy alone would only be considered if the recurrence score were lower, so in this scenario, chemotherapy should be included.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_0753a9f14230",
      "question": "A 72-year-old woman presents with severe, burning pain along the right thoracic dermatome three months after a vesicular rash in the same region. Physical exam reveals allodynia and hyperesthesia. She is started on an oral medication often used for chronic neuropathic pain syndromes, including her current diagnosis. Although the drug is known to bind to the alpha-2-delta subunit of voltage-gated calcium channels, its full cellular mechanism in relieving neuropathic pain is not completely understood. What best describes the nature of this medication’s molecular target in the context of her pain relief?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Postherpetic neuralgia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0032768",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0657912",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown or incompletely characterized cellular or molecular interaction",
      "reasoning_path": "Postherpetic neuralgia → treatment with pregabalin → binds alpha-2-delta subunit of calcium channels → full mechanism for analgesia remains incompletely understood",
      "umls_path": [
        "Postherpetic neuralgia",
        "may_be_treated_by",
        "Pregabalin",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is experiencing postherpetic neuralgia, a chronic neuropathic pain syndrome often treated with gabapentinoids such as pregabalin. While pregabalin is known to bind to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, this interaction does not fully explain its analgesic effects. The downstream effects leading to pain relief—such as modulation of neurotransmitter release and neuronal excitability—remain only partially elucidated. Thus, the precise cellular or molecular mechanism by which pregabalin alleviates neuropathic pain is still considered incompletely characterized. Clinicians should recognize that while the drug is effective for this indication, its exact molecular target and action pathway are not fully defined.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_992934189a71",
      "question": "A 54-year-old woman is diagnosed with dermatomyositis after presenting with progressive proximal muscle weakness and characteristic heliotrope rash. She is started on a medication sometimes used as adjunctive therapy, which is thought to exert antifibrotic effects but for which the precise cellular or molecular mechanism remains undefined. What is the current scientific understanding regarding the cellular or molecular target of this medication in the treatment of dermatomyositis?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Dermatomyositis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011633",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0543464",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The cellular or molecular mechanism of action of aminobenzoate potassium in dermatomyositis is unknown.",
      "reasoning_path": "Dermatomyositis may be treated with aminobenzoate potassium, but its cellular or molecular mechanism of action has not been defined.",
      "umls_path": [
        "Dermatomyositis",
        "may_be_treated_by",
        "Aminobenzoate Potassium",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Aminobenzoate potassium has been used as an adjunct in the management of dermatomyositis, especially in patients with significant skin involvement or fibrotic changes. Despite its use, the exact cellular or molecular mechanism by which it confers therapeutic benefit remains poorly characterized. There is speculation that it may influence collagen cross-linking or modulate fibrotic pathways, but no definitive target or pathway has been confirmed in clinical pharmacology literature. As such, the drug's precise mechanism in the context of dermatomyositis is considered unknown. This underscores the need for further research into its pharmacodynamics and potential molecular interactions in patients with this autoimmune myopathy.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_002686e52253",
      "question": "In the OpenTargets platform, what tractability information is available for the target with Ensembl ID ENSG00000188389 and approved symbol PDCD1, where the value is True?",
      "tool_calls": [
        {
          "tool": "opentargets.tractability",
          "params": {
            "target_id": "ENSG00000188389",
            "value": true
          }
        }
      ],
      "answer": [
        {
          "modality": "SM",
          "label": "Structure with Ligand"
        },
        {
          "modality": "SM",
          "label": "High-Quality Ligand"
        },
        {
          "modality": "AB",
          "label": "Approved Drug"
        },
        {
          "modality": "AB",
          "label": "UniProt loc high conf"
        },
        {
          "modality": "AB",
          "label": "GO CC high conf"
        },
        {
          "modality": "AB",
          "label": "UniProt SigP or TMHMM"
        },
        {
          "modality": "PR",
          "label": "Literature"
        },
        {
          "modality": "PR",
          "label": "UniProt Ubiquitination"
        },
        {
          "modality": "PR",
          "label": "Small Molecule Binder"
        },
        {
          "modality": "OC",
          "label": "Advanced Clinical"
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_d4dffcfad9a2",
      "question": "A 32-year-old man presents to the infectious diseases clinic with several months of slowly progressive, hypopigmented skin patches and numbness in his distal extremities. Skin biopsy confirms infection with an acid-fast bacillus. He is started on a multidrug regimen that includes an agent known to bind the β-subunit of bacterial DNA-dependent RNA polymerase, thereby suppressing transcription. Which pharmacologic class best describes the mechanism by which this drug halts the growth of the causative organism?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Leprosy, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0023343",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0035608",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Nucleic Acid Synthesis Inhibitors",
      "reasoning_path": "Patient with leprosy → receives rifampin → rifampin inhibits DNA-dependent RNA polymerase → blocks RNA synthesis → nucleic acid synthesis inhibitor.",
      "umls_path": [
        "Leprosy, unspecified",
        "may_be_treated_by",
        "Rifampin",
        "has_mechanism_of_action",
        "Nucleic Acid Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is being treated for leprosy (Hansen's disease), which is caused by Mycobacterium leprae, an acid-fast organism. Rifampin is a cornerstone of therapy for this infection. The drug exerts its effect by binding to the β-subunit of the bacterial DNA-dependent RNA polymerase, thereby inhibiting RNA synthesis. This action prevents transcription of essential bacterial genes, leading to bactericidal activity. Because the primary molecular target is an enzyme essential for transcription, rifampin is classified as a nucleic acid synthesis inhibitor. Its mechanism is distinct from drugs that target cell wall synthesis or protein synthesis. In Mycobacterium leprae, inhibition of RNA synthesis effectively stops bacterial replication, making nucleic acid synthesis inhibition the key pharmacologic principle in this scenario.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_a80e92b724d7",
      "question": "In a patient with resected stage III non-small cell lung cancer (NSCLC) who has completed definitive concurrent chemoradiation and shows no evidence of disease, if the tumor harbors both an EGFR exon 19 deletion and high PD-L1 expression, should consolidation therapy prioritize durvalumab or osimertinib?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
              "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Contralateral mediastinal node negative",
              "Ipsilateral mediastinal node positive (T4, N2)",
              "Definitive concurrent chemoradiation (category 1)",
              "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)"
            ]
          }
        }
      ],
      "answer": "In this context, consolidation therapy should prioritize osimertinib if the tumor harbors an EGFR exon 19 deletion, regardless of PD-L1 status. Durvalumab is not the preferred option for patients with sensitizing EGFR mutations, as clinical evidence supports the use of osimertinib in this molecular subgroup.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_36da367b6ae8",
      "question": "For a patient diagnosed with squamous cell carcinoma of the lung and confirmed stage IIIA disease (T4, N1) with no evidence of distant metastasis on FDG-PET/CT and brain MRI, is comprehensive molecular testing for EGFR, ALK, and other targetable mutations an essential prerequisite before initiating perioperative therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Comprehensive molecular testing is not considered an essential prerequisite for initiating perioperative therapy in stage IIIA squamous cell carcinoma of the lung, as actionable mutations are rare in this subtype and molecular profiling is recommended but not mandatory prior to surgery or chemoradiation.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_6db02974fe51",
      "question": "A 67-year-old man is admitted to the emergency department after an episode of dizziness and near-syncope. His ECG shows third-degree atrioventricular (AV) block with a ventricular rate of 30 beats per minute. He is hypotensive and has cool extremities. The medical team initiates intravenous therapy with a drug that increases heart rate and contractility by stimulating adrenergic receptors through a dose-dependent agonist effect. Through which class of molecular mechanism does this medication primarily exert its beneficial action in this setting?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Heart block"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0018794",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0013030",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Dopamine agonists—by stimulating dopamine and adrenergic receptors",
      "reasoning_path": "Symptomatic heart block causes bradycardia and low cardiac output. Dopamine is used acutely; it acts as a dopamine and adrenergic receptor agonist, increasing heart rate and contractility, thereby improving perfusion.",
      "umls_path": [
        "Heart block",
        "may_be_treated_by",
        "Dopamine",
        "has_mechanism_of_action",
        "Dopamine Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In cases of symptomatic third-degree AV block, cardiac output may fall dangerously low due to bradycardia. While pacing is definitive, temporizing pharmacologic support can be provided. Dopamine, when administered intravenously at moderate doses, acts as a dopamine receptor agonist and also stimulates beta-1 adrenergic receptors, leading to increased heart rate (positive chronotropy) and contractility (positive inotropy). At higher doses, it also activates alpha-adrenergic receptors, increasing vascular tone. The initial effect is mediated primarily through dopamine and beta-1 adrenergic receptor agonism, which is critical for improving perfusion in patients with bradyarrhythmias due to AV block. Thus, dopamine’s therapeutic benefit in this context is best described as a dopamine agonist mechanism, involving direct receptor stimulation to enhance cardiac output.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_6286e605de37",
      "question": "A 4-week-old infant is brought to the clinic for poor weight gain, vomiting, and darkening of the skin. Laboratory studies reveal hyponatremia, hyperkalemia, and elevated 17-hydroxyprogesterone. Genetic testing confirms a diagnosis of a steroidogenic enzyme deficiency causing impaired cortisol synthesis. The pediatric endocrinologist starts the infant on a medication that suppresses endogenous adrenocorticotropic hormone (ACTH) and reduces adrenal androgen excess by mimicking physiological glucocorticoid action. Through which molecular mechanism does this therapy exert its anti-inflammatory effect, particularly by decreasing leukotriene-mediated inflammation?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Congenital Adrenal Hyperplasia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001627",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0612688",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Inhibition of lipoxygenase pathways (lipoxygenase inhibitors)",
      "reasoning_path": "CAH → glucocorticoid deficiency → hydrocortisone replacement → glucocorticoid receptor activation → downregulation of lipoxygenase pathway → decreased leukotriene synthesis → anti-inflammatory effect.",
      "umls_path": [
        "Congenital Adrenal Hyperplasia",
        "may_be_treated_by",
        "Hydrocortisone cypionate",
        "has_mechanism_of_action",
        "Lipoxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In congenital adrenal hyperplasia (CAH), deficient cortisol synthesis leads to increased ACTH and excess androgen production. Hydrocortisone cypionate, a synthetic glucocorticoid, is used as replacement therapy to restore cortisol levels and suppress ACTH, thus reducing excessive adrenal androgen synthesis. At the molecular level, glucocorticoids exert anti-inflammatory actions by multiple mechanisms, including the inhibition of phospholipase A2 and suppression of pro-inflammatory genes. Notably, they also decrease the activity of the lipoxygenase pathway by reducing the expression of enzymes involved in leukotriene synthesis. This leads to decreased production of potent inflammatory mediators (leukotrienes), contributing to the overall anti-inflammatory effect of glucocorticoids. Therefore, hydrocortisone cypionate aligns mechanistically with lipoxygenase inhibitors in this context, as it reduces leukotriene synthesis and inflammation via this pathway.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_b0e2ee8bffc0",
      "question": "A 10-year-old girl is diagnosed with a rare congenital disorder characterized by multiple fractures with minimal trauma, blue sclerae, and evidence of bone fragility since infancy. Her pediatrician, seeking alternative therapies to improve bone strength, considers a hormone that decreases osteoclastic bone resorption by binding to specific cell surface receptors. Through downstream effects, this therapy ultimately influences the composition and integrity of the bone matrix. Which category of molecular targets is most directly responsible for the drug's therapeutic impact on bone strength in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Osteogenesis imperfecta"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0029434",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0006668",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Structural macromolecules (such as collagen within the bone matrix)",
      "reasoning_path": "Osteogenesis imperfecta → bone fragility due to collagen defects → calcitonin reduces bone resorption → preserves bone matrix (structural macromolecules) → increased bone strength.",
      "umls_path": [
        "Osteogenesis imperfecta",
        "may_be_treated_by",
        "calcitonin",
        "has_mechanism_of_action",
        "Structural Macromolecules"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Osteogenesis imperfecta is a genetic disorder marked by defective collagen synthesis, leading to brittle bones and frequent fractures. Calcitonin is a hormone that can be used experimentally to inhibit osteoclast activity and reduce bone resorption. When calcitonin binds to its receptors on osteoclasts, it suppresses their function, slowing the breakdown of bone. The primary therapeutic effect in this context is the preservation of the bone’s extracellular matrix, particularly collagen, which is the major structural macromolecule giving bone its tensile strength. By maintaining collagen and other matrix proteins, calcitonin indirectly supports bone strength, counteracting the pathological fragility seen in osteogenesis imperfecta. Therefore, the molecular targets most directly relevant to the drug’s effect in this setting are the structural macromolecules constituting the bone matrix.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_e5bf37875593",
      "question": "A 65-year-old man with a history of myelodysplastic syndrome presents with worsening fatigue and pallor. Laboratory investigation reveals a microcytic anemia with increased ring sideroblasts on bone marrow biopsy. After failing to respond to pyridoxine therapy, he is initiated on a parenteral agent that incorporates into DNA and RNA, leading to hypomethylation and impaired proliferation of abnormal hematopoietic cells. Which drug class best describes the primary mechanism underlying the therapeutic action of this agent in his condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Sideroblastic anemia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002896",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004475",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Nucleoside synthesis inhibitors",
      "reasoning_path": "Patient with refractory sideroblastic anemia → treated with azacitidine → azacitidine is a nucleoside analog → inhibits DNA methyltransferase (hypomethylating agent) → impairs abnormal cell proliferation via nucleoside synthesis inhibition.",
      "umls_path": [
        "Sideroblastic anemia",
        "may_be_treated_by",
        "Azacitidine",
        "has_mechanism_of_action",
        "Nucleoside Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has refractory sideroblastic anemia in the context of myelodysplastic syndrome (MDS), characterized by ineffective erythropoiesis and ring sideroblasts. When first-line therapy (such as pyridoxine) fails, hypomethylating agents like azacitidine are considered. Azacitidine is a nucleoside analog that incorporates into DNA and RNA, where it inhibits DNA methyltransferase enzymes. This inhibition leads to global hypomethylation, reactivation of silenced genes, and impaired proliferation of abnormal hematopoietic cells. The key molecular mechanism is the inhibition of nucleoside synthesis and subsequent DNA methylation, which is particularly effective in MDS and refractory sideroblastic anemia. Thus, the therapeutic effect in this case is best explained by the drug’s action as a nucleoside synthesis inhibitor, disrupting aberrant epigenetic regulation and cell growth.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_8b11739a203b",
      "question": "A 42-year-old woman with longstanding fatigue, muscle weakness, and recent neurological symptoms is diagnosed with a metabolic disorder related to impaired mitochondrial function, manifesting as a deficiency in certain essential cellular substrates. Her physician initiates therapy with a compound that acts as a substrate and cofactor in mitochondrial energy metabolism, aiming to restore normal cellular processes. Which general pharmacological mechanism best describes how this agent supports recovery in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Deficiency diseases"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011156",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3859597",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Biological macromolecular activity",
      "reasoning_path": "Metabolic deficiency → impaired mitochondrial function → acetylcarnitine supplementation → supports enzymes/cofactors → restores biological macromolecular activity and energy production.",
      "umls_path": [
        "Deficiency diseases",
        "may_be_treated_by",
        "acetylcarnitine hydrochloride, DL-",
        "has_mechanism_of_action",
        "Biological Macromolecular Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this scenario, the patient's symptoms and diagnosis point toward a deficiency disease affecting mitochondrial energy production. Acetylcarnitine hydrochloride is often used as a supplement in such contexts because it acts directly on fundamental cellular processes. Specifically, acetylcarnitine serves as a substrate and cofactor for enzymes involved in fatty acid transport and oxidation within mitochondria, thereby supporting ATP generation. The mechanism underlying its therapeutic benefit is not simply receptor agonism or enzyme inhibition; rather, it modulates the activity and function of biological macromolecules—such as enzymes and coenzymes—by providing necessary substrates and facilitating essential biochemical reactions. Thus, its pharmacological action is classified under 'biological macromolecular activity,' reflecting its role in directly influencing the function of key molecules involved in energy metabolism, especially in deficiency states where these pathways are compromised.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_a3d485a53a5d",
      "question": "In the OpenTargets platform, what tractability information is available for the target with Ensembl ID ENSG00000169083 and approved symbol AR, where the value is True?",
      "tool_calls": [
        {
          "tool": "opentargets.tractability",
          "params": {
            "target_id": "ENSG00000169083",
            "value": true
          }
        }
      ],
      "answer": [
        {
          "modality": "SM",
          "label": "Approved Drug"
        },
        {
          "modality": "SM",
          "label": "Structure with Ligand"
        },
        {
          "modality": "SM",
          "label": "High-Quality Ligand"
        },
        {
          "modality": "SM",
          "label": "High-Quality Pocket"
        },
        {
          "modality": "SM",
          "label": "Druggable Family"
        },
        {
          "modality": "AB",
          "label": "GO CC high conf"
        },
        {
          "modality": "PR",
          "label": "Advanced Clinical"
        },
        {
          "modality": "PR",
          "label": "Literature"
        },
        {
          "modality": "PR",
          "label": "UniProt Ubiquitination"
        },
        {
          "modality": "PR",
          "label": "Database Ubiquitination"
        },
        {
          "modality": "PR",
          "label": "Small Molecule Binder"
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "path_aba101df4d7f",
      "question": "For a patient with stage IIIB non-small cell lung cancer (T2, N3) and no evidence of extrathoracic metastatic disease, is initial pathologic confirmation of N3 disease with mediastinoscopy or EBUS biopsy an implicit prerequisite for subsequent treatment planning, or can imaging studies alone suffice?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Pathologic confirmation of N3 disease—such as by mediastinoscopy or EBUS biopsy—is an essential prerequisite before treatment planning in stage IIIB (T2, N3) non-small cell lung cancer. Imaging studies alone are insufficient, as tissue confirmation is required to accurately assign stage and select appropriate therapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_052f12eb0949",
      "question": "In a patient with non-small cell lung cancer staged as IIIB (T2, N3), if mediastinal N3 lymph node status has not yet been pathologically confirmed but imaging studies including FDG-PET/CT and brain MRI suggest N3 disease, is it appropriate to proceed directly to treatment for stage IIIB disease, or is pathological confirmation of N3 disease a necessary prerequisite before initiation of definitive treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "N3 nodes positive, M0",
              "Stage IIIB or Stage IIIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)"
            ]
          }
        }
      ],
      "answer": "Pathological confirmation of N3 lymph node involvement is a necessary prerequisite before initiating definitive treatment for stage IIIB (T2, N3) non-small cell lung cancer. Imaging studies alone are insufficient to establish the diagnosis, as invasive biopsy methods such as mediastinoscopy or EBUS are required to confirm N3 status for accurate staging and appropriate therapeutic planning.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_6611df276563",
      "question": "In the OpenTargets platform, does the tractability information indicate that the target with Ensembl ID ENSG00000185499 and approved symbol MUC1 has value set to True?",
      "tool_calls": [
        {
          "tool": "opentargets.tractability",
          "params": {
            "target_id": "ENSG00000185499",
            "value": true
          }
        }
      ],
      "answer": [
        {
          "modality": "SM",
          "label": "Structure with Ligand"
        },
        {
          "modality": "SM",
          "label": "Med-Quality Pocket"
        },
        {
          "modality": "AB",
          "label": "Advanced Clinical"
        },
        {
          "modality": "AB",
          "label": "UniProt loc high conf"
        },
        {
          "modality": "AB",
          "label": "GO CC high conf"
        },
        {
          "modality": "AB",
          "label": "UniProt loc med conf"
        },
        {
          "modality": "AB",
          "label": "UniProt SigP or TMHMM"
        },
        {
          "modality": "AB",
          "label": "Human Protein Atlas loc"
        },
        {
          "modality": "OC",
          "label": "Advanced Clinical"
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "path_1324f582c8e4",
      "question": "For a patient with localized, invasive, non-inflammatory, non-metastatic breast cancer who achieves a pathological complete response (ypT0N0) after neoadjuvant pembrolizumab-containing therapy and is hormone receptor-negative/HER2-negative, is adjuvant pembrolizumab indicated only for those considered high-risk?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
              "Preoperative systemic therapy see BINV-M 1",
              "Response to preoperative systemic therapy and tumor is operable",
              "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
              "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
              "HR-negative/ HER2-negative",
              "ypT0N0 or pCR",
              "For high-risk. Adjuvant pembrolizumab (if pembrolizumab-containing regimen was given preoperatively)"
            ]
          }
        }
      ],
      "answer": "Yes, adjuvant pembrolizumab is indicated specifically for hormone receptor-negative/HER2-negative patients who are classified as high-risk and have received a preoperative pembrolizumab-containing regimen, even if they achieve a pathologic complete response after neoadjuvant therapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_deb1d810c95b",
      "question": "For a patient with non-small cell lung cancer staged as T1aN0M0 who is operable, if preoperative pulmonary function testing (PFT) reveals severe impairment, is primary surgical resection with mediastinal lymph node dissection still the preferred initial treatment compared to non-surgical options?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Nodes negative",
              "Treatment (NSCL-9)",
              "T1, N0",
              "Operable",
              "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
              "Adjuvant Treatment (NSCL-4)",
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "No. In the setting of severe preoperative pulmonary dysfunction, primary surgical resection—even in operable T1aN0M0 non-small cell lung cancer—may not be feasible or safe. Non-surgical modalities such as stereotactic body radiotherapy should be prioritized due to increased perioperative risk.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_de167a5fbf23",
      "question": "A 59-year-old woman with chronic periodontal inflammation is prescribed a topical dental agent at her biannual cleaning. The hygienist notes that, while this compound is sometimes recommended to help reduce gingival bleeding and plaque formation, current pharmacology texts do not detail its molecular mechanism of action in this setting. Which best describes the current understanding of this agent’s mechanism in periodontal disease management?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Periodontal disease"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0031090",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3256380",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Stannous fluoride is used in periodontal disease, but its mechanism of action in this context is unclear—the cellular or molecular basis is not established in current literature.",
      "umls_path": [
        "Periodontal disease",
        "may_be_treated_by",
        "stannous fluoride dihydrate",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Stannous fluoride is occasionally used as an adjunct in periodontal disease to reduce plaque and gingival inflammation. However, although it shows some clinical benefit, the precise molecular or cellular mechanism by which it exerts these effects remains undefined. Most pharmacologic references acknowledge the compound’s role in caries prevention via enamel remineralization and antibacterial activity, but its actions in periodontal tissues are not well characterized. There is no established receptor interaction, signaling pathway, or specific cellular target attributed to stannous fluoride’s effects in periodontal therapy. Thus, its mechanism in this context is classified as unknown at the molecular level.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_fdc8dc40d120",
      "question": "A 32-year-old woman presents with sudden onset of unilateral visual loss and pain on eye movement. Ophthalmologic examination confirms decreased visual acuity and a central scotoma. MRI reveals inflammation of the optic nerve without evidence of multiple sclerosis. She is started on a medication that acts as a synthetic analog of an endogenous anterior pituitary peptide, leading to increased adrenal steroidogenesis. Which pharmacological mechanism best explains how this therapy exerts its beneficial effect in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Optic neuritis, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0029134",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3818725",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Pituitary hormone receptor agonism (specifically, activation of the ACTH receptor)",
      "reasoning_path": "Acute optic neuritis → anti-inflammatory therapy needed → ACTH analog used → binds pituitary hormone receptors (melanocortin 2) on adrenal cortex → increases cortisol → reduces inflammation.",
      "umls_path": [
        "Optic neuritis, unspecified",
        "may_be_treated_by",
        "Corticotropin",
        "has_mechanism_of_action",
        "Pituitary Hormone Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s presentation is consistent with acute optic neuritis, an inflammatory demyelinating condition of the optic nerve. In cases where rapid recovery is desired or autoimmune etiology is suspected, therapy may involve an ACTH (adrenocorticotropic hormone) analog. ACTH is a pituitary hormone that stimulates the adrenal cortex by binding to melanocortin 2 receptors (a type of pituitary hormone receptor) on adrenal cortical cells. This action increases synthesis and release of glucocorticoids (cortisol), which have potent anti-inflammatory and immunosuppressive properties that help reduce optic nerve inflammation and facilitate visual recovery. Therefore, the drug’s therapeutic effect is mediated through agonism at pituitary hormone receptors, specifically by mimicking endogenous ACTH to stimulate corticosteroid production.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_530f91d85d3d",
      "question": "A 24-year-old woman of Middle Eastern descent with a history of recurrent fevers, serositis, and painful erythematous nodules on her lower legs has been diagnosed with a hereditary autoinflammatory disorder. Despite maximal tolerated doses of colchicine, she continues to experience frequent attacks. Her rheumatologist initiates treatment with a monoclonal antibody that specifically neutralizes a proinflammatory cytokine implicated in her disease pathogenesis. Which cytokine is directly inhibited by this therapy to achieve clinical benefit?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Familial Mediterranean fever"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0031069",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2718773",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Interleukin-1 beta",
      "reasoning_path": "FMF unresponsive to colchicine is treated with canakinumab, which targets and inhibits interleukin-1 beta, the cytokine driving autoinflammatory attacks.",
      "umls_path": [
        "Familial Mediterranean fever",
        "may_be_treated_by",
        "Canakinumab-containing product",
        "has_target",
        "Interleukin-1 Beta"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has Familial Mediterranean fever (FMF), an inherited autoinflammatory condition marked by recurrent fevers and serosal inflammation. The mainstay of FMF management is colchicine, but some patients remain symptomatic despite optimal therapy. In such refractory cases, biologic agents are considered. Canakinumab is a monoclonal antibody that selectively binds and neutralizes interleukin-1 beta (IL-1β), a key proinflammatory cytokine central to FMF pathogenesis. IL-1β mediates fever and inflammation by activating downstream signaling that drives leukocyte recruitment and cytokine release. By directly inhibiting IL-1β, canakinumab dampens the inflammatory cascade, reducing the frequency and severity of FMF episodes. The choice of this therapy is based on the mechanistic role of IL-1β in the disease and the antibody’s specificity for this cytokine.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_553484dee9ee",
      "question": "A 42-year-old woman presents with intermittent episodes of vertigo and aural fullness. On examination, she has no hearing loss or nystagmus, but reports that her symptoms are alleviated after starting an antihistamine medication containing a compound known to modulate certain ion channels involved in neurotransmitter release. Which class of pharmacological interactions most directly contributes to this medication's therapeutic action in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Unspecified disorder of ear"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0013447",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0052759",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Calcium Channel Interactions",
      "reasoning_path": "Patient presents with vestibular symptoms → treated with azatadine → azatadine modulates calcium channels → reduced abnormal neurotransmitter release in vestibular system → symptom improvement.",
      "umls_path": [
        "Unspecified disorder of ear",
        "may_be_treated_by",
        "Azatadine-containing product",
        "has_mechanism_of_action",
        "Calcium Channel Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient's symptoms—vertigo and aural fullness—are suggestive of inner ear dysfunction, for which antihistamines such as azatadine may be prescribed to alleviate symptoms. Azatadine, beyond its antihistaminic properties, is known to interact with calcium channels. Calcium channels play a key role in neuronal excitability and neurotransmitter release within the vestibular pathways. By modulating these channels, azatadine can decrease abnormal neural signaling that contributes to vertigo and related symptoms. This calcium channel interaction is therefore a crucial mechanism that underlies the drug's clinical benefit in this scenario. Understanding this pathway requires linking the clinical presentation (vestibular symptoms), the choice of medication (azatadine), and the drug's effect on calcium channel activity, which directly leads to symptom relief.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_8efa521e423d",
      "question": "In a patient with non-small cell lung cancer (NSCLC) staged as IIIC (T3, N3) by imaging, is pathologic confirmation of N3 disease a necessary prerequisite before initiating definitive chemoradiotherapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 3–4",
              "Systemic Therapy for Metastatic Disease (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes. Pathologic confirmation of N3 disease is required before proceeding to definitive chemoradiotherapy in clinically staged IIIC (T3, N3) NSCLC, as accurate nodal status directly impacts stage, prognosis, and treatment selection.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_f626b209ec76",
      "question": "In patients with peripheral stage IA (T1abc, N0) non-small cell lung cancer undergoing resection, if preoperative pulmonary function tests (PFTs) have not been performed and the patient has a history of chronic obstructive pulmonary disease (COPD), can surgery proceed directly without PFT assessment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (peripheral T1abc, N0)",
              "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treatment",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
              "Surgery after preoperative systemic therapy, if planned",
              "N0–1",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "No, surgery should not proceed without preoperative pulmonary function tests in patients with stage IA NSCLC and a history of COPD. Assessment of lung function is essential to evaluate surgical risk and optimize perioperative management, regardless of tumor stage.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_b5a67b281298",
      "question": "A 34-year-old woman with a history of a rare inherited blistering skin disorder characterized by severe sweating and recurrent erosions is prescribed an injectable therapy. This medication is a modified neurotoxin designed to provide long-lasting inhibition of a specific neurotransmitter release at cholinergic nerve terminals. Which molecular target is directly responsible for mediating the symptomatic relief provided by this treatment?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Genodermatosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0037277",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C5704827",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Acetylcholine transporter interactions (specifically, inhibition of acetylcholine release at the neuromuscular junction and autonomic nerve endings)",
      "reasoning_path": "Inherited skin disorders may be complicated by hyperhidrosis. DaxibotulinumtoxinA-lanm, a botulinum toxin, alleviates symptoms by inhibiting acetylcholine release at cholinergic synapses, directly targeting acetylcholine transporter interactions.",
      "umls_path": [
        "Genodermatosis",
        "may_be_treated_by",
        "daxibotulinumtoxinA-lanm",
        "has_mechanism_of_action",
        "Acetylcholine Transporter Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with a rare genodermatosis, such as epidermolysis bullosa or another inherited blistering disorder, is experiencing symptoms exacerbated by excessive sweating (hyperhidrosis). DaxibotulinumtoxinA-lanm is a long-acting botulinum toxin formulation approved for conditions like severe axillary hyperhidrosis and studied in skin disorders with symptomatic hyperhidrosis. The drug achieves its effect by cleaving SNARE proteins necessary for acetylcholine vesicle fusion and release at cholinergic synapses. By directly interfering with acetylcholine transporter interactions, it prevents the neurotransmitter's exocytosis, reducing sweat production and alleviating discomfort associated with skin erosions. The therapeutic effect does not target the underlying genetic defect, but rather provides symptomatic management by modulating the molecular machinery responsible for acetylcholine-mediated exocrine gland stimulation.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_4987fa4e0839",
      "question": "For a patient with Stage IA (T1abc, N0) non-small cell lung cancer who has undergone a resection with positive surgical margins (R1 or R2), is radiotherapy an equally preferred alternative to re-resection as primary management for margin positivity, or is it considered a secondary choice?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (T1abc, N0); Margins positive (R1, R2)",
              "Resection (preferred) or RT (category 2B)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Radiotherapy is considered a secondary (category 2B) option for positive surgical margins (R1 or R2) after resection in Stage IA (T1abc, N0) non-small cell lung cancer; re-resection is the preferred management when feasible.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_095d9f18d9a9",
      "question": "In a patient with newly diagnosed, non-metastatic invasive breast cancer (clinical stage cT1c, cN0, HER2-positive) who is being considered for preoperative systemic therapy, if axillary imaging reveals a single suspicious lymph node and subsequent needle biopsy confirms nodal involvement with successful placement of a marker, does this nodal status require axillary lymph node dissection after mastectomy if, post-preoperative therapy, only one sentinel lymph node remains positive?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS not possible",
              "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
              "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
              "SLN mapping and excision",
              "SLN positive",
              "Mastectomy",
              "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • Adjuvant RT planned with intentional inclusion of undissected axilla at risk",
              "Yes to all",
              "Consider no further axillary surgery"
            ]
          }
        }
      ],
      "answer": "No, in this scenario, axillary lymph node dissection can be omitted if, after preoperative systemic therapy and mastectomy, there is only one positive sentinel lymph node and the nodal involvement was limited and appropriately marked before treatment. This approach is supported if adjuvant radiotherapy is planned to intentionally include the at-risk undissected axilla.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_c7faca9bd853",
      "question": "A 42-year-old woman with a history of atopic dermatitis presents with worsening pruritic, erythematous plaques on her forearms and neck. She has tried emollients and topical corticosteroids with only partial relief. Her dermatologist prescribes a new topical cream containing a compound structurally related to vitamin A, aiming to improve her skin symptoms by influencing keratinocyte behavior. Through which general molecular mechanism does this class of agent exert its therapeutic effect in her chronic skin condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Dermatitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011603",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4291322",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme interactions—modulation of skin enzyme activity",
      "reasoning_path": "Vitamin A derivatives (retinoids) are prescribed for dermatitis; these agents act by modulating multiple enzyme activities in the skin, which alters cell differentiation and inflammation, thereby alleviating dermatitic symptoms.",
      "umls_path": [
        "Dermatitis",
        "may_be_treated_by",
        "VITAMIN A MYRISTATE",
        "has_mechanism_of_action",
        "Enzyme Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Vitamin A derivatives (retinoids) are sometimes used topically to treat chronic dermatitis when other therapies are insufficient. Their therapeutic benefit stems from their ability to interact with nuclear receptors that regulate gene expression in skin cells, especially keratinocytes. Upon binding, these agents modulate the transcription of genes involved in cellular proliferation, differentiation, and inflammation. A key component of this process involves altering the activity of enzymes responsible for synthesizing and degrading proteins and lipids in the epidermis. By changing enzyme activity, retinoids correct abnormal keratinization, decrease inflammation, and promote healthier skin turnover. This broad enzymatic modulation underlies their effectiveness in managing chronic inflammatory skin diseases like dermatitis.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_685430237405",
      "question": "In a patient with stage IIIB (T1–2, N3) non-small cell lung cancer (NSCLC) who has not yet undergone pulmonary function testing or mediastinal lymph node pathological confirmation, is it appropriate to proceed directly to systemic therapy based solely on imaging findings of N3 nodal involvement?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, it is not appropriate. Pathological confirmation of N3 disease is required before systemic therapy initiation in stage IIIB NSCLC, as imaging findings alone are insufficient to guide definitive treatment decisions. Pulmonary function testing is also necessary for comprehensive pre-treatment assessment.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_cabbe681995f",
      "question": "A 67-year-old woman presents with chronic knee pain that worsens with activity and improves with rest. Examination reveals crepitus and mild joint swelling. She is diagnosed with osteoarthritis and started on an oral medication that targets a key enzyme in the biosynthesis of pro-inflammatory mediators derived from arachidonic acid. Which pharmacological class does this drug's mechanism of action most likely belong to, considering its effect on pain and inflammation?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Osteoarthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0029408",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0031990",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cyclooxygenase inhibitors",
      "reasoning_path": "Osteoarthritis → treated with NSAIDs (e.g., piroxicam) → NSAIDs inhibit cyclooxygenase → decreased prostaglandin synthesis → reduced pain and inflammation.",
      "umls_path": [
        "Osteoarthritis",
        "may_be_treated_by",
        "Piroxicam",
        "has_mechanism_of_action",
        "Cyclooxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Osteoarthritis commonly presents with joint pain and stiffness, and nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed for symptomatic relief. NSAIDs achieve their therapeutic effects by inhibiting cyclooxygenase (COX) enzymes—specifically COX-1 and COX-2—in the arachidonic acid pathway. These enzymes catalyze the conversion of arachidonic acid to prostaglandins, which are lipid mediators responsible for promoting inflammation, pain, and swelling. By inhibiting cyclooxygenase, NSAIDs reduce prostaglandin synthesis, leading to decreased inflammation and analgesia. This pharmacologic mechanism underlies the clinical improvement seen in patients with osteoarthritis who are prescribed these agents. Thus, the general pharmacological class is cyclooxygenase inhibitors, which includes commonly used drugs such as ibuprofen, naproxen, and piroxicam.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_9f4c36b8f72b",
      "question": "In patients with operable, non-inflammatory, non-metastatic (M0) HER2-positive breast cancer staged as cT1c, cN0, is it appropriate to initiate preoperative systemic therapy if the tumor is also triple-negative, and how does this impact the prioritization of preoperative therapy versus immediate surgery?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS possible",
              "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
              "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
              "HR-positive/ HER2-positive",
              "ypT1–4,N0 or ypN≥1",
              "If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1) and If HR-positive, adjuvant endocrine therapy (category 1) "
            ]
          }
        }
      ],
      "answer": "For both cT1c, cN0, HER2-positive and cT1c, cN0, triple-negative breast cancer, preoperative systemic therapy is a recommended option given the higher recurrence risk and potential for downstaging, and it should be prioritized over immediate surgery to maximize systemic control and assess tumor response.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_c1716fe50f87",
      "question": "What diseases are associated with the target GABRA2 (Ensembl ID ENSG00000151834) that have a minimum relevance score of 0.5 in OpenTargets?",
      "tool_calls": [
        {
          "tool": "opentargets.search",
          "params": {
            "target_id": "ENSG00000151834",
            "min_score": 0.5
          }
        }
      ],
      "answer": [
        {
          "disease_id": "MONDO_0007079",
          "disease_name": "alcohol dependence",
          "score": 0.6822312544230996
        },
        {
          "disease_id": "EFO_0000474",
          "disease_name": "epilepsy",
          "score": 0.6094869099517665
        },
        {
          "disease_id": "MONDO_0002009",
          "disease_name": "major depressive disorder",
          "score": 0.6092447483627642
        },
        {
          "disease_id": "EFO_0004698",
          "disease_name": "insomnia",
          "score": 0.605489364142408
        },
        {
          "disease_id": "EFO_0004262",
          "disease_name": "panic disorder",
          "score": 0.6030885772056018
        },
        {
          "disease_id": "HP_0000713",
          "disease_name": "Agitation",
          "score": 0.6027471988105273
        },
        {
          "disease_id": "EFO_0006788",
          "disease_name": "anxiety disorder",
          "score": 0.6018767594987441
        },
        {
          "disease_id": "EFO_0005230",
          "disease_name": "anxiety",
          "score": 0.6002551308485161
        },
        {
          "disease_id": "MONDO_0005277",
          "disease_name": "migraine disorder",
          "score": 0.5951950676466844
        },
        {
          "disease_id": "HP_0001250",
          "disease_name": "Seizure",
          "score": 0.5893008788199434
        },
        {
          "disease_id": "EFO_0003843",
          "disease_name": "pain",
          "score": 0.5779874672066261
        },
        {
          "disease_id": "MONDO_0002050",
          "disease_name": "depressive disorder",
          "score": 0.5657344809584639
        },
        {
          "disease_id": "EFO_1001892",
          "disease_name": "generalized anxiety disorder",
          "score": 0.5555024176430615
        },
        {
          "disease_id": "EFO_0007453",
          "disease_name": "postpartum depression",
          "score": 0.5554546488183064
        },
        {
          "disease_id": "MONDO_0016532",
          "disease_name": "Lennox-Gastaut syndrome",
          "score": 0.5533871689213433
        },
        {
          "disease_id": "EFO_0008526",
          "disease_name": "status epilepticus",
          "score": 0.5481340929891784
        },
        {
          "disease_id": "MONDO_0100062",
          "disease_name": "developmental and epileptic encephalopathy",
          "score": 0.5360687652530066
        },
        {
          "disease_id": "EFO_0007498",
          "disease_name": "Stiff-Person syndrome",
          "score": 0.5261379875719714
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_d018eece4296",
      "question": "A 62-year-old woman presents with profuse watery diarrhea, abdominal pain, and low-grade fever two weeks after completing a course of clindamycin for a dental infection. Stool studies are positive for Clostridioides difficile toxin. Despite initial therapy with oral vancomycin, her symptoms persist and flexible sigmoidoscopy shows yellow-white plaques on an erythematous mucosa consistent with pseudomembranous colitis. She is started on an agent that specifically inhibits a key enzyme required for bacterial transcription, thereby blocking synthesis of essential genetic material. Which drug class most accurately describes the primary molecular mechanism responsible for the therapeutic effect of this agent in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "pseudomembranous enterocolitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0014358",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0065023",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Nucleic Acid Synthesis Inhibitors",
      "reasoning_path": "C. difficile pseudomembranous colitis is treated with fidaxomicin, which inhibits bacterial RNA polymerase, blocking nucleic acid synthesis and thus bacterial survival.",
      "umls_path": [
        "pseudomembranous enterocolitis",
        "may_be_treated_by",
        "Fidaxomicin-containing product",
        "has_mechanism_of_action",
        "Nucleic Acid Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has severe, recurrent Clostridioides difficile infection, manifesting as pseudomembranous colitis. Fidaxomicin is an oral antibiotic often used in such cases due to its narrow spectrum of activity against C. difficile and minimal systemic absorption. Fidaxomicin exerts its antibacterial effect by inhibiting the sigma-dependent transcription of bacterial RNA polymerase, thereby blocking the initiation of RNA synthesis. This inhibition prevents the bacteria from synthesizing the nucleic acids required for protein production and cellular replication, ultimately leading to bacterial cell death. Therefore, fidaxomicin is classified as a nucleic acid synthesis inhibitor. Its targeted action at the level of RNA polymerase is particularly effective against C. difficile and helps preserve normal gut flora, reducing the risk of recurrence.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_5e884bc6116e",
      "question": "In a patient with stage IIB non-small cell lung cancer who has undergone surgical resection resulting in R2 margins (gross residual disease), is concurrent chemoradiation an appropriate treatment option, or must re-resection always be attempted first?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
              "R2; Resection + systemic therapy or Concurrent chemoradiation",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "For stage IIB non-small cell lung cancer patients with R2 resection (gross residual disease), concurrent chemoradiation is considered an appropriate option without a mandatory requirement for re-resection, as definitive radiotherapy with or without chemotherapy is standard when gross residual tumor remains after surgery.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_09f66df3ac07",
      "question": "A 43-year-old man with longstanding numbness and skin lesions on his forearms is diagnosed with a chronic infectious disease characterized by granulomatous skin nodules and peripheral neuropathy. He develops painful erythematous skin nodules and fever, consistent with an acute inflammatory complication of his disease. After standard antimicrobial therapy fails to resolve these inflammatory episodes, his physician prescribes a drug known for its teratogenicity and immunomodulatory actions. This drug exerts its therapeutic effect by inhibiting a key signaling protein involved in angiogenesis and inflammation. Which molecular target is most directly responsible for the drug’s immunomodulatory benefit in this clinical scenario?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Leprosy, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0023343",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0039736",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Vascular Endothelial Growth Factor A (VEGF-A)",
      "reasoning_path": "Leprosy with erythema nodosum leprosum is managed with thalidomide, which exerts its immunomodulatory effect mainly by inhibiting VEGF-A, thereby reducing inflammation and angiogenesis.",
      "umls_path": [
        "Leprosy, unspecified",
        "may_be_treated_by",
        "Thalidomide",
        "has_target",
        "Vascular Endothelial Growth Factor A"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient is experiencing erythema nodosum leprosum, a severe inflammatory complication of leprosy. Thalidomide is indicated for such complications due to its immunomodulatory and anti-inflammatory properties. The drug’s major therapeutic effect in this context is attributed to its ability to inhibit the production of vascular endothelial growth factor A (VEGF-A), a key molecule mediating angiogenesis and inflammation. By suppressing VEGF-A, thalidomide reduces the vascular permeability and leukocyte recruitment that drive erythema nodosum leprosum. Although thalidomide also modulates other cytokines such as TNF-α, the inhibition of VEGF-A is particularly relevant to the control of inflammation and tissue remodeling in leprosy reactions. Thus, the immunomodulatory benefit in this context is primarily mediated by antagonism of VEGF-A signaling.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_28a0a03278d3",
      "question": "Which diseases are associated with the target ADRB1 (Ensembl ID ENSG00000043591) with a minimum relevance score of 0.5 according to OpenTargets?",
      "tool_calls": [
        {
          "tool": "opentargets.search",
          "params": {
            "target_id": "ENSG00000043591",
            "min_score": 0.5
          }
        }
      ],
      "answer": [
        {
          "disease_id": "EFO_0000537",
          "disease_name": "hypertension",
          "score": 0.7380868313944822
        },
        {
          "disease_id": "EFO_0000319",
          "disease_name": "cardiovascular disease",
          "score": 0.7226449889389978
        },
        {
          "disease_id": "EFO_0000612",
          "disease_name": "myocardial infarction",
          "score": 0.621455472135067
        },
        {
          "disease_id": "EFO_0004190",
          "disease_name": "open-angle glaucoma",
          "score": 0.6054383766600698
        },
        {
          "disease_id": "MONDO_0005041",
          "disease_name": "glaucoma",
          "score": 0.6052929074382162
        },
        {
          "disease_id": "EFO_0003144",
          "disease_name": "heart failure",
          "score": 0.605211246931498
        },
        {
          "disease_id": "EFO_0003913",
          "disease_name": "angina pectoris",
          "score": 0.6042628258043483
        },
        {
          "disease_id": "EFO_1001069",
          "disease_name": "ocular hypertension",
          "score": 0.6023499440422849
        },
        {
          "disease_id": "MONDO_0005277",
          "disease_name": "migraine disorder",
          "score": 0.6017771202951928
        },
        {
          "disease_id": "EFO_0000373",
          "disease_name": "congestive heart failure",
          "score": 0.5969404304978806
        },
        {
          "disease_id": "MONDO_0004979",
          "disease_name": "asthma",
          "score": 0.5956618584578418
        },
        {
          "disease_id": "EFO_0004278",
          "disease_name": "sudden cardiac arrest",
          "score": 0.589990668915091
        },
        {
          "disease_id": "HP_0004308",
          "disease_name": "Ventricular arrhythmia",
          "score": 0.5828331327750093
        },
        {
          "disease_id": "HP_0100806",
          "disease_name": "Sepsis",
          "score": 0.5821904690958367
        },
        {
          "disease_id": "EFO_0003843",
          "disease_name": "pain",
          "score": 0.5810776283404744
        },
        {
          "disease_id": "EFO_0007486",
          "disease_name": "sinusitis",
          "score": 0.5808925299048607
        },
        {
          "disease_id": "EFO_0005251",
          "disease_name": "hypotension",
          "score": 0.5766132028285715
        },
        {
          "disease_id": "EFO_0000712",
          "disease_name": "stroke",
          "score": 0.575737308541932
        },
        {
          "disease_id": "EFO_0004612",
          "disease_name": "high density lipoprotein cholesterol measurement",
          "score": 0.5731118915460562
        },
        {
          "disease_id": "EFO_0006834",
          "disease_name": "septic shock",
          "score": 0.5659732343116494
        },
        {
          "disease_id": "EFO_0006335",
          "disease_name": "systolic blood pressure",
          "score": 0.5614462803678716
        },
        {
          "disease_id": "EFO_0004530",
          "disease_name": "triglyceride measurement",
          "score": 0.5599462207306656
        },
        {
          "disease_id": "EFO_0000275",
          "disease_name": "atrial fibrillation",
          "score": 0.5598458035051157
        },
        {
          "disease_id": "MONDO_0005271",
          "disease_name": "allergic disease",
          "score": 0.5587297348479079
        },
        {
          "disease_id": "EFO_0006336",
          "disease_name": "diastolic blood pressure",
          "score": 0.552003070367453
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "ret_eff804ca8b3c",
      "question": "What is the PMID of the article titled “Vogt Koyanagi Harada disease with bilateral disc edema diagnosed as Arnold Chiari malformation with papilledema: The blurred margin between ophthalmology and neurology,” authored by Agrawal A and published in the Indian Journal of Ophthalmology in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"Vogt Koyanagi Harada disease with bilateral disc edema diagnosed as Arnold Chiari malformation with papilledema\"[ti] AND Agrawal A[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40434450"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_9cefa5e6f0ec",
      "question": "In a patient with stage IIA (T2b, N0) non-small cell lung cancer (NSCLC) who underwent surgical resection with positive margins (R1/R2), and with no evidence of distant metastasis or disseminated disease, does the recommendation for additional local therapy (re-resection or radiotherapy) implicitly exclude patients with unresectable local disease from these options?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIA (T2b, N0); Margins positive (R1, R2)",
              "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Yes, the consideration for additional local therapy such as re-resection or radiotherapy following surgery with positive margins is based on the implicit assumption of resectability or localized disease. Patients with unresectable local disease or evidence of distant metastasis are excluded from these options and should instead be directed toward systemic therapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_18c30c9f54ec",
      "question": "A 38-year-old woman with a history of recurrent episodes of petechiae and mucosal bleeding is diagnosed with a chronic autoimmune disorder characterized by low platelet counts. After inadequate response to corticosteroids, she is started on a biologic agent that exerts its immunomodulatory effect by binding to a specific cell surface receptor, triggering the JAK-STAT signaling pathway and modulating immune cell activity. Through which molecular complex does this therapy primarily mediate its clinical benefit in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Thrombocytopenic Purpura"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0857305",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021735",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Interferon alpha receptor complex",
      "reasoning_path": "Patient with ITP → treated with interferon alfa-2b → drug binds interferon alpha receptor complex → activates JAK-STAT → immunomodulation → improved platelet count.",
      "umls_path": [
        "Thrombocytopenic Purpura",
        "may_be_treated_by",
        "Recombinant Interferon Alfa-2b",
        "has_target",
        "Interferon Alpha Receptor Complex"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has chronic immune thrombocytopenic purpura (ITP), an autoimmune condition leading to platelet destruction. When corticosteroids are insufficient, interferon alfa-2b may be used for its immunomodulatory properties. The therapeutic action of interferon alfa-2b begins when it binds to the interferon alpha receptor complex on immune cell surfaces. This binding activates the JAK-STAT signaling cascade, leading to changes in gene expression that suppress aberrant immune responses and enhance immune regulation. These downstream effects help increase platelet counts by reducing the autoimmune destruction of platelets. Thus, the primary molecular target responsible for the observed clinical benefit is the interferon alpha receptor complex.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_a51ac5cfa0bf",
      "question": "A 67-year-old man with a six-month history of progressive exertional dyspnea and dry cough is diagnosed with idiopathic pulmonary fibrosis based on high-resolution CT and lung biopsy findings. He is started on an oral antifibrotic agent that inhibits multiple receptor tyrosine kinases, including those involved in angiogenesis and inflammatory responses. Among its targets is a receptor expressed on macrophages, which mediates signaling that promotes fibrotic tissue remodeling. Through inhibition of this receptor, the medication helps slow disease progression. Which receptor is specifically involved in macrophage signaling and is inhibited by this therapy, thereby contributing to its clinical benefit in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Idiopathic Pulmonary Fibrosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1800706",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2930789",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Macrophage Colony-Stimulating Factor 1 Receptor (CSF1R)",
      "reasoning_path": "Idiopathic pulmonary fibrosis is treated with nintedanib, which inhibits multiple tyrosine kinases, including CSF1R; CSF1R inhibition reduces profibrotic macrophage signaling, slowing disease progression.",
      "umls_path": [
        "Idiopathic Pulmonary Fibrosis",
        "may_be_treated_by",
        "Nintedanib-containing product",
        "has_target",
        "Macrophage Colony-Stimulating Factor 1 Receptor"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Idiopathic pulmonary fibrosis is a chronic, progressive lung disease characterized by fibroblast activation and excessive extracellular matrix deposition. Nintedanib, a multi-tyrosine kinase inhibitor, is approved for the treatment of this condition. Its therapeutic efficacy derives from inhibition of several receptor tyrosine kinases, including PDGFR, FGFR, VEGFR, and the macrophage colony-stimulating factor 1 receptor (CSF1R). CSF1R is expressed on macrophages and monocytes and plays a central role in their proliferation, differentiation, and survival. In the context of pulmonary fibrosis, CSF1R-driven macrophage activation contributes to ongoing inflammation and fibrotic remodeling. By inhibiting CSF1R, nintedanib disrupts profibrotic macrophage signaling, thereby attenuating the recruitment and activation of fibroblasts and reducing the progression of fibrosis. This molecular mechanism complements the drug’s broader anti-fibrotic and anti-inflammatory actions mediated by blockade of other kinases, resulting in slowed decline of lung function in patients with idiopathic pulmonary fibrosis.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_13ba3ff4aa9e",
      "question": "A 14-year-old boy presents with progressive weakness and wasting of the distal muscles of his hands and feet. He has difficulty gripping objects and frequent tripping. Neurological examination reveals distal muscle atrophy, decreased deep tendon reflexes, but no sensory deficits. Genetic testing confirms an autosomal recessive form of distal hereditary motor neuronopathy. He is enrolled in a clinical trial for a medication designed to increase survival motor neuron (SMN) protein levels by modifying pre-mRNA splicing. This drug is also known to inhibit a transporter involved in cellular drug and toxin handling. Which molecular target is directly inhibited by this medication to contribute to its pharmacologic profile?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "NEURONOPATHY, DISTAL HEREDITARY MOTOR, AUTOSOMAL RECESSIVE 2"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1854023",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C5139676",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Multidrug and Toxin Extrusion Transporter 2 K (MATE2-K)",
      "reasoning_path": "Distal hereditary motor neuronopathy is treated with Risdiplam, which raises SMN protein by modulating SMN2 splicing. Risdiplam also directly inhibits the MATE2-K transporter, impacting drug disposition and contributing to its pharmacologic activity.",
      "umls_path": [
        "NEURONOPATHY, DISTAL HEREDITARY MOTOR, AUTOSOMAL RECESSIVE 2",
        "may_be_treated_by",
        "Risdiplam",
        "has_mechanism_of_action",
        "Multidrug and Toxin Extrusion Transporter 2 K Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This adolescent has an autosomal recessive distal hereditary motor neuronopathy, a group of disorders characterized by degeneration of lower motor neurons. Risdiplam, a small molecule splicing modifier, is being investigated as a treatment because it promotes inclusion of exon 7 in SMN2 transcripts, increasing functional SMN protein. Additionally, Risdiplam inhibits Multidrug and Toxin Extrusion Transporter 2 K (MATE2-K), a renal transporter responsible for excreting certain drugs and endogenous compounds. Inhibiting MATE2-K can alter pharmacokinetics and potentially influence cellular handling of metabolites, which may contribute to both therapeutic and adverse effects. Understanding Risdiplam’s dual mechanisms—SMN2 splicing modification and MATE2-K inhibition—is essential for predicting drug interactions, optimizing efficacy, and managing safety in patients with hereditary motor neuronopathies.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_ed4014a09f1b",
      "question": "In a patient with pathologically confirmed N3 non-small cell lung cancer (NSCLC) presenting with stage IIIC disease (T3, N3), if separate pulmonary nodules are also detected, does this finding extend the indication for management from locoregional to distant metastatic disease protocols?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, the presence of separate pulmonary nodules in a patient with stage IIIC (T3, N3) NSCLC reclassifies the disease to either stage IIIA, IIB, or IV, depending on the location and characteristics of the nodules. This shifts management from locoregional to protocols appropriate for limited or distant metastatic disease.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_c8fa37a4768e",
      "question": "A 52-year-old woman with a history of cholelithiasis enrolls in a clinical trial testing an experimental enzymatic treatment for her biliary stones. The investigational drug is known to deplete a specific amino acid substrate, ultimately affecting cellular processes dependent on this molecule. During the study, laboratory analyses show a marked reduction in the serum levels of this amino acid. Which biomolecule is the direct target of the enzymatic therapy being studied?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Biliary calculus"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0008350",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003993",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Asparagine",
      "reasoning_path": "The enzyme used in this experimental therapy is asparaginase, which directly hydrolyzes asparagine, depleting its serum levels and affecting dependent cells.",
      "umls_path": [
        "Biliary calculus",
        "may_be_treated_by",
        "Asparaginase",
        "has_target",
        "Asparagine"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient is participating in a trial evaluating an enzyme-based therapy for biliary calculi. The agent described depletes a key amino acid, which points toward asparaginase, an enzyme classically used in oncology for its ability to hydrolyze asparagine. Asparaginase catalyzes the conversion of asparagine to aspartic acid and ammonia, thereby reducing systemic asparagine levels. Certain cell types—most notably some leukemic cells—are unable to synthesize asparagine de novo and rely on extracellular sources; depleting asparagine causes cytotoxicity in these cells. In the context of experimental use for biliary calculi, the molecular target remains the same: asparagine. The reduction in serum asparagine following drug administration confirms this mechanistic pathway. Thus, asparagine is the direct substrate and molecular target of asparaginase therapy in this setting.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_cec2ba0e4fcc",
      "question": "An 8-year-old boy is evaluated for persistent short stature and hypotonia. He has a notable history of hyperphagia and developmental delay. Genetic testing confirms a chromosomal abnormality consistent with a specific syndrome. His pediatric endocrinologist prescribes a recombinant polypeptide that mimics an anterior pituitary hormone to address his primary growth concern. Which class of pharmacological action is responsible for the therapeutic effect of this intervention in his condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Prader-Willi syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0032897",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0143083",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Pituitary hormone receptor agonists",
      "reasoning_path": "A child with a genetic syndrome and growth deficiency receives a synthetic growth hormone. The drug acts by activating growth hormone receptors, making its pharmacological class a pituitary hormone receptor agonist.",
      "umls_path": [
        "Prader-Willi syndrome",
        "may_be_treated_by",
        "Somatrem-containing product",
        "has_mechanism_of_action",
        "Pituitary Hormone Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Children with this genetic syndrome often present with growth hormone deficiency, contributing to short stature. The prescribed medication is a synthetic analogue of growth hormone, functioning as an agonist at growth hormone (somatotropin) receptors. By activating these receptors, the drug stimulates downstream pathways that promote linear growth, increase muscle mass, and decrease body fat. This pharmacological approach directly targets the underlying hormone deficiency rather than just mitigating symptoms. The primary clinical benefit is achieved through receptor-mediated activation, classifying the agent as a pituitary hormone receptor agonist. This is a core therapeutic strategy in pediatric patients with growth impairment due to this syndrome.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_748b5b18d4ab",
      "question": "In the OpenTargets platform, what tractability information is available for the target with Ensembl ID ENSG00000117601 and approved symbol SERPINC1, where the value is True?",
      "tool_calls": [
        {
          "tool": "opentargets.tractability",
          "params": {
            "target_id": "ENSG00000117601",
            "value": true
          }
        }
      ],
      "answer": [
        {
          "modality": "SM",
          "label": "Structure with Ligand"
        },
        {
          "modality": "SM",
          "label": "High-Quality Pocket"
        },
        {
          "modality": "SM",
          "label": "Druggable Family"
        },
        {
          "modality": "AB",
          "label": "GO CC high conf"
        },
        {
          "modality": "AB",
          "label": "UniProt loc med conf"
        },
        {
          "modality": "AB",
          "label": "UniProt SigP or TMHMM"
        },
        {
          "modality": "PR",
          "label": "Small Molecule Binder"
        },
        {
          "modality": "OC",
          "label": "Approved Drug"
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_44772a8f8b9b",
      "question": "A 19-year-old woman presents to the dermatology clinic with numerous inflamed nodules and cysts on her face, chest, and back. She reports that topical retinoids and oral antibiotics have not improved her condition over the past six months. The dermatologist prescribes an oral medication known to reduce sebaceous gland size and sebum production by affecting gene transcription through nuclear receptor pathways. Which specific nuclear receptor is directly modulated by this medication to exert its therapeutic effects in severe nodulocystic acne?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Acne"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001144",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0022265",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Retinoid X Receptor (RXR)",
      "reasoning_path": "Severe nodulocystic acne unresponsive to standard therapy is treated with isotretinoin, which exerts its effects through nuclear retinoid receptors. Isotretinoin binds to and modulates the Retinoid X Receptor (RXR), altering gene expression that reduces sebaceous gland activity and sebum production.",
      "umls_path": [
        "Acne",
        "may_be_treated_by",
        "isotretinoin",
        "has_target",
        "Retinoid X Receptor"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has severe nodulocystic acne that has failed conventional therapies, prompting initiation of isotretinoin, a systemic retinoid. Isotretinoin primarily works by binding to nuclear receptors in the retinoid receptor family, including Retinoic Acid Receptors (RARs) and Retinoid X Receptors (RXRs). The RXR is a ligand-activated transcription factor that forms heterodimers with other nuclear receptors, thereby influencing the expression of genes controlling cell proliferation, differentiation, and apoptosis. In sebaceous glands, RXR activation leads to decreased cell proliferation and sebaceous gland atrophy, resulting in reduced sebum production and improvement of acne lesions. Thus, the retinoid's clinical benefit in severe acne is directly linked to its modulation of the RXR, making this nuclear receptor the primary molecular target in this context.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_073e715a284a",
      "question": "A 34-year-old woman with a long-standing history of severe, recurrent migraines is unresponsive to triptan therapy and is prescribed a medication that acts as a partial agonist at multiple monoamine receptors, including those for serotonin and dopamine. Shortly after starting therapy, she reports improvement in her headache frequency and severity. Which receptor interaction is most directly relevant to the therapeutic vasoconstrictive and neurotransmitter-modulating effects of this drug in migraine management?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Migraine"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0149931",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0086248",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Dopamine receptor interactions",
      "reasoning_path": "Migraine refractory to triptans may be treated with ergotamine tartrate, whose efficacy relies in part on dopamine receptor interactions that mediate vasoconstriction and modulate neurotransmitter activity, thus alleviating migraine symptoms.",
      "umls_path": [
        "Migraine",
        "may_be_treated_by",
        "Ergotamine Tartrate",
        "has_mechanism_of_action",
        "Dopamine Receptor Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Ergotamine tartrate is an ergot alkaloid used for acute migraine attacks, particularly when other treatments fail. Its antimigraine efficacy is multifactorial, but a key component is its action as a partial agonist at dopamine receptors (specifically D2-like receptors), in addition to 5-HT (serotonin) receptors. Dopamine receptor activation contributes to cranial vasoconstriction and modulates neuronal transmission involved in migraine pathophysiology. These effects help counteract the vasodilation and neurogenic inflammation thought to underlie migraine attacks. Furthermore, dopamine agonism may reduce the release of vasoactive neuropeptides and decrease transmission in pain pathways. While serotonin receptor interactions (e.g., 5-HT1B/1D) are also pharmacologically significant for ergotamine, the question focuses on the receptor type highlighted for its contribution to both vasoconstriction and neurotransmitter modulation—key therapeutic actions in migraine relief.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_05e7ddba6ab9",
      "question": "A 52-year-old woman is hospitalized for acute kidney inflammation with hematuria, hypertension, and mild metabolic acidosis. She develops muscle cramps and her labs reveal a low serum magnesium level. The clinical team initiates intravenous administration of a hydrated inorganic salt to correct her electrolyte imbalance and stabilize her acid-base status. Which general pharmacological property of this agent underlies its role in managing her metabolic disturbance in the context of nephritis?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Nephritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0027697",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4741891",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Acid-base activity",
      "reasoning_path": "Nephritis leads to metabolic acidosis and hypomagnesemia; magnesium sulfate dihydrate is given to correct these, acting through acid-base activity to restore homeostasis.",
      "umls_path": [
        "Nephritis",
        "may_be_treated_by",
        "magnesium sulfate dihydrate",
        "has_mechanism_of_action",
        "Acid-Base Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In patients with nephritis, renal impairment can disrupt electrolyte and acid-base homeostasis, often resulting in metabolic acidosis and hypomagnesemia. Magnesium sulfate dihydrate is administered to correct magnesium deficits and can also influence the body's acid-base balance. By providing magnesium ions and associated sulfate, this agent acts as a systemic buffer, helping to mitigate the acidotic state seen in nephritis. Its therapeutic benefit in this setting is not due to direct anti-inflammatory or immunosuppressive effects, but rather to its capacity to restore electrolyte levels and modulate acid-base equilibrium. Thus, the clinical utility of magnesium sulfate dihydrate in nephritis primarily stems from its acid-base activity, which can help stabilize the patient's metabolic state and reduce symptoms related to electrolyte and pH imbalances.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_1f855f6e4bd7",
      "question": "A 55-year-old woman with type 2 diabetes mellitus is struggling to achieve glycemic control despite standard therapy. She asks her clinician about over-the-counter supplements that might help lower her blood glucose. After reviewing available evidence, her clinician discusses a supplement that is thought to act by sequestering trace metals within cells, thereby modifying cellular metabolism and improving insulin sensitivity. Which specific pharmacological property of this supplement underlies its potential glucose-lowering effect in patients like hers?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Diabetes Mellitus"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011849",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0163657",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Iron chelating activity",
      "reasoning_path": "Type 2 diabetes is sometimes treated adjunctively with chromium picolinate, which acts by chelating iron, thereby affecting metabolic signaling and insulin sensitivity.",
      "umls_path": [
        "Diabetes Mellitus",
        "may_be_treated_by",
        "Chromium Picolinate",
        "has_mechanism_of_action",
        "Iron Chelating Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Chromium picolinate is a dietary supplement sometimes considered as adjunct therapy in type 2 diabetes mellitus, though its efficacy remains controversial. Chromium is an essential trace element that influences carbohydrate and lipid metabolism, potentially enhancing insulin action. One proposed mechanism is its iron chelating activity: chromium picolinate binds intracellular iron, reducing free iron availability. This chelation may decrease oxidative stress and modify the activity of key metabolic enzymes sensitive to iron status, ultimately improving insulin receptor function and glucose uptake in peripheral tissues. By modulating cellular iron and thus influencing metabolic signaling, chromium picolinate’s iron chelating property forms the pharmacological basis for its possible glucose-lowering effect. However, the clinical benefit is modest and should not replace established diabetes therapies.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_a4cd3c918900",
      "question": "A 25-year-old woman presents with progressive lower limb stiffness, spasticity, and weakness. She reports difficulty walking and frequent muscle cramps. Her family history is positive for similar neurological symptoms. Genetic testing confirms a diagnosis of an inherited spastic paraparesis. Her neurologist prescribes a drug that binds divalent metal ions, forming stable complexes that are then excreted in the urine. What is the principal pharmacological property of this medication that addresses the underlying pathophysiology in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Westphal-Strumpell syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0019202",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0030817",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Chelating activity",
      "reasoning_path": "Hereditary spastic paraplegia can involve toxic metal accumulation; penicillamine's key pharmacological action is chelation of metal ions, enabling their removal and reducing toxicity.",
      "umls_path": [
        "Westphal-Strumpell syndrome",
        "may_be_treated_by",
        "Penicillamine",
        "has_mechanism_of_action",
        "Chelating Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Hereditary spastic paraplegia (HSP) is a group of genetic disorders characterized by progressive lower limb spasticity and weakness. In certain metabolic subtypes of HSP, abnormal accumulation of metal ions, such as copper, can contribute to neurotoxicity and exacerbate symptoms. Penicillamine is a chelating agent that binds divalent metal ions like copper, forming soluble complexes that are eliminated renally. By reducing the tissue burden of these metals, penicillamine may ameliorate neurological symptoms associated with their accumulation. The therapeutic benefit of penicillamine in this context is therefore due to its chelating activity, not any direct neuromodulatory effect. Understanding this mechanism is crucial for selecting and monitoring therapy, especially in hereditary disorders with a metabolic component.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_81cc0d5ad76a",
      "question": "A 65-year-old man with progressive exertional dyspnea and non-productive cough is diagnosed with idiopathic pulmonary fibrosis after high-resolution CT reveals subpleural reticular opacities and honeycombing. He is started on an oral antifibrotic agent that inhibits several tyrosine kinase receptors, including those for vascular endothelial growth factor, platelet-derived growth factor, and fibroblast growth factor, among others. This drug slows disease progression by interrupting signaling pathways that mediate fibroblast proliferation and extracellular matrix deposition. Which specific molecular target, when inhibited by this medication, contributes significantly to its antifibrotic effect in this patient’s lung disease?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Idiopathic Pulmonary Fibrosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1800706",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3529778",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Macrophage Colony-Stimulating Factor 1 Receptor (CSF1R)",
      "reasoning_path": "IPF pathogenesis involves fibrogenic signaling; nintedanib inhibits multiple tyrosine kinase receptors, and CSF1R blockade is key to its antifibrotic effect through suppression of macrophage-mediated fibrosis.",
      "umls_path": [
        "Idiopathic Pulmonary Fibrosis",
        "may_be_treated_by",
        "Nintedanib esilate",
        "has_target",
        "Macrophage Colony-Stimulating Factor 1 Receptor"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Idiopathic pulmonary fibrosis (IPF) involves fibroblast proliferation and excessive matrix deposition, leading to progressive lung scarring. Nintedanib is an oral tyrosine kinase inhibitor prescribed to slow IPF progression. Its mechanism targets multiple receptor tyrosine kinases, notably those for VEGF, PDGF, FGF, and CSF1R. CSF1R (macrophage colony-stimulating factor 1 receptor) is a key mediator in the activation and survival of macrophages, which are central to the fibrogenic process. By inhibiting CSF1R, nintedanib disrupts macrophage-driven profibrotic signaling and reduces fibroblast recruitment and activation, thus mitigating progression of fibrosis. Although nintedanib affects additional targets, blockade of CSF1R is crucial for modulating the inflammatory and fibrotic pathways central to IPF pathogenesis. Understanding nintedanib’s multi-targeted approach, especially its inhibition of CSF1R, is essential to appreciating how it alters disease biology in IPF.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_c99d2e095252",
      "question": "In ClinicalTrials.gov, which completed interventional phase 2 studies for multiple myeloma involving carfilzomib started in August 2007 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "overallStatus=COMPLETED;phases=PHASE2;conditions=Multiple Myeloma;interventions.name=carfilzomib;startDateFrom=2007-08-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00511238"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_a4262f0f38ae",
      "question": "A 67-year-old man with a history of ischemic heart disease is brought to the emergency department after suddenly developing palpitations and lightheadedness. His ECG reveals a wide-complex tachycardia consistent with sustained ventricular tachycardia. After standard therapies prove ineffective, he is given an intravenous agent known for its strong affinity for divalent cations in plasma. Shortly after administration, his arrhythmia resolves. Which molecular mechanism best explains how this agent exerts its antiarrhythmic effect in this setting?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Ventricular tachycardia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0042514",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0013618",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Calcium chelation (reduction of free extracellular calcium)",
      "reasoning_path": "Ventricular tachycardia is driven by abnormal ion flux; a chelating agent like edetic acid binds extracellular calcium, reducing its availability, which stabilizes cardiac action potentials and suppresses arrhythmias.",
      "umls_path": [
        "Ventricular tachycardia",
        "may_be_treated_by",
        "Edetic acid",
        "has_mechanism_of_action",
        "Calcium Chelating Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In ventricular tachycardia, abnormal cardiac myocyte excitability and conduction often stem from disordered ion flux, particularly involving calcium. The administered agent in this scenario is a chelating compound with high affinity for divalent cations, such as calcium. By binding extracellular calcium, the agent reduces the availability of free calcium ions necessary for myocardial depolarization and contraction. Lowering extracellular calcium dampens the inward calcium current during cardiac action potentials, thereby stabilizing myocyte membranes and reducing arrhythmogenic activity. This mechanism is distinct from traditional antiarrhythmic drugs, as it directly alters the ionic environment rather than blocking specific ion channels. Thus, the therapeutic effect in this case is most directly explained by the drug’s calcium chelating activity, which decreases cardiac excitability and can terminate certain ventricular arrhythmias.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_4f02ede01ee9",
      "question": "In ClinicalTrials.gov, which completed interventional phase 3 studies that started in December 2006 investigated atrial fibrillation, stroke, or embolism with Rivaroxaban as an intervention in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "overallStatus=COMPLETED;phases=PHASE3;startDateFrom=2006-12-01;conditions=Atrial Fibrillation,Stroke,Embolism;interventions.name=Rivaroxaban;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00403767"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_ea6f0913bf6c",
      "question": "A 7-year-old child presents with multiple small, dome-shaped, umbilicated papules on the trunk, which have persisted for several months with mild pruritus but no systemic symptoms. The dermatologist applies a topical agent in-office that induces blistering of the lesions by disrupting crucial protein functions within keratinocytes, ultimately leading to cell lysis and lesion resolution. Which pharmacologic class best describes the mechanism of action of this agent?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Molluscum contagiosum"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0026393",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0006886",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme Inhibitors",
      "reasoning_path": "Molluscum contagiosum → treated with cantharidin → cantharidin inhibits keratinocyte enzymes → enzyme inhibition leads to blistering and resolution of lesions.",
      "umls_path": [
        "Molluscum contagiosum",
        "may_be_treated_by",
        "Cantharidin",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This child’s skin lesions are consistent with molluscum contagiosum, a viral infection often seen in children. Cantharidin is a topical therapy frequently used to treat these lesions. It works by inhibiting specific enzymes within epidermal cells, particularly serine proteases involved in cell adhesion and protein structure maintenance. This enzymatic inhibition leads to the breakdown of desmosomal proteins, resulting in acantholysis (loss of cell-to-cell adhesion) and subsequent blister formation. The immune response to the blisters then helps clear the viral infection. Thus, the therapeutic effect is mediated by the enzyme-inhibiting properties of cantharidin, making 'enzyme inhibitors' the correct pharmacologic class for its mechanism of action.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_c5ed3fdb837c",
      "question": "A 34-year-old sheep farmer presents with fever, right upper quadrant abdominal pain, and eosinophilia. Imaging reveals hepatic lesions, and serologic testing confirms infection with a liver fluke. The patient is prescribed an oral antiparasitic agent whose therapeutic effect relies on inhibition of a specific hepatic enzyme involved in xenobiotic metabolism. Through which class of enzyme inhibitors does this drug exert its primary antiparasitic action, potentially altering the metabolism of other co-administered drugs?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Fascioliasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0015652",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0077071",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cytochrome P450 2A6 inhibitors",
      "reasoning_path": "Fascioliasis → treated with triclabendazole → acts via CYP2A6 inhibition → affects both antiparasitic efficacy and drug metabolism.",
      "umls_path": [
        "Fascioliasis",
        "may_be_treated_by",
        "Triclabendazole",
        "has_mechanism_of_action",
        "Cytochrome P450 2A6 Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has acute fascioliasis, a parasitic infection caused by Fasciola hepatica. The first-line treatment for fascioliasis is triclabendazole. The drug’s antiparasitic mechanism involves disruption of microtubule function in the parasite and, importantly, inhibition of the host's cytochrome P450 2A6 (CYP2A6) enzyme. By inhibiting CYP2A6, triclabendazole interferes with the parasite’s detoxification pathways and can also impact the metabolism of other drugs processed by this hepatic enzyme. Understanding this mechanism is crucial because CYP2A6 inhibition may increase levels of medications metabolized by this pathway, leading to potential drug-drug interactions. Thus, the relevant enzyme class involved in triclabendazole’s mechanism is the cytochrome P450 2A6 inhibitors.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_35187bb9bc77",
      "question": "A 54-year-old man with a history of bicuspid aortic valve presents with fever, malaise, and new-onset heart murmur. Blood cultures grow Enterococcus faecalis. After starting intravenous penicillin G, his physician adds a second antibiotic to increase bactericidal activity by exploiting synergistic effects through inhibition of bacterial protein production at the ribosomal level. Which pharmacological class best describes the mechanism of action of this adjunctive antibiotic?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Endocarditis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0014118",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002499",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Protein synthesis inhibitors",
      "reasoning_path": "Patient has endocarditis; aminoglycoside is added for synergy; aminoglycosides work by binding the 30S ribosomal subunit and inhibiting bacterial protein synthesis; this defines them as protein synthesis inhibitors.",
      "umls_path": [
        "Endocarditis",
        "may_be_treated_by",
        "Amikacin-containing product",
        "has_mechanism_of_action",
        "Protein Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with infective endocarditis due to Enterococcus faecalis is being treated with penicillin G and an added aminoglycoside. Aminoglycosides (e.g., gentamicin) are used in combination with cell wall-active agents for certain endocarditis cases because they enhance bactericidal activity through a synergistic mechanism. Aminoglycosides act by binding to the 30S subunit of the bacterial ribosome, causing misreading of mRNA and inhibition of protein synthesis, which ultimately leads to bacterial cell death. This mechanism classifies aminoglycosides as protein synthesis inhibitors. Their action is distinct from cell wall synthesis inhibitors (e.g., beta-lactams) and is critical in infections where dual therapy provides superior outcomes, such as enterococcal endocarditis.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_146291856001",
      "question": "In a patient with non-small cell lung cancer presenting with a solitary pulmonary nodule in the same lobe as the primary tumor (T3, N1), and biopsy-proven synchronous lesions raising suspicion for multiple primary lung cancers, but with no evidence of extrathoracic disease on FDG-PET/CT and brain MRI, does the presence of multiple lesions necessarily alter the treatment strategy compared to a single T3, N1 lesion?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
              "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "No disease outside of chest",
              "Pathologic mediastinal lymph node evaluation",
              "N0–1",
              "Initial Treatment (NSCL-12)"
            ]
          }
        }
      ],
      "answer": "If biopsy confirms synchronous multiple primary lung cancers without extrathoracic disease, management may diverge from the standard T3, N1 solitary lesion pathway. Each lesion must be evaluated individually for resectability and staging, and treatment should be tailored to address each primary, rather than applying a uniform strategy for a single T3, N1 tumor.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_84a2bf6133b6",
      "question": "A 44-year-old woman develops widespread pruritic wheals and facial swelling within hours after receiving an injection of heterologous antitoxin for suspected rabies exposure. She is administered an intramuscular corticosteroid with a prolonged duration of action to control her symptoms. This medication exerts its primary therapeutic effect by binding to a cytoplasmic receptor that modulates gene transcription, broadly suppressing inflammatory and immune responses. Which type of receptor does this drug target to achieve its clinical benefit in this hypersensitivity reaction?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Urticaria caused by serum"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0036830",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0077004",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Glucocorticoid receptor",
      "reasoning_path": "Serum therapy causes a hypersensitivity reaction (urticaria). Triamcinolone hexacetonide is given. Its anti-inflammatory action comes from agonism of intracellular glucocorticoid receptors, which modulate gene expression to suppress immune responses.",
      "umls_path": [
        "Urticaria caused by serum",
        "may_be_treated_by",
        "Triamcinolone Hexacetonide",
        "has_mechanism_of_action",
        "Glucocorticoid Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient is experiencing serum sickness–related urticaria, a type III hypersensitivity reaction following exposure to foreign serum proteins. Triamcinolone hexacetonide, a long-acting synthetic glucocorticoid, is administered to suppress the immune-mediated inflammation underlying her symptoms. This drug diffuses into target cells and binds to cytoplasmic glucocorticoid receptors, forming a complex that translocates to the nucleus. There, it alters the transcription of numerous genes, downregulating pro-inflammatory cytokines and upregulating anti-inflammatory mediators. The net result is broad suppression of immune cell activation, vascular permeability, and mediator release, effectively controlling urticaria and angioedema. Thus, the primary pharmacological effect is mediated by agonism of glucocorticoid receptors, not histamine or adrenergic receptors.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_3fa611ce3b7a",
      "question": "In a patient newly diagnosed with non-small cell lung cancer (NSCLC), presenting simultaneously with a primary tumor in one lung and a solitary pulmonary nodule in the contralateral lung (clinical stage IVA: N0, M1a), is it appropriate to consider treatment as for two independent primary lung cancers if both lesions are deemed curable?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
              "Pathologic Diagnosis of NSCLC",
              "Clinical Stage",
              "Multiple lung cancers",
              "Treatment (NSCL-12)"
            ]
          }
        }
      ],
      "answer": "Yes, in the presence of a solitary pulmonary nodule in the contralateral lung in an otherwise potentially curable setting (stage IVA: N0, M1a), current clinical practice supports treating these as two primary lung tumors, provided both are amenable to curative intent interventions.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_ec48de55ae0d",
      "question": "A 68-year-old woman presents with bone pain and an elevated alkaline phosphatase level. Radiographs reveal mixed lytic and sclerotic lesions in the pelvis and femur, consistent with a diagnosis of disorganized bone remodeling. Her physician prescribes a hormone therapy known to directly inhibit the activity of cells responsible for bone resorption. This medication binds to and affects which key structural component within the bone matrix to achieve its therapeutic effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Paget disease of bone"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0029401",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0006668",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Structural macromolecules (such as collagen) in the bone matrix",
      "reasoning_path": "Paget disease involves excessive osteoclast-mediated bone resorption; calcitonin inhibits osteoclasts, reducing breakdown of structural macromolecules (collagen) in the bone matrix.",
      "umls_path": [
        "Paget disease of bone",
        "may_be_treated_by",
        "calcitonin",
        "has_mechanism_of_action",
        "Structural Macromolecules"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Paget disease of bone is characterized by abnormal, excessive bone turnover due to increased osteoclastic activity, leading to disorganized bone architecture. Calcitonin is a hormone therapy sometimes used in this condition because it directly inhibits osteoclasts, the cells responsible for bone resorption. Osteoclasts mediate bone breakdown by acting on structural macromolecules—primarily collagen and other proteins—within the bone matrix. By binding to osteoclast receptors, calcitonin reduces the resorptive activity of these cells, thereby decreasing the degradation of the bone’s structural proteins. The net effect is a reduction in bone turnover, which alleviates symptoms and helps normalize bone remodeling. Therefore, the molecular target relevant to this drug’s action is the structural macromolecules, such as collagen, that make up the bone matrix.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_c5e8ef36035f",
      "question": "A 68-year-old woman with a history of COPD is admitted to the hospital with fever, productive cough, and shortness of breath. Chest radiography reveals a right lower lobe infiltrate. She is started on an intravenous antibiotic that targets the synthesis of bacterial cell walls by binding and inactivating penicillin-binding proteins in the periplasmic space of the pathogen. This drug’s clinical benefit in her infection derives from which class of molecular action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Pneumonia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0032285",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1882383",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Transpeptidase inhibitors",
      "reasoning_path": "Pneumonia → empiric beta-lactam therapy → binds penicillin-binding proteins → blocks transpeptidase activity → inhibits cell wall synthesis → bacterial lysis and infection control.",
      "umls_path": [
        "Pneumonia",
        "may_be_treated_by",
        "Piperacillin anhydrous",
        "has_mechanism_of_action",
        "Transpeptidase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient is being treated for community-acquired pneumonia, likely caused by Streptococcus pneumoniae or other typical respiratory pathogens. Beta-lactam antibiotics, such as penicillins and cephalosporins, are standard empiric therapy. These drugs exert their antibacterial effect by binding to and inhibiting transpeptidase enzymes (also known as penicillin-binding proteins), which catalyze the final cross-linking steps of peptidoglycan synthesis—a critical component of the bacterial cell wall. Inhibiting transpeptidases weakens the cell wall, leading to osmotic instability and bacterial cell lysis. This mechanism is highly specific to bacteria, as mammalian cells lack peptidoglycan and associated enzymes, explaining the favorable therapeutic index of beta-lactams. Thus, the most relevant drug action class that mediates the effect of beta-lactams in treating pneumonia is transpeptidase inhibition.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_0c349cd10951",
      "question": "A 32-year-old woman is admitted for management of persistent vaginal bleeding several weeks after a molar pregnancy was diagnosed and evacuated. Ultrasound reveals retained intrauterine tissue. Her clinician selects a pharmacologic agent to induce uterine contractions and facilitate expulsion of the remaining trophoblastic tissue. This medication is a synthetic analog of a naturally occurring lipid compound that binds to specific G-protein-coupled receptors on myometrial cells. Which molecular mechanism most directly accounts for the therapeutic effect of this agent in promoting uterine evacuation in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Gestational trophoblastic disease"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2931618",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0012472",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Agonism of prostaglandin (EP) receptors",
      "reasoning_path": "Retained trophoblastic tissue requires uterine evacuation; dinoprostone, a PGE2 analog, activates prostaglandin (EP) receptors on myometrial cells, leading to uterine contractions and expulsion of tissue.",
      "umls_path": [
        "Gestational trophoblastic disease",
        "may_be_treated_by",
        "Dinoprostone-containing product",
        "has_mechanism_of_action",
        "Prostaglandin Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient is experiencing retained gestational trophoblastic tissue after a molar pregnancy. The primary clinical goal is to induce uterine contractions to expel this tissue pharmacologically. Dinoprostone is a synthetic analog of prostaglandin E2 (PGE2), a naturally occurring lipid mediator. Dinoprostone binds to and activates prostaglandin E (EP) receptors on uterine smooth muscle cells. Activation of these G-protein-coupled receptors stimulates intracellular signaling pathways that increase intracellular calcium, leading to myometrial contractions and cervical ripening. These effects facilitate the expulsion of retained trophoblastic tissue. The therapeutic benefit in this context is thus directly mediated by agonism of prostaglandin receptors, which is exploited by dinoprostone-containing products. This mechanism distinguishes prostaglandin analogs from other uterotonic agents such as oxytocin or ergot derivatives, which act via different receptors.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_ef60e593c48b",
      "question": "For a patient with stage IIIA (T1–2, N2) non-small cell lung cancer who underwent definitive chemoradiation and currently has no clinical or radiographic evidence of disease, is brain MRI with contrast indicated as part of routine surveillance in the absence of neurological symptoms?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
              "R2; Concurrent chemoradiation",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, routine brain MRI with contrast is not indicated for surveillance in asymptomatic patients with stage IIIA non-small cell lung cancer post-definitive chemoradiation and no evidence of disease. Imaging of the brain is reserved for cases with neurological symptoms or clinical suspicion of recurrence.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_a770cf78a6f3",
      "question": "A 62-year-old man with a history of hypertension and hyperlipidemia presents to his primary care physician with acute pain and swelling in his right first metatarsophalangeal joint. Laboratory evaluation reveals elevated serum uric acid levels, and he is diagnosed with gout. He reports self-medicating with an over-the-counter anti-inflammatory that contains acetylsalicylic acid. His symptoms have not improved, and his physician explains that certain anti-inflammatory medications can worsen gout by interacting with an enzyme involved in prostaglandin synthesis and urate excretion. Which enzyme is directly inhibited by this class of drugs, thereby influencing both inflammation and uric acid handling in the setting of gout?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Gout, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0018099",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004057",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 2 (COX-2)",
      "reasoning_path": "Patient with gout took aspirin, which inhibits Prostaglandin G/H Synthase 2 (COX-2); this affects prostaglandin synthesis and uric acid excretion, explaining why aspirin is not recommended in gout management.",
      "umls_path": [
        "Gout, unspecified",
        "may_be_treated_by",
        "Aspirin-containing product",
        "has_target",
        "Prostaglandin G/H Synthase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient’s gout flare—a manifestation of monosodium urate crystal deposition—can be exacerbated by medications that affect uric acid excretion or promote inflammation. Aspirin (acetylsalicylic acid) is an anti-inflammatory drug that inhibits the enzyme Prostaglandin G/H Synthase 2 (also known as cyclooxygenase-2, or COX-2). Inhibition of this enzyme decreases prostaglandin synthesis, reducing inflammation but also influencing renal urate handling. At low doses, aspirin decreases uric acid excretion, potentially worsening hyperuricemia and gout. Higher doses, which are used less commonly due to toxicity, can have uricosuric effects but are not recommended. The primary molecular target for aspirin’s anti-inflammatory action is therefore Prostaglandin G/H Synthase 2. For gout, nonsteroidal anti-inflammatory drugs (NSAIDs) that do not significantly impair uric acid excretion—such as indomethacin—are preferred. Understanding the mechanism of aspirin’s target enzyme is crucial for selecting appropriate therapy in patients with gout.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_46aa000e6f42",
      "question": "A 58-year-old man presents with gradual vision changes and brownish deposits at the corneal margin observed on slit-lamp examination. He has a history of chronic anemia treated with repeated blood transfusions. The ophthalmologist suspects a corneal disorder associated with metal accumulation and prescribes a medication administered via eye drops that binds metal ions, forming stable complexes that are then excreted. Which molecular mechanism best explains how this treatment alleviates his ocular symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Unspecified corneal disorder"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0010034",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011148",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Iron chelation—deferoxamine binds excess iron, preventing iron-mediated oxidative damage in corneal tissue",
      "reasoning_path": "Corneal iron accumulation causes oxidative damage; deferoxamine chelates iron, lowering local iron levels and preventing further injury.",
      "umls_path": [
        "Unspecified corneal disorder",
        "may_be_treated_by",
        "Deferoxamine Mesylate",
        "has_mechanism_of_action",
        "Iron Chelating Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient exhibits signs of corneal iron deposition (e.g., brownish rings), likely from chronic transfusional iron overload. Accumulation of free iron in ocular tissues promotes generation of reactive oxygen species via Fenton chemistry, resulting in oxidative stress and cellular injury. Deferoxamine is a chelating agent that binds ferric iron (Fe3+), forming a water-soluble complex that is readily eliminated from the body. By sequestering excess iron, deferoxamine reduces oxidative damage to corneal cells and can halt or reverse vision changes associated with iron deposition. This mechanism underlies its therapeutic use in corneal disorders linked to iron overload, as well as in systemic iron toxicity. Thus, the primary pharmacological action in this context is iron chelation, which interrupts the pathogenic process of iron-induced tissue injury.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_8f202e38254d",
      "question": "For a patient with stage I non–small cell lung cancer (NSCLC) who received primary treatment consisting solely of surgery, if persistent, unexplained radiographic abnormalities appear during routine follow-up, is more frequent imaging required even in the absence of symptoms?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
              "R1; Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Severe hemoptysis",
              "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, in the presence of residual or new radiographic abnormalities during follow-up after surgery for stage I NSCLC, more frequent imaging is warranted to promptly detect recurrence or progression, regardless of the presence of symptoms. Regular surveillance intervals may not be sufficient in this scenario.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_f70290dee120",
      "question": "For a patient with Stage IA (T1abc, N0) non–small cell lung cancer who has positive surgical margins (R1 or R2), is it appropriate to proceed with radiotherapy as definitive local treatment if the patient is not a candidate for re-resection?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (T1abc, N0); Margins positive (R1, R2)",
              "Resection (preferred) or RT (category 2B)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes; for Stage IA (T1abc, N0) non–small cell lung cancer patients with positive margins (R1 or R2) who cannot undergo further surgical resection, radiotherapy is an accepted alternative local treatment, although it is considered a category 2B recommendation and may have less robust supporting evidence compared to re-resection.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_8afe8d1a71b4",
      "question": "A 42-year-old woman presents with fatigue, weight loss, and hyperpigmentation. Laboratory evaluation reveals hyponatremia, hyperkalemia, low morning cortisol, and elevated ACTH. She is diagnosed with primary adrenal insufficiency and started on a synthetic corticosteroid. This agent not only replaces deficient glucocorticoids but also suppresses pro-inflammatory eicosanoid production by inhibiting an enzyme critical in leukotriene synthesis. Which enzyme is directly inhibited by this medication, contributing to its anti-inflammatory effects in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Addison's Disease"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001403",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0113286",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lipoxygenase",
      "reasoning_path": "Addison’s disease causes cortisol deficiency; dexamethasone restores glucocorticoid function and suppresses inflammation partly by inhibiting lipoxygenase, reducing leukotriene-mediated inflammatory responses.",
      "umls_path": [
        "Addison's Disease",
        "may_be_treated_by",
        "Dexamethasone Sodium Phosphate",
        "has_mechanism_of_action",
        "Lipoxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In primary adrenal insufficiency (Addison's disease), patients lack adequate endogenous cortisol, a hormone with significant anti-inflammatory properties. Dexamethasone sodium phosphate is a potent synthetic glucocorticoid that restores deficient cortisol activity. In addition to binding glucocorticoid receptors and modulating gene transcription, dexamethasone exerts its anti-inflammatory effects by inhibiting enzymes involved in eicosanoid synthesis. Specifically, it inhibits lipoxygenase, an enzyme responsible for converting arachidonic acid into leukotrienes—potent mediators of inflammation. By reducing leukotriene synthesis, dexamethasone decreases inflammatory cell recruitment and edema. This mechanism contributes to its therapeutic benefits in conditions involving inflammation, such as Addison’s disease, where immune-mediated destruction of the adrenal cortex is common. Thus, the inhibition of lipoxygenase is a key pharmacological action of dexamethasone’s anti-inflammatory profile, in addition to its classic genomic effects.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_6c2d3f82466d",
      "question": "A 52-year-old woman presents with widespread erythema and scaling involving over 90% of her body surface area, accompanied by pruritus and malaise. She is diagnosed with erythroderma and started on systemic therapy to rapidly control inflammation. The prescribed medication is known to suppress the production of pro-inflammatory mediators, in part by inhibiting the synthesis of leukotrienes through a specific enzymatic pathway. Which enzyme pathway targeted by this agent is most directly responsible for the reduction in leukotriene-mediated inflammation in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Erythroderma"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011606",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0010137",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lipoxygenase pathway inhibition",
      "reasoning_path": "Erythroderma leads to severe inflammation; corticosteroids inhibit phospholipase A2, reducing arachidonic acid; this decreases leukotriene synthesis via the lipoxygenase pathway, which diminishes inflammation.",
      "umls_path": [
        "Erythroderma",
        "may_be_treated_by",
        "Therapeutic Cortisone",
        "has_mechanism_of_action",
        "Lipoxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Erythroderma is a severe inflammatory skin disorder often requiring systemic corticosteroids for rapid symptom control. The anti-inflammatory action of corticosteroids involves suppression of multiple pathways, including the inhibition of phospholipase A2, which leads to decreased production of arachidonic acid. This, in turn, reduces the synthesis of downstream inflammatory mediators such as prostaglandins and leukotrienes. Specifically, corticosteroids decrease leukotriene production by inhibiting the lipoxygenase pathway, which converts arachidonic acid into leukotrienes—key contributors to inflammation, vasodilation, and leukocyte recruitment. By limiting leukotriene synthesis, corticosteroids help control the widespread inflammation seen in erythroderma. Thus, the inhibition of the lipoxygenase pathway is a critical mechanism underlying the therapeutic effect of corticosteroids in this setting.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_ed0cb39c2117",
      "question": "A 22-year-old woman with transfusion-dependent anemia presents for enrollment in a clinical trial for a novel therapy. Genetic testing confirmed a diagnosis of a hemoglobinopathy characterized by reduced beta-globin chain synthesis. The investigational agent she receives is known to increase fetal hemoglobin levels by altering chromatin structure and gene transcription through epigenetic modification. Which molecular target is primarily responsible for mediating this drug’s effect on globin gene expression?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Beta thalassemia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0005283",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0718066",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Histone deacetylase",
      "reasoning_path": "Beta thalassemia → need to increase HbF → drug inhibits HDAC → increased histone acetylation → upregulation of gamma-globin gene transcription → increased HbF → improved anemia.",
      "umls_path": [
        "Beta thalassemia",
        "may_be_treated_by",
        "Sodium Phenylbutyrate",
        "has_target",
        "Histone Deacetylase"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient with beta thalassemia has insufficient beta-globin chain production, leading to severe anemia. Increasing fetal hemoglobin (HbF) levels can compensate for this deficiency. Certain agents, such as sodium phenylbutyrate, are being investigated for their ability to induce HbF by modifying chromatin structure. These drugs act by inhibiting histone deacetylases (HDACs), enzymes that remove acetyl groups from histone proteins, resulting in a more condensed, transcriptionally inactive chromatin state. HDAC inhibition leads to increased histone acetylation, relaxing chromatin and promoting transcription of genes, including those encoding gamma-globin chains (a component of HbF). By targeting HDACs, these agents upregulate fetal hemoglobin production, thus mitigating the clinical severity of beta thalassemia. Therefore, the molecular target primarily responsible for this drug’s therapeutic effect is histone deacetylase.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_f9d618795547",
      "question": "In a patient with advanced non-small cell lung cancer (NSCLC) of adenocarcinoma subtype, who has recurrence in mediastinal lymph nodes after prior radiotherapy, and whose tumor tests negative for EGFR, ALK, ROS1, and other actionable driver mutations, as well as PD-L1 expression less than 1%, is immunotherapy alone an appropriate initial systemic treatment option, or should chemotherapy be prioritized?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "PD-L1 <1% and negative for actionable molecular biomarkers above"
            ]
          }
        }
      ],
      "answer": "For advanced non-small cell lung cancer of adenocarcinoma subtype with negative actionable mutations and PD-L1 expression less than 1%, immunotherapy alone is not recommended. In this setting, platinum-based chemotherapy, either alone or in combination with immunotherapy, should be prioritized as initial systemic treatment according to standard clinical practice.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_e4942c7eaf97",
      "question": "A 54-year-old woman with a long-standing history of joint pain, morning stiffness lasting over an hour, and symmetrical swelling of her hands presents for follow-up. She reports significant improvement in pain and swelling after starting a new medication prescribed by her rheumatologist. This drug is known to selectively inhibit an inducible enzyme responsible for the conversion of arachidonic acid to pro-inflammatory prostaglandins, while sparing the constitutive isoform found in the gastrointestinal tract. Which molecular target is most directly responsible for the anti-inflammatory effect observed in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Rheumatoid arthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003873",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0083381",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 2 (COX-2)",
      "reasoning_path": "Rheumatoid arthritis causes inflammation; selective NSAIDs (e.g., meloxicam) inhibit COX-2 (prostaglandin G/H synthase 2), reducing inflammatory prostaglandin production and relieving symptoms.",
      "umls_path": [
        "Rheumatoid arthritis",
        "may_be_treated_by",
        "Meloxicam",
        "has_target",
        "Prostaglandin G/H Synthase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has rheumatoid arthritis—a chronic, autoimmune inflammatory disease primarily affecting synovial joints. Nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently used for symptomatic relief. Traditional NSAIDs inhibit both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), leading to reduced prostaglandin synthesis but also increased gastrointestinal risk due to COX-1 inhibition. Selective NSAIDs such as meloxicam or celecoxib preferentially inhibit COX-2 (prostaglandin G/H synthase 2), the inducible isoform upregulated during inflammation. COX-2 catalyzes the conversion of arachidonic acid to prostaglandins, which mediate pain, swelling, and other inflammatory responses in rheumatoid arthritis. By selectively inhibiting COX-2, these drugs decrease inflammatory prostaglandins, providing symptom relief while minimizing disruption of protective prostaglandins produced by COX-1 in the GI tract. Thus, the primary molecular target responsible for the therapeutic effect in this scenario is prostaglandin G/H synthase 2 (COX-2).",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_a8a7c55688c0",
      "question": "A 40-year-old woman is admitted for persistent vomiting and nasogastric suction following bowel obstruction surgery. Laboratory tests reveal metabolic alkalosis. Her physician prescribes a supplement containing both arginine and aspartate to support her recovery. This therapy is intended to help correct her acid-base disturbance by acting at the molecular level to influence cellular processes. Which general type of pharmacological action underlies the effect of this compound in improving her metabolic state?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Alkalosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002063",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0052327",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Biological macromolecular activity",
      "reasoning_path": "Metabolic alkalosis is treated with arginine aspartate, which acts by modulating biological macromolecules and cellular metabolic processes to help restore acid-base balance.",
      "umls_path": [
        "Alkalosis",
        "may_be_treated_by",
        "Arginine aspartate",
        "has_mechanism_of_action",
        "Biological Macromolecular Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In patients with metabolic alkalosis, the acid-base imbalance often arises from a loss of hydrogen ions (e.g., via vomiting or gastric suction), resulting in elevated blood pH. Arginine aspartate supplementation is sometimes used to help correct such disturbances. These amino acids serve as substrates and modulators for various enzymes and metabolic pathways, ultimately affecting the function of biological macromolecules (such as proteins, nucleic acids, and enzymes) in cells. By providing these substrates, the therapy can support cellular processes that help restore acid-base balance, such as enhancing renal excretion of bicarbonate or facilitating ammoniagenesis. This action is not due to a direct effect on ion channels or receptors, but rather through broader modulation of cellular metabolism and macromolecular function. Thus, the underlying pharmacological action is best classified as biological macromolecular activity.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_a7008de2e828",
      "question": "A 54-year-old woman with a history of recurrent superficial fungal skin infections presents with a new erythematous, scaly patch on her forearm. Her physician recommends a topical antiseptic agent that is known to have broad-spectrum antimicrobial properties, including activity against fungi, but whose exact molecular mechanism in the treatment of skin fungal infections is not well established. Which of the following best describes the current understanding of this agent’s cellular or molecular action in this context?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Dermatomycosis, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011630",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2826352",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown Cellular or Molecular Interaction",
      "reasoning_path": "Dermatomycosis is sometimes treated with povidone K12, but its exact molecular mechanism in this context is uncharacterized in the literature.",
      "umls_path": [
        "Dermatomycosis, unspecified",
        "may_be_treated_by",
        "Povidone K12",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this scenario, the patient is prescribed a topical antiseptic, povidone K12, for dermatomycosis. Povidone-iodine compounds are known for broad-spectrum antimicrobial activity, but the precise cellular or molecular mechanism by which povidone K12 exerts antifungal effects in human skin infections is not clearly characterized in the current literature. While its general antimicrobial effects are thought to be due to free iodine release, which disrupts microbial proteins and cell structures, specific molecular targets or pathways relevant to fungal cell death remain unconfirmed. Therefore, the best answer is that the cellular or molecular mechanism of povidone K12 in dermatomycosis is currently unknown.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_c04c2637af10",
      "question": "A 48-year-old woman presents with progressive tightening and thickening of the skin on her hands and face, accompanied by Raynaud phenomenon and mild joint discomfort. Laboratory studies reveal positive anti-centromere antibodies. She is diagnosed with limited cutaneous systemic sclerosis. To manage her symptoms and prevent disease progression, her rheumatologist prescribes an immunomodulatory agent that interferes with DNA and RNA synthesis in rapidly dividing immune cells. Which class of drug mechanisms best explains the immunosuppressive therapeutic effect of this medication in systemic sclerosis?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Systemic sclerosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0036421",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1383389",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Nucleic acid synthesis inhibitors",
      "reasoning_path": "Systemic sclerosis involves autoimmune-mediated fibrosis; immunosuppressive therapy is given to inhibit immune cell proliferation. Agents like mycophenolate mofetil or azathioprine act by inhibiting nucleic acid synthesis, suppressing lymphocyte proliferation and immune response.",
      "umls_path": [
        "Systemic sclerosis",
        "may_be_treated_by",
        "Chloroquine hydrochloride",
        "has_mechanism_of_action",
        "Nucleic Acid Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Systemic sclerosis is a chronic autoimmune connective tissue disease characterized by immune-mediated fibrosis of the skin and internal organs. Immunosuppressive therapy is often used to reduce disease activity and prevent organ involvement. Drugs such as mycophenolate mofetil, azathioprine, and methotrexate are commonly employed; these agents exert their effects by inhibiting enzymes critical for nucleic acid synthesis, such as inosine monophosphate dehydrogenase (for mycophenolate) or amidophosphoribosyltransferase (for azathioprine). By blocking DNA and RNA synthesis, these drugs preferentially suppress the proliferation of lymphocytes, which are key mediators of the autoimmune response in systemic sclerosis. This leads to reduced inflammation and tissue damage. Therefore, the class of drug mechanisms responsible for the immunosuppressive effects in this context is nucleic acid synthesis inhibition.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_9b2f3d87ae93",
      "question": "A 28-year-old pregnant woman in her second trimester is diagnosed with pelvic inflammatory disease. To avoid fetal harm, her physician selects an antibiotic that is effective against anaerobic bacteria and has a strong safety profile in pregnancy. This medication works by binding to and inactivating enzymes critical for bacterial cell wall synthesis, leading to bacterial lysis. What is the general pharmacological class describing the mechanism of action of this medication?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Infections and Pregnancy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0032965",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0700471",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme Inhibitors",
      "reasoning_path": "Pregnant patient with infection → need for safe, effective antibiotic → cephalosporin (e.g., cefotetan) chosen for anaerobic coverage and safety → mechanism is inhibition of bacterial cell wall enzymes (PBPs) → classified as enzyme inhibitor.",
      "umls_path": [
        "Infections and Pregnancy",
        "may_be_treated_by",
        "Cefotetan Disodium",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Infections during pregnancy, such as pelvic inflammatory disease, require antibiotic therapy that is both effective and safe for the developing fetus. Cephalosporins—specifically second-generation agents like cefotetan—are often chosen due to their broad spectrum, including anaerobic coverage, and established safety profile in pregnancy. These agents exert their antibacterial effect by binding to and inhibiting penicillin-binding proteins (PBPs), which are bacterial enzymes essential for the cross-linking of peptidoglycan strands in the cell wall. This inhibition disrupts cell wall synthesis, ultimately causing bacterial cell death via lysis. Since the drug's primary action is through the inhibition of enzymatic activity required for cell wall construction, it is classified pharmacologically as an enzyme inhibitor. This mechanism underlies the clinical efficacy and safety of cephalosporins like cefotetan in treating infections during pregnancy.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_32c12bfc63a9",
      "question": "A 22-year-old woman presents with severe lower abdominal cramping and pelvic pain that occurs predictably during the first two days of her menstrual period each month. She states the pain is so intense that it interferes with her daily activities, but she finds significant relief when taking an over-the-counter medication for pain. This medication is known to act by blocking a key enzyme responsible for the conversion of arachidonic acid into pro-inflammatory mediators that stimulate uterine contractions. Which molecular target is primarily inhibited by this medication to alleviate her symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Dysmenorrhea"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0013390",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020740",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 2 (COX-2)",
      "reasoning_path": "Dysmenorrhea is mediated by prostaglandin-induced uterine contractions; ibuprofen inhibits prostaglandin G/H synthase 2 (COX-2), reducing prostaglandin synthesis and alleviating pain.",
      "umls_path": [
        "Dysmenorrhea",
        "may_be_treated_by",
        "Ibuprofen",
        "has_target",
        "Prostaglandin G/H Synthase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "The patient's symptoms are consistent with primary dysmenorrhea, which is commonly caused by excessive production of uterine prostaglandins during menstruation. Prostaglandins, notably prostaglandin F2α, increase uterine contractions and pain. Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), provides symptomatic relief by inhibiting the enzyme prostaglandin G/H synthase 2 (COX-2). This enzyme catalyzes the conversion of arachidonic acid to prostaglandin H2, an essential precursor of various prostaglandins. By blocking COX-2, ibuprofen reduces prostaglandin synthesis, thereby decreasing uterine muscle contractions, local inflammation, and pain. Although ibuprofen also inhibits COX-1, its therapeutic effect in dysmenorrhea is primarily due to COX-2 inhibition in endometrial and uterine tissues. Thus, the primary molecular target for symptom relief in this scenario is prostaglandin G/H synthase 2 (COX-2).",
      "type": "kg_reasoning"
    },
    {
      "id": "path_360fef91e947",
      "question": "In a patient with unresectable stage IIIB (T4, N2) non-small cell lung cancer confirmed by mediastinoscopy, who has completed definitive concurrent chemoradiation, is durvalumab consolidation therapy appropriate if the patient harbors an EGFR exon 19 deletion mutation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
              "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Contralateral mediastinal node positive (T4, N3)",
              "Definitive concurrent chemoradiation (category 1)",
              "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)"
            ]
          }
        }
      ],
      "answer": "Durvalumab consolidation is not the standard approach for patients with EGFR exon 19 deletion mutation after chemoradiation; instead, osimertinib is preferred as consolidation therapy, reflecting evidence for targeted benefit in this molecular subgroup.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_c3dc09fb64b9",
      "question": "In a patient diagnosed with stage IIIB non-small cell lung cancer (defined as T1–2, N3) who has not yet undergone pathologic confirmation of N3 disease, is it acceptable to proceed directly to systemic therapy without invasive nodal biopsy such as mediastinoscopy, EBUS, or needle biopsy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, systemic therapy initiation for stage IIIB non-small cell lung cancer is contingent upon pathologic confirmation of N3 disease using invasive modalities like mediastinoscopy, EBUS, or needle biopsy. Imaging alone is insufficient; pathologic verification of mediastinal or supraclavicular nodal involvement is a mandatory prerequisite for this treatment decision.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_330da861c40a",
      "question": "For a patient with stage I non–small cell lung cancer (T1, N0) who is deemed medically inoperable due to high surgical risk after evaluation by a thoracic surgeon, does the recommendation of definitive radiation therapy, preferably stereotactic ablative radiotherapy (SABR), implicitly exclude the use of surgical resection as a primary treatment option?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Nodes negative",
              "Treatment (NSCL-9)",
              "T1, N0",
              "Medically inoperable, high surgical risk as determined by thoracic surgeroni, and those who decline surgery after thoracic surgical consultation",
              "Definitive RT, preferably SABR",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)"
            ]
          }
        }
      ],
      "answer": "Yes, in patients with stage I (T1, N0) non–small cell lung cancer who are medically inoperable or have high surgical risk as determined by a thoracic surgeon, definitive radiation therapy—preferably SABR—is the standard approach, and surgical resection is not considered a viable primary treatment option in these circumstances.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_abc71a0ac732",
      "question": "A 48-year-old man with a history of severe, recurrent, unilateral headaches accompanied by tearing and nasal congestion is diagnosed with a chronic primary headache disorder. He is started on a medication administered intranasally during acute attacks. Shortly after, he experiences severe limb pain and pallor following the addition of a new oral antifungal agent. Laboratory evaluation reveals no evidence of infection or thrombosis. Which drug class likely interacted with his headache medication to precipitate these symptoms, and what is the molecular mechanism underlying this adverse interaction?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Chronic cluster headache"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0009088",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0771983",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cytochrome P450 3A inhibitors; these agents inhibit the metabolism of dihydroergotamine, leading to elevated plasma levels and increased risk of vasoconstrictive complications.",
      "reasoning_path": "Dihydroergotamine is metabolized by CYP3A; CYP3A inhibitors reduce its clearance, causing toxic vasoconstriction.",
      "umls_path": [
        "Chronic cluster headache",
        "may_be_treated_by",
        "dihydroergotamine tartrate",
        "has_mechanism_of_action",
        "Cytochrome P450 3A Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is being treated for chronic cluster headache with dihydroergotamine, an ergot alkaloid that acts as an agonist at serotonergic and adrenergic receptors, causing vasoconstriction to abort headache attacks. Dihydroergotamine is primarily metabolized by hepatic cytochrome P450 3A (CYP3A) enzymes. When potent CYP3A inhibitors—such as certain azole antifungals—are co-administered, they markedly decrease the metabolic clearance of dihydroergotamine. This results in dangerously elevated plasma concentrations of the drug, greatly increasing its vasoconstrictive effects. The resultant excessive vasoconstriction can manifest as limb ischemia, pain, and pallor, as seen in this patient. The central mechanistic pathway involves CYP3A inhibition leading to reduced drug metabolism and heightened risk of serious adverse vascular events. Therefore, CYP3A inhibitors are contraindicated with dihydroergotamine due to this well-characterized pharmacokinetic and pharmacodynamic interaction.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_aac63d690e59",
      "question": "For a patient with localized, invasive, non-inflammatory, non-metastatic (M0) breast cancer, who is cT1c, cN0 and has HER2-negative and hormone receptor-negative (triple-negative) disease, does the presence of a comorbid moderate renal insufficiency (eGFR 35 mL/min/1.73m²) affect candidacy for preoperative systemic therapy as per standard criteria?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS not possible",
              "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
              "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
              "Any ypN+: RT is indicated to the chest wall + comprehensive RNI with inclusion of any portion of the undissected axilla at risk."
            ]
          }
        }
      ],
      "answer": "Moderate renal insufficiency (eGFR 35 mL/min/1.73m²) does not inherently preclude preoperative systemic therapy in triple-negative, localized breast cancer, but it may require selection or dose adjustment of certain chemotherapeutic agents. Careful regimen choice and monitoring are necessary, but systemic therapy remains indicated based on tumor subtype and stage.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_b761213b2015",
      "question": "In a patient with stage II non-small cell lung cancer who underwent definitive radiotherapy as primary treatment, does the recommended surveillance frequency in the first three years differ from a patient with stage II disease who received surgery with or without chemotherapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, the recommended surveillance frequency differs: after definitive radiotherapy, follow-up with history and physical examination plus chest CT (with or without contrast) is every 3–6 months for the first 3 years. In contrast, for surgical patients (with or without chemotherapy), surveillance is every 6 months for 2–3 years.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_feb78e391e7e",
      "question": "A 32-year-old man presents with slowly enlarging, painless ulcerative lesions on his genitalia. He reports no recent travel but is sexually active with multiple partners. Physical examination reveals beefy red, granulomatous ulcers without lymphadenopathy. A tissue smear shows intracellular bacteria with a safety-pin appearance. He is started on an oral medication that binds to the 30S ribosomal subunit, blocking aminoacyl-tRNA attachment and thereby halting bacterial protein elongation. Which general pharmacological class does this agent belong to, based on its primary mechanism of action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Granuloma inguinale"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0018190",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0058731",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Protein synthesis inhibitors",
      "reasoning_path": "Granuloma inguinale → treated with doxycycline → doxycycline binds 30S ribosomal subunit → inhibits protein synthesis → classified as a protein synthesis inhibitor.",
      "umls_path": [
        "Granuloma inguinale",
        "may_be_treated_by",
        "Doxycycline Hyclate",
        "has_mechanism_of_action",
        "Protein Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has features consistent with granuloma inguinale (donovanosis), a sexually transmitted infection caused by Klebsiella (Calymmatobacterium) granulomatis. The first-line treatment is doxycycline hyclate. Doxycycline is a bacteriostatic antibiotic that exerts its effect by binding to the 30S subunit of the bacterial ribosome. This binding prevents the attachment of aminoacyl-tRNA to the mRNA-ribosome complex, thereby inhibiting the addition of new amino acids to the growing peptide chain. As a result, bacterial protein synthesis is disrupted, inhibiting bacterial growth and replication. Antibiotics with this mechanism are classified as protein synthesis inhibitors, which include tetracyclines, macrolides, aminoglycosides, and others. Thus, the correct pharmacological class for doxycycline, in the context of treating granuloma inguinale, is protein synthesis inhibitors.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_1764c61990b3",
      "question": "A 45-year-old woman presents with proximal muscle weakness and myalgias. Laboratory testing reveals elevated creatine kinase and positive anti-Jo-1 antibodies, confirming a diagnosis of inflammatory myopathy. To manage her muscle discomfort and spasms, her physician prescribes a centrally acting muscle relaxant typically used for musculoskeletal pain, even though its mechanism is not fully understood. Which best describes the current understanding of this drug’s molecular mechanism as it relates to its use in this patient’s condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Myositis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0027121",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0025659",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "A patient with myositis is treated with methocarbamol for muscle relaxation. Unlike other muscle relaxants, methocarbamol's exact cellular or molecular mechanism of action remains unidentified.",
      "umls_path": [
        "Myositis",
        "may_be_treated_by",
        "Methocarbamol",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Methocarbamol is a centrally acting muscle relaxant commonly prescribed for symptomatic relief of muscle spasms or discomfort, including in patients with inflammatory myopathies such as polymyositis or dermatomyositis. However, despite its widespread use, the precise cellular or molecular pathway by which methocarbamol reduces muscle spasm remains undetermined. Unlike agents with well-characterized actions (such as baclofen, a GABA-B agonist, or tizanidine, an alpha-2 adrenergic agonist), methocarbamol’s action is presumed to be central but lacks a clearly identified receptor or molecular target. This uncertainty is reflected in clinical guidelines and pharmacologic references, which acknowledge symptomatic benefit but also emphasize the unknown nature of its mechanism. Thus, when considering its use in inflammatory myopathies, clinicians rely on empirical evidence of efficacy rather than a defined mechanistic rationale.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_7c38f90f0150",
      "question": "What is the PMID of the article titled “A rare case of rectal malignant melanoma with long-term survival: case report and literature review,” authored by Huang H and published in the World Journal of Surgical Oncology in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"A rare case of rectal malignant melanoma with long-term survival\"[ti] AND Huang H[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40483466"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_4446dd5fdd7f",
      "question": "For a patient with stage IIA (T2b, N0) non-small cell lung cancer who underwent complete surgical resection but has positive margins (R1 or R2), is adjuvant external-beam radiotherapy routinely indicated regardless of prior chemotherapy administration, or is its use limited to specific clinical scenarios?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIA (T2b, N0); Margins positive (R1, R2)",
              "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Severe hemoptysis",
              "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Adjuvant external-beam radiotherapy after surgery with positive margins (R1 or R2) in stage IIA non-small cell lung cancer is not routinely indicated for all patients; its use is typically considered in cases with residual microscopic or gross disease, and the decision may depend on prior chemotherapy and patient-specific risk factors.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_c084fcef8293",
      "question": "In a patient with non-small cell lung cancer and radiologically confirmed N3 disease, if there is no pathological confirmation of N3 involvement, is it appropriate to proceed with initial treatment for stage I–IIIA disease instead of stage IIIB-IIIC treatment pathways?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No. Management decisions for advanced-stage NSCLC with radiographically suspected N3 involvement require pathological confirmation of N3 disease; without such confirmation, using initial treatment protocols designated for stage I–IIIA rather than stage IIIB–IIIC is appropriate because true N3 status has not been established.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_1760b11f0d54",
      "question": "In a patient diagnosed with non-small cell lung cancer, presenting with stage IVA (N0, M1a) characterized by a single contralateral lung nodule, is it appropriate to manage this case as two primary lung cancers instead of metastatic disease if both lesions are independently deemed curable?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)"
            ]
          }
        }
      ],
      "answer": "Yes, when a patient with stage IVA (N0, M1a) non-small cell lung cancer presents with a solitary contralateral lung nodule and both lesions are considered independently resectable and curable, it is appropriate to treat them as two primary tumors rather than metastatic disease, potentially offering curative treatment for both.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_ab2da36634ed",
      "question": "A 10-year-old girl with a two-year history of polyarticular joint swelling and morning stiffness continues to experience active synovitis despite methotrexate and NSAID therapy. Her rheumatologist recommends initiating a subcutaneous medication that is a recombinant monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α), thereby reducing inflammation and immune-mediated joint damage. To which therapeutic drug class does this agent belong based on its mechanism of action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Juvenile idiopathic arthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3495559",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C5816470",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Biological Response Modifiers",
      "reasoning_path": "Refractory JIA → anti-TNF-α monoclonal antibody (adalimumab-aaty) → immune modulation → biological response modifier class.",
      "umls_path": [
        "Juvenile idiopathic arthritis",
        "may_be_treated_by",
        "adalimumab-aaty",
        "has_mechanism_of_action",
        "Biological Response Modifiers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has refractory juvenile idiopathic arthritis (JIA), as evidenced by persistent joint inflammation despite conventional therapy. The medication described is adalimumab-aaty, a fully human monoclonal antibody that binds and neutralizes TNF-α, a pro-inflammatory cytokine central to JIA pathogenesis. By blocking TNF-α, adalimumab-aaty disrupts downstream inflammatory signaling, reducing synovial proliferation, inflammatory cell recruitment, and tissue damage. Agents like adalimumab-aaty are classified as biological response modifiers because they modulate specific components of the immune response, contrasting with non-selective immunosuppressants. The use of these targeted biologics has significantly improved outcomes in autoimmune diseases such as JIA, especially in patients unresponsive to first-line therapies. Thus, the drug’s mechanistic class is biological response modifiers, reflecting its targeted immune system modulation.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_72142066368e",
      "question": "A 34-year-old woman living in a tropical area develops multiple pruritic papules and nodules on her lower legs after returning from a camping trip. Skin scrapings reveal parasitic organisms. Her physician recommends a topical antiseptic that contains povidone. Although it is commonly used for wound disinfection, the exact manner by which this agent impacts the cutaneous parasites is not clarified in the scientific literature. Based on current understanding, what is the most accurate description of the pharmacological action of this agent against her infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Parasitic infection of skin"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0037280",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0032856",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Cutaneous parasitic infection → Physician prescribes povidone-containing antiseptic → Literature lacks defined mechanism for antiparasitic action → Mechanism is described as unknown cellular or molecular interaction.",
      "umls_path": [
        "Parasitic infection of skin",
        "may_be_treated_by",
        "Povidone-containing product",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Povidone-containing antiseptics, such as povidone-iodine, are widely employed for their broad antimicrobial properties, including activity against bacteria, some viruses, fungi, and occasionally parasites. However, while their use in wound care and infection prevention is well established, the precise cellular or molecular mechanisms by which they exert antiparasitic effects—especially in cutaneous parasitic infections—remain undefined. Unlike targeted antiparasitic drugs with known mechanisms (e.g., inhibition of specific parasite enzymes or metabolic pathways), povidone-iodine likely acts through general oxidative or membrane-disruptive effects, but this has not been conclusively characterized at the cellular or molecular level. Therefore, the most accurate pharmacological description for its action in this context is that the mechanism remains unknown.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_ee086280b61a",
      "question": "In a patient diagnosed with squamous cell non-small cell lung cancer who has a confirmed KRAS G12C mutation and has previously received radiotherapy, is broad molecular profiling including EGFR, ALK, ROS1, and additional driver mutations still recommended as a standard step before initiating systemic therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "KRAS G12C mutation positive"
            ]
          }
        }
      ],
      "answer": "Yes, broad molecular profiling is recommended even in squamous cell carcinoma with a known KRAS G12C mutation and prior radiotherapy. Comprehensive testing, including driver mutations such as EGFR, ALK, ROS1, and others, is essential to rule out actionable alterations, as rare molecular targets may also be present in squamous histology and impact systemic therapy selection.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_470a6fd490a1",
      "question": "For a patient with stage II non–small cell lung cancer (NSCLC) who underwent definitive radiotherapy as the primary treatment, is it appropriate to follow the same chest CT surveillance frequency as for a stage III NSCLC patient after completion of primary therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Yes; in both stage II NSCLC patients treated with definitive radiotherapy and stage III NSCLC patients, the recommended surveillance includes history and physical examination plus chest CT with or without contrast every 3–6 months for the first 3 years, then every 6 months for 2 additional years, and then annually with low-dose non–contrast chest CT.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_1ee9cfda9cd1",
      "question": "In a patient with advanced squamous non-small cell lung cancer who is found to have RET rearrangement positivity on broad molecular profiling, is RET-targeted therapy a valid first-line treatment option, or does the squamous histology exclude this approach despite the molecular finding?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1a: pleural or pericardial effusion",
              "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
              "Positive",
              "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "RET rearrangement positive"
            ]
          }
        }
      ],
      "answer": "RET-targeted therapy is not considered a standard first-line option for advanced squamous non-small cell lung cancer, even when RET rearrangement is detected; squamous histology generally excludes patients from targeted RET inhibitor therapy outside of select clinical trial settings, as supporting evidence is primarily in non-squamous subtypes.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_ada1ab23d509",
      "question": "A 62-year-old woman with a history of chronic inflammatory disease presents with progressive fatigue, nephrotic-range proteinuria, and hepatomegaly. Laboratory studies reveal elevated creatinine and low albumin. A fat pad biopsy demonstrates apple-green birefringence under polarized light with Congo red staining. Her physician prescribes an agent that replenishes intracellular glutathione and provides direct antioxidant effects. Which pharmacological property of this medication is most relevant to its ability to slow organ damage in her underlying disorder?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Amyloidosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002726",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0887741",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Free radical scavenging (antioxidant) activity",
      "reasoning_path": "Amyloidosis causes tissue damage via oxidative stress. Acetylcysteine increases glutathione and directly neutralizes free radicals, providing antioxidant protection that can slow progression of organ injury.",
      "umls_path": [
        "Amyloidosis",
        "may_be_treated_by",
        "Zinc, Acetylcysteine",
        "has_mechanism_of_action",
        "Free Radical Scavenging Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient has clinical and histological findings consistent with systemic amyloidosis, a condition marked by extracellular deposition of misfolded protein fibrils in various organs, leading to progressive organ dysfunction. Oxidative stress contributes to tissue injury in amyloidosis through the generation of reactive oxygen species (ROS), which damage cellular proteins, lipids, and DNA. Acetylcysteine is a precursor to glutathione, a major intracellular antioxidant, and can directly scavenge free radicals. Its pharmacological benefit in amyloidosis is mainly attributed to this antioxidant property, as reducing oxidative stress may limit further tissue damage and slow disease progression. While acetylcysteine has other roles (e.g., mucolysis or acetaminophen antidote), its therapeutic rationale in amyloidosis is based on its free radical scavenging activity, which targets the harmful oxidative environment found in affected tissues.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_a2055cf08eac",
      "question": "A 34-year-old man who recently returned from rural Brazil presents with intermittent fever, abdominal discomfort, and blood in his stool. Laboratory testing reveals eosinophilia, and stool ova and parasite examination confirms infection with Schistosoma mansoni. He is started on a medication that is effective against the adult worm stage of this parasite, but clinical pharmacology resources note that the precise cellular or molecular mechanism of the drug’s antiparasitic action remains unclear. Which best describes the current understanding of this drug’s molecular mechanism of action in treating his infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Schistosomiasis due to schistosoma mansoni"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0036330",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0029994",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Schistosoma mansoni infection is treated with oxamniquine; however, its precise molecular target or mechanism remains unknown despite clinical efficacy.",
      "umls_path": [
        "Schistosomiasis due to schistosoma mansoni",
        "may_be_treated_by",
        "Oxamniquine-containing product",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Oxamniquine is an antiparasitic agent used in the treatment of Schistosoma mansoni infection, particularly in regions where alternative therapies may be less effective or unavailable. While clinical studies have demonstrated oxamniquine's efficacy against the adult worm stage of S. mansoni, its precise molecular mechanism of action has not been fully elucidated. Unlike some antiparasitics with well-characterized targets (such as praziquantel, which increases parasite membrane permeability to calcium), oxamniquine’s action is believed to involve interference with nucleic acid metabolism or neuromuscular function, but no specific cellular target or molecular pathway has been conclusively identified. As such, the current understanding in clinical pharmacology is that oxamniquine’s antiparasitic effect is mediated by an unknown cellular or molecular interaction. This highlights the need for ongoing research into mechanisms of action for antiparasitic drugs, particularly those used in endemic settings.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_065fea29b369",
      "question": "A 48-year-old man presents with enlargement of his hands, coarse facial features, and joint pain. Laboratory evaluation reveals elevated serum IGF-1 and failure of growth hormone suppression after oral glucose administration. MRI of the pituitary shows a 1.5-cm macroadenoma. He is started on a synthetic peptide medication that exerts its effects by activating a specific G protein–coupled receptor subtype on pituitary somatotrophs, leading to reduced growth hormone secretion. Which receptor is primarily responsible for the therapeutic action of this agent in his condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Acromegaly"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001206",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0724649",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Somatostatin receptor type 5",
      "reasoning_path": "Acromegaly is caused by GH excess; somatostatin analogs treat it by binding SSTR5 on pituitary cells, suppressing GH secretion and lowering IGF-1 levels.",
      "umls_path": [
        "Acromegaly",
        "may_be_treated_by",
        "Octreotide acetate",
        "has_target",
        "Somatostatin Receptor Type 5"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has acromegaly due to a pituitary adenoma secreting excess growth hormone (GH). Standard treatment includes somatostatin analogs such as octreotide or lanreotide. These drugs mimic endogenous somatostatin, which inhibits GH release by binding to somatostatin receptors on pituitary somatotrophs. While there are multiple somatostatin receptor subtypes (SSTR1–5), clinical evidence shows that SSTR2 and SSTR5 are most relevant for GH suppression, with SSTR5 being particularly important for the efficacy of octreotide and related analogs. By activating SSTR5, the drug decreases adenylate cyclase activity, reducing cAMP and ultimately suppressing GH secretion. This mechanism underlies the reduction in IGF-1 and improvement of acromegalic symptoms. Thus, the primary molecular target mediating the therapeutic effect in acromegaly is the somatostatin receptor type 5.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_37af9d538b97",
      "question": "For an adult patient with multiple incidentally detected subsolid pulmonary nodules measuring less than 6 mm each on chest CT, who also has a history of pulmonary fibrosis, is serial CT follow-up at 3–6 months still generally appropriate, or does the presence of underlying pulmonary fibrosis fundamentally alter the recommended surveillance strategy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Incidental finding of nodule suspicious for lung cancer",
              "Multidisciplinary evaluation, Smoking cessation counseling",
              "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
              "Subsolid nodules Follow-up (DIAG-3)",
              "Incidental finding: subsolid nodule(s) on chest CT",
              "Multiple subsolid nodules",
              "<6 mm • CT at 3–6 mo • If stable, consider CT at 2 and 4 y"
            ]
          }
        }
      ],
      "answer": "Underlying pulmonary fibrosis does not in itself preclude standard serial CT surveillance for multiple subsolid nodules less than 6 mm; initial follow-up at 3–6 months remains appropriate. However, fibrosis may complicate radiologic assessment, so multidisciplinary review is essential, but the surveillance interval is not fundamentally altered solely due to pulmonary fibrosis.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_81fc915b429b",
      "question": "What is the PMID of the article titled “[Allergology: what's new in 2024],” authored by Pérez-Codesido S and published in Revue medicale suisse in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"[Allergology \"[ti] AND Pérez-Codesido S[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "39812277"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_ad536f407e4f",
      "question": "A 34-year-old traveler returns from an endemic region and is diagnosed with malaria after presenting with fevers, chills, and malaise. He is prescribed a recently approved antimalarial medication that is structurally related to primaquine and effective against both blood and liver stages of Plasmodium species. Despite its clinical efficacy, the detailed molecular processes by which this drug exerts its antimalarial activity have not yet been fully elucidated. Which statement best characterizes the current understanding of this medication’s cellular or molecular mechanism of action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Malaria, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0024530",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0903411",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The precise cellular or molecular mechanism of action of this antimalarial agent remains uncharacterized.",
      "reasoning_path": "A patient with malaria is treated with tafenoquine. Although tafenoquine is effective against multiple Plasmodium stages, its detailed cellular or molecular mechanism remains uncharacterized according to current scientific knowledge.",
      "umls_path": [
        "Malaria, unspecified",
        "may_be_treated_by",
        "Tafenoquine-containing product",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Tafenoquine is a novel antimalarial agent structurally related to primaquine and is used for the radical cure and prophylaxis of malaria, including activity against liver hypnozoites and blood stages. While it is clinically effective and approved for use in humans, the exact cellular or molecular mechanism by which tafenoquine kills Plasmodium parasites has not been clearly defined. In vitro and in vivo studies suggest possible mechanisms such as induction of oxidative stress or interference with parasite mitochondrial function, but none have been conclusively proven. Therefore, the best current understanding is that tafenoquine’s precise molecular target or pathway remains unknown, and further research is required to elucidate its mechanism.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_6ec3a6ca7502",
      "question": "A 54-year-old man is admitted to the ICU with hypotension, tachycardia, fever, and evidence of multi-organ dysfunction. Blood cultures grow Gram-negative rods. Despite broad-spectrum antibiotics and supportive care, he remains critically ill with laboratory results showing elevated D-dimer and low platelet count. He is started on an intravenous medication that is a recombinant form of a human protein, and which exerts its effect by enhancing the degradation of clotting factors Va and VIIIa, thereby reducing microvascular thrombosis and inflammation. Which general pharmacological class best characterizes the mechanism of action of this therapy in the management of his condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Sepsis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0243026",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1170744",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme activators",
      "reasoning_path": "Severe sepsis leads to dysregulated coagulation and inflammation. Drotrecogin alfa (activated) is recombinant activated protein C, which acts by activating endogenous enzymatic pathways (inactivating factors Va and VIIIa). Therefore, its mechanism is classified as an enzyme activator.",
      "umls_path": [
        "Sepsis",
        "may_be_treated_by",
        "drotrecogin alfa (activated), lyophilized",
        "has_mechanism_of_action",
        "Enzyme Activators"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has severe sepsis with evidence of disseminated intravascular coagulation (DIC), as indicated by low platelets and elevated D-dimer. In this context, drotrecogin alfa (activated), a recombinant form of activated protein C, may be administered. The drug functions as an enzyme activator: it increases the activity of endogenous protein C, which has anticoagulant, anti-inflammatory, and profibrinolytic properties. Activated protein C inactivates clotting factors Va and VIIIa, reducing thrombin formation and limiting the formation of microvascular clots that contribute to multi-organ dysfunction in sepsis. By enhancing the activity of this enzyme, the drug helps to restore the balance between coagulation and anticoagulation, addressing one of the central pathogenic mechanisms of severe sepsis. Thus, the therapeutic effect is best described as belonging to the class of enzyme activators.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_5473baf5c4d4",
      "question": "In a patient with completely resected stage IA (T1abc, N0) non-small cell lung cancer found to have positive surgical margins (R1 or R2), is the recommendation for additional radiotherapy predicated on the inability to perform re-resection, or can radiotherapy be considered as an alternative regardless of surgical feasibility?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (T1abc, N0); Margins positive (R1, R2)",
              "Resection (preferred) or RT (category 2B)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Radiotherapy may be considered as an alternative for patients with completely resected stage IA (T1abc, N0) non-small cell lung cancer and positive margins (R1, R2), even if re-resection remains feasible; however, resection is the preferred approach, with radiotherapy as a category 2B option rather than strictly a salvage modality when re-resection cannot be performed.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_c2d9512623aa",
      "question": "For a patient with pathologically confirmed N3 non-small cell lung cancer (either Stage IIIB T1–2, N3 or Stage IIIC T3, N3), if brain MRI with contrast shows asymptomatic brain metastases, is local treatment of brain lesions warranted prior to initiating systemic therapy for disseminated disease?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "In patients with N3 non-small cell lung cancer and asymptomatic brain metastases detected on contrast-enhanced MRI, systemic therapy is typically prioritized as the initial treatment for disseminated disease. Local treatment of brain lesions may be considered for symptomatic or oligometastatic cases, but is not routinely warranted before starting systemic therapy in asymptomatic patients.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_ef99c1bc3d20",
      "question": "A 58-year-old woman with a long-standing history of chronic hepatitis C infection is started on a new antiviral regimen. Shortly after, her clinician reviews her medication profile for potential drug-drug interactions, focusing on the risk of altered plasma concentrations of other agents due to inhibition of a specific ATP-binding cassette (ABC) transporter protein responsible for multidrug resistance and xenobiotic efflux. Which pharmacological class of inhibitors is most relevant to this mechanism in the context of her new hepatitis C therapy, and what is the principal transporter affected?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Viral hepatitis C"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0019196",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4079582",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Breast Cancer Resistance Protein (BCRP) inhibitors—velpatasvir inhibits BCRP, altering drug transport and increasing the risk of interactions.",
      "reasoning_path": "Velpatasvir is prescribed for hepatitis C. It inhibits the BCRP transporter, an ABC efflux protein. BCRP inhibition alters substrate drug kinetics, so the relevant pharmacological mechanism is BCRP inhibition.",
      "umls_path": [
        "Viral hepatitis C",
        "may_be_treated_by",
        "Velpatasvir-containing product",
        "has_mechanism_of_action",
        "Breast Cancer Resistance Protein Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Velpatasvir, a component of several direct-acting antiviral regimens for chronic hepatitis C, not only targets viral proteins but also inhibits the breast cancer resistance protein (BCRP, also known as ABCG2). BCRP is an efflux transporter expressed in the intestine, liver, kidney, and blood-brain barrier, playing a crucial role in the pharmacokinetics of many drugs by limiting their absorption and facilitating excretion. When BCRP is inhibited, plasma concentrations of BCRP substrate drugs (such as certain statins, anticancer agents, and antivirals) can rise, increasing the risk of toxicity. Thus, when a patient is prescribed velpatasvir, clinicians must consider the possibility of pharmacokinetic drug-drug interactions mediated by BCRP inhibition. The mechanistic pathway involves velpatasvir binding to BCRP and blocking its transporter function, leading to reduced efflux and increased systemic exposure to coadministered BCRP substrates.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_ce371a991cad",
      "question": "For a patient with stage III non-small cell lung cancer who achieved complete remission after definitive chemoradiotherapy, if new radiographic abnormalities are found during follow-up but the patient is completely asymptomatic, is it appropriate to routinely perform an FDG-PET/CT to investigate these findings?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "No, routine use of FDG-PET/CT is not indicated for asymptomatic patients with new radiographic abnormalities during follow-up of stage III non-small cell lung cancer; increased imaging may be considered, but FDG-PET/CT should be reserved for clinical suspicion of recurrence or metastatic disease, not for all incidental findings without symptoms.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_a43193b61de1",
      "question": "In ClinicalTrials.gov, which completed interventional phase 3 studies for Migraine Disorders started in July 2008 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "overallStatus=COMPLETED;phases=PHASE3;conditions=Migraine Disorders;startDateFrom=2008-07-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00623636"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_7d1a1665c2e1",
      "question": "For a patient with stage IIA (T2b, N0) non-small cell lung cancer who underwent complete surgical resection with negative margins (R0), is routine surveillance with FDG-PET/CT and brain MRI with contrast recommended during follow-up if there is no clinical or radiographic evidence of disease recurrence?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIA (T2b, N0); Margins negative (R0)",
              "Observe or Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, in the absence of clinical or radiographic suspicion of recurrence, routine surveillance with FDG-PET/CT and brain MRI with contrast is not recommended after R0 resection for stage IIA non-small cell lung cancer. Standard follow-up entails history, physical examination, and chest CT at specified intervals.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_4c3b6406fa09",
      "question": "A 54-year-old woman with a history of chronic joint pain, morning stiffness lasting over an hour, and symmetrical swelling in her wrists and metacarpophalangeal joints is diagnosed with a systemic inflammatory disorder. She is started on a medication that rapidly alleviates pain and reduces joint swelling. This drug exerts its effect by inhibiting an enzyme responsible for converting arachidonic acid to pro-inflammatory mediators, thereby decreasing local prostaglandin concentrations. Which molecular target is primarily inhibited by this medication to achieve its anti-inflammatory effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Rheumatoid arthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003873",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021246",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 2 (COX-2)",
      "reasoning_path": "Rheumatoid arthritis causes inflammation → Indomethacin prescribed for symptom control → Indomethacin inhibits COX-2 (Prostaglandin G/H Synthase 2) → Reduced prostaglandin synthesis → Decreased inflammation and pain.",
      "umls_path": [
        "Rheumatoid arthritis",
        "may_be_treated_by",
        "Indomethacin",
        "has_target",
        "Prostaglandin G/H Synthase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has rheumatoid arthritis, characterized by chronic inflammation of synovial joints. Nonsteroidal anti-inflammatory drugs (NSAIDs) like indomethacin are commonly used for rapid symptom relief. Indomethacin acts by inhibiting cyclooxygenase (COX) enzymes, specifically Prostaglandin G/H Synthase 2, also known as COX-2. COX-2 catalyzes the conversion of arachidonic acid to prostaglandin H2, a precursor to various prostaglandins that mediate inflammation, pain, and swelling. By blocking COX-2, indomethacin reduces the synthesis of these pro-inflammatory prostaglandins, thereby diminishing the inflammatory response and relieving symptoms. This mechanism is central to the anti-inflammatory effects of NSAIDs in conditions like rheumatoid arthritis. Although indomethacin also inhibits COX-1, its therapeutic effect in inflammation primarily relates to COX-2 inhibition.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_08c3078d21d5",
      "question": "For a patient with stage IB (T2a, N0) non-small cell lung cancer who has undergone complete surgical resection with microscopically positive margins (R1), is adjuvant radiation therapy always indicated, or is surveillance without further treatment a reasonable option in some circumstances?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (T2a, N0); Margins positive (R1, R2)",
              "Resection (preferred) ± systemic therapy or RT",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Adjuvant radiation therapy is not always mandatory for stage IB (T2a, N0) non-small cell lung cancer with positive surgical margins (R1). Surveillance may be considered in selected patients when further resection is unfeasible and the risk of recurrence is deemed low. The decision depends on individual risk assessment and multidisciplinary evaluation.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_38667f0938c7",
      "question": "A 62-year-old woman presents with gradual, painless loss of peripheral vision in both eyes over several years. Ophthalmologic examination reveals increased intraocular pressure and optic disc cupping. She is diagnosed with a chronic ocular condition and started on an eye drop that activates certain G protein-coupled receptors, leading to enhanced outflow of aqueous humor through the trabecular meshwork. Which class of receptor does this medication primarily target to achieve its therapeutic effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Open-angle glaucoma, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0017612",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0700536",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Adrenergic beta2-Agonists",
      "reasoning_path": "Open-angle glaucoma causes increased intraocular pressure. Epinephrine bitartrate acts as a beta2-adrenergic receptor agonist, increasing aqueous humor outflow via the trabecular meshwork, thus lowering intraocular pressure.",
      "umls_path": [
        "Open-angle glaucoma, unspecified",
        "may_be_treated_by",
        "Epinephrine bitartrate",
        "has_mechanism_of_action",
        "Adrenergic beta2-Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has classic findings of open-angle glaucoma, characterized by elevated intraocular pressure and optic disc cupping due to impaired aqueous humor drainage. Epinephrine bitartrate, though less commonly used today, is a sympathomimetic agent used in the treatment of open-angle glaucoma. Its ocular hypotensive effect is primarily mediated by agonism at beta2-adrenergic receptors in the ciliary body. Beta2 receptor activation increases cyclic AMP, which relaxes the trabecular meshwork and facilitates aqueous humor outflow through the conventional pathway, thereby lowering intraocular pressure. While epinephrine also has alpha-adrenergic effects, its primary mechanism in reducing intraocular pressure involves beta2-adrenergic receptor-mediated outflow enhancement rather than decreased production (which is the main effect of alpha2 agonists). Understanding this mechanism is fundamental to rational pharmacologic management of glaucoma.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_708d68117d63",
      "question": "A 22-year-old woman with progressive gait instability, dysarthria, and lower limb weakness is diagnosed with a hereditary neurodegenerative disorder characterized by mitochondrial dysfunction and iron accumulation in the nervous system. She is prescribed a recently approved medication that activates the Nrf2 pathway and acts as an inducer of a specific cytochrome P450 enzyme, which can alter the metabolism of other co-administered drugs. Which cytochrome P450 enzyme is most relevant to the pharmacologic action of this therapy?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Friedreich's ataxia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0016719",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4519135",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cytochrome P450 2C8",
      "reasoning_path": "Friedreich's ataxia is treated with omaveloxolone, which induces CYP2C8 as part of its pharmacologic profile.",
      "umls_path": [
        "Friedreich's ataxia",
        "may_be_treated_by",
        "Omaveloxolone",
        "has_mechanism_of_action",
        "Cytochrome P450 2C8 Inducers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with Friedreich's ataxia is treated with omaveloxolone, a drug that activates Nrf2 and induces cellular antioxidant responses. A key pharmacologic feature of omaveloxolone is its ability to induce the cytochrome P450 2C8 (CYP2C8) enzyme. CYP2C8 is involved in the oxidative metabolism of various drugs. Induction of CYP2C8 by omaveloxolone can lead to increased metabolism and decreased plasma concentration of drugs that are CYP2C8 substrates, which is important for drug-drug interaction considerations. The therapeutic effect in Friedreich's ataxia primarily involves Nrf2 activation, but CYP2C8 induction is a significant molecular action impacting overall pharmacology and safety. Selecting CYP2C8 identifies the correct mechanistic target affected by this therapy.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_7a37422074e0",
      "question": "For a patient with newly diagnosed stage IIIB (T1–2, N3) non-small cell lung cancer and confirmed squamous cell carcinoma histology, is broad molecular profiling including EGFR, ALK, ROS1, and other driver mutations routinely required even in the absence of non-squamous features?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "For confirmed squamous cell carcinoma, broad molecular profiling—including EGFR, ALK, and ROS1 testing—is not routinely required unless there are non-squamous components, young age, or minimal smoking history. In pure squamous cell carcinoma of standard risk factors, routine molecular testing is not indicated.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_b8239deddaff",
      "question": "A 47-year-old woman with a history of chronic vomiting due to an eating disorder presents with confusion, muscle cramps, and paresthesias. Laboratory studies reveal a metabolic alkalosis. After initial supportive care, she is given a therapeutic agent that works by modifying the activity of certain large, cellular molecules involved in acid-base regulation. Which mechanistic category best describes the molecular action of this therapy?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Alkalosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002063",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0301556",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Biological macromolecular activity",
      "reasoning_path": "Metabolic alkalosis is treated with arginine hydrochloride, which acts by modifying the activity of biological macromolecules (such as enzymes and transporters) that regulate acid-base homeostasis.",
      "umls_path": [
        "Alkalosis",
        "may_be_treated_by",
        "arginine hydrochloride",
        "has_mechanism_of_action",
        "Biological Macromolecular Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s metabolic alkalosis, often due to excessive loss of gastric acid from vomiting, can be managed with agents like arginine hydrochloride. Arginine hydrochloride acts by influencing the function of biological macromolecules—specifically, it increases hydrogen ion availability, thereby helping correct the alkalosis. The mechanism involves altering the activity of enzymes and transporters that regulate acid-base balance at the cellular level. In the context of pharmacology, such interventions are classified under the mechanism-of-action category of 'biological macromolecular activity,' as they modulate the structure or function of proteins and other large cellular molecules essential for maintaining homeostasis. Thus, the best description of the mechanism is its impact on biological macromolecules important for pH regulation.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_6ffec4d33859",
      "question": "In a patient with stage IIB non–small cell lung cancer who achieved R0 resection and received adjuvant chemotherapy, if a new pulmonary nodule is detected one year after primary treatment, is routine FDG-PET/CT or brain MRI indicated during surveillance imaging?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, for stage I–II non–small cell lung cancer post primary treatment with surgery and chemotherapy, routine FDG-PET/CT and brain MRI are not recommended for surveillance. These imaging modalities become indicated only if there is suspicion of recurrence or new clinical/radiographic abnormalities.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_cf7877837fc9",
      "question": "A 62-year-old woman with a history of type 2 diabetes is brought to the emergency department after being found confused and diaphoretic at home. Her capillary blood glucose is 37 mg/dL. Paramedics administer an intravenous solution that rapidly improves her mental status and stabilizes her vital signs. This agent acts by serving as an essential substrate for cellular energy metabolism and directly participates in glycolysis and other metabolic pathways. Considering its mechanism, what is the principal category of molecular targets involved in mediating this therapeutic response?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Hypoglycemia, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020615",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1876722",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Structural macromolecules—primarily enzymes and transporters that catalyze and facilitate glucose metabolism",
      "reasoning_path": "Severe hypoglycemia is treated with intravenous glucose, which restores energy balance by serving as a substrate for cellular metabolic enzymes and transporters—structural macromolecules critical for glycolysis and ATP production.",
      "umls_path": [
        "Hypoglycemia, unspecified",
        "may_be_treated_by",
        "Beta-D-Glucopyranose",
        "has_mechanism_of_action",
        "Structural Macromolecules"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this clinical scenario, the patient was treated for severe hypoglycemia with intravenous glucose. Glucose acts not by binding to a single receptor or modulating a specific signaling pathway, but by serving as a critical substrate for numerous cellular enzymes and transporters (structural macromolecules). These include glycolytic enzymes, glucose transporters, and components of the citric acid cycle, all of which are necessary for restoring cellular ATP production and reversing the symptoms of neuroglycopenia. The rapid improvement following administration is due to glucose's direct participation in metabolic pathways that replenish energy stores. Thus, the primary biological targets mediating the therapeutic effect are structural macromolecules involved in glucose uptake and metabolism.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_379fcb0c266e",
      "question": "In a patient with advanced non-small cell lung cancer (adenocarcinoma subtype) who tests positive for ALK rearrangement during first-line systemic therapy, is it appropriate to initiate an ALK inhibitor such as alectinib before completing the planned systemic therapy, or should this therapy be completed first?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "ALK rearrangement positive",
              "ALK rearrangement",
              "ALK rearrangement discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by alectinib (preferred) or brigatinib (preferred) or lorlatinib (preferred) or ceritinib or crizotinib",
              "Progression",
              "Subsequent Therapy (NSCL-28)"
            ]
          }
        }
      ],
      "answer": "The recommended approach is to complete the planned first-line systemic therapy, including any maintenance treatment, before initiating ALK inhibitor therapy like alectinib. Early interruption of systemic therapy for targeted ALK inhibition is not standard unless significant clinical circumstances require a change in strategy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_643181f7b713",
      "question": "For a patient with unresectable stage IIIB non-small cell lung cancer (T4, N2) who has completed definitive concurrent chemoradiation, if testing reveals an EGFR exon 19 deletion mutation, is it appropriate to prioritize adjuvant osimertinib over durvalumab as consolidation therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
              "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Contralateral mediastinal node positive (T4, N3)",
              "Definitive concurrent chemoradiation (category 1)",
              "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)"
            ]
          }
        }
      ],
      "answer": "Yes; in patients with unresectable stage IIIB NSCLC harboring an EGFR exon 19 deletion who have completed chemoradiation, adjuvant osimertinib should be prioritized as consolidation therapy over durvalumab, as targeted therapy is specifically indicated for this molecular subtype, while durvalumab is primarily used in EGFR wild-type cases.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_bb9989369ec3",
      "question": "A 54-year-old woman presents to the clinic with fever, productive cough, and shortness of breath. Sputum culture grows Gram-negative coccobacilli identified as a member of the Moraxellaceae family. She is started on an oral antibiotic that disrupts bacterial cell wall synthesis by binding to and inhibiting transpeptidase enzymes. Which general pharmacological class best describes the primary molecular mechanism underlying the therapeutic effect of this medication in treating her infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Moraxellaceae Infections"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1258225",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3486462",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme inhibitors",
      "reasoning_path": "Moraxellaceae infection → cefdinir prescribed → inhibits bacterial transpeptidases (penicillin-binding proteins) → blocks cell wall synthesis → classified as enzyme inhibitor.",
      "umls_path": [
        "Moraxellaceae Infections",
        "may_be_treated_by",
        "CEFDINIR MONOHYDRATE",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Cefdinir is a third-generation cephalosporin prescribed for infections caused by Gram-negative organisms, including Moraxellaceae species such as Acinetobacter and Moraxella catarrhalis. Its therapeutic efficacy results from inhibition of bacterial cell wall synthesis. Specifically, cefdinir binds to penicillin-binding proteins (transpeptidases), which are essential enzymes for crosslinking peptidoglycan strands in the bacterial cell wall. By irreversibly inhibiting these enzymes, cefdinir compromises cell wall integrity, leading to bacterial lysis and death. This mechanism of action places cefdinir within the general pharmacological class of enzyme inhibitors, as it targets and inhibits the function of crucial bacterial enzymes rather than acting on host cells. Understanding this mechanism is key to recognizing why cefdinir and other beta-lactams are effective against many Gram-negative pathogens, including those in the Moraxellaceae family.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_aca8ded7bbe7",
      "question": "In a patient with advanced or metastatic squamous cell carcinoma of the lung and confirmed diffuse brain metastases, molecular profiling reveals an EGFR exon 19 deletion. Is EGFR-targeted systemic therapy prioritized over palliative external-beam radiotherapy for brain lesions in this context?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "EGFR exon 19 deletion or exon 21 L858R mutation positive"
            ]
          }
        }
      ],
      "answer": "In squamous cell lung carcinoma with diffuse brain metastases and confirmed EGFR exon 19 deletion, initial palliative external-beam radiotherapy is prioritized for symptomatic control of brain lesions, while EGFR-targeted therapy is considered subsequently. Immediate systemic EGFR TKI therapy does not replace the need for urgent local brain-directed treatment in this symptomatic and diffuse CNS setting.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_586ca51a0075",
      "question": "An elderly woman with limited mobility develops a non-healing ulcer over her sacrum during a prolonged hospital stay. Her wound care team initiates a topical medication containing a zinc compound that is believed to aid healing by reducing local inflammation. This agent is known to inhibit a specific pro-inflammatory cytokine pathway. Which class of molecular targets is directly responsible for mediating the anti-inflammatory and wound-healing effects of this zinc-containing therapy in pressure injuries?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Pressure injury"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4554531",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0286382",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Interleukin-6 antagonists",
      "reasoning_path": "Pressure injury leads to chronic inflammation. Polaprezinc, a zinc-containing agent, is used to treat it. The agent acts as an interleukin-6 antagonist, reducing local inflammation and promoting healing via IL-6 pathway inhibition.",
      "umls_path": [
        "Pressure injury",
        "may_be_treated_by",
        "polaprezinc",
        "has_mechanism_of_action",
        "Interleukin-6 Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Pressure injuries, especially in immobile patients, are characterized by chronic inflammation and delayed healing. Zinc-containing agents such as polaprezinc have been used to promote wound healing in these settings. Polaprezinc exerts its therapeutic effect in part by antagonizing interleukin-6 (IL-6), a key pro-inflammatory cytokine that drives local inflammation and impairs tissue repair. By blocking IL-6 signaling, polaprezinc reduces inflammatory cell infiltration and cytokine production in the wound microenvironment. This anti-inflammatory action supports re-epithelialization and granulation tissue formation, thereby enhancing the healing process of pressure ulcers. The primary molecular target underlying these benefits is the IL-6 pathway, specifically through its antagonism. Thus, interleukin-6 antagonists are directly responsible for the clinical efficacy of this zinc-containing agent in the management of pressure injuries.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_6bbc6def6b65",
      "question": "A 3-month-old infant is brought to the clinic for evaluation of sudden, brief episodes of flexor spasms involving the trunk and limbs, occurring in clusters throughout the day. EEG reveals hypsarrhythmia, and the child is diagnosed with a severe infantile epileptic disorder. The neurologist prescribes an injectable medication that acts by stimulating specific receptors on the adrenal cortex to enhance endogenous steroid hormone production. Which pharmacological class best describes the mechanism of action of this therapy in controlling the patient’s seizures?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "West syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0037769",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3818725",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Pituitary hormone receptor agonists",
      "reasoning_path": "Infantile spasms (West syndrome) are treated with ACTH, which acts as an agonist at pituitary hormone receptors (melanocortin 2 receptor), stimulating adrenal steroid production and exerting anticonvulsant effects.",
      "umls_path": [
        "West syndrome",
        "may_be_treated_by",
        "Corticotropin",
        "has_mechanism_of_action",
        "Pituitary Hormone Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The infant described has clinical and electroencephalographic features characteristic of West syndrome (infantile spasms). First-line medical therapy often includes adrenocorticotropic hormone (ACTH, or corticotropin), an agent that exerts its effects by binding to and activating melanocortin 2 receptors on the adrenal cortex—these are a subset of pituitary hormone receptors. Activation of these receptors stimulates adrenal steroidogenesis, resulting in increased production of endogenous corticosteroids. The elevation in corticosteroid levels is believed to suppress abnormal neuronal activity and inflammation that contribute to infantile spasms. Thus, the medication’s therapeutic effect is mediated through agonism of pituitary hormone receptors—specifically, those regulating adrenal steroid synthesis—defining its pharmacological class.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_f4cded8f4c89",
      "question": "In the OpenTargets database, what information is available regarding the target MTOR and the event heart disease?",
      "tool_calls": [
        {
          "tool": "opentargets.safety",
          "params": {
            "symbol": "MTOR",
            "event": "heart disease"
          }
        }
      ],
      "answer": {
        "biosamples": [
          {
            "tissueLabel": "cardiovascular system",
            "tissueId": "UBERON_0004535"
          }
        ],
        "effects": "absence"
      },
      "type": "retrieval"
    },
    {
      "id": "path_9a3e0b2c7820",
      "question": "In a patient with stage IIIA non-small cell lung cancer presenting with a T4 tumor extension involving the mediastinum and N1 nodal status, but with adequate pulmonary function and resectable disease by imaging, should concurrent chemoradiation be prioritized over initial surgical resection?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Unresectable disease",
              "Treatment (NSCL-7)",
              "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
              "Systemic therapy or Concurrent chemoradiation",
              "Surgical reevaluation including chest CT ± PET/CT",
              "Surgery",
              "Margins negative (R0)",
              "Observe or Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "For stage IIIA NSCLC with T4, N1 disease that is technically resectable and with adequate pulmonary reserve, concurrent chemoradiation is generally prioritized as the standard initial approach. Surgery is typically reconsidered only if there is a favorable response to induction therapy or if complete resection can be confidently achieved.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_1f9d603e4ad6",
      "question": "What is the PMID of the article titled \"Revolutionizing pediatric neurology care: telemedicine advancements and regulatory impact in the Northeast of Brazil,\" authored by Rodrigues DLG and published in Arquivos de Neuro-Psiquiatria in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"Revolutionizing pediatric neurology care\"[ti] AND Rodrigues DLG[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40262814"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_81be19eb4091",
      "question": "A 34-year-old woman presents with red, itchy, watery eyes and mild eyelid swelling that worsens during spring. She has a history of seasonal allergies and no significant medical problems. Slit-lamp examination reveals conjunctival injection and mild chemosis without discharge. She is prescribed a topical ophthalmic agent known to stabilize mast cells and inhibit downstream effects of histamine release. Which molecular pathway is directly targeted by this medication to alleviate her ocular symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Keratoconjunctivitis, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0022573",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0126120",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Histamine H1 receptor antagonism",
      "reasoning_path": "Allergen exposure → mast cell degranulation → histamine release → H1 receptor activation → allergic symptoms; lodoxamide blocks H1 receptors, reducing inflammation and symptoms.",
      "umls_path": [
        "Keratoconjunctivitis, unspecified",
        "may_be_treated_by",
        "Lodoxamide",
        "has_mechanism_of_action",
        "Histamine H1 Receptor Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has allergic keratoconjunctivitis, characterized by ocular itching, redness, and swelling due to allergen-triggered mast cell degranulation. This process releases histamine and other mediators, which act on H1 receptors in ocular tissues, causing vasodilation, increased permeability, and nerve stimulation leading to symptoms. Lodoxamide is a mast cell stabilizer that also exhibits antihistaminic properties by antagonizing histamine H1 receptors. By blocking these receptors, lodoxamide prevents histamine-mediated inflammatory responses, reducing conjunctival edema, erythema, and pruritus. Therefore, the therapeutic effect of lodoxamide in allergic keratoconjunctivitis is primarily due to its action as a histamine H1 receptor antagonist, directly interfering with the histamine signaling pathway responsible for the allergic symptoms.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_c30887024ab0",
      "question": "A 54-year-old man with a history of coronary artery disease presents for evaluation of persistently elevated LDL cholesterol despite dietary modifications and statin therapy. His physician adds a medication that is not absorbed in the gastrointestinal tract and works locally in the intestine by binding negatively charged molecules, thereby increasing their fecal excretion and decreasing their recirculation to the liver. Which molecular mechanism is primarily responsible for this agent’s lipid-lowering effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Hyperlipoproteinemia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020476",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0008402",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Binding of bile acids in the intestine, interrupting their enterohepatic circulation",
      "reasoning_path": "Resins bind bile acids in the intestine → decrease enterohepatic recirculation → increased fecal excretion → liver uses cholesterol to make more bile acids → upregulation of LDL receptors → lower plasma LDL.",
      "umls_path": [
        "Hyperlipoproteinemia",
        "may_be_treated_by",
        "Cholestyramine",
        "has_mechanism_of_action",
        "Bile-acid Binding Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with hyperlipoproteinemia is prescribed a non-absorbable resin, such as cholestyramine or colestipol. These agents function by binding bile acids in the intestinal lumen. Normally, bile acids are synthesized from cholesterol in the liver, secreted into the intestine to aid in fat digestion, and then reabsorbed in the terminal ileum to be recycled (enterohepatic circulation). By binding bile acids, these resins prevent their reabsorption, leading to increased fecal excretion. As a result, the hepatic bile acid pool decreases, prompting the liver to convert more cholesterol into bile acids to replenish the pool. This process upregulates hepatic LDL receptors and increases clearance of LDL cholesterol from the blood, thereby lowering plasma LDL levels. The primary pharmacological action responsible for the lipid-lowering effect is the binding and removal of bile acids, disrupting their normal recirculation and ultimately lowering cholesterol.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_95c7bf6e66a5",
      "question": "For a patient diagnosed with metastatic squamous cell carcinoma of the lung confirmed to harbor a BRAF V600E mutation, is it appropriate to prioritize BRAF-targeted therapy over standard platinum-based chemotherapy as first-line systemic treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "BRAF V600E mutation positive"
            ]
          }
        }
      ],
      "answer": "Yes, in metastatic squamous cell carcinoma of the lung with a confirmed BRAF V600E mutation, BRAF-targeted therapy is prioritized over standard platinum-based chemotherapy, provided the patient's clinical status allows. This approach is supported by evidence favoring targeted agents for actionable mutations, regardless of histologic subtype, when validated by molecular profiling.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_2e41d3d79224",
      "question": "A 34-year-old woman with a history of progressive fatigue, weight loss, and skin hyperpigmentation is found to have hyponatremia and hypotension. Laboratory testing confirms primary adrenal insufficiency. She is started on a medication that not only replaces deficient hormones but also decreases inflammation by blocking the synthesis of leukotrienes. This anti-inflammatory effect is achieved by inhibiting enzymes responsible for converting arachidonic acid into pro-inflammatory mediators. Which class of enzyme inhibitors best describes the molecular mechanism by which this drug reduces inflammation?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Addison's Disease"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001403",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011779",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lipoxygenase inhibitors",
      "reasoning_path": "Addison's disease → corticosteroid therapy → corticosteroids inhibit lipoxygenase enzymes → reduced leukotriene synthesis → decreased inflammation.",
      "umls_path": [
        "Addison's Disease",
        "may_be_treated_by",
        "Dexamethasone isonicotinate",
        "has_mechanism_of_action",
        "Lipoxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has primary adrenal insufficiency (Addison's disease), which requires corticosteroid replacement. Some synthetic corticosteroids, such as dexamethasone and its derivatives, also exert anti-inflammatory effects by interfering with pathways involved in eicosanoid synthesis. Specifically, they can inhibit lipoxygenase enzymes, which convert arachidonic acid into leukotrienes—potent inflammatory mediators that contribute to immune cell recruitment and vascular permeability. By blocking lipoxygenase activity, corticosteroids reduce leukotriene production, thereby decreasing inflammation. This mechanism is distinct from their suppression of gene transcription for pro-inflammatory cytokines or inhibition of phospholipase A2. In the context of Addison's disease, the anti-inflammatory properties of corticosteroids are beneficial when immune-mediated inflammation is present or when stress responses are needed. Thus, the relevant class of enzyme inhibitors for this corticosteroid’s mechanism is lipoxygenase inhibitors.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_776a834ba713",
      "question": "A 9-year-old child with a history of spastic cerebral palsy presents with increased muscle tone and painful leg spasms, interfering with physical therapy and daily activities. The clinician initiates a centrally acting medication known to enhance inhibitory neurotransmission in the spinal cord by acting as an agonist at a specific class of chloride channel-linked receptors. Which receptor type is directly responsible for mediating the therapeutic muscle relaxant effects of this treatment?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Cerebral Palsy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0007789",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004609",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "GABA B receptor",
      "reasoning_path": "Child with spastic cerebral palsy → muscle rigidity/spasticity → prescribed baclofen → baclofen is a GABA B receptor agonist → GABA B activation reduces neuronal excitability in spinal cord → muscle relaxation.",
      "umls_path": [
        "Cerebral Palsy",
        "may_be_treated_by",
        "Baclofen",
        "has_mechanism_of_action",
        "GABA A Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with spastic cerebral palsy is prescribed a centrally acting muscle relaxant to reduce spasticity. Baclofen is commonly used in this context. Mechanistically, baclofen is a selective agonist at GABA B receptors, which are G protein-coupled receptors located primarily in the CNS, including the spinal cord. When activated, GABA B receptors increase potassium conductance and decrease calcium influx in neurons, leading to hyperpolarization and reduced neurotransmitter release. This results in decreased excitatory transmission and reduces muscle tone and spasms. In contrast, GABA A receptors are ligand-gated chloride channels and are the primary targets of benzodiazepines and barbiturates, not baclofen. Therefore, the therapeutic effect of baclofen in spasticity is mediated specifically via GABA B receptor agonism, not GABA A receptors.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_3440e6d8767a",
      "question": "A 40-year-old man with schizophrenia is admitted to the hospital after developing high fever, severe muscle rigidity, and confusion following an increase in his antipsychotic medication. Laboratory studies reveal elevated creatine kinase, leukocytosis, and myoglobinuria. He is diagnosed with a life-threatening drug reaction and started on a medication that acts directly on skeletal muscle by inhibiting calcium release from the sarcoplasmic reticulum. Which pharmacological class is most closely related to the primary mechanism of action of this drug?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Neuroleptic malignant syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0027849",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0010976",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Calcium channel antagonists",
      "reasoning_path": "NMS involves muscle rigidity; dantrolene treats this by blocking ryanodine receptors, reducing calcium release from the sarcoplasmic reticulum—an action mechanistically similar to calcium channel antagonists.",
      "umls_path": [
        "Neuroleptic malignant syndrome",
        "may_be_treated_by",
        "Dantrolene-containing product",
        "has_mechanism_of_action",
        "Calcium Channel Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is experiencing neuroleptic malignant syndrome (NMS), a rare but severe reaction to dopamine antagonist medications, characterized by hyperthermia, muscle rigidity, and autonomic instability. The main issue in NMS is sustained muscle contraction leading to hyperthermia and rhabdomyolysis. Dantrolene is used in this setting because it directly inhibits the ryanodine receptor on the sarcoplasmic reticulum in skeletal muscle. This action prevents the release of calcium ions into the cytoplasm, thereby reducing excitation-contraction coupling and muscle rigidity. The pharmacological class most closely related to this mechanism is calcium channel antagonists, as dantrolene’s effect is to antagonize (block) the release of calcium required for muscle contraction. Unlike other calcium channel blockers (which act on voltage-gated channels in cardiac or smooth muscle), dantrolene acts on the intracellular calcium release mechanism, but the principle—antagonizing calcium flow—is shared.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_922227594f3e",
      "question": "In a patient with stage IIIA non-small cell lung cancer who achieved an R0 resection and completed sequential chemotherapy, if new small asymptomatic lung nodules are detected on surveillance imaging but there is no evidence of disseminated disease on chest CT and PET/CT, should observation be preferred over initiation of systemic therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
              "Sequential chemotherapy and consider RT",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Yes, in the absence of disseminated disease and if the nodules are asymptomatic and stable, observation is preferred over systemic therapy. Systemic therapy is reserved for cases with evidence of recurrence or disseminated disease, while observation is appropriate when curative treatment has been completed and no progression is detected.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_1156e8c0e89e",
      "question": "A 40-year-old individual presents to the emergency department with palpitations and a rapid, regular pulse. Electrocardiogram reveals a narrow-complex tachycardia consistent with recurrent supraventricular tachycardia. The patient is hemodynamically stable and is prescribed an oral medication that acts preferentially on cardiac tissue to slow conduction through the atrioventricular node and decrease heart rate, with minimal effect on bronchial or vascular smooth muscle. Which molecular target is primarily responsible for mediating the therapeutic effect of this medication in treating his arrhythmia?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Supraventricular Tachycardia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0039240",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0025859",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Beta-1 adrenergic receptor",
      "reasoning_path": "SVT causes rapid heart rate → cardioselective beta-blocker prescribed → metoprolol blocks beta-1 adrenergic receptors in the heart → slows AV nodal conduction and decreases heart rate, controlling arrhythmia.",
      "umls_path": [
        "Supraventricular Tachycardia",
        "may_be_treated_by",
        "Metoprolol-containing product",
        "has_target",
        "Beta-1 Adrenergic Receptor"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Supraventricular tachycardia (SVT) involves rapid electrical impulses originating above the ventricles, leading to increased heart rate. Management often includes drugs that slow AV nodal conduction and reduce myocardial excitability. Cardioselective beta-blockers, such as metoprolol, act primarily by antagonizing beta-1 adrenergic receptors, which are highly expressed in cardiac tissue. Beta-1 blockade decreases the effects of endogenous catecholamines like norepinephrine, resulting in reduced heart rate (negative chronotropy), decreased conduction velocity (negative dromotropy), and decreased myocardial contractility (negative inotropy). This helps restore normal rhythm and control symptoms. Because metoprolol is selective for beta-1 receptors at therapeutic doses, it has less action on beta-2 receptors in bronchial and vascular smooth muscle, reducing the risk of bronchospasm or peripheral vasoconstriction compared to non-selective agents. Thus, the clinical benefit in SVT arises mainly from selective antagonism of the beta-1 adrenergic receptor.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_3a14d9170f5d",
      "question": "A 54-year-old woman presents with frequent, involuntary, forceful blinking and closure of her eyelids, which has progressively interfered with reading and driving. Neurologic examination is unremarkable except for intermittent bilateral eyelid spasms. Her neurologist administers an injection of a biologic agent that acts by preventing the presynaptic release of a neurotransmitter at the neuromuscular junction, thereby reducing abnormal muscle contractions. Which drug class most directly describes the mechanism by which this therapy relieves her symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Blepharospasm"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0005747",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4759195",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Acetylcholine release inhibitors",
      "reasoning_path": "Blepharospasm involves excessive eyelid muscle activity. Botulinum toxins such as prabotulinumtoxinA-xvfs are injected locally, where they inhibit acetylcholine release at neuromuscular junctions, decreasing muscle contractions and relieving symptoms.",
      "umls_path": [
        "Blepharospasm",
        "may_be_treated_by",
        "prabotulinumtoxinA-xvfs",
        "has_mechanism_of_action",
        "Acetylcholine Release Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has blepharospasm, a form of focal dystonia characterized by involuntary contractions of the orbicularis oculi muscles. The mainstay of symptomatic treatment is local injection of a botulinum toxin preparation, such as prabotulinumtoxinA-xvfs. These agents act at the neuromuscular junction by cleaving SNARE proteins, which are essential for vesicular fusion and exocytosis of acetylcholine from presynaptic terminals. By inhibiting acetylcholine release, these drugs prevent stimulation of nicotinic receptors on the muscle, leading to reduced contraction of the targeted muscle group. This pharmacologic action directly addresses the pathophysiology of excessive muscle activity, providing temporary relief from spasms. Therefore, acetylcholine release inhibitors best describe the drug class relevant to this mechanism.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_7c8ea42c2646",
      "question": "In a patient with multiple primary lung cancers staged as N0–1, if definitive local therapy is judged not feasible, but one nodule demonstrates radiographic growth while others are stable, should systemic therapy be initiated rather than observation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Multiple lung cancers (suspected or confirmed) (N0–1)",
              "Multidisciplinary evaluation",
              "Dominant nodule with evidence of growth",
              "Definitive local therapy not possible",
              "Palliative chemotherapy ± local palliative therapy or Observe",
              "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
              "Distant metastases",
              "Disseminated metastases",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes; the presence of a dominant nodule with evidence of growth in the context of unresectable multiple lung cancers supports initiation of palliative systemic therapy over observation, as active disease progression outweighs the rationale for mere surveillance.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_9109f35ea154",
      "question": "A 54-year-old man with a history of hyperuricemia presents to the clinic with a red, swollen, and exquisitely tender left first metatarsophalangeal joint that developed overnight. He is diagnosed with an acute monoarticular arthritis and prescribed a nonsteroidal anti-inflammatory drug (NSAID) known to inhibit a key enzyme in the arachidonic acid pathway, thereby reducing the synthesis of inflammatory mediators. Which molecular target is primarily responsible for the anti-inflammatory benefit of this medication in his current condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Gout, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0018099",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0025041",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 1 (COX-1)",
      "reasoning_path": "Acute gout is treated with NSAIDs like meclofenamate, which inhibit prostaglandin G/H synthase 1 (COX-1), blocking prostaglandin synthesis and reducing inflammation.",
      "umls_path": [
        "Gout, unspecified",
        "may_be_treated_by",
        "Meclofenamate Sodium",
        "has_target",
        "Prostaglandin G/H Synthase 1"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "In this vignette, the patient is experiencing an acute gout flare, characterized by rapid onset pain and inflammation due to monosodium urate crystal deposition in the joint. Meclofenamate sodium is an NSAID, a class of medications that exerts anti-inflammatory and analgesic effects by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), also known as prostaglandin G/H synthases. These enzymes catalyze the conversion of arachidonic acid to prostaglandin H2, a precursor for various prostaglandins involved in vasodilation, increased vascular permeability, and pain sensitization. By inhibiting prostaglandin G/H synthase 1 (COX-1), meclofenamate sodium decreases the production of these inflammatory mediators, thereby reducing joint inflammation and pain during a gout flare. This mechanism is fundamental to the therapeutic efficacy of NSAIDs in acute gout management.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_13defc96483f",
      "question": "For a patient with resectable stage IIIA non-small cell lung cancer (NSCLC) and positive mediastinal lymph nodes following pathologic evaluation, does the recommendation for perioperative therapy implicitly require that no evidence of distant metastases has been identified by FDG-PET/CT and brain MRI with contrast?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, the recommendation for perioperative therapy in resectable stage IIIA NSCLC with positive mediastinal lymph nodes is predicated on the absence of distant metastatic disease on FDG-PET/CT and brain MRI. Detection of metastases would redirect management toward systemic therapy rather than local or perioperative interventions.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_737a102579c3",
      "question": "In a patient with stage II non-small cell lung cancer (T1abc–2ab, N1) and normal pulmonary function tests, is it mandatory to perform brain MRI with contrast before surgery, or is this imaging only indicated for stage IIIA or higher?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "For stage II non-small cell lung cancer, brain MRI with contrast is recommended but not mandatory prior to surgery. Routine preoperative brain MRI is standard for stage II and stage IIIA disease, whereas its use in stage IB is optional. Therefore, for stage II patients, brain MRI should be performed, but in lower stages, it can be omitted at the clinician’s discretion.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_c8464cdc6303",
      "question": "For a patient with stage I non-small cell lung cancer who underwent definitive radiotherapy as primary treatment, is the initial post-treatment imaging surveillance frequency the same as for a patient with stage I disease treated with surgery alone?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
              "Sequential chemotherapy and consider RT",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Severe hemoptysis",
              "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "No, patients with stage I disease treated with definitive radiotherapy require more intensive imaging surveillance—history and physical plus chest CT every 3–6 months for 3 years—whereas those treated with surgery ± chemotherapy undergo imaging every 6 months for 2–3 years initially.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_dc009e6f6462",
      "question": "In a patient with newly diagnosed non-small cell lung cancer presenting with multiple pulmonary lesions and an ECOG performance status of 2, but without previously documented biomarker testing, is it appropriate to initiate systemic therapy for metastatic disease without waiting for molecular results?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 0–2",
              "Multiple lesions",
              "Systemic Therapy for Metastatic Disease (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Systemic therapy for metastatic non-small cell lung cancer can be initiated in patients with multiple lesions and ECOG PS 0–2; however, current clinical practice requires biomarker testing prior to systemic treatment selection. Empiric therapy may occasionally proceed if rapid symptom control is necessary, but targeted or immunotherapy regimens should await molecular results whenever feasible.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_c3e31d4dd50e",
      "question": "For a patient with stage IA (T1aN0) non-small cell lung cancer who has positive surgical margins (R1), is re-operation preferred over radiotherapy for margin management even if the patient has moderate chronic obstructive pulmonary disease and borderline pulmonary function?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (T1abc, N0); Margins positive (R1, R2)",
              "Resection (preferred) or RT (category 2B)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Re-operation is generally preferred for positive margins in stage IA NSCLC; however, in patients with moderate COPD and borderline pulmonary function, the risks of surgery may outweigh benefits. In such cases, radiotherapy becomes an appropriate alternative for margin management despite being a category 2B option.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_706faea27121",
      "question": "In a patient with stage IIIA non-small cell lung cancer (NSCLC) who has undergone resection and is found to have a positive margin (R1), is it implied that sequential or concurrent chemoradiation is indicated regardless of adjuvant chemotherapy being administered prior to knowledge of margin status?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
              "R1; Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Yes, the identification of an R1 (positive margin) after resection in stage IIIA NSCLC implies an indication for either sequential or concurrent chemoradiation, independent of whether adjuvant chemotherapy was already administered. The primary driver for chemoradiation in this setting is the positive margin, not the prior use of adjuvant chemotherapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_74049a6a0302",
      "question": "A 42-year-old man with a history of schizophrenia is brought to the emergency department after developing confusion, high fever, muscle rigidity, and autonomic instability two days after starting a new antipsychotic medication. Laboratory studies reveal elevated creatine kinase and leukocytosis. The medical team administers an intravenous muscle relaxant that acts directly on skeletal muscle by inhibiting calcium release from the sarcoplasmic reticulum. Which pharmacological class describes the mechanism of action of this agent in treating this patient’s acute symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Neuroleptic malignant syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0027849",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0010977",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Calcium channel antagonists (direct-acting skeletal muscle relaxant)",
      "reasoning_path": "Neuroleptic malignant syndrome causes muscle rigidity and hyperthermia. Dantrolene treats this by inhibiting ryanodine receptor–mediated calcium release in skeletal muscle, classifying it as a calcium channel antagonist.",
      "umls_path": [
        "Neuroleptic malignant syndrome",
        "may_be_treated_by",
        "Dantrolene Sodium",
        "has_mechanism_of_action",
        "Calcium Channel Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is experiencing neuroleptic malignant syndrome (NMS), a life-threatening complication of antipsychotic therapy characterized by muscle rigidity, hyperthermia, and autonomic dysfunction. The main pharmacologic intervention is dantrolene, a direct-acting skeletal muscle relaxant. Dantrolene works by binding to the ryanodine receptor (RyR1) on the sarcoplasmic reticulum of skeletal muscle, inhibiting the release of calcium ions necessary for muscle contraction. By decreasing cytosolic calcium, dantrolene reduces sustained muscle contraction and lowers heat production, thereby addressing both rigidity and hyperthermia in NMS. The pharmacological class best describing this mechanism is calcium channel antagonists, specifically those acting at the level of intracellular calcium release channels in skeletal muscle. This is distinct from other muscle relaxants, which may act centrally or at the neuromuscular junction. Thus, dantrolene’s efficacy in NMS is due to its direct antagonism of calcium release from the sarcoplasmic reticulum in skeletal muscle.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_6ec6d573547d",
      "question": "What diseases are associated with the target SSTR5 (Ensembl ID ENSG00000162009) with a minimum relevance score of 0.5 according to OpenTargets?",
      "tool_calls": [
        {
          "tool": "opentargets.search",
          "params": {
            "target_id": "ENSG00000162009",
            "min_score": 0.5
          }
        }
      ],
      "answer": [
        {
          "disease_id": "EFO_0004627",
          "disease_name": "IGF-1 measurement",
          "score": 0.6476252709982938
        },
        {
          "disease_id": "EFO_1001485",
          "disease_name": "acromegaly",
          "score": 0.6067395600201799
        },
        {
          "disease_id": "EFO_0000616",
          "disease_name": "neoplasm",
          "score": 0.5824586874970201
        },
        {
          "disease_id": "EFO_1001901",
          "disease_name": "neuroendocrine neoplasm",
          "score": 0.5489261783160067
        },
        {
          "disease_id": "EFO_0004243",
          "disease_name": "carcinoid tumor",
          "score": 0.5254176332829494
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "path_6d23c501b5b5",
      "question": "In a patient with a stage IIB non-small cell lung cancer (T3, N0), who is found to have a separate pulmonary nodule in the same lobe as the primary tumor, does this presentation remain classified as stage IIB, or does the presence of the additional nodule change the staging to a more advanced group?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)"
            ]
          }
        }
      ],
      "answer": "The presence of a separate pulmonary nodule in the same lobe as the primary tumor in non-small cell lung cancer upstages the tumor to T3; if nodal status remains N0–1, this is still classified as stage IIB or IIIA depending on N status. Thus, the additional nodule in the same lobe does not automatically shift classification outside the IIB or IIIA categories but indicates a higher T descriptor within these stages.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_2479050bd66f",
      "question": "A 61-year-old woman with a history of small cell lung cancer presents with confusion, weakness, and mild nausea. Laboratory studies reveal a serum sodium of 122 mmol/L (normal: 135–145 mmol/L) and low plasma osmolality. Urine sodium is inappropriately elevated, and urine osmolality is higher than plasma osmolality. Despite fluid restriction, her sodium remains low. Her physician prescribes an antibiotic that is known to interfere with renal responsiveness to antidiuretic hormone by inhibiting a fundamental cellular process in the collecting duct. Which drug class's mechanism of action is responsible for this effect on water regulation in the kidney?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Syndrome of Inappropriate Antidiuretic Hormone Secretion"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021141",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0282125",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Protein synthesis inhibitors",
      "reasoning_path": "SIADH causes persistent ADH-mediated water retention; demeclocycline, a tetracycline antibiotic, inhibits protein synthesis in renal collecting duct cells, thereby reducing ADH responsiveness and promoting free water excretion.",
      "umls_path": [
        "Syndrome of Inappropriate Antidiuretic Hormone Secretion",
        "may_be_treated_by",
        "Demeclocycline Hydrochloride",
        "has_mechanism_of_action",
        "Protein Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This clinical vignette describes a patient with persistent hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH), evidenced by hypotonic, euvolemic hyponatremia, high urine sodium, and high urine osmolality. The patient is treated with demeclocycline, a tetracycline antibiotic. Demeclocycline's therapeutic benefit in SIADH is attributed to its ability to antagonize the action of antidiuretic hormone (ADH) at the renal collecting ducts. Mechanistically, demeclocycline inhibits protein synthesis in renal tubular cells. This inhibition interferes with the cellular signaling cascades and protein insertion needed for aquaporin-2 channel expression and trafficking in response to ADH. As a result, the kidneys are less able to reabsorb free water, helping to correct hyponatremia. Thus, the primary pharmacologic action responsible for demeclocycline’s effect in SIADH is its role as a protein synthesis inhibitor, which underlies its antagonism of ADH-mediated water reabsorption.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_6238d0682448",
      "question": "A 35-year-old woman presents with persistent fatigue, unrefreshing sleep, and impaired concentration for over six months, with no identifiable medical or psychiatric cause. After other etiologies are excluded, she is diagnosed with a disorder characterized by chronic, unexplained fatigue. Her physician initiates a medication that is primarily used as an antidepressant and functions by increasing synaptic levels of a specific monoamine neurotransmitter through transporter inhibition. Which pharmacological mechanism underlies this medication's potential benefit in alleviating her symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Chronic fatigue syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0015674",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C5678685",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Serotonin reuptake inhibition",
      "reasoning_path": "Chronic fatigue syndrome is treated off-label with venlafaxine, whose main mechanism at standard doses is serotonin reuptake inhibition, leading to increased serotonergic neurotransmission and symptom improvement.",
      "umls_path": [
        "Chronic fatigue syndrome",
        "may_be_treated_by",
        "venlafaxine besylate",
        "has_mechanism_of_action",
        "Serotonin Uptake Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is diagnosed with chronic fatigue syndrome, a disorder with unclear pathophysiology but often associated with mood disturbances and altered neurotransmission. Venlafaxine, the prescribed medication, is a serotonin-norepinephrine reuptake inhibitor (SNRI). In the context of chronic fatigue syndrome, its efficacy is thought to derive mainly from its ability to inhibit the serotonin transporter (SERT), thereby increasing serotonin levels in the synaptic cleft. Enhanced serotonergic neurotransmission is linked to improved mood, energy, and sleep regulation—domains frequently disrupted in chronic fatigue syndrome. Although venlafaxine also inhibits norepinephrine reuptake at higher doses, at standard doses its predominant action is on serotonin reuptake. This mechanism is believed to mitigate some of the neuropsychiatric and somatic symptoms of chronic fatigue syndrome, even though the evidence base is limited. Thus, the primary pharmacological mechanism relevant to this context is serotonin reuptake inhibition.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_f0adbb8dc713",
      "question": "For a patient with non-small cell lung cancer presenting with a solitary pulmonary nodule in the contralateral lung (M1a, stage IVA, N0), is this clinical scenario managed as two primary lung tumors only if both lesions are considered potentially curable?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
              "Pathologic Diagnosis of NSCLC",
              "Clinical Stage",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Pretreatment Evaluation (NSCL-8)"
            ]
          }
        }
      ],
      "answer": "Yes; in cases of solitary contralateral lung nodules (M1a, stage IVA, N0), management as two primary lung tumors is appropriate only if both lesions are deemed potentially curable, otherwise the approach defaults to systemic therapy for metastatic disease.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_e170505a9210",
      "question": "In ClinicalTrials.gov, which recruiting interventional studies that started in June 2022 are investigating Bexmarilimab in Finland?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "overallStatus=RECRUITING;startDateFrom=2022-06-01;interventions.name=Bexmarilimab",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT05428969"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_239ed2144537",
      "question": "A 34-year-old woman with a long-standing history of intermittent abdominal pain, bloating, and irregular bowel habits presents to her primary care provider. She describes alternating constipation and diarrhea, with incomplete stool evacuation. After diagnostic work-up excludes other causes, she is started on a non-absorbed oral agent that remains within the gastrointestinal tract and is neither metabolized nor systemically absorbed. Within weeks, she reports improved stool consistency and fewer symptoms. Which pharmacological property of this agent is most directly responsible for her symptomatic improvement?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Irritable bowel syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0022104",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0054480",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Stool bulking activity (increasing stool mass within the intestinal lumen)",
      "reasoning_path": "IBS causes abnormal bowel habits—bulk-forming, non-absorbed agents like calcium polycarbophil increase stool mass—this normalizes bowel consistency and motility, relieving IBS symptoms.",
      "umls_path": [
        "Irritable bowel syndrome",
        "may_be_treated_by",
        "Calcium Polycarbophil",
        "has_mechanism_of_action",
        "Stool Bulking Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient's symptoms are consistent with irritable bowel syndrome (IBS), characterized by disordered bowel habits and abdominal discomfort. Non-absorbed agents such as bulk-forming laxatives (e.g., calcium polycarbophil) are commonly utilized in IBS management, particularly in patients with constipation-predominant or mixed symptom patterns. These agents act locally in the gut by absorbing water and swelling, thereby increasing stool volume and mass. This bulking effect stretches the colonic wall, stimulating peristalsis, which helps normalize bowel transit and consistency. By making stools softer and more formed, these agents can relieve both constipation and the sense of incomplete evacuation. The lack of systemic absorption minimizes adverse effects and drug interactions. Thus, the primary pharmacological action responsible for symptom relief in this context is the agent’s ability to increase stool bulk, thereby regulating bowel movements and alleviating IBS symptoms.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_c66d147f779a",
      "question": "In a patient with stage IIB (T3, N0) non-small cell lung cancer who has undergone surgical resection but is found to have positive margins (R1), is concurrent chemoradiation an appropriate postoperative treatment, or should sequential systemic therapy followed by radiotherapy be preferred?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
              "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Disseminated metastases",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Concurrent chemoradiation is an appropriate postoperative treatment option for stage IIB (T3, N0) non-small cell lung cancer with positive surgical margins (R1); both concurrent and sequential approaches are recommended, but concurrent chemoradiation is often preferred due to potentially improved local control, provided the patient’s performance status and comorbidities permit intensive therapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_5a582543df54",
      "question": "In a patient with stage IIIB (T3, N2) non-small cell lung cancer who previously received thoracic radiotherapy and now presents with mediastinal lymph node recurrence without evidence of distant metastases, is concurrent chemoradiation an appropriate therapeutic option?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Concurrent chemoradiation is not appropriate in this scenario, as prior thoracic radiotherapy is a relative contraindication for repeat concurrent chemoradiation due to increased risk of cumulative toxicity; alternative approaches such as systemic therapy or observation should be considered.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_6d5c44f77d4e",
      "question": "A 68-year-old woman with progressive shortness of breath and dry cough is diagnosed with pulmonary fibrosis based on clinical and radiographic findings. Her arterial blood gas shows hypoxemia, and she is started on long-term supplemental oxygen therapy. In addition to improving her blood oxygenation, what pharmacological mechanism could explain a cellular protective effect of oxygen in the fibrotic lung tissue, specifically regarding mitigation of oxidative cellular damage?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Pulmonary Fibrosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0034069",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0030054",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Free radical scavenging activity",
      "reasoning_path": "Pulmonary fibrosis involves oxidative injury; oxygen therapy corrects hypoxemia and, via free radical scavenging activity, helps mitigate oxidative cellular damage in lung tissue.",
      "umls_path": [
        "Pulmonary Fibrosis",
        "may_be_treated_by",
        "Oxygen",
        "has_mechanism_of_action",
        "Free Radical Scavenging Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In patients with pulmonary fibrosis, chronic hypoxemia often necessitates supplemental oxygen therapy to improve tissue oxygenation. However, the pathophysiology of pulmonary fibrosis also involves oxidative stress and damage from reactive oxygen species (ROS), which contribute to ongoing epithelial injury and fibrotic remodeling. Oxygen, while essential for tissue metabolism, can paradoxically increase ROS production at high concentrations. Nonetheless, at therapeutic levels, oxygen may exert a protective effect by supporting endogenous antioxidant systems and facilitating the scavenging of free radicals. This free radical scavenging activity helps to reduce cellular injury from oxidative stress, which is particularly relevant in the inflamed and damaged pulmonary tissue characteristic of fibrosis. Thus, beyond its primary role in correcting hypoxemia, the free radical scavenging properties of oxygen contribute to cellular protection in this setting.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_7f96b41513db",
      "question": "A 42-year-old woman presents with progressive difficulty seeing at night and dry, rough skin. She reports a diet low in animal products and leafy vegetables. Ophthalmic examination reveals Bitot's spots, and laboratory tests confirm a low serum retinol level. She is started on a supplement that is a storage form of a fat-soluble vitamin important for vision and epithelial integrity. Which key molecular mechanism of this agent helps protect her ocular tissues in the context of her deficiency?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Unspecified vitamin A deficiency"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0042842",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0073115",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Free radical scavenging (antioxidant) activity",
      "reasoning_path": "Vitamin A deficiency leads to oxidative tissue stress; retinyl palmitate supplementation restores antioxidant (free radical scavenging) defenses, protecting ocular tissues.",
      "umls_path": [
        "Unspecified vitamin A deficiency",
        "may_be_treated_by",
        "Retinyl Palmitate",
        "has_mechanism_of_action",
        "Free Radical Scavenging Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient displays signs of vitamin A deficiency, such as night blindness (nyctalopia) and Bitot's spots. The therapy selected, retinyl palmitate, is an esterified storage form of vitamin A. Beyond its role as a precursor for retinal (essential for rhodopsin in phototransduction), vitamin A also acts as a potent antioxidant. In deficiency states, ocular and epithelial cells are more susceptible to oxidative damage due to impaired scavenging of reactive oxygen species (ROS). Retinyl palmitate helps restore antioxidant capacity by directly neutralizing free radicals, thereby reducing lipid peroxidation and cellular injury in eye tissues. This free radical scavenging activity is a key pharmacological mechanism underlying the therapeutic benefit of retinyl palmitate in patients with vitamin A deficiency, alongside its roles in vision and epithelial maintenance.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_5a5e2eb51512",
      "question": "For a patient with stage IIA (T2b, N0) non-small cell lung cancer who underwent complete resection (R0) and received no adjuvant chemotherapy or radiotherapy, is routine brain MRI indicated during scheduled surveillance if the patient is asymptomatic?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIA (T2b, N0); Margins negative (R0)",
              "Observe or Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, routine brain MRI is not indicated for surveillance in asymptomatic patients with stage IIA (T2b, N0) non-small cell lung cancer who had complete resection without adjuvant therapy. Surveillance should rely on history, physical examination, and chest CT; brain MRI is reserved for evaluations triggered by symptoms or suspected recurrence.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_cdfe51ec8541",
      "question": "A 34-year-old woman presents with redness, irritation, and mild swelling in her right eye for two days. There is no history of trauma, contact lens use, or systemic illness. Examination reveals conjunctival injection without discharge or corneal involvement. The ophthalmologist prescribes a topical suspension that suppresses ocular inflammation via modulation of arachidonic acid metabolism, ultimately reducing the synthesis of pro-inflammatory mediators. Through inhibition of which enzyme class does this medication achieve part of its anti-inflammatory effect in the conjunctival tissue?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Conjunctivitis, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0009763",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0724587",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lipoxygenase inhibitors—by decreasing leukotriene synthesis, thereby reducing inflammation.",
      "reasoning_path": "Corticosteroids inhibit phospholipase A2 → less arachidonic acid → less substrate for lipoxygenase → reduced leukotriene synthesis → decreased ocular inflammation.",
      "umls_path": [
        "Conjunctivitis, unspecified",
        "may_be_treated_by",
        "Fluorometholone Acetate",
        "has_mechanism_of_action",
        "Lipoxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Corticosteroid ophthalmic suspensions, such as fluorometholone, are used to treat inflammatory eye conditions like conjunctivitis. Their anti-inflammatory mechanism involves inhibiting phospholipase A2, which reduces arachidonic acid release from membrane phospholipids. This limits substrate availability for both cyclooxygenase (COX) and lipoxygenase (LOX) pathways. Specifically, inhibition of the lipoxygenase pathway decreases leukotriene synthesis, important mediators of inflammation, vascular permeability, and chemotaxis. Reduced leukotriene production leads to diminished recruitment of inflammatory cells and less conjunctival swelling and irritation. While corticosteroids exert broad effects, the suppression of lipoxygenase activity is a key contributor to their therapeutic action in ocular inflammation. Thus, inhibition of lipoxygenase enzymes is implicated in their mechanism of action in this setting.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_db53a54d11a2",
      "question": "A 68-year-old man with a history of intermittent calf pain on walking is diagnosed with peripheral arterial disease secondary to chronic atherosclerosis. After lifestyle interventions prove insufficient, his physician prescribes a vasodilator that acts by stimulating specific G protein-coupled receptors on vascular smooth muscle, leading to relaxation and increased peripheral blood flow. Which class of receptor is the primary molecular target of this medication's action in improving his claudication symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Arteriosclerosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003850",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0282213",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Beta-adrenergic receptors (adrenergic beta-agonists)",
      "reasoning_path": "Peripheral vascular disease → isoxsuprine prescribed → isoxsuprine stimulates beta-adrenergic receptors on vascular smooth muscle → increased cAMP → vasodilation → improved blood flow and symptoms.",
      "umls_path": [
        "Arteriosclerosis",
        "may_be_treated_by",
        "Isoxsuprine hydrochloride",
        "has_mechanism_of_action",
        "Adrenergic beta-Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with peripheral arterial disease due to atherosclerosis experiences symptoms of intermittent claudication related to reduced arterial blood flow. Isoxsuprine hydrochloride, the prescribed medication, is a vasodilator that works by stimulating beta-adrenergic receptors—specifically beta-2 receptors—on vascular smooth muscle. Activation of these G protein-coupled receptors increases intracellular cAMP, resulting in smooth muscle relaxation and vasodilation. This mechanism improves peripheral circulation and reduces symptoms of claudication by enabling greater blood flow to ischemic tissues. Thus, the therapeutic effect of isoxsuprine in peripheral vascular disease is mediated by its function as an adrenergic beta-agonist acting on beta-adrenergic receptors.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_a953c021e257",
      "question": "A 55-year-old man with no prior cardiovascular disease presents for routine evaluation. His fasting lipid panel reveals a total cholesterol of 270 mg/dL and LDL cholesterol of 180 mg/dL. After dietary interventions fail to sufficiently lower his LDL, his physician initiates a daily oral medication that acts by competitively inhibiting the hepatic enzyme responsible for converting HMG-CoA to mevalonate, a key step in cholesterol biosynthesis. What is the main molecular mechanism by which this therapy reduces serum cholesterol levels?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Hypercholesterolemia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020443",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1101838",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Inhibition of HMG-CoA reductase (hydroxymethylglutaryl-CoA reductase)",
      "reasoning_path": "Pitavastatin is a statin that lowers cholesterol by competitively inhibiting hepatic HMG-CoA reductase, reducing cholesterol synthesis and increasing LDL clearance.",
      "umls_path": [
        "Hypercholesterolemia",
        "may_be_treated_by",
        "Pitavastatin-containing product",
        "has_mechanism_of_action",
        "Hydroxymethylglutaryl-CoA Reductase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient has hypercholesterolemia with elevated LDL cholesterol despite lifestyle modification. Statins, such as pitavastatin, are the first-line pharmacologic agents for lowering LDL cholesterol. These drugs function by inhibiting HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for endogenous cholesterol synthesis in hepatocytes. By blocking this enzyme, statins decrease hepatic cholesterol production, leading to upregulation of LDL receptors on hepatocyte surfaces and increased clearance of circulating LDL particles. This dual mechanism—reduced synthesis and increased uptake—results in a significant reduction in serum LDL and total cholesterol, which lowers cardiovascular risk. The primary molecular target and mechanism is competitive inhibition of HMG-CoA reductase, distinguishing statins from other lipid-lowering agents such as bile acid sequestrants or PCSK9 inhibitors.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_77a103e7ef24",
      "question": "In a postmenopausal woman with ER-positive, HER2-negative, stage IV (M1) breast cancer without bone or visceral crisis, who has progressed on first-line endocrine therapy within one year, is immediate initiation of additional cytotoxic chemotherapy required, or is continuation of alternative lines of endocrine therapy still preferred until visceral crisis or unacceptable toxicity develops?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Metastatic (M1) invasive breast cancer",
              "Stage IV (M1) or Recurrent disease",
              "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
              "Stage IV (M1) or Recurrent",
              "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
              "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
              "Recurrent unresectable (local or regional) or stage IV (M1) disease",
              "Bone disease not present",
              "ER- and/or PR-positive; HER2-negative",
              "BINV-22",
              "No visceral crisis and Prior endocrine therapy within 1 y",
              "Postmenopausal",
              "Systemic therapy",
              "Continue endocrine therapy until progression or unacceptable toxicity",
              "Progression",
              "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy",
              "Alternate systemic therapy",
              "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
              "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
            ]
          }
        }
      ],
      "answer": "Continuation of alternative lines of endocrine therapy remains preferred until the onset of visceral crisis or unacceptable toxicity. Immediate initiation of additional cytotoxic chemotherapy is not required in the absence of visceral crisis, as sequential endocrine therapies should be exhausted first in ER-positive, HER2-negative, postmenopausal metastatic breast cancer.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_0a92ac3bbbf1",
      "question": "For a patient with resected stage IIA (T2b, N0) non-small cell lung cancer who has negative surgical margins (R0) and preserved pulmonary function, is adjuvant systemic therapy preferred over observation, or are both options considered appropriate according to current standard practice?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (peripheral T1abc, N0)",
              "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
              "Negative mediastinal nodes",
              "Operable",
              "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
              "Adjuvant Treatment (NSCL-4)",
              "Stage IIA (T2b, N0); Margins negative (R0)",
              "Observe or Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "Both observation and adjuvant systemic therapy are considered appropriate options for patients with stage IIA (T2b, N0) non-small cell lung cancer who have undergone complete surgical resection with negative margins (R0) and have preserved pulmonary function, as current practice guidelines do not mandate adjuvant therapy in this setting.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_4596175e8ce1",
      "question": "A 52-year-old woman with obesity, type 2 diabetes, and persistently elevated liver enzymes undergoes imaging that reveals increased hepatic fat without significant alcohol use. She is enrolled in a clinical trial for a novel oral medication that selectively binds to nuclear receptors in hepatocytes, leading to increased hepatic fatty acid oxidation and decreased lipogenesis. Which drug class best describes the mechanism of action of this investigational therapy?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Fatty Liver Disease"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3241937",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3850197",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Thyroid hormone receptor agonists",
      "reasoning_path": "NAFLD is treated by enhancing hepatic lipid metabolism; resmetirom acts as a selective thyroid hormone receptor-beta agonist, so its class is thyroid hormone receptor agonists.",
      "umls_path": [
        "Fatty Liver Disease",
        "may_be_treated_by",
        "Resmetirom",
        "has_mechanism_of_action",
        "Thyroid Hormone Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has nonalcoholic fatty liver disease (NAFLD), characterized by hepatic fat accumulation in the absence of significant alcohol intake. The described investigational agent, which increases fatty acid oxidation and reduces lipogenesis by acting on nuclear receptors in the liver, matches the mechanism of resmetirom. Resmetirom is a selective thyroid hormone receptor-beta (THR-β) agonist. THR-β receptors are primarily expressed in the liver, and their activation enhances transcription of genes involved in lipid metabolism, promoting breakdown of fatty acids and reducing fat synthesis. Unlike non-selective thyroid hormone agonists, selective THR-β agonists aim to provide metabolic benefits within the liver without significant systemic thyroid hormone effects. Thus, the drug class that encompasses this mechanism is 'thyroid hormone receptor agonists.'",
      "type": "kg_reasoning"
    },
    {
      "id": "path_34e15ecec405",
      "question": "In a patient with stage IIIA non-small cell lung cancer (T4 tumor invading the spine, N0–1), who also presents with mediastinal lymph node recurrence after initial surgery but has not previously received radiotherapy, is concurrent chemoradiation an appropriate treatment option?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, for stage IIIA NSCLC patients with mediastinal lymph node recurrence after surgery and no prior radiotherapy, concurrent chemoradiation is an established treatment strategy, as the absence of previous thoracic radiation allows for definitive local therapy targeting locoregional recurrence.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_d4d8eec0fcab",
      "question": "A 41-year-old woman is diagnosed with a hepatic trematode infection after presenting with right upper quadrant pain and eosinophilia. She is prescribed a medication historically used for amoebiasis, but occasionally utilized off-label for her parasitic infection. When reviewing her case, the clinical team notes that while the drug is effective in some contexts, the precise way it acts at the cellular or molecular level against this particular parasite is not well established. What is currently understood about the mechanism of action of this therapeutic agent in treating her infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Infection by Fascioloides"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0015655",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0282162",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The cellular or molecular mechanism of action of Emetine Hydrochloride against Fascioloides infection is currently unknown.",
      "reasoning_path": "Fascioloides infection may be treated with Emetine Hydrochloride, but the specific cellular or molecular mechanism by which it acts against this parasite is uncharacterized.",
      "umls_path": [
        "Infection by Fascioloides",
        "may_be_treated_by",
        "Emetine Hydrochloride",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Emetine Hydrochloride has been used to treat various protozoal and some helminthic infections. In the case of hepatic trematode infections such as those caused by Fascioloides species, its use is based on observed antiparasitic effects rather than a clearly defined molecular mechanism. While Emetine is known to inhibit protein synthesis in some protozoa by acting on the 40S ribosomal subunit, there is no definitive evidence describing its molecular target or cellular pathway in Fascioloides parasites. Thus, its antiparasitic action in this context remains uncharacterized in current pharmacological literature.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_12405bba9a6b",
      "question": "In ClinicalTrials.gov, what interventional studies for Type 2 Diabetes Mellitus involving exenatide or long acting release exenatide started in April 2006 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "conditions=Type 2 Diabetes Mellitus;interventions.name=exenatide,long acting release,exenatide;startDateFrom=2006-04-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00308139"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_ddeef184a722",
      "question": "In a patient with newly diagnosed metastatic squamous cell carcinoma of the lung who has negative results for EGFR, ALK, KRAS, ROS1, BRAF, NTRK, METex14 skipping, RET, and ERBB2 (HER2) mutations, as well as PD-L1 expression less than 1%, does this molecular profile preclude the use of first-line targeted therapy, and does it directly indicate the priority of systemic chemotherapy over targeted treatments?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "PD-L1 <1% and negative for actionable molecular biomarkers above"
            ]
          }
        }
      ],
      "answer": "Yes, the absence of actionable molecular alterations and low PD-L1 expression preclude first-line targeted therapy in metastatic squamous cell lung cancer. In this context, systemic chemotherapy becomes the preferred initial treatment, as there are no molecular targets or high PD-L1 expression to justify targeted or immunotherapy as first-line options.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_714b2e836488",
      "question": "In a patient with newly diagnosed stage IIIA non-small cell lung cancer (T1–2, N3), if mediastinal N3 involvement is confirmed only by FDG-PET/CT without pathologic verification via biopsy or mediastinoscopy, is it clinically justified to proceed directly to systemic therapy for metastatic disease?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (peripheral T1abc, N0)",
              "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, reliance solely on FDG-PET/CT for N3 mediastinal node involvement is insufficient to define metastatic disease; pathologic confirmation through biopsy or mediastinoscopy is required before systemic therapy is initiated, as imaging alone may produce false positives.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_43ec4e5c9804",
      "question": "An 82-year-old woman with advanced dementia, limited mobility, and a history of type 2 diabetes presents with a non-healing ulcer over her sacrum that has persisted for several months despite standard wound care. Her physician considers adding a compound known to chelate metal ions and protect gastric mucosa, which also exhibits unique effects on cellular signaling pathways. This agent enhances wound healing by influencing gene expression patterns critical for cellular proliferation and tissue repair. Through what primary molecular mechanism does this agent promote recovery in chronic pressure ulcers?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Pressure injury"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4554531",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0286382",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Modulation of transcription factor activity",
      "reasoning_path": "Chronic pressure injury → impaired healing → polaprezinc considered → modulates transcription factors (e.g., NF-κB, Nrf2) → alters gene expression → promotes wound healing.",
      "umls_path": [
        "Pressure injury",
        "may_be_treated_by",
        "polaprezinc",
        "has_mechanism_of_action",
        "Transcription Factor Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Chronic pressure injuries are characterized by impaired healing due to sustained inflammation, poor perfusion, and dysregulated cellular responses. The agent under consideration, polaprezinc, is a chelated complex of zinc and L-carnosine originally used for gastric ulcers, but has shown promise in wound healing. Its beneficial effects in pressure injuries are attributed to the modulation of transcription factor activity within cells at the wound site. Specifically, polaprezinc can influence the activity of transcription factors such as NF-κB and Nrf2, which regulate the expression of genes involved in antioxidant defenses, inflammation, and cell proliferation. By altering the transcriptional profile of wound-associated cells, polaprezinc promotes a microenvironment favorable to tissue repair and regeneration. This molecular mechanism—direct modulation of transcription factor activity—distinguishes it from therapies that act solely via antimicrobial, structural, or metabolic pathways.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_27993ae156c2",
      "question": "A 45-year-old man recently immigrated from East Asia and presents with right upper quadrant discomfort and a history of eating raw freshwater fish. Stool examination reveals operculated eggs consistent with a liver fluke infection. He is started on a medication that targets helminth microtubule formation but is also known to alter hepatic drug metabolism. If this patient is prescribed another medication metabolized by a specific hepatic enzyme, which pharmacokinetic interaction should be anticipated due to this therapy’s effect on hepatic enzymes?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Clonorchiasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0009021",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001911",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Albendazole induces cytochrome P450 1A, potentially increasing clearance and reducing plasma concentrations of co-administered drugs metabolized by CYP1A.",
      "reasoning_path": "Liver fluke infection → albendazole therapy → CYP1A induction → increased metabolism of CYP1A substrates → possible reduced efficacy of co-administered drugs.",
      "umls_path": [
        "Clonorchiasis",
        "may_be_treated_by",
        "Albendazole",
        "has_mechanism_of_action",
        "Cytochrome P450 1A Inducers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Albendazole is commonly used to treat liver fluke infections such as clonorchiasis. Beyond its antiparasitic mechanism of disrupting helminth microtubule polymerization, albendazole can induce hepatic cytochrome P450 1A (CYP1A) enzymes. Induction of CYP1A increases the metabolic activity of the liver toward drugs that are substrates of this enzyme, potentially leading to decreased effectiveness of those drugs by accelerating their clearance from the body. Therefore, when albendazole is co-administered with other medications metabolized by CYP1A, clinicians must consider the potential for reduced therapeutic levels and possible loss of efficacy. Understanding this interaction is important for safe and effective pharmacologic management in patients requiring albendazole.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_30afef1e813b",
      "question": "A 32-year-old woman presents with multiple rough, skin-colored papules on the dorsal surface of her hands. She reports that these lesions have persisted for several months, gradually increasing in size and number. After clinical assessment, she is diagnosed with common warts and is prescribed an over-the-counter medication containing magnesium salicylate tetrahydrate. Upon researching its use for this indication, you find that its specific cellular or molecular mechanism for treating these lesions is not clearly defined in the literature. What is the mechanistic classification for this drug's action in the management of her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Verruca vulgaris"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3665596",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0795642",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown Cellular or Molecular Interaction",
      "reasoning_path": "Patient with verruca vulgaris is treated with magnesium salicylate tetrahydrate; literature review reveals the mechanism in this setting is uncharacterized, so it is classified as unknown cellular or molecular interaction.",
      "umls_path": [
        "Verruca vulgaris",
        "may_be_treated_by",
        "magnesium salicylate tetrahydrate",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient has verruca vulgaris (common warts), a viral skin infection usually managed with topical therapies. Magnesium salicylate tetrahydrate is sometimes used off-label for this condition, yet its mechanistic action in wart treatment is not described in reputable pharmacological sources or established medical literature. While salicylates can act as keratolytics and anti-inflammatory agents, there is no evidence detailing how magnesium salicylate tetrahydrate impacts the viral life cycle, keratinocyte proliferation, or immune response in verruca vulgaris. Therefore, its mechanistic classification in this clinical context is considered 'unknown cellular or molecular interaction.'",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_6e889cabf449",
      "question": "A 54-year-old woman presents with shortness of breath and chest discomfort. Imaging reveals a pleural effusion, and thoracentesis yields a milky, triglyceride-rich fluid. She is diagnosed with an accumulation of lymphatic fluid in the pleural space. Her physician initiates a dietary regimen that replaces long-chain fats with a specific type of lipid, aiming to reduce lymphatic flow and pleural fluid accumulation. Which molecular component is most directly bypassed by this dietary intervention, explaining its therapeutic effect in this condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Chylothorax"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0008733",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0724624",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Chylomicron structural macromolecules (e.g., apolipoproteins, phospholipids)",
      "reasoning_path": "Chylothorax involves chyle (chylomicron-rich lymph) in the pleural space. MCTs are absorbed straight into the portal vein and do not require chylomicron formation, thus bypassing the need for structural macromolecules used in chylomicron assembly and reducing lymphatic lipid transport.",
      "umls_path": [
        "Chylothorax",
        "may_be_treated_by",
        "Medium chain triglyceride-containing product",
        "has_mechanism_of_action",
        "Structural Macromolecules"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In chylothorax, lymphatic fluid rich in chylomicrons accumulates in the pleural space due to disruption or obstruction of the thoracic duct. The standard non-surgical intervention is dietary modification, specifically substituting long-chain triglycerides (LCTs) with medium-chain triglycerides (MCTs). Unlike LCTs, which require packaging into chylomicrons—a process involving structural macromolecules like apolipoproteins and phospholipids—MCTs are absorbed directly into the portal circulation and do not enter the lymphatic system. This bypasses the need for chylomicron assembly and transport via lymphatics, thereby reducing the flow of chyle and subsequent pleural accumulation. Thus, the structural macromolecules involved in chylomicron formation are the primary molecular targets circumvented by MCT-based dietary therapy, explaining its beneficial mechanism in managing chylothorax.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_ff753b223368",
      "question": "A 38-year-old man with advanced HIV presents with altered mental status and focal neurological deficits. MRI of the brain reveals multiple ring-enhancing lesions. He is diagnosed with a viral encephalitis due to a herpesvirus, and therapy is initiated with a drug that must be activated by viral kinases before inhibiting a specific viral enzyme responsible for elongating DNA strands. Which class of antiviral medications is most directly responsible for halting viral replication in this setting by interfering with synthesis of new viral genomes?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "AIDS Associated Opportunistic Infection"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0162526",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001367",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "DNA polymerase inhibitors",
      "reasoning_path": "AIDS → opportunistic viral infection (herpesvirus) → antiviral therapy (acyclovir/ganciclovir) → drug activation by viral kinase → inhibition of viral DNA polymerase → blockade of viral DNA synthesis → halted viral replication.",
      "umls_path": [
        "AIDS Associated Opportunistic Infection",
        "may_be_treated_by",
        "Acyclovir",
        "has_mechanism_of_action",
        "DNA Polymerase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with AIDS and opportunistic viral encephalitis (such as herpes simplex virus or cytomegalovirus) is treated with an antiviral that requires activation by viral kinases and subsequently inhibits the viral DNA polymerase enzyme. Drugs such as acyclovir, ganciclovir, and related agents are nucleoside analogs that, once phosphorylated, act as chain terminators and directly inhibit the activity of viral DNA polymerase. By blocking this enzyme, these drugs prevent the synthesis of viral DNA, thereby stopping viral replication. This mechanism is crucial for controlling opportunistic viral infections in immunocompromised patients, as their immune systems are unable to clear these viruses effectively. DNA polymerase inhibitors are therefore the mainstay of therapy for herpesvirus-related encephalitis and other similar opportunistic infections in patients with AIDS.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_a7fdc4368e22",
      "question": "A 34-year-old woman presents with ongoing erythematous, flaky patches and mild pruritus affecting her cheeks and forehead. She reports using a prescribed topical cream that has provided moderate relief. The medication is a synthetic corticosteroid ester designed for high skin penetration and reduced systemic effects. Its anti-inflammatory benefit derives in part from suppressing the biosynthesis of leukotrienes and other mediators by blocking a key enzyme in arachidonic acid metabolism. Which enzyme inhibition is a principal contributor to the therapeutic actions of this topical treatment in her facial skin condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Dermatoses, Facial"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0015456",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0082944",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lipoxygenase",
      "reasoning_path": "Facial dermatoses are treated with topical corticosteroids like hydrocortisone aceponate, which suppress inflammation through direct inhibition of lipoxygenase, thereby reducing leukotriene-mediated inflammatory responses in the skin.",
      "umls_path": [
        "Dermatoses, Facial",
        "may_be_treated_by",
        "Hydrocortisone aceponate",
        "has_mechanism_of_action",
        "Lipoxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient’s persistent facial dermatoses are treated with hydrocortisone aceponate, a topical corticosteroid formulated for enhanced local effect. Corticosteroids exert anti-inflammatory effects by multiple mechanisms, including induction of lipocortin, which inhibits phospholipase A2, thus reducing arachidonic acid release. Downstream, corticosteroids also decrease the activity of cyclooxygenase (COX) and lipoxygenase enzymes, both of which convert arachidonic acid into pro-inflammatory mediators. Lipoxygenase catalyzes the formation of leukotrienes, potent chemotactic and inflammatory agents involved in skin inflammation. By suppressing lipoxygenase, hydrocortisone aceponate reduces leukotriene synthesis, diminishing inflammation and symptoms in facial dermatoses. This mechanism complements the overall immunosuppressive and anti-inflammatory actions of corticosteroids, helping to control erythema, swelling, and pruritus in localized skin diseases.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_c71cd61de7ab",
      "question": "In ClinicalTrials.gov, which interventional studies for Relapsing-Remitting Multiple Sclerosis with BG00012 as a main intervention started in January 2007 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "conditions=Relapsing-Remitting Multiple Sclerosis;interventions.name=BG00012;startDateFrom=2007-01-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00420212"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_6a18d26b06d9",
      "question": "A 42-year-old man presents with persistent fatigue, low-grade fever, and pruritus. Laboratory studies reveal marked eosinophilia (absolute eosinophil count > 1,500/µL) and evidence of end-organ involvement, including mild hepatomegaly and an elevated serum creatinine. After other secondary causes are excluded, he is diagnosed with an idiopathic disorder characterized by sustained eosinophilia and tissue damage. He is started on a recombinant cytokine therapy that exerts its effects by broadly modulating immune cell activity and inhibiting abnormal eosinophil proliferation. Which general drug class best describes the mechanism by which this therapy achieves its clinical benefit in this disorder?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Hypereosinophilic syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1540912",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0164613",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Biological Response Modifiers",
      "reasoning_path": "Hypereosinophilic syndrome features uncontrolled eosinophil proliferation. Interferon Alfacon-1, a recombinant cytokine, is used therapeutically for its immune-modulating actions. Its mechanism is best described as that of a biological response modifier, as it alters immune cell function to reduce eosinophil-mediated pathology.",
      "umls_path": [
        "Hypereosinophilic syndrome",
        "may_be_treated_by",
        "Interferon Alfacon-1",
        "has_mechanism_of_action",
        "Biological Response Modifiers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s presentation is consistent with hypereosinophilic syndrome, a disorder marked by sustained, unexplained eosinophilia and organ dysfunction. One therapeutic strategy is the use of Interferon Alfacon-1, a recombinant type I interferon. Interferon Alfacon-1 acts by enhancing the cytotoxic capabilities of immune effector cells and suppressing aberrant eosinophil proliferation. Instead of targeting a single molecular pathway, this agent broadly modulates immune responses, altering cytokine production and immune cell activity. Drugs that work by altering the host’s immune response to achieve therapeutic effects are classified as biological response modifiers. This class includes various agents (such as interferons and interleukins) that modify the immune system’s activity to treat malignancies, autoimmune conditions, or immune-mediated disorders like hypereosinophilic syndrome.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_f322f2f404f1",
      "question": "A 68-year-old man presents with progressive shortness of breath and a dry cough over the past year. High-resolution CT of the chest reveals reticular opacities and honeycombing predominantly in the lower lung zones. Lung biopsy confirms usual interstitial pneumonia. He is started on a medication that inhibits multiple receptor tyrosine kinases involved in fibroblast proliferation and angiogenesis. Which receptor, when inhibited by this therapy, directly contributes to reducing fibroblast activity and limiting fibrotic progression in his condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Idiopathic Pulmonary Fibrosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1800706",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3529778",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Vascular Endothelial Growth Factor Receptor",
      "reasoning_path": "IPF involves fibroblast-driven fibrosis; nintedanib inhibits VEGF receptor signaling, reducing fibroblast activity and angiogenesis to slow disease progression.",
      "umls_path": [
        "Idiopathic Pulmonary Fibrosis",
        "may_be_treated_by",
        "Nintedanib esilate",
        "has_target",
        "Vascular Endothelial Growth Factor Receptor"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has idiopathic pulmonary fibrosis (IPF), a disease characterized by progressive scarring of the lung interstitium due to abnormal fibroblast proliferation and excess extracellular matrix deposition. Nintedanib, an approved therapy for IPF, is a small-molecule tyrosine kinase inhibitor that targets several growth factor receptors, including the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR). Inhibition of VEGFR is particularly important in IPF, as VEGF signaling contributes to aberrant angiogenesis and fibroblast activation, both of which are implicated in the pathogenesis of pulmonary fibrosis. By blocking VEGFR-mediated signaling, nintedanib reduces fibroblast proliferation, migration, and collagen deposition, thereby slowing fibrotic progression and preserving lung function.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_1658c5caf59e",
      "question": "For a patient with stage I non-small cell lung cancer who has undergone surgical resection but whose surgical margins are positive (R1 or R2), is surveillance with regular chest CT imaging a sufficient post-operative strategy, or is additional local treatment always indicated?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (T2a, N0); Margins positive (R1, R2)",
              "Resection (preferred) ± systemic therapy or RT",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Surveillance alone is not sufficient for a stage I non-small cell lung cancer patient with positive surgical margins (R1 or R2) after resection. Additional local treatment, such as re-resection or radiotherapy, is generally indicated to address the residual disease risk before initiating routine surveillance imaging.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_39df7b0bb22f",
      "question": "In a patient with stage IIIB non-small cell lung cancer characterized by T1–2 primary tumor and confirmed N3 nodal involvement, if the pulmonary function tests reveal severely impaired lung function, is surgical resection still considered an appropriate initial treatment option compared to non-surgical local therapies such as external-beam radiation or SABR?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "N3 nodes positive, M0",
              "Stage IIIB or Stage IIIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Surgical resection is generally contraindicated in patients with stage IIIB NSCLC and severely impaired pulmonary function. In such cases, non-surgical local therapies like external-beam radiation therapy or stereotactic ablative radiotherapy (SABR) are preferred due to unacceptable operative risk and likely poor postoperative outcomes.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_d167777f40cb",
      "question": "For a patient with localized, operable, non-inflammatory, non-metastatic (M0) breast cancer that is HR-positive and HER2-positive, if the pathological complete response (pCR, ypT0N0) is achieved after preoperative systemic therapy, is adjuvant HER2-directed therapy with trastuzumab ± pertuzumab still indicated regardless of initial nodal status?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS possible",
              "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
              "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
              "HR-positive/ HER2-positive",
              "ypT0N0 or pCR",
              "Endocrine therapy (category 1) + complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
            ]
          }
        }
      ],
      "answer": "Yes, adjuvant HER2-directed therapy with trastuzumab is indicated for all HR-positive/HER2-positive patients achieving pCR after preoperative systemic therapy, with the addition of pertuzumab for initially node-positive cases; the need for HER2-targeted therapy does not depend on achievement of pCR alone.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_fb7e0bb20b46",
      "question": "A 68-year-old woman with a history of hypertension and a recent ischemic cerebrovascular event is prescribed a new oral medication to improve blood flow characteristics and reduce the risk of further complications. The drug is known to have hemorheologic effects, improving erythrocyte flexibility and decreasing blood viscosity, but its precise mechanism at the cellular and molecular level is not fully characterized. Which best describes the current understanding of this therapy's mechanism of action in stroke patients?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Stroke"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0038454",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0030899",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction (precise mechanism not fully characterized)",
      "reasoning_path": "Ischemic stroke is sometimes managed with pentoxifylline for its hemorheologic effects, but the drug's precise cellular or molecular mechanism remains undetermined.",
      "umls_path": [
        "Stroke",
        "may_be_treated_by",
        "Pentoxifylline",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is being treated with a hemorheologic agent after an ischemic stroke. Pentoxifylline is a medication sometimes used to improve microcirculatory blood flow by reducing blood viscosity and increasing erythrocyte flexibility. Although its clinical benefit in certain vascular disorders is recognized, the precise cellular and molecular mechanisms by which pentoxifylline exerts these effects remain unclear. It is proposed to act through various biochemical pathways, including inhibition of phosphodiesterase and modulation of cytokine production, but no single well-defined target has been established. As such, the therapy's mechanism of action is best described as unknown or incompletely understood at the cellular and molecular levels.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_2b001ec4e3d5",
      "question": "A 19-year-old woman with a history of recurrent oral and cutaneous fungal infections is diagnosed with a rare, inherited immunodeficiency causing chronic mucocutaneous candidiasis. Topical therapy with a violet-colored dye is initiated, as standard antifungals have failed. According to current pharmacological references, what is known about this agent’s cellular or molecular mechanism of action in the treatment of her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Chronic Mucocutaneous Candidiasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0006845",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3848552",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The precise cellular or molecular mechanism of gentian violet cation’s antifungal activity is unknown.",
      "reasoning_path": "Gentian violet is used for chronic mucocutaneous candidiasis. Unlike many antifungals, its exact cellular or molecular mechanism is not established in major pharmacological references.",
      "umls_path": [
        "Chronic Mucocutaneous Candidiasis",
        "may_be_treated_by",
        "gentian violet cation",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Gentian violet is occasionally used as a topical antifungal agent for chronic mucocutaneous candidiasis, particularly when other treatments are ineffective or unavailable. Despite its long history of clinical use, authoritative pharmacological sources do not delineate a well-characterized or specific cellular or molecular mechanism of action for gentian violet’s antifungal effects. The compound is believed to interfere with cellular processes in fungi, but the exact targets or pathways at the molecular level remain unidentified. This lack of mechanistic clarity distinguishes gentian violet from other antifungals, such as azoles or polyenes, whose mechanisms are well defined (e.g., inhibition of ergosterol synthesis or disruption of fungal membranes). Therefore, when asked about how gentian violet cation exerts its antifungal effects, the most accurate answer—based on current pharmacological literature—is that its molecular mechanism remains unknown.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_c6e9e8e5b379",
      "question": "A 19-year-old woman presents with severe lower abdominal cramping and pelvic pain that occur predictably during the first two days of her menstrual periods. She reports that these symptoms have been present since menarche and are not associated with heavy bleeding or other medical conditions. Her clinician recommends an over-the-counter medication that provides rapid symptom relief by blocking the cyclooxygenase step in prostaglandin synthesis, thereby decreasing uterine muscle contractions and pain. Which specific enzyme is directly inhibited by this medication to achieve its therapeutic effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Dysmenorrhea"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0013390",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020740",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 1 (Cyclooxygenase-1)",
      "reasoning_path": "Dysmenorrhea is mediated by excess prostaglandins. NSAIDs (e.g., ibuprofen) block prostaglandin synthesis by inhibiting prostaglandin G/H synthase 1 (COX-1), thus alleviating pain.",
      "umls_path": [
        "Dysmenorrhea",
        "may_be_treated_by",
        "Ibuprofen",
        "has_target",
        "Prostaglandin G/H Synthase 1"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Primary dysmenorrhea is caused by excessive endometrial prostaglandin production, which increases uterine contractility and pain during menstruation. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen are first-line therapies for this condition. NSAIDs exert their effect by directly inhibiting cyclooxygenase enzymes—specifically, prostaglandin G/H synthase 1 (COX-1)—which catalyze the conversion of arachidonic acid to prostaglandin precursors. By blocking this step, NSAIDs reduce the synthesis of prostaglandins in the endometrium, leading to decreased uterine contractions and relief of menstrual pain. Thus, the therapeutic benefit in dysmenorrhea is achieved through direct inhibition of prostaglandin G/H synthase 1.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_520e17923d16",
      "question": "In a patient with non-small cell lung cancer staged as IIIB (T1–2, N3) confirmed by mediastinal lymph node biopsy, but with severely impaired pulmonary function on PFTs, is surgical resection still considered an appropriate initial treatment option?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "N3 nodes positive, M0",
              "Stage IIIB or Stage IIIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease"
            ]
          }
        }
      ],
      "answer": "No, surgical resection is not considered appropriate for stage IIIB (T1–2, N3) non-small cell lung cancer, especially when the patient presents with significantly impaired pulmonary function. For this stage and N3 involvement, non-surgical modalities such as chemoradiotherapy are standard; poor pulmonary reserve further contraindicates surgery due to high operative risk.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_a3bccfd7e2f3",
      "question": "A 42-year-old woman with a history of hypertension and lower extremity edema is diagnosed with nephrotic syndrome after presenting with periorbital swelling, heavy proteinuria, and hypoalbuminemia. She is started on a diuretic that is structurally distinct from classic thiazides but exhibits similar natriuretic effects, and is known to act on renal tubule ion channels. Which renal tubular ion channel is primarily targeted to achieve therapeutic diuresis in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Nephrotic Syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0027726",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021186",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Potassium channels in the distal convoluted tubule",
      "reasoning_path": "Nephrotic syndrome causes edema → indapamide is prescribed → indapamide acts on the distal tubule → it inhibits sodium-chloride symporters and modulates potassium channels → potassium channel modulation enhances natriuresis and diuresis → edema improves.",
      "umls_path": [
        "Nephrotic Syndrome",
        "may_be_treated_by",
        "Indapamide",
        "has_mechanism_of_action",
        "Potassium Channel Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In nephrotic syndrome, sodium and water retention lead to edema. Thiazide-like diuretics such as indapamide are often used when loop diuretics are insufficient. Indapamide’s diuretic effect is achieved by inhibiting sodium-chloride symporters in the distal convoluted tubule, but it also modulates potassium channels. By interacting with potassium channels, indapamide alters tubular cell membrane potential, which enhances sodium and water excretion and further influences electrolyte handling. This dual action helps reduce fluid overload in nephrotic syndrome. The modulation of potassium channels is therefore a significant mechanism by which indapamide promotes diuresis and resolves edema in this context.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_93734ec40c2e",
      "question": "A 45-year-old man presents with persistent fatigue, weight loss, and a pruritic skin rash. Laboratory tests reveal marked leukocytosis and a peripheral eosinophil count of 12,000/μL. Bone marrow biopsy shows eosinophilic hyperplasia without evidence of acute leukemia. Molecular testing identifies a FIP1L1-PDGFRA fusion gene. He is started on a medication that selectively inhibits a receptor tyrosine kinase implicated in abnormal eosinophil proliferation, resulting in a dramatic reduction in eosinophil count and symptom resolution. Which molecular target does this medication most directly inhibit to achieve clinical benefit in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Hypereosinophilic syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1540912",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0935989",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Mast/Stem Cell Growth Factor Receptor Kit (KIT)",
      "reasoning_path": "Hypereosinophilic syndrome with a FIP1L1-PDGFRA fusion is treated with imatinib, which exerts its effect by inhibiting the Mast/Stem Cell Growth Factor Receptor Kit (KIT), reducing abnormal eosinophil proliferation.",
      "umls_path": [
        "Hypereosinophilic syndrome",
        "may_be_treated_by",
        "Imatinib",
        "has_target",
        "Mast/Stem Cell Growth Factor Receptor Kit"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has a myeloproliferative variant of hypereosinophilic syndrome associated with a FIP1L1-PDGFRA fusion gene, which drives constitutive activation of a receptor tyrosine kinase. Imatinib, a tyrosine kinase inhibitor, is used in this setting due to its ability to selectively inhibit several kinases, including the platelet-derived growth factor receptor (PDGFRA) and the Mast/Stem Cell Growth Factor Receptor Kit (KIT). Inhibition of KIT is particularly relevant in cases where aberrant activation of this receptor contributes to pathological eosinophil proliferation and survival. By blocking the ATP-binding site of the KIT receptor, imatinib disrupts downstream proliferative signaling, thereby reducing eosinophil production and ameliorating symptoms. Thus, the primary molecular target in imatinib’s therapeutic effect for this condition is the KIT receptor.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_2e2b5786e4c4",
      "question": "For a patient with advanced nonsquamous non-small cell lung cancer showing bone metastases and an identified elevated risk of fracture, is it appropriate to proceed directly with systemic therapy without first considering orthopedic stabilization and palliative radiotherapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Bone metastases",
              "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "PD-L1 <1% and negative for actionable molecular biomarkers above"
            ]
          }
        }
      ],
      "answer": "No, for advanced nonsquamous NSCLC with bone metastases and a high fracture risk, orthopedic stabilization and palliative external-beam radiotherapy should be prioritized before systemic therapy to prevent pathological fracture and associated morbidity.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_e540f7b8330d",
      "question": "In a patient with advanced squamous cell lung carcinoma who is found to have an ERBB2 (HER2) mutation and retains a performance status of 0–2 after progression on first-line therapy, is ado-trastuzumab emtansine considered a standard treatment option only if fam-trastuzumab deruxtecan-nxki is not available or not tolerated?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "ERBB2 (HER2) mutation positive",
              "ERBB2 (HER2) mutation",
              "Progression",
              "Preferred: Fam-trastuzumab deruxtecan-nxki or Other Recommended: Ado-trastuzumab emtansine",
              "Progression",
              "PS 0–2",
              "Systemic Therapy, Subsequent"
            ]
          }
        }
      ],
      "answer": "Yes, in this clinical setting, fam-trastuzumab deruxtecan-nxki is prioritized as the preferred systemic therapy after progression, while ado-trastuzumab emtansine is regarded as an alternative when the preferred agent is unavailable or not tolerated, reflecting established treatment sequencing for ERBB2 (HER2)-mutant squamous cell lung carcinoma.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_ed06a1bd6f10",
      "question": "In a premenopausal woman with recurrent, unresectable, ER- and/or PR-positive, HER2-negative stage IV metastatic breast cancer, with no visceral crisis and no prior endocrine therapy within the last year, is the use of selective estrogen receptor modulators contingent on confirmation of hormone receptor positivity via new biopsy at recurrence, or can the original primary tumor status be solely relied upon to guide therapy selection?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Metastatic (M1) invasive breast cancer",
              "Stage IV (M1) or Recurrent disease",
              "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
              "Stage IV (M1) or Recurrent",
              "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
              "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
              "Recurrent unresectable (local or regional) or stage IV (M1) disease",
              "Bone disease not present",
              "ER- and/or PR-positive; HER2-negative",
              "BINV-22",
              "No visceral crisis and No prior endocrine therapy within 1 y",
              "Premenopausal",
              "Selective ER modulators",
              "Continue endocrine therapy until progression or unacceptable toxicity",
              "Progression",
              "Progression or unacceptable toxicity on first-line endocrine therapy",
              "Systemic therapy",
              "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
              "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
            ]
          }
        }
      ],
      "answer": "Selective estrogen receptor modulators should be used based on the current hormone receptor status, which requires confirmation of ER and PR expression on a biopsy of at least the first recurrence. Treatment decisions should not rely solely on the primary tumor profile, as receptor status may change at recurrence.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_9781276a4168",
      "question": "A patient with invasive, non-inflammatory, non-metastatic breast cancer is clinically staged as cT1c, cN0, and has HER2-positive disease. Is preoperative systemic therapy a justified approach in this case, or is it recommended only for cT2 or node-positive tumors?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS not possible",
              "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
              "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
              "HR-positive/ HER2-negative",
              "ypT0N0 or pCR",
              "Adjuvant endocrine therapy (category 1)"
            ]
          }
        }
      ],
      "answer": "Preoperative systemic therapy is justified for cT1c, cN0, HER2-positive breast cancer. Its indication is not confined to cT2 or node-positive cases; HER2-positive status in cT1c tumors serves as an independent criterion warranting neoadjuvant systemic treatment.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_e4854c2ea5d6",
      "question": "In a patient with non-small cell lung cancer classified as stage IIIB (T1–2, N3), if pathologic confirmation of N3 disease has not yet been obtained but clinical evidence strongly suggests N3 involvement on imaging, is it acceptable to proceed directly with definitive chemoradiotherapy without invasive nodal sampling?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "N3 nodes positive, M0",
              "Stage IIIB or Stage IIIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treatment"
            ]
          }
        }
      ],
      "answer": "No, proceeding with definitive chemoradiotherapy in stage IIIB (T1–2, N3) non-small cell lung cancer requires pathologic confirmation of N3 nodal involvement. Imaging alone is insufficient for treatment planning; invasive sampling such as mediastinoscopy, EBUS, or needle biopsy is mandatory to establish N3 disease before initiating definitive therapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_82896b3997ad",
      "question": "A 45-year-old recreational tennis player presents with persistent lateral elbow pain that worsens with activity and has not improved after several months of conservative therapy. His physician prescribes a nonsteroidal anti-inflammatory drug that, in addition to its cyclooxygenase inhibition, is known to modulate intracellular cyclic nucleotide signaling by inhibiting a specific phosphodiesterase isozyme. Through which molecular target does this medication most directly exert its additional anti-inflammatory effects relevant to tendinopathy?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Tendinopathy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1568272",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0038792",
            "rela": "has_target"
          }
        }
      ],
      "answer": "cGMP-specific 3',5'-cyclic phosphodiesterase",
      "reasoning_path": "Chronic tendinopathy → sulindac prescribed → sulindac inhibits COX and cGMP-specific phosphodiesterase → increased cGMP → anti-inflammatory effect.",
      "umls_path": [
        "Tendinopathy",
        "may_be_treated_by",
        "Sulindac",
        "has_target",
        "cGMP-Specific 3',5'-Cyclic Phosphodiesterase"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has chronic lateral epicondylitis (tendinopathy) treated with sulindac, an NSAID. While its primary mechanism is inhibition of cyclooxygenase (COX) enzymes, sulindac and its metabolites also inhibit cGMP-specific 3',5'-cyclic phosphodiesterase (PDE), leading to increased intracellular cGMP levels. Elevated cGMP can modulate various cellular processes, including reducing inflammatory signaling and altering pain pathways. Inhibition of this PDE isozyme is particularly relevant in tissues with ongoing inflammation, such as chronic tendinopathy, as it dampens pro-inflammatory mediator release and may promote resolution of tissue injury. Therefore, sulindac’s action on cGMP-specific 3',5'-cyclic phosphodiesterase represents a secondary but significant mechanism that contributes to its therapeutic effect in musculoskeletal inflammatory conditions.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_50c7016c7498",
      "question": "For a patient with stage IIIC (T3, N3) non-small cell lung cancer (NSCLC) and pathologically confirmed squamous cell carcinoma, is broad molecular profiling, including EGFR, ALK, ROS1, and other common oncogenic drivers, still recommended, or should molecular testing be limited due to the histologic subtype?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Broad molecular profiling is still recommended in advanced or metastatic squamous cell carcinoma, as actionable mutations such as EGFR, BRAF, MET, and others can occasionally occur. Therefore, comprehensive molecular testing including PD-L1 assessment should be conducted regardless of the squamous histology.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_817e329fe091",
      "question": "For a patient with newly diagnosed stage IVA, M1b squamous cell carcinoma of the lung harboring an EGFR S768I mutation, is erlotinib an appropriate first-line systemic therapy regardless of the patient's smoking history?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "EGFR S768I, L861Q, and/or G719X mutation positive",
              "EGFR S768I, L861Q, and/or G719X mutations",
              "EGFR mutation discovered prior to first-line systemic therapy",
              "Other Recommended: Erlotinib or Gefitinib or Dacomitinib",
              "Progression",
              "Subsequent Therapy (NSCL-23)"
            ]
          }
        }
      ],
      "answer": "Yes, erlotinib is an appropriate first-line systemic therapy for a patient with stage IVA, M1b squamous cell carcinoma harboring an EGFR S768I mutation, irrespective of smoking history. Molecular targeted therapy selection is guided primarily by the presence of actionable EGFR mutations, and erlotinib is recommended for these uncommon but sensitizing variants.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_4cb9808af35d",
      "question": "A 35-year-old man from an endemic region presents with prolonged fever, weight loss, hepatosplenomegaly, and pancytopenia. Bone marrow aspirate reveals intracellular protozoan parasites consistent with visceral leishmaniasis. He is started on an oral medication that disrupts essential membrane-dependent processes in the parasite by interacting with specific cell-surface lipid receptors, ultimately leading to parasite cell death. Which class of molecular targets does this medication primarily engage to exert its antiparasitic effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Kala-Azar"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0023290",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0068006",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lysophospholipid receptors",
      "reasoning_path": "Visceral leishmaniasis is treated orally with miltefosine, which exerts its effect by interacting with and disrupting lysophospholipid receptors on Leishmania parasites.",
      "umls_path": [
        "Kala-Azar",
        "may_be_treated_by",
        "Miltefosine",
        "has_mechanism_of_action",
        "Lysophospholipid Receptor Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this scenario, the patient is diagnosed with visceral leishmaniasis, a protozoal infection. An effective oral therapy for this disease is miltefosine. Miltefosine’s antiparasitic activity arises from its interaction with lysophospholipid receptors on the surface of Leishmania parasites. By modulating these membrane-associated receptors, miltefosine disrupts crucial signaling pathways and membrane dynamics necessary for parasite survival and replication. This interaction compromises the integrity and function of the parasite’s plasma membrane, ultimately causing cell death. The selectivity of miltefosine for lysophospholipid receptors on the parasite, as opposed to human host cells, underpins its clinical use in treating visceral leishmaniasis. Thus, the drug’s therapeutic effect is dependent on its primary action at the level of lysophospholipid receptors.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_b523b2cf62a8",
      "question": "In a patient with non-small cell lung cancer presenting with stage II disease (T2b, N0) and moderate restrictive ventilatory impairment identified on pulmonary function tests, is standard perioperative therapy, including surgical resection, still generally considered appropriate without modification solely due to the pulmonary comorbidity?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, the presence of moderate restrictive ventilatory impairment on pulmonary function tests may significantly impact both surgical eligibility and perioperative management in stage II NSCLC. Standard perioperative therapy—including surgery—may require modification or may even be contraindicated, depending on detailed functional assessment.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_89f8dd077ced",
      "question": "In a patient with stage IIIB non-small cell lung cancer (T3, N2) who achieved R0 resection after concurrent chemoradiation and now has no clinical or radiographic evidence of disease at follow-up, is FDG-PET/CT routinely indicated as part of surveillance imaging in the absence of suspicious symptoms or abnormal findings?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
              "R2; Concurrent chemoradiation",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, FDG-PET/CT is not routinely indicated for surveillance in patients with no evidence of disease after definitive treatment for stage IIIB non-small cell lung cancer. Standard follow-up includes history and physical examination and chest CT at prescribed intervals, with FDG-PET/CT reserved for suspicious new or ambiguous findings.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_92c5e8b063bd",
      "question": "A 32-year-old traveler returns from a trip to South America with several days of abdominal cramps, bloody diarrhea, and low-grade fever. Stool microscopy confirms the presence of motile trophozoites consistent with an intestinal protozoal infection. He is prescribed a nitroimidazole agent known for its high efficacy against this organism. Upon reviewing the drug’s pharmacologic profile, the clinician notes that, while clinical effectiveness is well established, the precise cellular or molecular mechanism by which this agent eradicates the pathogen is not fully understood. Which best describes the current scientific understanding of this drug's mechanism of action in treating this infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Amebiasis, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002438",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0040263",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Patient diagnosed with amebiasis → Tinidazole prescribed for treatment → Tinidazole is clinically effective → Exact molecular or cellular mechanism remains unidentified → Best described as 'unknown cellular or molecular interaction'.",
      "umls_path": [
        "Amebiasis, unspecified",
        "may_be_treated_by",
        "Tinidazole",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is diagnosed with amebiasis, a protozoal infection most often caused by Entamoeba histolytica. Tinidazole, a nitroimidazole antibiotic, is commonly used and highly effective in treating both intestinal and extraintestinal forms of amebiasis. The clinical efficacy of tinidazole is well documented, but the exact molecular target or pathway it affects within the protozoan is not fully elucidated. While it is generally believed that tinidazole, like other nitroimidazoles, undergoes reduction within anaerobic organisms to generate reactive intermediates that damage DNA and other critical molecules, the specific proteins or biochemical interactions responsible for its anti-amebic effect remain undefined. Therefore, the current scientific consensus is that the precise cellular or molecular mechanism of action of tinidazole in amebiasis is unknown.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_cacfe0e74802",
      "question": "What is the PMID of the article titled “[Practical guideline for short bowel syndrome]” by first author Dabsch S, published in Zeitschrift fur Gastroenterologie in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"[Practical guideline for short bowel syndrome].\"[ti] AND Dabsch S[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40360142"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_7dd71cec156d",
      "question": "A 72-year-old woman presents with a new onset of severe, throbbing headaches, scalp tenderness, and jaw claudication. She also reports transient episodes of blurred vision. Laboratory tests reveal an elevated erythrocyte sedimentation rate and C-reactive protein. Temporal artery biopsy confirms a granulomatous vasculitis with multinucleated giant cells. To reduce her risk of vision loss and control vascular inflammation, her rheumatologist initiates a biologic therapy that specifically blocks a receptor critical for a pro-inflammatory cytokine involved in the disease pathogenesis. Which molecular target is directly modulated by this therapy to achieve clinical benefit in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Giant cell arteritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0039483",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1609165",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Interleukin-6 receptor alpha subunit",
      "reasoning_path": "Giant cell arteritis involves IL-6-driven inflammation; tocilizumab, a monoclonal antibody, blocks the IL-6 receptor alpha subunit, preventing IL-6-mediated signaling and reducing disease activity.",
      "umls_path": [
        "Giant cell arteritis",
        "may_be_treated_by",
        "Tocilizumab-containing product",
        "has_target",
        "Interleukin-6 Receptor Subunit Alpha"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "The patient's presentation is consistent with giant cell arteritis, a large-vessel vasculitis characterized by granulomatous inflammation of the temporal arteries, leading to headache, jaw claudication, and risk of vision loss. Interleukin-6 (IL-6) is an important pro-inflammatory cytokine implicated in the pathogenesis of giant cell arteritis. Tocilizumab is a monoclonal antibody biologic that binds specifically to the IL-6 receptor alpha subunit, preventing IL-6 from activating its receptor and downstream inflammatory signaling pathways. By directly inhibiting the IL-6 receptor, tocilizumab reduces vascular inflammation, thereby alleviating symptoms and lowering the risk of complications such as vision loss in patients with giant cell arteritis.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_3da58e6a17c9",
      "question": "A 7-year-old child presents with frequent fractures, cranial nerve compression symptoms, and radiographic evidence of diffuse skeletal sclerosis. Genetic testing confirms a diagnosis of a rare bone disorder characterized by defective osteoclast-mediated bone resorption. The patient is started on a recombinant cytokine therapy that enhances macrophage and osteoclast activation, aiming to improve bone remodeling and hematopoiesis. Through which general pharmacologic mechanism does this therapy primarily exert its beneficial effect in this disease?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Osteopetrosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0029454",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021741",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Biological response modification (via immune modulation)",
      "reasoning_path": "Osteopetrosis → defective osteoclasts → interferon gamma-1b treatment → immune system activation (macrophages/osteoclasts) → improved bone remodeling via biological response modification.",
      "umls_path": [
        "Osteopetrosis",
        "may_be_treated_by",
        "Interferon gamma-1b-containing product",
        "has_mechanism_of_action",
        "Biological Response Modifiers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Osteopetrosis is a disorder marked by dysfunctional or absent osteoclast activity, resulting in dense but brittle bones, impaired marrow space, and systemic complications. Interferon gamma-1b is a recombinant cytokine used in severe cases to stimulate the immune system, particularly macrophages and osteoclast precursors. By binding to its receptor, interferon gamma-1b activates the JAK-STAT signaling pathway, leading to increased expression of genes that promote the differentiation and function of osteoclasts. This immune modulation helps partially restore bone resorption and remodeling, alleviating the clinical manifestations of osteopetrosis. Thus, the therapeutic benefit arises from broad biological response modification, specifically through the enhancement of innate immune and bone cell activity.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_0bdcf5b0117a",
      "question": "A 67-year-old woman with a long-standing history of knee pain and morning stiffness is diagnosed with osteoarthritis after imaging reveals joint space narrowing and osteophyte formation. She is prescribed an oral medication for symptomatic relief, which works by inhibiting a key enzyme responsible for converting arachidonic acid to inflammatory mediators, thereby reducing pain and swelling. Which molecular target is primarily responsible for the therapeutic mechanism of this class of drugs in osteoarthritis?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Osteoarthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0029408",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0025041",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 1 (Cyclooxygenase-1, COX-1)",
      "reasoning_path": "Osteoarthritis pain is mediated by prostaglandins; Meclofenamate sodium inhibits prostaglandin G/H synthase 1 (COX-1), reducing prostaglandin synthesis and alleviating symptoms.",
      "umls_path": [
        "Osteoarthritis",
        "may_be_treated_by",
        "Meclofenamate Sodium",
        "has_target",
        "Prostaglandin G/H Synthase 1"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Patients with osteoarthritis often experience pain and inflammation due to increased production of prostaglandins within the affected joints. Meclofenamate sodium, an NSAID, provides symptom relief by inhibiting the enzyme prostaglandin G/H synthase 1 (also known as cyclooxygenase-1 or COX-1). This enzyme catalyzes the conversion of arachidonic acid to prostaglandin H2, a precursor for various pro-inflammatory prostaglandins. By blocking this step, the drug decreases prostaglandin synthesis, leading to reduced inflammation, pain, and swelling. The clinical benefit in osteoarthritis is thus directly linked to the inhibition of this enzyme and the subsequent decrease in inflammatory mediator levels.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_da6c309eacfe",
      "question": "In a patient with recurrent or metastatic non-small cell lung carcinoma (NSCLC) of adenocarcinoma histology who has previously received thoracic radiotherapy and now presents with mediastinal lymph node recurrence, should broad molecular profiling, including tests for EGFR, ALK, ROS1, and PD-L1, still be prioritized before determining further systemic therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Yes, broad molecular profiling—encompassing EGFR, ALK, ROS1, BRAF, NTRK, MET exon 14 skipping, RET, HER2 mutations, and PD-L1 expression—remains essential even after prior radiotherapy, as molecular targets and immunotherapy suitability directly guide subsequent systemic treatment decisions in recurrent or metastatic NSCLC.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_e0179231fe74",
      "question": "In ClinicalTrials.gov, which interventional studies for Clostridium Infections or Diarrhea involving PAR-101/OPT-80 or Vancomycin started in October 2006 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "conditions=Clostridium Infections,Diarrhea;interventions.name=PAR-101/OPT-80,Vancomycin;startDateFrom=2006-10-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00468728"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_f189a6d96c2a",
      "question": "In a patient with newly diagnosed non-small cell lung cancer presenting with T2 primary tumor and biopsy-confirmed N3 supraclavicular lymph node involvement but no detected distant metastases, is initial surgical resection an appropriate first-line treatment option?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "N3 nodes positive, M0",
              "Stage IIIB or Stage IIIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Distant metastases",
              "Disseminated metastases",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, initial surgical resection is not appropriate; biopsy-confirmed N3 supraclavicular lymph node involvement in non-small cell lung cancer without distant metastases denotes stage IIIB/C disease, which is not considered operable. The standard management prioritizes systemic therapy or chemoradiation rather than upfront surgery.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_c99a33298fd3",
      "question": "A 68-year-old man with progressive shortness of breath and dry cough undergoes high-resolution chest CT, which reveals subpleural reticulations and honeycombing consistent with a fibrosing interstitial lung disease. Lung function tests show a reduced forced vital capacity and diffusing capacity for carbon monoxide. He is diagnosed with idiopathic pulmonary fibrosis and started on an oral agent that inhibits several receptor tyrosine kinases involved in fibroblast activation and proliferation. Which specific receptor is directly inhibited by this therapy and plays a central role in reducing fibroblast-driven fibrosis in this disease?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Idiopathic Pulmonary Fibrosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1800706",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2930789",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Vascular Endothelial Growth Factor Receptor (VEGFR)",
      "reasoning_path": "Idiopathic pulmonary fibrosis involves fibroblast-driven fibrosis; nintedanib is prescribed as an antifibrotic agent; nintedanib inhibits multiple tyrosine kinase receptors, including VEGFR; VEGFR inhibition reduces fibroblast proliferation and fibrogenesis, slowing disease progression.",
      "umls_path": [
        "Idiopathic Pulmonary Fibrosis",
        "may_be_treated_by",
        "Nintedanib-containing product",
        "has_target",
        "Vascular Endothelial Growth Factor Receptor"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Idiopathic pulmonary fibrosis (IPF) is characterized by excessive fibroblast activation and deposition of extracellular matrix, leading to progressive loss of lung function. One of the mainstays of antifibrotic therapy in IPF is nintedanib, an oral multi-tyrosine kinase inhibitor. Nintedanib exerts its effects by directly inhibiting several receptor tyrosine kinases, including those for platelet-derived growth factor (PDGFR), fibroblast growth factor (FGFR), and especially vascular endothelial growth factor receptor (VEGFR). Inhibition of VEGFR reduces angiogenesis and disrupts signaling pathways that promote fibroblast proliferation and differentiation into myofibroblasts, thereby slowing the progression of fibrosis. By targeting VEGFR, nintedanib helps limit the pathological tissue remodeling central to IPF. Thus, the direct inhibition of VEGFR is a key mechanism underlying the drug's antifibrotic activity in this condition.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_c90102f53cf8",
      "question": "For a patient with localized invasive, non-inflammatory, M0 breast cancer who has undergone breast-conserving surgery with negative axillary nodes and presents with a centrally located pT2 tumor that is grade 3, but has no lymphovascular invasion and is hormone-receptor positive, does the presence of only the grade 3 feature justify the use of comprehensive regional nodal irradiation in addition to whole breast irradiation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "Negative axillary nodes",
              "WBRT ± boost to tumor bed, and consider comprehensive regional nodal irradiation (RNI) in patients with central/medial tumors, pT3 tumors, or pT2 tumors and one of the following high-risk features: grade 3, extensive lymphovascular invasion (LVI), or hormone-receptor (HR)-negative."
            ]
          }
        }
      ],
      "answer": "Yes. In patients with centrally located pT2 breast tumors and negative axillary nodes, the presence of any single high-risk feature—such as grade 3 histology—meets the criteria to consider comprehensive regional nodal irradiation in addition to whole breast irradiation, regardless of lymphovascular invasion or hormone-receptor status.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_6431d357c35b",
      "question": "In a patient with multiple primary lung cancers staged as N0–1, who presents with symptomatic superior vena cava (SVC) obstruction without evidence of previous chemoradiotherapy, should concurrent chemoradiation be considered over exclusive SVC stent placement for initial management?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Multiple lung cancers (suspected or confirmed) (N0–1)",
              "Multidisciplinary evaluation",
              "Dominant nodule with evidence of growth",
              "Definitive local therapy not possible",
              "Palliative chemotherapy ± local palliative therapy or Observe",
              "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, in patients with symptomatic SVC obstruction and no prior chemoradiotherapy, concurrent chemoradiation is recommended as initial management over stent-only placement, as it addresses both underlying tumor burden and symptom relief. SVC stenting may be added for rapidly worsening symptoms but does not replace definitive local control.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_424276e98b5c",
      "question": "For a patient with completely resected stage II non-small cell lung cancer who has completed adjuvant chemotherapy and shows no evidence of disease on imaging, is routine use of FDG-PET/CT recommended during follow-up surveillance for recurrence?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "No, routine FDG-PET/CT is not recommended for surveillance in this scenario. Standard follow-up involves history and physical examination with chest CT at defined intervals, while FDG-PET/CT should be reserved for evaluating suspected recurrence or specific findings, not as part of routine monitoring.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_34520b164bc0",
      "question": "A 32-year-old woman with a long-standing history of moderate-to-severe atopic dermatitis experiences frequent relapses despite high-potency topical corticosteroids and emollient therapy. She reports persistent pruritic, excoriated plaques on her forearms and neck. Her dermatologist prescribes a recently approved monoclonal antibody that selectively targets and neutralizes a cytokine central to type 2 inflammatory responses, thereby reducing skin inflammation and itching. Which molecular target is directly antagonized by this therapy to achieve clinical improvement in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Atopic neurodermatitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011615",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C5564314",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Interleukin-13 (IL-13)",
      "reasoning_path": "Atopic dermatitis is Th2-driven → IL-13 is a key cytokine → tralokinumab-ldrm is a monoclonal antibody against IL-13 → IL-13 antagonism reduces inflammation and symptoms.",
      "umls_path": [
        "Atopic neurodermatitis",
        "may_be_treated_by",
        "tralokinumab-ldrm",
        "has_mechanism_of_action",
        "Interleukin-13 Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Atopic dermatitis is driven by type 2 helper T-cell (Th2) immune responses, with cytokines such as interleukin-4 (IL-4) and interleukin-13 (IL-13) playing pivotal roles in promoting inflammation, pruritus, and barrier dysfunction. In patients refractory to topical therapies, targeted biologics may be considered. Tralokinumab-ldrm is a monoclonal antibody that specifically binds to IL-13, preventing it from interacting with its receptor. This blockade interrupts downstream signaling pathways that lead to skin inflammation and the characteristic eczematous lesions. By inhibiting IL-13, tralokinumab-ldrm decreases Th2-mediated cytokine activity, resulting in significant symptom reduction and skin healing. Thus, the primary therapeutic effect is achieved through antagonism of interleukin-13.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_69ef26588952",
      "question": "A 34-year-old man presents with visual disturbances and eosinophilia after recently returning from a hiking trip in rural Central America. Serology confirms a diagnosis of visceral larva migrans caused by a helminthic infection. He is started on a broad-spectrum anthelmintic agent that requires hepatic activation and is known to accelerate the metabolism of several co-administered medications. When reviewing his medication list, which hepatic enzyme system should be closely monitored due to its induction by this antiparasitic therapy?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Toxocariasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0040553",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001911",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cytochrome P450 1A enzymes",
      "reasoning_path": "Patient with toxocariasis is treated with albendazole, which induces CYP1A enzymes, necessitating monitoring of co-administered drugs metabolized by this pathway.",
      "umls_path": [
        "Toxocariasis",
        "may_be_treated_by",
        "Albendazole",
        "has_mechanism_of_action",
        "Cytochrome P450 1A Inducers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Albendazole is a benzimidazole anthelmintic commonly used to treat helminthic infections such as toxocariasis (visceral larva migrans). After oral administration, albendazole undergoes first-pass hepatic metabolism to its active sulfoxide form. Importantly, albendazole induces hepatic cytochrome P450 (CYP) 1A enzymes. This induction increases the metabolic clearance of other drugs that are substrates for these enzymes, potentially reducing their therapeutic efficacy. When patients are prescribed albendazole, clinicians should be aware of possible drug interactions, especially with medications metabolized by CYP1A, such as certain antiepileptics, theophylline, and some antidepressants. Monitoring for decreased effectiveness or the need for dosage adjustments of these co-administered drugs is important during albendazole therapy. This pharmacokinetic property is central to safe clinical use and highlights the importance of understanding drug-enzyme interactions with antiparasitic medications.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_dd8cea8b0a42",
      "question": "In a patient with localized, invasive, non-inflammatory, non-metastatic (M0) breast cancer, clinical stage cT2N0M0, who undergoes total mastectomy and axillary staging with identification of 1–3 positive axillary lymph nodes, does the recommendation for postmastectomy radiotherapy to the chest wall and regional nodal irradiation implicitly require that the patient has not received preoperative systemic therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "1–3 positive axillary nodes",
              "Strongly consider RT to chest wall + comprehensive RNI (including any portion of the undissected axilla at risk)."
            ]
          }
        }
      ],
      "answer": "Yes; the strong consideration for postmastectomy radiotherapy to the chest wall plus comprehensive regional nodal irradiation in patients with 1–3 positive nodes applies in the context of patients who did not receive preoperative systemic therapy, as the number of positive nodes reflects untreated disease burden.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_6e035dc20a65",
      "question": "A 4-year-old boy is brought to the clinic with a two-day history of ear pain, fever, and irritability. Otoscopic examination reveals a bulging, erythematous tympanic membrane consistent with acute otitis media. The physician prescribes an oral antibiotic that is activated in the body and works by binding to and inactivating transpeptidase enzymes essential for bacterial cell wall synthesis. Considering the mechanism of the prescribed medication, which general pharmacological class does this agent belong to?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Unspecified otitis media"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0029882",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0108938",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme inhibitors",
      "reasoning_path": "Acute otitis media treated with cefpodoxime proxetil → drug acts by inhibiting bacterial transpeptidase enzymes (PBPs) → pharmacological class is enzyme inhibitors.",
      "umls_path": [
        "Unspecified otitis media",
        "may_be_treated_by",
        "Cefpodoxime Proxetil",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This vignette describes a typical case of acute otitis media in a child, a common pediatric infection. The prescribed agent, an oral antibiotic that requires in vivo activation and acts by binding to transpeptidases, fits the profile of cefpodoxime proxetil, a third-generation cephalosporin. Cephalosporins, like other β-lactam antibiotics, exert their bactericidal effect by inhibiting penicillin-binding proteins (PBPs), specifically transpeptidases, which are enzymes crucial for cross-linking peptidoglycan chains during bacterial cell wall synthesis. By inhibiting these enzymes, the antibiotic compromises the structural integrity of the bacterial cell wall, leading to cell lysis and death. Thus, the pharmacological class that describes this mechanism is 'enzyme inhibitors'—more specifically, inhibitors of bacterial cell wall synthesis enzymes.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_f56377052561",
      "question": "A 48-year-old recreational tennis player presents with persistent lateral elbow pain that has failed to improve with rest and physical therapy. She is diagnosed with chronic tendinopathy and started on a nonsteroidal anti-inflammatory drug (NSAID) for symptomatic relief. This medication acts by directly inhibiting a key enzyme involved in the conversion of arachidonic acid to pro-inflammatory mediators. Through which molecular target does this treatment exert its primary anti-inflammatory effect in her affected tissue?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Tendinopathy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1568272",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021246",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 2 (COX-2)",
      "reasoning_path": "Chronic tendinopathy is treated symptomatically with indomethacin, which reduces inflammation by inhibiting the COX-2 enzyme (Prostaglandin G/H Synthase 2), leading to decreased prostaglandin synthesis.",
      "umls_path": [
        "Tendinopathy",
        "may_be_treated_by",
        "Indomethacin",
        "has_target",
        "Prostaglandin G/H Synthase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) used to manage pain and inflammation associated with chronic tendinopathy. The primary mechanism of action of indomethacin is the inhibition of cyclooxygenase enzymes, specifically Prostaglandin G/H Synthase 2, commonly referred to as COX-2. This enzyme catalyzes the conversion of arachidonic acid to prostaglandin H2, a precursor to various prostaglandins that mediate inflammation, pain, and swelling. Inhibition of COX-2 results in reduced synthesis of these pro-inflammatory prostaglandins, thereby decreasing local inflammation and alleviating symptoms. While indomethacin also inhibits COX-1, its anti-inflammatory efficacy, particularly in inflamed tissues such as those involved in tendinopathy, is primarily attributed to COX-2 inhibition. This molecular action underlies its clinical benefit in reducing tendon pain and swelling, though long-term use may be limited by side effects related to COX inhibition elsewhere in the body.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_da173c185023",
      "question": "A 7-year-old girl presents to the pediatric clinic with a three-day history of ear pain, fever, and irritability. Otoscopic examination reveals a bulging, erythematous tympanic membrane with decreased mobility. She is otherwise healthy and has no medication allergies. The clinician prescribes an oral antibiotic that interferes with the final stages of bacterial cell wall synthesis by binding to and inhibiting transpeptidase enzymes. To which general pharmacological class does this drug’s primary mechanism of action belong?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Unspecified otitis media"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0029882",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2699131",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme Inhibitors",
      "reasoning_path": "Child with otitis media → treated with cefaclor → cefaclor inhibits transpeptidase enzymes (PBPs) → prevents bacterial cell wall synthesis → drug is classified as an enzyme inhibitor.",
      "umls_path": [
        "Unspecified otitis media",
        "may_be_treated_by",
        "Cefaclor anhydrous",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This clinical scenario describes a child with acute otitis media, a common pediatric infection often treated with antibiotics. Cefaclor, the prescribed agent, is a second-generation cephalosporin. Its antibacterial activity depends on binding to penicillin-binding proteins (PBPs), which are bacterial transpeptidase enzymes crucial for cross-linking peptidoglycan chains in the cell wall. Inhibition of these enzymes prevents cell wall synthesis, leading to bacterial lysis and death. Because the principal mechanism involves the inhibition of a bacterial enzyme, cefaclor is correctly classified in the general pharmacological class of enzyme inhibitors. This mechanism underlies the drug’s therapeutic efficacy against the most common otopathogens, including Streptococcus pneumoniae and Haemophilus influenzae. Thus, the key mechanistic step is the blockade of bacterial transpeptidases, placing cefaclor in the enzyme inhibitor category.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_4ca33f42da3a",
      "question": "In a newly diagnosed patient with stage IVA non-small cell lung cancer (adenocarcinoma subtype) whose tumor harbors an EGFR exon 19 deletion, if molecular testing for ALK rearrangement is still pending, is it appropriate to initiate first-line EGFR-targeted therapy before ALK results are available?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "EGFR exon 19 deletion or exon 21 L858R mutation positive",
              "EGFR exon 19 deletion or exon 21 L858R mutations",
              "EGFR mutation discovered prior to first-line systemic therapy",
              "Useful in Certain Circumstances: Erlotinib + ramucirumab or Erlotinib + bevacizumab or Dacomitinib (category 1) or Afatinib (category 1) or Erlotinib (category 1) or Gefitinib (category 1)",
              "Progression: Subsequent Therapy (NSCL-23)"
            ]
          }
        }
      ],
      "answer": "Yes, it is appropriate to start first-line EGFR-targeted therapy in a patient with stage IVA non-small cell lung adenocarcinoma harboring an EGFR exon 19 deletion, even if ALK testing is pending. This is because actionable EGFR mutations independently justify targeted therapy initiation regardless of ALK status, given their rarity of overlap and immediate treatment priority.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_2bae911c03c7",
      "question": "In the OpenTargets platform, can you provide the tractability information for the target with Ensembl ID ENSG00000163599 and approved symbol CTLA4, where the value is True?",
      "tool_calls": [
        {
          "tool": "opentargets.tractability",
          "params": {
            "target_id": "ENSG00000163599",
            "value": true
          }
        }
      ],
      "answer": [
        {
          "modality": "SM",
          "label": "Structure with Ligand"
        },
        {
          "modality": "AB",
          "label": "Approved Drug"
        },
        {
          "modality": "AB",
          "label": "UniProt loc high conf"
        },
        {
          "modality": "AB",
          "label": "GO CC high conf"
        },
        {
          "modality": "AB",
          "label": "UniProt SigP or TMHMM"
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_9e30d0b07b95",
      "question": "A 54-year-old woman presents with progressive symmetric weakness of her arms and legs, decreased deep tendon reflexes, and numbness over several months. Nerve conduction studies reveal demyelination, and a diagnosis of an acquired immune-mediated polyneuropathy is made. Her neurologist initiates intravenous immunoglobulin therapy. This treatment consists of pooled IgG from thousands of donors and is believed to ameliorate her disease by directly interfering with pathogenic components of the immune response. Through which principal immunological mechanism does this therapy most directly reduce her neurological symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Chronic inflammatory demyelinating polyneuritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0393819",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0085297",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Neutralization of pathogenic autoantibodies by intravenous immunoglobulin (IGIV)",
      "reasoning_path": "CIDP is driven by autoantibody-mediated nerve damage; IGIV is administered to neutralize these autoantibodies, reducing immune-mediated demyelination and resulting neurological deficits.",
      "umls_path": [
        "Chronic inflammatory demyelinating polyneuritis",
        "may_be_treated_by",
        "IGIV",
        "has_mechanism_of_action",
        "Antigen Neutralization"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disorder characterized by immune-mediated demyelination of peripheral nerves, resulting in weakness and sensory loss. Intravenous immunoglobulin (IGIV) is a mainstay of treatment for CIDP. Its therapeutic benefit is primarily attributed to the neutralization of circulating pathogenic autoantibodies. IGIV contains pooled IgG antibodies that can bind and sequester these harmful autoantibodies, reducing their availability to attack neural antigens. Additionally, IGIV may modulate Fc receptor function, complement activation, and cytokine networks, but direct antigen or autoantibody neutralization is the most immediate and central mechanism. By decreasing the pathogenic immune response, IGIV helps to prevent further demyelination and facilitates neurological recovery in patients with CIDP.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_b9f8e24f9743",
      "question": "In a patient with advanced or metastatic squamous cell carcinoma of the lung and confirmed RET rearrangement, should RET-targeted therapy be prioritized over standard platinum-based chemotherapy as first-line systemic treatment, assuming broad molecular profiling and PD-L1 testing have been performed?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "RET rearrangement positive"
            ]
          }
        }
      ],
      "answer": "Yes, for advanced or metastatic squamous cell lung carcinoma with RET rearrangement, RET-targeted therapy should be prioritized over standard platinum-based chemotherapy as first-line treatment, consistent with the paradigm of applying actionable molecular alterations regardless of histology when adequate tissue and broad molecular profiling are available.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_0d2ea26bc99b",
      "question": "For a patient with NSCLC who is found to have supraclavicular lymph node involvement (N3) and no evidence of extrathoracic metastatic disease on FDG-PET/CT, is definitive concurrent chemoradiation still an appropriate treatment approach, or does the N3 status necessitate immediate systemic therapy for distant disease?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "In NSCLC patients with N3 mediastinal or supraclavicular lymph node involvement but no extrathoracic metastases, definitive concurrent chemoradiation remains an appropriate curative-intent option. Systemic therapy for distant disease is reserved for cases with confirmed extrathoracic metastases, not solely N3 nodal status.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_b04f8b1eaa3a",
      "question": "What is the PMID of the article titled “[Evidence-based guidelines in gastroenterological medical care: a survey among members of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS) on acceptance, application and optimization],” authored by Bachmann J and published in Zeitschrift fur Gastroenterologie in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"[Evidence-based guidelines in gastroenterological medical care\"[ti] AND Bachmann J[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40306647"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_e51a8aa988e1",
      "question": "For a patient with stage IIA (T2b, N0) non–small cell lung cancer who has undergone R0 resection without adjuvant therapy, and subsequently develops locoregional mediastinal lymph node recurrence without prior radiotherapy, which is the preferred initial treatment: concurrent chemoradiation or systemic therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIA (T2b, N0); Margins negative (R0)",
              "Observe or Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Concurrent chemoradiation is the preferred initial treatment in this scenario. Locoregional mediastinal lymph node recurrence after R0 surgery, in the absence of previous radiotherapy, warrants definitive intent salvage chemoradiation rather than systemic therapy alone.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_e671df1f9447",
      "question": "In a patient with newly diagnosed stage IIIC (T3, N3) non-small cell lung cancer who presents with limited distant metastases and localized symptoms, should palliative external-beam radiotherapy be prioritized over systemic therapy for immediate symptom control?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "For patients with stage IIIC NSCLC and limited distant metastases who have localized symptomatic disease, palliative external-beam radiotherapy is prioritized for immediate relief of symptoms. Systemic therapy remains essential for controlling systemic disease, but local radiotherapy directly addresses acute symptom burden.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_4a2a55f97661",
      "question": "For a patient with stage I non-small cell lung cancer (NSCLC) who underwent primary surgical resection without adjuvant radiotherapy and is currently free of clinical or radiographic evidence of disease, is routine annual brain MRI surveillance recommended as part of standard follow-up?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "No, routine annual brain MRI surveillance is not recommended for a stage I NSCLC patient post-surgery without adjuvant radiotherapy and no evidence of recurrence; brain MRI is reserved for recurrence evaluation or if clinically indicated, not for routine surveillance in early-stage disease.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_8594640bd78c",
      "question": "In a patient with stage IIIA non–small cell lung cancer (T2, N2, M0) and confirmed EGFR exon 19 deletion, who is medically inoperable and has completed definitive concurrent chemoradiation, which adjuvant therapy should be prioritized: durvalumab or osimertinib?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "N1 or N2 nodes positive, M0",
              "Treatment (NSCL-10)",
              "Mediastinal Biopsy Findings",
              "T1–3, N1 nodes positive, M0",
              "Medically inoperable, high surgical risk as determined by thoracic surgeonI and those who decline surgery after thoracic surgical consultation",
              "Definitive concurrent chemoradiation (category 1)",
              "Durvalumab (category 1 stage III; category 2A stage II) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1 stage III; category 2A stage II)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "For a patient with stage IIIA NSCLC harboring an EGFR exon 19 deletion who is medically inoperable and has received definitive concurrent chemoradiation, adjuvant osimertinib should be prioritized over durvalumab due to EGFR mutation status, as osimertinib shows significant benefit in this setting, while durvalumab is not recommended for EGFR-mutated NSCLC.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_8495c65499d1",
      "question": "A 38-year-old woman presents with progressive fatigue, weight loss, and hyperpigmentation of her skin and oral mucosa. Laboratory studies reveal hyponatremia, hyperkalemia, and low morning cortisol levels. She is diagnosed with primary adrenal insufficiency and started on a medication that acts by binding to cytoplasmic receptors, translocating to the nucleus, and altering transcription of genes involved in metabolism and immune response. Through which molecular mechanism does this medication exert its therapeutic effects in restoring homeostasis for this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Addison's Disease"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001403",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0057598",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Agonism of corticosteroid hormone receptors (glucocorticoid and mineralocorticoid receptors)",
      "reasoning_path": "Primary adrenal insufficiency is treated with corticosteroids. These drugs bind intracellular glucocorticoid (and mineralocorticoid) receptors, translocate to the nucleus, and modulate gene transcription to restore deficient hormone effects.",
      "umls_path": [
        "Addison's Disease",
        "may_be_treated_by",
        "Dexamethasone Acetate",
        "has_mechanism_of_action",
        "Corticosteroid Hormone Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s diagnosis of primary adrenal insufficiency (Addison’s disease) is characterized by deficient production of endogenous corticosteroids. The standard treatment involves administration of exogenous corticosteroids, such as hydrocortisone or prednisone. These drugs enter target cells and bind intracellular corticosteroid receptors (glucocorticoid and, when needed, mineralocorticoid receptors). Upon ligand binding, the receptor-ligand complex translocates to the nucleus, where it modulates gene transcription. This leads to upregulation of genes involved in glucose metabolism, vascular tone, and immune suppression, while also providing salt-retaining effects when mineralocorticoid activity is required. By mimicking the effects of physiologic corticosteroids, this approach restores homeostasis, corrects electrolyte imbalances, and reverses the clinical features of adrenal insufficiency. The primary molecular mechanism, therefore, is agonism of intracellular corticosteroid hormone receptors, resulting in altered gene expression.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_319d9fefb20c",
      "question": "A 27-year-old immunocompetent woman presents with numerous flesh-colored, rough papules on her fingers and dorsal hands that have gradually increased in number over the past six months. She is concerned about cosmetic appearance and minor discomfort. After topical therapies fail, her dermatologist prescribes a treatment that works by modulating the immune response to inhibit viral genome replication. Which molecular target is most directly inhibited by this therapy to achieve its clinical effect in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Verruca vulgaris"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3665596",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0391001",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "RNA replicase",
      "reasoning_path": "Verruca vulgaris (HPV infection) may be treated with interferon alfa, which induces cellular antiviral proteins that inhibit viral RNA replicase, impairing viral replication and facilitating wart resolution.",
      "umls_path": [
        "Verruca vulgaris",
        "may_be_treated_by",
        "PEG-interferon alfa-2a",
        "has_mechanism_of_action",
        "RNA Replicase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Common warts (verruca vulgaris) are caused by human papillomavirus (HPV), a DNA virus that relies on host and, to some degree, viral machinery for genome replication. When topical therapies are ineffective, systemic immunomodulators such as interferon alfa can be considered, especially in recalcitrant or extensive cases. Interferon alfa exerts its antiviral effect by inducing the production of cellular proteins that inhibit viral replication. One of the key actions is the inhibition of viral RNA replicase, an enzyme required for viral RNA synthesis. By blocking RNA replicase, interferon prevents the synthesis of new viral genomes and proteins, thereby reducing viral load and promoting lesion regression. Thus, the primary molecular target involved in the therapeutic effect of this treatment is RNA replicase.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_ee57804d7a1b",
      "question": "A 62-year-old woman with myelodysplastic syndrome is started on a chemotherapeutic agent that forms covalent bonds with DNA, leading to cross-linking and impaired DNA replication, particularly affecting rapidly dividing hematopoietic cells. After several cycles of therapy, her blood counts improve. Which class of drug mechanisms best explains the therapeutic action of this medication in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Bone Marrow Disorder"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0005956",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0079083",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Nucleic acid synthesis inhibitors",
      "reasoning_path": "Myelodysplastic syndrome (bone marrow disorder) → treated with carboplatin → carboplatin forms DNA cross-links → inhibits DNA replication and repair → nucleic acid synthesis inhibition mediates therapeutic effect.",
      "umls_path": [
        "Bone Marrow Disorder",
        "may_be_treated_by",
        "Carboplatin",
        "has_mechanism_of_action",
        "Nucleic Acid Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with myelodysplastic syndrome, a bone marrow disorder, is treated with a drug that forms DNA cross-links, disrupting DNA replication and transcription in dividing cells. Carboplatin, a platinum-based chemotherapeutic, exerts its cytotoxic effects by forming intrastrand and interstrand DNA cross-links. This damages DNA, triggers apoptosis, and inhibits cell proliferation, particularly in rapidly dividing hematopoietic progenitors. The primary mechanism underlying its therapeutic effect is inhibition of nucleic acid synthesis—specifically, DNA synthesis—by interfering with replication and repair processes. This class of mechanism is especially relevant in hematologic malignancies and bone marrow disorders, where abnormal cell proliferation underlies disease pathology. Thus, nucleic acid synthesis inhibition is central to carboplatin’s clinical efficacy in this context.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_f354974a7d06",
      "question": "A 67-year-old woman with poorly controlled diabetes presents with a non-healing ulcer over her right heel that has persisted for several months despite appropriate wound care. Laboratory evaluation reveals marginally low serum zinc levels. Her clinician initiates oral supplementation with an agent that is essential for numerous metalloenzyme activities, supports protein synthesis, and facilitates cellular proliferation and migration during tissue repair. Which fundamental pharmacological property of this supplement most directly underlies its ability to promote healing in her chronic wound?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Skin ulcer"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0037299",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0149368",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Electrolyte activity—zinc functions as a trace electrolyte, essential for cellular processes involved in tissue repair and regeneration.",
      "reasoning_path": "Chronic skin ulcers benefit from zinc acetate due to its pharmacological role as an electrolyte, supporting cellular and enzymatic functions necessary for wound healing.",
      "umls_path": [
        "Skin ulcer",
        "may_be_treated_by",
        "Zinc acetate",
        "has_mechanism_of_action",
        "Electrolyte Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Zinc is a trace element that serves as a crucial cofactor for multiple enzymes involved in DNA synthesis, cell division, and protein synthesis, all of which are vital for wound healing. In chronic ulcers, especially in patients with underlying risk factors such as diabetes, cellular proliferation and tissue regeneration are impaired. Zinc’s pharmacological activity as a bioavailable electrolyte enables it to support the function of key metalloenzymes and transcription factors that regulate these reparative processes. Zinc deficiency impairs keratinocyte migration, collagen synthesis, and immune response, leading to delayed wound closure. Supplementation with zinc acetate restores these essential enzymatic activities, thereby promoting tissue repair. The fundamental mechanism is not antimicrobial or anti-inflammatory per se, but rather its direct role as an electrolyte supporting the metabolic and structural needs of healing tissues.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_f4808d7670af",
      "question": "A 28-year-old woman returns from a trip to West Africa with a three-day history of high fevers, chills, and headache. Laboratory testing reveals thrombocytopenia and intraerythrocytic ring forms on peripheral blood smear. She is started on an oral medication that impairs the parasite's ability to replicate by interfering with its nucleic acid synthesis. Which pharmacological class best describes the mechanism by which this medication treats her infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Falciparum malaria [malignant tertian]"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0024535",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0055447",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Nucleic Acid Synthesis Inhibitors",
      "reasoning_path": "Falciparum malaria is diagnosed; chloroquine acts by inhibiting nucleic acid synthesis in the parasite, classifying it as a nucleic acid synthesis inhibitor.",
      "umls_path": [
        "Falciparum malaria [malignant tertian]",
        "may_be_treated_by",
        "Chloroquine Phosphate",
        "has_mechanism_of_action",
        "Nucleic Acid Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient presents with classic symptoms and laboratory findings consistent with falciparum malaria. The mainstay of treatment for uncomplicated cases has traditionally included antimalarial agents such as chloroquine in regions without resistance. Chloroquine and related drugs act by accumulating within the acidic food vacuole of Plasmodium falciparum, where they inhibit the polymerization of heme and disrupt nucleic acid synthesis. By interfering with DNA and RNA formation, these agents block parasite replication and survival. Therefore, the primary pharmacological class responsible for this antimalarial effect is nucleic acid synthesis inhibitors. Understanding both the clinical presentation and the mechanistic pathway of the drug’s action is essential for selecting the most appropriate therapy and anticipating potential resistance patterns.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_1ba9fdc435b0",
      "question": "In a patient with invasive, non-inflammatory, non-metastatic (M0) breast cancer, hormone receptor-negative (ER-negative, PR-negative), HER2-negative, with a primary tumor size of 0.9 cm (pT1), and axillary node status pN0, is adjuvant chemotherapy still considered appropriate if the patient has a significant cardiac comorbidity that increases the risk of anthracycline toxicity?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
              "ER-negative and PR-negative",
              "HER2-negative",
              "BINV-10",
              "Ductal/NST, Lobular, Mixed, Micropapillary, Metaplastic",
              "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
              "Tumor 0.6–1.0 cm",
              "Consider adjuvant chemotherapy",
              "Follow-Up (BINV-17)"
            ]
          }
        }
      ],
      "answer": "Adjuvant chemotherapy may be considered for hormone receptor-negative, HER2-negative, node-negative breast cancer with a tumor size of 0.9 cm; however, significant cardiac comorbidity contraindicates standard anthracycline-based regimens. Alternative non-anthracycline chemotherapy could be considered, but the risk–benefit ratio must be carefully assessed given increased toxicity risk.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_f49df3daad40",
      "question": "For a patient with stage IIB (T3, N0) non-small cell lung cancer who underwent complete surgical resection but has positive margins (R1), is systemic therapy alone sufficient, or should chemoradiation (sequential or concurrent) be considered as the preferred option?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
              "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "In stage IIB (T3, N0) NSCLC with R1 resection margins, chemoradiation—either sequential or concurrent—should be considered over systemic therapy alone, as radiotherapy is necessary to address residual microscopic disease at the surgical margin and reduce the risk of locoregional recurrence. Systemic therapy alone is not adequate in this context.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_274658a80cc9",
      "question": "A 70-year-old woman with progressive central vision loss is diagnosed with neovascular (wet) age-related macular degeneration. After failing standard anti-VEGF therapy, her ophthalmologist considers an alternative involving a recombinant immunomodulatory protein. This therapy exerts its effects by binding to a specific cell surface receptor complex, triggering JAK-STAT signaling to modulate immune activity and inhibit abnormal blood vessel growth in the retina. Which molecular complex is directly targeted by this treatment to produce its therapeutic effects?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Macular Degeneration"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0024437",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021735",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Interferon alpha receptor complex",
      "reasoning_path": "Neovascular macular degeneration may be treated with recombinant interferon alfa-2b, which acts by binding to the interferon alpha receptor complex, triggering JAK-STAT signaling and resulting in immunomodulation and anti-angiogenic effects.",
      "umls_path": [
        "Macular Degeneration",
        "may_be_treated_by",
        "Recombinant Interferon Alfa-2b",
        "has_target",
        "Interferon Alpha Receptor Complex"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Recombinant interferon alfa-2b is sometimes used as an off-label immunomodulatory therapy in refractory cases of neovascular macular degeneration. Its mechanism of action depends on direct engagement with the interferon alpha receptor complex expressed on target cells. Upon binding, this receptor complex activates the JAK-STAT pathway, leading to transcription of genes that both modulate the immune response and inhibit angiogenesis. By suppressing the abnormal growth of blood vessels in the retina, this mechanism can help slow disease progression and preserve vision. The specificity of this therapy’s effect is fundamentally determined by its interaction with the interferon alpha receptor complex, making it the principal molecular target required for downstream therapeutic actions in this context.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_9fe6d70bf6a4",
      "question": "A 42-year-old man with a long-standing history of hepatitis B infection presents with fatigue and mild jaundice. Laboratory tests confirm superinfection with hepatitis D virus. After specialist consultation, he is started on a biologic therapy that signals via a transmembrane receptor complex, leading to activation of the JAK-STAT pathway and induction of antiviral gene expression. Which molecular complex in hepatocytes is the essential mediator of this drug’s therapeutic antiviral effects?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Viral hepatitis D"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011226",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021735",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Interferon alpha receptor complex",
      "reasoning_path": "Recombinant interferon binds the interferon alpha receptor complex → JAK-STAT signaling → transcription of antiviral genes → inhibition of hepatitis D replication.",
      "umls_path": [
        "Viral hepatitis D",
        "may_be_treated_by",
        "Recombinant Interferon Alfa-2b",
        "has_target",
        "Interferon Alpha Receptor Complex"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient with hepatitis D superinfection is treated with recombinant interferon therapy. Recombinant interferon alfa binds to the interferon alpha receptor complex expressed on hepatocytes. Upon ligand binding, this receptor complex activates intracellular Janus kinases (JAKs), which phosphorylate STAT transcription factors. Activated STATs dimerize and translocate to the nucleus, where they induce the expression of antiviral proteins and other immune-modulating genes. The resulting antiviral state inhibits hepatitis D virus replication within infected hepatocytes. Thus, the interferon alpha receptor complex is the direct molecular target mediating interferon’s therapeutic effects. Without engagement of this receptor, downstream signaling and the antiviral response would not occur, rendering the therapy ineffective.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_74ce94faf920",
      "question": "For a patient with non-small cell lung cancer presenting with a separate pulmonary nodule located in the same lobe as the primary tumor (classified as T3, N0–1), is surgery following planned preoperative systemic therapy contingent upon having negative mediastinal nodal status (N0–1), or would the presence of N2 disease preclude immediate surgical intervention in favor of chemoradiation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
              "Surgery after preoperative systemic therapy, if planned",
              "N2",
              "Margins positive",
              "R2",
              "Concurrent chemoradiation",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "Surgery following planned preoperative systemic therapy is appropriate when mediastinal lymph node status is N0–1; the presence of N2 involvement shifts the preferred treatment to concurrent chemoradiation rather than immediate surgery, due to higher risk of systemic disease and local recurrence.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_122969a56ccd",
      "question": "A 42-year-old woman presents with episodic palpitations, lightheadedness, and rapid heartbeat. Her ECG confirms a diagnosis of recurrent supraventricular tachycardia. She is prescribed a medication that is known to selectively antagonize a G protein-coupled receptor subtype predominantly found in cardiac tissue, resulting in decreased heart rate and slowed atrioventricular nodal conduction. Which molecular target is directly responsible for mediating the therapeutic effects of this agent in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Supraventricular Tachycardia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0039240",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004147",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Beta-1 adrenergic receptor",
      "reasoning_path": "Supraventricular tachycardia is treated with atenolol, which acts via selective antagonism of cardiac beta-1 adrenergic receptors, decreasing sympathetic-mediated heart rate and conduction.",
      "umls_path": [
        "Supraventricular Tachycardia",
        "may_be_treated_by",
        "Atenolol",
        "has_target",
        "Beta-1 Adrenergic Receptor"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient's recurrent supraventricular tachycardia requires rate control, which can be achieved by reducing sympathetic stimulation of the heart. Atenolol, the prescribed agent, is a cardioselective beta-blocker that acts as an antagonist at the beta-1 adrenergic receptor, a G protein-coupled receptor primarily located in the myocardium. By blocking the beta-1 receptor, atenolol reduces the effects of endogenous catecholamines (epinephrine and norepinephrine), leading to decreased heart rate (negative chronotropy), reduced contractility (negative inotropy), and slowed conduction through the atrioventricular node. These actions are particularly effective in controlling supraventricular arrhythmias, as they limit the ability of abnormal impulses to propagate, thereby restoring and maintaining normal sinus rhythm. The selectivity for beta-1 receptors minimizes unwanted bronchoconstrictive effects mediated by beta-2 receptors in the lungs, making atenolol suitable for patients with cardiac arrhythmias.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_44664f0ff116",
      "question": "A 62-year-old man presents to the clinic with acute onset of severe pain, redness, and swelling in his right first metatarsophalangeal joint. He has a history of episodic joint inflammation and was recently diagnosed with hyperuricemia. After confirming the diagnosis of gouty arthritis, his physician prescribes a nonsteroidal anti-inflammatory drug (NSAID) that is known to inhibit an enzyme involved in cyclic nucleotide signaling, thereby reducing inflammatory mediator production. Which molecular target is most directly responsible for the therapeutic anti-inflammatory effect of this medication in acute gout?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Articular gout"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003868",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0038792",
            "rela": "has_target"
          }
        }
      ],
      "answer": "cGMP-Specific 3',5'-Cyclic Phosphodiesterase",
      "reasoning_path": "Acute gout causes joint inflammation; sulindac (an NSAID) relieves symptoms by inhibiting cGMP-Specific 3',5'-Cyclic Phosphodiesterase, reducing inflammatory mediator production.",
      "umls_path": [
        "Articular gout",
        "may_be_treated_by",
        "Sulindac",
        "has_target",
        "cGMP-Specific 3',5'-Cyclic Phosphodiesterase"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "In this scenario, the patient is experiencing an acute gout flare characterized by intense joint inflammation due to monosodium urate crystal deposition. NSAIDs are first-line agents for symptom control. Sulindac, the NSAID described here, not only inhibits the cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis but also acts on cGMP-specific 3',5'-cyclic phosphodiesterase. By inhibiting this enzyme, sulindac modulates intracellular levels of cyclic GMP, which influences leukocyte activity and inflammatory mediator release. The reduction in cGMP breakdown leads to decreased recruitment and activation of inflammatory cells at the site of crystal deposition. This dual mechanism underlies sulindac’s effectiveness in controlling the pain and swelling associated with acute gout attacks.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_ce82b64be907",
      "question": "A 48-year-old woman with a 20-year history of plaque psoriasis that has not responded to topical corticosteroids, phototherapy, or methotrexate is started on an oral immunosuppressive agent formulated for improved bioavailability. Despite clinical improvement in her skin lesions, her physician notes that the precise molecular or cellular mechanism underlying the drug’s efficacy in psoriasis is not well defined. Which statement best describes the current understanding of this immunosuppressive agent's mechanism of action in managing her disease?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Psoriasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0033860",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0771305",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The exact cellular and molecular mechanism by which modified cyclosporine treats psoriasis remains unclear.",
      "reasoning_path": "Modified cyclosporine is used in refractory psoriasis, but its exact molecular and cellular mechanism of efficacy in this context is not fully established.",
      "umls_path": [
        "Psoriasis",
        "may_be_treated_by",
        "cyclosporine, modified",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In patients with severe, refractory psoriasis, modified cyclosporine—a calcineurin inhibitor—may be used to suppress immune-mediated skin inflammation. While cyclosporine is known to broadly inhibit T-cell activation by preventing the transcription of interleukin-2, the exact molecular and cellular pathways responsible for its effectiveness in psoriasis specifically remain incompletely understood. Research suggests that cyclosporine interferes with several steps in immune signaling and keratinocyte proliferation, yet the precise sequence of interactions and the direct cellular targets involved in the resolution of psoriatic plaques have not been fully elucidated. As a result, despite robust clinical evidence supporting its use, the detailed pathophysiology of cyclosporine’s benefit in psoriasis is still classified as unknown at the molecular and cellular levels. This underscores the complexity of both the disease process and the agent’s immunomodulatory actions.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_b6b6e512a868",
      "question": "For a patient with unresectable stage IIIA non-small cell lung cancer (T4, N1), who harbors an EGFR exon 19 deletion mutation, is it appropriate to use durvalumab for consolidation following definitive concurrent chemoradiation, or should osimertinib be preferred as the consolidation therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Chest wall",
              "Treatment (NSCL-7)",
              "Stage IIIA (T4, N0–1) unresectable",
              "Definitive concurrent chemoradiation (category 1)",
              "Durvalumab (category 1) or Osimertinib (category 1) (if EGFR exon 19 deletion or L858R)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)"
            ]
          }
        }
      ],
      "answer": "In patients with unresectable stage IIIA NSCLC harboring EGFR exon 19 deletion, osimertinib is preferred over durvalumab as post–concurrent chemoradiation consolidation therapy, given evidence of improved efficacy in this molecular subgroup and increased risk of adverse events associated with immunotherapy in EGFR-mutant patients.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_44d08721dd1a",
      "question": "In the OpenTargets platform, what tractability information is available for the target with Ensembl ID ENSG00000239732 and approved symbol TLR9, where the value is True?",
      "tool_calls": [
        {
          "tool": "opentargets.tractability",
          "params": {
            "target_id": "ENSG00000239732",
            "value": true
          }
        }
      ],
      "answer": [
        {
          "modality": "SM",
          "label": "Approved Drug"
        },
        {
          "modality": "SM",
          "label": "High-Quality Ligand"
        },
        {
          "modality": "SM",
          "label": "Druggable Family"
        },
        {
          "modality": "AB",
          "label": "GO CC high conf"
        },
        {
          "modality": "AB",
          "label": "UniProt SigP or TMHMM"
        },
        {
          "modality": "PR",
          "label": "Database Ubiquitination"
        },
        {
          "modality": "PR",
          "label": "Small Molecule Binder"
        },
        {
          "modality": "OC",
          "label": "Advanced Clinical"
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "path_ee33c8f40b41",
      "question": "In a patient with non-inflammatory, non-metastatic invasive breast cancer, estrogen receptor-negative, progesterone receptor-negative, and HER2-negative subtype, tumor size greater than 1 cm, and with up to micrometastatic axillary lymph node involvement (pN1mi only), is adjuvant chemotherapy still indicated if the patient has significant cardiac comorbidity potentially increasing chemotherapy-related risk?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
              "ER-negative and PR-negative",
              "HER2-negative",
              "BINV-10",
              "Ductal/NST, Lobular, Mixed, Micropapillary, Metaplastic",
              "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
              "Tumor >1 cm",
              "Adjuvant chemotherapy (category 1)",
              "Follow-Up (BINV-17)"
            ]
          }
        }
      ],
      "answer": "Although adjuvant chemotherapy is category 1 and generally indicated for ER-, PR-, HER2-negative breast cancers larger than 1 cm with pN0 or pN1mi, significant cardiac comorbidity may contraindicate certain chemotherapy regimens. Anthracyclines should be avoided in this context, and alternative regimens or omission of chemotherapy should be considered based on cardiac risk assessment.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_04df0a5ee00d",
      "question": "A 44-year-old woman presents with several weeks of pruritus and jaundice. Laboratory studies reveal elevated conjugated bilirubin and alkaline phosphatase. Imaging shows no biliary obstruction. She is diagnosed with intrahepatic cholestasis and advised to begin a nutritional supplement rich in long-chain polyunsaturated fatty acids. The supplement is thought to exert its benefit by enhancing a specific metabolic process within hepatocytes, leading to modulation of bile acid synthesis and improved liver function. Which hepatic molecular process is most directly responsible for the therapeutic effect of this intervention?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Intrahepatic cholestasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0008372",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4719544",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Oxidation activity (increased hepatic fatty acid β-oxidation)",
      "reasoning_path": "Intrahepatic cholestasis → omega-3 fatty acid supplementation → increased hepatic β-oxidation → altered bile acid metabolism and improved liver function.",
      "umls_path": [
        "Intrahepatic cholestasis",
        "may_be_treated_by",
        "fish oil (containing omega-3 acids)",
        "has_mechanism_of_action",
        "Oxidation Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Intrahepatic cholestasis is characterized by impaired bile formation or flow within the liver, leading to accumulation of bile acids and related symptoms such as pruritus and jaundice. Fish oil supplements, which are rich in omega-3 fatty acids, can ameliorate cholestasis. The key pharmacological mechanism involves the enhancement of oxidation activity within hepatocytes, specifically through increased β-oxidation of fatty acids. This process reduces hepatic triglyceride accumulation, alters bile acid composition, and exerts anti-inflammatory effects, all of which contribute to improved bile flow and reduced cholestatic injury. By promoting oxidation, omega-3 fatty acids modulate gene expression involved in lipid metabolism (e.g., upregulation of PPAR-α), ultimately improving hepatocyte function and ameliorating symptoms of cholestasis.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_861446a1d120",
      "question": "A 29-year-old traveler returns from a beach vacation with intensely pruritic, serpiginous, erythematous tracks on his feet. He is diagnosed with a parasitic skin infection acquired from walking barefoot on contaminated sand. His physician prescribes an oral medication that disrupts parasite survival by interfering with metabolic enzymes essential for energy production in the organism. To which general pharmacological class does this treatment belong, based on its mechanism of action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "larva migrans"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0023048",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0039832",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme Inhibitors",
      "reasoning_path": "Cutaneous larva migrans is treated with thiabendazole, which acts as an enzyme inhibitor by blocking metabolic enzymes in the parasite, thereby impairing its survival.",
      "umls_path": [
        "larva migrans",
        "may_be_treated_by",
        "Thiabendazole",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has cutaneous larva migrans, a skin infestation caused by hookworm larvae (typically Ancylostoma braziliense) penetrating the epidermis. The mainstay pharmacologic therapy is thiabendazole, an antiparasitic drug. Thiabendazole exerts its effect by inhibiting the parasite's mitochondrial fumarate reductase, a key enzyme in the electron transport chain necessary for energy production. By blocking this enzyme, thiabendazole disrupts the parasite's ATP synthesis, ultimately leading to its death. This mechanism classifies thiabendazole, and similar agents, as enzyme inhibitors. The clinical improvement in cutaneous larva migrans with such treatment is due to the targeted interruption of essential metabolic pathways in the parasite, not direct effects on the host.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_00d4777cf446",
      "question": "In a patient with stage IIIA non–small cell lung cancer who has undergone chemoradiation and now presents with a completely resectable isolated locoregional recurrence, is surgical resection considered the preferred treatment option over external-beam radiotherapy or stereotactic ablative radiotherapy (SABR)?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
              "R1; Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, for a patient with a completely resectable isolated locoregional recurrence of non–small cell lung cancer after chemoradiation, surgical resection is regarded as the preferred treatment option compared to external-beam radiotherapy or SABR. This preference is based on potential for complete tumor removal and improved local control if the recurrence is operable.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_cc75b4f6ce9f",
      "question": "In a patient with stage IVA non-small cell lung cancer characterized by a single contralateral pulmonary nodule (N0, M1a), if both lung tumors are considered individually resectable and there is no evidence of mediastinal nodal involvement or distant metastasis, should management proceed as two primary lung cancers rather than as metastatic disease?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)"
            ]
          }
        }
      ],
      "answer": "Yes, in the scenario of stage IVA non-small cell lung cancer with a solitary contralateral pulmonary nodule and no mediastinal or distant metastases, if both tumors are deemed individually resectable, treatment should follow the approach for synchronous primary lung cancers rather than metastatic disease.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_b775084d64b7",
      "question": "A 54-year-old woman presents with diffuse, intense erythema and scaling covering over 90% of her body surface area. She is admitted for supportive care and started on a systemic medication that acts by entering target cells, binding to cytoplasmic receptors, and ultimately suppressing the synthesis of pro-inflammatory mediators. This medication reduces the production of certain lipid-derived molecules responsible for chemotaxis and increased vascular permeability during inflammation. Which enzyme system, directly inhibited as part of this drug's anti-inflammatory mechanism, is primarily responsible for these lipid mediators?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Erythroderma"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011606",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0056391",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lipoxygenase enzymes",
      "reasoning_path": "Cortisone acetate (glucocorticoid) → binds cytoplasmic receptor → represses phospholipase A2 and lipoxygenase enzyme expression → reduces leukotriene synthesis → decreases inflammation in erythroderma.",
      "umls_path": [
        "Erythroderma",
        "may_be_treated_by",
        "Cortisone Acetate",
        "has_mechanism_of_action",
        "Lipoxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient has erythroderma and is treated with cortisone acetate, a glucocorticoid. Glucocorticoids exert their anti-inflammatory effect by binding to cytoplasmic glucocorticoid receptors, altering gene transcription. This leads to upregulation of anti-inflammatory proteins and downregulation of pro-inflammatory mediators. One critical mechanism is the inhibition of phospholipase A2, which reduces arachidonic acid availability. Downstream, this results in decreased synthesis of prostaglandins and leukotrienes. The synthesis of leukotrienes depends on the lipoxygenase enzyme pathway. By suppressing the expression of lipoxygenase enzymes, glucocorticoids reduce leukotriene-mediated inflammation, which is especially important in severe inflammatory skin conditions like erythroderma. Thus, the anti-inflammatory efficacy of cortisone acetate is directly related to its inhibition of lipoxygenase enzymes responsible for leukotriene production.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_e5159b0d016d",
      "question": "A 34-year-old woman with splenomegaly, easy bruising, and chronic fatigue is diagnosed with a lysosomal storage disorder following genetic and enzymatic assays. Her physician initiates intravenous therapy with a recombinant enzyme, which is designed to replace the activity of a deficient lysosomal hydrolase. This treatment helps clear accumulated substrate from affected tissues, including the liver. Which pharmacological mechanism most directly accounts for the clinical efficacy of this recombinant therapy in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Unspecified disorder of liver"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0023895",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0102139",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Direct enzymatic replacement—restoring deficient lysosomal enzyme activity",
      "reasoning_path": "Gaucher disease involves glucocerebrosidase deficiency; recombinant enzyme therapy provides exogenous enzymatic activity, restoring substrate catabolism in affected tissues.",
      "umls_path": [
        "Unspecified disorder of liver",
        "may_be_treated_by",
        "Alglucerase",
        "has_mechanism_of_action",
        "Enzymatic Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s clinical presentation, together with the use of recombinant enzyme therapy, suggests a diagnosis of Gaucher disease, a lysosomal storage disorder caused by deficiency of glucocerebrosidase. Alglucerase (and its successors, such as imiglucerase) is a recombinant form of the missing enzyme. The therapy works by directly supplementing the absent or deficient glucocerebrosidase activity in macrophages of the liver, spleen, and bone marrow. The exogenous enzyme hydrolyzes accumulated glucocerebroside, reducing substrate burden and alleviating organomegaly and cytopenias. The mechanism is not receptor-mediated or immunomodulatory, but rather involves provision of enzymatic activity at the cellular level, compensating for the inherited metabolic defect. Thus, the therapeutic benefit is a direct consequence of replacing the lost lysosomal enzymatic function, allowing catabolism of sphingolipid substrates.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_126a8c0c6ce0",
      "question": "In a patient with stage IIB non-small cell lung cancer (T3, N0) who has undergone surgical resection but is found to have positive microscopic margins (R1), does the recommendation for resection followed by systemic therapy or chemoradiation implicitly assume there is no evidence of distant metastatic disease at the time of postoperative evaluation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
              "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Severe hemoptysis",
              "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Yes, the recommendation for resection plus systemic therapy or chemoradiation after R1 resection in stage IIB (T3, N0) non-small cell lung cancer presumes that there is no clinical or radiographic evidence of distant metastatic disease, as the treatment intent remains locoregional control.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_7c465d333e5d",
      "question": "In a patient with locally recurrent or advanced non-small cell lung cancer identified as squamous cell carcinoma, if broad molecular profiling unexpectedly reveals an EGFR exon 20 insertion mutation, does this result support the routine use of EGFR-targeted therapy in this context?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "EGFR exon 20 insertion mutation positive"
            ]
          }
        }
      ],
      "answer": "Presence of an EGFR exon 20 insertion mutation in squamous cell carcinoma is rare and does not routinely justify EGFR-targeted therapy, as current evidence and clinical guidelines primarily support EGFR inhibitor use in non-squamous, especially adenocarcinoma, subtypes. Molecular findings in squamous histology should be interpreted with caution, considering potential diagnostic or sampling limitations.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_8b5a4679755e",
      "question": "A 12-year-old boy is admitted to the hospital with polyuria, polydipsia, unintentional weight loss, and fatigue. Laboratory results reveal hyperglycemia, glucosuria, and elevated HbA1c. He is diagnosed with an absolute deficiency of pancreatic beta-cell function. The medical team initiates therapy with an intermediate-acting injectable protein derived from animal pancreas. This medication binds to a specific cell-surface receptor, triggering a kinase-mediated cascade that promotes glucose uptake and utilization in target tissues. Which class of pharmacologic mechanism is responsible for this drug’s primary therapeutic effect in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "TYPE 1 DIABETES MELLITUS"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011854",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0770221",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Insulin receptor agonists",
      "reasoning_path": "Type 1 diabetes → insulin deficiency → exogenous insulin therapy → binds/activates insulin receptors (agonist) → increased glucose uptake/utilization → lowered blood glucose.",
      "umls_path": [
        "TYPE 1 DIABETES MELLITUS",
        "may_be_treated_by",
        "lente insulin, beef",
        "has_mechanism_of_action",
        "Insulin Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This boy has new-onset type 1 diabetes mellitus, which results from autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency. Exogenous insulin replacement is essential for survival and glycemic control. Lente insulin, an intermediate-acting preparation derived from beef pancreas, mimics endogenous insulin. It functions by binding to and activating insulin receptors, which are transmembrane tyrosine kinase receptors present on target tissues such as muscle and adipose cells. Activation of these receptors initiates intracellular signaling cascades (notably via the PI3K/Akt pathway), promoting translocation of glucose transporters to the cell membrane, increased cellular glucose uptake, and enhanced glycogen synthesis, thereby reducing blood glucose levels. This insulin receptor agonism is the fundamental pharmacologic mechanism underlying the therapeutic action of all exogenous insulin formulations in type 1 diabetes.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_30ca67aea27e",
      "question": "In a patient with metastatic (stage IV, M1) invasive breast cancer that is ER- and/or PR-positive and HER2-negative, who presents with rapid progression of liver metastases resulting in impaired hepatic function and clinical symptoms, should initial systemic therapy be prioritized over endocrine therapy, regardless of previous endocrine sensitivity?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Metastatic (M1) invasive breast cancer",
              "Stage IV (M1) or Recurrent disease",
              "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
              "Stage IV (M1) or Recurrent",
              "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
              "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
              "Recurrent unresectable (local or regional) or stage IV (M1) disease",
              "Bone disease not present",
              "ER- and/or PR-positive; HER2-negative",
              "BINV-22",
              "Visceral crisis",
              "Consider initial systemic therapy",
              "Continue therapy until progression or unacceptable toxicity",
              "Progression",
              "For those with visceral crisis: Progression or unacceptable toxicity on first-line systemic therapy",
              "Alternate systemic therapy",
              "Most patients will be candidates for multiple lines of systemic therapy to palliate advanced breast cancer. At each reassessment clinicians should assess value of ongoing treatment, the risks and benefits of an additional line of systemic therapy, patient performance status, and patient preferences through a shared decision-making process.",
              "Consider no further cytotoxic therapy and Continue supportive care (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Supportive Care)"
            ]
          }
        }
      ],
      "answer": "Yes. In the setting of visceral crisis—characterized by life-threatening organ dysfunction such as rapidly progressive liver metastases—initial systemic cytotoxic therapy is prioritized over endocrine therapy, irrespective of hormone receptor sensitivity or prior endocrine responsiveness, to rapidly control disease and stabilize organ function.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_9c05f8488dbd",
      "question": "For a patient with multiple primary lung cancers classified as N0–1, who has undergone surgery with or without chemotherapy and is currently disease-free, does the initiation of annual low-dose non–contrast-enhanced chest CT surveillance immediately after treatment comply with the standard follow-up protocol boundaries?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Multiple lung cancers (suspected or confirmed) (N0–1)",
              "Multidisciplinary evaluation",
              "Stable or very slow-growing disease",
              "Observation",
              "Surveillance",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)"
            ]
          }
        }
      ],
      "answer": "No, in patients with stage I–II disease treated primarily with surgery ± chemotherapy, the standard follow-up protocol requires H&P and chest CT ± contrast every 6 months for 2–3 years post-treatment before transitioning to annual low-dose non–contrast chest CT. Immediate annual surveillance omits the initial intensive monitoring phase and does not comply with the recommended protocol.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_2aaa03e1b4c8",
      "question": "A 68-year-old woman with a history of vertebral compression fracture and low bone mineral density is evaluated for further management of her postmenopausal osteoporosis. She is started on a medication that is known to localize to hydroxyapatite in bone and is taken up preferentially at sites of active bone remodeling. This agent directly impairs the function of cells responsible for bone resorption, thereby reducing bone turnover and increasing bone mineral density. Which molecular process primarily explains the therapeutic action of this medication in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Postmenopausal osteoporosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0029458",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4316864",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Risedronate binds to bone surfaces and inhibits osteoclast-mediated bone resorption",
      "reasoning_path": "Risedronate binds to bone surfaces (hydroxyapatite), is ingested by osteoclasts, disrupts their function, and inhibits bone resorption to improve bone density.",
      "umls_path": [
        "Postmenopausal osteoporosis",
        "may_be_treated_by",
        "Risedronate sodium anhydrous",
        "has_mechanism_of_action",
        "Bone Surface Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Postmenopausal osteoporosis is characterized by increased bone resorption due to decreased estrogen, resulting in reduced bone mass and increased fracture risk. Risedronate is a bisphosphonate that has a high affinity for hydroxyapatite in bone and accumulates at sites of active bone remodeling. Its therapeutic effect is achieved through direct inhibition of osteoclasts—the cells responsible for bone resorption. Risedronate is internalized by osteoclasts during the bone resorption process and disrupts the mevalonate pathway, which is critical for osteoclast function and survival. This leads to osteoclast apoptosis and a reduction in bone resorption activity. By limiting bone breakdown, risedronate slows overall bone turnover and allows bone formation to predominate, ultimately increasing bone density and reducing fracture risk in postmenopausal women.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_47b7a33ef53d",
      "question": "For a patient with pathologically confirmed stage IIIC (T3, N3) non–small cell lung cancer who has not previously undergone a brain MRI or FDG-PET/CT, is it appropriate to proceed directly to metastatic disease treatment without first completing these imaging assessments?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 3–4",
              "Systemic Therapy for Metastatic Disease (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, it is not appropriate. Brain MRI with contrast and FDG-PET/CT are essential for accurate staging and detection of occult metastases. Skipping these imaging studies may lead to inappropriate treatment selection and missed metastatic sites, thus violating standard diagnostic and therapeutic sequencing.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_9ff746fb22c5",
      "question": "A 47-year-old woman presents to the emergency department with a three-day history of productive cough, fever, and shortness of breath. Chest auscultation reveals crackles in the right lower lung field, and a chest X-ray confirms right lower lobe consolidation. She is diagnosed with community-acquired pneumonia and started on an oral antibiotic that acts by binding to and inhibiting specific bacterial enzymes critical for cell wall synthesis. Which general pharmacological class best describes the mechanism by which this drug exerts its therapeutic effect in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Community-acquired infections"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0206171",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0108938",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme inhibitors",
      "reasoning_path": "Community-acquired pneumonia → treated with cefpodoxime proxetil → drug binds/inhibits bacterial penicillin-binding proteins → blocks cell wall synthesis → classified as enzyme inhibitor.",
      "umls_path": [
        "Community-acquired infections",
        "may_be_treated_by",
        "Cefpodoxime Proxetil",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with community-acquired pneumonia is treated with cefpodoxime proxetil, an oral third-generation cephalosporin. Cephalosporins are β-lactam antibiotics that function by targeting and inhibiting bacterial penicillin-binding proteins (PBPs). PBPs are a group of enzymes involved in the final stages of bacterial cell wall (peptidoglycan) synthesis. Inhibition of these enzymes prevents proper cross-linking of the cell wall, ultimately leading to cell lysis and bacterial death. The primary pharmacological class for drugs that work via this mechanism is 'enzyme inhibitors,' as they interfere directly with the enzymatic processes essential for bacterial viability. This mechanism underlies the therapeutic effect of cefpodoxime proxetil in treating community-acquired infections such as pneumonia.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_5e1f21262a7e",
      "question": "In ClinicalTrials.gov, which interventional studies for malignant melanoma started in December 2005 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "conditions=Malignant Melanoma;startDateFrom=2005-12-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00135408"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_85b75bf76d83",
      "question": "A 55-year-old woman presents with recurrent episodes of facial flushing, watery diarrhea, and wheezing. Laboratory evaluation reveals elevated urinary 5-hydroxyindoleacetic acid (5-HIAA). Imaging studies identify a small bowel mass with liver metastases. She is started on a therapy that functions by binding to a specific cell surface receptor complex, leading to activation of intracellular signaling cascades that suppress tumor growth and secretion of vasoactive substances. Which molecular target mediates the therapeutic effects of this drug?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Carcinoid syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0024586",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021735",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Interferon alpha receptor complex",
      "reasoning_path": "Carcinoid syndrome causes hormone-mediated symptoms; recombinant interferon alfa-2b binds the interferon alpha receptor complex, activating JAK-STAT signaling to inhibit tumor growth and hormone secretion.",
      "umls_path": [
        "Carcinoid syndrome",
        "may_be_treated_by",
        "Recombinant Interferon Alfa-2b",
        "has_target",
        "Interferon Alpha Receptor Complex"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "The patient’s symptoms and biochemical findings are classic for carcinoid syndrome, due to a neuroendocrine tumor secreting serotonin and other vasoactive substances. When standard therapies such as somatostatin analogs are insufficient, recombinant interferon alfa-2b can be used. Interferon alfa-2b is a cytokine that exerts its effects by binding to the interferon alpha receptor complex (IFNAR1/IFNAR2) on the surface of target cells. This receptor engagement triggers the JAK-STAT signaling pathway, leading to transcription of genes with antiproliferative and immunomodulatory effects. In carcinoid syndrome, activation of these pathways suppresses tumor growth and reduces secretion of hormones responsible for the syndrome’s symptoms. Thus, the therapeutic action hinges on the drug’s interaction with the interferon alpha receptor complex.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_c39d2f104159",
      "question": "For a patient with stage II non-small cell lung cancer who completed primary treatment with definitive surgery but not radiotherapy, is it appropriate to schedule chest CT scans every 3–6 months for the first 3 years post-treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No; for patients with stage I–II non-small cell lung cancer treated with surgery (± chemotherapy) and no radiotherapy, chest CT should be performed every 6 months for 2–3 years, not every 3–6 months, which is reserved for those who received radiotherapy or have stage III–IV disease.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_6c1fd9579dae",
      "question": "For a patient with non-small cell lung cancer presenting with a solitary nodule in the contralateral lung (TNM stage IVA, N0, M1a), under what condition can the disease be managed as two primary lung tumors instead of metastatic disease, and what is the clinical significance of this distinction?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)"
            ]
          }
        }
      ],
      "answer": "If both lung tumors are deemed technically resectable and potentially curable based on comprehensive staging and evaluation, the disease can be managed as two primary lung cancers rather than as metastatic (stage IV) disease. This distinction is clinically significant because it allows for curative-intent local treatments, as opposed to palliative systemic therapy typically used for metastatic disease.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_bd23bde0a20b",
      "question": "What diseases are associated with the target VEGFA (Ensembl ID: ENSG00000112715) that have a minimum relevance score of 0.5 in OpenTargets?",
      "tool_calls": [
        {
          "tool": "opentargets.search",
          "params": {
            "target_id": "ENSG00000112715",
            "min_score": 0.5
          }
        }
      ],
      "answer": [
        {
          "disease_id": "EFO_0003770",
          "disease_name": "diabetic retinopathy",
          "score": 0.6932347881851066
        },
        {
          "disease_id": "EFO_0001365",
          "disease_name": "age-related macular degeneration",
          "score": 0.6665555315949537
        },
        {
          "disease_id": "EFO_0004683",
          "disease_name": "wet macular degeneration",
          "score": 0.6476087898752155
        },
        {
          "disease_id": "MONDO_0003005",
          "disease_name": "macular retinal edema",
          "score": 0.6097517588270926
        },
        {
          "disease_id": "EFO_0003060",
          "disease_name": "non-small cell lung carcinoma",
          "score": 0.6087877695991972
        },
        {
          "disease_id": "MONDO_0007254",
          "disease_name": "breast cancer",
          "score": 0.6059865671870243
        },
        {
          "disease_id": "EFO_0000519",
          "disease_name": "glioblastoma multiforme",
          "score": 0.5982316317852503
        },
        {
          "disease_id": "EFO_0000616",
          "disease_name": "neoplasm",
          "score": 0.5862326674018541
        },
        {
          "disease_id": "MONDO_0008170",
          "disease_name": "ovarian cancer",
          "score": 0.5800076417695079
        },
        {
          "disease_id": "EFO_0000681",
          "disease_name": "renal cell carcinoma",
          "score": 0.5694020403701061
        },
        {
          "disease_id": "EFO_0009606",
          "disease_name": "macular degeneration",
          "score": 0.555548018962268
        },
        {
          "disease_id": "EFO_0005753",
          "disease_name": "ocular vascular disease",
          "score": 0.5534659283285505
        },
        {
          "disease_id": "EFO_0004348",
          "disease_name": "hematocrit",
          "score": 0.55285111012504
        },
        {
          "disease_id": "EFO_0004142",
          "disease_name": "colorectal neoplasm",
          "score": 0.5478684635098685
        },
        {
          "disease_id": "EFO_0004509",
          "disease_name": "hemoglobin measurement",
          "score": 0.5449002982232724
        },
        {
          "disease_id": "EFO_0000365",
          "disease_name": "colorectal adenocarcinoma",
          "score": 0.5374340766437499
        },
        {
          "disease_id": "EFO_0004305",
          "disease_name": "erythrocyte count",
          "score": 0.5349187677828824
        },
        {
          "disease_id": "MONDO_0002974",
          "disease_name": "cervical cancer",
          "score": 0.5260745672808066
        },
        {
          "disease_id": "EFO_0004833",
          "disease_name": "neutrophil count",
          "score": 0.5169023635797916
        },
        {
          "disease_id": "EFO_0004309",
          "disease_name": "platelet count",
          "score": 0.516222059164415
        },
        {
          "disease_id": "EFO_0004308",
          "disease_name": "leukocyte count",
          "score": 0.5155786031905498
        },
        {
          "disease_id": "EFO_0004541",
          "disease_name": "HbA1c measurement",
          "score": 0.5079954977179357
        },
        {
          "disease_id": "EFO_0001075",
          "disease_name": "ovarian carcinoma",
          "score": 0.5049013414897878
        },
        {
          "disease_id": "EFO_0010977",
          "disease_name": "macrovascular complications of diabetes",
          "score": 0.5030392466541774
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "ret_3b1ff5aea7dd",
      "question": "Which diseases are associated with the target HMGCR (Ensembl ID ENSG00000113161) in OpenTargets with a minimum relevance score of 0.5?",
      "tool_calls": [
        {
          "tool": "opentargets.search",
          "params": {
            "target_id": "ENSG00000113161",
            "min_score": 0.5
          }
        }
      ],
      "answer": [
        {
          "disease_id": "EFO_0001645",
          "disease_name": "coronary artery disease",
          "score": 0.7354210413763757
        },
        {
          "disease_id": "HP_0003124",
          "disease_name": "Hypercholesterolemia",
          "score": 0.7134804415331388
        },
        {
          "disease_id": "EFO_0004911",
          "disease_name": "familial hypercholesterolemia",
          "score": 0.7062842345494592
        },
        {
          "disease_id": "EFO_0000712",
          "disease_name": "stroke",
          "score": 0.6886397436109586
        },
        {
          "disease_id": "EFO_0000319",
          "disease_name": "cardiovascular disease",
          "score": 0.6678091738874605
        },
        {
          "disease_id": "MONDO_0005148",
          "disease_name": "type 2 diabetes mellitus",
          "score": 0.6616871782418438
        },
        {
          "disease_id": "MONDO_0021187",
          "disease_name": "hyperlipidemia",
          "score": 0.6350788050804366
        },
        {
          "disease_id": "EFO_0004611",
          "disease_name": "low density lipoprotein cholesterol measurement",
          "score": 0.6184965686087083
        },
        {
          "disease_id": "EFO_0000612",
          "disease_name": "myocardial infarction",
          "score": 0.6131184301992288
        },
        {
          "disease_id": "EFO_0003913",
          "disease_name": "angina pectoris",
          "score": 0.6064609536402142
        },
        {
          "disease_id": "EFO_0000373",
          "disease_name": "congestive heart failure",
          "score": 0.6022659200947904
        },
        {
          "disease_id": "HP_0003119",
          "disease_name": "Abnormal circulating lipid concentration",
          "score": 0.6007584109825959
        },
        {
          "disease_id": "MONDO_0004975",
          "disease_name": "Alzheimer disease",
          "score": 0.5867829879498245
        },
        {
          "disease_id": "EFO_0003914",
          "disease_name": "atherosclerosis",
          "score": 0.5861026124539934
        },
        {
          "disease_id": "EFO_0000400",
          "disease_name": "diabetes mellitus",
          "score": 0.5860025650062239
        },
        {
          "disease_id": "EFO_0004615",
          "disease_name": "apolipoprotein B measurement",
          "score": 0.5839853322431114
        },
        {
          "disease_id": "EFO_0004574",
          "disease_name": "total cholesterol measurement",
          "score": 0.5800503216654831
        },
        {
          "disease_id": "EFO_0000537",
          "disease_name": "hypertension",
          "score": 0.5791448751092161
        },
        {
          "disease_id": "EFO_0008317",
          "disease_name": "very low density lipoprotein cholesterol measurement",
          "score": 0.5767911452542042
        },
        {
          "disease_id": "EFO_0005772",
          "disease_name": "neurodegenerative disease",
          "score": 0.5698901125414565
        },
        {
          "disease_id": "EFO_0010351",
          "disease_name": "cholesteryl ester measurement",
          "score": 0.5679137164152953
        },
        {
          "disease_id": "EFO_0004529",
          "disease_name": "lipid measurement",
          "score": 0.5656225892517532
        },
        {
          "disease_id": "EFO_0020946",
          "disease_name": "phospholipids:total lipids ratio",
          "score": 0.5644333913345423
        },
        {
          "disease_id": "EFO_0020943",
          "disease_name": "cholesterol:total lipids ratio",
          "score": 0.5638526943162178
        },
        {
          "disease_id": "MONDO_0005301",
          "disease_name": "multiple sclerosis",
          "score": 0.5634667674564039
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "path_c9bf5ec00dc4",
      "question": "In a patient with newly diagnosed metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology, who harbors an EGFR L861Q mutation but also has a concurrent KRAS mutation detected by broad molecular profiling, is first-line treatment with erlotinib or gefitinib still considered appropriate irrespective of the KRAS alteration?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "EGFR S768I, L861Q, and/or G719X mutation positive",
              "EGFR S768I, L861Q, and/or G719X mutations",
              "EGFR mutation discovered prior to first-line systemic therapy",
              "Other Recommended: Erlotinib or Gefitinib or Dacomitinib",
              "Progression",
              "Subsequent Therapy (NSCL-23)"
            ]
          }
        }
      ],
      "answer": "Yes, first-line treatment with erlotinib or gefitinib is indicated for metastatic NSCLC with sensitizing EGFR mutations such as L861Q, regardless of the presence of a concurrent KRAS mutation, as EGFR mutation status remains the primary driver for targeted therapy selection in this context.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_3b119c73c651",
      "question": "A 54-year-old woman is diagnosed with trigeminal neuralgia and started on a first-line anticonvulsant. Two months later, her warfarin dose requirements have increased, and her physician notes subtherapeutic INR values despite good adherence. Laboratory testing rules out malabsorption, and no new medications have been started except for the anticonvulsant. Which drug-metabolizing enzyme is most likely being induced by her new medication, leading to lower plasma concentrations of drugs such as warfarin?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Trigeminal neuralgia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0040997",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0006949",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cytochrome P450 2C19",
      "reasoning_path": "Trigeminal neuralgia treated with carbamazepine; carbamazepine induces CYP2C19; induced CYP2C19 accelerates metabolism of co-administered CYP2C19 substrates, lowering their plasma levels.",
      "umls_path": [
        "Trigeminal neuralgia",
        "may_be_treated_by",
        "Carbamazepine",
        "has_mechanism_of_action",
        "Cytochrome P450 2C19 Inducers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Carbamazepine is a first-line therapy for trigeminal neuralgia and is also a potent inducer of cytochrome P450 enzymes, particularly CYP2C19, among others. By upregulating the expression of this enzyme, carbamazepine accelerates the hepatic metabolism of drugs that are CYP2C19 substrates, such as warfarin, certain antidepressants, and antiepileptics. This increased metabolic clearance leads to reduced plasma concentrations and diminished therapeutic effects of the affected drugs, necessitating closer monitoring and possible dose adjustments. The patient’s presentation of subtherapeutic INR after starting carbamazepine, despite adherence and no other confounding factors, is a classic example of this drug–drug interaction. Recognizing enzyme induction is crucial when prescribing carbamazepine, as it can impact the efficacy and safety of concurrent therapies.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_5f183e0dc92b",
      "question": "A 48-year-old agricultural worker from rural Brazil presents with chronic mucocutaneous ulcers, weight loss, and hoarseness. Biopsy of an oral lesion shows multiple budding yeast cells consistent with a dimorphic fungal infection. He is started on intravenous therapy with a medication that binds to a component of the fungal cell membrane, forming pores and causing cell death. The drug’s molecular target is a sterol molecule not found in human cell membranes but crucial for fungal membrane integrity. The mechanism of this agent is most closely related to which class of antifungal drugs?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Paracoccidioidomycosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0030409",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1145701",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Ergosterol synthesis inhibitors",
      "reasoning_path": "Paracoccidioidomycosis → amphotericin B liposome → binds ergosterol in fungal membranes → disrupts membrane integrity → mechanism parallels ergosterol synthesis inhibitors, which also target ergosterol pathways.",
      "umls_path": [
        "Paracoccidioidomycosis",
        "may_be_treated_by",
        "Amphotericin B liposome",
        "has_mechanism_of_action",
        "Ergosterol Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has paracoccidioidomycosis, a systemic mycosis caused by Paracoccidioides species, confirmed by dimorphic yeast on biopsy. Amphotericin B liposome is a polyene antifungal that binds to ergosterol, an essential sterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause cell death. Although amphotericin B directly binds ergosterol rather than inhibiting its synthesis, its mechanism centers on targeting ergosterol, a pathway also disrupted by azoles and allylamines (ergosterol synthesis inhibitors). Both drug classes ultimately compromise ergosterol-dependent membrane function, leading to fungal cell death. Therefore, the mechanism of amphotericin B is most similar to that of ergosterol synthesis inhibitors, as both disrupt the fungal cell membrane by interfering with ergosterol, though by distinct molecular actions.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_88932bccd390",
      "question": "A 67-year-old man with castration-resistant prostate cancer is enrolled in a clinical trial after progression on standard androgen deprivation therapy. He is started on an experimental regimen including a repurposed anthelmintic agent, originally used for treating tapeworm infections. Recent laboratory studies suggest that this drug inhibits a specific truncated nuclear receptor variant, which is implicated in therapy resistance due to its constitutive activity and lack of ligand-binding domain. Which molecular target is most relevant to the mechanism by which this antiparasitic agent may overcome hormone therapy resistance in prostate cancer?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Helminth infection, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0018889",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0028017",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Androgen Receptor Splice Variant 3 (AR-V3)",
      "reasoning_path": "Patient with resistant prostate cancer → receives niclosamide (anthelmintic) → drug shown to inhibit AR-V3 (truncated androgen receptor) → AR-V3 drives therapy resistance → inhibition may restore response to hormone therapy.",
      "umls_path": [
        "Helminth infection, unspecified",
        "may_be_treated_by",
        "Niclosamide-containing product",
        "has_target",
        "Androgen Receptor Splice Variant 3"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient with advanced, treatment-resistant prostate cancer is receiving niclosamide, a drug historically used for helminthic infections. Beyond its antiparasitic action, niclosamide has been found to inhibit the androgen receptor splice variant 3 (AR-V3), a truncated form of the androgen receptor lacking the ligand-binding domain. AR-V3 is constitutively active and drives tumor growth even in the absence of androgens, contributing to resistance against standard androgen deprivation therapies. By targeting AR-V3, niclosamide interferes with persistent AR signaling, offering a promising approach to overcoming resistance mechanisms in prostate cancer. This illustrates how drugs can have off-target effects or repurposed uses based on their molecular interactions beyond their original indications.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_b8cb06a47185",
      "question": "In patients with stage IVA non–small cell lung cancer presenting with a malignant pleural effusion and confirmed EGFR exon 20 insertion mutation, is immune checkpoint inhibitor monotherapy a preferred first-line option over targeted therapy when broad molecular profiling has been performed?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1a: pleural or pericardial effusion",
              "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
              "Positive",
              "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "EGFR exon 20 insertion mutation positive"
            ]
          }
        }
      ],
      "answer": "No, for stage IVA non–small cell lung cancer with a confirmed EGFR exon 20 insertion mutation, targeted therapy specifically addressing the EGFR exon 20 alteration is preferred over immune checkpoint inhibitor monotherapy as first-line treatment, assuming broad molecular profiling has identified this actionable mutation.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_28c279e4360e",
      "question": "In a premenopausal woman with ER-positive, HER2-negative, non-metastatic invasive ductal breast carcinoma, pT2N0 after total mastectomy with axillary staging, if the primary tumor measures 0.6 cm, is 21-gene RT-PCR testing still strongly recommended if she is being considered for adjuvant chemotherapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
              "ER-positive and/or PR-positive",
              "HER2-negative",
              "Premenopausal",
              "pT1-3 AND pN0",
              "Ductal/NST, Lobular, Mixed, Micropapillary",
              "Tumor >0.5 cm and pN0",
              "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
              "Not done",
              "Adjuvant endocrine therapy ± ovarian suppression/ablation",
              "Follow-Up (BINV-17)"
            ]
          }
        }
      ],
      "answer": "Yes, 21-gene RT-PCR assay is strongly recommended for ER-positive, HER2-negative, node-negative tumors larger than 0.5 cm in premenopausal women as a decisive tool for adjuvant chemotherapy consideration, regardless of surgical method or histologic subtype among those listed.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_093f5dd7cad9",
      "question": "A 54-year-old woman with a history of mild dry, gritty eyes and intermittent blurry vision is evaluated for chronic ocular discomfort. Examination reveals reduced tear meniscus height and punctate epithelial erosions on fluorescein staining, consistent with tear film instability. She is started on a topical agent derived from vitamin A that is known to preserve corneal epithelial integrity. Through which principal molecular mechanism does this therapy help maintain ocular surface health in patients with tear film disorders?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Tear film insufficiency, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0043349",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0042839",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Free radical scavenging (antioxidant) activity",
      "reasoning_path": "Tear film instability → oxidative stress on ocular surface → vitamin A derivative (retinol) administered → retinol acts as free radical scavenger (antioxidant) → decreased oxidative damage → improved epithelial integrity and tear film stability.",
      "umls_path": [
        "Tear film insufficiency, unspecified",
        "may_be_treated_by",
        "Retinol",
        "has_mechanism_of_action",
        "Free Radical Scavenging Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Chronic tear film insufficiency leads to increased oxidative stress and damage to the ocular surface epithelium. Vitamin A derivatives, such as retinol, are prescribed to support ocular surface health due to their antioxidant properties. These compounds act as free radical scavengers, neutralizing reactive oxygen species that accumulate in tear-deficient states. By reducing oxidative stress, retinol preserves epithelial cell integrity, promotes mucin production, and supports corneal healing. This mechanism directly addresses the underlying pathophysiology of tear film instability by minimizing oxidative damage, thereby improving epithelial barrier function and patient symptoms.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_30ccc51172e3",
      "question": "For a patient with a history of resected stage II non–small cell lung cancer (NSCLC) who has completed adjuvant chemotherapy, if routine surveillance detects a new isolated pulmonary nodule but no symptoms or evidence of disseminated disease, should FDG-PET/CT or brain MRI be routinely performed during surveillance imaging?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Severe hemoptysis",
              "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "No, neither FDG-PET/CT nor brain MRI is routinely indicated in the surveillance imaging of asymptomatic patients with resected stage II NSCLC and no evidence of disseminated disease; these modalities are reserved for suspected recurrence or new symptoms suggestive of metastasis.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_9318c98f8744",
      "question": "A 32-year-old woman recently returned from Southeast Asia and presents with cyclical fevers, chills, and malaise. Blood smear confirms Plasmodium vivax infection. She is started on a regimen that includes a medication specifically intended to eradicate dormant liver forms of the parasite and prevent relapse. When discussing the pharmacological action of this agent, her physician explains that while its clinical efficacy is established, the precise cellular and molecular mechanism responsible for its antimalarial effects remains uncertain. Which best describes the current understanding of this drug’s mechanism of action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Vivax malaria [benign tertian]"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0024537",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0033126",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Vivax malaria requires eradication of hypnozoites; primaquine is prescribed but its exact molecular mechanism remains unresolved.",
      "umls_path": [
        "Vivax malaria [benign tertian]",
        "may_be_treated_by",
        "Primaquine-containing product",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Primaquine is used to eliminate hypnozoites in Plasmodium vivax malaria, thus preventing relapse. While its clinical utility is well established, the exact cellular or molecular mechanism by which primaquine exerts its antimalarial effects, particularly against hepatic dormant forms, has not been conclusively determined. Hypotheses include generation of reactive oxygen species or interference with mitochondrial function in the parasite, but definitive molecular targets have not been identified. Therefore, the pharmacodynamics of primaquine are best described as involving an unknown or incompletely understood cellular or molecular interaction.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_d78db8b3e43a",
      "question": "A 42-year-old woman with chronic fatigue, salt craving, and postural dizziness is diagnosed with primary adrenal insufficiency following abnormal ACTH stimulation testing. She is prescribed a medication that not only replaces deficient hormones but also provides anti-inflammatory benefits by decreasing the synthesis of certain eicosanoids. The drug achieves this in part by inhibiting an enzyme critical to leukotriene formation from arachidonic acid. Which enzyme class inhibition is central to this anti-inflammatory mechanism?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Hypoadrenalism"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001623",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0032950",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lipoxygenase inhibitors (lipoxygenase enzyme inhibition)",
      "reasoning_path": "Adrenal insufficiency → corticosteroid therapy (prednisolone) → inhibition of lipoxygenase enzyme → decreased leukotriene synthesis → reduced inflammation.",
      "umls_path": [
        "Hypoadrenalism",
        "may_be_treated_by",
        "Prednisolone",
        "has_mechanism_of_action",
        "Lipoxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In primary adrenal insufficiency, patients lack adequate glucocorticoids. Synthetic corticosteroids such as prednisolone are administered to replace deficient cortisol and provide anti-inflammatory effects. Corticosteroids exert their anti-inflammatory action through several pathways, one of which involves inhibition of phospholipase A2, leading to reduced arachidonic acid release. Additionally, corticosteroids downregulate the expression of enzymes involved in the conversion of arachidonic acid to inflammatory mediators. Specifically, inhibition of the lipoxygenase enzyme prevents the synthesis of leukotrienes, potent mediators of inflammation, bronchoconstriction, and vascular permeability. By decreasing leukotriene production, corticosteroids help mitigate inflammatory responses, which is especially beneficial in managing chronic inflammation seen in hypoadrenalism. Thus, the class of enzyme inhibition most directly related to this mechanism is the lipoxygenase inhibitors.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_9e2cd887c28c",
      "question": "In a patient with stage II non-small cell lung cancer (T1abc–2ab, N1 or T2b, N0) and known significantly reduced pulmonary function on preoperative pulmonary function tests (PFTs), is surgical resection still a recommended treatment option, or should alternative local therapies such as external-beam radiotherapy or stereotactic ablative radiotherapy (SABR) be prioritized due to increased perioperative risk?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "For stage II non-small cell lung cancer patients with significantly impaired pulmonary function demonstrated on PFTs, surgical resection is typically contraindicated due to a high risk of perioperative complications. In such cases, alternative local therapies—external-beam radiotherapy or stereotactic ablative radiotherapy (SABR)—are prioritized as curative-intent treatments.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_30b82f5e3429",
      "question": "A 54-year-old woman presents with fever, productive cough, and pleuritic chest pain. Chest X-ray reveals a lobar infiltrate, and sputum cultures confirm Streptococcus pneumoniae. She is started on an oral antibiotic from the fluoroquinolone class that rapidly improves her symptoms. This agent acts by inhibiting a specific bacterial enzyme essential for DNA replication and chromosome segregation. Which bacterial enzyme is directly inhibited by this antibiotic, leading to bacterial cell death?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Pneumonia due to Streptococcus, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0155862",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0533545",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Topoisomerase IV",
      "reasoning_path": "Streptococcus pneumoniae infection is treated with gemifloxacin, which kills bacteria by inhibiting topoisomerase IV, thereby blocking DNA replication and cell division.",
      "umls_path": [
        "Pneumonia due to Streptococcus, unspecified",
        "may_be_treated_by",
        "Gemifloxacin-containing product",
        "has_mechanism_of_action",
        "Topoisomerase 4 Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Gemifloxacin is a fluoroquinolone antibiotic commonly used to treat community-acquired pneumonia, including cases caused by Streptococcus pneumoniae. The primary mechanism by which gemifloxacin exerts its bactericidal effect is through inhibition of bacterial type II topoisomerases, specifically topoisomerase IV. In Streptococcus species, topoisomerase IV plays a crucial role in decatenating replicated DNA during cell division. By inhibiting this enzyme, gemifloxacin prevents the separation of newly replicated chromosomes, ultimately halting bacterial DNA replication and leading to cell death. This mechanism is distinct from the inhibition of DNA gyrase, which is more prominent in other bacteria. Understanding this molecular target is essential for predicting antibiotic efficacy and resistance patterns, as mutations in the topoisomerase IV gene can confer fluoroquinolone resistance in streptococci.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_05a8bebbc8bb",
      "question": "For a patient with stage IIA (T2b, N0) non-small cell lung cancer who has undergone complete surgical resection (R0) without prior radiotherapy, does the recommendation for surveillance with history, physical examination, and chest CT every 6 months for 2–3 years instead of every 3–6 months for 3 years imply that radiotherapy as a part of initial treatment is the key determinant for more intensive early imaging follow-up?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIA (T2b, N0); Margins negative (R0)",
              "Observe or Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, the surveillance interval of every 6 months for 2–3 years is specifically applied to stage I–II patients treated primarily with surgery (with or without chemotherapy) but not radiotherapy. If radiotherapy was included in the primary treatment, a more intensive imaging schedule of every 3–6 months for 3 years is warranted, indicating that initial use of radiotherapy is the key factor for determining more frequent follow-up.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_c8a36d5e50dc",
      "question": "In a patient with advanced squamous cell carcinoma of the lung, if a MET exon 14 skipping mutation is identified prior to the initiation of systemic therapy, but concurrent severe hepatic impairment is present, is capmatinib or tepotinib therapy still considered an appropriate first-line treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "METex14 skipping mutation positive",
              "METex14 skipping mutation",
              "METex14 skipping mutation discovered prior to first-line systemic therapy",
              "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
              "Progression",
              "Preferred Capmatinib or Tepotinib",
              "Progression",
              "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
            ]
          }
        }
      ],
      "answer": "Capmatinib and tepotinib are standard first-line targeted therapies for advanced NSCLC with MET exon 14 skipping mutations. However, in the presence of severe hepatic impairment, both agents are relatively contraindicated due to their hepatic metabolism and potential toxicity, and alternative treatment approaches should be considered.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_c5100b000b9f",
      "question": "For a patient with stage IIB non–small cell lung cancer (T3, N0) who underwent complete surgical resection with negative margins and subsequently received adjuvant chemotherapy, is routine FDG-PET/CT indicated during scheduled surveillance imaging in the absence of any clinical or radiographic suspicion of recurrence?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Routine FDG-PET/CT is not indicated during surveillance for a stage IIB non–small cell lung cancer patient after complete resection and adjuvant chemotherapy if there is no evidence of clinical or radiographic recurrence; surveillance should consist of history, physical examination, and chest CT at defined intervals.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_2a338c4e73e8",
      "question": "What is the PMID of the 2025 Arquivos de Neuro-Psiquiatria article titled \"How great was the influence of his origins and descendants on Charcot's behaviors?\" by first author Teive HAG?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"How great was the influence of his origins and descendants on Charcot's behaviors?\"[ti] AND Teive HAG[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40345673"
      ],
      "type": "retrieval"
    },
    {
      "id": "ret_a96d43fbfdd4",
      "question": "In the OpenTargets platform, what tractability information is available for the target with Ensembl ID ENSG00000196230 and approved symbol TUBB, where the value is True?",
      "tool_calls": [
        {
          "tool": "opentargets.tractability",
          "params": {
            "target_id": "ENSG00000196230",
            "value": true
          }
        }
      ],
      "answer": [
        {
          "modality": "SM",
          "label": "Approved Drug"
        },
        {
          "modality": "SM",
          "label": "Structure with Ligand"
        },
        {
          "modality": "SM",
          "label": "High-Quality Ligand"
        },
        {
          "modality": "SM",
          "label": "Druggable Family"
        },
        {
          "modality": "AB",
          "label": "GO CC high conf"
        },
        {
          "modality": "PR",
          "label": "UniProt Ubiquitination"
        },
        {
          "modality": "PR",
          "label": "Database Ubiquitination"
        },
        {
          "modality": "PR",
          "label": "Half-life Data"
        },
        {
          "modality": "PR",
          "label": "Small Molecule Binder"
        },
        {
          "modality": "OC",
          "label": "Approved Drug"
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "path_0d40933fdced",
      "question": "In a patient with stage I non-small cell lung cancer who received primary radiation therapy rather than surgery, should the initial surveillance interval for physical examination and chest CT be every 6 months, or more frequently within the first three years?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
              "R2; Concurrent chemoradiation",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "For patients with stage I non-small cell lung cancer treated primarily with radiation therapy, initial surveillance with physical examination and chest CT should occur every 3–6 months during the first three years after treatment, rather than a fixed 6-month interval. This schedule accounts for the higher recurrence risk and specific imaging needs post-radiation.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_c2c8c9cf69e6",
      "question": "In a patient with localized, non-inflammatory, non-metastatic (M0) breast cancer, who has clinical stage cT2, cN1 disease confirmed by needle biopsy, is it appropriate to omit axillary lymph node dissection if, after preoperative systemic therapy and subsequent surgery, only one sentinel lymph node is found positive, whole-breast radiotherapy is planned, and no palpable lymph nodes are detected at surgery?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS not possible",
              "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
              "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
              "SLN mapping and excision",
              "SLN positive",
              "Breast-conserving surgery",
              "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • WBRT planned",
              "Yes to all",
              "No further axillary surgery"
            ]
          }
        }
      ],
      "answer": "No, in this scenario, omission of axillary lymph node dissection is not appropriate because preoperative (neoadjuvant) systemic therapy has been given. The criteria allowing omission require no preoperative chemotherapy; thus, for patients who received preoperative therapy, axillary dissection remains indicated if sentinel node(s) are positive.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_1c63866025ab",
      "question": "In a patient with stage IIIA NSCLC (T1–2, N2) who has a history of prior thoracic radiotherapy, is locoregional recurrence involving mediastinal lymph nodes still an absolute indication for repeat radiotherapy, or is systemic therapy preferred in this context?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "For patients with stage IIIA NSCLC (T1–2, N2) who have previously received thoracic radiotherapy and develop locoregional recurrence involving mediastinal lymph nodes, systemic therapy is preferred over repeat radiotherapy due to cumulative toxicity risks. Repeat radiotherapy is generally not indicated unless strictly individualized.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_c8319e81d084",
      "question": "In a patient with advanced squamous cell carcinoma of the lung who is found to have a ROS1 rearrangement during the course of first-line systemic therapy, is it necessary to complete the planned systemic regimen, or should ROS1-targeted therapy be initiated immediately upon detection of the rearrangement?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "ROS1 rearrangement positive",
              "ROS1 rearrangement",
              "ROS1 rearrangement discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by entrectinibr (preferred), crizotinib (preferred), repotrectinibr (preferred), or ceritinib",
              "Progression",
              "Subsequent Therapy (NSCL-31)"
            ]
          }
        }
      ],
      "answer": "According to standard clinical practice, if a ROS1 rearrangement is identified during ongoing first-line systemic therapy for advanced squamous cell carcinoma, the recommended approach is to complete the current systemic regimen, including maintenance, if the patient is deriving benefit and tolerating treatment. ROS1-targeted therapy is typically initiated following completion or interruption of the planned regimen, not immediately upon rearrangement detection.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_42785d9e12a0",
      "question": "A 38-year-old woman presents with episodes of dark-colored urine in the morning, fatigue, and shortness of breath. Laboratory studies reveal anemia, elevated lactate dehydrogenase, low haptoglobin, and a positive sucrose lysis test. Flow cytometry demonstrates deficiency of CD55 and CD59 on erythrocytes. She is diagnosed with a rare hematologic disorder characterized by complement-mediated intravascular hemolysis. Her hematologist initiates a novel therapy that binds and inhibits a central component of the complement cascade, thereby reducing hemolysis and transfusion requirements. Which specific complement protein is directly targeted by this treatment to prevent red blood cell destruction?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Paroxysmal nocturnal hemoglobinuria"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0024790",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C5418501",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Complement C3",
      "reasoning_path": "PNH causes RBC lysis via unregulated complement activity. Pegcetacoplan targets and inhibits C3, the central component required for complement activation, halting the pathway and preventing hemolysis.",
      "umls_path": [
        "Paroxysmal nocturnal hemoglobinuria",
        "may_be_treated_by",
        "Pegcetacoplan",
        "has_target",
        "Complement C3"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has paroxysmal nocturnal hemoglobinuria (PNH), a disorder caused by an acquired deficiency of glycosylphosphatidylinositol (GPI) anchors, leading to loss of complement-regulatory proteins (CD55, CD59) on red blood cells. This deficiency renders RBCs susceptible to complement-mediated lysis. Pegcetacoplan is a complement inhibitor that binds directly to complement protein C3, preventing its activation. By inhibiting C3, pegcetacoplan blocks the generation of C3b and subsequent downstream events in the complement cascade, including the formation of the membrane attack complex (MAC), thereby reducing intravascular hemolysis and symptoms of PNH.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_b4c200349b85",
      "question": "A 34-year-old traveler returns from a hiking trip in Central America and develops watery, foul-smelling diarrhea, abdominal cramps, and bloating. Stool analysis reveals flagellated protozoa consistent with a specific intestinal parasite. He is started on an oral antibiotic from the nitroimidazole class, which is considered first-line therapy for this infection. However, upon reviewing pharmacology texts, you note that the detailed cellular and molecular mechanism by which this drug kills the pathogen is not fully understood. Based on this information, how is the drug’s mechanism of action best classified?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Giardiasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0017536",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0025872",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Giardiasis diagnosis → metronidazole prescribed → mechanism suspected to involve reduction and DNA disruption → literature confirms mechanism not definitively elucidated → thus, classified as unknown cellular or molecular interaction.",
      "umls_path": [
        "Giardiasis",
        "may_be_treated_by",
        "Metronidazole",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has giardiasis, an intestinal infection caused by Giardia lamblia, for which metronidazole—a nitroimidazole antibiotic—is standard therapy. While metronidazole is highly effective and widely used, the precise cellular and molecular mechanism by which it acts against Giardia remains an area of ongoing research. Pharmacological literature suggests that metronidazole is reduced by anaerobic organisms to form reactive intermediates; these intermediates are thought to disrupt DNA and other critical macromolecules within the parasite. However, despite these hypotheses, the exact molecular targets and pathways remain incompletely characterized. Therefore, in academic and clinical contexts, the drug’s mechanism is classified as 'unknown cellular or molecular interaction,' reflecting this uncertainty despite clear clinical efficacy.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_acab42758a45",
      "question": "A 54-year-old woman with a history of longstanding diabetes mellitus is admitted for progressive lower extremity edema and frothy urine. Laboratory evaluation shows hypoalbuminemia, proteinuria, and elevated creatinine, consistent with nephrotic syndrome secondary to diabetic nephropathy. Due to refractory edema, she receives intravenous infusions of a plasma-derived protein to increase her intravascular oncotic pressure. Which class of pharmacologic agent best describes the mechanism by which this therapy exerts its principal effect in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Nephropathy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0022658",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0304925",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Structural macromolecule (human albumin) restoring plasma oncotic pressure",
      "reasoning_path": "Diabetic nephropathy causes proteinuria and hypoalbuminemia; human albumin is administered as a structural macromolecule to restore plasma oncotic pressure and reduce edema.",
      "umls_path": [
        "Nephropathy",
        "may_be_treated_by",
        "Albumin human",
        "has_mechanism_of_action",
        "Structural Macromolecules"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In nephrotic syndrome, significant protein loss in the urine leads to hypoalbuminemia, resulting in decreased plasma oncotic (colloid osmotic) pressure and subsequent edema. Human albumin is administered intravenously to replenish plasma protein levels and restore oncotic pressure within the vascular compartment. This helps shift fluid from the interstitial space back into the vasculature, reducing edema and supporting intravascular volume. Albumin functions primarily as a structural macromolecule, rather than acting through receptor-mediated or enzymatic pathways. Its therapeutic effect relies on its physical properties—chiefly, its ability to exert oncotic pressure—rather than direct modulation of cellular signaling. Therefore, its mechanism is best described as that of a structural macromolecule, which is distinct from most small-molecule drugs or biologics targeting receptors or enzymes.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_b8224c49b40d",
      "question": "In a patient diagnosed with non-small cell lung cancer staged as T1–3, N2, M0, if mediastinal lymph node involvement is confirmed, does the recommendation for systemic therapy with or without radiotherapy require the patient to be without distant metastases for eligibility?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (peripheral T1abc, N0)",
              "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "N1 or N2 nodes positive, M0",
              "Treatment (NSCL-10)",
              "Mediastinal Biopsy Findings",
              "T1–3, N2 nodes positive, M0",
              "Systemic therapy ± RT",
              "Progression",
              "Local: RT (if feasible) ± chemotherapy"
            ]
          }
        }
      ],
      "answer": "Yes, the use of systemic therapy with or without radiotherapy in T1–3, N2, M0 non-small cell lung cancer is predicated on the absence of distant metastases (M0). If distant metastases are present (M1), this treatment approach is no longer appropriate and systemic therapy alone for metastatic disease should be considered.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_9a7cba209044",
      "question": "In a patient with stage IIA non-small cell lung cancer (T2b, N0) who underwent surgical resection with positive margins (R1 or R2) and has no clinical or radiographic evidence of disease postoperatively, is it appropriate to follow the same surveillance imaging schedule as patients who received definitive radiotherapy as primary treatment, or should the follow-up frequency differ?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIA (T2b, N0); Margins positive (R1, R2)",
              "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Surveillance imaging frequency should differ: after surgery (with or without chemotherapy) for stage I–II disease, chest CT is recommended every 6 months for 2–3 years, then annually, whereas those treated with definitive radiotherapy require chest CT every 3–6 months for 3 years, then every 6 months for 2 years, and then annually. The follow-up is more intensive post-radiotherapy due to different local recurrence risks.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_8fde55718615",
      "question": "In a patient with non-small cell lung cancer staged as IIIB (T1–2, N3), if pathological confirmation of N3 disease cannot be obtained due to inaccessible lymph nodes, is proceeding with stage III-specific treatment still justified based on imaging findings alone?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "N3 nodes positive, M0",
              "Stage IIIB or Stage IIIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Nodes negative",
              "Treatment (NSCL-9)"
            ]
          }
        }
      ],
      "answer": "No. Definitive stage III-specific treatment in non-small cell lung cancer requires pathological confirmation of N3 disease; imaging alone is insufficient for treatment determination due to the risk of false-positive findings, and tissue diagnosis remains essential for accurate staging and clinical decision-making.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_eb9b829492e2",
      "question": "A 55-year-old woman with a long-standing history of joint pain and morning stiffness presents with swollen, tender metacarpophalangeal joints bilaterally. Laboratory studies reveal elevated rheumatoid factor and C-reactive protein levels. Her rheumatologist prescribes a medication that provides symptomatic relief by inhibiting the enzyme responsible for converting arachidonic acid to prostaglandins, thereby reducing inflammation and pain. Which specific molecular target does this medication inhibit to achieve its therapeutic effects in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Rheumatoid arthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003873",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021246",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 1 (Cyclooxygenase-1, COX-1)",
      "reasoning_path": "Rheumatoid arthritis causes inflammation; NSAIDs treat inflammation by inhibiting prostaglandin synthesis; the key molecular target is prostaglandin G/H synthase 1 (COX-1).",
      "umls_path": [
        "Rheumatoid arthritis",
        "may_be_treated_by",
        "Indomethacin",
        "has_target",
        "Prostaglandin G/H Synthase 1"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has classic symptoms of rheumatoid arthritis, an autoimmune inflammatory disease characterized by synovial joint inflammation and destruction. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for symptomatic relief of pain and inflammation. The primary mechanism of NSAIDs is the inhibition of cyclooxygenase enzymes (COX-1 and COX-2), also known as prostaglandin G/H synthases. These enzymes catalyze the conversion of arachidonic acid to prostaglandin H2, a precursor for various pro-inflammatory prostaglandins. By blocking COX-1 (and often COX-2), NSAIDs decrease the synthesis of these mediators, leading to reduced vasodilation, edema, and pain associated with rheumatoid arthritis. Therefore, the therapeutic effect is directly attributed to the inhibition of prostaglandin G/H synthase 1 (COX-1).",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_d215a4d9b32f",
      "question": "In ClinicalTrials.gov, which interventional studies for Multiple Myeloma using bortezomib started in December 2004 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "conditions=Multiple Myeloma;interventions.name=bortezomib;startDateFrom=2004-12-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00111319"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_33a62231f553",
      "question": "A 34-year-old sheep farmer from rural South America presents with several weeks of right upper quadrant abdominal pain, low-grade fever, and eosinophilia. Imaging reveals biliary duct dilation and liver lesions. Serology confirms infection with a liver fluke. He is prescribed an anthelmintic agent that exerts part of its therapeutic effect by inhibiting a specific hepatic cytochrome P450 isoenzyme, thereby altering the metabolism of both endogenous and exogenous compounds. Which class of enzyme inhibitors is most relevant to the primary mechanism of this therapy?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Fascioliasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0015652",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0077071",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cytochrome P450 2B6 inhibitors",
      "reasoning_path": "Fascioliasis → treated with triclabendazole → triclabendazole inhibits hepatic CYP2B6 → CYP2B6 inhibitors are mechanistically relevant.",
      "umls_path": [
        "Fascioliasis",
        "may_be_treated_by",
        "Triclabendazole",
        "has_mechanism_of_action",
        "Cytochrome P450 2B6 Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has fascioliasis, a parasitic infection typically caused by Fasciola hepatica. The first-line treatment is triclabendazole, a benzimidazole derivative. In addition to impairing microtubule function in the parasite, triclabendazole is known to inhibit the cytochrome P450 2B6 (CYP2B6) isoenzyme in the human liver. CYP2B6 metabolizes various drugs and endogenous substrates. Inhibition of CYP2B6 can lead to altered drug levels and potential interactions. The relevance of CYP2B6 inhibition lies both in the drug’s metabolism and its role in potential drug-drug interactions during treatment. Therefore, the class of enzyme inhibitors most directly associated with this therapy’s mechanism is cytochrome P450 2B6 inhibitors.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_355607a1e184",
      "question": "In a patient with advanced squamous cell carcinoma of the lung and a history of prior radiotherapy, is broad molecular profiling, including EGFR, ALK, and other targetable alterations, still recommended as part of initial evaluation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "EGFR exon 19 deletion or exon 21 L858R mutation positive"
            ]
          }
        }
      ],
      "answer": "Yes, broad molecular profiling, including EGFR, ALK, KRAS, ROS1, BRAF, METex14 skipping, RET, and ERBB2 (HER2), as well as PD-L1 testing, is indicated in advanced squamous cell carcinoma regardless of prior radiotherapy history, to identify potential targets for systemic therapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_22f18a8a0527",
      "question": "In patients with stage I–II non–small cell lung cancer who underwent primary treatment with surgery and have no clinical or radiographic evidence of disease, is routine brain MRI with contrast required during scheduled surveillance imaging?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (T1abc, N0); Margins positive (R1, R2)",
              "Resection (preferred) or RT (category 2B)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "No, routine brain MRI with contrast is not indicated for surveillance in stage I–II non–small cell lung cancer patients treated with surgery and without clinical or radiographic evidence of disease; surveillance should use history, physical exam, and periodic chest CT, reserving brain MRI for cases of suspected recurrence or neurologic symptoms.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_d15586dba526",
      "question": "In a patient with stage IVB non-small cell lung cancer (NSCLC) who is found to have both an EGFR exon 20 insertion mutation and high PD-L1 expression (≥50%), is amivantamab-vmjw preferred over first-line immune checkpoint inhibitor monotherapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "EGFR exon 20 insertion mutation positive",
              "EGFR exon 20 insertion mutation",
              "Systemic therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
              "Tumor response evaluation",
              "Progression",
              "Amivantamab-vmjw",
              "Systemic Therapy, Subsequent (NSCL-K 4 of 5)"
            ]
          }
        }
      ],
      "answer": "Amivantamab-vmjw is specifically indicated for advanced NSCLC with EGFR exon 20 insertion mutations after progression on platinum-based chemotherapy. Despite high PD-L1 expression, first-line immune checkpoint inhibitor monotherapy is not preferred because immunotherapy is less effective in EGFR-mutant NSCLC. Targeted therapy or platinum-based chemotherapy remains the initial standard; amivantamab-vmjw is reserved for use after chemotherapy failure.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_e8973500a64c",
      "question": "A 57-year-old woman is diagnosed with a thyroid nodule exhibiting increased uptake on radionuclide imaging. After further evaluation, she is treated with a radiopharmaceutical agent that is selectively taken up by thyroid follicular cells and emits low-energy gamma radiation. Despite its use in ablating hyperfunctioning thyroid tissue, the precise details of this agent’s cytotoxic action at the cellular or molecular level remain unclear. What is the best current understanding of the specific mechanism by which this agent acts in thyroid tissue?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Unspecified disorder of thyroid"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0040128",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0796396",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Radioactive iodine I 125 is concentrated in thyroid tissue and emits cytotoxic radiation, but the detailed cellular or molecular mechanism underlying its therapeutic effects remains undefined.",
      "umls_path": [
        "Unspecified disorder of thyroid",
        "may_be_treated_by",
        "iodine I 125",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Radioactive iodine isotopes, such as iodine I 125, are used therapeutically for certain thyroid disorders due to their selective uptake by thyroid follicular cells, which utilize iodine in hormone synthesis. Once administered, the isotope is concentrated within the thyroid gland, where it emits radiation—primarily low-energy gamma rays in the case of I 125. This radiation is thought to damage and eventually destroy hyperactive thyroid tissue, reducing hormone output or ablating nodules. However, while the macroscopic effects (tissue destruction via irradiation) are well recognized, the detailed molecular or cellular mechanisms—such as which biomolecules or cellular structures are the primary targets of radiation-induced damage, and the exact pathways leading to cell death—are not fully elucidated for iodine I 125. Thus, the best current description of its mechanism in this context is that it acts via an unknown cellular or molecular interaction.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_de255a596846",
      "question": "A 65-year-old fair-skinned man with a history of extensive sun exposure presents with multiple rough, scaly, erythematous patches on his scalp and forearms. Biopsy confirms a diagnosis of a premalignant epidermal lesion associated with ultraviolet light damage. He is prescribed a topical gel that alleviates these lesions by blocking an enzyme required for prostaglandin synthesis, resulting in reduced local inflammation and cellular proliferation. Which drug class is responsible for this agent's therapeutic mechanism in this scenario?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Keratosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0022593",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0012091",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cyclooxygenase inhibitors",
      "reasoning_path": "Actinic keratosis is treated topically with diclofenac, which works by inhibiting cyclooxygenase, decreasing prostaglandin synthesis, inflammation, and keratinocyte proliferation.",
      "umls_path": [
        "Keratosis",
        "may_be_treated_by",
        "Diclofenac",
        "has_mechanism_of_action",
        "Cyclooxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This clinical vignette describes actinic keratosis, a premalignant skin lesion commonly seen in older adults with significant sun exposure. The topical treatment referenced is diclofenac, which is a nonsteroidal anti-inflammatory drug (NSAID). Diclofenac's primary mechanism is the inhibition of cyclooxygenase (COX) enzymes—specifically COX-1 and COX-2—that catalyze the conversion of arachidonic acid to prostaglandins. Prostaglandins promote inflammation, pain, and cellular proliferation. By inhibiting cyclooxygenase, diclofenac reduces both the inflammatory response and the abnormal proliferation of keratinocytes characteristic of actinic keratosis. The clinical efficacy of topical diclofenac in this setting is therefore due to its ability to block prostaglandin synthesis via cyclooxygenase inhibition, making cyclooxygenase inhibitors the drug class responsible for this therapeutic effect.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_c3b924d50147",
      "question": "In a patient diagnosed with non-small cell lung cancer, if two pulmonary nodules are detected in different ipsilateral lobes, both staged as T4, N0–1, does this clinical scenario still allow for surgical intervention as a primary treatment approach, or does it necessitate an immediate transition to systemic therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
              "Pathologic Diagnosis of NSCLC",
              "Clinical Stage",
              "Stage IB, peripheral (T2a, N0); Stage I, central (T1abc–T2a, N0); Stage II (T1abc–T2ab, N1; T2b, N0); Stage IIB (T3, N0)f; Stage IIIA (T3, N1)",
              "Pretreatment Evaluation (NSCL-3)"
            ]
          }
        }
      ],
      "answer": "When two pulmonary nodules are located in different ipsilateral lobes and staged as T4, N0–1, surgical resection remains a viable primary treatment option if both lesions are deemed potentially curable. Systemic therapy is not mandated solely by the presence of two ipsilateral nodules; curative-intent surgery should be considered if resectability criteria are fulfilled.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_254c5674f6c1",
      "question": "In a patient newly diagnosed with stage IVA (M1b) non-small cell lung cancer presenting with a solitary brain metastasis and confirmed adenocarcinoma histology, should comprehensive molecular profiling be prioritized before local therapy to the brain, and does this requirement apply regardless of the presence or absence of neurological symptoms?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Yes, comprehensive molecular profiling is essential and should be prioritized before proceeding with local therapy to a solitary brain metastasis in stage IVA (M1b) adenocarcinoma, regardless of neurological symptoms, as the results can directly influence systemic treatment decisions and targeted therapy selection.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_0894226e37b9",
      "question": "In the OpenTargets platform, what tractability information is available for the target with Ensembl ID ENSG00000142208 and approved symbol AKT1, where the value is True?",
      "tool_calls": [
        {
          "tool": "opentargets.tractability",
          "params": {
            "target_id": "ENSG00000142208",
            "value": true
          }
        }
      ],
      "answer": [
        {
          "modality": "SM",
          "label": "Advanced Clinical"
        },
        {
          "modality": "SM",
          "label": "Structure with Ligand"
        },
        {
          "modality": "SM",
          "label": "High-Quality Ligand"
        },
        {
          "modality": "SM",
          "label": "High-Quality Pocket"
        },
        {
          "modality": "SM",
          "label": "Druggable Family"
        },
        {
          "modality": "AB",
          "label": "UniProt loc high conf"
        },
        {
          "modality": "AB",
          "label": "GO CC high conf"
        },
        {
          "modality": "PR",
          "label": "Literature"
        },
        {
          "modality": "PR",
          "label": "UniProt Ubiquitination"
        },
        {
          "modality": "PR",
          "label": "Database Ubiquitination"
        },
        {
          "modality": "PR",
          "label": "Half-life Data"
        },
        {
          "modality": "PR",
          "label": "Small Molecule Binder"
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_b75c8c8d8abc",
      "question": "A 34-year-old woman presents with symptoms of otitis externa, including ear pain, mild swelling, and purulent discharge. Her physician prescribes topical drops containing an agent that acts by structurally mimicking a bacterial nutrient, thereby competitively blocking an essential enzymatic step in microbial folate synthesis. This drug ultimately inhibits bacterial growth by depriving the organism of necessary cofactors for DNA replication. Which pharmacological class best describes the mechanism of action of this agent in treating her infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Unspecified disorder of ear"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0013447",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0282356",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Para-aminobenzoic acid (PABA) inhibitors",
      "reasoning_path": "Otitis externa → prescribed sulfacetamide sodium → sulfonamide class → mimics PABA → inhibits dihydropteroate synthase → blocks folic acid synthesis → antibacterial effect via PABA inhibitor mechanism.",
      "umls_path": [
        "Unspecified disorder of ear",
        "may_be_treated_by",
        "Sulfacetamide Sodium",
        "has_mechanism_of_action",
        "Para-Aminobenzoic Acid Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Sulfacetamide sodium is a sulfonamide antibiotic commonly used for localized infections such as otitis externa. Its antibacterial effect is achieved by mimicking para-aminobenzoic acid (PABA), an essential substrate for bacterial dihydropteroate synthase. By competitively inhibiting this enzyme, sulfacetamide prevents the synthesis of dihydrofolic acid, a precursor for folic acid. Because bacteria require folic acid for nucleotide and DNA synthesis—and cannot obtain it exogenously—this interruption halts growth and replication. Human cells are unaffected because they acquire folate from the diet and do not rely on this bacterial pathway. Thus, the therapeutic benefit in ear infections hinges on sulfacetamide’s action as a PABA inhibitor, selectively targeting microbial metabolism without significant host toxicity.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_17702ea54c0b",
      "question": "For a patient with stage IB (T2a, N0) non-small cell lung cancer who has undergone complete surgical resection with negative margins (R0), does the option of adjuvant systemic therapy inherently imply the presence of additional high-risk pathological features beyond tumor size and nodal status?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (T2a, N0); Margins negative (R0)",
              "Observe or Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "No, the option of adjuvant systemic therapy in stage IB (T2a, N0) non-small cell lung cancer with R0 resection does not inherently imply additional high-risk pathological features; it may be considered in stage IB purely based on tumor size or clinical factors, even in the absence of other high-risk characteristics.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_c886efd9597f",
      "question": "A 47-year-old woman with diabetes presents with a deep, erythematous ulcer on her lower leg, surrounded by induration and purulent drainage. She is diagnosed with a complicated skin and soft tissue infection and is started on an intravenous antibiotic known for its activity against methicillin-resistant Staphylococcus aureus (MRSA). This agent exerts its antibacterial effect by binding to and inhibiting a critical bacterial enzyme involved in the synthesis of the peptidoglycan cell wall. Which pharmacological class best describes the mechanism of action of this antibiotic?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Skin Infection"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0037278",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2955460",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme inhibitors",
      "reasoning_path": "Complicated skin infection → ceftaroline fosamil chosen for MRSA coverage → binds PBPs (bacterial enzymes) → inhibits cell wall synthesis → classified as enzyme inhibitor.",
      "umls_path": [
        "Skin Infection",
        "may_be_treated_by",
        "Ceftaroline Fosamil Acetate",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Ceftaroline fosamil is a fifth-generation cephalosporin used to treat complicated skin and soft tissue infections, including those caused by MRSA. Its antibacterial effect is mediated through binding to penicillin-binding proteins (PBPs), particularly PBP2a, which is responsible for resistance in MRSA. By binding to these bacterial enzymes, ceftaroline inhibits the final transpeptidation step in peptidoglycan synthesis, compromising cell wall integrity and leading to bacterial cell death. This mechanism classifies ceftaroline, and other beta-lactams, as enzyme inhibitors, since they directly inhibit key bacterial enzymes required for the synthesis of the cell wall. Thus, the therapeutic effect in complicated skin infections is achieved through enzyme inhibition.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_6602163e0b79",
      "question": "In a patient with stage IVA non-small cell lung cancer presenting with malignant pleural effusion and confirmed squamous cell carcinoma histology, is broad molecular profiling including EGFR, ALK, and other driver mutations still warranted, or can molecular testing be omitted due to the squamous subtype?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1a: pleural or pericardial effusion",
              "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
              "Positive",
              "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Broad molecular profiling, including EGFR, ALK, KRAS, ROS1, BRAF, and other actionable mutations, is still warranted in advanced squamous cell carcinoma of the lung, especially if the patient is a non-smoker or has small biopsy/cytology specimens, as actionable alterations may occasionally be present; molecular testing should not be omitted solely based on squamous histology.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_448da40da5dd",
      "question": "For a patient with completely resected stage III NSCLC (T1–2, N2 or T3, N1 or T3, N2), with negative surgical margins and no evidence of residual or metastatic disease after adjuvant systemic therapy, is routine surveillance with brain MRI indicated in the absence of neurological symptoms?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Bone metastases",
              "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, routine surveillance with brain MRI is not indicated in asymptomatic patients with completely resected stage III NSCLC and no evidence of residual or metastatic disease. Brain MRI should be reserved for patients with neurological symptoms or suspected recurrence, as routine use is not supported in the absence of clinical concerns.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_90745ac94ff9",
      "question": "A 34-year-old man with advanced HIV presents with confusion, fever, and new-onset seizures. Brain MRI reveals multiple ring-enhancing lesions, and cerebrospinal fluid PCR confirms infection with Toxoplasma gondii. He is started on a medication that acts by inhibiting the mitochondrial electron transport chain in the parasite, ultimately impairing DNA and RNA synthesis. Which class of pharmacologic action best describes this drug's mechanism in treating his infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Meningoencephalitis due to toxoplasmosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0085315",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0165603",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Nucleic acid synthesis inhibitors",
      "reasoning_path": "Toxoplasma infection in the CNS is treated with atovaquone, which inhibits the parasite's mitochondrial electron transport chain, leading to impaired nucleic acid synthesis and reduced replication.",
      "umls_path": [
        "Meningoencephalitis due to toxoplasmosis",
        "may_be_treated_by",
        "Atovaquone",
        "has_mechanism_of_action",
        "Nucleic Acid Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this immunocompromised patient, Toxoplasma gondii causes meningoencephalitis, characterized by ring-enhancing lesions and neurological symptoms. Atovaquone is prescribed for toxoplasmosis, especially in patients intolerant to first-line therapies. Its primary mechanism involves inhibition of the mitochondrial electron transport chain at the cytochrome bc1 complex in the parasite. This disruption depletes ATP and essential cofactors, thereby impairing the synthesis of nucleic acids (DNA and RNA), which are necessary for parasite replication and survival. By inhibiting nucleic acid synthesis, atovaquone effectively limits parasite proliferation and contributes to the resolution of infection. Understanding this pathway is critical in recognizing why atovaquone is effective for protozoal infections like toxoplasmosis, particularly in immunosuppressed individuals.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_236398f7e099",
      "question": "A 29-year-old woman is diagnosed with cervicitis after presenting with dysuria and mucopurulent cervical discharge. She is started on an oral antibiotic that targets bacterial folate synthesis by acting as a structural analog of para-aminobenzoic acid. During a follow-up visit, her physician reviews her medication list and notes she is also taking warfarin. The physician is concerned about a potential drug interaction due to inhibition of a specific hepatic drug-metabolizing enzyme by the antibiotic. Which class of enzyme inhibitors is most relevant to consider when evaluating the risk of elevated warfarin levels in this scenario?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Chlamydiaceae Infection"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0008153",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0038689",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cytochrome P450 2C9 inhibitors",
      "reasoning_path": "Sulfonamides inhibit CYP2C9; warfarin is metabolized by CYP2C9; co-administration increases warfarin levels due to CYP2C9 inhibition.",
      "umls_path": [
        "Chlamydiaceae Infection",
        "may_be_treated_by",
        "Sulfamethoxazole-containing product",
        "has_mechanism_of_action",
        "Cytochrome P450 2C9 Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient is being treated with a sulfonamide antibiotic, likely sulfamethoxazole, for a presumed Chlamydia trachomatis infection. Sulfamethoxazole functions by inhibiting bacterial dihydropteroate synthase, but it also has significant effects on human drug metabolism. Specifically, sulfamethoxazole is a known inhibitor of the cytochrome P450 2C9 (CYP2C9) enzyme in the liver. Warfarin is primarily metabolized by CYP2C9; inhibition of this enzyme decreases warfarin clearance, leading to increased plasma concentrations and elevated bleeding risk. When considering potential drug interactions with sulfonamides, it is crucial to assess whether co-administered drugs are substrates of CYP2C9. Therefore, cytochrome P450 2C9 inhibitors are the relevant class of enzyme inhibitors to consider when evaluating the risk of increased warfarin levels and other drug interactions in this context.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_a2e402730c97",
      "question": "For a patient with stage IA (T1a-c, N0) non-small cell lung cancer who has positive surgical margins (R1 or R2) after resection, is it necessary that they have undergone resection rather than definitive radiotherapy in order to qualify for the described surveillance schedule of H&P and chest CT with or without contrast every 6 months for 2–3 years, then annually?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (T1abc, N0); Margins positive (R1, R2)",
              "Resection (preferred) or RT (category 2B)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "No; both patients who have undergone resection and those treated with definitive radiotherapy are eligible for the surveillance schedule described, as either resection (preferred) or radiotherapy can serve as primary treatment for stage IA with positive margins. Surveillance recommendations are not restricted exclusively to surgical candidates.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_4b35c26d2c8e",
      "question": "A 55-year-old man presents to the clinic with acute onset of severe pain, redness, and swelling in his right first metatarsophalangeal joint. He has a history of hypertension and hyperlipidemia but no prior joint issues. His physician diagnoses acute gouty arthritis and prescribes a nonsteroidal anti-inflammatory drug (NSAID) from the anthranilic acid (fenamate) class to manage pain and inflammation. This medication exerts its therapeutic effect by directly inhibiting a key enzyme involved in converting arachidonic acid to pro-inflammatory mediators. Which enzyme is the primary molecular target of this treatment, leading to symptom relief in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Gout, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0018099",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0025041",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 2 (COX-2)",
      "reasoning_path": "Gouty inflammation is mediated by prostaglandins. Meclofenamate sodium, an NSAID, inhibits prostaglandin synthesis via direct inhibition of COX-2 (Prostaglandin G/H Synthase 2), leading to reduced inflammation and pain.",
      "umls_path": [
        "Gout, unspecified",
        "may_be_treated_by",
        "Meclofenamate Sodium",
        "has_target",
        "Prostaglandin G/H Synthase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "In acute gout, monosodium urate crystals trigger intense inflammation via activation of immune cells and release of cytokines. A central component in the inflammatory cascade is the synthesis of prostaglandins, which amplify pain and swelling. Meclofenamate sodium, an NSAID of the fenamate class, is used for symptomatic relief by inhibiting prostaglandin synthesis. Its main molecular target is Prostaglandin G/H Synthase 2, also known as cyclooxygenase-2 (COX-2). By blocking this enzyme, meclofenamate sodium prevents the conversion of arachidonic acid to prostaglandin H2, the precursor of various pro-inflammatory prostanoids. This inhibition reduces local vasodilation, edema, and sensitization of nociceptors, thereby alleviating the pain and inflammation characteristic of acute gouty attacks. While both COX-1 and COX-2 can be affected by NSAIDs, COX-2 is particularly relevant in sites of inflammation. In summary, direct inhibition of COX-2 is responsible for the anti-inflammatory and analgesic effects of meclofenamate sodium in gout.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_1d5e906caf1d",
      "question": "A 35-year-old woman presents with pruritic, erythematous skin lesions after returning from a trip to an area endemic for cutaneous parasitic infections. A dermatologist diagnoses her with a superficial parasitic skin infestation and prescribes a topical preparation that contains Povidone K30. While reviewing the pharmacology of this agent, you note that the literature does not describe a well-defined cellular or molecular target for its antiparasitic effects. Which term most accurately characterizes the molecular mechanism of action of this topical medication in her treatment?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Parasitic infection of skin"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0037280",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1655449",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "A patient with a parasitic skin infection receives Povidone K30; literature review shows the drug’s precise molecular mechanism is not defined, so its action is best described as an unknown cellular or molecular interaction.",
      "umls_path": [
        "Parasitic infection of skin",
        "may_be_treated_by",
        "Povidone K30",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Povidone K30 (polyvinylpyrrolidone) is widely used in topical antiseptic formulations, often as a complex with iodine (povidone-iodine). Although effective against a broad spectrum of pathogens, including some parasites, the precise cellular or molecular mechanism by which Povidone K30 exerts antiparasitic effects is not clearly established in the literature. Unlike many antiparasitic drugs that have well-characterized targets (such as inhibition of specific enzymes or disruption of ion channels), Povidone K30’s action is generally attributed to its ability to act as a carrier for iodine, facilitating antiseptic activity. However, when referenced on its own (not as a carrier for an active antimicrobial), its pharmacologic effect is not defined at the molecular or cellular level. Therefore, the most accurate descriptor for its mechanism in this context is an 'unknown cellular or molecular interaction.'",
      "type": "kg_reasoning"
    },
    {
      "id": "path_d04c99415e9c",
      "question": "In a patient with stage IIIB non-small cell lung cancer characterized by T3 tumor and N2 nodal involvement, who is medically inoperable due to poor pulmonary function as assessed by pulmonary function tests, should definitive radiotherapy (preferably SABR) be prioritized over surgical intervention?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Nodes negative",
              "Treatment (NSCL-9)",
              "T2a–3, N0",
              "Medically inoperable, high surgical risk as determined by thoracic surgeroni, and those who decline surgery after thoracic surgical consultation",
              "Definitive RT, preferably SABR",
              "Consider adjuvant chemotherapyp for high-risk stage II",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "Yes, for medically inoperable patients with stage IIIB (T3, N2) non-small cell lung cancer, definitive radiotherapy, with stereotactic ablative body radiotherapy (SABR) as the preferred modality if technically feasible, should be prioritized. Surgical intervention is not indicated in patients deemed inoperable due to high surgical risk.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_a2d1e351c373",
      "question": "In a premenopausal woman with non-inflammatory, non-metastatic, HER2-negative, ER-positive invasive breast cancer (tumor size 1.2 cm, pN0, ductal subtype), is adjuvant chemotherapy still indicated if her 21-gene recurrence score is 25?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
              "ER-positive and/or PR-positive",
              "HER2-negative",
              "Premenopausal",
              "pT1-3 AND pN0",
              "Ductal/NST, Lobular, Mixed, Micropapillary",
              "Tumor >0.5 cm and pN0",
              "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
              "Recurrence score ≥26",
              "Adjuvant chemotherapy followed by endocrine therapy ± ovarian suppression/ablation",
              "Follow-Up (BINV-17)"
            ]
          }
        }
      ],
      "answer": "No, adjuvant chemotherapy is strongly considered only if the 21-gene recurrence score is 26 or higher; with a score of 25, chemotherapy is generally not recommended, and endocrine therapy with or without ovarian suppression is preferred.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_01d6a4a7915a",
      "question": "A 62-year-old woman presents to the ophthalmology clinic with persistent dryness, irritation, and a gritty sensation in both eyes for several months. Examination reveals decreased tear breakup time and punctate epithelial erosions on the corneal surface. She is started on topical retinyl acetate drops. This agent is known to provide cytoprotective effects for the ocular surface epithelium. Through which primary molecular mechanism does this medication help stabilize the tear film and alleviate her symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Tear film insufficiency, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0043349",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0073109",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Free radical scavenging activity (antioxidant effect)",
      "reasoning_path": "Tear film insufficiency exposes the ocular surface to oxidative stress; retinyl acetate acts as an antioxidant, scavenging free radicals and reducing oxidative damage, thereby stabilizing the tear film.",
      "umls_path": [
        "Tear film insufficiency, unspecified",
        "may_be_treated_by",
        "Retinyl Acetate",
        "has_mechanism_of_action",
        "Free Radical Scavenging Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Retinyl acetate, a form of vitamin A used as an ophthalmic preparation, benefits patients with tear film insufficiency (dry eye) by protecting ocular surface cells from oxidative damage. In the setting of chronic tear deficiency, the corneal and conjunctival epithelium are exposed to increased oxidative stress due to reduced lubrication and increased environmental exposure. Retinyl acetate acts as an antioxidant, neutralizing reactive oxygen species (free radicals) that would otherwise damage cell membranes and proteins on the ocular surface. By reducing oxidative stress, it preserves epithelial integrity, supports mucin production, and contributes to tear film stability. Therefore, the primary pharmacological mechanism underlying its therapeutic action is its free radical scavenging (antioxidant) activity, which directly mitigates oxidative injury and supports recovery of the ocular surface in patients with tear film insufficiency.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_d35bf925d91e",
      "question": "A 62-year-old woman with systemic amyloidosis is being considered for adjunctive therapy to limit further tissue damage. The consulting team discusses an agent commonly used as a mucolytic and known for its antioxidant properties. It acts by breaking disulfide bonds and directly scavenging reactive oxygen species. Which principal pharmacodynamic effect underlies the potential benefit of this drug in amyloidosis?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Amyloidosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002726",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001047",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Reduction activity (disruption of disulfide bonds and antioxidant effect)",
      "reasoning_path": "Amyloidosis involves protein aggregates; acetylcysteine acts via reduction of disulfide bonds and antioxidant effects, disrupting amyloid and reducing tissue damage.",
      "umls_path": [
        "Amyloidosis",
        "may_be_treated_by",
        "Acetylcysteine",
        "has_mechanism_of_action",
        "Reduction Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In systemic amyloidosis, misfolded protein aggregates with stable disulfide bonds accumulate in tissues, leading to organ dysfunction. Acetylcysteine, a mucolytic agent, is being considered for its off-label use due to its potent reduction activity. This drug contains a free sulfhydryl group that can break disulfide bonds in protein aggregates, potentially destabilizing amyloid fibrils. Additionally, acetylcysteine replenishes intracellular glutathione, a major endogenous antioxidant, thereby mitigating oxidative stress associated with amyloid deposition. By targeting both the structural integrity of amyloid fibrils and reducing oxidative tissue injury, acetylcysteine’s reduction activity is central to its potential therapeutic effect in amyloidosis. The mechanistic rationale extends beyond mucus thinning to broader redox modulation and protein aggregate disruption, which may help slow disease progression.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_a606312266fb",
      "question": "For a patient with stage IA (T1abc, N0) non-small cell lung cancer who has undergone resection but has a microscopically positive margin (R1), is it mandatory to perform adjuvant radiotherapy, or can surveillance alone be considered as a reasonable alternative?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (T1abc, N0); Margins positive (R1, R2)",
              "Resection (preferred) or RT (category 2B)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "In the setting of stage IA (T1abc, N0) non-small cell lung cancer with positive surgical margins (R1) after resection, both re-resection (preferred) and adjuvant radiotherapy (category 2B) are options; however, surveillance alone is not recommended as a standard alternative due to the risk of local recurrence associated with positive margins.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_ba3eac7d33d3",
      "question": "A 34-year-old sheep farmer is diagnosed with hepatic cystic lesions after presenting with right upper quadrant pain and imaging revealing hydatid cysts. He is prescribed a medication that impairs parasite microtubule assembly and requires hepatic activation to its sulfoxide form for optimal efficacy. The clinician notes that the patient is also taking medications known to induce hepatic drug-metabolizing enzymes. Through which enzyme class might these co-medications most directly alter the pharmacokinetics and therapeutic effect of this antiparasitic agent?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Echinococcosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0013502",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001911",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cytochrome P450 enzymes (specifically CYP1A subfamily)",
      "reasoning_path": "Albendazole requires hepatic conversion (mainly by CYP1A enzymes) to its active form; CYP1A inducers can alter this process, affecting drug efficacy in echinococcosis.",
      "umls_path": [
        "Echinococcosis",
        "may_be_treated_by",
        "Albendazole",
        "has_mechanism_of_action",
        "Cytochrome P450 1A Inducers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Albendazole, used to treat echinococcosis, is a prodrug that must be metabolized by hepatic cytochrome P450 enzymes—particularly CYP1A isoforms—into its active sulfoxide metabolite. This active form is responsible for disrupting microtubule formation in parasites. Concomitant use of medications that induce CYP1A enzymes can increase the rate of albendazole metabolism, potentially altering plasma levels of both the prodrug and its active metabolite. Depending on the balance between formation and clearance, this can either enhance or reduce therapeutic efficacy. Therefore, the cytochrome P450 enzyme family, especially the CYP1A subfamily, directly mediates both the activation and the metabolism of albendazole, influencing its clinical effectiveness in treating echinococcosis.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_0071eea530f3",
      "question": "What is the PMID of the 2025 BMC Pulmonary Medicine article titled “Impact of irae characteristics on efficacy of consolidative immunotherapy following chemoradiotherapy in locally advanced NSCLC,” with Wang X as the first author?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"Impact of irae characteristics on efficacy of consolidative immunotherapy following chemoradiotherapy in locally advanced NSCLC.\"[ti] AND Wang X[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40483449"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_404e7326dffa",
      "question": "In cases of multiple lung cancers (suspected or confirmed) classified as N0–1, where a dominant nodule shows evidence of growth and definitive local therapy is not possible, does the selection of palliative chemotherapy inherently assume the presence of symptomatic disease, or can it also be considered for asymptomatic patients?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Multiple lung cancers (suspected or confirmed) (N0–1)",
              "Multidisciplinary evaluation",
              "Dominant nodule with evidence of growth",
              "Definitive local therapy not possible",
              "Palliative chemotherapy ± local palliative therapy or Observe",
              "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
              "Locoregional recurrence or symptomatic local disease",
              "Severe hemoptysis",
              "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Palliative chemotherapy may be considered regardless of symptom presence in this scenario. While symptomatic disease often prompts intervention, the recommendation does not strictly require symptoms, and palliative chemotherapy can be appropriate for both symptomatic and asymptomatic patients when definitive local therapy is unfeasible.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_ba824251df16",
      "question": "A 22-year-old woman presents to her primary care provider with complaints of severe lower abdominal pain occurring monthly for the first two days of her menstrual period. She describes the pain as cramping, interfering with daily activities, and partially responsive to over-the-counter acetaminophen. On examination, there are no pelvic masses or tenderness outside of menstruation. She is prescribed a medication that alleviates her symptoms by blocking an enzyme responsible for the conversion of arachidonic acid to pro-inflammatory mediators that promote smooth muscle contraction in the uterus. Through inhibition of which molecular target does this drug achieve symptom relief in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Dysmenorrhea"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0013390",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0022635",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 2 (Cyclooxygenase-2, COX-2)",
      "reasoning_path": "Dysmenorrhea involves prostaglandin-mediated uterine contractions; ketoprofen inhibits COX-2 (prostaglandin G/H synthase 2), reducing prostaglandin synthesis and thereby alleviating menstrual pain.",
      "umls_path": [
        "Dysmenorrhea",
        "may_be_treated_by",
        "Ketoprofen",
        "has_target",
        "Prostaglandin G/H Synthase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has primary dysmenorrhea, characterized by painful menstrual cramps due to excessive uterine contractions mediated by increased prostaglandin production. Ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID), is prescribed for symptomatic relief. Its therapeutic effect is achieved by inhibiting the enzyme prostaglandin G/H synthase 2 (also known as cyclooxygenase-2 or COX-2), which catalyzes the conversion of arachidonic acid to prostaglandin precursors. By reducing prostaglandin synthesis, ketoprofen diminishes uterine smooth muscle contraction and associated pain, directly addressing the pathophysiology of dysmenorrhea.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_abe56de3d134",
      "question": "In a patient with stage IVA non-small cell lung cancer of adenocarcinoma subtype, who tests positive for RET rearrangement discovered during ongoing first-line systemic therapy, is it appropriate to switch to selpercatinib before completing the current systemic regimen, or should selpercatinib initiation be delayed until the planned first-line therapy and maintenance are finished?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "RET rearrangement positive",
              "RET rearrangement",
              "RET rearrangement discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by selpercatinib (preferred), pralsetinib (preferred), cabozantinib",
              "Progression",
              "Systemic Therapy Adenocarcinoma or Squamous Cell Carcinoma"
            ]
          }
        }
      ],
      "answer": "Initiation of selpercatinib in this context should be delayed until the completion or interruption of the planned first-line systemic therapy, including maintenance, rather than switching immediately upon RET rearrangement discovery. This approach aligns with optimal sequencing to maximize efficacy and avoid premature discontinuation of standard first-line regimens.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_9c500821ed6e",
      "question": "For a patient with stage IA peripheral non-small cell lung cancer (T1a-c, N0), if pulmonary function tests have not yet been completed, should surgical resection proceed before obtaining these results, or is preoperative pulmonary function assessment mandatory to determine operability?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (peripheral T1abc, N0)",
              "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Distant metastases",
              "Limited metastases",
              "Stage IV, M1b (NSCL-15)"
            ]
          }
        }
      ],
      "answer": "Preoperative pulmonary function assessment is mandatory in stage IA peripheral non-small cell lung cancer if not previously performed. Proceeding to surgical resection without prior evaluation of pulmonary reserve is not appropriate, as operability and perioperative risk must be reliably assessed before surgery is undertaken.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_4cecb720a467",
      "question": "A 62-year-old woman with a prior myocardial infarction and persistently elevated LDL cholesterol despite dietary changes is unable to tolerate statins due to severe muscle pain. Her physician prescribes a medication that inhibits a key enzyme upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway. Through this mechanism, her LDL cholesterol levels decrease significantly over several months. Which class of pharmacological agents best describes the primary mechanism by which this medication lowers cholesterol in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Atherosclerotic Cardiovascular Disease"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004153",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3659310",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme inhibitors",
      "reasoning_path": "A patient with ASCVD and statin intolerance is treated with bempedoic acid. Bempedoic acid inhibits ATP-citrate lyase (an enzyme in cholesterol synthesis), resulting in decreased cholesterol and LDL levels. This places the drug in the enzyme inhibitor class.",
      "umls_path": [
        "Atherosclerotic Cardiovascular Disease",
        "may_be_treated_by",
        "Bempedoic Acid",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has established atherosclerotic cardiovascular disease and requires secondary prevention with LDL-lowering therapy. Due to statin intolerance, her physician selects bempedoic acid, an oral agent that inhibits ATP-citrate lyase—an enzyme acting early in the cholesterol synthesis pathway, upstream of HMG-CoA reductase. By blocking ATP-citrate lyase, bempedoic acid reduces the availability of acetyl-CoA for cholesterol production in the liver, thereby lowering hepatic cholesterol synthesis. This leads to upregulation of LDL receptors and increased clearance of LDL cholesterol from the bloodstream. The defining pharmacologic mechanism of bempedoic acid is enzyme inhibition, specifically targeting ATP-citrate lyase. Thus, the best description of its class based on mechanism is enzyme inhibitors.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_cb0dd0f70125",
      "question": "A 68-year-old woman develops bradykinesia, rigidity, and resting tremor several weeks after starting a new antipsychotic medication. Her neurologist initiates therapy with a medication that is known to block certain ion channels in neurons of the basal ganglia, leading to increased presynaptic dopamine release and reduced motor symptoms. Which type of pharmacological interaction best explains the therapeutic effect of this agent in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Secondary Parkinsonism"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0030569",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002403",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Ion channel interactions",
      "reasoning_path": "Secondary parkinsonism from antipsychotic → treated with amantadine → amantadine blocks NMDA (ion) channels → increased dopamine release → improved motor symptoms.",
      "umls_path": [
        "Secondary Parkinsonism",
        "may_be_treated_by",
        "Amantadine-containing product",
        "has_mechanism_of_action",
        "Ion Channel Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is experiencing drug-induced parkinsonism, a form of secondary parkinsonism, likely due to dopamine receptor blockade from her antipsychotic. Amantadine is prescribed to alleviate her motor symptoms. Mechanistically, amantadine works primarily by blocking NMDA-type glutamate receptors, which are ion channels, in the central nervous system. This blockade reduces excitatory neurotransmission and indirectly enhances dopaminergic activity by increasing dopamine release and inhibiting its reuptake. The net result is improved motor function in patients with parkinsonian symptoms. While amantadine has other effects (such as modest anticholinergic action), its primary therapeutic benefit in parkinsonism is mediated through its interaction with neuronal ion channels. Thus, the principal pharmacological interaction responsible for its effect is modulation of ion channels in the CNS.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_d703709e72ce",
      "question": "In patients with stage IIIB (T4, N2) or stage IIIC (T4, N3) non-small cell lung cancer who have confirmed N2–3 disease but also present with diffuse brain metastases, is initiating palliative external-beam radiotherapy prioritized over systemic therapy for symptomatic management?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
              "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "For patients with stage IIIB or IIIC NSCLC and diffuse brain metastases, palliative external-beam radiotherapy is prioritized to rapidly alleviate neurological symptoms, but systemic therapy should also be initiated to address extracranial disease burden. Both approaches are important, but symptomatic brain involvement typically warrants immediate local control.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_e623c4100f53",
      "question": "For a patient with completely resected stage IIA (T2b, N0) non–small cell lung cancer and negative surgical margins (R0), is routine surveillance with FDG-PET/CT or brain MRI indicated in the absence of symptoms or abnormal findings on chest CT?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIA (T2b, N0); Margins negative (R0)",
              "Observe or Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "No, in completely resected stage IIA (T2b, N0) non–small cell lung cancer with negative margins, routine surveillance with FDG-PET/CT or brain MRI is not indicated if there are no symptoms or abnormal imaging findings; standard surveillance should include history, physical examination, and periodic chest CT only.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_314906ca84fd",
      "question": "A 52-year-old woman with a history of chronic joint pain and morning stiffness lasting over an hour presents for management of persistent hand swelling and discomfort. Physical exam reveals symmetrical swelling and tenderness of the metacarpophalangeal joints. She is started on an oral medication for symptomatic relief, which acts by inhibiting a key enzyme in the arachidonic acid pathway, thereby decreasing synthesis of pro-inflammatory mediators. Which molecular target does this medication primarily inhibit to achieve its anti-inflammatory effect in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Rheumatoid arthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003873",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020740",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 2 (COX-2)",
      "reasoning_path": "Rheumatoid arthritis causes joint inflammation → NSAIDs are prescribed → NSAIDs inhibit cyclooxygenase enzymes → COX-2 (Prostaglandin G/H Synthase 2) mediates prostaglandin synthesis in inflammation → Inhibition of COX-2 reduces inflammatory mediators and symptoms.",
      "umls_path": [
        "Rheumatoid arthritis",
        "may_be_treated_by",
        "Ibuprofen",
        "has_target",
        "Prostaglandin G/H Synthase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has rheumatoid arthritis, characterized by chronic inflammation of synovial joints. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, are frequently prescribed for symptomatic relief. These drugs exert their anti-inflammatory and analgesic effects mainly by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), also known as Prostaglandin G/H Synthases. The COX-2 isoform (Prostaglandin G/H Synthase 2) is inducible at sites of inflammation and is primarily responsible for the synthesis of prostaglandins that mediate pain, fever, and swelling. By blocking COX-2, NSAIDs reduce prostaglandin production, decreasing inflammation and alleviating symptoms. Although most traditional NSAIDs inhibit both COX-1 and COX-2, the anti-inflammatory benefit in rheumatoid arthritis is mainly attributed to COX-2 inhibition, as this reduces local inflammatory prostaglandin levels in affected joints.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_ec6d6626d25e",
      "question": "A 60-year-old postmenopausal woman presents with chronic vulvar itching, burning, and thinning of the vulvar skin. Physical examination reveals white, atrophic, shiny plaques affecting the labia minora and perineal region. She is started on a topical medication that binds intracellular nuclear receptors, leading to gene transcription changes that promote epithelial maturation and skin elasticity. Which class of pharmacological action best explains this medication's therapeutic effect in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Vulvar Lichen Sclerosus"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0022783",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0012145",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Estrogen receptor agonists",
      "reasoning_path": "Vulvar lichen sclerosus → atrophic vulvar epithelium → topical dienestrol → binds estrogen receptors → nuclear gene transcription → tissue regeneration and symptom relief.",
      "umls_path": [
        "Vulvar Lichen Sclerosus",
        "may_be_treated_by",
        "Dienestrol-containing product",
        "has_mechanism_of_action",
        "Estrogen Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has vulvar lichen sclerosus, a chronic inflammatory dermatosis characterized by epithelial atrophy, pruritus, and increased risk of vulvar scarring. Estrogen deficiency can exacerbate symptoms by reducing vulvar skin thickness and elasticity, particularly in postmenopausal women. Dienestrol is a synthetic estrogen administered topically to mimic endogenous estrogen effects. By acting as an agonist at estrogen receptors, dienestrol binds to nuclear hormone receptors in vulvar epithelial and stromal cells. This binding triggers receptor dimerization, nuclear translocation, and alteration of gene expression, leading to increased epithelial proliferation, improved skin hydration, and restoration of tissue integrity. The therapeutic benefit in vulvar lichen sclerosus thus derives from dienestrol’s estrogen receptor agonism, which counteracts atrophic changes and alleviates symptoms. The main molecular target is the estrogen receptor, and the drug’s action is best classified as estrogen receptor agonism.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_20408db15ffe",
      "question": "In a patient with completely resected Stage IIIA (T1–2, N2) non-small cell lung cancer who had positive surgical margins (R1), if chemoradiation is delivered sequentially rather than concurrently, does this choice imply any difference in required surveillance imaging frequency in the first three years after treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
              "R1; Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, for patients with Stage III non-small cell lung cancer treated with chemoradiation following positive margin resection, the surveillance protocol—chest CT with or without contrast every 3–6 months for the first 3 years—remains the same, regardless of whether chemoradiation was delivered sequentially or concurrently.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_4cd1539c2e04",
      "question": "What is the unique PMID for the 2025 BMJ Open Quality article titled “Clinical impact of Choosing Wisely Canada hepatology recommendations: an interrupted time-series analysis using data from GEMINI,” authored by Shin S?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"Clinical impact of Choosing Wisely Canada hepatology recommendations\"[ti] AND Shin S[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40122575"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_109f84bf08ea",
      "question": "A 62-year-old man is brought to the emergency department with sudden onset chest pain radiating to his left arm. Electrocardiogram reveals ST-segment elevations in the anterior leads, and troponin levels are elevated. He is diagnosed with an acute myocardial infarction due to coronary artery thrombosis. As part of his initial management, he receives an intravenous infusion of an anticoagulant derived from animal mucosa. This medication acts by binding to a plasma cofactor, resulting in rapid inactivation of several clotting factors and preventing further propagation of the clot. Which molecular target is primarily responsible for the antithrombotic action of this intervention in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Coronary artery thrombosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0010072",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1445698",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Thrombin (via antithrombin III activation)",
      "reasoning_path": "Acute coronary thrombosis is managed with heparin, which binds antithrombin III; this complex inactivates thrombin, thereby blocking fibrin formation and clot propagation.",
      "umls_path": [
        "Coronary artery thrombosis",
        "may_be_treated_by",
        "Bovine heparin sodium",
        "has_mechanism_of_action",
        "Thrombin Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is experiencing an acute myocardial infarction resulting from coronary artery thrombosis, a situation in which rapid anticoagulation is essential to prevent further clot extension. The administered drug—bovine heparin sodium—is an anticoagulant that exerts its effect by binding to and enhancing the activity of antithrombin III, an endogenous inhibitor of several coagulation factors. The most critical target in this context is thrombin (factor IIa), a serine protease responsible for converting fibrinogen to fibrin, thus stabilizing the clot. By accelerating antithrombin III-mediated inactivation of thrombin (and, to a lesser extent, factor Xa), heparin prevents new clot formation and halts further growth of the existing thrombus. This molecular mechanism is key in the acute setting for reducing the risk of further vascular occlusion and myocardial damage.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_32b6a7fd9451",
      "question": "For a patient with operable, localized, non-inflammatory breast cancer who was initially cT2N1M0, received preoperative systemic therapy, and now has only one axillary lymph node with residual disease on pathology, can breast-conserving surgery with surgical axillary staging followed by adjuvant systemic therapy and whole breast radiation still be considered appropriate, or is axillary lymph node dissection mandatory in this scenario?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS possible",
              "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
              "Adjuvant systemic therapy (BINV-16) + WBRT",
              "HR-positive/ HER2-positive",
              "ypT0N0 or pCR",
              "Endocrine therapy (category 1) + complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
            ]
          }
        }
      ],
      "answer": "Breast-conserving surgery with surgical axillary staging, adjuvant systemic therapy, and whole breast radiation remains appropriate when only one axillary node is pathologically positive post-preoperative systemic therapy. Axillary lymph node dissection is not mandatory if only a single node harbors residual disease and there is no extensive nodal involvement, in line with current surgical management principles.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_e2cc7645bcfd",
      "question": "In ClinicalTrials.gov, which completed interventional studies for Multiple Sclerosis involving Fingolimod 1.25 mg as an intervention started in May 2006 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "overallStatus=COMPLETED;conditions=Multiple Sclerosis;interventions.name=Fingolimod 1.25 mg;startDateFrom=2006-05-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00340834"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_4472a8281267",
      "question": "In a patient with invasive, non-metastatic breast cancer of pure mucinous histology, tumor size 0.9 cm (pT1), ER-positive, HER2-negative, and axillary node status pN0, is adjuvant endocrine therapy indicated even if the histology is considered favorable and the tumor is less than 1 cm?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "Favorable histologic type: • Pure tubular • Pure mucinous • Pure cribriform • Adenoid cystic (conventional), secretory carcinoma, and other salivary carcinomas • Rare low-grade forms of metaplastic carcinoma • Other rare forms",
              "ER-positive and/or PR-positive or ER-negative and PR-negative",
              "Favorable Histologies (BINV-11)",
              "Pure tubular • Pure mucinous • Pure cribriform",
              "ER-positive and/or PR-positive, HER2-negative",
              "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
              "<1 cm",
              "Consider adjuvant endocrine therapy for risk reduction",
              "Follow-Up (BINV-17)"
            ]
          }
        }
      ],
      "answer": "Yes; despite favorable histology and small tumor size (<1 cm), consideration of adjuvant endocrine therapy for risk reduction is appropriate in ER-positive, HER2-negative cases, as per current treatment standards for localized breast cancer.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_4cb05f559f75",
      "question": "A 42-year-old man presents with persistent pruritic, erythematous, and flaky patches along his scalp and nasolabial folds. After failing standard antifungal shampoos, he is prescribed a topical preparation containing a complex mixture derived from coal. While his symptoms improve over several weeks, the clinician notes that the precise molecular mechanism by which this agent acts in his skin condition is not fully established. Which statement best reflects the current understanding of the molecular action of this therapy?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Seborrheic dermatitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0036508",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0009137",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The precise cellular or molecular mechanism of coal tar in treating seborrheic dermatitis is unknown.",
      "reasoning_path": "Coal tar is prescribed for seborrheic dermatitis, but despite observed clinical benefits, its cellular or molecular mechanism of action has not been clearly defined.",
      "umls_path": [
        "Seborrheic dermatitis",
        "may_be_treated_by",
        "Coal tar-containing product",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Coal tar has been used topically for decades in the management of seborrheic dermatitis, as well as other dermatologic conditions such as psoriasis. Its clinical efficacy is thought to involve anti-proliferative, anti-inflammatory, and possibly keratolytic effects, but robust mechanistic data are lacking. The chemical composition of coal tar is highly complex, consisting of thousands of polycyclic aromatic hydrocarbons and phenols, making it difficult to ascribe its therapeutic benefit to a single pathway or cellular target. Although some studies suggest effects on DNA synthesis and epidermal turnover, no definitive molecular interaction has been identified. Therefore, while coal tar is effective in practice, its cellular or molecular mechanism in seborrheic dermatitis remains unclear.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_6f3f69a64fe1",
      "question": "A 68-year-old man with a history of diabetes and peripheral arterial disease presents to the emergency department with a swollen, foul-smelling, purplish foot ulcer that is oozing pus. Examination reveals crepitus and necrotic tissue consistent with wet gangrene. In addition to antibiotics and surgical evaluation, the care team considers a therapy that involves exposing the affected limb to high concentrations of oxygen under increased atmospheric pressure. This intervention is hypothesized to improve healing by enhancing tissue oxygenation and modulating processes at the molecular level. Through which primary molecular mechanism does this therapy limit further tissue injury and promote recovery in such cases?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Gangrene"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0017086",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0030054",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Free radical scavenging activity",
      "reasoning_path": "Wet gangrene involves tissue hypoxia and infection; hyperbaric oxygen increases tissue oxygenation, which enhances free radical scavenging capacity, reducing oxidative stress and supporting tissue recovery.",
      "umls_path": [
        "Gangrene",
        "may_be_treated_by",
        "Oxygen",
        "has_mechanism_of_action",
        "Free Radical Scavenging Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Hyperbaric oxygen therapy (HBOT) is sometimes used as an adjunct in the management of wet gangrene, especially when there is compromised tissue oxygenation. HBOT increases the amount of dissolved oxygen in plasma, directly raising tissue oxygen levels. One of the key molecular mechanisms by which HBOT confers benefit is through the enhancement of free radical scavenging activity. In ischemic and infected tissues, excess reactive oxygen species (ROS) can contribute to cellular damage and impede healing. By increasing tissue oxygenation, HBOT supports the production of antioxidant enzymes and molecules that neutralize these ROS, thereby limiting oxidative stress and tissue injury. This reduction in oxidative damage helps preserve viable tissue, controls the spread of infection, and facilitates wound healing. Thus, while HBOT may have additional antimicrobial and angiogenic effects, its primary molecular benefit in gangrenous tissues lies in augmenting free radical scavenging to mitigate oxidative injury.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_17d65011996c",
      "question": "In the OpenTargets platform, can you provide the tractability information for the target with Ensembl ID ENSG00000134853 and approved symbol PDGFRA, where the value is True?",
      "tool_calls": [
        {
          "tool": "opentargets.tractability",
          "params": {
            "target_id": "ENSG00000134853",
            "value": true
          }
        }
      ],
      "answer": [
        {
          "modality": "SM",
          "label": "Approved Drug"
        },
        {
          "modality": "SM",
          "label": "Structure with Ligand"
        },
        {
          "modality": "SM",
          "label": "High-Quality Ligand"
        },
        {
          "modality": "SM",
          "label": "Druggable Family"
        },
        {
          "modality": "AB",
          "label": "Approved Drug"
        },
        {
          "modality": "AB",
          "label": "UniProt loc high conf"
        },
        {
          "modality": "AB",
          "label": "GO CC high conf"
        },
        {
          "modality": "AB",
          "label": "UniProt SigP or TMHMM"
        },
        {
          "modality": "PR",
          "label": "UniProt Ubiquitination"
        },
        {
          "modality": "PR",
          "label": "Database Ubiquitination"
        },
        {
          "modality": "PR",
          "label": "Half-life Data"
        },
        {
          "modality": "PR",
          "label": "Small Molecule Binder"
        },
        {
          "modality": "OC",
          "label": "Approved Drug"
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_d107cf0ad1c0",
      "question": "A 27-year-old woman presents with a thin, grayish vaginal discharge and a characteristic fishy odor. A wet mount reveals clue cells, and her physician diagnoses her with a common vaginal infection. She is prescribed an oral agent that is effective in treating anaerobic and protozoal pathogens. In a pharmacology discussion, you are asked to explain the detailed molecular target and mechanism by which this drug acts against the causative organisms in her condition. What is currently known about its cellular or molecular mechanism in this context?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Bacterial vaginosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0085166",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0025872",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The precise cellular or molecular mechanism of metronidazole in bacterial vaginosis remains unclear.",
      "reasoning_path": "Metronidazole is prescribed for bacterial vaginosis; its general mechanism involves reactive nitro radical formation and DNA disruption in anaerobes, but the exact molecular target in bacterial vaginosis is unknown.",
      "umls_path": [
        "Bacterial vaginosis",
        "may_be_treated_by",
        "Metronidazole",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Metronidazole is the standard therapy for bacterial vaginosis, a condition primarily involving overgrowth of anaerobic bacteria such as Gardnerella vaginalis and other anaerobes. While metronidazole’s general antimicrobial action involves reduction of its nitro group by anaerobic organisms to form reactive metabolites that disrupt DNA synthesis and cause cell death, the exact molecular interactions and primary targets in the mixed flora of bacterial vaginosis have not been fully elucidated. Specifically, there is no definitive evidence identifying the cellular or molecular targets responsible for its clinical effectiveness against the polymicrobial environment of bacterial vaginosis. Thus, while its efficacy is well established clinically, the detailed mechanism in this context remains incompletely understood.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_5ad29fc270e6",
      "question": "In a patient with newly diagnosed stage II non–small cell lung cancer (T1abc–T2ab, N1 or T2b, N0), who also has significant renal dysfunction precluding contrast-enhanced imaging, is it still justified to perform a brain MRI as part of initial staging?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Yes. Brain MRI with contrast is routinely indicated in stage II non–small cell lung cancer for initial staging, as intracranial metastases may alter management; if contrast is contraindicated due to renal dysfunction, non-contrast brain MRI or alternative brain imaging should still be considered to adequately assess for brain metastasis.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_d277c4f27e8a",
      "question": "For a patient with advanced non-small cell lung cancer (adenocarcinoma subtype), presenting with diffuse brain metastases and a PD-L1 expression of less than 1%, while all actionable molecular abnormalities (EGFR, ALK, ROS1, BRAF, NTRK1/2/3, MET exon 14 skipping, RET, ERBB2) are negative, is systemic immunotherapy still an appropriate first-line treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "PD-L1 <1% and negative for actionable molecular biomarkers above"
            ]
          }
        }
      ],
      "answer": "No, in this scenario, first-line systemic immunotherapy is not recommended. For advanced nonsquamous NSCLC patients who are PD-L1 <1% and have no actionable driver alterations, standard first-line therapy typically consists of platinum-based chemotherapy, with concurrent or sequential use of immunotherapy generally reserved for higher PD-L1 expression or after initial chemotherapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_96207139986e",
      "question": "A 54-year-old woman with a longstanding history of symmetric joint pain, morning stiffness, and progressive hand deformities is diagnosed with rheumatoid arthritis. After nonsteroidal anti-inflammatory drugs and methotrexate provide only partial relief, her rheumatologist initiates a gold-based injectable medication as a disease-modifying therapy. This agent is thought to exert its immunomodulatory effects by inhibiting an enzyme involved in intracellular signaling cascades that regulate immune cell activation and cytokine production. Through direct interaction with its molecular target, the drug dampens inflammatory processes within the synovium. Which specific intracellular enzyme is primarily inhibited by this gold-based therapy, contributing to its disease-modifying action in rheumatoid arthritis?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Rheumatoid arthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003873",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0018034",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Protein Kinase C Iota Type",
      "reasoning_path": "Rheumatoid arthritis is treated with gold sodium thiomalate when standard therapies are inadequate. Gold sodium thiomalate exerts immunomodulatory effects by inhibiting protein kinase C iota type, thereby disrupting signaling pathways that drive immune activation and inflammation.",
      "umls_path": [
        "Rheumatoid arthritis",
        "may_be_treated_by",
        "Gold sodium thiomalate-containing product",
        "has_target",
        "Protein Kinase C Iota Type"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "In rheumatoid arthritis, immune-mediated inflammation leads to joint damage. Gold-based therapies such as gold sodium thiomalate are disease-modifying antirheumatic drugs (DMARDs) used when first-line treatments are insufficient. The immunomodulatory effect of gold compounds is partly attributed to their inhibition of protein kinase C iota type, an enzyme that plays a critical role in intracellular signaling pathways within immune cells. By inhibiting this kinase, gold sodium thiomalate interferes with the activation and proliferation of T cells and macrophages, as well as the production of pro-inflammatory cytokines. This mechanism helps to reduce synovial inflammation and slow the progression of joint destruction in rheumatoid arthritis. Thus, the therapeutic benefit of gold-based DMARDs is closely linked to their effect on protein kinase C iota type.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_f7bfb30f7c7c",
      "question": "In a patient with stage IA non-small cell lung cancer (T1abc, N0) who undergoes surgical resection but is found to have positive margins (R1 or R2), does the recommendation for re-resection or adjuvant radiotherapy implicitly require the absence of distant metastasis at the time of decision-making?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (T1abc, N0); Margins positive (R1, R2)",
              "Resection (preferred) or RT (category 2B)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, the consideration of re-resection or adjuvant radiotherapy for stage IA non-small cell lung cancer with positive margins is predicated on the disease being localized without evidence of distant metastasis. The presence of metastatic disease would shift management toward systemic therapy rather than local interventions.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_5863c7807c2f",
      "question": "A 43-year-old man presents with persistent fatigue, night sweats, and a pruritic skin rash. Laboratory evaluation reveals marked leukocytosis with a differential showing 40% eosinophils. Bone marrow biopsy confirms marked eosinophilic hyperplasia. Following an initial course of corticosteroids with minimal improvement, he is started on a tyrosine kinase inhibitor that is also a first-line agent in chronic myeloid leukemia, resulting in rapid normalization of his eosinophil count and resolution of symptoms. Genetic testing is positive for a constitutively active fusion tyrosine kinase. Which molecular abnormality is primarily targeted by this medication to produce clinical remission in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Hypereosinophilic syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1540912",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0939537",
            "rela": "has_target"
          }
        }
      ],
      "answer": "BCR-ABL fusion protein (constitutively active tyrosine kinase)",
      "reasoning_path": "Hypereosinophilic syndrome with dramatic response to imatinib suggests a driving fusion tyrosine kinase, most commonly BCR-ABL, which is imatinib’s main target in CML and responsive HES cases.",
      "umls_path": [
        "Hypereosinophilic syndrome",
        "may_be_treated_by",
        "Imatinib Mesylate",
        "has_target",
        "Fusion protein BCR-ABL"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient with hypereosinophilic syndrome (HES) failed to respond to corticosteroids but showed a rapid and dramatic clinical response to a tyrosine kinase inhibitor commonly used in chronic myeloid leukemia (CML), which strongly suggests imatinib. Imatinib acts primarily by inhibiting the BCR-ABL fusion protein, a constitutively active tyrosine kinase resulting from the Philadelphia chromosome translocation (t(9;22)). While BCR-ABL is the molecular driver in CML, rare cases of HES may harbor this or similar fusion kinases (such as FIP1L1-PDGFRA), rendering them sensitive to imatinib. The clinical effectiveness of imatinib in this case indicates that the patient’s HES is driven by a constitutively active fusion tyrosine kinase, most characteristically BCR-ABL, which imatinib targets, leading to normalization of eosinophil counts and symptom resolution.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_3c7003c1dfe1",
      "question": "In patients with multiple non-small cell lung cancers (N0–1 stage) where the dominant nodule shows evidence of growth but definitive local therapy is not feasible, does the choice of palliative chemotherapy ± local palliative therapy necessarily exclude the option of close observation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Multiple lung cancers (suspected or confirmed) (N0–1)",
              "Multidisciplinary evaluation",
              "Dominant nodule with evidence of growth",
              "Definitive local therapy not possible",
              "Palliative chemotherapy ± local palliative therapy or Observe",
              "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, in patients with unresectable multiple lung cancers and a growing dominant nodule, palliative chemotherapy with or without local therapy does not strictly exclude close observation; both strategies remain options depending on symptom burden and overall patient status.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_ae43779eaf4c",
      "question": "For a patient with resectable Stage IA (peripheral T1abc, N0) non-small cell lung cancer who exhibits significant impairment on pulmonary function tests (PFTs), does surgical resection remain the recommended first-line treatment over non-surgical modalities such as stereotactic body radiotherapy (SBRT)?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (peripheral T1abc, N0)",
              "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 3–4",
              "Systemic Therapy for Metastatic Disease (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "In patients with Stage IA (peripheral T1abc, N0) NSCLC and significant pulmonary dysfunction indicated by impaired PFTs, surgical resection may not be the preferred first-line treatment. Non-surgical modalities such as stereotactic body radiotherapy (SBRT) are prioritized due to increased perioperative risk, making SBRT the standard for surgically high-risk or medically inoperable patients.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_18a15aa7b179",
      "question": "In a patient diagnosed with stage IIIA non-small cell lung cancer (T4, N1) and confirmed positive mediastinal lymph nodes, is stereotactic radiosurgery (SRS) alone for a single brain metastasis appropriate if the patient’s performance status is 0–2 and no extracranial progression is present, or should surgical resection of the brain lesion be prioritized?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 0–2",
              "Limited progression confirmed",
              "Brain",
              "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
              "Treatment of Thoracic Disease (NSCL-16)"
            ]
          }
        }
      ],
      "answer": "For a patient with stage IIIA non-small cell lung cancer, a single brain metastasis, and good performance status (0–2), stereotactic radiosurgery (SRS) alone is an appropriate local therapy. Surgical resection is prioritized only if the brain lesion is symptomatic or if tissue diagnosis is required, followed by SRS or whole brain radiotherapy; otherwise, SRS alone suffices.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_f7826fe22b55",
      "question": "For a patient with stage I non-small cell lung cancer who underwent surgery with positive margins (R1/R2), if the patient has significant renal impairment precluding the use of contrast agents, is routine post-treatment surveillance with non–contrast-enhanced chest CT still appropriate for early detection of recurrence?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (T2a, N0); Margins positive (R1, R2)",
              "Resection (preferred) ± systemic therapy or RT",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, non–contrast-enhanced chest CT remains appropriate for surveillance in stage I NSCLC patients after surgery, even with positive margins and renal impairment, as contrast enhancement is not mandatory for routine follow-up and does not compromise the ability to detect early recurrence.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_bbfdf5550e4d",
      "question": "A 54-year-old woman with a longstanding history of joint pain and morning stiffness is diagnosed with chronic inflammatory arthritis. She reports increased swelling and decreased mobility in her hands despite nonsteroidal anti-inflammatory drug therapy. Her rheumatologist initiates a new medication, which exerts anti-inflammatory effects not only by altering gene transcription but also by suppressing the synthesis of certain lipid-derived inflammatory mediators. This suppression is achieved through inhibition of an enzyme pathway responsible for leukotriene production. Which class of enzymes is primarily inhibited to reduce these pro-inflammatory mediators in her treatment?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Rheumatism"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0035435",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0071839",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lipoxygenase inhibitors",
      "reasoning_path": "Corticosteroids reduce inflammation in chronic arthritis by suppressing leukotriene synthesis via inhibition of the lipoxygenase enzyme pathway.",
      "umls_path": [
        "Rheumatism",
        "may_be_treated_by",
        "Prednisolone Acetate",
        "has_mechanism_of_action",
        "Lipoxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Chronic inflammatory arthritis, such as rheumatoid arthritis, involves ongoing joint inflammation driven by both cytokines and lipid mediators like leukotrienes. Corticosteroids, commonly used in this setting, reduce inflammation through multiple mechanisms. In addition to suppressing pro-inflammatory gene expression, corticosteroids inhibit phospholipase A2, reducing arachidonic acid release. They also indirectly inhibit the lipoxygenase pathway, which converts arachidonic acid into leukotrienes—potent mediators of inflammation, chemotaxis, and vascular permeability. By decreasing leukotriene synthesis, corticosteroids dampen inflammatory cell recruitment and tissue damage. Thus, the molecular target relevant to this anti-inflammatory pathway is the lipoxygenase enzyme class, as their inhibition lowers leukotriene levels and helps control symptoms of chronic rheumatism.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_17ea4ac3714b",
      "question": "A 62-year-old woman with a history of myelodysplastic syndrome presents with worsening fatigue and pallor. Laboratory evaluation confirms persistent anemia despite prior transfusions and supportive care. Bone marrow biopsy shows dysplastic erythroid precursors with ineffective hematopoiesis. She is started on a parenteral medication that integrates into nucleic acids and inhibits an enzyme responsible for adding methyl groups to cytosine residues, thereby altering the epigenetic landscape of hematopoietic cells. Which molecular enzyme is directly inhibited by this therapy to exert its disease-modifying effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Refractory Anemia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002893",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004475",
            "rela": "has_target"
          }
        }
      ],
      "answer": "tRNA (Cytosine(38)-C(5))-Methyltransferase",
      "reasoning_path": "Myelodysplastic syndrome with refractory anemia is treated with azacitidine, which acts as a hypomethylating agent. Azacitidine inhibits tRNA (Cytosine(38)-C(5))-Methyltransferase, reducing cytosine methylation, altering gene expression, and improving hematopoietic cell function.",
      "umls_path": [
        "Refractory Anemia",
        "may_be_treated_by",
        "Azacitidine",
        "has_target",
        "tRNA (Cytosine(38)-C(5))-Methyltransferase"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient's refractory anemia as part of myelodysplastic syndrome is managed with a hypomethylating agent, such as azacitidine. Azacitidine incorporates into both DNA and RNA and inhibits methyltransferase enzymes. In particular, it targets tRNA (Cytosine(38)-C(5))-Methyltransferase, the enzyme that catalyzes methylation of cytosine-38 residues in tRNA. By inhibiting this enzyme, azacitidine reduces abnormal methylation patterns, which can reactivate silenced genes crucial for normal cell differentiation and apoptosis. The demethylation effect helps restore normal hematopoietic function and can improve cytopenias seen in myelodysplastic syndromes. Thus, the disease-modifying benefit in refractory anemia is mediated, in part, via direct inhibition of tRNA (Cytosine(38)-C(5))-Methyltransferase.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_055bca04c74e",
      "question": "A 28-year-old woman presents to the emergency department with a severe, pulsating headache localized to her right temple, accompanied by sensitivity to light and mild nausea. She reports having similar episodes twice a month, each lasting several hours and often preceded by visual disturbances. She is administered an oral medication that rapidly alleviates her symptoms. This medication is known to act as an agonist at a specific serotonin receptor subtype, leading to cranial vasoconstriction and decreased release of pro-inflammatory neuropeptides from trigeminal nerve endings. Which receptor is the direct molecular target responsible for this drug’s therapeutic effect in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Migraine"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0149931",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0772420",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Serotonin 1B receptor",
      "reasoning_path": "Migraine → triptan administration → triptan acts as 5-HT1B receptor agonist → cranial vasoconstriction and decreased neurogenic inflammation → symptom relief.",
      "umls_path": [
        "Migraine",
        "may_be_treated_by",
        "Rizatriptan Benzoate",
        "has_mechanism_of_action",
        "Serotonin 1b Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s presentation is consistent with migraine, a disorder involving neurogenic inflammation and vasodilation of cranial blood vessels. Acute migraine attacks are commonly treated with triptans, such as rizatriptan, which are selective agonists at serotonin 1B (5-HT1B) and 1D (5-HT1D) receptors. The primary therapeutic effect comes from agonism of the 5-HT1B receptor, resulting in constriction of dilated cranial vessels and inhibition of pro-inflammatory neuropeptide release from trigeminal nerve endings. This dual action relieves migraine pain and associated symptoms. Triptans’ specificity for 5-HT1B receptors underlies both their efficacy and their contraindication in patients with cardiovascular disease. Therefore, the direct molecular target mediating the therapeutic effect of rizatriptan in migraine is the serotonin 1B receptor.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_fa76fd1fe31a",
      "question": "A 54-year-old woman with a history of chronic hepatitis C presents for follow-up. She reports stable liver function tests but expresses interest in complementary therapies, specifically mentioning her use of an over-the-counter herbal supplement containing milk thistle. She asks whether the supplement has a known mechanism of action at the cellular or molecular level in the management of her liver disease. Based on current scientific evidence, what can you tell her about the cellular or molecular mechanism underlying milk thistle’s purported effects in chronic hepatitis?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Chronic hepatitis, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0019189",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0937640",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The cellular or molecular mechanism of milk thistle in chronic hepatitis is unknown.",
      "reasoning_path": "Milk thistle is used in chronic hepatitis, but its precise cellular or molecular mechanism in liver disease remains unknown and uncharacterized.",
      "umls_path": [
        "Chronic hepatitis, unspecified",
        "may_be_treated_by",
        "Milk Thistle",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "While milk thistle (Silybum marianum) is commonly used as an herbal supplement by patients with chronic liver disease, including hepatitis, its cellular or molecular mechanism of action remains uncharacterized. Existing clinical and preclinical studies have proposed possible antioxidant, anti-inflammatory, and antifibrotic effects, but these are not definitively established, nor is there a clear target or pathway identified in human hepatocytes or immune cells. No consensus exists regarding how milk thistle exerts therapeutic effects—if any—in chronic hepatitis. As a result, clinicians cannot recommend milk thistle based on a defined pharmacologic mechanism, and its efficacy and safety profile remain uncertain. Patients should be advised that, despite its popularity and some anecdotal support, the supplement’s molecular actions and clinical benefits are not well supported by robust scientific data.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_8b6f7dc4491b",
      "question": "In the OpenTargets platform, what tractability information is available for the target with Ensembl ID ENSG00000176890 and approved symbol TYMS, where the value is True?",
      "tool_calls": [
        {
          "tool": "opentargets.tractability",
          "params": {
            "target_id": "ENSG00000176890",
            "value": true
          }
        }
      ],
      "answer": [
        {
          "modality": "SM",
          "label": "Approved Drug"
        },
        {
          "modality": "SM",
          "label": "Structure with Ligand"
        },
        {
          "modality": "SM",
          "label": "High-Quality Ligand"
        },
        {
          "modality": "SM",
          "label": "High-Quality Pocket"
        },
        {
          "modality": "SM",
          "label": "Druggable Family"
        },
        {
          "modality": "PR",
          "label": "UniProt Ubiquitination"
        },
        {
          "modality": "PR",
          "label": "Database Ubiquitination"
        },
        {
          "modality": "PR",
          "label": "Small Molecule Binder"
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_20d42491c86b",
      "question": "A 52-year-old woman presents with joint pain and swelling affecting her fingers and knees, along with scaly plaques on her elbows and scalp. Laboratory findings reveal elevated inflammatory markers and imaging shows erosive changes in the affected joints. After inadequate response to NSAIDs and methotrexate, she is prescribed an oral gold-containing medication known for its immunomodulatory effects via inhibition of a mitochondrial enzyme involved in cellular redox homeostasis. Which mitochondrial enzyme is directly inhibited by this therapy to exert its anti-inflammatory action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "psoriatic arthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003872",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004320",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Thioredoxin reductase 2, mitochondrial",
      "reasoning_path": "Psoriatic arthritis resistant to standard DMARDs may be treated with auranofin, which exerts its effect by inhibiting mitochondrial thioredoxin reductase 2, thereby altering redox signaling and immune responses.",
      "umls_path": [
        "psoriatic arthritis",
        "may_be_treated_by",
        "Auranofin",
        "has_target",
        "Thioredoxin Reductase 2, Mitochondrial"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient with psoriatic arthritis has not responded to first-line therapies and is started on an oral gold-based drug, specifically auranofin. Auranofin is unique among disease-modifying antirheumatic drugs (DMARDs) due to its ability to inhibit mitochondrial thioredoxin reductase 2. This enzyme plays a critical role in maintaining the redox balance within cells by facilitating the reduction of oxidized thioredoxin. Inhibition of thioredoxin reductase 2 disrupts this balance, leading to increased oxidative stress and modulation of immune cell function. This mechanism dampens inflammatory pathways implicated in autoimmune conditions such as psoriatic arthritis. Thus, the primary molecular target for the therapeutic effect of auranofin in this context is mitochondrial thioredoxin reductase 2.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_4a7f4fc141af",
      "question": "In a patient with advanced non-small cell lung cancer (adenocarcinoma subtype) who tests positive for BRAF V600E mutation during ongoing first-line systemic therapy, is it appropriate to initiate targeted therapy with dabrafenib plus trametinib immediately, or should the planned systemic therapy (including maintenance) be completed first?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "BRAF V600E mutation positive",
              "BRAF V600E MUTATION",
              "BRAF V600E mutation discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by dabrafenib + trametinib (preferred) or encorafenib + binimetinib (preferred)",
              "Progression",
              "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
            ]
          }
        }
      ],
      "answer": "For advanced non-small cell lung cancer patients with BRAF V600E mutation discovered during first-line systemic therapy, current evidence supports the completion of planned systemic therapy, including maintenance, before initiating targeted therapy with dabrafenib plus trametinib or similar regimens, unless clinical circumstances necessitate earlier intervention.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_4703f33acbd0",
      "question": "In women diagnosed with ER-positive ductal carcinoma in situ (DCIS) who undergo breast-conserving surgery and whole breast irradiation, is the use of tamoxifen for 5 years appropriate for risk reduction in both premenopausal and postmenopausal patients, or should aromatase inhibitors be considered preferentially in certain subgroups?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "DCIS Tis,N0,M0, Encapsulated or solid papillary carcinoma (SPC)",
              "History and physical exam • Diagnostic bilateral mammogram • Pathology review • Determination of tumor estrogen receptor (ER) status • Genetic counseling for patients at risk of hereditary breast cancer • Breast MRI as indicated",
              "Breast-conserving surgery (BCS) without lymph node surgery",
              "Whole breast radiation therapy (WBRT) (category 1) with or without boost to tumor bed or Accelerated partial breast irradiation/partial breast irradiation (APBI/PBI) or No RT (category 2B)",
              "Postsurgical Treatment (DCIS-2)",
              "Risk reduction therapy for ipsilateral breast following BCS: • Consider endocrine therapy for 5 years for patients with ER-positive DCIS, if ➤ Treated with BCS and RT (category 1) ➤ Treated with excision alone • Endocrine therapy ➤ Tamoxifen for premenopausal patients ➤ Tamoxifen or aromatase inhibitor for postmenopausal patients with some advantage for aromatase inhibitor therapy in patients <60 years or with concerns for thromboembolism Risk reduction therapy for contralateral breast: • Counseling regarding risk reduction",
              "First mammogram 6–12 mo, after breast-conservation therapy (category 2B) and annually thereafter"
            ]
          }
        }
      ],
      "answer": "For premenopausal women with ER-positive DCIS treated with breast-conserving surgery and radiation, tamoxifen is recommended for risk reduction. In postmenopausal patients, both tamoxifen and aromatase inhibitors are valid options, but aromatase inhibitors may be preferred in those under age 60 or with increased risk of thromboembolism, reflecting a tailored approach based on menopausal status and risk factors.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_1df8fc2b7fb5",
      "question": "In a patient with invasive, non-inflammatory, non-metastatic (M0) breast cancer who is clinically staged as cT2, cN0, and has not received preoperative chemotherapy, if three sentinel lymph nodes (SLNs) are found positive during mastectomy and adjuvant radiotherapy including the undissected axilla is planned, can omission of further axillary surgery still be considered?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS possible",
              "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
              "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
              "SLN mapping and excision",
              "SLN positive",
              "Mastectomy",
              "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • Adjuvant RT planned with intentional inclusion of undissected axilla at risk",
              "Yes to all",
              "Consider no further axillary surgery"
            ]
          }
        }
      ],
      "answer": "No. The omission of further axillary surgery in this scenario is not appropriate because this approach is limited to cases with only 1–2 positive SLNs. The finding of three positive SLNs exceeds the defined boundary, so standard management would recommend further axillary intervention.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_a85598c15b2d",
      "question": "In ClinicalTrials.gov, which completed interventional studies for Multiple Sclerosis involving Fingolimod started in June 2006 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "overallStatus=COMPLETED;conditions=Multiple Sclerosis;interventions.name=Fingolimod;startDateFrom=2006-06-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00355134"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_ed781a961031",
      "question": "A 45-year-old woman with a history of pulmonary tuberculosis presents after failing multiple first- and second-line antibiotic regimens due to resistance confirmed by sputum cultures. She is started on a novel oral medication that works by binding to a key enzyme involved in generating the proton motive force required for ATP production in Mycobacterium tuberculosis. What is the general pharmacologic class that best describes the mechanism of action of this medication?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Multidrug-Resistant Tuberculosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0206526",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3530515",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme Inhibitors",
      "reasoning_path": "Multidrug-resistant TB → bedaquiline prescribed → inhibits bacterial ATP synthase → mechanism is enzyme inhibition → class: enzyme inhibitors.",
      "umls_path": [
        "Multidrug-Resistant Tuberculosis",
        "may_be_treated_by",
        "Bedaquiline fumarate",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has multidrug-resistant tuberculosis, a challenging infection that resists standard antimycobacterial agents. The newer drug prescribed targets an essential bacterial enzyme: ATP synthase. By binding to the c subunit of mycobacterial ATP synthase, the drug blocks the enzyme's function, preventing the synthesis of ATP, which is crucial for bacterial energy metabolism and survival. This mechanism is highly specific, as mammalian ATP synthase is not affected at therapeutic concentrations. The agent in question is bedaquiline, which represents a significant advance in the treatment of resistant TB. Mechanistically, any drug that acts by directly inhibiting an enzymatic process—here, ATP synthase—fits within the broader pharmacologic class of enzyme inhibitors. Thus, bedaquiline's classification as an enzyme inhibitor reflects its ability to disrupt pathogen survival by blocking a key microbial enzyme.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_10a75373a3fc",
      "question": "A 45-year-old man presents with persistent fatigue, weight loss, and recurrent episodes of skin itching. Laboratory evaluation reveals marked leukocytosis with a predominant eosinophilia. Bone marrow biopsy confirms a diagnosis of a myeloproliferative disorder characterized by sustained eosinophil overproduction. He is initiated on a cytoreductive medication that inhibits the enzyme ribonucleotide reductase, thereby disrupting deoxyribonucleotide synthesis and impairing DNA replication in rapidly dividing cells. Which drug class best describes the mechanism by which this agent reduces eosinophil counts in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Hypereosinophilic syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1540912",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020402",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Nucleic acid synthesis inhibitors",
      "reasoning_path": "Hypereosinophilic syndrome involves unchecked eosinophil proliferation. Hydroxyurea, a cytoreductive drug, inhibits ribonucleotide reductase, blocking DNA synthesis and cell division; thus, it is classified as a nucleic acid synthesis inhibitor.",
      "umls_path": [
        "Hypereosinophilic syndrome",
        "may_be_treated_by",
        "Hydroxyurea",
        "has_mechanism_of_action",
        "Nucleic Acid Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with a myeloproliferative variant of hypereosinophilic syndrome is being treated with a cytoreductive agent aimed at reducing abnormal eosinophil proliferation. The drug described inhibits ribonucleotide reductase, a key enzyme in the conversion of ribonucleotides to deoxyribonucleotides, which are essential for DNA synthesis. By blocking this step, the medication impedes DNA replication, particularly in rapidly dividing hematopoietic cells such as eosinophil precursors. This leads to a reduction in eosinophil production and amelioration of symptoms. The agent in question is hydroxyurea, which belongs to the class of nucleic acid synthesis inhibitors. Its primary cytoreductive effect is mediated by interfering with nucleic acid metabolism, making this drug class the best descriptor of its mechanism in controlling hypereosinophilia.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_d7be76bbe8f6",
      "question": "In patients with stage I–II non-small cell lung cancer who have undergone primary treatment including definitive radiotherapy (but not surgery), should routine follow-up imaging utilize low-dose non–contrast-enhanced chest CT at every surveillance interval during the first five years post-treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIA (T2b, N0); Margins positive (R1, R2)",
              "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Resectable recurrence",
              "Resection (preferred); External-beam RT or SABR",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No; for stage I–II non-small cell lung cancer treated primarily with radiotherapy, surveillance imaging during the first three years should use chest CT with or without contrast every 3–6 months, followed by chest CT with or without contrast every six months for two years, and only thereafter transition to annual low-dose non–contrast-enhanced chest CT.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_bab246474652",
      "question": "A 34-year-old woman plans a cruise and reports a history of severe nausea and vomiting during previous boat trips, despite trying non-pharmacological interventions. Her physician prescribes a medication known to prevent symptoms by blocking a specific neurotransmitter in the brain's chemoreceptor trigger zone. Which receptor class antagonism best explains this drug’s ability to reduce her motion-induced symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Motion sickness"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0026603",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0772132",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Dopamine antagonists",
      "reasoning_path": "Clinical vignette describes motion sickness → Promethazine is prescribed → Promethazine blocks dopamine D2 receptors in CTZ → Dopamine antagonism interrupts emetic signaling → Symptoms are prevented.",
      "umls_path": [
        "Motion sickness",
        "may_be_treated_by",
        "promethazine dioxide",
        "has_mechanism_of_action",
        "Dopamine Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Motion sickness is mediated by excessive stimulation of the vestibular system, which then activates the chemoreceptor trigger zone (CTZ) and vomiting center in the medulla. Dopamine, histamine, acetylcholine, and serotonin neurotransmitter pathways are all involved in these processes. Promethazine, a commonly used antiemetic for motion sickness, is a phenothiazine derivative that primarily acts as a dopamine D2 receptor antagonist in the CTZ. By blocking dopamine receptors, promethazine reduces neuronal signaling that would otherwise trigger the vomiting reflex. Although promethazine also has antihistaminic and anticholinergic properties, its antiemetic efficacy in motion sickness is most closely related to dopamine receptor blockade. Therefore, the mechanism of action relevant to this therapy is best described as dopamine antagonism, which interrupts the emetogenic pathway and effectively prevents motion-induced nausea and vomiting.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_c3d10a15a77c",
      "question": "A 42-year-old man with advanced HIV presents with progressive dyspnea, nonproductive cough, and fever. Chest X-ray reveals bilateral interstitial infiltrates. Bronchoalveolar lavage confirms infection with an opportunistic pathogen that requires folate for nucleic acid synthesis. He is started on an oral medication that specifically inhibits the microbial dihydrofolate reductase enzyme, thereby blocking a key step in nucleotide biosynthesis. Which drug class is most directly responsible for this medication’s therapeutic effect against the identified pathogen?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Pneumocystosis pneumonia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1535939",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0771053",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Folic acid metabolism inhibitors",
      "reasoning_path": "Trimethoprim treats Pneumocystis pneumonia by inhibiting microbial dihydrofolate reductase, thereby blocking folic acid metabolism and impairing DNA synthesis.",
      "umls_path": [
        "Pneumocystosis pneumonia",
        "may_be_treated_by",
        "trimethoprim lactate",
        "has_mechanism_of_action",
        "Folic Acid Metabolism Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In immunocompromised patients, Pneumocystis pneumonia is caused by Pneumocystis jirovecii, an organism that relies on folate metabolism for DNA synthesis. Trimethoprim lactate is commonly used in this setting; it acts by inhibiting dihydrofolate reductase, an enzyme essential for converting dihydrofolate to tetrahydrofolate. This step is crucial for the synthesis of purines and thymidine, the building blocks of DNA. By blocking this enzyme, trimethoprim disrupts nucleic acid synthesis, preventing replication and survival of the pathogen. The therapeutic effect thus arises from the drug’s ability to inhibit folic acid metabolism, classifying it as a folic acid metabolism inhibitor. This mechanism is distinct from other antimicrobial classes and is particularly effective against microorganisms with high dependence on endogenous folate pathways, such as Pneumocystis jirovecii.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_7db02a27715f",
      "question": "In a patient with a solitary pulmonary nodule staged as IIIA and confirmed absence of extrathoracic metastatic disease after FDG-PET/CT and brain MRI, does the recommendation for external-beam radiotherapy imply that endobronchial obstruction or locoregional recurrence is present?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Yes, the use of external-beam radiotherapy in this context typically implies the presence of endobronchial obstruction, locoregional recurrence, or symptomatic local disease requiring local control measures, rather than routine use in all stage IIIA solitary pulmonary nodules.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_86bbf06ce872",
      "question": "In a patient with non-metastatic, invasive breast cancer (clinical stage cT2, ER-positive and HER2-positive, with at least one ipsilateral lymph node metastasis >2 mm detected post-surgery), is adjuvant chemotherapy with trastuzumab plus pertuzumab and endocrine therapy preferred over adjuvant chemotherapy with trastuzumab and endocrine therapy alone, and what clinical situation would justify selection of one regimen over the other?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
              "ER-positive and/or PR-positive",
              "HER2-positive",
              "BINV-5",
              "Ductal/NST • Lobular • Mixed • Micropapillary",
              "pN+ (≥1 ipsilateral metastases >2 mm)",
              "Adjuvant chemotherapy with trastuzumab (category 1) and endocrine therapy or Adjuvant chemotherapy with trastuzumab + pertuzumab (category 1, preferred) and endocrine therapy",
              "Follow-Up (BINV-17)"
            ]
          }
        }
      ],
      "answer": "Adjuvant chemotherapy with trastuzumab plus pertuzumab and endocrine therapy is preferred for patients with HER2-positive, node-positive early breast cancer, due to superior efficacy shown in high-risk groups. Chemotherapy with trastuzumab without pertuzumab may be considered only if pertuzumab is contraindicated or not tolerated. Node positivity and HER2 overexpression strongly support dual HER2 blockade unless there are adverse factors.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_1ca92538e034",
      "question": "In ClinicalTrials.gov, what interventional studies for hormone-refractory prostate cancer that started in May 2000 used sipuleucel-T as a main intervention?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "conditions=Hormone-Refractory Prostate Cancer;interventions.name=sipuleucel-T;startDateFrom=2000-05-01",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT01133704"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_47c7cc607166",
      "question": "A 32-year-old man presents with several months of lower back pain and morning stiffness that improves with exercise. Imaging reveals bilateral sacroiliitis. His physician starts him on a medication that provides symptomatic relief by directly inhibiting an enzyme responsible for catalyzing the conversion of arachidonic acid to pro-inflammatory mediators. Through which molecular mechanism does this medication exert its primary therapeutic effect in this patient's inflammatory condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Ankylosing spondylitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0038013",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020740",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Inhibition of Prostaglandin G/H Synthase 2 (COX-2)",
      "reasoning_path": "Ankylosing spondylitis causes inflammation; NSAIDs like ibuprofen inhibit COX-2 (Prostaglandin G/H Synthase 2), decreasing prostaglandin-mediated inflammatory responses.",
      "umls_path": [
        "Ankylosing spondylitis",
        "may_be_treated_by",
        "Ibuprofen",
        "has_target",
        "Prostaglandin G/H Synthase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has ankylosing spondylitis, a chronic inflammatory disorder primarily affecting the axial skeleton. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, are first-line treatments for symptom relief due to their anti-inflammatory properties. These effects are mediated through the direct inhibition of the enzyme Prostaglandin G/H Synthase 2, also known as cyclooxygenase-2 (COX-2). COX-2 is an inducible enzyme that converts arachidonic acid into prostaglandin H2, the precursor of various prostaglandins involved in inflammation, pain, and fever. By inhibiting COX-2, NSAIDs reduce prostaglandin synthesis, thereby decreasing inflammation and its associated symptoms. This mechanism underlies the clinical benefit observed in patients with ankylosing spondylitis and other inflammatory arthritides.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_36f8b3a8b04b",
      "question": "A 67-year-old woman presents to the emergency department with sudden onset of severe eye pain, blurred vision, headache, and seeing halos around lights. Her intraocular pressure is markedly elevated. After confirmation of the diagnosis, she is started on a topical ophthalmic medication that increases acetylcholine levels in the eye, leading to contraction of the ciliary muscle and increased outflow of aqueous humor. Through which primary pharmacological mechanism does this medication achieve its therapeutic effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Angle Closure Glaucoma"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0017605",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0057361",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cholinesterase inhibition",
      "reasoning_path": "Angle closure glaucoma—demecarium bromide prescribed—inhibits cholinesterase—increases acetylcholine—stimulates ciliary muscle—increases aqueous outflow—reduces intraocular pressure.",
      "umls_path": [
        "Angle Closure Glaucoma",
        "may_be_treated_by",
        "Demecarium bromide",
        "has_mechanism_of_action",
        "Cholinesterase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s acute symptoms, including sudden ocular pain, visual disturbances, and elevated intraocular pressure, are characteristic of angle closure glaucoma. In this emergency, rapid reduction of intraocular pressure is essential to prevent optic nerve damage. Demecarium bromide, the medication described, is a reversible cholinesterase inhibitor. By inhibiting acetylcholinesterase, it increases the availability of acetylcholine at muscarinic receptors in the eye. This heightened cholinergic stimulation causes contraction of the ciliary muscle, which opens the trabecular meshwork and enhances the outflow of aqueous humor, thereby lowering intraocular pressure. The primary pharmacological mechanism is cholinesterase inhibition, which underlies the therapeutic effect in this setting. This mechanism increases parasympathetic (muscarinic) activity locally, directly addressing the pathophysiological blockage of aqueous humor drainage in angle closure glaucoma.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_a5b9519c3973",
      "question": "In a patient with stage IA (T1aN0) non-small cell lung cancer who has undergone surgical resection but has positive margins (R1), is definitive radiation therapy always required, or does re-resection remain the preferred option when feasible?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (T1abc, N0); Margins positive (R1, R2)",
              "Resection (preferred) or RT (category 2B)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "For stage IA (T1aN0) non-small cell lung cancer with positive resection margins (R1), repeat surgical resection is preferred when feasible. Definitive radiation therapy is considered a secondary (category 2B) option if re-resection is not possible. Therefore, re-resection takes priority over radiation in the absence of surgical contraindications.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_ebc3cb703acf",
      "question": "A 28-year-old woman presents with a thin, grayish vaginal discharge and a fishy odor. Microscopic examination of vaginal secretions reveals clue cells. She is prescribed an antibiotic known to bind the 50S ribosomal subunit and disrupt bacterial protein synthesis. Which general pharmacologic class does her prescribed treatment belong to, and what is the mechanistic basis for its effectiveness in this condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Bacterial vaginosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0085166",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0055880",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Protein synthesis inhibitors—these antibiotics inhibit bacterial ribosomal function, thereby blocking essential protein production and suppressing pathogenic growth.",
      "reasoning_path": "Bacterial vaginosis is treated with clindamycin, which binds the bacterial 50S ribosomal subunit, inhibiting protein synthesis and thereby suppressing bacterial growth.",
      "umls_path": [
        "Bacterial vaginosis",
        "may_be_treated_by",
        "clindamycin palmitate",
        "has_mechanism_of_action",
        "Protein Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has clinical and microscopic findings consistent with bacterial vaginosis. Standard therapy includes antibiotics that specifically target the causative bacteria. Clindamycin is commonly used and acts by binding to the 50S subunit of the bacterial ribosome. This binding prevents peptide chain elongation, effectively inhibiting protein synthesis, which is essential for bacterial survival and proliferation. By targeting bacterial ribosomes—structures distinct from human ribosomes—protein synthesis inhibitors suppress the growth of the polymicrobial flora associated with bacterial vaginosis. This pharmacologic class includes drugs like clindamycin and macrolides, which share this mechanism. The effectiveness of these agents in bacterial vaginosis relies on their ability to halt bacterial protein production, reducing bacterial load and resolving symptoms.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_266584a9d6b3",
      "question": "A 62-year-old man is admitted to the emergency department after collapsing at home. Paramedics document an irregular, rapid, and disorganized ventricular rhythm on ECG. After initial attempts at electrical cardioversion, his rhythm remains unstable. He is given an intravenous medication known to enhance cardiac automaticity and conduction velocity through stimulation of specific G protein-coupled receptors that increase intracellular cAMP. Which drug class is most directly responsible for these pharmacologic effects in cardiac tissue?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Ventricular fibrillation"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0042510",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0022245",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Adrenergic beta2-Agonists",
      "reasoning_path": "Patient with ventricular fibrillation receives a drug that stimulates beta-adrenergic receptors, increasing cAMP in cardiac cells; this effect is mediated by adrenergic beta2-agonists.",
      "umls_path": [
        "Ventricular fibrillation",
        "may_be_treated_by",
        "Isoproterenol-containing product",
        "has_mechanism_of_action",
        "Adrenergic beta2-Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this clinical scenario, the patient is experiencing ventricular fibrillation—a life-threatening arrhythmia characterized by chaotic electrical activity and ineffective ventricular contraction. In select cases, drugs that act as adrenergic beta-agonists (such as isoproterenol) may be considered to increase heart rate and improve conduction when bradyarrhythmia or asystole complicate resuscitation. These agents exert their effect by stimulating beta-adrenergic receptors (specifically beta1 and beta2 subtypes) on cardiac myocytes. Activation of these G protein-coupled receptors leads to increased intracellular cyclic AMP (cAMP), which enhances calcium influx, increases automaticity, and improves conduction velocity. The primary drug class responsible for this molecular mechanism is adrenergic beta2-agonists. Although not first-line for ventricular fibrillation itself, understanding their mechanism helps clarify how they influence cardiac electrophysiology and contractility in arrhythmia management.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_83152ad4d4d4",
      "question": "For a patient with a solitary pulmonary nodule in the contralateral lung and confirmed stage IVA (N0, M1a) non-small cell lung cancer (NSCLC), does surgical management implicitly require that both lesions are deemed individually curable and thus be treated as two primary lung tumors?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
              "Pathologic Diagnosis of NSCLC",
              "Clinical Stage",
              "Stage IVA (M1b)",
              "Pretreatment Evaluation (NSCL-15)"
            ]
          }
        }
      ],
      "answer": "Yes, surgical management in the setting of a solitary contralateral lung nodule and stage IVA (N0, M1a) NSCLC presupposes that both lesions are separately resectable with curative intent and should be managed as two primary tumors if both are considered individually curable.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_f59b6f930009",
      "question": "For a patient with localized invasive, non-inflammatory breast cancer (clinical stage cT1–T2, negative axillary nodes, tumor size 5.1 cm, and surgical margins ≥1 mm after total mastectomy and axillary staging), is postmastectomy radiotherapy omitted in this scenario?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "Negative axillary nodes and tumor ≤5 cm and margins ≥1 mm",
              "No RT"
            ]
          }
        }
      ],
      "answer": "No, omission of postmastectomy radiotherapy is not indicated in this scenario since the tumor size exceeds 5 cm; the established criteria for omission include negative axillary nodes, tumor size ≤5 cm, and margins ≥1 mm. A tumor larger than 5 cm does not meet omission criteria.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_b17057d70587",
      "question": "A 42-year-old woman presents with recurrent episodes of rapid vision loss in one eye, followed by progressive weakness and numbness in both legs. MRI reveals longitudinally extensive lesions in the spinal cord, and serum testing identifies antibodies against aquaporin-4. After a confirmed diagnosis, she is started on a monoclonal antibody therapy designed to deplete pathogenic immune cells contributing to her disease. This drug specifically binds to a surface molecule expressed from early B-cell development through plasmablasts, but not on plasma cells. Which molecular target does this therapy engage to reduce disease activity in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Neuromyelitis optica"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0027873",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4519594",
            "rela": "has_target"
          }
        }
      ],
      "answer": "B-Lymphocyte Antigen CD19 (CD19)",
      "reasoning_path": "Neuromyelitis optica involves autoantibody-mediated CNS injury; inebilizumab reduces this by binding CD19 on B cells and plasmablasts, causing their depletion and lowering pathogenic antibody levels.",
      "umls_path": [
        "Neuromyelitis optica",
        "may_be_treated_by",
        "Inebilizumab-containing product",
        "has_target",
        "B-Lymphocyte Antigen CD19"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has neuromyelitis optica spectrum disorder (NMOSD), an autoimmune disease characterized by the presence of anti-aquaporin-4 antibodies produced by B cells. Therapies that decrease pathogenic B-cell populations can reduce disease activity. Inebilizumab is a humanized monoclonal antibody used in NMOSD that targets CD19, a cell surface antigen expressed broadly throughout B-cell development, including on precursor and memory B cells, as well as plasmablasts. By binding to CD19, inebilizumab induces B-cell depletion via antibody-dependent cellular cytotoxicity and other immune mechanisms. This reduces the pool of B cells capable of differentiating into antibody-secreting cells, thereby lowering the production of pathogenic antibodies responsible for the neurological damage seen in NMOSD. Targeting CD19, rather than CD20, allows broader depletion, including plasmablasts implicated in autoantibody production.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_24f7c52ea646",
      "question": "For a patient with stage I–II non-small cell lung cancer who underwent primary treatment with surgery followed by adjuvant radiotherapy, which follow-up imaging schedule is more appropriate during the first three years after treatment: H&P and chest CT every 6 months, or H&P and chest CT every 3–6 months?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "In a patient with stage I–II non-small cell lung cancer who received surgery and adjuvant radiotherapy, the preferred follow-up imaging schedule during the first three years is H&P and chest CT every 3–6 months, as the addition of radiotherapy aligns their surveillance requirements with those of stage III or treated oligometastatic disease.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_8eecefb6fe6c",
      "question": "A 52-year-old woman with a history of schizophrenia presents with intense inner restlessness and an inability to sit still after starting a new antipsychotic medication. She reports constant pacing and describes feeling compelled to move her legs. Trials of dose reduction, beta-blockers, and benzodiazepines have not relieved her symptoms. Her neurologist prescribes a medication that is also used as an antiviral agent and is known to modulate dopaminergic transmission. Through which primary pharmacological mechanism does this agent provide symptomatic relief in this scenario?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Drug-Induced Akathisia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0162550",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002404",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Dopamine release enhancer and NMDA receptor antagonist; Amantadine relieves drug-induced akathisia primarily by enhancing dopamine release and antagonizing NMDA receptors in the central nervous system.",
      "reasoning_path": "Drug-induced akathisia is caused by antipsychotic-induced dopamine blockade. Amantadine is prescribed for refractory cases. Its clinical effect in movement disorders is via CNS dopamine release enhancement and NMDA receptor antagonism, not M2 protein inhibition.",
      "umls_path": [
        "Drug-Induced Akathisia",
        "may_be_treated_by",
        "Amantadine sulfate",
        "has_mechanism_of_action",
        "M2 Protein Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient has antipsychotic-induced akathisia, a movement disorder characterized by restlessness, often due to dopamine D2 receptor blockade. Amantadine, although originally developed as an antiviral, is used off-label for extrapyramidal symptoms because it enhances dopamine release and inhibits NMDA-type glutamate receptors, thereby restoring dopaminergic-cholinergic balance in the basal ganglia. The M2 protein inhibition is relevant for its antiviral effect (influenza A), not for akathisia. Therefore, amantadine’s therapeutic benefit in this context is due to its action as a dopamine release enhancer and NMDA receptor antagonist, not M2 protein inhibition.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_f0ff7c3d9a2d",
      "question": "For a patient with localized, invasive, non-inflammatory, non-metastatic breast cancer presenting as cT1c, cN0, HER2-negative, hormone receptor-negative (triple-negative) disease, is preoperative systemic therapy indicated according to the stated clinical criteria, or is this approach reserved for tumors that are HER2-positive or node-positive?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS possible",
              "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
              "Adjuvant systemic therapy (BINV-16) + WBRT",
              "Any cN0, ypN0: Adjuvant RT to whole breast ± boost to tumor bed"
            ]
          }
        }
      ],
      "answer": "Preoperative systemic therapy is indicated for cT1c, cN0 triple-negative breast cancer, as well as for cT1c, cN0 HER2-positive or cT2/cN+ tumors. Thus, this therapeutic approach is not reserved exclusively for HER2-positive or node-positive disease but also applies to triple-negative tumors of size T1c (≥1 and <2 cm).",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_bcbb977d7aa7",
      "question": "In a patient with advanced non-small cell lung cancer of adenocarcinoma subtype, if an ALK rearrangement is identified prior to the initiation of first-line systemic therapy, does the use of ceritinib as first-line treatment implicitly require EGFR mutation status to be negative or unavailable?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "ALK rearrangement positive",
              "ALK rearrangement",
              "ALK rearrangement discovered prior to first-line systemic therapy",
              "Other Recommended Ceritinibr (category 1)",
              "Progression",
              "Subsequent Therapy (NSCL-28)"
            ]
          }
        }
      ],
      "answer": "Yes, the use of ceritinib as first-line therapy in advanced adenocarcinoma-type NSCLC with a confirmed ALK rearrangement presumes that the tumor is EGFR wild-type or that clinically relevant EGFR mutations are absent, as ALK inhibitor therapy is specifically indicated for ALK-positive, EGFR-negative cases.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_2f310f1ada56",
      "question": "A 28-year-old woman presents to the dermatology clinic with a pruritic, erythematous rash localized to sun-exposed areas of her forearms and face. She reports that the lesions appear within hours after spending time outdoors and resolve over several days, leaving mild hyperpigmentation. She has a history of photosensitivity but no systemic symptoms. Her dermatologist recommends a topical preparation that acts as a shield against ultraviolet radiation by physically and chemically impeding the penetration of UV light through the epidermis. Through which general class of mechanism does this topical agent most effectively prevent her cutaneous injury?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Photodermatitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0031762",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0950387",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Physiochemical activity",
      "reasoning_path": "Photodermatitis is managed with topical UV filters like cinoxate, which protect by directly absorbing and filtering UV radiation—this is a physiochemical mode of action, not a receptor- or enzyme-mediated effect.",
      "umls_path": [
        "Photodermatitis",
        "may_be_treated_by",
        "Cinoxate",
        "has_mechanism_of_action",
        "Physiochemical Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In patients with photosensitive skin disorders such as photodermatitis, topical agents that serve as sunscreens are commonly used for prophylaxis. These agents, including compounds like cinoxate, function by absorbing, scattering, or reflecting ultraviolet (UV) radiation, thereby preventing UV photons from reaching and damaging viable skin cells. This protection is not mediated via receptor binding, enzyme inhibition, or immunomodulation, but rather by a direct physicochemical interaction with incident UV rays. By dissipating or blocking the energy of harmful wavelengths, such agents reduce DNA damage and reactive oxygen species generation in the skin—key factors in the pathogenesis of photodermatitis. Therefore, the primary mechanism by which these topical preparations prevent cutaneous phototoxicity is best categorized as physiochemical activity.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_3e54cdde8321",
      "question": "A 62-year-old woman with a known diagnosis of multiple myeloma presents with confusion, constipation, and muscle weakness. Laboratory evaluation reveals a serum calcium of 13.2 mg/dL (normal: 8.5–10.5 mg/dL). She is admitted and started on intravenous fluids and a corticosteroid, which, in addition to its immunosuppressive effects, decreases the production of pro-inflammatory mediators derived from arachidonic acid. The drug's therapeutic action in this setting is partly due to inhibition of an enzyme class involved in leukotriene synthesis. Which enzyme class is most directly inhibited by this corticosteroid to help manage her hypercalcemia?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Hypercalcemia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020437",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0889299",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lipoxygenase inhibitors",
      "reasoning_path": "Malignancy-induced hypercalcemia → corticosteroid therapy → reduction of inflammatory mediators → inhibition of lipoxygenase enzymes → decreased leukotriene synthesis → reduced bone resorption and serum calcium.",
      "umls_path": [
        "Hypercalcemia",
        "may_be_treated_by",
        "Prednisolone sodium metazoate",
        "has_mechanism_of_action",
        "Lipoxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In malignancy-associated hypercalcemia, corticosteroids are often used to reduce serum calcium levels, especially when the underlying process involves increased vitamin D production or inflammation. Corticosteroids inhibit the transcription of genes encoding inflammatory enzymes, including lipoxygenase. Lipoxygenase enzymes catalyze the conversion of arachidonic acid to leukotrienes, potent inflammatory mediators. By inhibiting lipoxygenase activity, corticosteroids reduce leukotriene-mediated bone resorption and inflammatory cytokine production, both of which can contribute to hypercalcemia through increased osteoclast activation and bone turnover. Therefore, the therapeutic effect of corticosteroids in this context is partly mediated by their action as lipoxygenase inhibitors, reducing inflammation-driven calcium mobilization from bone.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_98abab1c942b",
      "question": "A 47-year-old woman from Southeast Asia presents with right upper quadrant discomfort and intermittent fever. Laboratory tests reveal elevated liver enzymes, and stool analysis identifies eggs consistent with liver fluke infection. She is diagnosed with a chronic helminthic infection and started on a benzimidazole antiparasitic agent. This drug is known to undergo hepatic metabolism and can alter the clearance of other co-administered medications by inducing specific metabolic enzymes. Which class of hepatic enzymes is primarily upregulated by this therapy, facilitating both its own and other drugs' metabolism?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Opisthorchiasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0029106",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001911",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cytochrome P450 1A Inducers",
      "reasoning_path": "Opisthorchiasis → treated with albendazole → metabolized by CYP enzymes → induces CYP1A enzymes → increased metabolism of itself and other drugs via CYP1A.",
      "umls_path": [
        "Opisthorchiasis",
        "may_be_treated_by",
        "Albendazole",
        "has_mechanism_of_action",
        "Cytochrome P450 1A Inducers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has opisthorchiasis, a liver fluke infection, for which albendazole is a common treatment. Albendazole’s antiparasitic action is due to inhibition of microtubule polymerization in parasites. However, its pharmacokinetic profile is highly relevant: albendazole is metabolized by hepatic cytochrome P450 enzymes, particularly those in the CYP1A family. Importantly, albendazole can also induce CYP1A enzymes, increasing their activity. This enzyme induction can enhance the metabolic clearance of albendazole itself (autoinduction) as well as other drugs metabolized by the same pathway, potentially leading to reduced efficacy of co-administered medications. The clinical significance lies in monitoring for drug interactions and adjusting dosages of drugs that are CYP1A substrates when given with albendazole. Thus, the most relevant class of metabolic enzyme modulators for albendazole’s mechanism, especially regarding drug-drug interactions and its pharmacological effects, is the cytochrome P450 1A inducers.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_4ffe2898b7bd",
      "question": "For a patient with confirmed stage IIIC (T4, N3) non-small cell lung cancer and no evidence of distant metastases on brain MRI and FDG-PET/CT, if endobronchial obstruction is present causing local symptoms, should endobronchial intervention such as laser or stent placement take priority over initiating systemic therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
              "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Endobronchial intervention, including laser or stent placement, should be prioritized to relieve symptoms of endobronchial obstruction before initiating systemic therapy, as immediate airway compromise requires local control to stabilize the patient and ensure airway patency.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_a445eb11a11e",
      "question": "A 46-year-old man with a history of intravenous drug use is admitted after developing fever, malaise, and a new heart murmur. Blood cultures grow Enterococcus faecalis, and transthoracic echocardiography reveals a vegetation on the mitral valve. He is started on an intravenous antibiotic that binds penicillin-binding proteins and disrupts cross-linking of peptidoglycan layers in the bacterial cell wall. Which class of drug mechanism underlies the effectiveness of this antibiotic in treating his infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Bacterial endocarditis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0014121",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0724526",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Transpeptidase inhibitors",
      "reasoning_path": "Bacterial endocarditis requires bactericidal antibiotics; ampicillin binds PBPs (transpeptidases), preventing cell wall synthesis and causing bacterial lysis.",
      "umls_path": [
        "Bacterial endocarditis",
        "may_be_treated_by",
        "Ampicillin anhydrous",
        "has_mechanism_of_action",
        "Transpeptidase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has infective endocarditis due to Enterococcus faecalis. Ampicillin, a beta-lactam antibiotic, is commonly used to treat such infections. Its therapeutic effect depends on its ability to bind to and inhibit bacterial transpeptidase enzymes, also known as penicillin-binding proteins (PBPs). These enzymes are essential for the cross-linking of peptidoglycan strands, a critical step in bacterial cell wall synthesis. By blocking transpeptidases, ampicillin disrupts cell wall integrity, leading to osmotic instability and bacterial cell lysis. This mechanism is particularly important in eradicating actively dividing bacteria in endocardial vegetations. Thus, the primary mechanism responsible for ampicillin's efficacy in this clinical scenario is inhibition of transpeptidase-mediated cross-linking in the bacterial cell wall.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_b0aded01b591",
      "question": "In a patient with advanced or metastatic non-small cell lung cancer (adenocarcinoma, large cell, or NSCLC not otherwise specified), whose tumor demonstrates PD-L1 expression less than 1% and is negative for all listed actionable molecular biomarkers, does the absence of EGFR, ALK, ROS1, BRAF, KRAS, NTRK, METex14, RET, and ERBB2 (HER2) mutations unequivocally indicate that targeted therapy is not appropriate as initial systemic treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Disseminated metastases",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "PD-L1 <1% and negative for actionable molecular biomarkers above"
            ]
          }
        }
      ],
      "answer": "Yes, in this clinical setting, the absence of actionable alterations in EGFR, ALK, ROS1, BRAF, KRAS, NTRK, METex14, RET, and ERBB2 (HER2), along with PD-L1 expression less than 1%, means that targeted therapy agents directed at these mutations are not indicated for initial systemic treatment; standard management would proceed with non-targeted therapy options such as platinum-based chemotherapy or immunotherapy, as per current guidelines.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_7128f9f7d2c1",
      "question": "In ClinicalTrials.gov, which interventional studies for Obesity or Type 2 Diabetes involving VI-0521 started in November 2007 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "conditions=Obesity,Type 2 Diabetes;interventions.name=VI-0521;startDateFrom=2007-11-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00553787"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_2158fe43c68b",
      "question": "In a patient with non-small cell lung cancer presenting with T4 tumor extension involving resectable invasion of the mediastinum (N0–1 disease), is concurrent chemoradiation still recommended if the patient has severely impaired pulmonary function tests (PFTs) not amenable to improvement?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Trachea/carina or mediastinum",
              "Treatment (NSCL-7)",
              "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
              "Systemic therapy or Concurrent chemoradiation",
              "Surgical reevaluation including chest CT ± PET/CT",
              "Surgery",
              "Margins positive (R1, R2)",
              "Resection and/or RT boost",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "Concurrent chemoradiation is generally contraindicated in patients with severely impaired pulmonary function because of the high risk of treatment-related morbidity and mortality. For such patients, alternative approaches such as systemic therapy alone or individualized, less intensive regimens should be considered.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_8c99b7b6c1aa",
      "question": "In the OpenTargets platform, what tractability information is available for the target with Ensembl ID ENSG00000151834 and approved symbol GABRA2 where the value is True?",
      "tool_calls": [
        {
          "tool": "opentargets.tractability",
          "params": {
            "target_id": "ENSG00000151834",
            "value": true
          }
        }
      ],
      "answer": [
        {
          "modality": "SM",
          "label": "Approved Drug"
        },
        {
          "modality": "SM",
          "label": "High-Quality Ligand"
        },
        {
          "modality": "SM",
          "label": "Druggable Family"
        },
        {
          "modality": "AB",
          "label": "GO CC high conf"
        },
        {
          "modality": "AB",
          "label": "UniProt loc med conf"
        },
        {
          "modality": "AB",
          "label": "UniProt SigP or TMHMM"
        },
        {
          "modality": "AB",
          "label": "Human Protein Atlas loc"
        },
        {
          "modality": "PR",
          "label": "Half-life Data"
        },
        {
          "modality": "PR",
          "label": "Small Molecule Binder"
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "path_22dcb2bbb14d",
      "question": "In patients with advanced or metastatic non–small cell lung cancer who are found to have an NTRK1/2/3 gene fusion during first-line systemic therapy, is it appropriate to complete the planned systemic therapy (including maintenance), or is it preferable to interrupt and switch to a selective TRK inhibitor such as larotrectinib, entrectinib, or repotrectinib?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "NTRK1/2/3 gene fusion positive",
              "NTRK1/2/3 gene fusion",
              "NTRK1/2/3 gene fusion discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by larotrectinib, entrectinib, or repotrectinib",
              "Progression",
              "Repotrectinib (if not previously given) or Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
              "Progression",
              "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
            ]
          }
        }
      ],
      "answer": "For patients with advanced or metastatic non–small cell lung cancer who are newly identified as having an NTRK1/2/3 gene fusion during first-line systemic therapy, it is recommended to either complete the planned systemic therapy (including maintenance) or interrupt and switch to a TRK inhibitor; both strategies are acceptable, and individualized clinical factors should guide the choice, as there is no absolute preference.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_93f287014a67",
      "question": "For a patient with stage IA non-small cell lung cancer (T1abc, N0) who has undergone surgical resection resulting in positive margins (R1 or R2) but is medically inoperable for re-resection, is adjuvant radiotherapy unequivocally standard of care, or does its use fall outside category 1 recommendations, implying a lower level of evidence or consensus?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (T1abc, N0); Margins positive (R1, R2)",
              "Resection (preferred) or RT (category 2B)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Severe hemoptysis",
              "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Adjuvant radiotherapy in this setting is not category 1 standard of care; it is classified as a category 2B recommendation, reflecting lower-level evidence or less consensus regarding its routine use when resection is not feasible after positive margins.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_8e8b20b05707",
      "question": "In ClinicalTrials.gov, what interventional studies for bone metastases that started in April 2006 used Denosumab or Zoledronic Acid as interventions?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "conditions=Bone Metastases;interventions.name=Denosumab,Zoledronic Acid;startDateFrom=2006-04-01",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00321464"
      ],
      "type": "retrieval"
    },
    {
      "id": "ret_e1876760d8cb",
      "question": "What is the PMID of the article titled \"Diversity is essential in cardiovascular medicine and subspecialties: A comprehensive report of gender, racial, and ethnic representation among cardiovascular fellows from 2005 to 2022,\" authored by Obeidat O and published in Current Problems in Cardiology in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"Diversity is essential in cardiovascular medicine and subspecialties\"[ti] AND Obeidat O[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40311855"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_629e39c8a8f5",
      "question": "In a patient with stage IIIA non-small cell lung cancer (T1–2, N2; T3, N1) who has undergone complete surgical resection with negative margins (R0), is brain MRI with contrast recommended as a routine part of initial surveillance if no neurological symptoms are present?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
              "Sequential chemotherapy and consider RT",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, routine brain MRI with contrast is not recommended for initial surveillance in stage IIIA non-small cell lung cancer after complete resection with negative margins, unless neurological symptoms or other clinical indications are present. Surveillance relies on history, physical examination, and chest CT.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_28f38c0f5425",
      "question": "In a patient with operable, invasive, non-metastatic breast cancer (M0), who has a clinically negative axilla (cN0) on examination and imaging, but presents with two sentinel lymph nodes positive after undergoing breast-conserving surgery, can omission of axillary lymph node dissection (ALND) still be considered appropriate if the patient has received preoperative systemic (neoadjuvant) therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS not possible",
              "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
              "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
              "SLN mapping and excision",
              "SLN positive",
              "Breast-conserving surgery",
              "Meets ALL of the following criteria: • cT1–T2, cN0 • No preoperative chemotherapy • 1–2 positive SLNs • WBRT planned",
              "No",
              "ALND level I/II"
            ]
          }
        }
      ],
      "answer": "Omission of axillary lymph node dissection (ALND) is not considered appropriate in this scenario, as the eligibility for skipping ALND after finding 1–2 positive sentinel lymph nodes applies only to patients who have not received preoperative systemic therapy. Preoperative (neoadjuvant) therapy alters nodal evaluation and exclusion criteria for ALND omission.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_f574c3bb75e4",
      "question": "A 45-year-old contact lens wearer presents with redness, pain, and blurred vision in his right eye. Slit-lamp examination reveals a corneal ulcer with feathery margins. Corneal scrapings grow filamentous fungi. The ophthalmologist prescribes a topical agent that targets a crucial fungal cell membrane component, ultimately leading to increased membrane permeability and cell death. Through which molecular mechanism does this drug exert its therapeutic effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Fungal infection of eye"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0015405",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0027444",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Disruption of ergosterol synthesis in the fungal cell membrane",
      "reasoning_path": "Fungal keratitis → topical natamycin prescribed → natamycin targets ergosterol in fungal cell membrane → disruption of ergosterol synthesis/function → increased membrane permeability → fungal cell death.",
      "umls_path": [
        "Fungal infection of eye",
        "may_be_treated_by",
        "Natamycin",
        "has_mechanism_of_action",
        "Ergosterol Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has fungal keratitis, a serious ocular infection often caused by filamentous fungi such as Fusarium or Aspergillus. The mainstay of topical treatment is natamycin, an antifungal agent. Natamycin acts by binding to ergosterol, a key sterol in the fungal cell membrane, and disrupting its synthesis or function. Ergosterol is essential for maintaining fungal cell membrane integrity and fluidity. When natamycin disrupts ergosterol, it increases membrane permeability, causing leakage of intracellular components and subsequent fungal cell death. This mechanism is specific to fungi, as mammalian cells contain cholesterol, not ergosterol, making natamycin selectively toxic to fungal pathogens while sparing human tissues. Thus, the therapeutic effect in fungal keratitis relies on natamycin's ability to disrupt ergosterol in fungal membranes, which impairs cell viability and resolves the infection.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_f90d21bf74ab",
      "question": "For a patient with stage IIB non-small cell lung cancer (T3, N0) who achieved R0 resection followed by adjuvant chemotherapy, but now presents with an asymptomatic endobronchial obstruction detected during surveillance imaging, should local interventions such as laser or stent placement be preferred over systemic therapy as the initial management?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
              "R2; Resection + systemic therapy or Concurrent chemoradiation",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "In the setting of an isolated, asymptomatic endobronchial obstruction without evidence of disseminated disease, local interventions such as laser or stent placement are preferred as the initial management strategy. Systemic therapy is reserved for cases with disseminated disease or if local interventions are not feasible or effective.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_c5d2c342d0d1",
      "question": "In a patient with completely resected stage IIIA (T1–2, N2) non-small cell lung cancer who underwent definitive surgery and adjuvant chemotherapy, but not radiotherapy, is it appropriate to apply the intensive chest CT surveillance schedule recommended for stage III patients treated with radiotherapy, or should the less frequent schedule used for stage I–II surgery ± chemotherapy cases be preferred?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
              "R2; Concurrent chemoradiation",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "The intensive surveillance schedule with chest CT every 3–6 months for 3 years is specifically recommended for stage III patients who received radiotherapy; in purely surgically managed stage III patients without radiotherapy, the rationale for more frequent imaging is less clear, so applying the less intensive schedule (every 6 months for 2–3 years, then annually) is reasonable unless there are additional risk factors warranting closer follow-up.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_a950108c9dc4",
      "question": "In ClinicalTrials.gov, which completed interventional studies for Diabetes Mellitus, Type 2 started in August 2007 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "overallStatus=COMPLETED;conditions=Diabetes Mellitus, Type 2;startDateFrom=2007-08-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00518882"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_eb2c45f21e61",
      "question": "A 32-year-old woman presents with intermittent abdominal pain, diarrhea, and an urticarial rash. She recently returned from a trip to rural Southeast Asia. Stool examination reveals rhabditiform larvae consistent with a nematode infection. She is started on an oral medication that disrupts essential metabolic pathways in the parasite by targeting key enzymes required for survival. Through what general mechanism does this medication exert its antiparasitic effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Strongyloidiasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0038463",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0039832",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme inhibition",
      "reasoning_path": "Strongyloidiasis → treated with thiabendazole → inhibits parasite enzymes (e.g., fumarate reductase) → disrupts metabolic pathways → classified as enzyme inhibition.",
      "umls_path": [
        "Strongyloidiasis",
        "may_be_treated_by",
        "Thiabendazole",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has strongyloidiasis, caused by infection with the nematode Strongyloides stercoralis. Treatment often includes an anthelmintic such as thiabendazole. Thiabendazole's antiparasitic activity is primarily due to its ability to inhibit critical enzymes in the parasite, particularly those involved in energy metabolism like fumarate reductase. By interfering with these metabolic enzymes, the drug disrupts the parasite’s ability to generate ATP and carry out essential biochemical processes, ultimately leading to its death. This mechanism is classified as enzyme inhibition, a general pharmacologic approach that targets specific proteins responsible for catalyzing vital reactions within the pathogen. Enzyme inhibition is a common strategy in antiparasitic therapy, as it allows for selective toxicity against the parasite while minimizing effects on the human host.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_44c4de2a1922",
      "question": "For a 72-year-old man with a 20 pack-year smoking history and stable solid pulmonary nodule measuring 5 mm on chest CT, complicated by underlying pulmonary fibrosis, is it appropriate to discontinue routine imaging follow-up after 12 months of stability?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Incidental finding of nodule suspicious for lung cancer",
              "Multidisciplinary evaluation, Smoking cessation counseling",
              "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
              "Solid nodules Follow-up (DIAG-2)",
              "Incidental finding: solid nodule(s) on chest CT",
              "High risk",
              "< 6 mm CT at 12 mo (optional)",
              "Stable No routine follow-up"
            ]
          }
        }
      ],
      "answer": "No; in patients with high-risk factors such as extensive smoking history and underlying pulmonary fibrosis, discontinuing imaging follow-up solely based on nodule stability for 12 months is not appropriate, as their risk of malignancy remains elevated regardless of nodule size.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_e98a82da62f9",
      "question": "A 32-year-old woman reports abdominal cramping, bloating, and diarrhea after consuming dairy products. She is diagnosed with a condition characterized by the inability to fully digest lactose due to low enzyme activity in the small intestine. Her physician recommends an over-the-counter enzyme supplement to be taken with meals containing dairy, which reduces her symptoms. Despite its clinical efficacy, the precise cellular or molecular mechanism of how this supplement acts within the gut to relieve symptoms is not fully characterized. What best describes the current understanding of this therapy's molecular mechanism of action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Lactose Intolerance"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0022951",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0083183",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Lactose intolerance is managed with lactase enzyme supplements, but the detailed molecular and cellular mechanism by which these supplements reduce symptoms is not clearly defined.",
      "umls_path": [
        "Lactose Intolerance",
        "may_be_treated_by",
        "Lactase",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Lactose intolerance results from insufficient lactase enzyme activity, leading to undigested lactose reaching the colon, where it is fermented by bacteria, causing gastrointestinal symptoms. Oral lactase supplements are used to break down dietary lactose in the gut before it reaches the colon, thereby preventing symptoms. While the clinical benefit is well established, the exact molecular interactions and pathways by which exogenous lactase operates in the gastrointestinal tract—particularly how it survives gastric conditions, interacts with intestinal mucosa, and is distributed within the lumen—remain incompletely understood. Therefore, the current consensus is that the precise cellular or molecular mechanism of action for lactase supplements is unknown.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_d138081a27dc",
      "question": "A 60-year-old woman reports chronic ocular discomfort, including dryness and burning sensations, especially after prolonged screen use. On examination, there is mild conjunctival injection and reduced tear meniscus height, consistent with tear film instability. Her ophthalmologist prescribes an eye drop formulation containing a vitamin A derivative to improve her symptoms. This agent is known to reduce local oxidative stress and stabilize the ocular surface microenvironment. Through which principal molecular mechanism does this treatment promote improvement in her ocular surface disease?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Tear film insufficiency, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0043349",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0073115",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Free radical scavenging (antioxidant) activity—Retinyl Palmitate reduces oxidative damage on the ocular surface.",
      "reasoning_path": "Retinyl Palmitate is prescribed for tear film insufficiency. Its key therapeutic mechanism is antioxidant activity; it scavenges free radicals, reducing oxidative stress and protecting ocular surface cells, thereby improving symptoms.",
      "umls_path": [
        "Tear film insufficiency, unspecified",
        "may_be_treated_by",
        "Retinyl Palmitate",
        "has_mechanism_of_action",
        "Free Radical Scavenging Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Retinyl Palmitate, an ester of vitamin A, is used topically to treat ocular surface disorders like tear film insufficiency and dry eye disease. The ocular surface is particularly vulnerable to oxidative damage due to constant environmental exposure and inflammation. In this context, Retinyl Palmitate acts as an antioxidant, scavenging free radicals and reducing oxidative stress. This protective effect helps stabilize the tear film, preserves epithelial integrity, and promotes a healthier microenvironment for ocular surface cells. The improvement in tear film and reduction of symptoms is not due to direct stimulation of tear production or anti-inflammatory activity but primarily due to the compound’s free radical scavenging properties. By mitigating oxidative damage, Retinyl Palmitate supports repair and maintenance of the ocular surface, leading to symptomatic relief in patients with tear film insufficiency.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_92f74159f211",
      "question": "A 52-year-old woman presents with persistent lower back pain and morning stiffness lasting over an hour, which improves with movement. Imaging reveals sacroiliac joint erosion and vertebral syndesmophytes. She is started on a medication for symptom relief that works by inhibiting an enzyme responsible for converting arachidonic acid into pro-inflammatory mediators. Which enzyme's inhibition is most directly responsible for the reduction in her spinal inflammation?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Arthritis of spine"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0949690",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0025041",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 2 (COX-2)",
      "reasoning_path": "Spinal arthritis → NSAID (meclofenamate sodium) prescribed → NSAIDs inhibit cyclooxygenase enzymes → COX-2 (Prostaglandin G/H Synthase 2) generates inflammatory prostaglandins → Inhibition of COX-2 reduces inflammation and relieves symptoms.",
      "umls_path": [
        "Arthritis of spine",
        "may_be_treated_by",
        "Meclofenamate Sodium",
        "has_target",
        "Prostaglandin G/H Synthase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient shows signs of inflammatory spinal arthritis—likely ankylosing spondylitis—characterized by back pain, stiffness, and radiographic changes. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as meclofenamate sodium, are commonly used for symptom control in this context. The anti-inflammatory effects of NSAIDs are primarily due to inhibition of cyclooxygenase enzymes (COX-1 and COX-2), also known as prostaglandin G/H synthases. Among these, COX-2 (Prostaglandin G/H Synthase 2) is the main inducible enzyme at sites of inflammation and is chiefly responsible for synthesizing prostaglandins that mediate pain, swelling, and inflammatory responses. By inhibiting COX-2, meclofenamate sodium decreases prostaglandin production, thereby reducing inflammation and alleviating symptoms of spinal arthritis. Thus, inhibition of Prostaglandin G/H Synthase 2 is the principal molecular mechanism for the drug's therapeutic effect in this patient.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_9367de681fe0",
      "question": "A 42-year-old man recently returned from a trip to West Africa and presents with episodic swelling of his right eyelid and transient subcutaneous migratory swellings. Laboratory tests reveal eosinophilia, and microfilariae are seen on blood smear. He is started on a medication that is effective against tissue-dwelling nematodes and is known to exert part of its effect through inhibition of an enzyme involved in prostaglandin synthesis, thereby modulating inflammatory responses. Which drug class is responsible for this mechanism of action in treating his infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Loiasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0023968",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0700531",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cyclooxygenase inhibitors",
      "reasoning_path": "Loiasis diagnosed → Treated with diethylcarbamazine → Diethylcarbamazine inhibits cyclooxygenase → Reduces prostaglandin-mediated inflammation → Cyclooxygenase inhibitors are the relevant drug class.",
      "umls_path": [
        "Loiasis",
        "may_be_treated_by",
        "Diethylcarbamazine citrate",
        "has_mechanism_of_action",
        "Cyclooxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s presentation is consistent with loiasis, a filarial infection caused by Loa loa. The standard therapy for this infection is diethylcarbamazine citrate. While its antiparasitic effect primarily involves increasing parasite susceptibility to host immune mechanisms, part of its efficacy is attributed to the inhibition of cyclooxygenase (COX) enzymes. COX enzymes are responsible for the synthesis of prostaglandins, which mediate inflammation and immune responses. By inhibiting COX, diethylcarbamazine reduces local inflammation and modifies the immune response, aiding in the clearance of the parasite and reducing symptoms. Thus, cyclooxygenase inhibitors underlie this aspect of the drug’s mechanism of action.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_7e59f970cf01",
      "question": "A 24-year-old college student presents with red, watery eyes and a gritty sensation for the past three days. Examination reveals bilateral conjunctival injection and scant watery discharge, but no purulent material or visual acuity loss. He is diagnosed with a self-limited ocular infection and prescribed topical eye drops known for their potent anti-inflammatory properties. These drops function by binding to intracellular receptors, translocating to the nucleus, and altering transcription of various inflammatory genes, ultimately suppressing cytokine production and immune cell recruitment. Which receptor class mediates the therapeutic effect of this medication in reducing ocular inflammation?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Viral Conjunctivitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0009774",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0772364",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Corticosteroid hormone receptors",
      "reasoning_path": "Viral conjunctivitis is treated symptomatically with corticosteroids, which bind and activate corticosteroid hormone receptors, suppressing inflammatory gene expression.",
      "umls_path": [
        "Viral Conjunctivitis",
        "may_be_treated_by",
        "Loteprednol",
        "has_mechanism_of_action",
        "Corticosteroid Hormone Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient described has viral conjunctivitis, a condition in which inflammation is a key component of symptoms. While supportive care is first-line, topical corticosteroids like loteprednol may be used in certain cases to reduce inflammation and discomfort. The anti-inflammatory action of these drugs results from their ability to bind cytoplasmic corticosteroid hormone receptors. Upon binding, the receptor-drug complex translocates to the nucleus, where it acts as a transcription factor, modulating gene expression. This leads to decreased synthesis of pro-inflammatory cytokines (e.g., IL-1, TNF-α), inhibition of leukocyte migration, and reduced expression of adhesion molecules, collectively dampening the inflammatory response. Thus, the therapeutic effect in viral conjunctivitis derives from agonist activity at corticosteroid hormone receptors, not from direct antiviral action.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_4e77210acfaa",
      "question": "A 42-year-old man presents with several months of pruritic, erythematous, flaky patches on his scalp and nasolabial folds. Physical examination reveals greasy scales and mild erythema in affected areas. He is prescribed a topical corticosteroid, resulting in marked improvement of symptoms within two weeks. This medication's therapeutic benefit in his skin condition is partly due to suppression of an enzyme pathway involved in the synthesis of pro-inflammatory mediators from arachidonic acid. Which enzyme inhibition most directly contributes to the drug's anti-inflammatory effect in this scenario?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Seborrheic dermatitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0036508",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0700603",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lipoxygenase inhibition",
      "reasoning_path": "Seborrheic dermatitis → topical corticosteroid (betamethasone) → inhibition of lipoxygenase → reduced leukotriene synthesis → decreased inflammation → symptom improvement.",
      "umls_path": [
        "Seborrheic dermatitis",
        "may_be_treated_by",
        "Betamethasone sodium phosphate",
        "has_mechanism_of_action",
        "Lipoxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Topical corticosteroids such as betamethasone sodium phosphate are standard treatments for inflammatory skin disorders, including seborrheic dermatitis. Their mechanism of action involves broad immunosuppressive and anti-inflammatory effects. At the molecular level, glucocorticoids inhibit phospholipase A2, reducing arachidonic acid release, and also decrease transcription of genes encoding enzymes such as cyclooxygenase and lipoxygenase. Inhibition of lipoxygenase decreases leukotriene synthesis, thereby reducing leukocyte recruitment and cutaneous inflammation. In seborrheic dermatitis, this limits the inflammatory response to Malassezia species and other triggers, alleviating erythema, scaling, and pruritus. While corticosteroids affect multiple inflammatory pathways, suppression of lipoxygenase-mediated leukotriene production is a key contributor to symptom control in this setting.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_9c06758fa458",
      "question": "In a patient with NSCLC and limited distant metastases (oligometastatic disease), should local ablative therapy be prioritized over immediate initiation of systemic therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "For NSCLC patients with oligometastatic disease, local ablative therapy, such as surgery or stereotactic body radiotherapy, can be prioritized if the disease is limited and technically accessible, as evidence supports its potential for prolonged survival. However, immediate systemic therapy remains the mainstay for patients with higher metastatic burden or unfavorable clinical features.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_9741a4251228",
      "question": "In a patient with advanced or metastatic non-small cell lung cancer (NSCLC), histologically confirmed as adenocarcinoma and harboring an NTRK1 gene fusion detected before any systemic therapy, is it necessary to confirm EGFR mutation, ALK rearrangement, or PD-L1 status before initiating first-line NTRK inhibitor therapy such as larotrectinib or entrectinib?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "NTRK1/2/3 gene fusion positive",
              "NTRK1/2/3 gene fusion",
              "NTRK1/2/3 gene fusion discovered prior to first-line systemic therapy",
              "Preferred: Larotrectinibrr or Entrectinibrr or Repotrectinibrr",
              "Progression",
              "Repotrectinib (if not previously given) or Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
              "Progression",
              "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
            ]
          }
        }
      ],
      "answer": "No, the identification of an NTRK1 gene fusion prior to first-line treatment is a sufficient molecular indication to initiate first-line NTRK inhibitor therapy, such as larotrectinib or entrectinib, regardless of EGFR mutation, ALK rearrangement, or PD-L1 status. Additional biomarker results are not required to proceed with these targeted agents.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_9b9aa6dbd314",
      "question": "In a premenopausal woman diagnosed with invasive, ER-positive, HER2-negative, pT2N0 ductal breast carcinoma greater than 0.5 cm, if the 21-gene recurrence score is 16–25, is adjuvant chemotherapy always mandatory, or could endocrine therapy alone be an appropriate alternative in specific scenarios?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
              "ER-positive and/or PR-positive",
              "HER2-negative",
              "Premenopausal",
              "pT1-3 AND pN0",
              "Ductal/NST, Lobular, Mixed, Micropapillary",
              "Tumor >0.5 cm and pN0",
              "Strongly consider 21-gene RT-PCR assay if candidate for chemotherapy (category 1)",
              "Recurrence score 16–25",
              "Adjuvant chemotherapy followed by endocrine therapy ± ovarian suppression/ablation",
              "Follow-Up (BINV-17)"
            ]
          }
        }
      ],
      "answer": "For premenopausal women with ER-positive, HER2-negative, node-negative invasive breast cancer and a 21-gene recurrence score of 16–25, adjuvant chemotherapy followed by endocrine therapy is strongly supported; endocrine therapy alone is generally not considered sufficient due to evidence of chemotherapy benefit within this group.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_7a5dba4ba929",
      "question": "In a patient with localized, invasive, non-metastatic (M0), HR-positive, HER2-positive breast cancer who undergoes preoperative systemic therapy and subsequently achieves a pathological complete response (ypT0N0), is completion of 1 year of HER2-directed therapy with trastuzumab still indicated, or does the absence of residual disease allow omission of targeted therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS not possible",
              "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
              "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
              "HR-positive/ HER2-positive",
              "ypT0N0 or pCR",
              "Endocrine therapy (category 1) + complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1)"
            ]
          }
        }
      ],
      "answer": "Completion of 1 year of HER2-directed therapy with trastuzumab remains indicated, regardless of achieving a pathological complete response (ypT0N0) after preoperative systemic therapy in HR-positive, HER2-positive, non-metastatic breast cancer. The absence of residual disease does not warrant omission of HER2-targeted therapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_282e429da4dd",
      "question": "A 47-year-old man presents with persistent fatigue, pruritus, and episodes of abdominal pain. Laboratory studies reveal leukocytosis with a marked elevation in eosinophil count. Bone marrow biopsy confirms a diagnosis of a myeloproliferative disorder characterized by sustained eosinophilia. After corticosteroids prove insufficient, his hematologist initiates a therapy known to stimulate immune cell activity and enhance the body's defense mechanisms. Through which broad mechanistic class does this treatment primarily exert its therapeutic effects in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Hypereosinophilic syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1540912",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021734",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Biological response modifiers",
      "reasoning_path": "Hypereosinophilic syndrome → insufficient response to corticosteroids → interferon alfa-2a therapy → enhances immune cell function → classified as a biological response modifier.",
      "umls_path": [
        "Hypereosinophilic syndrome",
        "may_be_treated_by",
        "Interferon alfa-2a-containing product",
        "has_mechanism_of_action",
        "Biological Response Modifiers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this scenario, the patient has hypereosinophilic syndrome, a disorder marked by persistent eosinophilia leading to end-organ damage. When standard corticosteroids fail, interferon alfa-2a may be prescribed. This agent is not directly cytotoxic but modulates immune responses by stimulating cytotoxic T lymphocytes, natural killer cells, and enhancing antigen presentation. Such actions help reduce eosinophil counts and mitigate disease manifestations. These effects do not arise from traditional cytotoxicity or immunosuppression, but rather from modifying the host immune environment to counteract pathological processes. Drugs acting mainly by boosting or altering immune function are categorized as biological response modifiers. Thus, interferon alfa-2a's principal mechanism in this context is as a biological response modifier.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_ed506b41ab82",
      "question": "For a patient with stage IB (T2a, N0) non-small cell lung cancer who has undergone surgical resection but with microscopically positive margins (R1), is adjuvant radiation therapy routinely warranted, or can observation alone be considered an appropriate post-operative management option in this scenario?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (T2a, N0); Margins positive (R1, R2)",
              "Resection (preferred) ± systemic therapy or RT",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "In stage IB (T2a, N0) non-small cell lung cancer with R1 margin after surgery, adjuvant radiation therapy is not routinely required; observation alone can be an appropriate option if there is no clinical or radiographic evidence of residual disease, though re-resection may also be considered if feasible.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_4f1e6724e149",
      "question": "A 69-year-old man with a history of hypertension and type 2 diabetes presents to clinic after experiencing several episodes of palpitations and lightheadedness. An ECG confirms atrial fibrillation. After initial management, his cardiologist starts him on an antiarrhythmic agent commonly used for rhythm control in this condition. Upon reviewing the literature, you note that, despite its clinical use, the exact cellular or molecular target responsible for its therapeutic action in atrial fibrillation is not clearly defined. Which best describes the current understanding of this drug’s mechanism-of-action classification in atrial fibrillation?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Atrial fibrillation"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004238",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0012702",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Atrial fibrillation is treated with disopyramide, but the detailed mechanism by which it acts in this arrhythmia is not fully elucidated; thus, its mechanism is classified as unknown cellular or molecular interaction.",
      "umls_path": [
        "Atrial fibrillation",
        "may_be_treated_by",
        "Disopyramide-containing product",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient is treated for atrial fibrillation with an antiarrhythmic agent. While disopyramide is a class Ia antiarrhythmic that blocks sodium channels and has anticholinergic properties, the precise cellular or molecular mechanism by which it produces its antiarrhythmic effects in atrial fibrillation remains unclear. Although its primary pharmacologic action is known, the full pathway and its relevance to the suppression of atrial fibrillation have not been conclusively elucidated. Therefore, in this context, the drug’s mechanism-of-action classification is considered unknown at the precise cellular or molecular level.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_1a4ddef9bd29",
      "question": "In a patient with stage IVA, M1b squamous cell carcinoma of the lung who tests positive for EGFR L861Q mutation and is currently receiving first-line systemic therapy, does the potential addition of maintenance therapy before switching to EGFR TKI suggest that molecular features take precedence over immediate targeted therapy initiation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "EGFR S768I, L861Q, and/or G719X mutation positive",
              "EGFR S768I, L861Q, and/or G719X mutations",
              "EGFR mutation discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by erlotinib or gefitinib or dacomitinib",
              "Progression",
              "Subsequent Therapy (NSCL-23)"
            ]
          }
        }
      ],
      "answer": "Yes. For stage IVA, M1b squamous cell carcinoma with an EGFR L861Q mutation discovered during first-line systemic treatment, completing the planned systemic therapy, including maintenance phase, is prioritized before initiation of targeted therapy with an EGFR TKI. This reflects that treatment sequence and ongoing systemic therapy are given priority, even when actionable mutations are identified mid-course.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_3d3d83c866ba",
      "question": "For a patient with non-small cell lung cancer who presents with separate pulmonary nodules located in the same lobe as the primary tumor (classified as T3, N0–1), is surgical resection still considered the primary treatment option if the patient has normal pulmonary function and no evidence of mediastinal lymph node involvement on FDG-PET/CT?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (peripheral T1abc, N0)",
              "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
              "Surgery after preoperative systemic therapy, if planned",
              "N2",
              "Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E) or Sequential chemotherapy + Consider RT",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "Yes, surgical resection remains the mainstay treatment for non-small cell lung cancer with separate nodules in the same lobe (T3, N0–1) when pulmonary function is adequate and mediastinal lymph nodes are negative, as there is no indication for upstaging or primary non-surgical management in this setting.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_3df1540ad66c",
      "question": "For a patient with non-small cell lung cancer staged as IIIC (T3, N3) who has not previously undergone pulmonary function testing (PFTs) or brain MRI with contrast, can systemic therapy initiation proceed before performing these assessments, or are these tests required prerequisites that should be completed first?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 0–2",
              "Limited progression confirmed",
              "Other site",
              "Treatment of Thoracic Disease (NSCL-16)"
            ]
          }
        }
      ],
      "answer": "Pulmonary function testing and brain MRI with contrast are required prerequisites prior to initiating systemic therapy in newly identified stage IIIC (T3, N3) non-small cell lung cancer, as they provide essential information for treatment planning and exclusion of occult brain metastases or pulmonary contraindications.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_0f4b291d019c",
      "question": "A chest CT reveals multiple subsolid pulmonary nodules, with the most suspicious nodule measuring precisely 6 mm in greatest diameter. Is an initial follow-up CT scan at 3–6 months still indicated, or does the 6 mm threshold represent an exclusion for this surveillance strategy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Incidental finding of nodule suspicious for lung cancer",
              "Multidisciplinary evaluation, Smoking cessation counseling",
              "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
              "Subsolid nodules Follow-up (DIAG-3)",
              "Incidental finding: subsolid nodule(s) on chest CT",
              "Multiple subsolid nodules",
              "≥6 mm • CT at 3–6 mo • Subsequent management based on most suspicious nodule(s)"
            ]
          }
        }
      ],
      "answer": "An initial follow-up CT scan at 3–6 months is still indicated when the most suspicious subsolid pulmonary nodule measures exactly 6 mm. The ≥6 mm threshold includes nodules that are precisely 6 mm, not excluding them from recommended surveillance.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_a5ab20304cc8",
      "question": "A 27-year-old woman presents with chronic diarrhea, weight loss, and iron deficiency anemia. Laboratory studies reveal positive anti-tissue transglutaminase antibodies, and a duodenal biopsy shows villous atrophy and crypt hyperplasia. She is diagnosed with an immune-mediated enteropathy and started on a gluten-free diet. To address ongoing fat malabsorption, her clinician prescribes a nutritional supplement composed of triglycerides that bypass conventional lymphatic absorption and are instead directly transported via the portal circulation. Which class of molecular targets is most directly involved in facilitating intestinal absorption of this supplement, thereby supporting her nutritional status?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Celiac disease"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0007570",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0724624",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Structural macromolecules (cellular membrane components of enterocytes)",
      "reasoning_path": "Celiac disease causes villous atrophy and fat malabsorption; medium chain triglycerides are absorbed directly across enterocyte membranes, relying on structural macromolecules for uptake.",
      "umls_path": [
        "Celiac disease",
        "may_be_treated_by",
        "Medium chain triglyceride-containing product",
        "has_mechanism_of_action",
        "Structural Macromolecules"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In celiac disease, immune-mediated damage to the small intestinal mucosa leads to villous atrophy and impaired absorption of nutrients, especially fats. Standard dietary fats, composed of long-chain triglycerides, require emulsification and micelle formation for absorption, processes that are compromised when villi are damaged. Medium chain triglycerides (MCTs), in contrast, are more water-soluble and can be absorbed directly by the enterocytes without the need for bile salts or micellar packaging. This direct absorption is facilitated by the structural macromolecules of the enterocyte membrane, allowing MCTs to enter the portal vein and reach the liver rapidly. Therefore, the therapeutic effect of MCT supplementation in patients with malabsorptive states like celiac disease is primarily mediated by interaction with and passage through the structural macromolecules (e.g., lipid bilayer components) of intestinal epithelial cells, rather than by engagement with protein receptors or enzymes.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_64be1844365e",
      "question": "For a patient with advanced or metastatic non-small cell lung cancer (NSCLC) who has histologically confirmed adenocarcinoma and is found to be ALK rearrangement positive on broad molecular profiling, does the selection of an ALK inhibitor as first-line systemic therapy presuppose negative results for other actionable driver mutations such as EGFR or ROS1?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "ALK rearrangement positive"
            ]
          }
        }
      ],
      "answer": "Yes; the initiation of ALK inhibitor therapy in advanced or metastatic NSCLC with an ALK rearrangement is predicated on the absence of other mutually exclusive driver mutations such as EGFR or ROS1, as concurrent actionable alterations are exceedingly rare and may alter targeted therapy selection.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_b99e8d4aeed4",
      "question": "A 29-year-old woman with a longstanding history of excessive daytime sleepiness presents for evaluation of sudden episodes of muscle weakness precipitated by laughter and surprise. She describes these events as brief and reversible, with full awareness throughout. Her physician prescribes a central nervous system depressant that is known to reduce these episodes by enhancing inhibitory neurotransmission within the brain. Which receptor does this medication primarily target to alleviate her symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Cataplexy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0007384",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0000503",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "GABA B receptor",
      "reasoning_path": "Cataplexy is treated with sodium oxybate, which acts as a GABA B receptor agonist, enhancing inhibitory neurotransmission to reduce muscle weakness episodes.",
      "umls_path": [
        "Cataplexy",
        "may_be_treated_by",
        "4-hydroxybutyrate",
        "has_mechanism_of_action",
        "GABA B Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is experiencing cataplexy, a hallmark symptom of narcolepsy characterized by sudden, transient episodes of muscle weakness triggered by strong emotions. The most effective pharmacotherapy for cataplexy is sodium oxybate (gamma-hydroxybutyrate, GHB), which is a central nervous system depressant. Sodium oxybate acts primarily as an agonist at the GABA B receptor, a metabotropic receptor that mediates inhibitory neurotransmission in the CNS. By activating GABA B receptors, sodium oxybate increases neuronal inhibition, which helps stabilize the abnormal neuronal excitability underlying cataplexy and reduces the frequency and severity of these episodes. Although GABA A receptors are also involved in CNS inhibition, sodium oxybate’s therapeutic effect in cataplexy is primarily mediated through GABA B receptor agonism, not GABA A receptors or other neurotransmitter systems. Thus, the molecular basis for sodium oxybate’s effect in cataplexy is its action at GABA B receptors.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_5aff1bda8d18",
      "question": "In patients with stage I–II non-small cell lung cancer who have undergone primary treatment including surgical resection with positive margins (R1 or R2), does the surveillance protocol involving H&P and chest CT every 6 months for 2–3 years, followed by annual low-dose chest CT, also apply to those who received adjuvant radiotherapy after surgery?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (T2a, N0); Margins positive (R1, R2)",
              "Resection (preferred) ± systemic therapy or RT",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, the described surveillance protocol applies to stage I–II patients treated with surgery, regardless of whether adjuvant radiotherapy was administered postoperatively; the imaging intervals do not change due to the addition of radiotherapy in this context.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_03e2a83eeab3",
      "question": "A 54-year-old woman presents with multiple rough, scaly patches on the backs of her hands and forearms that have gradually increased in size over the past year. She has a history of outdoor work and significant sun exposure. After diagnosis, her dermatologist prescribes a topical agent known to modulate cellular proliferation by inhibiting a receptor tyrosine kinase involved in keratinocyte growth signaling. Which molecular receptor is most directly targeted by this therapy, mediating its effectiveness in treating her skin lesions?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Keratosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0022593",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0733397",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Insulin-Like Growth Factor 1 Receptor (IGF-1R)",
      "reasoning_path": "Actinic keratosis involves dysregulated keratinocyte proliferation. Masoprocol is used topically for this indication and exerts its effect by inhibiting IGF-1R, reducing aberrant cell growth and promoting lesion resolution.",
      "umls_path": [
        "Keratosis",
        "may_be_treated_by",
        "Masoprocol-containing product",
        "has_target",
        "Insulin-Like Growth Factor 1 Receptor"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "The patient’s presentation is consistent with actinic (solar) keratosis, a precancerous skin lesion associated with chronic UV exposure. Masoprocol (nordihydroguaiaretic acid) is a topical agent sometimes used to treat hyperproliferative skin disorders, including keratosis. Its mechanism involves inhibition of the insulin-like growth factor 1 receptor (IGF-1R), a receptor tyrosine kinase that mediates keratinocyte proliferation and survival. By blocking IGF-1R signaling, masoprocol reduces keratinocyte growth and encourages lesion regression. Thus, the therapeutic effect of masoprocol in this context depends on modulation of IGF-1R, which is critical for the abnormal cellular proliferation seen in keratosis.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_1610ce1d83b9",
      "question": "A 21-year-old woman diagnosed with cystic fibrosis has recently started a combination modulator therapy that includes a novel agent to improve CFTR protein function. At her follow-up visit, she reports starting a new medication for depression. Before co-prescribing, her clinician reviews potential drug interactions, noting that the cystic fibrosis therapy is metabolized by a specific hepatic enzyme involved in phase I drug metabolism. Which class of enzyme inhibitors should the clinician be especially cautious about to avoid altered plasma concentrations of the CFTR modulator?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Cystic Fibrosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0010674",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C5139717",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cytochrome P450 2D6 inhibitors",
      "reasoning_path": "Cystic fibrosis is treated with CFTR modulators like elexacaftor, which are metabolized by CYP2D6; co-administration of CYP2D6 inhibitors can elevate drug levels and risk toxicity.",
      "umls_path": [
        "Cystic Fibrosis",
        "may_be_treated_by",
        "Elexacaftor",
        "has_mechanism_of_action",
        "Cytochrome P450 2D6 Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "CFTR modulator therapies, such as those containing elexacaftor, are increasingly used in patients with cystic fibrosis to enhance the function of defective CFTR proteins. These agents are metabolized primarily by hepatic cytochrome P450 enzymes, notably CYP2D6. When CYP2D6 inhibitors (such as certain selective serotonin reuptake inhibitors or antipsychotics) are co-administered, they can inhibit the metabolism of the CFTR modulator. This inhibition may lead to increased plasma concentrations of the drug, thereby raising the risk of dose-related adverse effects or toxicity. Clinicians must therefore assess all concomitant medications for CYP2D6 inhibitory potential before initiating therapy. Understanding this mechanistic pathway is crucial for preventing harmful drug interactions and optimizing therapeutic efficacy in patients with cystic fibrosis.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_109711721613",
      "question": "A 45-year-old woman presents with chronic, pruritic, erythematous plaques on the dorsal aspects of her hands. She has tried emollients with limited relief. Her dermatologist prescribes a topical medication known to reduce inflammation by interfering with the synthesis of inflammatory mediators derived from arachidonic acid. Which pharmacological class is directly responsible for decreasing leukotriene-mediated inflammation in this treatment?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Dermatoses, Hand"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0018567",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0055900",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lipoxygenase inhibitors",
      "reasoning_path": "Chronic hand dermatitis is treated with topical corticosteroids; certain agents (e.g., clocortolone pivalate) inhibit lipoxygenase, reducing leukotriene synthesis and inflammation.",
      "umls_path": [
        "Dermatoses, Hand",
        "may_be_treated_by",
        "Clocortolone pivalate",
        "has_mechanism_of_action",
        "Lipoxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this scenario, the patient is experiencing chronic hand dermatitis, which is commonly treated with topical corticosteroids. The anti-inflammatory effects of corticosteroids are multifaceted, but one key mechanism involves the inhibition of enzymes responsible for producing inflammatory mediators. Specifically, corticosteroids induce the synthesis of lipocortin, which in turn inhibits phospholipase A2, thereby reducing arachidonic acid availability. Some corticosteroids, such as clocortolone pivalate, also exhibit activity that inhibits the lipoxygenase pathway. Lipoxygenase is the enzyme responsible for converting arachidonic acid into leukotrienes, potent mediators of inflammation. By inhibiting lipoxygenase, these agents reduce leukotriene synthesis, thereby decreasing leukotriene-mediated inflammatory responses in the skin and providing symptomatic relief. Thus, the pharmacological class responsible for this action is lipoxygenase inhibitors.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_fd8ee4d2a0e2",
      "question": "In a patient with squamous cell carcinoma of the lung, advanced stage with distant metastases, and molecular testing identifying an EGFR exon 20 insertion mutation, should targeted therapy be prioritized over standard platinum-based chemotherapy as first-line systemic treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "EGFR exon 20 insertion mutation positive"
            ]
          }
        }
      ],
      "answer": "In cases of advanced squamous cell lung carcinoma with an identified EGFR exon 20 insertion mutation, targeted therapies specifically developed for this genetic alteration—such as amivantamab or mobocertinib—are recommended as first-line options if available, instead of standard platinum-based chemotherapy, due to improved efficacy in this molecularly defined subgroup.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_d7a74f85db42",
      "question": "A 41-year-old woman presents with progressive shortness of breath and fatigue over several months. She has no significant cardiac history but is found to have elevated right ventricular systolic pressure and signs of right heart strain on echocardiogram. Right heart catheterization confirms a diagnosis of pulmonary arterial hypertension (PAH). She is enrolled in a clinical trial for a new biologic agent that binds a receptor in the TGF-β superfamily, inhibiting its signaling and thereby decreasing abnormal proliferation and remodeling of pulmonary vasculature. Which receptor is the primary molecular target of this therapy, mediating its beneficial effects in PAH?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Pulmonary Arterial Hypertension"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2973725",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2699571",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Activin Receptor Type-2A (ACVR2A)",
      "reasoning_path": "Pulmonary arterial hypertension features dysregulated TGF-β signaling → Sotatercept binds and inhibits Activin Receptor Type-2A (ACVR2A) → Decreased pro-proliferative/fibrotic activity in pulmonary vessels → Reduced vascular remodeling and improved PAH.",
      "umls_path": [
        "Pulmonary Arterial Hypertension",
        "may_be_treated_by",
        "sotatercept",
        "has_target",
        "Activin Receptor Type-2A"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "The patient has pulmonary arterial hypertension, a disease characterized by progressive narrowing and remodeling of pulmonary arterioles, often due to dysregulated signaling in pathways that govern vascular cell proliferation and fibrosis. One key pathway implicated is the TGF-β (transforming growth factor-beta) superfamily, which includes activins and bone morphogenetic proteins (BMPs). Sotatercept, a novel therapy, acts as a ligand trap for select TGF-β superfamily ligands by binding to Activin Receptor Type-2A (ACVR2A). This receptor is a serine/threonine kinase that, when activated by its ligands, promotes pro-proliferative and pro-fibrotic signaling in pulmonary vascular cells. By sequestering these ligands and inhibiting ACVR2A activation, sotatercept reduces pathological remodeling and helps restore normal vascular function, improving symptoms and outcomes in PAH.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_abba6477dcfb",
      "question": "A 34-year-old woman with relapsed B-cell acute lymphoblastic leukemia receives chimeric antigen receptor (CAR) T-cell therapy. Within 48 hours, she develops high fever, hypotension, and tachycardia. Laboratory studies reveal markedly elevated C-reactive protein and ferritin, consistent with a severe systemic inflammatory response. She is treated with an intravenous monoclonal antibody that binds a specific cytokine receptor, thereby inhibiting downstream pro-inflammatory signaling. Which molecular target is directly antagonized by this therapy to control her acute symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "cytokine release syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0948245",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1609165",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Soluble interleukin-6 receptor subunit alpha (IL-6Rα)",
      "reasoning_path": "CAR T-cell therapy triggers CRS, driven by IL-6; tocilizumab binds and inhibits IL-6Rα, blocking IL-6 signaling and reducing inflammation.",
      "umls_path": [
        "cytokine release syndrome",
        "may_be_treated_by",
        "Tocilizumab-containing product",
        "has_target",
        "Soluble Interleukin-6 Receptor Subunit Alpha"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient is experiencing cytokine release syndrome (CRS), a common and potentially life-threatening complication after CAR T-cell therapy, characterized by excessive immune activation and systemic inflammation. Interleukin-6 (IL-6) is a key cytokine implicated in the pathogenesis of CRS, mediating fever, vascular permeability, and organ dysfunction. Tocilizumab is a monoclonal antibody used as first-line therapy for severe CRS. It works by binding specifically to both membrane-bound and soluble forms of the interleukin-6 receptor alpha subunit (IL-6Rα), preventing IL-6 from engaging its receptor and activating downstream JAK/STAT signaling pathways. This blockade rapidly reduces the inflammatory cascade, alleviating symptoms such as fever and hypotension. Thus, the therapeutic effect in CRS is achieved through direct antagonism of the soluble interleukin-6 receptor subunit alpha.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_0138e267ce65",
      "question": "A 54-year-old woman with poorly controlled diabetes presents with fever, malaise, and a painful, fluctuant swelling in her left thigh. Imaging reveals a deep soft tissue abscess. She is started on broad-spectrum antibiotics including a drug commonly used against anaerobic bacteria and protozoa. This agent is known to be activated by microbial nitroreductases, generating reactive intermediates that cause nonspecific damage to microbial DNA and proteins. However, in the context of complex abscess environments, the exact molecular or cellular interactions responsible for its effectiveness remain incompletely understood. Based on this information, what best describes the documented mechanism by which this agent acts in deep tissue abscesses?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Abscess"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0000833",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0282239",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "A patient with a deep abscess is treated with metronidazole, which is activated by microbial nitroreductases but its exact molecular action in this context is not fully elucidated; thus, the mechanism remains unknown.",
      "umls_path": [
        "Abscess",
        "may_be_treated_by",
        "Metronidazole hydrochloride",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Metronidazole is commonly prescribed for anaerobic infections, including deep soft tissue abscesses. Its classic mechanism involves reduction of its nitro group by microbial enzymes, leading to the production of reactive intermediates that disrupt DNA synthesis and protein structure in susceptible organisms. However, the specific molecular or cellular targets of metronidazole within the polymicrobial and hypoxic environment of deep abscesses are not fully defined. Variability in microbial populations, oxygen levels, and host factors may alter drug activation and efficacy, making the precise mechanism of action in this clinical setting uncertain. Thus, while metronidazole is clinically effective, its detailed mechanism in deep tissue abscesses is still characterized as unknown or incompletely understood.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_4a6db382bfae",
      "question": "For a patient with invasive, non-inflammatory, non-metastatic (M0) breast cancer who has a tumor size of 0.4 cm, is ER-positive and/or PR-positive but HER2-positive, does the option of adjuvant chemotherapy with trastuzumab and endocrine therapy still apply, or is it limited only to larger tumors?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
              "ER-positive and/or PR-positive",
              "HER2-positive",
              "BINV-5",
              "Ductal/NST • Lobular • Mixed • Micropapillary",
              "pT1, pT2, or pT3; and pN0 or pNmi (≤2 mm axillary node metastasis)",
              "Tumor ≤0.5 cm",
              "pN0",
              "Consider adjuvant endocrine therapy or Consider adjuvant chemotherapy with trastuzumab (category 2B) and endocrine therapy",
              "Follow-Up (BINV-17)"
            ]
          }
        }
      ],
      "answer": "Adjuvant chemotherapy with trastuzumab and endocrine therapy may be considered even for tumors ≤0.5 cm if they are HER2-positive, although the decision is category 2B. Therefore, the option is not limited only to larger tumors but reflects a lower level of consensus for very small tumors.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_d1acda9781fb",
      "question": "In the OpenTargets database, what are the associations between the target symbol HRH1 and the event allergic responses of flare, flush and wheal?",
      "tool_calls": [
        {
          "tool": "opentargets.safety",
          "params": {
            "symbol": "HRH1",
            "event": "allergic responses of flare, flush and wheal"
          }
        }
      ],
      "answer": {
        "biosamples": [
          {
            "tissueLabel": "cardiovascular system",
            "tissueId": "UBERON_0004535"
          },
          {
            "tissueLabel": "immune",
            "tissueId": "UBERON_0002405"
          }
        ],
        "effects": [
          {
            "dosing": "general",
            "direction": "Activation/Increase/Upregulation"
          }
        ]
      },
      "type": "retrieval"
    },
    {
      "id": "kg_67c891671fa0",
      "question": "A 6-year-old child presents with profuse watery diarrhea and abdominal cramps after returning from a camping trip. Stool testing confirms infection with an intracellular protozoan that inhabits the small intestinal epithelium. The patient is started on a medication that blocks the parasite’s ATP synthesis by interfering with the mitochondrial electron transport chain, ultimately leading to energy depletion and parasite death. Which class of agents best describes the molecular action of the prescribed medication?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Infection by Cryptosporidium"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0010418",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0068788",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Uncouplers",
      "reasoning_path": "Cryptosporidium infection is treated with nitazoxanide, whose antiparasitic effect stems from uncoupling the protozoan’s mitochondrial oxidative phosphorylation, thereby disrupting ATP synthesis and leading to parasite death.",
      "umls_path": [
        "Infection by Cryptosporidium",
        "may_be_treated_by",
        "Nitazoxanide",
        "has_mechanism_of_action",
        "Uncouplers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Nitazoxanide is commonly used to treat infections caused by Cryptosporidium, a protozoan that disrupts gastrointestinal function. The drug’s antiparasitic efficacy is due to its ability to interfere with the parasite’s mitochondria, specifically by uncoupling oxidative phosphorylation. This means that nitazoxanide disrupts the normal proton gradient across the mitochondrial membrane, which is essential for ATP synthesis. Without efficient ATP production, the parasite cannot sustain vital energy-dependent processes, leading to its elimination. This mechanism is distinct from typical antibiotics or antiprotozoals that target DNA or protein synthesis, and instead exploits a fundamental vulnerability in protozoan energy metabolism. Thus, the therapeutic effect of nitazoxanide in Cryptosporidium infection is best explained by its function as an uncoupler of oxidative phosphorylation, resulting in mitochondrial dysfunction and parasite death.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_f6818e40ebe9",
      "question": "In a patient with advanced non-squamous non-small cell lung cancer harboring an EGFR exon 19 deletion who develops disease progression after completing first-line systemic therapy, does the recommendation to administer osimertinib as subsequent therapy depend on prior exposure to EGFR tyrosine kinase inhibitors?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "EGFR exon 19 deletion or exon 21 L858R mutation positive",
              "EGFR exon 19 deletion or exon 21 L858R mutations",
              "EGFR mutation discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by osimertinib (preferred) or amivantamab-vmjw + lazertinib",
              "Progression: Subsequent Therapy (NSCL-22)"
            ]
          }
        }
      ],
      "answer": "Yes, the use of osimertinib as subsequent therapy is specifically intended for patients with EGFR exon 19 deletion or exon 21 L858R mutations who either complete or interrupt EGFR TKI-based first-line treatment and then progress. If no prior EGFR TKI treatment was given, osimertinib would be indicated as frontline therapy rather than as subsequent treatment.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_fd429df346ae",
      "question": "In ClinicalTrials.gov, what interventional studies for metastatic colorectal cancer with panitumumab and FOLFIRI started in June 2006?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "conditions=Metastatic Colorectal Cancer;interventions.name=Panitumumab;interventions.name=FOLFIRI;startDateFrom=2006-06-01",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00339183"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_f962dc515ac3",
      "question": "For a patient with stage IIB (T3, N0) non-small cell lung cancer who underwent surgical resection with positive margins (R2 resection), is it clinically appropriate to proceed directly to surveillance without additional systemic therapy or concurrent chemoradiation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
              "R2; Resection + systemic therapy or Concurrent chemoradiation",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, proceeding directly to surveillance is not clinically appropriate for stage IIB (T3, N0) non-small cell lung cancer with R2 resection. Incomplete resection (R2) requires additional systemic therapy and/or concurrent chemoradiation to address residual disease before initiating routine surveillance.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_5968928944de",
      "question": "In a patient with stage IIIB non-small cell lung cancer presenting with T3N2 disease, is the evaluation for perioperative therapy contingent upon confirmation that there are no distant metastases on FDG-PET/CT and brain MRI with contrast?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Distant metastases",
              "Bone metastases",
              "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes, perioperative therapy evaluation in stage IIIB (T3N2) non-small cell lung cancer presumes the absence of distant metastases, as confirmed by FDG-PET/CT and brain MRI with contrast. Presence of metastases would shift management to systemic or palliative therapies rather than perioperative interventions.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_72985c0e6c7e",
      "question": "A 7-year-old child presents to the clinic with complaints of perianal itching and restlessness at night. On examination, the pediatrician suspects a common intestinal nematode infection and prescribes an oral medication known to paralyze the worms, facilitating their expulsion in the stool. This drug achieves its effect by enhancing inhibitory chloride currents at ligand-gated ion channels found on the parasite's neuromuscular junctions, leading to flaccid paralysis. Which class of molecular targets is responsible for mediating this pharmacologic action in the nematode?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Infection caused by Nematoda"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0027583",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0137095",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "GABA A receptors (ligand-gated chloride channels)",
      "reasoning_path": "Nematode infection → piperazine administration → GABA A receptor agonism in worm muscle → chloride influx → hyperpolarization and paralysis → expulsion from host.",
      "umls_path": [
        "Infection caused by Nematoda",
        "may_be_treated_by",
        "Piperazine phosphate",
        "has_mechanism_of_action",
        "GABA A Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The scenario involves a suspected nematode (likely Enterobius vermicularis) infection, commonly treated with anthelmintics such as piperazine. Piperazine works by mimicking the action of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in nematodes. It acts as an agonist at GABA A receptors—ligand-gated chloride channels—located on the muscle cells of the worms. Activation of these receptors increases chloride influx, hyperpolarizes the cell membrane, and inhibits depolarization, leading to neuromuscular blockade and flaccid paralysis. The immobilized worms are then expelled via peristalsis. Importantly, this mechanism targets GABA A receptors in nematodes, as GABAergic transmission is not the primary inhibitory pathway in human somatic neuromuscular junctions, conferring selectivity and safety of the drug. Thus, the primary molecular targets responsible for this therapeutic effect are nematode GABA A receptors.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_ad4f99c4b28f",
      "question": "In ClinicalTrials.gov, which interventional studies for Melanoma with ipilimumab as the main intervention started in April 2006 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "conditions=Melanoma;interventions.name=ipilimumab;startDateFrom=2006-04-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00289640"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_969fe32d02eb",
      "question": "A 42-year-old woman with a history of recurrent oral thrush and persistent erythematous rashes on her trunk and extremities is diagnosed with chronic mucocutaneous candidiasis. She is started on an oral antifungal agent that specifically targets fungal cell membrane synthesis by inhibiting a key enzyme in sterol biosynthesis. After several weeks, her symptoms improve. Which molecular pathway is directly inhibited by this medication to achieve its antifungal effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Chronic Mucocutaneous Candidiasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0006845",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0076110",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Inhibition of ergosterol synthesis via blockade of squalene epoxidase",
      "reasoning_path": "Patient with chronic mucocutaneous candidiasis → treated with terbinafine → terbinafine inhibits squalene epoxidase → blocks ergosterol synthesis → disrupts fungal cell membranes → antifungal effect.",
      "umls_path": [
        "Chronic Mucocutaneous Candidiasis",
        "may_be_treated_by",
        "Terbinafine",
        "has_mechanism_of_action",
        "Ergosterol Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Chronic mucocutaneous candidiasis is a persistent fungal infection that often requires systemic antifungal therapy. Terbinafine is an allylamine antifungal agent frequently used in this context. Its primary mechanism involves inhibition of the fungal enzyme squalene epoxidase, a critical step in the biosynthetic pathway that produces ergosterol—a major structural component of fungal cell membranes. By blocking squalene epoxidase, terbinafine leads to ergosterol depletion, destabilizing the fungal cell membrane and causing cell death. This mechanism is distinct from that of azole antifungals, which inhibit a later step in ergosterol synthesis. Human cells use cholesterol, not ergosterol, so selective toxicity is achieved. Thus, the therapeutic effect of terbinafine in treating chronic mucocutaneous candidiasis relies directly on its inhibition of ergosterol synthesis.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_0aa32e8bfb4a",
      "question": "A 55-year-old woman presents with a six-month history of burning, gritty sensation in both eyes, which worsens throughout the day. She works in an air-conditioned office and reports frequent use of digital devices. On examination, her conjunctivae are mildly injected, and tear breakup time is reduced. She is prescribed an ophthalmic solution containing a high-molecular-weight cellulose derivative. This agent provides symptomatic relief by forming a viscous, protective film over the ocular surface. Through which principal pharmacological property does this agent alleviate her symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Dry Eye Syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0013238",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3538037",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Demulcent activity",
      "reasoning_path": "Dry eye syndrome causes ocular irritation; carboxymethylcellulose sodium is prescribed; its demulcent activity forms a protective film that soothes and shields the ocular surface, relieving symptoms.",
      "umls_path": [
        "Dry Eye Syndrome",
        "may_be_treated_by",
        "CARBOXYMETHYLCELLULOSE SODIUM (0.7 CARBOXYMETHYL SUBSTITUTION PER SACCHARIDE; 100-200 MPA.S AT 1%)",
        "has_mechanism_of_action",
        "Demulcent Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient's clinical features are consistent with dry eye syndrome, a condition characterized by insufficient tear production or increased tear evaporation, leading to ocular surface irritation. The topical agent prescribed—containing carboxymethylcellulose sodium—is a high-molecular-weight cellulose derivative commonly used in artificial tears. Its primary mechanism is demulcent activity: it coats the ocular surface, forming a lubricating and protective film that mimics natural tears. This film reduces friction between the eyelids and the cornea, soothes irritated tissues, and decreases evaporation, thereby relieving discomfort, burning, and foreign body sensation. Demulcents do not address the underlying inflammatory or secretory abnormalities, but are essential for symptomatic management. Other pharmacological options for dry eye (e.g., cyclosporine) target inflammation, but carboxymethylcellulose sodium works mainly through its physical, soothing, and protective properties as a demulcent.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_14ca8403551f",
      "question": "A 42-year-old woman presents with dysuria, urinary frequency, and suprapubic tenderness. Urinalysis reveals leukocyte esterase and nitrites; urine culture grows Proteus mirabilis. She is prescribed a parenteral agent that acts by covalently binding to bacterial transpeptidases, thereby preventing peptidoglycan cross-linking in the cell wall. What is the general pharmacological class that describes this agent's mechanism of action against the pathogen?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Proteus infection"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0033700",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0700471",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme Inhibitors",
      "reasoning_path": "Proteus UTI → cefotetan disodium prescribed → cephalosporin mechanism → inhibits PBPs (bacterial enzymes) → disrupts cell wall synthesis → classified as enzyme inhibitor.",
      "umls_path": [
        "Proteus infection",
        "may_be_treated_by",
        "Cefotetan Disodium",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has a urinary tract infection due to Proteus mirabilis, a Gram-negative rod. The prescribed drug, cefotetan disodium, is a second-generation cephalosporin. Cephalosporins act by irreversibly inhibiting penicillin-binding proteins (PBPs), which are essential bacterial enzymes (transpeptidases) involved in the final step of peptidoglycan cross-linking for cell wall synthesis. By inhibiting these key enzymes, cefotetan disrupts cell wall integrity, leading to cell lysis and bacterial death (bactericidal activity). The broad pharmacological class for such agents is 'enzyme inhibitors,' as their primary mechanism is the inhibition of bacterial enzymes critical for cell wall construction. This mechanism makes cephalosporins effective against many Gram-negative bacteria, including Proteus species, which are often resistant to other antibiotics. Thus, the therapeutic effect in this case is mediated by enzyme inhibition.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_70dc47429727",
      "question": "In a patient with advanced non-small cell lung cancer (NSCLC) of adenocarcinoma histology, who is confirmed to have an NTRK1 gene fusion and high PD-L1 expression (≥50%), which first-line systemic treatment should be prioritized: a selective TRK inhibitor or PD-1/PD-L1 immune checkpoint inhibitor monotherapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Disseminated metastases",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "NTRK1/2/3 gene fusion positive"
            ]
          }
        }
      ],
      "answer": "For advanced NSCLC with a confirmed NTRK1 fusion, first-line therapy should prioritize a selective TRK inhibitor, as targeted therapy demonstrates higher efficacy and response rates in oncogene-driven tumors. High PD-L1 expression does not supersede guideline-first targeted therapy when actionable oncogenic drivers are present.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_ad3a5b59d65b",
      "question": "In ClinicalTrials.gov, which completed interventional studies for Non-Hodgkins Lymphoma involving Lenalidomide started in August 2005 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "overallStatus=COMPLETED;conditions=Non-Hodgkins Lymphoma;interventions.name=Lenalidomide;startDateFrom=2005-08-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00179660"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_23e77e19ccd8",
      "question": "A 58-year-old man presents with gradual, painless loss of peripheral vision over several months. Ophthalmologic examination reveals cupping of the optic disc and elevated intraocular pressure. The patient is started on eye drops containing a drug that activates a specific G protein-coupled receptor subtype associated with the sympathetic nervous system. This receptor activation leads to increased aqueous humor outflow from the eye. Which receptor class is most directly responsible for the therapeutic effect of this medication in lowering intraocular pressure?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Open-angle glaucoma, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0017612",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0059446",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Adrenergic beta2-agonist",
      "reasoning_path": "Open-angle glaucoma → need to lower IOP → sympathomimetic prescribed → beta2-adrenergic receptor activated → increased aqueous humor outflow → reduced IOP.",
      "umls_path": [
        "Open-angle glaucoma, unspecified",
        "may_be_treated_by",
        "1,2-Benzenediol, 4-(1-hydroxy-2-(methylamino)ethyl)-, mono(hydrogen sulfate) (ester), (R)-",
        "has_mechanism_of_action",
        "Adrenergic beta2-Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In cases of open-angle glaucoma, reducing intraocular pressure (IOP) is crucial to prevent optic nerve damage. Some sympathomimetic drugs—specifically, adrenergic beta2-agonists—achieve this by stimulating beta2-adrenergic receptors present in the ciliary body and trabecular meshwork. Activation of these receptors increases cyclic AMP levels, which in turn enhances aqueous humor outflow via the trabecular and uveoscleral pathways. By facilitating outflow, beta2-agonists directly lower IOP. This mechanism distinguishes them from other classes like alpha2-agonists (which reduce aqueous production) or muscarinic agonists (which also increase outflow, but via a different receptor type). Thus, the primary molecular target responsible for the therapeutic benefit of these sympathomimetic agents in open-angle glaucoma is the beta2-adrenergic receptor.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_5f480efc2e4e",
      "question": "A 55-year-old woman with a 10-year history of poorly controlled type 2 diabetes presents with burning pain and tingling in her feet that worsens at night. Neurological exam reveals decreased pinprick and vibration sensation in a stocking distribution. She is started on a medication that increases her energy and also significantly reduces her neuropathic pain. This medication works by inhibiting the reuptake of certain monoamine neurotransmitters in the central nervous system, thereby enhancing descending pain modulation pathways. Which class of pharmacologic agents best describes the mechanism responsible for her symptom relief?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Diabetic Neuropathy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011882",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1505020",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Serotonin uptake inhibitors",
      "reasoning_path": "Painful diabetic neuropathy is treated with duloxetine, which inhibits serotonin reuptake, thereby boosting descending inhibitory pain pathways and reducing neuropathic pain.",
      "umls_path": [
        "Diabetic Neuropathy",
        "may_be_treated_by",
        "Duloxetine Hydrochloride",
        "has_mechanism_of_action",
        "Serotonin Uptake Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has painful diabetic neuropathy, a common complication of chronic diabetes that manifests as burning, tingling, and sensory loss. Duloxetine, a medication frequently used to treat this condition, is a serotonin-norepinephrine reuptake inhibitor (SNRI). Its analgesic effect in neuropathic pain is primarily due to inhibition of serotonin (and norepinephrine) reuptake in the central nervous system. By blocking serotonin reuptake, duloxetine increases synaptic serotonin levels, which enhances descending inhibitory pathways in the spinal cord that suppress pain transmission. This mechanism is distinct from typical analgesics like NSAIDs or opioids, as it directly modulates neurotransmitter activity involved in pain perception. Therefore, the class ‘serotonin uptake inhibitors’ is most directly responsible for the therapeutic effect in this setting.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_9815aa9eb2c4",
      "question": "In a patient with stage IVA NSCLC of adenocarcinoma subtype, newly identified with an EGFR S768I mutation during ongoing first-line systemic therapy, is it appropriate to transition directly to afatinib or osimertinib without completing the current planned systemic regimen, or is continuation and completion of initial therapy prioritized before introducing EGFR-targeted agents?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "EGFR S768I, L861Q, and/or G719X mutation positive",
              "EGFR S768I, L861Q, and/or G719X mutations",
              "EGFR mutation discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by afatinib (preferred) or osimertinib (preferred) or erlotinib or gefitinib or dacomitinib",
              "Progression",
              "Subsequent Therapy (NSCL-23)"
            ]
          }
        }
      ],
      "answer": "The standard approach is to complete the planned systemic therapy, including maintenance, before initiating afatinib or osimertinib. Immediate switch to EGFR-targeted agents is not prioritized unless interruption of initial therapy is required; thus, completion of initial treatment remains the preferred sequence.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_cd6222b08f96",
      "question": "In ClinicalTrials.gov, what interventional studies for relapsing-remitting multiple sclerosis involving Cladribine 5.25 mg/kg were started in April 2005?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "conditions=Relapsing-Remitting;interventions.name=Cladribine 5.25 mg/kg;startDateFrom=2005-04-01",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00213135"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_4bddcfbe50df",
      "question": "A 9-year-old boy from a rural area presents with several weeks of abdominal pain, diarrhea, and mild growth delay. Stool examination reveals barrel-shaped eggs with bipolar plugs. He is started on an antihelminthic medication that induces spastic paralysis of the parasite by disrupting its ability to relax muscles. Which drug class is responsible for this therapeutic effect, and through what molecular mechanism does it act on the parasite?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Infection by Trichuris trichiura"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0040954",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0034237",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cholinesterase inhibitors—by blocking cholinesterase activity, these agents cause sustained depolarization and paralysis of the helminth's musculature.",
      "reasoning_path": "Trichuris trichiura infection → treated with pyrantel pamoate → inhibits cholinesterase in parasite → sustained acetylcholine at neuromuscular junction → spastic paralysis and expulsion.",
      "umls_path": [
        "Infection by Trichuris trichiura",
        "may_be_treated_by",
        "Pyrantel pamoate",
        "has_mechanism_of_action",
        "Cholinesterase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This child has classic symptoms and diagnostic findings of Trichuris trichiura (whipworm) infection. Effective antihelminthic therapy for Trichuris includes agents that interfere with the parasite's neuromuscular function. Pyrantel pamoate is a commonly used drug in this setting; it acts as a depolarizing neuromuscular blocker by inhibiting cholinesterase activity in the parasite. This results in persistent activation of nicotinic acetylcholine receptors, leading to sustained muscle contraction and subsequent paralysis. The paralyzed helminths are then expelled from the gastrointestinal tract by normal peristalsis. The primary drug class mediating this effect is cholinesterase inhibitors, and the molecular target is the cholinesterase enzyme in the parasite's neuromuscular junction.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_bb0f21f4098c",
      "question": "A 58-year-old man with a history of cirrhosis presents with confusion, asterixis, and lethargy. Laboratory studies reveal elevated serum ammonia. He is started on an oral disaccharide that is not absorbed in the small intestine and reaches the colon, where it is metabolized by gut bacteria into acidic compounds. This process results in increased water retention in the colon and promotes the trapping and excretion of nitrogenous waste. Which pharmacologic property of this medication is primarily responsible for improving his mental status?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Hepatic encephalopathy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0019151",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0022957",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Osmotic activity",
      "reasoning_path": "Liver dysfunction raises systemic ammonia → lactulose is metabolized by gut flora → increased osmotic activity draws water into colon → acidification traps ammonia as NH4+ → increased excretion of ammonia → improved encephalopathy.",
      "umls_path": [
        "Hepatic encephalopathy",
        "may_be_treated_by",
        "Lactulose",
        "has_mechanism_of_action",
        "Osmotic Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Lactulose is a synthetic disaccharide used to treat hepatic encephalopathy, a condition characterized by neuropsychiatric dysfunction due to increased systemic ammonia levels in patients with liver failure. Lactulose is not absorbed in the small intestine; instead, it is metabolized by colonic bacteria into short-chain fatty acids, such as lactic acid and acetic acid, which acidify the colon. This acidification converts ammonia (NH3), a neurotoxin, into ammonium ion (NH4+), which cannot be reabsorbed and is thus excreted in the stool. Additionally, the osmotic activity of lactulose draws water into the colon, increasing stool liquidity and promoting bowel movements, further facilitating the removal of ammonia from the body. Therefore, the osmotic property of lactulose is central to its mechanism in relieving the neurologic symptoms of hepatic encephalopathy by enhancing ammonia excretion.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_e76a13ba1534",
      "question": "A 54-year-old woman with a 10-year history of joint pain and morning stiffness is diagnosed with an exacerbation of chronic inflammatory arthritis. To control her symptoms, her rheumatologist prescribes a medication that acts intracellularly to regulate gene expression involved in immune and inflammatory responses. Which molecular target is responsible for mediating the primary therapeutic effects of this drug in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Rheumatism"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0035435",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020268",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Glucocorticoid receptor",
      "reasoning_path": "Chronic inflammatory arthritis → hydrocortisone prescribed → drug acts via intracellular receptor → binds glucocorticoid receptor → translocates to nucleus → modulates gene transcription → suppresses inflammation.",
      "umls_path": [
        "Rheumatism",
        "may_be_treated_by",
        "Hydrocortisone",
        "has_target",
        "Glucocorticoid Receptor"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Hydrocortisone is a synthetic glucocorticoid commonly used for its anti-inflammatory and immunosuppressive properties in chronic inflammatory diseases such as rheumatoid arthritis. Its therapeutic action is primarily mediated via binding to the glucocorticoid receptor, an intracellular nuclear receptor. Once hydrocortisone binds to this receptor in the cytoplasm, the complex translocates to the nucleus, where it modulates transcription of numerous genes involved in immune and inflammatory pathways. This leads to decreased production of pro-inflammatory cytokines, reduced migration of immune cells to sites of inflammation, and suppression of the overall inflammatory response. The net effect is a reduction in joint swelling, pain, and tissue damage associated with chronic inflammatory arthritis. Other potential targets do not account for the broad anti-inflammatory efficacy of hydrocortisone in this clinical context.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_c08d944f95fb",
      "question": "In a patient with advanced squamous cell carcinoma of the lung and confirmed NTRK1/2/3 gene fusion, is the primary indication for initiating an NTRK-targeted therapy dependent on the absence of other actionable driver mutations such as EGFR, ALK, or ROS1?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Diffuse brain metastases",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "NTRK1/2/3 gene fusion positive"
            ]
          }
        }
      ],
      "answer": "Yes. NTRK inhibitor therapy is indicated for tumors with NTRK fusions, but only when no alternate approved actionable driver mutations (such as EGFR, ALK, or ROS1) are present, as NTRK inhibitors are reserved for cases lacking other targetable alterations with established first-line therapies.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_1c55394e1d93",
      "question": "A 58-year-old man with nonalcoholic fatty liver disease is enrolled in a clinical trial evaluating a new therapy for progressive hepatic fibrosis. This investigational medication selectively activates a nuclear receptor that modulates transcription of metabolic and fibrogenic genes, aiming to reduce hepatic steatosis and fibrotic progression. Which pharmacologic mechanism best describes the action of this agent in targeting liver fibrosis?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Liver Fibrosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0239946",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3850197",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Thyroid hormone receptor agonist activity—selective activation of thyroid hormone receptors",
      "reasoning_path": "Patient with liver fibrosis receives a drug that activates thyroid hormone receptors; this aligns with the mechanism of thyroid hormone receptor agonists.",
      "umls_path": [
        "Liver Fibrosis",
        "may_be_treated_by",
        "Resmetirom",
        "has_mechanism_of_action",
        "Thyroid Hormone Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Nonalcoholic fatty liver disease (NAFLD) and its progression to fibrosis are associated with disordered lipid metabolism and chronic inflammation. Recent therapies in clinical trials, such as resmetirom, target the thyroid hormone receptor (THR), particularly the THR-β isoform in hepatocytes. Agonists of this nuclear receptor increase hepatic fatty acid oxidation and modulate gene expression to decrease steatosis and inhibit fibrogenic pathways. By selectively activating the thyroid hormone receptor, these agents correct metabolic dysfunctions and attenuate fibrosis, which underlies their potential therapeutic role. This mechanism classifies them as thyroid hormone receptor agonists, a pharmacologic class distinct from other agents used in liver disease.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_fadeeb7f992d",
      "question": "In a patient with localized invasive breast cancer who presents with suspicious axillary lymph nodes on imaging, if the initial ultrasound-guided core biopsy of the most suspicious node is negative for malignancy, does the presence of clinical suspicion or imaging abnormality still necessitate axillary lymph node dissection, or is sentinel lymph node mapping and excision alone sufficient?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS possible",
              "BCS with surgical axillary staging (BINV-D) ± oncoplastic reconstruction",
              "Clinically suspicious (palpable) lymph nodes or Significant axillary lymph node disease burden on imaging or Preoperative systemic therapy being considered and suspicious lymph nodes at diagnosis on exam or imaging",
              "US-guided FNA or core biopsy + marker placement recommended in the most suspicious node",
              "FNA or core biopsy negative",
              "SLN mapping and excision",
              "SLN negative",
              "No further axillary surgery (category 1)"
            ]
          }
        }
      ],
      "answer": "If ultrasound-guided core biopsy of the most suspicious axillary node is negative for malignancy, sentinel lymph node (SLN) mapping and excision alone is sufficient; axillary lymph node dissection (ALND) is not indicated, even when clinical or imaging findings are suspicious.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_1d09b9de3281",
      "question": "In patients with non-small cell lung cancer (NSCLC) who have biopsy-proven synchronous lesions suggestive of multiple primary lung cancers and also present with a separate pulmonary nodule in the same lobe (T3, N0–1), should the disease be managed as intrapulmonary metastasis or as synchronous primary tumors, and how does this distinction affect the appropriate therapeutic approach?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Suspected multiple lung cancers (based on the presence of biopsy-proven synchronous lesions or history of lung cancer)",
              "Chest CT with contrast; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Disease outside of chest",
              "Systemic therapy for metastatic disease (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "When biopsy confirms synchronous lesions suggestive of multiple primary lung cancers, the disease should be managed as synchronous primary tumors, not intrapulmonary metastases. This distinction warrants individual staging and potentially curative treatment for each lesion, often favoring surgical resection or combined-modality therapy rather than systemic therapy typically used for metastatic disease.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_ab2d684f3f14",
      "question": "For a patient with stage III non-small cell lung cancer (NSCLC) who received definitive radiotherapy as the primary treatment and now demonstrates no evidence of clinical or radiographic disease, should routine follow-up imaging protocols include FDG-PET/CT scans, or is chest CT with or without contrast sufficient for surveillance in the absence of new symptoms or findings?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Routine follow-up imaging for stage III NSCLC post-definitive radiotherapy without evidence of disease should utilize chest CT with or without contrast, as FDG-PET/CT is not routinely indicated in asymptomatic patients during surveillance. FDG-PET/CT is reserved for patients with recurrence or new symptoms suggestive of disease.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_9a9fc0860f93",
      "question": "In patients with advanced non-small cell lung cancer (NSCLC) who harbor uncommon EGFR mutations such as S768I, L861Q, or G719X and have progressed after completing initial systemic therapy (including maintenance), does the subsequent use of afatinib or osimertinib necessarily imply these patients are negative for concurrent ALK rearrangements?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "EGFR S768I, L861Q, and/or G719X mutation positive",
              "EGFR S768I, L861Q, and/or G719X mutations",
              "EGFR mutation discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by afatinib (preferred) or osimertinib (preferred) or erlotinib or gefitinib or dacomitinib",
              "Progression",
              "Subsequent Therapy (NSCL-23)"
            ]
          }
        }
      ],
      "answer": "Yes, administration of afatinib or osimertinib as subsequent therapy for advanced NSCLC with EGFR S768I, L861Q, or G719X mutations presupposes the absence of concurrent ALK rearrangements, as activating ALK fusions and sensitizing EGFR mutations are generally mutually exclusive, and targeted therapy selection is predicated on the identified driver mutation.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_a05cfc5202d0",
      "question": "In a patient with stage IA peripheral non-small cell lung cancer (T1a-c, N0), if preoperative pulmonary function tests reveal severely impaired respiratory reserve, is surgical resection still considered the preferred primary treatment approach?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (peripheral T1abc, N0)",
              "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treatment",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
              "Surgery after preoperative systemic therapy, if planned",
              "N2",
              "Margins positive",
              "R1",
              "Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "For stage IA peripheral NSCLC, surgical resection is generally the standard primary treatment; however, in the presence of severely impaired pulmonary function, surgery is contraindicated due to high perioperative risk. In such cases, non-surgical options such as stereotactic body radiotherapy (SBRT) are preferred.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_22ed5ae9a525",
      "question": "A preterm neonate in the neonatal intensive care unit develops laboratory evidence of coagulopathy, including elevated prothrombin time and mild mucosal bleeding. The attending physician prescribes a parenteral formulation of a fat-soluble vitamin, which is standard practice for this condition. Although its clinical efficacy in correcting coagulopathy is well recognized, what is the current understanding of this therapy's precise cellular or molecular mechanism of action in premature infants?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Premature infants--Diseases"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021295",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0031862",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular mechanism",
      "reasoning_path": "Premature infants with coagulopathy receive phytonadione, but its detailed action at the cellular/molecular level in this context is not fully known.",
      "umls_path": [
        "Premature infants--Diseases",
        "may_be_treated_by",
        "Phytonadione",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Phytonadione (vitamin K1) is routinely administered to premature infants with coagulopathy to facilitate hepatic synthesis of active clotting factors by enabling γ-carboxylation of glutamate residues. While the clinical benefit is clear, the intricacies of how phytonadione interacts with immature hepatic and enzymatic systems at the cellular and molecular level in premature infants remain incompletely characterized. Differences in hepatic enzyme maturation, vitamin K recycling, and cofactor availability may affect efficacy or pharmacodynamics, but the specific molecular interactions in this population have not been fully elucidated. As a result, the exact mechanistic pathway by which phytonadione corrects coagulopathy in preterm infants is still not fully understood.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_bb1e9d65c45d",
      "question": "In a patient with non-small cell lung cancer staged as T3, N1, M0, and with adequate pulmonary function but a history of severe chronic kidney disease, is the use of perioperative contrast-enhanced brain MRI still indicated for staging purposes?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "N1 or N2 nodes positive, M0",
              "Treatment (NSCL-10)",
              "Mediastinal Biopsy Findings",
              "T1–3, N2 nodes positive, M0",
              "Systemic therapy ± RT",
              "Progression",
              "Local: RT (if feasible) ± chemotherapy"
            ]
          }
        }
      ],
      "answer": "In patients with T3, N1, M0 non-small cell lung cancer, perioperative contrast-enhanced brain MRI is typically indicated to rule out occult brain metastases; however, in the presence of severe chronic kidney disease, the risk of nephrogenic systemic fibrosis from gadolinium contraindicates contrast use, necessitating either non-contrast MRI or alternative imaging methods.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_2b9f281b111c",
      "question": "A 28-year-old woman with a history of recurrent painful vesicular lesions on her external genitalia is started on a biologic medication after failing first-line antiviral therapy. This agent is a recombinant cytokine that binds to a specific cell-surface receptor complex, activating intracellular JAK-STAT signaling and upregulating transcription of antiviral proteins. Which molecular complex is the primary mediator of this drug's therapeutic effect in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Genital herpes, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0019342",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021735",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Interferon Alpha Receptor Complex",
      "reasoning_path": "Patient with recurrent genital herpes → prescribed recombinant interferon alfa-2b → binds to interferon alpha receptor complex → triggers JAK-STAT signaling → upregulates antiviral proteins → mediates therapeutic effect.",
      "umls_path": [
        "Genital herpes, unspecified",
        "may_be_treated_by",
        "Recombinant Interferon Alfa-2b",
        "has_target",
        "Interferon Alpha Receptor Complex"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "In this vignette, the patient has recurrent genital herpes that has not responded to standard antiviral therapy. The physician prescribes recombinant interferon alfa-2b, a biologic cytokine that exerts antiviral effects by binding to the interferon alpha receptor complex on host cell surfaces. This receptor-ligand interaction activates the JAK-STAT signaling pathway, resulting in the transcription of numerous interferon-stimulated genes that inhibit viral replication and modulate immune responses. The upregulated proteins interfere with viral entry, translation, and assembly, helping control herpes simplex virus infection. Thus, the therapeutic efficacy of recombinant interferon alfa-2b in this context relies on its interaction with the interferon alpha receptor complex, which is the critical molecular target that initiates the cascade of antiviral defenses.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_0065fba3e453",
      "question": "A 62-year-old man with a history of poorly controlled hypertension and type 2 diabetes is admitted for acute worsening of renal function, evidenced by rising creatinine and oliguria. To improve his renal perfusion, he receives an intravenous medication that acts primarily by activating G protein–coupled receptors on vascular smooth muscle, leading to increased renal blood flow. Through which general pharmacologic class does this agent exert its therapeutic effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Nephropathy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0022658",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0282151",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Adrenergic agonists",
      "reasoning_path": "Nephropathy with decreased renal perfusion may be managed with drugs like dopamine, which exert their effect by stimulating adrenergic receptors, categorizing them as adrenergic agonists.",
      "umls_path": [
        "Nephropathy",
        "may_be_treated_by",
        "Dopamine hydrochloride",
        "has_mechanism_of_action",
        "Adrenergic Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In acute nephropathy with compromised renal perfusion, medications that stimulate adrenergic receptors—particularly dopamine at low doses—can be used to enhance renal blood flow. These drugs act as adrenergic agonists, activating dopamine and beta-1 adrenergic receptors on vascular smooth muscle and cardiac tissue. Dopamine, for example, binds to its receptors and, at certain doses, also stimulates beta-1 and alpha-adrenergic receptors, causing vasodilation in the renal vasculature, increased cardiac output, and improved glomerular filtration. The overall effect is to increase renal perfusion and promote diuresis, which may be beneficial in acute kidney injury. The defining mechanistic property of these agents is their ability to activate adrenergic (and sometimes dopaminergic) receptors, distinguishing them from other vasopressors or diuretics.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_6ff344866d05",
      "question": "A 44-year-old man with a 5-year history of joint pain and scaly plaques on his elbows and knees is diagnosed with psoriatic arthritis after imaging reveals erosive changes in several small joints. Despite trials of NSAIDs and methotrexate, his symptoms persist. He is started on a biologic agent that works by binding a specific inhibitory receptor expressed on activated T cells. This interaction blocks the engagement between T cells and antigen-presenting cells required for full T-cell activation. Inhibition of which molecular target is primarily responsible for the therapeutic effect of this medication in controlling his autoimmune inflammation?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "psoriatic arthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003872",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1619966",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Cytotoxic T-Lymphocyte Protein 4 (CTLA-4)",
      "reasoning_path": "Psoriatic arthritis involves aberrant T-cell activation. Abatacept binds CTLA-4, which inhibits the CD28-CD80/86 co-stimulatory pathway essential for T-cell activation, reducing autoimmune inflammation.",
      "umls_path": [
        "psoriatic arthritis",
        "may_be_treated_by",
        "Abatacept-containing product",
        "has_target",
        "Cytotoxic T-Lymphocyte Protein 4"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient’s refractory psoriatic arthritis is managed with a biologic that modulates T-cell activity. The described mechanism—binding an inhibitory receptor on activated T cells to block co-stimulatory signaling—refers to abatacept. Abatacept is a fusion protein combining the extracellular domain of CTLA-4 with an IgG Fc fragment. It binds to CD80/86 on antigen-presenting cells, preventing their interaction with CD28 on T cells. Normally, co-stimulatory signaling via CD28 is essential for full T-cell activation, proliferation, and cytokine production. By mimicking CTLA-4 (an endogenous negative regulator), abatacept competitively inhibits this step, dampening the autoimmune response that drives joint and skin inflammation in psoriatic arthritis. Thus, CTLA-4 is the direct molecular target mediating this drug’s effect.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_134c0b73255d",
      "question": "In a patient with stage IVB non-small cell lung cancer (adenocarcinoma subtype) presenting with confirmed ALK rearrangement prior to any systemic therapy, is the recommendation to initiate first-line treatment with crizotinib contingent upon availability of brain MRI to exclude central nervous system metastases, or does detection of ALK rearrangement alone suffice to proceed with targeted therapy regardless of CNS status?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "ALK rearrangement positive",
              "ALK rearrangement",
              "ALK rearrangement discovered prior to first-line systemic therapy",
              "Useful in Certain Circumstances Crizotinibb (category 1)",
              "Progression",
              "Subsequent Therapy (NSCL-29)"
            ]
          }
        }
      ],
      "answer": "Initiation of first-line crizotinib in ALK-rearranged advanced non-small cell lung cancer typically requires assessment of central nervous system involvement, as crizotinib has limited CNS penetration. Brain MRI should be performed to determine the presence of CNS metastases, which may influence both agent selection and subsequent management. Thus, detection of ALK rearrangement alone is insufficient; CNS status must be established prior to therapy decision.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_dbf2a6958e39",
      "question": "A 42-year-old woman with a 15-year history of relapsing-remitting multiple sclerosis has transitioned to gradual neurological decline without distinct relapses over the past two years. She presents with progressive lower extremity weakness, spasticity, and impaired gait stability. After evaluation, her neurologist initiates therapy with an oral fumarate derivative recently approved for her condition. Despite clinical improvement, her care team notes that the specific molecular mechanism by which this drug exerts its therapeutic effect in this neurodegenerative disease has not been fully elucidated. According to current scientific consensus, how is the mechanism of action of this agent best classified?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Secondary progressive multiple sclerosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0751965",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C5139729",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Diroximel fumarate is prescribed for secondary progressive MS, but the precise molecular mechanism is not fully known and is classified as unknown cellular or molecular interaction.",
      "umls_path": [
        "Secondary progressive multiple sclerosis",
        "may_be_treated_by",
        "Diroximel fumarate",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Diroximel fumarate, a fumarate derivative, is used for progressive forms of multiple sclerosis, including secondary progressive MS. Although it is believed to modulate the immune response and may have antioxidant or anti-inflammatory effects via pathways such as Nrf2 activation, the precise molecular and cellular mechanisms responsible for its clinical efficacy in MS remain unclear. Current scientific literature and regulatory resources classify its mechanism of action as not fully determined. This means that while its clinical benefit is established, the exact molecular targets and downstream effects responsible for disease modification are still unknown.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_b8d73b9f1b04",
      "question": "In a patient with advanced squamous non-small cell lung cancer presenting with Stage IVA, M1b disease and a performance status of 3–4, who is confirmed negative for actionable molecular alterations and has PD-L1 expression less than 1%, is there any indication for initial systemic therapy over best supportive care?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "PD-L1 <1% and negative for actionable molecular biomarkers above",
              "PD-L1 <1%",
              "INITIAL SYSTEMIC THERAPY",
              "PS 3–4",
              "Best supportive care NCCN Guidelines for Palliative Care"
            ]
          }
        }
      ],
      "answer": "No, in the setting of advanced squamous NSCLC with Stage IVA, M1b, poor performance status (PS 3–4), absence of actionable molecular biomarkers, and PD-L1 <1%, the recommended approach is best supportive care; initial systemic therapy is not indicated regardless of other factors.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_cf5959565c03",
      "question": "In patients with non-small cell lung cancer who present with separate pulmonary nodules located in the same lobe (T3, N0–1) versus those with nodules in a different ipsilateral non-primary lobe (T4, N0–1), is the consideration for surgery after preoperative systemic therapy equally applicable to both groups, or does the anatomical location alter the eligibility for surgical intervention?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
              "Surgery after preoperative systemic therapy, if planned",
              "N2",
              "Margins positive",
              "R2",
              "Concurrent chemoradiation",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "Surgical intervention after preoperative systemic therapy is applicable to both scenarios—separate nodules in the same lobe (T3, N0–1) and in a different ipsilateral non-primary lobe (T4, N0–1)—as both are considered for curative-intent resection if there is no distant metastasis and adequate functional reserve, with anatomical location alone not precluding surgery.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_120435268056",
      "question": "For a patient with multiple lung cancers classified as N0–1, if the dominant nodule shows clear growth but definitive local therapy is not possible, does this scenario inherently require the exclusion of surgical intervention as a management option?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Multiple lung cancers (suspected or confirmed) (N0–1)",
              "Multidisciplinary evaluation",
              "Dominant nodule with evidence of growth",
              "Definitive local therapy not possible",
              "Palliative chemotherapy ± local palliative therapy or Observe",
              "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes. When definitive local therapy is deemed not possible in the context of a growing dominant nodule and multiple lung cancers (N0–1), surgical intervention is inherently excluded since surgery qualifies as a form of definitive local therapy. Alternative strategies such as palliative chemotherapy or observation are indicated in this situation.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_62452ef68f61",
      "question": "What is the PMID for the article titled “Trends in self-citation rates in high-impact neurology, neuroscience, and psychiatry journals,” authored by Rosenblatt M and published in eLife in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"Trends in self-citation rates in high-impact neurology, neuroscience, and psychiatry journals.\"[ti] AND Rosenblatt M[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40366360"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_e2a555d8069d",
      "question": "In a patient with stage IV, M1b advanced non-small cell lung cancer (adenocarcinoma histology) who is confirmed to have a MET exon 14 skipping mutation prior to any first-line systemic therapy, is the use of capmatinib or tepotinib as first-line treatment predicated on the presence or absence of brain metastases?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "METex14 skipping mutation positive",
              "METex14 skipping mutation",
              "METex14 skipping mutation discovered prior to first-line systemic therapy",
              "Preferred: Capmatinib or Tepotinib",
              "Progression",
              "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
            ]
          }
        }
      ],
      "answer": "The selection of capmatinib or tepotinib as first-line therapy for advanced NSCLC with MET exon 14 skipping mutation does not depend on the presence or absence of brain metastases; both agents are recommended for all eligible patients regardless of central nervous system involvement.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_b5e3213d60e1",
      "question": "A 34-year-old woman presents with clusters of intensely pruritic vesicles and erosions on her elbows and knees. Biopsy reveals granular IgA deposits at the dermal-epidermal junction. She is started on a medication that reduces inflammatory gene transcription by binding to a cytoplasmic receptor, leading to nuclear translocation and modulation of gene expression. Which molecular target is responsible for the primary anti-inflammatory effect of this therapy in her skin condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Dermatitis herpetiformis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011608",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0025815",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Glucocorticoid receptor",
      "reasoning_path": "Dermatitis herpetiformis → treated with corticosteroids → corticosteroids bind glucocorticoid receptor → nuclear translocation → altered gene transcription → decreased inflammation",
      "umls_path": [
        "Dermatitis herpetiformis",
        "may_be_treated_by",
        "Methylprednisolone",
        "has_target",
        "Glucocorticoid Receptor"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has dermatitis herpetiformis, an autoimmune blistering disorder characterized by IgA deposition at the dermal-epidermal junction. Corticosteroids like methylprednisolone are sometimes used to control acute inflammation, especially when dietary modification or dapsone is insufficient or not tolerated. The primary anti-inflammatory effect of corticosteroids arises from their ability to bind the cytoplasmic glucocorticoid receptor, a ligand-activated transcription factor. Upon binding, the receptor-hormone complex translocates to the nucleus and regulates the transcription of target genes, broadly suppressing pro-inflammatory cytokines and adhesion molecules while upregulating anti-inflammatory proteins. This mechanism leads to reduced leukocyte infiltration, decreased antibody-mediated damage, and symptomatic relief in autoimmune skin disease. Therefore, the glucocorticoid receptor is essential for mediating the therapeutic effects of corticosteroids in dermatitis herpetiformis and other inflammatory conditions.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_5b85ae086376",
      "question": "A 42-year-old woman with a BMI of 33 kg/m² is seeking assistance for weight loss. She reports persistent overeating and difficulty controlling her appetite despite multiple attempts at diet and exercise. Her physician prescribes a medication previously used as an anorectic agent, which acts on central neurotransmitter pathways to reduce food intake. This drug increases the release of a specific monoamine in the hypothalamus, leading to early satiety and appetite suppression. Through modulation of which neurotransmitter receptor does this medication primarily exert its therapeutic effect in the management of her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Obesity, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0028754",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0282179",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Serotonin receptor",
      "reasoning_path": "Obesity—treated with fenfluramine—mechanism: increases serotonin release—stimulates serotonin receptors in hypothalamus—appetite suppressed.",
      "umls_path": [
        "Obesity, unspecified",
        "may_be_treated_by",
        "Fenfluramine hydrochloride",
        "has_mechanism_of_action",
        "Serotonin Receptor Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The clinical scenario describes a patient with obesity who is prescribed an appetite suppressant acting via central neurotransmitter pathways. Fenfluramine, a drug historically used for this purpose, achieves appetite suppression by increasing the synaptic release of serotonin, particularly in the hypothalamus. Elevated serotonin levels stimulate serotonin (5-HT2C) receptors, enhancing feelings of satiety and reducing caloric intake. This pharmacologic action distinguishes serotoninergic agents from those acting via noradrenergic or dopaminergic mechanisms. The efficacy of fenfluramine in obesity is thus primarily mediated by its interaction with serotonin receptors in the central nervous system, leading to diminished appetite and subsequent weight loss.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_703f38103b40",
      "question": "In patients with stage I–II non-small cell lung cancer who have undergone primary treatment with surgery and adjuvant chemotherapy, is routine brain MRI indicated as part of scheduled surveillance imaging if there are no clinical symptoms suggestive of central nervous system involvement?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (T1abc, N0); Margins positive (R1, R2)",
              "Resection (preferred) or RT (category 2B)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, routine brain MRI is not indicated for surveillance in asymptomatic stage I–II non-small cell lung cancer patients following surgery and adjuvant chemotherapy; brain MRI is reserved for evaluation of recurrence or when neurologic symptoms suggest possible brain metastases.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_79d8e4b4ea24",
      "question": "In a patient with stage IVA, metastatic (M1b) non-small cell lung cancer of squamous histology, who is found to have an NTRK1 gene fusion on molecular profiling prior to receiving any systemic therapy, is treatment with larotrectinib based on the assumption that broad molecular profiling—including NTRK fusion testing—has been successfully completed with adequate tissue sampling?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "NTRK1/2/3 gene fusion positive",
              "NTRK1/2/3 gene fusion",
              "NTRK1/2/3 gene fusion discovered prior to first-line systemic therapy",
              "Preferred: Larotrectinibrr or Entrectinibrr or Repotrectinibrr",
              "Progression",
              "Repotrectinib (if not previously given) or Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
              "Progression",
              "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
            ]
          }
        }
      ],
      "answer": "Yes, initiating larotrectinib in this scenario presumes that comprehensive molecular profiling has been performed using sufficient tumor tissue, confirming the presence of an actionable NTRK1 gene fusion as a driver alteration before starting first-line systemic therapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_e26564e49458",
      "question": "In a patient with invasive, non-inflammatory, non-metastatic (M0) breast cancer, clinical stage cT2N0, who is HER2-negative and triple-negative, is preoperative systemic therapy indicated based on standard criteria, or should primary surgery be prioritized in this setting?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS possible",
              "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
              "Adjuvant systemic therapy (BINV-16) + post-mastectomy RT",
              "cN+ and ypN0: Strongly consider RT to the chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk."
            ]
          }
        }
      ],
      "answer": "For a patient with cT2N0 breast cancer who is HER2-negative and triple-negative, preoperative systemic therapy is indicated according to current selection criteria. Primary surgery is not prioritized over neoadjuvant therapy in this scenario, as systemic treatment before surgery can improve pathologic response rates and guide further management.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_dd2db843b5d5",
      "question": "In a patient with advanced squamous cell carcinoma of the lung, if an ALK rearrangement is unexpectedly detected during first-line systemic therapy, is it appropriate to initiate crizotinib immediately, or should the current systemic therapy—including planned maintenance—be completed before switching to ALK-targeted treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "ALK rearrangement positive",
              "ALK rearrangement",
              "ALK rearrangement discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by crizotinib",
              "Progression",
              "Subsequent Therapy (NSCL-29)"
            ]
          }
        }
      ],
      "answer": "If an ALK rearrangement is discovered during first-line systemic therapy for advanced squamous cell carcinoma of the lung, completing the planned systemic therapy, including maintenance, or interrupting it to switch to crizotinib are both valid options. The decision should be individualized based on disease response, tolerability, and clinical urgency.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_4638e2da2578",
      "question": "In a patient with stage IVA (M1b) non-small cell lung cancer who has a confirmed brain metastasis and good performance status (PS 0–2), is it reasonable to proceed directly with stereotactic radiosurgery (SRS) for the brain lesion before obtaining pathologic confirmation of the metastatic site, if previous pathology is only from the primary lung tumor?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
              "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 0–2",
              "Limited progression confirmed",
              "Brain",
              "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
              "Treatment of Thoracic Disease (NSCL-16)"
            ]
          }
        }
      ],
      "answer": "No, direct stereotactic radiosurgery should not be performed without pathological confirmation of the metastatic lesion if feasible; current recommendations require pathologic confirmation of metastatic sites whenever possible to ensure accurate diagnosis and appropriate management, especially before initiating definitive local therapies.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_c295418e017c",
      "question": "In a patient with stage IIIB non-small cell lung cancer (T1–2, N3), if the diagnosis of N3 lymph node involvement is based solely on radiological findings without pathologic confirmation, is this sufficient to initiate definitive stage IIIB treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (peripheral T1abc, N0)",
              "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 0–2",
              "Limited progression confirmed",
              "Other site",
              "Treatment of Thoracic Disease (NSCL-16)"
            ]
          }
        }
      ],
      "answer": "No; initiation of definitive treatment for stage IIIB non-small cell lung cancer requires pathologic confirmation of N3 lymph node involvement. Radiological findings alone are insufficient, as pathological assessment (e.g., mediastinoscopy, EBUS, needle biopsy) is essential to establish N3 disease before proceeding with stage-specific therapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_04a9efbb1ff7",
      "question": "For a patient with stage IIIB non-small cell lung cancer (T1–2, N3, M0) and confirmed N3 disease by EBUS biopsy, is the use of durvalumab after definitive concurrent chemoradiation dependent on the presence or absence of EGFR exon 19 deletion or L858R mutation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "N3 nodes positive, M0",
              "Stage IIIB or Stage IIIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 positive",
              "Definitive concurrent chemoradiationm,s (category 1)",
              "Durvalumab (category 1) or Osimertinib (if EGFR exon 19 deletion or L858R) (category 1)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "No, the use of durvalumab as consolidation therapy following definitive concurrent chemoradiation is indicated for patients with unresectable stage III non-small cell lung cancer regardless of EGFR mutation status. The presence of EGFR exon 19 deletion or L858R mutation may warrant consideration of osimertinib, but durvalumab is not excluded by these mutations.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_4e7853162f2a",
      "question": "For a patient with resectable stage IIIA (T1–2, N2) non-small cell lung cancer, if mediastinal lymph node involvement is confirmed pathologically but the patient has significant impairment on pulmonary function tests (PFTs), is perioperative therapy still considered appropriate?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "N3 negative",
              "Initial treatment for stage I–IIIA (NSCL-8)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Perioperative therapy in resectable stage IIIA (T1–2, N2) non-small cell lung cancer presupposes adequate pulmonary function to tolerate surgery. Significant impairment on PFTs generally contraindicates surgical intervention, making perioperative therapy inappropriate unless pulmonary function can be optimized.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_3a507b098f2c",
      "question": "For a patient with non-small cell lung cancer presenting with a solitary nodule in the contralateral lung (stage IVA, N0, M1a), does the decision to treat as two primary lung tumors inherently require that both tumors are independently considered potentially curable?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
              "Pathologic Diagnosis of NSCLC",
              "Initial Evaluation",
              "H&P (include performance status + weight loss)"
            ]
          }
        }
      ],
      "answer": "Yes, the choice to approach a solitary contralateral lung nodule as two primary lung tumors is contingent on both tumors being independently deemed potentially curable based on clinical staging, functional assessment, and absence of unresectable disease elsewhere.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_ffba8cac9bcc",
      "question": "A 54-year-old woman with a longstanding history of joint stiffness and swelling in her hands is diagnosed with an inflammatory arthropathy. She has been taking an over-the-counter non-steroidal anti-inflammatory drug but now complains of persistent epigastric pain. Her physician considers switching her to a different medication in the same class that works by inhibiting an enzyme responsible for converting arachidonic acid into pro-inflammatory mediators. Which molecular target does this alternative drug primarily inhibit to exert its anti-inflammatory effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Rheumatoid arthritis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003873",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0022635",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 1 (COX-1)",
      "reasoning_path": "Rheumatoid arthritis involves inflammation managed by NSAIDs; ketoprofen is an NSAID that works by inhibiting COX-1 (Prostaglandin G/H Synthase 1), reducing prostaglandin-mediated inflammation.",
      "umls_path": [
        "Rheumatoid arthritis",
        "may_be_treated_by",
        "Ketoprofen",
        "has_target",
        "Prostaglandin G/H Synthase 1"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has rheumatoid arthritis, a chronic inflammatory disease characterized by immune-mediated joint destruction. NSAIDs are commonly used to reduce inflammation and alleviate pain in this condition. Ketoprofen is a non-selective NSAID that, like many others, inhibits cyclooxygenase enzymes. Specifically, it targets Prostaglandin G/H Synthase 1 (COX-1), a key enzyme in the biosynthesis of prostaglandins from arachidonic acid. Prostaglandins mediate inflammation, pain, and swelling in rheumatoid arthritis. By blocking COX-1, ketoprofen reduces prostaglandin production, thus diminishing inflammatory symptoms. However, inhibition of COX-1 in the gastrointestinal tract also reduces protective prostaglandins, which can lead to GI discomfort or ulceration—a common side effect in this drug class. The anti-inflammatory benefit in rheumatoid arthritis is directly linked to the suppression of prostaglandin synthesis via COX-1 inhibition.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_98a3bcbd6a17",
      "question": "In a patient with advanced non–small cell lung cancer (adenocarcinoma subtype) and an EGFR S768I mutation identified during first-line systemic therapy, is it appropriate to switch to osimertinib immediately upon mutation discovery, or should the current planned systemic therapy and maintenance be completed prior to osimertinib initiation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "EGFR S768I, L861Q, and/or G719X mutation positive",
              "EGFR S768I, L861Q, and/or G719X mutations",
              "EGFR mutation discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by osimertinib (preferred)",
              "Progression",
              "Subsequent Therapy (NSCL-22)"
            ]
          }
        }
      ],
      "answer": "For patients with advanced NSCLC and EGFR S768I mutation discovered during ongoing first-line systemic therapy, the preferred approach is to complete the planned systemic therapy, including any maintenance phase, before switching to osimertinib. Interrupting current therapy solely due to detection of this mutation is not recommended.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_5071fc6c8a45",
      "question": "For a patient with non-small cell lung cancer presenting with a separate pulmonary nodule in the same lobe as the primary tumor, staged as T3N0, is surgical resection still an appropriate treatment option, or does the presence of this additional nodule alter the indications for surgery?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
              "Surgery after preoperative systemic therapy, if planned",
              "N2",
              "Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E) or Sequential chemotherapy + Consider RT",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "Surgical resection remains an appropriate treatment for non-small cell lung cancer staged as T3N0 due to a separate pulmonary nodule within the same lobe, as this presentation falls within the criteria for surgery and does not in itself exclude resectability.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_89c4491b366b",
      "question": "What is the unique PMID for the article titled “On tending sprouts: empowering emerging immunologists in Latin America,” authored by Brunck MEG and published in Trends in Immunology in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"On tending sprouts\"[ti] AND Brunck MEG[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40050163"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_aaa4629c2060",
      "question": "In patients with stage IVA NSCLC, M1b disease, limited brain progression, an ECOG performance status of 0-2, and imaging-confirmed brain metastasis, if thoracic disease is deemed definitively treatable, should stereotactic radiosurgery (SRS) alone be considered as a definitive local therapy for the brain metastasis even in the presence of mild neurological symptoms, or is surgical resection preferred under these circumstances?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 0–2",
              "Limited progression confirmed",
              "Brain",
              "Stereotactic radiosurgery (SRS) alone or Surgical resection, if symptomatic or warranted for diagnosis, followed by SRS or whole brain RT (WBRT)",
              "Treatment of Thoracic Disease (NSCL-16)",
              "Definitive therapy for thoracic disease feasible",
              "Consider systemic therapy and restaging to confirm non-progression or Proceed to definitive therapy",
              "T1–3, N1",
              "Pathologic mediastinal nodal evaluation and Chemoradiation (preferred) or Surgical resection or Definitive RT",
              "Definitive local therapy for metastatic site if not already given",
              "Consider systemic therapy, if not already given"
            ]
          }
        }
      ],
      "answer": "For stage IVA, M1b NSCLC patients with limited, symptomatic brain metastasis and ECOG 0–2, surgical resection is preferred if symptoms are present or diagnosis is uncertain; SRS alone is typically reserved for asymptomatic or minimally symptomatic lesions. Thus, mild neurological symptoms favor surgical resection over SRS alone.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_3d7a4bfe83ad",
      "question": "A 52-year-old woman presents with a two-week history of redness, pain, and photophobia in her right eye. Ophthalmic examination reveals diffuse inflammation of the sclera without evidence of infection. She is started on topical therapy with a steroid agent frequently used in ophthalmology. The drug exerts its anti-inflammatory effect in part by inhibiting an enzyme pathway responsible for synthesizing leukotrienes from arachidonic acid, thereby reducing leukotriene-mediated inflammation. Which class of enzymes is most directly inhibited by this medication, leading to symptomatic improvement?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Scleritis, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0036416",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0065865",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lipoxygenase enzymes",
      "reasoning_path": "Scleritis → topical corticosteroid treatment → corticosteroid inhibits lipoxygenase enzymes → decreased leukotriene production → reduced ocular inflammation and symptom relief.",
      "umls_path": [
        "Scleritis, unspecified",
        "may_be_treated_by",
        "Medrysone",
        "has_mechanism_of_action",
        "Lipoxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this vignette, the patient presents with non-infectious scleritis, an inflammatory disorder of the sclera. Corticosteroids are commonly prescribed to reduce ocular inflammation. One such corticosteroid, medrysone, is used topically in ophthalmology. Its anti-inflammatory mechanism includes the inhibition of lipoxygenase enzymes, which are responsible for converting arachidonic acid into leukotrienes. Leukotrienes are potent mediators of inflammation, contributing to vascular permeability, leukocyte chemotaxis, and tissue damage. By inhibiting the lipoxygenase pathway, the corticosteroid reduces leukotriene synthesis, thereby diminishing inflammatory signaling and clinical symptoms in scleritis. While corticosteroids also inhibit phospholipase A2 and the cyclooxygenase pathway, lipoxygenase inhibition is particularly relevant for reducing leukotriene-driven ocular inflammation. Thus, symptomatic improvement in this patient is most directly associated with the inhibition of lipoxygenase enzymes.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_5acac2ed6d69",
      "question": "A 38-year-old woman with a history of Behçet's disease presents with frequent, painful oral ulcers that have not responded to corticosteroids, colchicine, or azathioprine. As a last resort, her physician prescribes an immunomodulatory agent once withdrawn from the market due to teratogenic effects but later reintroduced for refractory inflammatory conditions. Although her ulcers improve, the exact cellular or molecular mechanism by which this drug exerts its therapeutic benefit in oral ulceration remains uncertain. What is the most accurate description of this agent’s mode of action in this context?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Oral aphthae"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0038363",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0039736",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Thalidomide is prescribed for refractory oral aphthae; although various immunomodulatory and anti-inflammatory effects are proposed, its precise molecular mechanism in this indication remains undefined.",
      "umls_path": [
        "Oral aphthae",
        "may_be_treated_by",
        "Thalidomide",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Thalidomide has been used successfully to treat refractory oral aphthae, particularly in conditions like Behçet's disease. While its clinical efficacy is well-documented, the precise mechanism by which it alleviates oral ulceration is not fully understood. Thalidomide is known to have immunomodulatory, anti-inflammatory, and anti-angiogenic properties, including inhibition of TNF-alpha and modulation of other cytokines, but no single, well-characterized pathway explains its effect on oral aphthae. Therefore, the mode of action in this context is best described as an unknown or incompletely elucidated cellular or molecular interaction.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_be0c3a8e0010",
      "question": "A 48-year-old woman with a history of recurrent headaches and easy bruising is found to have a persistently elevated platelet count on routine bloodwork. Bone marrow biopsy reveals megakaryocytic hyperplasia, and molecular testing is negative for BCR-ABL1 but positive for a JAK2 mutation. She is started on a medication administered by subcutaneous injection once weekly, which is known to modulate immune signaling and inhibit the replication of abnormal hematopoietic cells by interfering with specific intracellular enzymes essential for viral and cellular RNA synthesis. Which class of molecular targets is primarily responsible for the therapeutic effect of this treatment in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Essential thrombocythemia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0040028",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0391001",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "RNA replicase enzymes",
      "reasoning_path": "Patient with essential thrombocythemia → treated with PEG-interferon alfa-2a → activates JAK-STAT signaling → induces expression of proteins that inhibit RNA replicase enzymes → decreased abnormal cell proliferation.",
      "umls_path": [
        "Essential thrombocythemia",
        "may_be_treated_by",
        "PEG-interferon alfa-2a",
        "has_mechanism_of_action",
        "RNA Replicase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Essential thrombocythemia is a myeloproliferative neoplasm characterized by excessive platelet production due to abnormal megakaryocyte proliferation. PEG-interferon alfa-2a is sometimes used to control platelet counts and reduce thrombotic risk in these patients. Its mechanism involves the induction of antiviral and antiproliferative cellular pathways. Specifically, PEG-interferon alfa-2a binds to type I interferon receptors, stimulating the JAK-STAT pathway and upregulating genes that encode proteins inhibiting viral and cellular RNA replication. The primary molecular targets affected are RNA replicase enzymes, which are essential for the synthesis of RNA in both viruses and rapidly dividing abnormal cells. By inhibiting these enzymes, interferon reduces the proliferation of clonal hematopoietic cells seen in essential thrombocythemia.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_64b5df459c27",
      "question": "In a patient with stage II non–small cell lung cancer who underwent definitive radiotherapy as primary treatment and currently shows no evidence of disease on imaging, is it appropriate to perform routine FDG-PET/CT or brain MRI during surveillance if the patient remains asymptomatic?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "No, routine FDG-PET/CT and brain MRI are not indicated for surveillance in asymptomatic patients with stage II non–small cell lung cancer after definitive radiotherapy. Surveillance should rely on clinical evaluation and periodic chest CT, reserving advanced imaging for situations involving new symptoms or radiographic abnormalities.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_60412c72ed0b",
      "question": "A 34-year-old woman presents with dysuria, urinary frequency, and malodorous urine. Urinalysis reveals alkaline pH, and urine culture grows a Gram-negative, urease-positive rod later identified as Proteus mirabilis. She is started on an oral antimicrobial agent that inhibits the activity of bacterial transpeptidases, disrupting the synthesis of peptidoglycan cross-links in the cell wall. Which pharmacological class best describes the mechanism of this prescribed agent?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Proteus infection"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0033700",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2699132",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme Inhibitors",
      "reasoning_path": "Proteus UTI treated with cefadroxil → cefadroxil inhibits bacterial transpeptidases (enzyme) → disrupts cell wall synthesis → pharmacological class: enzyme inhibitor.",
      "umls_path": [
        "Proteus infection",
        "may_be_treated_by",
        "Cefadroxil anhydrous",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has a urinary tract infection caused by Proteus mirabilis, which is known for producing urease and causing alkaline urine. She is treated with cefadroxil, a first-generation cephalosporin antibiotic. Cefadroxil, like other beta-lactam antibiotics, works by binding to and inhibiting bacterial transpeptidases (penicillin-binding proteins), which are essential enzymes for cross-linking peptidoglycan strands during cell wall synthesis. Inhibiting these enzymes leads to a weakened bacterial cell wall and eventual cell lysis. Drugs that act by blocking the function of enzymes, such as transpeptidases, are classified pharmacologically as enzyme inhibitors. Thus, cefadroxil’s mechanism of action in treating this infection is best described by the enzyme inhibitor class.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_d37dc9b9ba22",
      "question": "A 28-year-old woman with a history of abetalipoproteinemia presents with chronic diarrhea, steatorrhea, and signs of fat-soluble vitamin deficiency. Her physician initiates a therapeutic regimen that includes a lipid-based supplement to address her underlying deficiency. This agent exerts its pharmacological effect by interacting with large biomolecules within the body rather than directly engaging with small-molecule receptors or ion channels. Which fundamental molecular mechanism underlies the therapeutic activity of this lipid-based agent in her treatment?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Nutritional Disorder"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3714509",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0008377",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Biological macromolecular activity—interaction of the lipid supplement (e.g., cholesterol) with biological macromolecules such as membranes or enzymes.",
      "reasoning_path": "Lipid-based therapy is used in lipid absorption/metabolism disorders. The supplement (e.g., cholesterol) acts by integrating into membranes and interacting with macromolecules. Its effect is classified as 'biological macromolecular activity' because it modifies the structure/function of biological macromolecules rather than acting at a receptor or ion channel.",
      "umls_path": [
        "Nutritional Disorder",
        "may_be_treated_by",
        "Cholesterol",
        "has_mechanism_of_action",
        "Biological Macromolecular Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In abetalipoproteinemia and related nutritional disorders, patients have impaired absorption or metabolism of dietary lipids, leading to deficiencies in essential fatty acids and fat-soluble vitamins. Therapeutic intervention often includes lipid-based supplements (such as cholesterol or specific phospholipids) to restore necessary membrane components and facilitate nutrient absorption. These agents do not exert effects by binding to typical drug targets like neurotransmitter receptors or ion channels. Instead, they act at the molecular level by integrating into cellular membranes, altering membrane fluidity, or serving as substrates for enzymatic pathways. This activity is categorized as 'biological macromolecular activity,' meaning the therapeutic lipid modifies the function or structure of large biomolecules (e.g., membranes, enzymes) to exert its effect. This mechanistic approach addresses the underlying defect in the nutritional disorder by restoring or mimicking the biological roles of natural lipids, rather than modulating traditional signal transduction pathways.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_46a3a90cb3b7",
      "question": "What is the PMID of the article titled “Causal association between gut microbiota and endometrial cancer in European and East Asian populations: a two-sample Mendelian randomization study,” authored by Chen J and published in BMC Women's Health in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"Causal association between gut microbiota and endometrial cancer in European and East Asian populations\"[ti] AND Chen J[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40483441"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_f10e1a1cfc2c",
      "question": "In a patient with stage IVA non-small cell lung cancer presenting with a contralateral lung solitary nodule and confirmed N0, M1a status, if both foci are potentially resectable and have no evidence of mediastinal lymph node involvement or distant metastases, should these lesions be managed as two primary lung tumors or as intrapulmonary metastases, and what is the clinical rationale for the preferred approach?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
              "Pathologic Diagnosis of NSCLC",
              "Initial Evaluation",
              "Use the 5 A's Framework: Ask, Advise, Assess, Assist, Arrange"
            ]
          }
        }
      ],
      "answer": "In this context, these lesions should be managed as two primary lung tumors, not as intrapulmonary metastases. The absence of mediastinal lymph node involvement (N0) and solitary contralateral nodule (M1a) support the classification of synchronous primary tumors, allowing curative intent treatment for both foci as per established staging conventions.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_c383b1700a2c",
      "question": "In a patient with newly diagnosed stage IIIC (T4, N3) non-small cell lung cancer (NSCLC) with confirmed mediastinal N3 disease, if distant metastases are found on FDG-PET/CT, should systemic therapy be prioritized over local curative treatments such as surgery or definitive chemoradiotherapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
              "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Distant metastases",
              "Disseminated metastases",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Yes, the detection of distant metastases in stage IIIC (T4, N3) NSCLC indicates metastatic disease, where curative local treatments are no longer appropriate. Systemic therapy becomes the primary treatment approach, as the goal shifts from local control to managing disseminated disease.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_1f7bbf3dd1e2",
      "question": "For a patient with completely resected stage II NSCLC who received adjuvant radiotherapy as part of primary treatment, should routine surveillance imaging for the first 3 years after therapy be performed more frequently than annual intervals, and what is the rationale for the recommended surveillance schedule?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
              "R2; Concurrent chemoradiation",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Routine surveillance imaging during the first 3 years after primary treatment including radiotherapy for stage II NSCLC should be performed every 3–6 months, not annually. This approach enables earlier detection of recurrence or new primary tumors when risk is highest post-treatment, transitioning to less frequent annual imaging once the risk decreases.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_01afcc6bf6d5",
      "question": "In a patient with clinically localized, invasive, non-inflammatory, and non-metastatic breast cancer (M0) presenting as cT2N0 disease, if axillary ultrasound does not reveal suspicious lymph nodes and percutaneous biopsy is not performed, is it appropriate to proceed directly with preoperative systemic therapy without axillary biopsy and marker placement?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS not possible",
              "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
              "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
              "SLN mapping and excision",
              "SLN negative",
              "No further axillary surgery (category 1)"
            ]
          }
        }
      ],
      "answer": "No, direct initiation of preoperative systemic therapy is not appropriate in this scenario. Axillary imaging with ultrasound and biopsy with marker placement of the most suspicious or clinically positive axillary node is recommended prior to preoperative therapy, even in cN0 cases, to ensure accurate staging and surgical planning.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_6f60abdc5bae",
      "question": "In a patient newly diagnosed with stage IIIA non-small cell lung cancer (T3, N1) and symptomatic superior vena cava (SVC) obstruction who has not received prior chemoradiation, is concurrent chemoradiation with or without SVC stenting preferred over external-beam radiotherapy alone for immediate management?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Yes, concurrent chemoradiation with or without SVC stenting is the preferred immediate management for symptomatic SVC obstruction in untreated stage IIIA non-small cell lung cancer, as it addresses both tumor control and symptom relief. External-beam radiotherapy alone is an alternative if chemoradiation is not feasible, but combined modality therapy offers superior disease control.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_cb0a013d0d5e",
      "question": "For a patient with stage IIIB (T4, N2) non-small cell lung cancer who presents with metastatic disease limited to a single organ site, is locoregional concurrent chemoradiation still prioritized over systemic therapy, or should initial management focus on local therapy targeting the metastatic lesion?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
              "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "In the setting of stage IIIB (T4, N2) non-small cell lung cancer with limited metastatic disease to a single organ site, initial management should prioritize local therapy for the metastatic site in combination with standard concurrent chemoradiation for locoregional disease, as this approach targets both primary and oligometastatic lesions for potential long-term control rather than systemic therapy alone.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_a9e9c661f1d0",
      "question": "A 54-year-old woman presents with acute onset of right elbow pain and swelling following several days of repetitive gardening work. Examination reveals warmth, tenderness, and fluctuant swelling over the olecranon. She is diagnosed with a non-infectious inflammatory condition of the bursa. Her physician prescribes an oral medication that rapidly relieves her pain and swelling by blocking an enzyme necessary for the conversion of arachidonic acid to prostaglandins. Which enzyme is directly inhibited by this drug to produce its therapeutic effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Bursitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0006444",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020740",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 1 (Cyclooxygenase-1, COX-1)",
      "reasoning_path": "Bursitis → NSAID prescribed → NSAIDs inhibit cyclooxygenase → Decreased prostaglandin synthesis → Reduced inflammation and pain.",
      "umls_path": [
        "Bursitis",
        "may_be_treated_by",
        "Ibuprofen",
        "has_target",
        "Prostaglandin G/H Synthase 1"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has acute non-infectious bursitis, characterized by inflammation of a synovial bursa. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are commonly prescribed for symptom relief in such cases. NSAIDs exert their primary therapeutic effect by inhibiting the cyclooxygenase (COX) enzymes, also known as prostaglandin G/H synthases. These enzymes (COX-1 and COX-2) catalyze the conversion of arachidonic acid to prostaglandin H2, a precursor for various prostaglandins involved in mediating inflammation, pain, and swelling. By inhibiting COX-1 (and COX-2, to varying degrees), NSAIDs reduce prostaglandin synthesis, thereby decreasing inflammation and alleviating the symptoms of bursitis. Thus, the direct molecular target for the anti-inflammatory action of these drugs is prostaglandin G/H synthase 1 (COX-1).",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_418a07a4efd8",
      "question": "A 35-year-old woman presents with easy bruising and petechiae. Laboratory evaluation reveals isolated thrombocytopenia, and she is diagnosed with immune thrombocytopenic purpura. After initial corticosteroid therapy proves insufficient, her hematologist initiates intravenous therapy with an agent known to disrupt cell division by interfering with mitotic spindle formation. What is the primary cellular structure targeted by this agent to exert its therapeutic effect in this context?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Immune thrombocytopenic purpura"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0398650",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0042670",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Tubulin",
      "reasoning_path": "ITP unresponsive to steroids → use of vinca alkaloid → vinca alkaloid binds tubulin → inhibits microtubule formation → impairs immune cell proliferation → reduces platelet destruction.",
      "umls_path": [
        "Immune thrombocytopenic purpura",
        "may_be_treated_by",
        "Vinblastine",
        "has_target",
        "Tubulin"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient with immune thrombocytopenic purpura (ITP) is treated with a vinca alkaloid after first-line corticosteroids are inadequate. Vinca alkaloids, such as vinblastine or vincristine, are chemotherapeutic agents that act by binding to tubulin, the protein subunit of microtubules. By inhibiting tubulin polymerization, these drugs prevent the formation of microtubules, which are essential for mitotic spindle assembly and chromosome segregation during cell division. In ITP, this mechanism suppresses the proliferation of immune cells responsible for antibody-mediated platelet destruction. The therapeutic effect arises from reduced immune cell division, leading to decreased platelet destruction and improved platelet counts. Thus, tubulin is the primary molecular target mediating the therapeutic action of vinca alkaloids in this setting.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_9456786656de",
      "question": "In the OpenTargets platform, what tractability information is available for the target with Ensembl ID ENSG00000091879 and approved symbol ANGPT2 where the value is True?",
      "tool_calls": [
        {
          "tool": "opentargets.tractability",
          "params": {
            "target_id": "ENSG00000091879",
            "value": true
          }
        }
      ],
      "answer": [
        {
          "modality": "AB",
          "label": "Approved Drug"
        },
        {
          "modality": "AB",
          "label": "UniProt loc high conf"
        },
        {
          "modality": "AB",
          "label": "GO CC high conf"
        },
        {
          "modality": "AB",
          "label": "UniProt SigP or TMHMM"
        },
        {
          "modality": "OC",
          "label": "Advanced Clinical"
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "path_6fc9c47d07ef",
      "question": "In a patient with operable, invasive, non-metastatic breast cancer staged as cT1c, cN0, and triple-negative subtype, is preoperative systemic therapy an appropriate consideration, or should immediate surgical intervention be prioritized as the initial treatment modality?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS possible",
              "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
              "Adjuvant systemic therapy (BINV-16), no RT",
              "HR-positive/ HER2-positive",
              "ypT1–4,N0 or ypN≥1",
              "If ado-trastuzumab emtansine discontinued for toxicity, then complete (up to) 1 year of HER2-directed therapy with trastuzumab (category 1) ± pertuzumab. If node positive at initial staging, trastuzumab + pertuzumab (category 1) and If HR-positive, adjuvant endocrine therapy (category 1) "
            ]
          }
        }
      ],
      "answer": "For cT1c, cN0 triple-negative breast cancer, preoperative systemic therapy is an appropriate and guideline-based option, as these tumors are considered suitable for neoadjuvant treatment to optimize surgical outcomes and assess treatment response; immediate surgery is not the preferred first-line approach in this context.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_71ba08785ecb",
      "question": "What is the unique PMID for the 2025 Journal of Bodywork and Movement Therapies article titled \"Home-based remote dance program with biopsychosocial model improves quality of life in breast cancer patients: A randomized controlled trial,\" authored by Yang YH?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"Home-based remote dance program with biopsychosocial model improves quality of life in breast cancer patients\"[ti] AND Yang YH[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40483151"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_f697c329103b",
      "question": "A 42-year-old woman undergoing chemotherapy for breast cancer develops white, curd-like plaques on her buccal mucosa and tongue. She complains of mild discomfort when eating spicy foods. Her clinician prescribes a topical agent that interferes with fungal cell membrane synthesis by inhibiting a specific enzyme in the ergosterol biosynthetic pathway. Through which class of enzyme inhibition does this medication primarily exert its antifungal effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Candidiasis of mouth"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0006849",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0009074",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Squalene monooxygenase inhibitors",
      "reasoning_path": "Oral candidiasis → clotrimazole treatment → inhibition of ergosterol synthesis → squalene monooxygenase inhibition → impaired fungal cell membrane → symptom resolution.",
      "umls_path": [
        "Candidiasis of mouth",
        "may_be_treated_by",
        "Clotrimazole",
        "has_mechanism_of_action",
        "Squalene Monooxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Oral candidiasis is commonly seen in immunocompromised patients, such as those receiving chemotherapy. The most frequent causative organism is Candida albicans, which relies on ergosterol for maintaining fungal cell membrane integrity and function. Topical antifungals like clotrimazole are first-line therapy for uncomplicated cases. Clotrimazole works by inhibiting squalene monooxygenase, an enzyme crucial for the conversion of squalene to lanosterol, a precursor of ergosterol. Inhibition of this enzyme disrupts ergosterol synthesis, leading to increased membrane permeability and ultimately fungal cell death. By specifically targeting the squalene monooxygenase enzyme, clotrimazole effectively compromises the structural and functional integrity of the fungal cell membrane. This mechanism is distinct from agents that target other steps in the ergosterol pathway or other cellular processes, making squalene monooxygenase inhibition the primary molecular basis for this medication’s antifungal activity in oral candidiasis.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_b7f271d17d66",
      "question": "A 34-year-old man who recently emigrated from Southeast Asia presents with chronic abdominal discomfort, iron-deficiency anemia, and eosinophilia. Stool examination reveals ova consistent with hookworm infection, and he is diagnosed with an intestinal nematode infestation. He is started on a medication from the benzimidazole class that works by inhibiting microtubule polymerization in helminths. This drug is also known to induce certain hepatic metabolic enzymes, potentially altering the metabolism of co-administered drugs. Which specific class of hepatic enzymes is most relevant to the metabolic effects of this therapy, and what is the mechanism by which these enzymes are affected?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Necatoriasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0027528",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001911",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cytochrome P450 1A enzymes—induced by benzimidazole antihelminthics such as albendazole",
      "reasoning_path": "Albendazole treats hookworm infection and induces hepatic cytochrome P450 1A enzymes, altering metabolism of other drugs.",
      "umls_path": [
        "Necatoriasis",
        "may_be_treated_by",
        "Albendazole",
        "has_mechanism_of_action",
        "Cytochrome P450 1A Inducers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Albendazole, a benzimidazole antihelminthic, is commonly used to treat hookworm infections like necatoriasis. Its primary mechanism is to disrupt microtubule function in parasitic worms, leading to their death. Beyond its direct anti-parasitic activity, albendazole also has important pharmacokinetic effects: it can induce hepatic cytochrome P450 1A enzymes. These enzymes are responsible for metabolizing a variety of endogenous and exogenous substances, including many drugs. Induction of CYP1A can increase the metabolism of certain medications, potentially lowering their plasma concentrations and therapeutic effectiveness. This is especially relevant for patients taking drugs metabolized by CYP1A enzymes, as dose adjustments may be required to maintain efficacy. Recognizing the enzyme-inducing effects of benzimidazoles is crucial in clinical practice to anticipate drug-drug interactions and optimize patient safety and therapeutic outcomes.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_55e49dd4b0d6",
      "question": "A 54-year-old woman presents with pain and swelling over her right shoulder, worsened by activity and relieved by rest. Physical examination reveals localized tenderness and swelling over the subacromial bursa. She is diagnosed with bursitis. Her physician prescribes an anti-inflammatory medication known to reduce pain by inhibiting an enzyme involved in the breakdown of cyclic nucleotides, thereby modulating intracellular signaling pathways. Which enzyme is most directly inhibited by this medication, leading to its therapeutic effect in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Bursitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0006444",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0038792",
            "rela": "has_target"
          }
        }
      ],
      "answer": "cGMP-Specific 3',5'-Cyclic Phosphodiesterase",
      "reasoning_path": "Bursitis treated with sulindac; sulindac inhibits cGMP-specific phosphodiesterase, increasing cGMP, reducing inflammation.",
      "umls_path": [
        "Bursitis",
        "may_be_treated_by",
        "Sulindac",
        "has_target",
        "cGMP-Specific 3',5'-Cyclic Phosphodiesterase"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "The patient has bursitis, an inflammatory condition of the bursa, commonly managed with NSAIDs. Sulindac is an NSAID with a unique mechanism among its class: in addition to inhibiting cyclooxygenase (COX) enzymes, it also inhibits cGMP-specific 3',5'-cyclic phosphodiesterase. This enzyme degrades cyclic guanosine monophosphate (cGMP), a second messenger involved in many cellular processes, including vasodilation and modulation of inflammatory responses. By inhibiting this enzyme, sulindac increases intracellular cGMP levels, which can dampen inflammatory signaling pathways and contribute to analgesic and anti-inflammatory effects. Thus, the molecular target most directly affected by this drug, distinguishing it from other NSAIDs, is cGMP-specific phosphodiesterase. Identifying the specific enzyme target requires understanding both the pharmacologic profile of sulindac and the role of cyclic nucleotide metabolism in inflammation.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_d24949f4b5cb",
      "question": "For a patient with stage IVA non-small cell lung cancer (NSCLC) presenting with a malignant pleural effusion and confirmed KRAS G12C mutation in a squamous cell carcinoma subtype, is the recommendation to perform broad molecular profiling—including EGFR, ALK, and other driver mutations—still applicable, or does squamous histology generally exclude the need for such molecular testing?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1a: pleural or pericardial effusion",
              "FDG-PET/CT scan (if not previously done) • Brain MRI with contrast • Biomarker testing (NSCL-19) Thoracentesis or pericardiocentesis ± thoracoscopy if thoracentesis indeterminate",
              "Positive",
              "Local therapy if necessary (eg, pleurodesis, ambulatory small catheter drainage, pericardial window) + treatment for stage IV disease solitary site or distant disease (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "KRAS G12C mutation positive"
            ]
          }
        }
      ],
      "answer": "Broad molecular profiling, including testing for EGFR, ALK, and other actionable mutations, is now recommended even for patients with squamous cell carcinoma if sufficient tissue is available, particularly in advanced-stage disease. Squamous histology no longer categorically excludes the need for comprehensive molecular testing, as actionable mutations can occasionally be present.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_66707aee03da",
      "question": "In a patient with stage IIIB (T3, N2) non-small cell lung cancer presenting with symptomatic superior vena cava (SVC) obstruction, but who has previously received concurrent chemoradiation, is placement of an SVC stent still an appropriate management option?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Yes, for a patient with SVC obstruction and a history of prior concurrent chemoradiation, placement of a superior vena cava stent remains an appropriate management to promptly relieve obstructive symptoms, regardless of previous chemoradiation.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_61ad42a5e206",
      "question": "A 25-year-old woman presents with dysuria and purulent cervical discharge. Nucleic acid amplification testing confirms infection with Neisseria gonorrhoeae. She is prescribed an oral antibiotic that functions by interfering with bacterial chromosome separation during cell division. This drug exerts its effect by inhibiting which bacterial enzyme, thereby blocking DNA replication and leading to cell death?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Gonococcal Infection"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0018081",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0536495",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Topoisomerase IV",
      "reasoning_path": "Neisseria gonorrhoeae infection → treatment with fluoroquinolone (e.g., moxifloxacin) → inhibits bacterial topoisomerase IV → blocks DNA replication and segregation → bacterial cell death.",
      "umls_path": [
        "Gonococcal Infection",
        "may_be_treated_by",
        "Moxifloxacin",
        "has_mechanism_of_action",
        "Topoisomerase 4 Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has a confirmed Neisseria gonorrhoeae infection. Among the antibiotics used for such infections, some fluoroquinolones—such as moxifloxacin—are effective due to their mechanism of action on bacterial DNA replication. Moxifloxacin and related agents act by inhibiting bacterial topoisomerase IV, a type II topoisomerase. This enzyme is essential for the separation of interlinked daughter chromosomes during bacterial cell division. By inhibiting topoisomerase IV, the antibiotic prevents relaxation, decatenation, and proper segregation of DNA, ultimately leading to bacterial cell death. This mechanism specifically targets the bacterial enzyme, leaving human topoisomerases largely unaffected at therapeutic doses, which underlies the drug’s selectivity and efficacy in treating certain bacterial infections, including gonorrhea.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_6c8d2cafb6d2",
      "question": "For a patient with Stage IIA (T2b, N0) non-small cell lung cancer who underwent surgical resection with positive margins (R1 or R2), is adjuvant radiotherapy routinely indicated regardless of systemic therapy, or does its use depend upon additional clinicopathological factors?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIA (T2b, N0); Margins positive (R1, R2)",
              "Resection (preferred) ± systemic therapy or RT ± chemotherapy",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Adjuvant radiotherapy is not routinely indicated for all patients with positive margins after resection of Stage IIA (T2b, N0) non-small cell lung cancer. Its use depends on individual clinicopathological factors, including resection status, tumor characteristics, and patient comorbidities. Multidisciplinary assessment is required before recommending postoperative radiotherapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_ec041eefbbb9",
      "question": "A 42-year-old immunocompromised patient is hospitalized with a diffuse vesicular rash, fever, and evidence of viral pneumonia on imaging. Laboratory testing confirms a disseminated infection caused by a DNA virus. The patient is started on an intravenous antiviral agent that is a nucleoside analog; it is phosphorylated by viral kinases and then inhibits a viral enzyme responsible for genome replication. Which class of antiviral drugs operates via this same primary molecular mechanism?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Varicella"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0008049",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C2700247",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "DNA polymerase inhibitors",
      "reasoning_path": "Disseminated varicella-zoster is treated with vidarabine, a nucleoside analog that inhibits viral DNA polymerase. Other drugs in this class share the same mechanism, namely DNA polymerase inhibition.",
      "umls_path": [
        "Varicella",
        "may_be_treated_by",
        "Vidarabine Anhydrous",
        "has_mechanism_of_action",
        "DNA Polymerase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is experiencing severe varicella-zoster virus (VZV) infection, a DNA virus that requires viral DNA synthesis for replication. Vidarabine, the described antiviral, is a nucleoside analog that, after phosphorylation, competitively inhibits viral DNA polymerase. This inhibition halts viral DNA chain elongation, suppressing viral replication. Other agents with the same mechanism—such as acyclovir, ganciclovir, and foscarnet—also target viral DNA polymerase, making 'DNA polymerase inhibitors' the shared drug class. This class is particularly effective against viruses that replicate via DNA-dependent DNA polymerases, distinguishing them from agents that target RNA viruses or utilize different molecular targets. Understanding the mechanism is essential for rational antiviral selection, especially in immunocompromised patients where rapid viral suppression is critical.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_d8c513fa134d",
      "question": "In a patient with unresectable, ER- and/or PR-positive, HER2-positive stage IV invasive breast cancer without evidence of bone disease, is it necessary to confirm HER2 status on a biopsy of recurrent or metastatic tissue before initiating HER2-targeted systemic therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Metastatic (M1) invasive breast cancer",
              "Stage IV (M1) or Recurrent disease",
              "Workup for Recurrent or Stage IV (M1) Disease (BINV-18)",
              "Stage IV (M1) or Recurrent",
              "•History and physical exam•Discuss goals of therapy, adopt shared decision-making, and document course of care • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Imaging for systemic staging: ▸ Chest diagnostic CT ▸ contrast ▸ Abdomen ▸ pelvis diagnostic CT with contrast or MRI with contrast ▸ Brain MRI with contrast if suspicious CNS symptoms [hhh] ▸ Spine MRI with contrast if back pain or symptoms of cord compression ▸ Bone scan or sodium fluoride PET/CT (category 2B) ▸ Useful in certain circumstances FDG-PET/CT (consider FES-PET/CT for ER-positive disease) ▸ X-rays of symptomatic bones and long and weight-bearing bones abnormal on bone scan • Biomarker testing ▸ Biopsy of at least first recurrence of disease (consider re-biopsy if progression) [jjj] ▸ Evaluation of ER/PR and HER2 status [d] [iii] ▸ Comprehensive genomic and somatic profiling to identify candidates for targeted therapies [kkk] • Genetic counseling if patient is at risk for hereditary breast cancer [e] • Assess for distress [g]",
              "Systemic Treatment of Recurrent Unresectable (local or regional) or Stage IV (M1) (BINV-21) and Supportive care",
              "Recurrent unresectable (local or regional) or stage IV (M1) disease",
              "Bone disease not present",
              "ER- and/or PR-positive; HER2-positive",
              "BINV-24",
              "Systemic therapy + HER2-targeted therapy or Endocrine therapy ± HER2-targeted therapy (if premenopausal, consider ovarian ablation or suppression)",
              "Continue therapy until progression or unacceptable toxicity",
              "Progression (BINV-25)",
              "Progression on systemic therapy + HER2-targeted therapy",
              "Alternate systemic therapy + HER2-targeted therapy"
            ]
          }
        }
      ],
      "answer": "Yes, confirmation of HER2 status on recurrent or metastatic tissue is essential prior to initiating HER2-targeted therapy, as receptor expression may change between primary and metastatic sites, and current best practice requires treatment decisions to be based on the most recent pathological assessment.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_36c140337acb",
      "question": "In a patient with advanced or metastatic squamous cell carcinoma of the lung who is found to have a ROS1 rearrangement, is ROS1-targeted therapy recommended regardless of the squamous histology, or is the presence of squamous histology an exclusion criterion for ROS1 inhibitor treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "ROS1 rearrangement positive"
            ]
          }
        }
      ],
      "answer": "Current evidence and guidelines recommend ROS1-targeted therapy primarily for nonsquamous non-small cell lung cancer; squamous histology is generally considered an exclusion criterion for ROS1 inhibitor therapy unless there is clear evidence of a true driver mutation and no contraindications. Therefore, in patients with squamous histology, ROS1-targeted therapy is not routinely recommended.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_4df99c588b5c",
      "question": "A 25-year-old woman with lifelong generalized hypopigmentation and nystagmus seeks treatment to improve her skin pigmentation. Her dermatologist prescribes a photosensitizing agent, instructing her to take the medication orally prior to exposure to controlled ultraviolet A (UVA) light. This agent is known to intercalate into DNA and, upon activation by UVA, initiates photochemical reactions that ultimately enhance melanin synthesis in the skin. Which molecular process is most directly responsible for this agent's therapeutic action in increasing skin pigmentation?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Albinism"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001916",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0041086",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Photoabsorption—activation of the psoralen agent by UVA light",
      "reasoning_path": "Trioxsalen (a psoralen) is activated by UVA through photoabsorption, enabling photochemical reactions that promote melanin production in skin.",
      "umls_path": [
        "Albinism",
        "may_be_treated_by",
        "Trioxsalen",
        "has_mechanism_of_action",
        "Photoabsorption"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with albinism has deficient melanin production, resulting in hypopigmentation. The prescribed treatment is a psoralen (such as trioxsalen), which is used in photochemotherapy (PUVA) to stimulate melanogenesis. Psoralens intercalate into DNA and, upon exposure to UVA, absorb photons (photoabsorption). This initiates photochemical reactions, including DNA cross-linking and formation of reactive oxygen species, which stimulate melanocyte activity and melanin synthesis. The key molecular event is photoabsorption by the psoralen molecule, enabling these downstream effects. Without UVA-induced photoabsorption, the drug remains inactive. Thus, the therapeutic effect relies on the psoralen's ability to absorb photons, triggering a sequence that enhances skin pigmentation.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_ec52182b643f",
      "question": "A 29-year-old woman presents with chronic pelvic pain and dysmenorrhea that has progressively worsened over the past year. Laparoscopy confirms the presence of ectopic endometrial tissue on the ovaries and pelvic peritoneum. Her gynecologist initiates a novel oral therapy that acts at the pituitary level to suppress luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, leading to decreased ovarian estrogen production. Which pharmacologic class does this agent belong to, and how does its mechanism address her symptoms?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Endometriosis, site unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0014175",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C5235403",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Gonadotropin-releasing hormone (GnRH) receptor antagonists",
      "reasoning_path": "Endometriosis is estrogen-dependent. Linzagolix blocks pituitary GnRH receptors, suppressing LH/FSH, decreasing estrogen, and thus reducing endometriosis symptoms.",
      "umls_path": [
        "Endometriosis, site unspecified",
        "may_be_treated_by",
        "Linzagolix",
        "has_mechanism_of_action",
        "Gonadotropin Releasing Hormone Receptor Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Endometriosis symptoms are driven largely by estrogen-dependent growth of ectopic endometrial tissue. The patient's medication, linzagolix, is an oral GnRH receptor antagonist. By directly blocking GnRH receptors on pituitary gonadotropes, linzagolix rapidly suppresses the release of LH and FSH. This leads to a marked reduction in ovarian estrogen synthesis. Lower circulating estrogen diminishes stimulation of endometriotic implants, reducing inflammation, pain, and lesion progression. Unlike GnRH agonists, which initially cause a flare in gonadotropin release before downregulation, antagonists provide immediate suppression without this transient exacerbation. Thus, the therapeutic effect of linzagolix in endometriosis relies on its antagonism of pituitary GnRH receptors, resulting in hypoestrogenism and symptomatic relief.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_29165dedf6f2",
      "question": "For a patient with advanced or metastatic squamous cell carcinoma of the lung who is found to have an ERBB2 (HER2) mutation by broad molecular profiling, does the presence of this mutation automatically imply eligibility for targeted therapy regardless of PD-L1 expression status?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "ERBB2 (HER2) mutation positive"
            ]
          }
        }
      ],
      "answer": "No. Although the identification of an ERBB2 (HER2) mutation suggests potential eligibility for HER2-targeted therapy, current clinical practice typically prioritizes immunotherapy based on PD-L1 expression in squamous cell carcinoma. Targeted therapy eligibility remains investigational for ERBB2 mutations in this context and does not override standard PD-L1-driven treatment algorithms.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_d01a921a11f9",
      "question": "In a patient with stage IIB non-small cell lung cancer (T2b, N1) who has undergone surgery with negative margins (R0) but has mild chronic kidney disease, is annual surveillance with low-dose non–contrast-enhanced chest CT still appropriate, or does renal impairment necessitate a change in surveillance imaging modality or frequency?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Bone metastases",
              "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Annual low-dose non–contrast-enhanced chest CT remains appropriate for surveillance in this context. Mild chronic kidney disease does not necessitate changes to this modality or frequency, as non–contrast CT avoids contrast-induced nephropathy. Surveillance with non–contrast CT is suitable regardless of renal function.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_38d9ce097899",
      "question": "A 58-year-old woman presents with a several-month history of involuntary, forceful eyelid closure that interferes with her ability to read and perform daily activities. Neurological exam confirms frequent, sustained contractions of the orbicularis oculi muscles without other focal deficits. After inadequate relief from standard interventions, her neurologist initiates a medication that acts by blocking a specific neurotransmitter at its receptor sites, thereby reducing abnormal muscle activity. Which class of pharmacological agents is responsible for the therapeutic effect observed in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Blepharospasm"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0005747",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0354872",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Serotonin antagonists",
      "reasoning_path": "Blepharospasm involves abnormal muscle contractions; cyproheptadine’s therapeutic effect is due to serotonin receptor antagonism, which decreases neurotransmission driving these contractions.",
      "umls_path": [
        "Blepharospasm",
        "may_be_treated_by",
        "Cyproheptadine Hydrochloride",
        "has_mechanism_of_action",
        "Serotonin Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has refractory blepharospasm, a focal dystonia characterized by involuntary, excessive blinking or eyelid closure. Cyproheptadine hydrochloride, used off-label in such cases, is a first-generation antihistamine with additional antiserotonergic properties. Its therapeutic effect in blepharospasm is mainly attributed to antagonism of serotonin (5-HT) receptors, particularly 5-HT2. By blocking serotonin-mediated neurotransmission, cyproheptadine dampens abnormal signaling within motor pathways implicated in dystonia and muscle hyperactivity. Although it also has anticholinergic and antihistaminic effects, the predominant mechanism for blepharospasm control is serotonin receptor antagonism, which modulates central pathways that contribute to involuntary muscle contractions. Thus, the clinical benefit is derived from the drug’s action as a serotonin antagonist.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_dc091b7ed936",
      "question": "In a patient with newly diagnosed stage IIIA (T1–2, N2) non-small cell lung cancer and no prior thoracic radiotherapy, if both surgery and concurrent chemoradiation are technically feasible, which treatment approach should be prioritized as the initial management strategy, and why?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Concurrent chemoradiation should be prioritized as the initial management for stage IIIA (T1–2, N2) non-small cell lung cancer, given its established survival benefit and organ-preserving potential in this setting. Surgery is generally reserved for highly selected cases or as part of a multimodal approach post-induction therapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_df5a02ae9c3c",
      "question": "A 44-year-old man with a history of pulmonary tuberculosis presents with worsening cough, weight loss, and night sweats after failing multiple standard antibiotic regimens. Sputum cultures reveal Mycobacterium tuberculosis resistant to isoniazid, rifampin, fluoroquinolones, and second-line injectable agents. The infectious diseases team initiates therapy with a novel oral agent known to disrupt mycobacterial cellular metabolism by inhibiting a specific class of bacterial membrane transporters responsible for the uptake of key anionic substrates. Which transporter class is directly targeted by this drug to exert its antimycobacterial action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Extensively Drug-Resistant Tuberculosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1827301",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4310440",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Organic Anion Transporter 3 Inhibitors",
      "reasoning_path": "Patient has XDR-TB → Standard drugs ineffective → Pretomanid chosen for activity → Pretomanid inhibits bacterial OAT3 → Disrupts mycobacterial metabolism → Leads to bacterial death.",
      "umls_path": [
        "Extensively Drug-Resistant Tuberculosis",
        "may_be_treated_by",
        "Pretomanid",
        "has_mechanism_of_action",
        "Organic Anion Transporter 3 Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has extensively drug-resistant tuberculosis (XDR-TB), defined by resistance to both first- and several second-line anti-TB drugs. Pretomanid is a newer antimycobacterial agent used for XDR-TB. Its primary mechanism involves inhibition of the bacterial organic anion transporter 3 (OAT3), which impairs the uptake of essential anionic metabolites required for Mycobacterium tuberculosis survival. By blocking OAT3, pretomanid disrupts critical metabolic processes within the bacterium, leading to its death. This transporter inhibition is central to pretomanid’s efficacy in treating highly resistant TB strains, as it bypasses resistance mechanisms affecting more traditional drug targets. Thus, the central pharmacological effect of pretomanid in this setting is mediated by inhibition of organic anion transporter 3 in mycobacteria.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_68e1eb5f42f0",
      "question": "A 68-year-old woman with a history of hypertension presents with palpitations and mild shortness of breath. Her ECG reveals an irregularly irregular rhythm with absent P waves, consistent with atrial fibrillation. She is started on a medication that selectively inhibits a G protein-coupled receptor subtype most abundant in cardiac tissue, resulting in decreased sinoatrial node firing and slowed atrioventricular nodal conduction. Which receptor's antagonism is chiefly responsible for the therapeutic reduction in her ventricular rate?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Atrial fibrillation"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004238",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004147",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Beta-1 adrenergic receptor",
      "reasoning_path": "Atrial fibrillation → rate control needed → use of cardioselective beta-blocker → blocks beta-1 adrenergic receptors in the heart → decreases SA node firing and AV nodal conduction → reduced ventricular rate.",
      "umls_path": [
        "Atrial fibrillation",
        "may_be_treated_by",
        "Atenolol",
        "has_target",
        "Beta-1 Adrenergic Receptor"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "In atrial fibrillation, rapid and disorganized atrial impulses can lead to excessively fast ventricular rates. Rate control is essential to prevent symptoms and reduce the risk of tachycardia-induced cardiomyopathy. Cardioselective beta-blockers, such as atenolol or metoprolol, preferentially block beta-1 adrenergic receptors, which are G protein-coupled receptors primarily located in the heart. By antagonizing these receptors, these drugs decrease the effects of endogenous catecholamines (epinephrine and norepinephrine) on cardiac pacemaker cells. This leads to a reduction in the rate of depolarization at the sinoatrial (SA) node and slows conduction through the atrioventricular (AV) node. The net effect is a slower ventricular response, alleviating symptoms and improving hemodynamic stability. Beta-1 selectivity also minimizes side effects related to beta-2 receptor blockade, such as bronchoconstriction. Therefore, the primary molecular target mediating the drug’s therapeutic effect in rate control for atrial fibrillation is the beta-1 adrenergic receptor.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_9829aed6abb4",
      "question": "A 12-year-old boy with a lifelong history of recurrent nosebleeds and easy bruising is diagnosed with a congenital deficiency of a key clotting factor. During a recent episode of moderate bleeding, he receives an intravenous infusion of a recombinant biologic medication designed to substitute for his missing protein and facilitate the conversion of downstream zymogens into their active forms within the coagulation cascade. Which general pharmacological class most accurately describes the mechanism by which this therapy promotes hemostasis in his condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Factor VII deficiency"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0015503",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4064080",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme Activators",
      "reasoning_path": "Congenital clotting factor deficiency → Bleeding tendency → Recombinant factor replacement (e.g., Simoctocog Alfa) → Acts as enzyme activator in coagulation cascade → Promotes clot formation.",
      "umls_path": [
        "Factor VII deficiency",
        "may_be_treated_by",
        "Simoctocog Alfa",
        "has_mechanism_of_action",
        "Enzyme Activators"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has a congenital deficiency of a clotting factor, leading to impaired hemostasis. The described therapy is a recombinant biologic that substitutes for the missing factor and catalyzes the activation of downstream coagulation proteins. Simoctocog Alfa is a recombinant factor VIII, which, when infused, functions as a cofactor in the intrinsic pathway of coagulation. It activates factor X, which is a crucial zymogen in the production of thrombin and, ultimately, fibrin. By enhancing the activity of these enzymes, the therapy restores effective clot formation. Pharmacologically, such agents are classified as enzyme activators because their primary role is to augment or replace endogenous enzymes, directly promoting the enzymatic reactions necessary for coagulation. This is distinct from agents that act as inhibitors or non-enzymatic replacements, highlighting their mechanism as facilitators of enzyme-mediated processes vital for hemostasis.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_c6fe82496cf3",
      "question": "In a patient with Stage IVA non-small cell lung cancer (NSCLC) adenocarcinoma, found to have a ROS1 rearrangement during ongoing first-line systemic therapy, is it necessary to interrupt the ongoing therapy immediately to initiate a ROS1-targeted agent, or is it permissible to complete the planned systemic therapy including maintenance before switching to a ROS1-targeted therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "ROS1 rearrangement positive",
              "ROS1 rearrangement",
              "ROS1 rearrangement discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by entrectinibr (preferred), crizotinib (preferred), repotrectinibr (preferred), or ceritinib",
              "Progression",
              "Subsequent Therapy (NSCL-31)"
            ]
          }
        }
      ],
      "answer": "For patients with Stage IVA NSCLC adenocarcinoma in whom a ROS1 rearrangement is identified during first-line systemic therapy, it is acceptable to either complete the planned systemic therapy—including maintenance—or to interrupt it and switch to a ROS1-targeted agent such as entrectinib, crizotinib, or repotrectinib. Both approaches are considered appropriate according to current practice.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_1414d3bd2b2c",
      "question": "A 45-year-old woman presents with fever, localized pain, and swelling in her right thigh. Imaging reveals a deep soft tissue abscess. After drainage, she is started on an oral antimicrobial agent that is especially useful against anaerobic bacteria. While reviewing her medications, the clinician notes that, despite its clinical efficacy, the detailed cellular or molecular mechanism by which this drug acts is not fully classified in major pharmacological reference databases. Which statement best describes the current understanding of this drug’s mechanism of action according to formal pharmacological classification?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Abscess"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0000833",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0353490",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Deep abscess treated with metronidazole benzoate; pharmacological databases list its mechanism as unknown cellular or molecular interaction.",
      "umls_path": [
        "Abscess",
        "may_be_treated_by",
        "Metronidazole benzoate",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Metronidazole benzoate is commonly used to treat anaerobic infections such as deep soft tissue abscesses. While clinical studies demonstrate its effectiveness—primarily attributed to its reduction within anaerobic organisms leading to DNA strand breakage—the specific cellular or molecular interactions underlying its antimicrobial action are not fully characterized in formal pharmacological databases. As a result, its mechanism is often categorized as 'unknown cellular or molecular interaction.' This reflects a lack of comprehensive molecular pathway mapping in resources such as the UMLS or DrugBank, despite well-known clinical outcomes. Therefore, the most accurate formal description, according to current pharmacological classification systems, is that the drug’s precise mechanism remains officially unknown.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_cbe2af5e68cd",
      "question": "A 54-year-old man presents to the emergency department with fever, cough, and confusion. He recently returned from a hotel conference where several other attendees developed similar symptoms. Chest X-ray reveals patchy infiltrates, and urine antigen testing confirms infection with a Gram-negative intracellular pathogen. He is started on an antibiotic known for binding to the 50S ribosomal subunit of bacteria, thereby preventing translocation during protein synthesis. Which pharmacologic class best describes the mechanism of action underlying this antibiotic's efficacy against his pneumonia?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Legionella pneumonia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0023241",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0041165",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Protein synthesis inhibitors",
      "reasoning_path": "Legionella is an intracellular pathogen treated with macrolides, which work by binding to bacterial 50S ribosomes and inhibiting protein synthesis; thus, the drug's main mechanism is protein synthesis inhibition.",
      "umls_path": [
        "Legionella pneumonia",
        "may_be_treated_by",
        "Troleandomycin-containing product",
        "has_mechanism_of_action",
        "Protein Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s presentation is consistent with Legionella pneumophila pneumonia, a Gram-negative intracellular bacterium. Legionella is notoriously resistant to beta-lactams due to its intracellular lifestyle. Macrolide antibiotics, such as azithromycin, clarithromycin, or troleandomycin, are preferred because they achieve high intracellular concentrations and specifically inhibit bacterial protein synthesis. They do so by binding to the 50S ribosomal subunit, blocking the translocation step needed for elongation of the nascent peptide chain. By inhibiting this step, macrolides prevent bacteria from synthesizing essential proteins, thereby exerting a bacteriostatic (and sometimes bactericidal) effect. The central drug mechanism here is inhibition of bacterial protein synthesis—a class effect for all macrolide antibiotics. This mechanism is critical to their effectiveness against pathogens like Legionella, which rely on protein synthesis for survival within host cells.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_9f9c26e0021a",
      "question": "For a patient with completely resected stage IIB non-small cell lung cancer (NSCLC) with positive surgical margins (R1 resection), is chemoradiation with concurrent or sequential delivery preferred over re-resection combined with systemic therapy in the absence of medical contraindications to either approach?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
              "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Limited metastases",
              "Stage IV, M1b (NSCL-15)"
            ]
          }
        }
      ],
      "answer": "In the setting of completely resected stage IIB NSCLC with positive margins (R1), both re-resection with systemic therapy and chemoradiation are acceptable options. There is no definitive evidence demonstrating a clear superiority of concurrent or sequential chemoradiation over re-resection plus systemic therapy. The choice should be individualized based on resectability, patient comorbidities, and institutional expertise.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_ea31d36f2d1f",
      "question": "A 28-year-old man presents with new-onset seizures and chronic headaches. MRI of the brain reveals multiple ring-enhancing lesions with surrounding edema, and serologic testing supports a diagnosis of neurocysticercosis. He is started on an anti-parasitic agent that acts by disrupting the integrity of the parasite's membrane, specifically by facilitating increased influx of divalent cations. This causes sustained muscle contraction and subsequent paralysis of the parasite. Through which type of molecular interaction does this medication exert its therapeutic effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Cysticercosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0010678",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0032911",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Calcium channel interactions—praziquantel increases parasite membrane permeability to calcium ions via direct action on calcium channels.",
      "reasoning_path": "Patient with neurocysticercosis is given praziquantel; praziquantel acts directly on parasite calcium channels, causing increased calcium influx, paralysis, and parasite death.",
      "umls_path": [
        "Cysticercosis",
        "may_be_treated_by",
        "Praziquantel",
        "has_mechanism_of_action",
        "Calcium Channel Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Neurocysticercosis is caused by the larval stage of Taenia solium. Praziquantel is frequently used to treat this infection. Its mechanism of action involves direct interaction with parasite voltage-gated calcium channels, increasing their permeability to calcium ions. This leads to a rapid influx of calcium into the parasite’s cells, causing tetanic muscle contraction, paralysis, and eventual death of the parasite. Human neuronal and muscle calcium channels are much less sensitive to praziquantel, which accounts for its selective toxicity. The central molecular interaction is thus the alteration of parasite calcium channel function, not indirect effects or nonspecific membrane disruption. Recognizing this mechanistic pathway is essential for understanding both the efficacy and safety profile of the drug in treating cestode infections such as neurocysticercosis.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_9ec532bbaa3d",
      "question": "A 52-year-old woman with a BMI of 32 kg/m² and a history of hyperlipidemia undergoes evaluation for persistent fatigue and right upper quadrant discomfort. Laboratory studies reveal mildly elevated transaminases, and imaging shows increased hepatic echogenicity consistent with steatosis. Liver biopsy confirms nonalcoholic fatty liver disease (NAFLD) without significant fibrosis. She enrolls in a clinical trial and is randomized to receive an investigational oral agent designed to selectively activate a nuclear receptor involved in regulating cholesterol and triglyceride metabolism in hepatocytes. Which receptor class is the primary molecular target of this agent's therapeutic action in fatty liver disease?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Fatty liver"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0015695",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3850197",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Thyroid hormone receptor agonists",
      "reasoning_path": "NAFLD is treated with a THR-β agonist; resmetirom activates thyroid hormone receptors in hepatocytes, upregulating genes for lipid oxidation and decreasing liver fat.",
      "umls_path": [
        "Fatty liver",
        "may_be_treated_by",
        "Resmetirom",
        "has_mechanism_of_action",
        "Thyroid Hormone Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient has nonalcoholic fatty liver disease, a condition characterized by excessive hepatic fat accumulation. The investigational drug described matches the mechanism of resmetirom, a selective agonist of thyroid hormone receptor-beta (THR-β). THR-β is a nuclear receptor highly expressed in the liver, where it regulates genes controlling lipid metabolism. By activating this receptor, resmetirom enhances hepatic fatty acid oxidation and decreases lipogenesis, leading to reduced hepatic fat content. This targeted approach improves liver histology and metabolic parameters without significant systemic thyroid hormone effects. Thus, the drug’s therapeutic effect in fatty liver disease is mediated through agonism of the thyroid hormone receptor class.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_b90c57c32fac",
      "question": "For a patient with an incidentally detected, solid pulmonary nodule measuring 7 mm on chest CT, who also has a history of chronic obstructive pulmonary disease (COPD), does the standard recommendation for follow-up interval (CT at 6–12 months) still apply, or should the presence of COPD alter the imaging follow-up strategy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Incidental finding of nodule suspicious for lung cancer",
              "Multidisciplinary evaluation, Smoking cessation counseling",
              "Patient factors: Age, Smoking history, Previous cancer history, Family history, Occupational exposures, Other lung disease (chronic obstructive pulmonary disease [COPD], pulmonary fibrosis), Exposure to infectious agents (eg, endemic areas of fungal infections, tuberculosis) or risk factors or history suggestive of infection (eg, immune suppression, aspiration, infectious respiratory symptoms); Radiologic factors: Size, shape, and density of the pulmonary nodule, Associated parenchymal abnormalities (eg, scarring or suspicion of inflammatory changes), Fluorodeoxyglucose (FDG) avidity on FDG-PET/CT imaging",
              "Solid nodules Follow-up (DIAG-2)",
              "Incidental finding: solid nodule(s) on chest CT",
              "Low risk",
              "6–8 mm CT at 6–12 mo",
              "Stable Consider CT at 18–24 mo"
            ]
          }
        }
      ],
      "answer": "The standard follow-up interval of chest CT at 6–12 months for incidentally detected solid pulmonary nodules measuring 6–8 mm applies regardless of the presence of COPD, unless there are additional clinical or radiological signs suggesting acute infection, rapid nodule growth, or higher malignancy risk. COPD alone does not alter the surveillance interval.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_4af5aef29725",
      "question": "In a patient with invasive, non-inflammatory, non-metastatic (M0) breast cancer, clinical stage cT2N0, with a HER2-positive, ER-negative, PR-negative ductal carcinoma measuring 0.9 cm, and no evidence of axillary lymph node involvement, is the recommendation of adjuvant chemotherapy with trastuzumab strictly dependent on the tumor size being within 0.6–1.0 cm, or would this approach be considered for tumors slightly below 0.6 cm as well?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
              "ER-negative and PR-negative",
              "HER2-positive",
              "BINV-9",
              "Ductal/NST, Lobular, Mixed, Micropapillary",
              "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
              "Tumor 0.6–1.0 cm",
              "Consider adjuvant chemotherapy with trastuzumab"
            ]
          }
        }
      ],
      "answer": "Adjuvant chemotherapy with trastuzumab is generally considered for HER2-positive tumors measuring between 0.6 and 1.0 cm. For tumors smaller than 0.6 cm, especially node-negative, the benefit of such therapy is not well established and it is not routinely recommended; thus, the lower bound of 0.6 cm functions as a practical threshold.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_f2aa1c71c3bc",
      "question": "A 28-year-old patient with congenital lymphatic dysplasia develops severe hypoalbuminemia and edema due to persistent protein-losing enteropathy, despite maximal supportive therapy. The patient is started on an investigational monoclonal antibody that targets a key complement protein implicated in increased intestinal protein loss. Within weeks, his serum albumin rises and symptoms improve significantly. Through what fundamental pharmacological mechanism does this agent exert its clinical effect in this scenario?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Protein-losing enteropathy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0033680",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C5139913",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Pozelimab exerts its effect via targeted antibody interaction with complement protein C5, inhibiting its activity and thereby reducing complement-mediated intestinal damage and protein loss.",
      "reasoning_path": "Pozelimab is a monoclonal antibody targeting complement C5; its efficacy in protein-losing enteropathy derives from antibody-mediated inhibition of C5 activity, reducing intestinal protein loss.",
      "umls_path": [
        "Protein-losing enteropathy",
        "may_be_treated_by",
        "Pozelimab",
        "has_mechanism_of_action",
        "Antibody Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Protein-losing enteropathy (PLE) is marked by excessive gastrointestinal loss of serum proteins, often due to underlying lymphatic or inflammatory disorders. In certain refractory cases, therapies targeting the complement pathway have demonstrated benefit. Pozelimab is a monoclonal antibody that binds specifically to complement component C5, preventing its cleavage and subsequent formation of pro-inflammatory mediators such as C5a and the membrane attack complex (C5b-9). By blocking C5 activation, Pozelimab attenuates complement-mediated tissue injury and vascular leakage within the gut, thereby reducing protein loss. The therapeutic efficacy of Pozelimab fundamentally depends on its antibody-mediated neutralization of a disease-relevant molecular target, exemplifying the principle of specific antibody interactions as the core pharmacological mechanism.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_5ebd9d22bbc3",
      "question": "What is the PMID of the article titled “Assessment of plasma derived microbiome profiles in lung cancer using targeted and whole exome sequencing,” authored by Behel V and published in NPJ Systems Biology and Applications in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"Assessment of plasma derived microbiome profiles in lung cancer using targeted and whole exome sequencing.\"[ti] AND Behel V[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40483308"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_efb539c8c842",
      "question": "A 42-year-old woman with chronic gum inflammation and mild bleeding during brushing is instructed by her dentist to use a toothpaste containing stannous fluoride dihydrate as part of her oral hygiene regimen. During a dental research seminar, her provider is asked about the precise cellular or molecular mechanism underlying the therapeutic benefit of this agent in reducing gingival inflammation. What is the most accurate statement regarding the molecular mechanism of action of stannous fluoride dihydrate in gingivitis?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Gingivitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0017574",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3256380",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The precise cellular or molecular mechanism by which stannous fluoride dihydrate treats gingivitis is currently not fully understood.",
      "reasoning_path": "Stannous fluoride dihydrate is used for gingivitis, but its detailed mechanism in this context is not fully elucidated and remains unknown.",
      "umls_path": [
        "Gingivitis",
        "may_be_treated_by",
        "stannous fluoride dihydrate",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Stannous fluoride dihydrate is commonly recommended for patients with gingivitis due to its clinically observed benefits, such as reducing gum inflammation and bleeding. While its anti-caries effects are well established through remineralization of enamel and inhibition of bacterial metabolism, the exact cellular or molecular pathway responsible for its anti-gingivitis actions remains unclear. Proposed mechanisms include antimicrobial activity against oral pathogens and anti-inflammatory effects on gingival tissues, but direct molecular targets have not been conclusively identified. Therefore, the best-supported scientific position is that the detailed mechanism of action for stannous fluoride dihydrate in gingivitis is not fully defined at present.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_0f8ac69e7cd9",
      "question": "A 7-year-old boy is admitted to the hospital with acute onset of vomiting, confusion, and rapidly progressive lethargy following a recent viral illness treated with aspirin. Laboratory studies reveal elevated liver transaminases, hyperammonemia, and hypoglycemia. The medical team considers off-label use of a phenothiazine antipsychotic, primarily for symptomatic management of agitation and control of severe nausea. This agent is known to exert significant antagonistic effects on certain autonomic receptors. Which receptor-mediated mechanism is most relevant to the pharmacological effects of this drug in this clinical context?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Reye's syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0035400",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0031184",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Adrenergic alpha-antagonism",
      "reasoning_path": "Reye’s syndrome leads to neuropsychiatric and hepatic symptoms; perphenazine may be used for symptom control. Its clinical effects include alpha-adrenergic antagonism, which mediates sedative and antiemetic actions beneficial in this setting.",
      "umls_path": [
        "Reye's syndrome",
        "may_be_treated_by",
        "Perphenazine",
        "has_mechanism_of_action",
        "Adrenergic alpha-Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The child’s presentation is consistent with Reye’s syndrome, an acute, potentially life-threatening condition characterized by encephalopathy and hepatic dysfunction following aspirin use in viral illness. Perphenazine, a phenothiazine antipsychotic, is sometimes used off-label for severe agitation or refractory nausea in this setting. Among its several pharmacological actions, perphenazine exhibits significant antagonism at adrenergic alpha receptors. This alpha-adrenergic blockade can lead to sedation, reduced sympathetic outflow, and antiemetic effects—properties potentially beneficial in managing neuropsychiatric and gastrointestinal symptoms in Reye’s syndrome. While perphenazine also blocks dopamine D2 and histamine H1 receptors, its adrenergic alpha-antagonist activity is particularly relevant when considering its impact on autonomic symptoms and vascular tone. Therefore, when evaluating perphenazine’s effects in this context, adrenergic alpha-antagonism is the primary mechanism to consider.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_dd81d72edee1",
      "question": "A 34-year-old woman presents with five days of watery diarrhea, abdominal cramping, and mild fever after returning from vacation. Stool studies reveal no evidence of bacterial pathogens, and a presumptive diagnosis of viral gastroenteritis is made. To help manage her symptoms, she is advised to take an over-the-counter medication containing a compound that modifies the local gastrointestinal environment by altering pH and providing a protective coating. Through what primary molecular mechanism does this agent alleviate her symptoms in the context of her illness?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Viral Infection"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0042769",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0053790",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Acid-base activity—bismuth subgallate alters local pH and environment in the GI tract",
      "reasoning_path": "Viral gastroenteritis is treated symptomatically. Bismuth subgallate’s acid-base activity alters GI pH, providing mucosal protection and symptom relief.",
      "umls_path": [
        "Viral Infection",
        "may_be_treated_by",
        "Bismuth subgallate-containing product",
        "has_mechanism_of_action",
        "Acid-Base Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In viral gastroenteritis, there is no specific antiviral therapy, so symptom relief focuses on supportive measures. Bismuth subgallate is an over-the-counter agent that acts locally in the gastrointestinal tract. Its primary mechanism involves acid-base activity: it reacts with gastric acid, forming a mildly alkaline environment and a protective barrier over mucosal surfaces. This action can reduce irritation and help alleviate diarrhea by stabilizing the mucosal barrier and limiting further fluid loss. Additionally, the altered pH may inhibit the activity of some viral enzymes, but the principal therapeutic effect is symptomatic relief through modulation of the GI tract’s acid-base environment. This is distinct from direct antiviral or antimicrobial mechanisms.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_b427a8ac8171",
      "question": "For a patient with resected stage IIIA non-small cell lung cancer (T1–2, N2) who achieved R0 resection and completed adjuvant systemic therapy, if during surveillance a new small pulmonary nodule is detected without evidence of extrathoracic disease, is routine brain MRI with contrast warranted at this point?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Limited metastases",
              "Stage IV, M1b (NSCL-15)"
            ]
          }
        }
      ],
      "answer": "Routine brain MRI with contrast is not indicated in this scenario. Surveillance recommendations for resected stage III non-small cell lung cancer do not include brain MRI unless there are symptomatic findings or evidence of recurrence/metastasis. Brain MRI becomes appropriate only when recurrence or metastasis is suspected clinically or radiographically.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_85b182f30ff8",
      "question": "In a patient with advanced or metastatic squamous cell carcinoma of the lung who has undergone broad molecular profiling and is negative for EGFR, ALK, KRAS, ROS1, BRAF, NTRK, METex14, RET, and ERBB2 (HER2) mutations and has a PD-L1 expression level less than 1%, is it justified to use immune checkpoint inhibitor monotherapy as initial systemic therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Disseminated metastases",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "PD-L1 <1% and negative for actionable molecular biomarkers above"
            ]
          }
        }
      ],
      "answer": "No, for advanced squamous cell lung carcinoma lacking actionable mutations and with PD-L1 expression below 1%, immune checkpoint inhibitor monotherapy is not indicated as initial systemic therapy; platinum-based chemotherapy, with or without immunotherapy in combination regimens, is the recommended first-line approach according to standard guidelines.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_2db4b1578be6",
      "question": "In a patient with stage II non-small cell lung cancer who underwent surgical resection but has positive surgical margins (R1), is it justified to proceed directly to surveillance without additional chemoradiation or systemic therapy if there is no residual radiographic evidence of disease?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
              "R1; Resection + systemic therapy or Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Severe hemoptysis",
              "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "No, it is not justified. The presence of positive surgical margins (R1) after resection in stage II non-small cell lung cancer indicates a higher risk of local recurrence, and standard practice requires consideration of additional systemic therapy or chemoradiation before proceeding to surveillance, even if no residual disease is radiographically evident.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_319c18da9ba5",
      "question": "A 27-year-old woman reports excessive daytime sleepiness, frequent episodes where she suddenly falls asleep during conversations, and occasional brief losses of muscle tone triggered by laughter. Overnight polysomnography is unremarkable, but a multiple sleep latency test reveals rapid onset of REM sleep. Her neurologist prescribes a medication that increases arousal by blocking the reuptake of a specific monoamine neurotransmitter in the central nervous system. Which molecular pathway best explains the improvement in her wakefulness symptoms after starting this medication?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Narcolepsy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0027404",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0025810",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Inhibition of norepinephrine reuptake at synaptic terminals",
      "reasoning_path": "Narcolepsy leads to impaired arousal; norepinephrine reuptake inhibitors increase synaptic norepinephrine, activating arousal pathways and improving wakefulness.",
      "umls_path": [
        "Narcolepsy",
        "may_be_treated_by",
        "Methylphenidate-containing product",
        "has_mechanism_of_action",
        "Norepinephrine Uptake Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has narcolepsy, a disorder characterized by excessive daytime sleepiness and cataplexy. Stimulant medications, such as modafinil or methylphenidate, are frequently used to promote wakefulness. These agents work primarily by inhibiting the reuptake of norepinephrine at presynaptic terminals in the CNS, resulting in increased synaptic concentration of norepinephrine. The elevated norepinephrine level enhances activation of postsynaptic adrenergic receptors in brain regions responsible for arousal and alertness. This pharmacologic action counteracts the underlying problem of sleep-wake dysregulation in narcolepsy, thereby reducing daytime sleep attacks and improving the patient's ability to remain awake and attentive. While some stimulants may also influence dopamine pathways, the therapeutic effect in narcolepsy is most closely linked to norepinephrine reuptake inhibition.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_4e6c91ae7ab3",
      "question": "What is the unique PubMed ID (PMID) for the article titled “[Evolution of enterology as a science]” by Sabelnikova EA, published in Terapevticheskii arkhiv in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"[Evolution of enterology as a science].\"[ti] AND Sabelnikova EA[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40237759"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_b33470b6d876",
      "question": "In a patient with advanced squamous cell lung carcinoma and confirmed ERBB2 (HER2) mutation, is first-line use of fam-trastuzumab deruxtecan-nxki justified, or should molecular targeted therapies be reserved for adenocarcinoma histology only, according to the available evidence?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "ERBB2 (HER2) mutation positive",
              "ERBB2 (HER2) mutation",
              "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
              "Tumor response evaluation",
              "Response or stable disease",
              "Progression",
              "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
              "Progression",
              "PS 3–4",
              "Best supportive care: NCCN Guidelines for Palliative Care"
            ]
          }
        }
      ],
      "answer": "Fam-trastuzumab deruxtecan-nxki is an appropriate first-line systemic therapy for advanced squamous cell carcinoma with confirmed ERBB2 (HER2) mutation. Its use is not limited to adenocarcinoma histology; molecular targeted therapies should be considered in non-small cell lung cancer regardless of subtype when actionable mutations are present.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_1bd1c6eb2402",
      "question": "For a patient with advanced non-small cell lung cancer (adenocarcinoma subtype) who tests positive for EGFR S768I, L861Q, or G719X mutations but also presents with a very poor performance status (ECOG 3-4) due to extensive metastatic disease, is it still appropriate to initiate targeted therapy with erlotinib, gefitinib, or dacomitinib as first-line systemic treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "EGFR S768I, L861Q, and/or G719X mutation positive",
              "EGFR S768I, L861Q, and/or G719X mutations",
              "EGFR mutation discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by erlotinib or gefitinib or dacomitinib",
              "Progression",
              "Subsequent Therapy (NSCL-23)"
            ]
          }
        }
      ],
      "answer": "In patients with EGFR S768I, L861Q, or G719X mutations, targeted therapy with EGFR tyrosine kinase inhibitors such as erlotinib, gefitinib, or dacomitinib is the standard first-line approach. However, for those with ECOG performance status 3-4 not related to tumor burden, systemic therapy is generally not recommended. If poor performance status is primarily due to tumor burden, targeted therapy may still be considered, as responses can improve functional status.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_0800e21861f9",
      "question": "In a patient with stage II non-small cell lung cancer who is medically inoperable and has a history of significant restrictive lung disease demonstrated by poor pulmonary function tests, is stereotactic ablative radiotherapy (SABR) still preferred as the definitive treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "No nodal disease",
              "Medically inoperable, high surgical risk as determined by thoracic surgeon, and those who decline surgery after thoracic surgical consultation",
              "Definitive RT, preferably SABR",
              "Consider adjuvant chemotherapy for high-risk stage II",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)"
            ]
          }
        }
      ],
      "answer": "Yes, stereotactic ablative radiotherapy (SABR) remains the preferred definitive treatment for stage II non-small cell lung cancer in medically inoperable patients, including those with significant restrictive lung disease, as surgery is contraindicated. SABR provides effective local control while minimizing pulmonary toxicity compared to conventional radiotherapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_f64c548b02dc",
      "question": "A 57-year-old woman with a history of hypercholesterolemia is diagnosed with multiple small cholesterol gallstones after presenting with intermittent right upper quadrant pain. She is not a candidate for surgery and is started on an oral bile acid therapy that is intended to dissolve the stones over time. The precise molecular mechanism by which this agent facilitates gallstone dissolution is not fully established. Which best describes the current understanding of this drug’s cellular or molecular mechanism of action in the management of her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Biliary calculus"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0008350",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0042105",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Cholesterol gallstones are treated with ursodiol, a bile acid, which promotes stone dissolution through mechanisms that remain incompletely understood at the cellular or molecular level.",
      "umls_path": [
        "Biliary calculus",
        "may_be_treated_by",
        "Ursodiol",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient is being treated for cholesterol gallstones with a bile acid—most commonly ursodiol (ursodeoxycholic acid)—as a non-surgical dissolution therapy. Ursodiol is thought to decrease cholesterol saturation in bile, thereby promoting gradual dissolution of cholesterol stones. However, despite its clinical use, the exact mechanism at the cellular or molecular level remains unclear. Ursodiol may act by reducing hepatic secretion of cholesterol, altering bile acid composition, or stabilizing hepatocyte canalicular membranes, but no definitive molecular target or pathway has been proven. Thus, while the clinical outcome (stone dissolution) is well documented, the precise cellular or molecular interaction responsible is classified as unknown.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_141f7747e7fa",
      "question": "In a patient with stage IIIA non-small cell lung cancer presenting with a centrally located T4 tumor abutting the subclavian vessels and without evidence of extrathoracic metastasis, is preoperative MRI with contrast of the thoracic inlet mandatory for appropriate assessment, or can it be omitted if FDG-PET/CT and chest CT with contrast are both unremarkable?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Preoperative MRI with contrast of the thoracic inlet is mandatory in this scenario, as assessment of local invasion into the subclavian vessels or brachial plexus cannot be comprehensively achieved by FDG-PET/CT or chest CT alone; MRI provides superior soft tissue delineation necessary for surgical planning in superior sulcus or T4 lesions.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_ac5bc3be92e8",
      "question": "A 15-year-old recently diagnosed with a generalized seizure disorder characterized by early-morning myoclonic jerks and absence episodes is started on a well-tolerated antiepileptic medication. Although the drug is widely used for this indication and demonstrates reliable efficacy, the exact molecular or cellular mechanism underlying its anticonvulsant effect is not fully established. Which statement best describes the current understanding of how this agent achieves seizure control in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Juvenile myoclonic epilepsy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0270853",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0377265",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The precise cellular or molecular mechanism of action of levetiracetam remains unknown.",
      "reasoning_path": "Juvenile myoclonic epilepsy is treated with levetiracetam, but its exact cellular or molecular mechanism of action has not been fully elucidated.",
      "umls_path": [
        "Juvenile myoclonic epilepsy",
        "may_be_treated_by",
        "Levetiracetam",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This adolescent presents with juvenile myoclonic epilepsy, a generalized epilepsy syndrome that often responds well to levetiracetam. While levetiracetam is effective and frequently used for this condition, its anticonvulsant mechanism is not fully delineated. Unlike many other antiepileptic drugs, which have defined targets such as sodium channels, GABA receptors, or calcium channels, levetiracetam’s primary mechanism is not clearly linked to these pathways. Some studies suggest it binds to the synaptic vesicle protein SV2A and modulates neurotransmitter release, but the downstream effects leading to seizure control have not been completely clarified. Thus, its clinical utility is well established, but the detailed molecular basis for its action remains an area of ongoing research.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_81930e859fa3",
      "question": "In a patient with non-small cell lung cancer (NSCLC) staged as IIIA based on T4 primary tumor extension and N1 nodal involvement, if mediastinal lymph node metastasis is subsequently identified by pathological evaluation, does this change the clinical stage and potentially alter the eligibility for perioperative therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 0–2",
              "Limited progression confirmed",
              "Other site",
              "Treatment of Thoracic Disease (NSCL-16)"
            ]
          }
        }
      ],
      "answer": "Yes, the presence of pathologically confirmed mediastinal lymph node metastasis in NSCLC upgrades the disease to at least stage IIIB. This upstaging generally precludes standard perioperative therapy approaches and shifts the treatment focus to definitive or multimodal oncologic management.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_e275ab319e8d",
      "question": "In patients with stage IIIA non-small cell lung cancer and confirmed N3 lymph node involvement via EBUS biopsy, does the consideration of endobronchial interventions (such as laser ablation or stenting) necessarily imply the presence of symptomatic endobronchial obstruction?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (peripheral T1abc, N0)",
              "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Yes. The use of endobronchial interventions such as laser ablation or stenting in stage IIIA NSCLC with confirmed N3 involvement specifically targets the management of symptomatic endobronchial obstruction, as these procedures are indicated for palliative relief of airway compromise rather than for asymptomatic patients.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_dd16414a6b42",
      "question": "For a patient with early-stage, invasive, non-inflammatory, non-metastatic breast cancer who presents with a single axillary lymph node suspicious for metastasis on imaging and confirmed by percutaneous biopsy, is sentinel lymph node (SLN) mapping and excision still appropriate, or should axillary lymph node dissection (ALND) be preferred as the initial surgical intervention?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For operable breast cancers: see Breast and Axillary Evaluation Prior to Preoperative Systemic Therapy (BINV-13)",
              "Prior to preoperative systemic therapy, perform: • Core biopsy of breast with placement of image-detectable clips or marker(s), if not previously performed, should be performed prior to preoperative therapy to demarcate the tumor bed • Axillary imaging with ultrasound or MRI (if not previously done) and • Biopsy + marker placement recommended of the most suspicious and/or clinically positive axillary lymph node, if not previously done; only the most suspicious node should be marked and retrieved along with SLNs",
              "Preoperative systemic therapy based on HR and HER2 status",
              "Surgical Treatment and Adjuvant Therapy After Preoperative Systemic Therapy",
              "BCS possible",
              "Mastectomy and surgical axillary staging (BINV-D) ± reconstruction",
              "No palpable lymph node at diagnosis and limited axillary lymph node involvement on imaging confirmed by needle biopsy ± marker placement in the most suspicious node",
              "SLN mapping and excision",
              "SLN not identified",
              "ALND level I/II"
            ]
          }
        }
      ],
      "answer": "In patients with operable, non-metastatic breast cancer and limited axillary lymph node involvement confirmed by needle biopsy of the most suspicious node, SLN mapping and excision remain appropriate for axillary staging. ALND is reserved for cases where SLNs are not identified or there is extensive nodal disease; initial ALND is not routinely required in this scenario.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_312e8c16b78e",
      "question": "A 58-year-old woman with a several-year history of dry mouth and gritty eyes is diagnosed with an autoimmune exocrinopathy after serologic testing and minor salivary gland biopsy. She is started on artificial tears and saliva substitutes with partial relief. Her rheumatologist suggests supplementing with an omega-3 fatty acid, noting some evidence for benefit in her chronic sicca symptoms. However, when asked about the precise cellular or molecular pathway by which this supplement exerts its effect in her condition, what is the most accurate response?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Sjögren's syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1527336",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0125903",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The precise cellular or molecular mechanism of action of linolenic acid in Sjögren's syndrome remains unclear.",
      "reasoning_path": "Linolenic acid is used in Sjögren's syndrome, but its precise cellular or molecular mechanism of action in this indication remains unknown.",
      "umls_path": [
        "Sjögren's syndrome",
        "may_be_treated_by",
        "Linolenic acid",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Linolenic acid, an omega-3 fatty acid, is sometimes used as adjunctive therapy in Sjögren's syndrome to address dryness symptoms. While omega-3 fatty acids are thought to have anti-inflammatory effects, the specific cellular or molecular target relevant to Sjögren's syndrome—such as a receptor, signaling pathway, or immune cell modulation—has not been clearly established. Clinical benefit may stem from general immunomodulatory and anti-inflammatory properties observed with omega-3 supplementation, but direct mechanistic evidence in Sjögren's is lacking. Thus, although linolenic acid may provide symptomatic relief, the exact mechanism by which it acts at the molecular or cellular level in this autoimmune condition remains undefined.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_c0708afd97e5",
      "question": "A 32-year-old woman with a history of persistent, treatment-resistant warts on her hands is referred to dermatology after failing multiple topical and destructive therapies. The dermatologist proposes an off-label course of a recombinant cytokine, which has shown some benefit in similar cases. Despite clinical use, the underlying cellular or molecular action of this drug in the context of her condition is not clearly established. Which best describes the current understanding of the drug’s mechanism in managing her skin lesions?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Verruca vulgaris"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3665596",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0244714",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Interferon beta-1b is sometimes used for difficult verruca vulgaris, but its mechanism in this setting is not specifically defined at the cellular or molecular level.",
      "umls_path": [
        "Verruca vulgaris",
        "may_be_treated_by",
        "Interferon beta 1b (recombinant)",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Recalcitrant verruca vulgaris (common warts) may be treated with recombinant interferons, such as interferon beta-1b, especially when conventional therapies fail. Interferons are known to have broad antiviral and immunomodulatory properties, generally acting by enhancing the immune response against viral pathogens. However, in the specific context of verruca vulgaris, the precise cellular or molecular mechanism responsible for the therapeutic effect of interferon beta-1b is not well characterized. There is a lack of definitive evidence outlining how this agent interacts with viral or host cell targets in these lesions. Thus, while interferon therapy can lead to wart resolution in some cases, its exact mechanism of action for this indication remains uncertain and is best described as unknown at the cellular or molecular level.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_91172ad97ed6",
      "question": "A 62-year-old woman with diabetes presents with erythema, swelling, and purulent drainage from her lower leg after sustaining a minor injury. She is diagnosed with a severe soft tissue infection and started on an intravenous antibiotic known to disrupt bacterial cell wall synthesis by binding to and inhibiting transpeptidase enzymes. Through which broad pharmacological class does this medication exert its primary therapeutic action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Soft tissue infection"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0149778",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0007560",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme inhibitors",
      "reasoning_path": "Severe soft tissue infection is treated with ceftizoxime, which inhibits bacterial transpeptidase enzymes (PBPs), classifying it as an enzyme inhibitor.",
      "umls_path": [
        "Soft tissue infection",
        "may_be_treated_by",
        "Ceftizoxime-containing product",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is receiving ceftizoxime for a soft tissue infection. Ceftizoxime is a third-generation cephalosporin, which belongs to the beta-lactam class of antibiotics. These drugs act by binding to bacterial penicillin-binding proteins (PBPs), specifically the transpeptidase enzymes responsible for cross-linking peptidoglycan strands in the bacterial cell wall. By inhibiting these enzymes, ceftizoxime impedes the synthesis and structural integrity of the bacterial cell wall, leading to cell lysis and bacterial death. Thus, the primary pharmacological action is enzyme inhibition—specifically, inhibition of bacterial cell wall-synthesizing enzymes. This mechanism underlies the efficacy of ceftizoxime and similar antibiotics in the treatment of severe bacterial soft tissue infections.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_230389586a15",
      "question": "A 55-year-old man presents to the emergency department with intense pain, redness, and swelling in his right first metatarsophalangeal joint that began overnight. He has a history of hypertension and reports consuming alcohol at a party the previous evening. Examination shows a warm, erythematous, tender joint without evidence of trauma. He is diagnosed with acute monoarticular inflammation and started on a medication that rapidly alleviates his symptoms by blocking a key enzyme in the prostaglandin biosynthetic pathway. Which enzyme is most directly inhibited by this therapy, resulting in decreased production of inflammatory mediators in the affected joint?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Articular gout"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003868",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021246",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 1 (Cyclooxygenase-1, COX-1)",
      "reasoning_path": "Acute gout causes prostaglandin-mediated inflammation; indomethacin inhibits prostaglandin G/H synthase 1 (COX-1), reducing prostaglandin production and inflammation.",
      "umls_path": [
        "Articular gout",
        "may_be_treated_by",
        "Indomethacin",
        "has_target",
        "Prostaglandin G/H Synthase 1"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "The patient's acute monoarticular arthritis following dietary indiscretion is classic for a gout flare, driven by urate crystal-induced inflammation. Initial symptom control relies on anti-inflammatory agents such as indomethacin, a nonsteroidal anti-inflammatory drug (NSAID). Indomethacin exerts its effect by inhibiting prostaglandin G/H synthase 1 (COX-1), a critical enzyme in the conversion of arachidonic acid to prostaglandins. Prostaglandins amplify the inflammatory response, causing vasodilation, increased vascular permeability, and sensitization of pain fibers. By blocking COX-1, indomethacin reduces prostaglandin synthesis, leading to decreased inflammation, swelling, and pain in the joint. While indomethacin also inhibits COX-2, COX-1 plays a significant role in acute inflammatory signaling in this context. Thus, the primary molecular target responsible for its therapeutic effect in acute gout is prostaglandin G/H synthase 1.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_4f73dc22a4d7",
      "question": "In a patient with advanced non-small cell lung cancer of adenocarcinoma subtype and confirmed bone metastases, if a high risk of pathological fracture is present, should orthopedic stabilization and palliative radiotherapy be implemented before initiating systemic therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Bone metastases",
              "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "EGFR exon 19 deletion or exon 21 L858R mutation positive"
            ]
          }
        }
      ],
      "answer": "Yes, in patients with bone metastases from advanced adenocarcinoma subtype NSCLC and high risk of fracture, orthopedic stabilization and palliative external-beam radiotherapy should be performed prior to starting systemic therapy to prevent skeletal-related events and ensure appropriate supportive management.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_9442e62b59c9",
      "question": "For a patient with invasive, non-inflammatory, non-metastatic (M0) breast cancer, ER-negative, PR-negative, and HER2-negative profile, with a tumor size of 0.6 cm and pN0 status after breast-conserving surgery, is omission of adjuvant systemic therapy still appropriate, or does the tumor size exceeding 0.5 cm mandate systemic treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
              "ER-negative and PR-negative",
              "HER2-negative",
              "BINV-10",
              "Ductal/NST, Lobular, Mixed, Micropapillary, Metaplastic",
              "pT1, pT2, or pT3; and pN0 or pN1mi (≤2 mm axillary node metastasis)",
              "Tumor ≤0.5 cm",
              "pN0",
              "No adjuvant therapy",
              "Follow-Up (BINV-17)"
            ]
          }
        }
      ],
      "answer": "Adjuvant systemic therapy may be considered for tumors larger than 0.5 cm, especially in triple-negative breast cancer because of higher recurrence risk. For a tumor size of 0.6 cm (pT1b), adjuvant systemic therapy is generally indicated, and omission would not be appropriate except in exceptional cases of severe comorbidity.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_037791438cb9",
      "question": "A 44-year-old man presents with severe, unilateral periorbital pain occurring nightly for several weeks, accompanied by ipsilateral lacrimation and nasal congestion. Standard therapies have failed to provide relief. His neurologist prescribes a medication that acts as both an agonist and antagonist at several monoamine receptors, including those for serotonin, to help alleviate his symptoms. Through what general receptor mechanism does this medication primarily exert its therapeutic effect in treating this type of headache?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Chronic cluster headache"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0009088",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0771983",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Serotonin receptor modulation (agonism and antagonism)",
      "reasoning_path": "Chronic cluster headaches are treated with dihydroergotamine, which modulates serotonin receptors (agonist/antagonist actions) to reduce neurogenic inflammation and vasodilation implicated in headache attacks.",
      "umls_path": [
        "Chronic cluster headache",
        "may_be_treated_by",
        "dihydroergotamine tartrate",
        "has_mechanism_of_action",
        "Serotonin Antagonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s clinical presentation is consistent with chronic cluster headache, characterized by recurrent, severe, unilateral pain and autonomic symptoms. Dihydroergotamine tartrate is prescribed for refractory cases. Mechanistically, dihydroergotamine binds to multiple serotonin (5-HT) receptor subtypes, particularly 5-HT1B and 5-HT1D, where it acts as a partial agonist. It also has some antagonistic activity at other serotonin receptors. By modulating these serotonin receptors, dihydroergotamine causes cranial vasoconstriction and inhibits release of pro-inflammatory neuropeptides from trigeminal nerve endings, both of which are implicated in the pathophysiology of cluster headaches. Therefore, its therapeutic effect is primarily mediated by modulation (agonism and antagonism) of serotonin receptors, rather than exclusive antagonism or agonism, resulting in decreased headache frequency and severity.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_4cba6ffafecb",
      "question": "A 54-year-old woman with a history of chronic, treatment-refractory blistering skin disease is started on an oral gold-containing medication as a steroid-sparing agent. Shortly after initiation, laboratory monitoring is performed to assess potential impacts on cellular oxidative stress. This medication is known to inhibit a key mitochondrial enzyme critical for maintaining redox balance by reducing oxidized thioredoxin. Which specific molecular target is most directly inhibited by this therapy, leading to its immunomodulatory effects?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Pemphigus"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0030807",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004320",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Thioredoxin Reductase 2, Mitochondrial",
      "reasoning_path": "Pemphigus is treated with auranofin, which inhibits mitochondrial thioredoxin reductase 2, disrupting redox regulation in immune cells.",
      "umls_path": [
        "Pemphigus",
        "may_be_treated_by",
        "Auranofin",
        "has_target",
        "Thioredoxin Reductase 2, Mitochondrial"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "The patient described has pemphigus, an autoimmune blistering disorder, and is being treated with a gold-containing compound, auranofin. Auranofin exerts its immunosuppressive effects in part by inhibiting mitochondrial thioredoxin reductase 2. Thioredoxin reductase 2 is an essential mitochondrial enzyme that catalyzes the reduction of oxidized thioredoxin, maintaining cellular redox homeostasis and protecting cells from oxidative damage. Inhibition of this enzyme by auranofin increases oxidative stress within immune cells, thereby impairing their function and reducing autoimmune activity. This mechanism underlies its therapeutic benefit in autoimmune conditions such as pemphigus, where aberrant immune activation leads to tissue damage. Thus, the primary molecular target affected by auranofin in this context is mitochondrial thioredoxin reductase 2.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_62464228095b",
      "question": "In a patient with localized, invasive, non-inflammatory, non-metastatic (M0) breast cancer who had a primary tumor larger than 5 cm, negative axillary lymph nodes, and underwent total mastectomy with surgical axillary staging, is chest wall radiotherapy still indicated if the patient did not receive preoperative systemic therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "Negative axillary nodes and tumor >5 cm",
              "Consider RT to chest wall ± comprehensive RNI (including any portion of the undissected axilla at risk)."
            ]
          }
        }
      ],
      "answer": "Yes, postmastectomy radiotherapy to the chest wall—with or without comprehensive regional nodal irradiation—is recommended for patients with negative axillary nodes and a tumor size greater than 5 cm, regardless of whether preoperative systemic therapy was administered.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_319967b8909f",
      "question": "In a patient with advanced squamous cell lung carcinoma presenting with ECOG performance status 3 and confirmed PD-L1 expression less than 1% with no actionable molecular alterations, does this clinical scenario necessitate exclusion from all systemic therapy options and guide toward best supportive care exclusively?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "PD-L1 <1% and negative for actionable molecular biomarkers above",
              "PD-L1 <1%",
              "INITIAL SYSTEMIC THERAPY",
              "PS 3–4",
              "Best supportive care NCCN Guidelines for Palliative Care"
            ]
          }
        }
      ],
      "answer": "Yes, for advanced squamous cell lung carcinoma with ECOG performance status 3, PD-L1 <1%, and no actionable molecular targets, the standard clinical approach is to forego systemic therapy due to poor functional status and limited expected benefit, recommending best supportive care only.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_ffbbcb4faf51",
      "question": "In the OpenTargets platform, can you provide the tractability information for the target with Ensembl ID ENSG00000171105 and approved symbol INSR, where the value is True?",
      "tool_calls": [
        {
          "tool": "opentargets.tractability",
          "params": {
            "target_id": "ENSG00000171105",
            "value": true
          }
        }
      ],
      "answer": [
        {
          "modality": "SM",
          "label": "Advanced Clinical"
        },
        {
          "modality": "SM",
          "label": "Structure with Ligand"
        },
        {
          "modality": "SM",
          "label": "High-Quality Ligand"
        },
        {
          "modality": "SM",
          "label": "High-Quality Pocket"
        },
        {
          "modality": "SM",
          "label": "Druggable Family"
        },
        {
          "modality": "AB",
          "label": "GO CC high conf"
        },
        {
          "modality": "AB",
          "label": "UniProt loc med conf"
        },
        {
          "modality": "AB",
          "label": "UniProt SigP or TMHMM"
        },
        {
          "modality": "AB",
          "label": "Human Protein Atlas loc"
        },
        {
          "modality": "PR",
          "label": "Database Ubiquitination"
        },
        {
          "modality": "PR",
          "label": "Half-life Data"
        },
        {
          "modality": "PR",
          "label": "Small Molecule Binder"
        },
        {
          "modality": "OC",
          "label": "Approved Drug"
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "path_5e30806cca51",
      "question": "In a patient with non-matching histological subtype, such as tubular carcinoma of the breast, clinical stage cT2N0M0, ER-negative/PR-negative, and HER2-negative status, is standard adjuvant chemotherapy after total mastectomy with axillary staging (pN+) still indicated, or is this approach specific to ductal/NST, lobular, mixed, micropapillary, or metaplastic subtypes only?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "Total mastectomy with surgical axillary staging (category 1) ± reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
              "ER-negative and PR-negative",
              "HER2-negative",
              "BINV-10",
              "Ductal/NST, Lobular, Mixed, Micropapillary, Metaplastic",
              "pN+ (≥1 ipsilateral metastases >2 mm)",
              "Adjuvant chemotherapy (category 1)",
              "Follow-Up (BINV-17)"
            ]
          }
        }
      ],
      "answer": "Standard adjuvant chemotherapy after total mastectomy with axillary staging (pN+) is primarily indicated for invasive subtypes explicitly listed—ductal/NST, lobular, mixed, micropapillary, or metaplastic. Applying this approach to uncommon subtypes like tubular carcinoma requires further pathological risk assessment, as these subtypes may have distinct prognosis and sensitivity to systemic therapy.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_79356ea3c629",
      "question": "In a patient with advanced non-small cell lung cancer (adenocarcinoma histology), who tests positive for an EGFR S768I mutation prior to any systemic therapy, is it implied that molecular profiling has excluded co-occurring ALK and ROS1 rearrangements before proceeding with EGFR tyrosine kinase inhibitor treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "EGFR S768I, L861Q, and/or G719X mutation positive",
              "EGFR S768I, L861Q, and/or G719X mutations",
              "EGFR mutation discovered prior to first-line systemic therapy",
              "Other Recommended: Erlotinib or Gefitinib or Dacomitinib",
              "Progression",
              "Subsequent Therapy (NSCL-23)"
            ]
          }
        }
      ],
      "answer": "Yes, the recommendation to initiate EGFR tyrosine kinase inhibitor therapy in a patient with an EGFR S768I mutation presumes comprehensive molecular profiling has been performed, and that actionable co-alterations such as ALK or ROS1 rearrangements have been excluded, as these may direct alternative targeted strategies.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_2927bede55f3",
      "question": "For a patient with stage IB (T2a, N0) non-small cell lung cancer who has undergone complete surgical resection with negative margins, does the consideration of adjuvant systemic therapy inherently assume the presence of additional high-risk pathologic features, or can it be justified solely by the stage and margin status?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (T2a, N0); Margins negative (R0)",
              "Observe or Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "The consideration of adjuvant systemic therapy after complete resection with negative margins in stage IB (T2a, N0) non-small cell lung cancer generally presumes the existence of additional high-risk pathologic features; routine use based only on stage IB and negative margins is not standard without further high-risk factors such as lymphovascular invasion, poorly differentiated histology, or vascular invasion.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_2e9c95f30763",
      "question": "A 62-year-old man with a history of intermittent claudication and hyperlipidemia presents to the clinic for follow-up. His physician initiates a medication known to improve walking distance by inducing vasodilation and beneficially altering lipid profiles. This agent is understood to exert its effects by influencing intracellular biochemical pathways, ultimately leading to decreased triglyceride synthesis and enhanced peripheral blood flow. Through which general pharmacological mechanism does this medication primarily act to achieve its therapeutic goals?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Peripheral vascular disease, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0085096",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0772043",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme interactions",
      "reasoning_path": "Peripheral vascular disease is treated with nicotinic acid derivatives, which exert their effects primarily through enzyme interactions that regulate lipid metabolism and vascular tone.",
      "umls_path": [
        "Peripheral vascular disease, unspecified",
        "may_be_treated_by",
        "nicotinic acid propyl ester",
        "has_mechanism_of_action",
        "Enzyme Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with peripheral vascular disease (PVD) and hyperlipidemia is prescribed a medication that both dilates blood vessels and modifies lipid metabolism. Nicotinic acid (niacin) and its derivatives are known for these dual actions. They exert their primary effects via enzyme interactions—specifically, they inhibit hepatic diacylglycerol acyltransferase-2 (DGAT2), a rate-limiting enzyme in triglyceride synthesis, and reduce lipolysis in adipose tissue by inhibiting hormone-sensitive lipase. These actions lower circulating free fatty acids, reduce hepatic synthesis of very-low-density lipoprotein (VLDL), and subsequently lower LDL cholesterol while increasing HDL cholesterol. Additionally, niacin-mediated vasodilation occurs partly via prostaglandin-mediated pathways following enzyme modulation. Therefore, the unifying mechanism underlying both the lipid-modifying and vasodilatory effects is the interaction of the drug with key metabolic enzymes.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_aaab78d632fe",
      "question": "In a patient with metastatic non-small cell lung cancer (adenocarcinoma subtype) who tests positive for an EGFR exon 19 deletion, but whose tissue sample is insufficient for complete molecular profiling, is first-line treatment with amivantamab-vmjw plus lazertinib still clinically appropriate?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "EGFR exon 19 deletion or exon 21 L858R mutation positive",
              "EGFR exon 19 deletion or exon 21 L858R mutations",
              "EGFR mutation discovered prior to first-line systemic therapy",
              "Other Recommended: Amivantamab-vmjw + lazertinib (category 1)",
              "Progression: Subsequent Therapy (NSCL-22)"
            ]
          }
        }
      ],
      "answer": "First-line use of amivantamab-vmjw plus lazertinib is specifically indicated for metastatic non-small cell lung cancer harboring EGFR exon 19 deletion or exon 21 L858R mutations, regardless of whether all additional biomarkers have been profiled, provided that EGFR mutation is confirmed. Insufficient tissue for broader profiling does not preclude this treatment, as EGFR status is the critical determinant.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_8238b521e730",
      "question": "A 42-year-old woman develops worsening jaundice, hepatomegaly, and right upper quadrant pain two weeks after undergoing allogeneic hematopoietic stem cell transplantation. Laboratory tests reveal elevated bilirubin and transaminases, and imaging shows narrowing of hepatic veins with evidence of hepatic sinusoidal obstruction. She is started on a medication derived from bovine tissue that reduces endothelial cell activation and promotes degradation of fibrin clots within the hepatic microvasculature by enhancing the activity of endogenous enzymes responsible for converting plasminogen to plasmin. Which class of agents is primarily responsible for this drug's therapeutic mechanism in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Terminal hepatic lobular vascular occlusion"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0019156",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4083210",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Tissue plasminogen activators",
      "reasoning_path": "Hepatic sinusoidal obstruction → Defibrotide therapy → Enhanced tissue plasminogen activator activity → Increased plasmin generation → Fibrinolysis of hepatic microvascular clots → Clinical improvement.",
      "umls_path": [
        "Terminal hepatic lobular vascular occlusion",
        "may_be_treated_by",
        "Defibrotide (Bovine)",
        "has_mechanism_of_action",
        "Tissue Plasminogen Activators"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is experiencing hepatic sinusoidal obstruction syndrome (also known as veno-occlusive disease), a complication marked by occlusion of small hepatic veins leading to liver dysfunction after stem cell transplantation. Defibrotide is used in this setting for its ability to protect endothelial cells and promote fibrinolysis. Its primary mechanism involves enhancing the activity of tissue plasminogen activators, which convert plasminogen to plasmin and facilitate the breakdown of fibrin clots. This reduces vascular occlusion and improves sinusoidal blood flow, addressing the underlying pathophysiology of the disease. Thus, tissue plasminogen activators mediate the main therapeutic effect of defibrotide in hepatic veno-occlusive disease.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_96b6fca2e53c",
      "question": "A 42-year-old woman diagnosed with a rare inherited bleeding disorder characterized by prolonged prothrombin time and low circulating levels of a vitamin K–dependent coagulation factor is started on a synthetic vitamin K analogue. Despite improvement in her bleeding symptoms, her hematologist notes that the exact cellular or molecular mechanism by which this medication increases functional levels of the deficient coagulation factor in her condition remains unclear. Which statement best summarizes the current understanding of this drug's mechanism of action in this clinical context?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Factor II Deficiency"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4722227",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0127514",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Inherited Factor II deficiency is not primarily due to vitamin K lack. Menadiol sodium diphosphate, a vitamin K analogue, is sometimes used, but its mechanism in this setting is not elucidated at the cellular or molecular level.",
      "umls_path": [
        "Factor II Deficiency",
        "may_be_treated_by",
        "Menadiol sodium diphosphate",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In patients with congenital Factor II (prothrombin) deficiency, vitamin K analogues like menadiol sodium diphosphate are sometimes administered to try to enhance hepatic synthesis of functional prothrombin. Vitamin K is generally necessary for γ-carboxylation of certain coagulation factors, a process essential for their activity. However, in inherited Factor II deficiency, the underlying defect is often a genetic mutation affecting the factor II gene itself or its processing, not a deficiency of vitamin K or its cofactor activity. Thus, while vitamin K supplementation (including menadiol sodium diphosphate) may be attempted, the exact way—if any—in which it improves factor II functional levels or activity in these patients is not well defined. The drug’s molecular or cellular mechanism in this setting remains unknown, and any therapeutic effect is not clearly linked to the canonical vitamin K–dependent γ-carboxylation pathway.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_2755a9194165",
      "question": "A 54-year-old man is hospitalized with fever, headache, and new-onset confusion. Cerebrospinal fluid analysis suggests viral encephalitis. Epidemiological data indicate an outbreak of a mosquito-borne flavivirus in the region. The infectious diseases team considers an antiviral agent that is incorporated into viral RNA by the viral RNA-dependent RNA polymerase, resulting in inhibition of viral genome replication. Which pharmacological class best describes the primary mechanism of action of this agent in treating neuroinvasive viral infections?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Disease caused by West Nile virus"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0043124",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0035525",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme Inhibitors",
      "reasoning_path": "Flavivirus neuroinvasive disease → ribavirin considered → ribavirin inhibits viral RNA-dependent RNA polymerase → classified as enzyme inhibitor.",
      "umls_path": [
        "Disease caused by West Nile virus",
        "may_be_treated_by",
        "Ribavirin",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is presenting with symptoms consistent with neuroinvasive encephalitis caused by a flavivirus, such as West Nile virus. An antiviral agent under consideration is ribavirin, which is sometimes explored for off-label use against RNA viruses, including certain flaviviruses. Ribavirin exerts its main effect by acting as a nucleoside analog that competitively inhibits the viral RNA-dependent RNA polymerase. By being incorporated into the viral RNA, ribavirin causes premature termination of viral RNA synthesis and induces lethal mutagenesis, disrupting the replication of the viral genome. Thus, the primary pharmacological class describing its mechanism of action in this context is 'enzyme inhibitors,' specifically targeting the viral RNA polymerase enzyme. This mechanism underlies the drug’s antiviral effect, as inhibition of this enzyme is critical to halting viral replication and spread within the host.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_2f32a2031e52",
      "question": "A 54-year-old woman undergoes allogeneic stem cell transplantation for acute myeloid leukemia. Two months later, she develops a diffuse maculopapular rash, diarrhea, and elevated liver enzymes, consistent with a diagnosis of steroid-refractory graft-versus-host disease. Her care team initiates a medication that is also recognized for its anti-angiogenic properties and is known to reduce new blood vessel formation in inflamed tissues. Which molecular target is primarily responsible for mediating the anti-angiogenic and therapeutic effects of this agent in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Graft Versus Host Disease"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0018133",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0039736",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Vascular Endothelial Growth Factor A (VEGF-A)",
      "reasoning_path": "Steroid-refractory GVHD is treated with thalidomide, which inhibits angiogenesis by targeting VEGF-A, thereby reducing inflammation and tissue injury.",
      "umls_path": [
        "Graft Versus Host Disease",
        "may_be_treated_by",
        "Thalidomide",
        "has_target",
        "Vascular Endothelial Growth Factor A"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Steroid-refractory graft-versus-host disease (GVHD) is a severe complication following allogeneic hematopoietic stem cell transplantation, characterized by immune-mediated tissue injury. When standard immunosuppression fails, agents with additional mechanisms—such as thalidomide—are considered. Thalidomide is notable for its immunomodulatory and anti-angiogenic effects. A key therapeutic mechanism is inhibition of angiogenesis, which is pathologically upregulated in GVHD and sustains inflammation and tissue injury. Thalidomide achieves this by decreasing the expression and activity of vascular endothelial growth factor A (VEGF-A), a central mediator of endothelial cell proliferation and new blood vessel formation. By targeting VEGF-A, thalidomide reduces vascular supply to inflamed tissues, indirectly dampening immune cell infiltration and cytokine-mediated injury. Thus, VEGF-A is the molecular target most directly implicated in the anti-angiogenic and therapeutic benefit of thalidomide in steroid-refractory GVHD.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_00961710363c",
      "question": "A 34-year-old woman presents with facial pain, purulent nasal discharge, and fever for three days. Examination reveals tenderness over the maxillary sinuses and erythematous nasal mucosa. She is diagnosed with acute bacterial maxillary sinusitis and prescribed an oral third-generation cephalosporin. This agent exerts its therapeutic effect by binding to and inactivating transpeptidase enzymes crucial for bacterial cell wall synthesis. Which general pharmacological class describes the mechanism of action of this therapy?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Maxillary Sinusitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0024959",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0055011",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme Inhibitors",
      "reasoning_path": "Bacterial maxillary sinusitis is treated with a third-generation cephalosporin, which inhibits bacterial transpeptidase enzymes (penicillin-binding proteins) to block cell wall synthesis, classifying it as an enzyme inhibitor.",
      "umls_path": [
        "Maxillary Sinusitis",
        "may_be_treated_by",
        "Cefpodoxime-containing product",
        "has_mechanism_of_action",
        "Enzyme Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Acute maxillary sinusitis is often caused by bacterial pathogens such as Streptococcus pneumoniae and Haemophilus influenzae. Third-generation oral cephalosporins, like cefpodoxime, are frequently used for their expanded Gram-negative coverage and oral bioavailability. These drugs act by binding to penicillin-binding proteins (PBPs), which are transpeptidase enzymes involved in the final cross-linking steps of peptidoglycan synthesis in bacterial cell walls. By inhibiting these enzymes, cephalosporins prevent the formation of a functional cell wall, leading to bacterial lysis and death. This mode of action classifies them within the general pharmacological class of enzyme inhibitors, as their therapeutic effect is directly mediated through the inhibition of bacterial enzymes essential for cell viability.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_392c48da550d",
      "question": "For a patient with clinical stage cT1c, cN0 triple-negative breast cancer who is being considered for preoperative systemic therapy, if baseline liver function tests reveal significant hepatic impairment, is standard preoperative systemic chemotherapy still generally recommended in this scenario?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Considering preoperative systemic therapy",
              "Additional Workup Prior to Preoperative Systemic Therapy (BINV-12)",
              "cT2 or cN+ and M0 or cT1c, cN0 HER2-positive disease or cT1c, cN0 TNBC (For preoperative systemic therapy criteria, see BINV-M 1)",
              "Axillary assessment with exam • Consider ultrasound • Percutaneous biopsy of suspicious nodes • CBC • Comprehensive metabolic panel, including liver function tests and alkaline phosphatase • Additional tests to consider as clinically indicated • Chest diagnostic CT ± contrast • Abdomen ± pelvis diagnostic CT with contrast or MRI with contrast • Bone scan or sodium fluoride PET/CT (category 2B) • FDG-PET/CT • Breast MRI (optional), with special consideration for mammographically occult tumors, if not previously done",
              "For inoperable breast cancers: see Preoperative Systemic Therapy (BINV-15)",
              "Preoperative systemic therapy see BINV-M 1",
              "No response to preoperative systemic therapy and/or tumor remains inoperable",
              "Consider additional systemic therapy and/or preoperative radiation",
              "Response to preoperative systemic therapy and tumor is operable",
              "Mastectomy and surgical axillary staging + reconstruction (optional) or BCS with surgical axillary staging + oncoplastic reconstruction",
              "Adjuvant systemic therapy and Adjuvant RT to the whole breast or chest wall and comprehensive RNI with inclusion of any portion of the undissected axilla at risk.",
              "HR-negative/ HER2-positive",
              "ypT1–4,N0 or ypN≥1",
              "Ado-trastuzumab emtansine (category 1) alone for 14 cycles"
            ]
          }
        }
      ],
      "answer": "No, standard preoperative systemic chemotherapy for triple-negative breast cancer requires adequate hepatic function. Significant hepatic impairment is a contraindication to most standard regimens due to increased risk of toxicity; alternative approaches or dose modifications must be considered, and treatment may need to be postponed until liver function improves.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_acb8639cf28e",
      "question": "In a patient with newly diagnosed non-small cell lung cancer, if there is a solitary nodule in the contralateral lung and pathology reveals no lymph node involvement (N0) but evidence of M1a disease, should this case be managed as metastatic disease or as two primary lung cancers if both lesions are considered potentially curable?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
              "Pathologic Diagnosis of NSCLC",
              "Initial Evaluation",
              "Chemistry profile"
            ]
          }
        }
      ],
      "answer": "If both the primary lung tumor and solitary contralateral lung nodule are deemed potentially curable, this scenario should be managed as two primary lung cancers rather than as metastatic disease, despite the M1a designation, according to current NSCLC management principles.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_bf6890114379",
      "question": "A 54-year-old woman with a longstanding history of insomnia and uncomfortable sensations in her lower limbs, especially at night, enrolls in a clinical trial evaluating a novel compound containing elemental iron complexed with carbonyl groups. During the study, she reports mild improvement in symptoms. As part of the pharmacology review, which physiologic process—directly affected by this compound’s molecular action—should be closely monitored to assess both efficacy and safety in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "restless legs syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0035258",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0876769",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Electrolyte activity—iron pentacarbonyl can alter neuronal and muscular excitability by modulating electrolyte balance.",
      "reasoning_path": "Iron pentacarbonyl increases iron availability, which influences neuronal ion channel function and electrolyte activity, thereby modifying excitability of neurons and muscles relevant to RLS symptoms.",
      "umls_path": [
        "restless legs syndrome",
        "may_be_treated_by",
        "Iron pentacarbonyl",
        "has_mechanism_of_action",
        "Electrolyte Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Restless legs syndrome (RLS) is commonly associated with CNS dopaminergic dysfunction and iron deficiency. Iron pentacarbonyl is a compound that releases iron, potentially addressing underlying deficiency, but its molecular effects may extend further. Once administered, this agent can participate in redox chemistry and influence the function of various ion channels. Adequate iron is necessary for proper function of enzymes involved in neurotransmitter synthesis and for maintaining normal neuronal excitability. By modulating the bioavailability of iron, iron pentacarbonyl can alter the conductance of neuronal membranes via effects on sodium, potassium, and calcium channels, ultimately impacting electrolyte gradients and neuronal firing. Since both excessive and deficient electrolyte activity can lead to adverse neuromuscular events, monitoring for changes in electrolyte activity is crucial during therapy with iron pentacarbonyl. This helps ensure both effective symptom control and prevention of side effects such as arrhythmias, muscle cramping, or altered mental status.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_b948bc485582",
      "question": "For a patient with resected stage IIIA non-small cell lung cancer (T1–2, N2) who achieved R0 (negative) surgical margins and completed recommended adjuvant systemic chemotherapy, is routine use of FDG-PET/CT or brain MRI with contrast indicated during scheduled surveillance follow-up if there is no clinical or radiographic evidence of recurrence?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Routine use of FDG-PET/CT or brain MRI with contrast is not indicated during surveillance follow-up in this scenario without evidence of recurrence; standard follow-up should include history and physical examination and chest CT at specified intervals, reserving advanced imaging for suspicion of relapse or new symptoms.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_f208b9d51df3",
      "question": "In a patient with NSCLC classified as Stage II (T1abc–2ab, N1; T2b, N0) who presents with limited, surgically resectable brain metastasis (M1b), should the initial management prioritize local thoracic disease control or immediate treatment of the brain metastasis, and what is the rationale for this prioritization?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 0–2",
              "Limited progression confirmed",
              "Other site",
              "Treatment of Thoracic Disease (NSCL-16)"
            ]
          }
        }
      ],
      "answer": "For NSCLC patients with Stage II thoracic disease and limited, resectable brain metastasis, immediate treatment of the brain metastasis (such as surgery or stereotactic radiosurgery) is prioritized to prevent neurological deterioration, followed by local thoracic management. Prompt control of symptomatic or potentially life-threatening CNS lesions is essential before addressing the primary thoracic tumor.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_8579738928f3",
      "question": "A 32-year-old man presents to the dermatology clinic with concerns about gradual hair thinning at the vertex of his scalp over the past year. He is otherwise healthy, takes no medications, and has a family history of similar hair loss in his father. After evaluation, he is started on an oral medication that inhibits the enzyme responsible for the conversion of testosterone to a more potent androgen within hair follicles. Which specific enzyme does this medication target to reduce scalp hair loss in androgenetic alopecia?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Alopecia, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002170",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0060389",
            "rela": "has_target"
          }
        }
      ],
      "answer": "3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 2 (Type II 5-alpha-reductase)",
      "reasoning_path": "Androgenetic alopecia involves DHT-driven follicle miniaturization; finasteride reduces DHT by inhibiting type II 5-alpha-reductase (3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 2), the key enzyme in this conversion in scalp hair follicles.",
      "umls_path": [
        "Alopecia, unspecified",
        "may_be_treated_by",
        "Finasteride",
        "has_target",
        "3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has male-pattern hair loss, or androgenetic alopecia, which is mediated by increased dihydrotestosterone (DHT) activity in scalp hair follicles. DHT is synthesized from testosterone by the enzyme 5-alpha-reductase, of which there are two main isoforms. The type II isoform (3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 2) is predominant in hair follicles. Finasteride, a commonly used therapy for this condition, selectively inhibits this enzyme, thereby reducing local DHT levels. Lowering DHT in the scalp slows follicular miniaturization and can promote hair regrowth. The therapeutic benefit of finasteride in androgenetic alopecia thus depends on its blockade of type II 5-alpha-reductase, rather than type I (which is more prominent in other tissues).",
      "type": "kg_reasoning"
    },
    {
      "id": "path_da1940eb8c48",
      "question": "In a patient with advanced non-squamous non-small cell lung cancer (NSCLC) who has confirmed ALK rearrangement and concurrent bone metastases at risk of pathological fracture, should systemic ALK-targeted therapy be initiated before orthopedic stabilization and palliative radiotherapy, or is priority given to immediate local management of the bone lesion?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Bone metastases",
              "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "ALK rearrangement positive"
            ]
          }
        }
      ],
      "answer": "Immediate local management, including orthopedic stabilization and palliative radiotherapy, takes priority in the setting of bone metastases at high risk of fracture or spinal cord compression. Systemic ALK-targeted therapy can be initiated subsequently, but urgent intervention to prevent skeletal complications should not be delayed by systemic treatment considerations.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_a5ac12f1563e",
      "question": "In a premenopausal woman with invasive, HER2-negative, ER-positive and/or PR-positive ductal breast carcinoma, clinical stage T2N0M0, who is not considered for preoperative systemic therapy and undergoes breast-conserving surgery with negative axillary nodes, is adjuvant endocrine therapy reasonable if the primary tumor measures 0.4 cm (≤0.5 cm), or does its small size preclude the need for endocrine therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Localized breast cancer: Invasive, non-inflammatory, non-metastatic (M0)",
              "Clinical Stage cT1–T4, 2cN0,M0",
              "Criteria for preoperative systemic therapy (BINV-M)",
              "Not considering preoperative systemic therapy",
              "Locoregional treatment ▸ BCS Followed by RT (BINV-2) or ▸ Mastectomy Followed by RT (BINV-3)",
              "BCS with surgical axillary staging (category 1) ± oncoplastic reconstruction",
              "See BINV-4 to determine whether adjuvant systemic therapy is indicated",
              "• Ductal/NST • Lobular • Mixed • Micropapillary • Metaplastic",
              "ER-positive and/or PR-positive",
              "HER2-negative",
              "Premenopausal",
              "pT1-3 AND pN0",
              "Ductal/NST, Lobular, Mixed, Micropapillary",
              "Tumor ≤0.5 cm and pN0",
              "Consider adjuvant endocrine therapy (category 2B)",
              "Follow-Up (BINV-17)"
            ]
          }
        }
      ],
      "answer": "For a premenopausal woman with invasive, ER-positive and/or PR-positive, HER2-negative, node-negative breast cancer and a tumor size of ≤0.5 cm, adjuvant endocrine therapy may be considered according to category 2B evidence, indicating that the option remains reasonable even for tumors of this small size and is not categorically precluded.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_7fce1d3cd9ab",
      "question": "For a patient with non-small cell lung cancer presenting with superior vena cava (SVC) obstruction and no evidence of disseminated metastatic disease, is concurrent chemoradiation preferred over external-beam radiotherapy alone if the patient has not previously received chemoradiation?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (peripheral T1abc, N0)",
              "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Yes, for non-small cell lung cancer patients with SVC obstruction and no prior chemoradiation, concurrent chemoradiation is the preferred treatment over external-beam radiotherapy alone, as it offers improved local control and potential survival benefit in the absence of disseminated disease.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_691ecf3b3a59",
      "question": "What is the unique PMID for the 2025 Arquivos de Neuro-Psiquiatria article titled “A decade of whole-exome sequencing in Brazilian Neurology: from past insights to future perspectives,” authored by Quaio CRDC?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"A decade of whole-exome sequencing in Brazilian Neurology\"[ti] AND Quaio CRDC[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40360003"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_0419f92a1fd9",
      "question": "A 6-year-old child from a rural area presents with night blindness, frequent respiratory infections, and dry, scaly skin. Laboratory evaluation reveals decreased serum retinol levels. The pediatrician prescribes a vitamin A ester as part of the management plan. This compound is absorbed and metabolized to an active form that participates in several enzymatic processes, particularly those required for vision and epithelial cell maintenance. Through which general pharmacological mechanism does this therapy exert its therapeutic effects in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Unspecified vitamin A deficiency"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0042842",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4291322",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Modulation of enzyme-mediated biological processes",
      "reasoning_path": "Vitamin A esters are metabolized to active forms that serve as cofactors or substrates for enzymes involved in vision, immunity, and epithelial health, so their therapeutic effect is achieved through modulation of enzyme-mediated biological processes.",
      "umls_path": [
        "Unspecified vitamin A deficiency",
        "may_be_treated_by",
        "VITAMIN A MYRISTATE",
        "has_mechanism_of_action",
        "Enzyme Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Vitamin A deficiency manifests with symptoms like night blindness and epithelial dysfunction because vitamin A is integral to multiple enzymatic reactions. After administration, vitamin A esters are hydrolyzed to retinol, which is further oxidized to retinal and retinoic acid. Retinal is essential for the function of the visual pigment rhodopsin in photoreceptor cells, a process dependent on enzymatic transformations. Retinoic acid acts as a ligand for nuclear receptors to regulate gene transcription involved in immune function and epithelial integrity, but the initial conversion steps are enzyme-mediated. Thus, the primary pharmacological mechanism of vitamin A esters is to restore and enhance these enzyme-driven pathways, correcting the metabolic deficits seen in deficiency. This allows for recovery of vision, improved immune response, and normalization of epithelial cell turnover, addressing the clinical features observed in the patient.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_66d158bd325b",
      "question": "In a patient with stage IB (T2a, N0) non–small cell lung cancer who has positive surgical margins (R1, R2) following resection and no evidence of disseminated disease, is observation alone an acceptable management option, or should additional systemic therapy or radiotherapy be routinely pursued in this scenario?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (T2a, N0); Margins positive (R1, R2)",
              "Resection (preferred) ± systemic therapy or RT",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Observation alone is an acceptable management option if there is no evidence of disseminated disease after resection with positive margins, though additional systemic therapy or radiotherapy may also be considered. The choice should be individualized based on risk factors and patient status, but observation is a recognized approach in this context.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_06c6dd8cf9d9",
      "question": "A 7-year-old girl is admitted to the hospital with high fever, confusion, and repeated seizures. She has recently returned from a malaria-endemic region and blood smears confirm Plasmodium falciparum infection. Despite initiation of antimalarial therapy, her neurological symptoms persist. As an adjunct, her clinicians start a medication known to improve microcirculation in other settings and hypothesized to have anti-inflammatory effects, although its exact molecular mechanism in this context is not established. What is the best current understanding of the molecular target or mechanism by which this adjunct drug acts in cerebral malaria?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Cerebral malaria"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0024534",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0030899",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction; the precise mechanism of pentoxifylline in cerebral malaria is not established.",
      "reasoning_path": "Cerebral malaria may be treated with pentoxifylline adjunctively, but the specific molecular or cellular mechanism for its action in this disease is not established or characterized.",
      "umls_path": [
        "Cerebral malaria",
        "may_be_treated_by",
        "Pentoxifylline",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Pentoxifylline is sometimes used as adjunctive therapy in severe malaria due to its rheological and putative anti-inflammatory properties. In conditions like peripheral vascular disease, pentoxifylline is thought to improve red blood cell deformability and reduce blood viscosity, potentially enhancing microvascular flow. In cerebral malaria, it has been hypothesized—based on its effects in other contexts—that pentoxifylline might mitigate the inflammatory response or improve cerebral microcirculation. However, no clear or consistent cellular or molecular pathway has been identified as responsible for its putative beneficial effects in cerebral malaria. Studies have not established a specific receptor, enzyme, or signaling cascade targeted by pentoxifylline in this setting. Thus, its mechanism of action in cerebral malaria remains unknown.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_fcf412ff3b41",
      "question": "In a patient with advanced non-small cell lung cancer of adenocarcinoma subtype whose tumor harbors a BRAF V600E mutation detected during ongoing first-line systemic therapy, is it appropriate to switch immediately to dabrafenib plus trametinib upon identification of the mutation, or should the initial systemic therapy regimen be completed before initiating targeted therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "BRAF V600E mutation positive",
              "BRAF V600E MUTATION",
              "BRAF V600E mutation discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by dabrafenib + trametinib (preferred) or encorafenib + binimetinib (preferred)",
              "Progression",
              "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
            ]
          }
        }
      ],
      "answer": "For patients with advanced NSCLC harboring a BRAF V600E mutation identified during first-line systemic therapy, the recommended approach is to complete the planned initial systemic therapy, including maintenance, unless therapy needs to be interrupted. Targeted therapy with dabrafenib plus trametinib should be initiated thereafter, not immediately upon mutation discovery.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_96fe102e8cd6",
      "question": "In ClinicalTrials.gov, which completed interventional studies for chronic myelogenous leukemia started in July 2007 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "overallStatus=COMPLETED;conditions=Myelogenous Leukemia, Chronic;startDateFrom=2007-07-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00471497"
      ],
      "type": "retrieval"
    },
    {
      "id": "ret_52a4d30b99f6",
      "question": "What is the unique PubMed ID (PMID) for the article titled \"Assessing the prevalence, quality and compliance of data-sharing statements in gastroenterology publications: a cross-sectional analysis,\" authored by Moore J and published in BMJ Open in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"Assessing the prevalence, quality and compliance of data-sharing statements in gastroenterology publications\"[ti] AND Moore J[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40132820"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_3f97fcc3f9de",
      "question": "In patients with advanced squamous cell carcinoma of the lung who test positive for ERBB2 (HER2) mutation, is the use of fam-trastuzumab deruxtecan-nxki for systemic therapy predicated on molecular testing being performed as part of broad molecular profiling, or would isolated ERBB2 (HER2) testing suffice?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "ERBB2 (HER2) mutation positive",
              "ERBB2 (HER2) mutation",
              "Systemic therapy Adenocarcinoma or Squamous Cell Carcinoma",
              "Tumor response evaluation",
              "Response or stable disease",
              "4–6 cycles (total)",
              "Tumor response evaluation",
              "Response or stable disease",
              "Maintenance therapy",
              "Progression",
              "Preferred Fam-trastuzumab deruxtecan-nxki or Other Recommended Ado-trastuzumab emtansine",
              "Progression",
              "PS 3–4",
              "Best supportive care: NCCN Guidelines for Palliative Care"
            ]
          }
        }
      ],
      "answer": "The use of fam-trastuzumab deruxtecan-nxki in advanced squamous cell carcinoma with ERBB2 (HER2) mutation is predicated on detection of the mutation through broad molecular profiling, not isolated ERBB2 (HER2) testing; comprehensive profiling is the standard to accurately identify all relevant actionable mutations.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_b409ff7cd497",
      "question": "A 7-year-old boy from a rural community is brought to the clinic with complaints of intermittent abdominal pain and visible worms in his stool. Stool examination confirms the presence of Ascaris lumbricoides ova. The physician prescribes a medication that acts by inducing neuromuscular blockade in the parasite, leading to paralysis and subsequent expulsion via peristalsis. Through which molecular mechanism does this antiparasitic drug most effectively achieve its therapeutic action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Ascariasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003950",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0034235",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cholinesterase inhibition",
      "reasoning_path": "Ascariasis → treated with pyrantel → pyrantel inhibits cholinesterase in worms → causes neuromuscular blockade and paralysis → worm expulsion.",
      "umls_path": [
        "Ascariasis",
        "may_be_treated_by",
        "Pyrantel-containing product",
        "has_mechanism_of_action",
        "Cholinesterase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Ascariasis is a helminthic infection commonly treated with antiparasitic agents that incapacitate the worms, allowing for their expulsion. Pyrantel pamoate is a first-line drug for this purpose. It acts as a depolarizing neuromuscular blocking agent by inhibiting cholinesterase activity at the neuromuscular junction of the parasite. This inhibition results in the accumulation of acetylcholine, causing persistent activation of nicotinic acetylcholine receptors. Sustained depolarization ultimately leads to paralysis of the worm's musculature, which prevents attachment to the intestinal wall and facilitates removal by normal peristalsis. This mechanism specifically targets the parasite's neuromuscular system and does not affect human cholinesterase at therapeutic doses. Therefore, the efficacy of pyrantel in treating ascariasis is primarily due to its action as a cholinesterase inhibitor in nematodes.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_3f863d202a0e",
      "question": "In a patient with stage IIB (T3, N0) non-small cell lung cancer who underwent complete surgical resection with negative margins (R0), does the omission of documented mediastinal lymph node dissection or systematic lymph node sampling invalidate the indication for adjuvant systemic therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (peripheral T1abc, N0)",
              "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
              "Negative mediastinal nodes",
              "Operable",
              "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
              "Adjuvant Treatment (NSCL-4)",
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "Yes, the absence of mediastinal lymph node dissection or systematic sampling compromises accurate pathologic staging, which is a prerequisite for indicating adjuvant systemic therapy in resected stage IIB non-small cell lung cancer. Without thorough nodal assessment, reliable risk stratification for adjuvant treatment cannot be ensured.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_1c07e1071cc1",
      "question": "A 54-year-old man is diagnosed with a pulmonary fungal infection after presenting with fever, cough, and weight loss. Bronchoalveolar lavage grows a broad-based budding yeast. He is started on an oral antifungal agent that works by inhibiting the fungal cytochrome P450–dependent enzyme lanosterol 14-α-demethylase, thus impairing ergosterol synthesis. His physician reviews his medication list and warns of potential interactions with drugs metabolized by a specific hepatic enzyme, as the antifungal is a strong inhibitor of this enzyme and may raise serum concentrations of co-administered medications. Which drug-metabolizing enzyme should be most closely monitored for interactions in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Blastomycosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0005716",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0016277",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cytochrome P450 2C9 (CYP2C9)",
      "reasoning_path": "Blastomycosis is treated with fluconazole, which inhibits fungal lanosterol 14-α-demethylase. Fluconazole also inhibits human CYP2C9, so drugs metabolized by CYP2C9 require close monitoring due to potential increased serum levels.",
      "umls_path": [
        "Blastomycosis",
        "may_be_treated_by",
        "Fluconazole",
        "has_mechanism_of_action",
        "Cytochrome P450 2C9 Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with blastomycosis is prescribed fluconazole, a triazole antifungal that selectively inhibits fungal cytochrome P450–dependent lanosterol 14-α-demethylase, disrupting ergosterol synthesis and compromising fungal cell membrane integrity. However, fluconazole is also a potent inhibitor of human cytochrome P450 2C9 (CYP2C9), a major hepatic enzyme responsible for metabolizing various medications, such as warfarin, phenytoin, and some hypoglycemics. Co-administration with CYP2C9 substrates can lead to increased serum levels and a heightened risk of adverse effects or toxicity. Therefore, clinicians must exercise caution and monitor drugs extensively metabolized by CYP2C9 when a patient is treated with systemic fluconazole. This mechanistic interaction underscores the importance of understanding both the therapeutic and pharmacokinetic profiles of antifungal agents.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_f6fc4149b8bc",
      "question": "For a patient with stage IIIA non-small cell lung cancer (T3N1), is mediastinal lymph node pathologic evaluation mandatory prior to perioperative treatment initiation, or can imaging alone sufficiently guide management decisions?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "Pathologic confirmation of mediastinal lymph node status is mandatory before perioperative treatment in stage IIIA (T3N1) non-small cell lung cancer. Imaging alone does not provide sufficient diagnostic certainty for N status; tissue confirmation (e.g., mediastinoscopy, EBUS) is required to accurately guide further management.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_1cce9f1c3fe5",
      "question": "In a patient with stage IV, M1b non-small cell lung cancer who has limited distant metastases and a performance status of 3–4, is systemic therapy the recommended approach even in the presence of significant comorbidities such as severe cardiac dysfunction?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Limited metastases",
              "Stage IV, M1b (NSCL-15)",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 3–4",
              "Systemic Therapy for Metastatic Disease (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, systemic therapy is generally not recommended for patients with stage IV, M1b non-small cell lung cancer who have a performance status of 3–4 and significant comorbidities like severe cardiac dysfunction, as the risks and poor tolerance typically outweigh potential benefits in this setting.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_e623368b225a",
      "question": "In a patient with stage IVA, M1b non-small cell lung cancer (NSCLC) and good performance status (PS 0–2), if limited progression occurs exclusively in a non-thoracic metastatic site after initial systemic therapy, does proceeding to definitive chemoradiation to the thoracic disease remain an appropriate option?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 0–2",
              "Limited progression confirmed",
              "Other site",
              "Treatment of Thoracic Disease (NSCL-16)",
              "Definitive therapy for thoracic disease feasible",
              "Consider systemic therapy and restaging to confirm non-progression or Proceed to definitive therapy",
              "T1–3, N2, T4, N0–2",
              "Definitive chemoradiation"
            ]
          }
        }
      ],
      "answer": "Yes, in patients with stage IVA, M1b NSCLC and PS 0–2 who have limited progression only at an extra-thoracic metastatic site, definitive chemoradiation to the thoracic disease remains an appropriate option if definitive thoracic therapy is feasible, as local control may benefit overall outcomes in selected oligoprogressive settings.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_eaceb124d4ad",
      "question": "In a patient with stage IIIA non-small cell lung cancer characterized by resectable T4 tumor extension involving the mediastinum (N1), with negative surgical margins achieved after resection (R0), is adjuvant systemic therapy still considered appropriate even if the patient has significant impairment in pulmonary function as assessed by preoperative PFTs?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Trachea/carina or mediastinum",
              "Treatment (NSCL-7)",
              "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
              "Systemic therapy or Concurrent chemoradiation",
              "Surgical reevaluation including chest CT ± PET/CT",
              "Surgery",
              "Margins negative (R0)",
              "Observe or Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "No, significant pulmonary function impairment identified by preoperative PFTs would contraindicate adjuvant systemic therapy due to increased risk of treatment-related pulmonary toxicity. In such cases, observation and surveillance would be favored over additional systemic therapy following R0 resection.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_3915d4e015c3",
      "question": "In a patient with stage IVA, metastatic squamous cell carcinoma of the lung who is confirmed ALK rearrangement positive prior to first-line therapy, is broad molecular profiling still a prerequisite before starting ALK inhibitor treatment, or can targeted therapy be initiated based solely on the ALK result?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "ALK rearrangement positive",
              "ALK rearrangement",
              "ALK rearrangement discovered prior to first-line systemic therapy",
              "Useful in Certain Circumstances Crizotinibb (category 1)",
              "Progression",
              "Subsequent Therapy (NSCL-29)"
            ]
          }
        }
      ],
      "answer": "Initiation of ALK inhibitor therapy such as crizotinib is appropriate as first-line treatment in an ALK-rearranged squamous cell carcinoma once the ALK rearrangement is confirmed. Although comprehensive molecular profiling is recommended, the presence of an actionable ALK alteration is sufficient to proceed without delay for additional molecular results.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_6e27ffaacb70",
      "question": "A 34-year-old professional scuba diver is brought to the emergency department shortly after surfacing rapidly from a deep dive. He complains of joint pain, muscle weakness, and shortness of breath. Physical examination reveals patchy cyanosis and mild confusion. Suspecting a disorder caused by nitrogen bubbles forming in tissues and blood due to rapid decompression, the medical team initiates hyperbaric oxygen therapy. Beyond facilitating the elimination of inert gas bubbles, which molecular mechanism of oxygen therapy specifically helps limit tissue injury in this setting?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Caisson disease"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0011119",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0030054",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Free radical scavenging activity—oxygen therapy reduces oxidative tissue injury via neutralization of reactive oxygen species generated during reperfusion.",
      "reasoning_path": "Decompression sickness causes nitrogen bubbles; hyperbaric oxygen increases oxygen levels, speeds nitrogen elimination, and mitigates reperfusion injury by scavenging free radicals.",
      "umls_path": [
        "Caisson disease",
        "may_be_treated_by",
        "Oxygen",
        "has_mechanism_of_action",
        "Free Radical Scavenging Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In decompression sickness (also known as caisson disease), inert nitrogen bubbles form in blood and tissues following a rapid decrease in ambient pressure. These bubbles can cause mechanical obstruction, local ischemia, and endothelial injury. Hyperbaric oxygen therapy works primarily by increasing the partial pressure of oxygen, which helps dissolve and eliminate nitrogen bubbles more rapidly. However, another important mechanism is the reduction of oxidative tissue injury. During reperfusion, the reintroduction of oxygen can generate reactive oxygen species (ROS), leading to further tissue damage. Oxygen therapy, by promoting free radical scavenging activity, helps neutralize these ROS and limits the extent of reperfusion injury. Thus, the therapeutic benefit of hyperbaric oxygen in decompression sickness is due not only to physical elimination of nitrogen bubbles but also to its molecular action as a free radical scavenger, protecting tissues from oxidative stress.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_15252eb514fb",
      "question": "A 57-year-old woman presents with easy bruising and prolonged bleeding following minor injuries. Laboratory studies reveal a prolonged prothrombin time and markedly reduced plasma levels of a key coagulation factor involved in the conversion of prothrombin to thrombin. She is diagnosed with a rare inherited deficiency of this factor. Her hematologist prescribes a preparation containing a synthetic form of vitamin K (menadiol) to address her bleeding tendency. Despite clinical improvement, the precise cellular or molecular mechanism by which this therapy benefits her condition remains undefined. What is the current understanding of menadiol’s mechanism of action in treating this patient’s bleeding disorder?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Factor II Deficiency"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4722227",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0065932",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "The precise cellular or molecular mechanism by which menadiol treats Factor II deficiency is not clearly defined.",
      "reasoning_path": "Factor II deficiency → menadiol administration → unclear molecular mechanism for therapeutic effect.",
      "umls_path": [
        "Factor II Deficiency",
        "may_be_treated_by",
        "Menadiol-containing product",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Menadiol, a synthetic, water-soluble derivative of vitamin K, is sometimes used in bleeding disorders related to deficiencies in vitamin K-dependent clotting factors, including Factor II (prothrombin). Vitamin K is generally required for gamma-carboxylation of certain glutamate residues on clotting factors, which is essential for their activity. However, in patients with an inherited deficiency of Factor II, the pathophysiology may not be directly related to vitamin K absence, but rather a genetic defect in the factor itself. While menadiol can improve coagulation parameters in some clinical contexts, the detailed molecular mechanism by which it exerts a therapeutic effect in the setting of Factor II deficiency has not been clearly elucidated. Thus, its mechanism in this specific indication is considered unknown.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_92ced583112b",
      "question": "What is the PMID of the article titled “Mapping training programs for endoscopy nurses in gastroenterology: a scoping review,” authored by Parrella A and published in the European Journal of Gastroenterology & Hepatology in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"Mapping training programs for endoscopy nurses in gastroenterology\"[ti] AND Parrella A[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40207485"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_f88982008be4",
      "question": "A 42-year-old woman is diagnosed with tuberculous peritonitis after presenting with abdominal distension, fever, and ascites. She is started on a multidrug regimen that includes an injectable antibiotic known to bind irreversibly to the 30S subunit of the bacterial ribosome, causing misreading of mRNA and inhibition of protein elongation, ultimately leading to bacterial cell death. Which broad pharmacological class best describes the mechanism of action of this antibiotic in treating her infection?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Tuberculous peritonitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0041325",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3854019",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Protein synthesis inhibitors",
      "reasoning_path": "Aminoglycosides treat tuberculous peritonitis by binding the 30S ribosomal subunit, inhibiting bacterial protein synthesis and classifying them as protein synthesis inhibitors.",
      "umls_path": [
        "Tuberculous peritonitis",
        "may_be_treated_by",
        "Gentamicin",
        "has_mechanism_of_action",
        "Protein Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient is being treated for tuberculous peritonitis, which can be managed with aminoglycosides like gentamicin, especially in multidrug-resistant cases or when first-line drugs are contraindicated. Aminoglycosides exert their bactericidal effect by irreversibly binding to the 30S ribosomal subunit of susceptible bacteria. This disrupts the initiation complex of peptide formation, causes misreading of bacterial mRNA, and prevents proper elongation of the polypeptide chain, leading to production of nonfunctional or toxic proteins and ultimately cell death. This mechanism classifies aminoglycosides under the broad pharmacological class of protein synthesis inhibitors, as their main therapeutic target is the bacterial translation machinery. This is distinct from other antibiotic classes that inhibit cell wall synthesis, nucleic acid synthesis, or metabolic pathways.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_eaa8eeb2a3ab",
      "question": "For a patient with newly diagnosed stage IIIB (T3, N2) non-small cell lung cancer who presents with symptomatic superior vena cava (SVC) obstruction, and who has not previously received chemotherapy or radiation, is it appropriate to pursue concurrent chemoradiation rather than immediate SVC stent placement as the initial intervention?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "In the setting of symptomatic SVC obstruction due to stage IIIB (T3, N2) NSCLC, immediate SVC stent placement is prioritized to rapidly relieve symptoms. Concurrent chemoradiation can follow stenting but is not the initial intervention when urgent symptom relief is needed.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_6cf9682cbbb7",
      "question": "A 29-year-old woman presents with rapidly progressing, patchy hair loss on her scalp over the past four months. Physical examination reveals several well-demarcated, non-scarring alopecic plaques without erythema or scaling. Laboratory workup is unremarkable, and she is diagnosed with an autoimmune condition characterized by T-cell–mediated attack on hair follicles. She is started on a newly approved oral medication that selectively inhibits a specific member of the Janus kinase family, leading to decreased signaling of common γ-chain cytokines and reduced immune-mediated follicular damage. Which molecular target is most directly inhibited by this agent to achieve therapeutic benefit in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Alopecia areata"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002171",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C5418278",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Tyrosine-Protein Kinase JAK3",
      "reasoning_path": "Alopecia areata involves T-cell–mediated follicle destruction; ritlecitinib treats this by selectively inhibiting JAK3, thus blocking γc cytokine signaling and immune activation.",
      "umls_path": [
        "Alopecia areata",
        "may_be_treated_by",
        "Ritlecitinib",
        "has_target",
        "Tyrosine-Protein Kinase JAK3"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient’s clinical picture is consistent with alopecia areata, an autoimmune disorder in which cytotoxic T cells attack hair follicles, leading to non-scarring hair loss. The pathogenesis involves cytokine signaling through the common γ-chain (γc) receptor, which is mediated by Janus kinase 3 (JAK3). Ritlecitinib is an oral small-molecule inhibitor that selectively targets JAK3. By inhibiting JAK3, ritlecitinib blocks intracellular signaling for cytokines critical to lymphocyte activation and survival, such as IL-2, IL-4, IL-15, and IL-21. This reduces the aberrant immune response against hair follicles and promotes hair regrowth. Unlike other JAK inhibitors, ritlecitinib’s selectivity for JAK3 minimizes off-target effects associated with JAK1 or JAK2 inhibition, focusing its immunomodulatory action on lymphocyte-driven autoimmunity in alopecia areata.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_901d2ffac651",
      "question": "A 54-year-old woman with a history of fatigue, pruritus, and progressive jaundice is diagnosed with a chronic cholestatic liver disease after serologic testing reveals anti-mitochondrial antibodies. She is enrolled in a clinical trial investigating a medication designed to target nuclear receptors that regulate genes involved in lipid metabolism and inflammation. What is the primary molecular target of this agent, and how does its activation contribute to therapeutic effects in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Primary Biliary Cirrhosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0008312",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4508936",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Peroxisome proliferator-activated receptor (PPAR) delta agonist activity",
      "reasoning_path": "Primary biliary cholangitis involves cholestasis and inflammation → elafibranor is a PPAR-delta agonist → PPAR-delta activation regulates lipid metabolism and suppresses hepatic inflammation and fibrosis → leads to therapeutic benefit in this disease.",
      "umls_path": [
        "Primary Biliary Cirrhosis",
        "may_be_treated_by",
        "Elafibranor",
        "has_mechanism_of_action",
        "Peroxisome Proliferator-activated Receptor delta Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has primary biliary cholangitis, a chronic autoimmune liver disease characterized by destruction of intrahepatic bile ducts, leading to cholestasis and progressive liver dysfunction. Novel treatments aim to reduce inflammation and fibrosis while improving lipid metabolism. Elafibranor, the drug described, is a dual agonist at PPAR-alpha and PPAR-delta, but its therapeutic effect in cholestatic liver disease is most attributed to PPAR-delta activation. PPAR-delta is a nuclear receptor that, when activated, modulates transcription of genes involved in fatty acid oxidation, inflammation, and fibrogenesis. Activation of PPAR-delta leads to decreased hepatic inflammation and fibrosis and improved bile acid homeostasis, directly addressing the pathogenesis of primary biliary cholangitis. Therefore, the molecular target and mechanism underlying the therapeutic effect of elafibranor in this context is agonism of PPAR-delta.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_f914df9c29d7",
      "question": "A 42-year-old woman with chronic immune thrombocytopenic purpura (ITP) has failed first-line therapies, including corticosteroids and intravenous immunoglobulin. She is started on a treatment that consists of a recombinant cytokine known for its antiviral and immunomodulatory properties. This agent reduces the destruction of platelets by modifying the host immune response, particularly by altering cytokine profiles and enhancing the activity of immune effector cells. Which class best characterizes the mechanism by which this medication modulates immune function in her disease?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Thrombocytopenic Purpura"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0857305",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021735",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Biological Response Modifiers",
      "reasoning_path": "Chronic ITP involves autoantibody-driven platelet destruction; recombinant interferon alfa-2b is used as a biological response modifier, modulating cytokine production and immune cell activity to reduce platelet loss.",
      "umls_path": [
        "Thrombocytopenic Purpura",
        "may_be_treated_by",
        "Recombinant Interferon Alfa-2b",
        "has_mechanism_of_action",
        "Biological Response Modifiers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In chronic immune thrombocytopenic purpura (ITP), autoantibody-mediated platelet destruction leads to persistent low platelet counts and bleeding risk. When standard treatments like corticosteroids and IVIG fail, alternative immunomodulatory therapies are considered. Recombinant interferon alfa-2b is a synthetic form of a naturally occurring cytokine that exerts broad effects on the immune system. It acts as a biological response modifier by enhancing the cytotoxic activity of natural killer (NK) cells and macrophages, increasing antigen presentation, and altering the production of several cytokines (such as reducing Th2 cytokines while promoting Th1 responses). These actions together suppress the autoimmune process responsible for platelet destruction, thereby increasing platelet counts in some patients. The primary pharmacologic class describing this mechanism—modification of host immune responses to achieve therapeutic benefit—is 'biological response modifier.' This distinguishes it from agents with direct cytotoxic or immunosuppressive effects.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_f961752c44fa",
      "question": "In a patient with non-small cell lung cancer and a solitary nodule in the contralateral lung (stage IVA, N0, M1a), both lesions appear potentially curable. Should these be managed as two primary lung tumors or as metastatic disease?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
              "Pathologic Diagnosis of NSCLC",
              "Initial Evaluation",
              "Integrate palliative care"
            ]
          }
        }
      ],
      "answer": "When both the primary tumor and the solitary contralateral lung nodule are potentially curable, these should be managed as two primary lung tumors rather than as metastatic disease, allowing consideration of curative intent treatment for both lesions.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_252f0888c599",
      "question": "What diseases are associated with the target TYMS (Ensembl ID ENSG00000176890) in OpenTargets with a minimum relevance score of 0.5?",
      "tool_calls": [
        {
          "tool": "opentargets.search",
          "params": {
            "target_id": "ENSG00000176890",
            "min_score": 0.5
          }
        }
      ],
      "answer": [
        {
          "disease_id": "MONDO_0031057",
          "disease_name": "dyskeratosis congenita, digenic",
          "score": 0.6624847221561712
        },
        {
          "disease_id": "MONDO_0007254",
          "disease_name": "breast cancer",
          "score": 0.6158301524677086
        },
        {
          "disease_id": "EFO_0000616",
          "disease_name": "neoplasm",
          "score": 0.6126631639515382
        },
        {
          "disease_id": "MONDO_0015780",
          "disease_name": "dyskeratosis congenita",
          "score": 0.5978970703637825
        },
        {
          "disease_id": "EFO_0003060",
          "disease_name": "non-small cell lung carcinoma",
          "score": 0.5936403377930133
        },
        {
          "disease_id": "EFO_0000305",
          "disease_name": "breast carcinoma",
          "score": 0.5803040573304219
        },
        {
          "disease_id": "EFO_0004288",
          "disease_name": "colonic neoplasm",
          "score": 0.5761632237196096
        },
        {
          "disease_id": "EFO_0002496",
          "disease_name": "actinic keratosis",
          "score": 0.571121497445355
        },
        {
          "disease_id": "EFO_0004142",
          "disease_name": "colorectal neoplasm",
          "score": 0.5540211569980305
        },
        {
          "disease_id": "EFO_0003869",
          "disease_name": "breast neoplasm",
          "score": 0.5529090239497866
        },
        {
          "disease_id": "EFO_0000588",
          "disease_name": "mesothelioma",
          "score": 0.5473683845950184
        },
        {
          "disease_id": "EFO_0003897",
          "disease_name": "stomach neoplasm",
          "score": 0.5281388268081618
        },
        {
          "disease_id": "EFO_0000503",
          "disease_name": "gastric adenocarcinoma",
          "score": 0.5239588050333832
        },
        {
          "disease_id": "EFO_0000228",
          "disease_name": "adenocarcinoma",
          "score": 0.5091787603853702
        },
        {
          "disease_id": "EFO_0801066",
          "disease_name": "arabonate measurement",
          "score": 0.5010888651207076
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "path_aba0c3bebadd",
      "question": "In patients with multiple lung cancers (N0–1) and a dominant nodule showing evidence of growth, if definitive local therapy is not feasible, does proceeding directly to palliative chemotherapy necessarily exclude the possibility of subsequent local palliative interventions such as laser, stent placement, or external-beam radiotherapy if locoregional recurrence or endobronchial obstruction occurs?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Multiple lung cancers (suspected or confirmed) (N0–1)",
              "Multidisciplinary evaluation",
              "Dominant nodule with evidence of growth",
              "Definitive local therapy not possible",
              "Palliative chemotherapy ± local palliative therapy or Observe",
              "Therapy for Recurrence and Metastasis or Systemic Therapy for Metastatic Disease",
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, initiating palliative chemotherapy in patients with unresectable multiple lung cancers (N0–1) does not preclude later use of local palliative measures like laser, stent, or external-beam radiotherapy if locoregional recurrence or symptomatic endobronchial obstruction develops; local interventions remain appropriate for symptomatic management.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_b9aa5ba0769a",
      "question": "A 27-year-old woman presents with difficulty seeing in low-light conditions and reports bumping into objects at night. She has no significant past medical history and her physical exam reveals dry conjunctivae and Bitot's spots. Laboratory studies show low serum retinol levels. She is started on an oral supplement that must be metabolized within ocular tissues to form a key component of photoreceptor pigments. What category of pharmacological mechanism best describes how this therapy restores her night vision?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Night blindness, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0028077",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0042839",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Enzyme interactions—retinol’s therapeutic effect relies on enzymatic conversion to active retinal forms",
      "reasoning_path": "Vitamin A deficiency causes night blindness. Retinol supplementation must be enzymatically converted to retinal to restore photopigment function. Thus, enzyme interactions underlie the mechanism of action.",
      "umls_path": [
        "Night blindness, unspecified",
        "may_be_treated_by",
        "Retinol",
        "has_mechanism_of_action",
        "Enzyme Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s symptoms are classic for night blindness (nyctalopia), which is commonly caused by vitamin A (retinol) deficiency. Vitamin A is essential for the synthesis of retinal, the aldehyde form that combines with opsin to form rhodopsin, a photopigment necessary for vision in dim light. Retinol itself is inactive; it must be enzymatically oxidized first to retinal and then further processed in the visual cycle inside the retina. These conversions are catalyzed by specific enzymes (such as retinol dehydrogenase and retinal isomerase). Thus, the pharmacologic restoration of night vision following supplementation is entirely dependent on these enzyme-mediated transformations. The most relevant general pharmacological mechanism in this scenario is enzyme interaction, since the compound’s therapeutic benefit arises from its progressive enzymatic conversion to the active form required for normal phototransduction.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_eafaea0905e3",
      "question": "In a patient with advanced non-small cell lung cancer of adenocarcinoma subtype whose tumor harbors an NTRK gene fusion detected during first-line systemic therapy, is it acceptable to switch immediately to a TRK inhibitor (such as larotrectinib or entrectinib) before completion of planned systemic therapy, or should the initial therapy be completed first?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "NTRK1/2/3 gene fusion positive",
              "NTRK1/2/3 gene fusion",
              "NTRK1/2/3 gene fusion discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by larotrectinib, entrectinib, or repotrectinib",
              "Progression",
              "Repotrectinib (if not previously given) or Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
              "Progression",
              "Systemic Therapy Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)"
            ]
          }
        }
      ],
      "answer": "In this scenario, TRK inhibitor therapy should only begin after the completion or planned interruption of first-line systemic therapy, including maintenance. Initiating a TRK inhibitor before finishing or intentionally pausing the initial systemic treatment is not considered standard clinical practice in this molecularly defined context.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_947c1e183140",
      "question": "A 47-year-old woman with a history of diabetes mellitus presents with a warm, erythematous, and tender area on her lower leg. She is diagnosed with a soft tissue infection and started on a monobactam antibiotic that is especially useful for patients with a history of beta-lactam allergies. This drug functions by binding to a specific bacterial enzyme, thereby inhibiting the final transpeptidation step of cell wall synthesis. Through which molecular interaction does this antibiotic exert its antibacterial effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Cellulitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0007642",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0004521",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Covalent binding to penicillin-binding proteins (PBPs)",
      "reasoning_path": "Aztreonam treats soft tissue infections by covalently binding to bacterial PBPs, blocking cell wall transpeptidation and leading to bacterial death.",
      "umls_path": [
        "Cellulitis",
        "may_be_treated_by",
        "Aztreonam",
        "has_mechanism_of_action",
        "Antibody-Receptor Interactions"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient’s soft tissue infection is likely due to gram-negative bacteria, for which aztreonam is often prescribed, especially in individuals with allergies to other beta-lactam antibiotics. Aztreonam is a monobactam antibiotic that works by binding covalently to penicillin-binding proteins (PBPs), particularly PBP-3 in susceptible bacteria. This molecular interaction inhibits the transpeptidase activity necessary for cross-linking peptidoglycan chains, an essential step in bacterial cell wall synthesis. The result is a weakened cell wall, leading to cell lysis and bacterial death. Unlike antibody-receptor interactions, which are typical of immune responses, aztreonam’s effect relies on direct covalent inhibition of bacterial enzymes. Understanding this mechanism is crucial for selecting appropriate antimicrobial therapy, especially in cases of drug allergy or resistance.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_f02ed6899127",
      "question": "For a patient with squamous cell carcinoma of the lung who has a mediastinal lymph node recurrence after prior radiotherapy, and whose tumor is PD-L1 positive (≥1%) but negative for actionable molecular biomarkers, should broad molecular profiling still be performed, or is PD-L1 testing alone sufficient to guide systemic therapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "Prior RT",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "PD-L1 ≥1% and negative for actionable molecular biomarkers above"
            ]
          }
        }
      ],
      "answer": "Broad molecular profiling remains indicated even in PD-L1 positive squamous cell carcinoma with negative initial actionable biomarkers, as additional genomic alterations may emerge, especially after prior treatment. Comprehensive molecular testing ensures optimal identification of potential targetable mutations critical for systemic therapy selection.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_fe3c84a22ddc",
      "question": "A term neonate develops severe cyanosis and respiratory distress within hours of birth. Echocardiography reveals marked right ventricular hypertrophy and critical obstruction at the level of the pulmonic valve, with diminished pulmonary artery flow. The infant remains hypoxemic despite supplemental oxygen. The cardiology team initiates an intravenous infusion of a drug that mimics the effect of a naturally occurring eicosanoid, leading to vasodilation and smooth muscle relaxation in the ductus arteriosus. This pharmacologic intervention is essential to provide sufficient pulmonary blood flow until definitive surgical repair. Which class of receptor is primarily activated by the agent used to maintain ductal patency in this setting?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Pulmonic valve stenosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0034089",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002335",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Prostaglandin receptor agonists",
      "reasoning_path": "Critical pulmonic stenosis causes ductal-dependent pulmonary flow; alprostadil is given to keep the ductus arteriosus open; it acts as a prostaglandin receptor agonist on ductal smooth muscle, preventing closure and sustaining pulmonary circulation.",
      "umls_path": [
        "Pulmonic valve stenosis",
        "may_be_treated_by",
        "Alprostadil",
        "has_mechanism_of_action",
        "Prostaglandin Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In neonates with critical pulmonic valve stenosis, pulmonary blood flow is severely restricted due to obstruction at the valve. In fetal life, the ductus arteriosus allows blood to bypass the lungs; after birth, its closure can precipitate life-threatening hypoxemia in ductal-dependent lesions. Alprostadil, a synthetic analog of prostaglandin E1, is administered to maintain ductal patency. The therapeutic effect of alprostadil is mediated through activation of prostaglandin E1 (EP) receptors on the smooth muscle of the ductus arteriosus, resulting in increased intracellular cAMP, smooth muscle relaxation, and delayed closure of the ductus. This intervention temporarily restores pulmonary blood flow until definitive management. Therefore, the molecular target underlying this lifesaving therapy is the prostaglandin receptor.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_37c17d6b0cd3",
      "question": "What is the PMID of the article titled “Impact of the COVID-19 pandemic on the diagnosis, tumor characteristics, and survival outcomes of colorectal cancer: a retrospective cohort study,” authored by Yarikkaya E and published in Annals of Saudi Medicine in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"Impact of the COVID-19 pandemic on the diagnosis, tumor characteristics, and survival outcomes of colorectal cancer\"[ti] AND Yarikkaya E[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40482190"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_7ee75ae9fc01",
      "question": "A 28-year-old contact lens wearer presents with several days of severe eye pain, photophobia, and blurred vision in the left eye. On slit-lamp examination, there is a central corneal ulcer with perineural infiltrates. Laboratory analysis of corneal scrapings reveals a motile organism consistent with a free-living amoeba. The ophthalmologist prescribes a medication commonly used for fungal infections that acts by disrupting the integrity of certain pathogen cell membranes. Which molecular pathway is specifically inhibited by this class of drugs to exert its therapeutic effect against the causative organism?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Acanthamoeba keratitis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0000880",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C4550366",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Inhibition of ergosterol synthesis",
      "reasoning_path": "Acanthamoeba keratitis is treated with azole antifungals (like Levoketoconazole), which inhibit ergosterol synthesis, leading to impaired cell membrane function and pathogen death.",
      "umls_path": [
        "Acanthamoeba keratitis",
        "may_be_treated_by",
        "Levoketoconazole",
        "has_mechanism_of_action",
        "Ergosterol Synthesis Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient’s presentation is consistent with Acanthamoeba keratitis, a sight-threatening corneal infection often related to improper contact lens use and exposure to contaminated water. Acanthamoeba possesses a cell membrane that, like fungi, contains ergosterol or similar sterols critical for membrane fluidity and function. Agents such as Levoketoconazole target the biosynthesis of ergosterol by inhibiting key enzymes in the sterol synthesis pathway, particularly 14α-demethylase. This disruption leads to increased membrane permeability and loss of essential membrane functions in the pathogen, resulting in cell death. While primarily considered antifungals, these agents exploit the pathogen’s reliance on ergosterol, making them effective in treating Acanthamoeba infections. Thus, the molecular pathway specifically inhibited is ergosterol synthesis, which is essential for maintaining the integrity and viability of the Acanthamoeba cell membrane.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_cd7f2682ca88",
      "question": "In ClinicalTrials.gov, which interventional studies for hepatic encephalopathy with rifaximin or placebo started in December 2005 and are in phase 3?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "phases=PHASE3;conditions=Hepatic Encephalopathy;interventions.name=Rifaximin,Placebo;startDateFrom=2005-12-01",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00298038"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_2cdd0a0029d8",
      "question": "In a patient with non–small cell lung cancer presenting with a T3N1 tumor (AJCC Stage IIIA), pulmonary function tests reveal severely impaired lung function, but there is no extrathoracic metastatic disease or superior vena cava obstruction. Is perioperative therapy still a suitable consideration in this context?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, perioperative therapy requires adequate cardiopulmonary reserve; severely impaired pulmonary function precludes surgery, making perioperative therapy unsuitable. Non-surgical, non-perioperative modalities, such as definitive chemoradiation or radiotherapy, should be considered instead in this situation.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_227e392fe5d8",
      "question": "A 58-year-old woman with a history of heparin-induced thrombocytopenia (HIT) presents with a newly diagnosed deep vein thrombosis. Her physician initiates anticoagulation with a medication composed of glycosaminoglycans that acts primarily by enhancing the inhibition of factor Xa. This agent does not cross-react with heparin-induced antibodies and achieves its effect by potentiating the action of a natural plasma inhibitor against certain coagulation serine proteases. Which pharmacological class best describes the molecular mechanism responsible for this drug's anticoagulant effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Thrombocytopenia, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0040034",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0259507",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Serine proteinase inhibitors (serpins) potentiators",
      "reasoning_path": "Heparin contraindicated due to HIT → Danaparoid used → Danaparoid enhances antithrombin activity → Antithrombin inhibits serine proteases (factor Xa, thrombin) → Anticoagulant effect via serine proteinase inhibitor potentiation.",
      "umls_path": [
        "Thrombocytopenia, unspecified",
        "may_be_treated_by",
        "Danaparoid",
        "has_mechanism_of_action",
        "Serine Proteinase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In this scenario, the patient has a contraindication to heparin due to heparin-induced thrombocytopenia (HIT), so an alternative anticoagulant is needed. Danaparoid is commonly used in this setting because it consists of a mixture of glycosaminoglycans and does not cross-react with HIT antibodies. Its anticoagulant activity is mainly due to its ability to enhance the activity of antithrombin (a serine proteinase inhibitor), which in turn inhibits factor Xa and, to a lesser extent, thrombin. By reinforcing the inhibitory action of antithrombin on these serine proteases in the coagulation cascade, danaparoid reduces thrombin generation and prevents clot propagation. Thus, the class that best describes its mechanism is agents that potentiate serine proteinase (serpin) inhibitors.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_090840682d4e",
      "question": "In a patient with stage IIIC (T4, N3) non-small cell lung cancer and histologically confirmed squamous cell subtype, is broad molecular profiling for EGFR, ALK, KRAS, ROS1, BRAF, NTRK, METex14, RET, and ERBB2 (HER2) mutations indicated, or does the squamous histology alter the priority of comprehensive molecular testing?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIB (T4, N2) Stage IIIC (T4, N3)",
              "FDG-PET/CT scank (if not previously done) • Brain MRI with contrastq¶ • Pathologic confirmation of N2–3 disease by either: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "See Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Distant metastases",
              "Bone metastases",
              "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Even though actionable mutations are less frequent in squamous cell carcinoma, broad molecular profiling, including EGFR, ALK, KRAS, ROS1, BRAF, NTRK, METex14, RET, and ERBB2 (HER2), is still recommended to identify rare but clinically relevant alterations. Thus, squamous histology does not eliminate the priority of comprehensive molecular testing in advanced disease.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_1f2eca17fb30",
      "question": "A 35-year-old woman presents to a dermatology clinic with multiple rough, flesh-colored papules on her hands and fingers. She reports that these lesions have gradually increased in number over several months. After confirming a diagnosis of cutaneous warts caused by human papillomavirus, her dermatologist recommends a therapy that involves a recombinant protein known to boost the body's antiviral defenses through modulation of immune signaling pathways. Which pharmacologic class best characterizes the primary therapeutic mechanism of this agent in treating her skin lesions?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Verruca vulgaris"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3665596",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021735",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Biological Response Modifiers",
      "reasoning_path": "Cutaneous warts (verruca vulgaris) are caused by HPV. Recombinant interferon alfa-2b acts by boosting host antiviral immunity. Its mechanism is immune modulation, fitting the pharmacologic class of biological response modifiers.",
      "umls_path": [
        "Verruca vulgaris",
        "may_be_treated_by",
        "Recombinant Interferon Alfa-2b",
        "has_mechanism_of_action",
        "Biological Response Modifiers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient's cutaneous warts (verruca vulgaris) are caused by HPV infection. Conventional therapies (such as cryotherapy) may be insufficient for recalcitrant or extensive cases. Recombinant interferon alfa-2b can be used as an immune-modulating therapy in such situations. Interferon alfa-2b is a cytokine that enhances the immune response by inducing antiviral proteins, increasing the activity of natural killer cells and cytotoxic T lymphocytes, and upregulating the expression of major histocompatibility complex (MHC) molecules. By modulating these pathways, interferon alfa-2b helps the immune system recognize and clear virally infected cells. Pharmacologically, agents like interferon alfa-2b are classified as biological response modifiers because their primary mechanism involves altering host immune responses rather than directly targeting pathogens. This immune enhancement is central to their therapeutic action in viral infections such as verruca vulgaris.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_9a591ea347ab",
      "question": "A 52-year-old man presents with headaches, excessive sweating, and enlargement of his hands and facial features over several years. Laboratory tests reveal elevated serum IGF-1 and failure of growth hormone suppression on oral glucose tolerance testing. MRI shows a pituitary mass. He is started on a medication that mimics an endogenous peptide hormone and achieves clinical improvement by binding to a G protein-coupled receptor subtype on somatotroph cells, leading to reduced growth hormone secretion. Which receptor subtype does this drug primarily target to exert its therapeutic effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Acromegaly"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001206",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0028833",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Somatostatin receptor type 5 (SSTR5)",
      "reasoning_path": "Acromegaly → Excess GH → Treated with somatostatin analog (octreotide) → Binds SSTR5 on somatotrophs → Inhibits GH secretion → Clinical improvement.",
      "umls_path": [
        "Acromegaly",
        "may_be_treated_by",
        "Octreotide",
        "has_target",
        "Somatostatin Receptor Type 5"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has classic features of acromegaly, most commonly due to a pituitary somatotroph adenoma causing excess growth hormone (GH) secretion. The drug described is a somatostatin analog, such as octreotide or lanreotide. These peptides mimic endogenous somatostatin, an inhibitory hormone that suppresses GH release. The suppression occurs via binding to somatostatin receptors on pituitary somatotrophs. Of the five known somatostatin receptor subtypes (SSTR1–SSTR5), SSTR2 and SSTR5 are most important for GH regulation. Octreotide shows high affinity for SSTR2 but also binds SSTR5, and evidence indicates that SSTR5 is particularly relevant in mediating GH inhibition in acromegaly therapy. Targeting SSTR5 leads to reduced cAMP production and downstream inhibition of GH secretion, improving symptoms and lowering IGF-1 levels. Thus, the main therapeutic effect of somatostatin analogs in acromegaly is mediated via SSTR5.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_c12fc1deaa1e",
      "question": "In a patient with resected stage IIA (T2b, N0) non-small cell lung cancer who has undergone R0 surgery and is currently disease-free on imaging, is routine FDG-PET/CT or brain MRI surveillance recommended during follow-up, or should imaging be limited to scheduled chest CT scans?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIA (T2b, N0); Margins negative (R0)",
              "Observe or Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Routine FDG-PET/CT and brain MRI are not recommended for surveillance in resected stage IIA (T2b, N0) non-small cell lung cancer patients without clinical or radiographic evidence of disease. Follow-up imaging should be limited to scheduled chest CT scans, with additional modalities reserved for suspected recurrence based on symptoms or findings.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_38904f86d6a7",
      "question": "A 42-year-old woman presents with progressive shortness of breath and nonproductive cough. Chest imaging reveals bilateral hilar lymphadenopathy, and biopsy of a mediastinal lymph node shows noncaseating granulomas. She is started on a medication to control her symptoms, which works by binding to a cytoplasmic receptor, leading to altered gene transcription that downregulates pro-inflammatory cytokines and inhibits granuloma formation. Which molecular pathway is primarily responsible for the therapeutic effect of this medication in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Sarcoidosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0036202",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0071842",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Activation of glucocorticoid receptors (glucocorticoid receptor agonism)",
      "reasoning_path": "Sarcoidosis involves immune granulomas; treatment with prednisolone phosphate acts by activating glucocorticoid receptors, which alters gene transcription to suppress cytokine production and granuloma formation.",
      "umls_path": [
        "Sarcoidosis",
        "may_be_treated_by",
        "prednisolone phosphate",
        "has_mechanism_of_action",
        "Glucocorticoid Receptor Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s clinical presentation and biopsy findings are consistent with sarcoidosis, a granulomatous disease driven by immune-mediated inflammation. The first-line therapy for symptomatic sarcoidosis is a glucocorticoid such as prednisolone phosphate. The drug exerts its effect by diffusing across cell membranes and binding to cytoplasmic glucocorticoid receptors. This hormone-receptor complex then translocates to the nucleus, where it modulates transcription of genes involved in immune regulation. Specifically, glucocorticoids suppress the transcription of pro-inflammatory cytokines (such as IL-2, TNF-alpha, and IFN-gamma) and promote anti-inflammatory mediators. This results in the inhibition of T-cell activation and macrophage function, which are central to granuloma formation and maintenance. Thus, the primary molecular pathway for the therapeutic action of prednisolone phosphate in sarcoidosis is agonism of the glucocorticoid receptor, leading to reduced inflammation and granuloma resolution.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_c73121b0c84f",
      "question": "For a patient with completely resected Stage IIB non-small cell lung cancer (T3N0, R0 margins) who remains disease-free after adjuvant chemotherapy, is routine use of FDG-PET/CT or brain MRI indicated during standard surveillance imaging in the first two years post-treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Endobronchial obstruction",
              "Any combination of the following: Laser/stent/other surgery; External-beam RT or brachytherapym; Photodynamic therapy",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Routine use of FDG-PET/CT or brain MRI is not indicated for surveillance in disease-free patients with Stage IIB non-small cell lung cancer post-complete resection and adjuvant therapy; surveillance should be performed with H&P and chest CT, reserving FDG-PET/CT or brain MRI only for suspected recurrence or new symptoms.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_1ae60beba25a",
      "question": "In patients with surgically resected stage IIIA (T1–2, N2) non-small cell lung cancer who are found to have positive surgical margins (R1), is chemoradiation the standard adjuvant therapy regardless of whether the initial surgery included complete mediastinal lymph node dissection?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Nodes negative",
              "Treatment (NSCL-9)",
              "T1, N0",
              "Operable",
              "Surgical exploration and resectionl + mediastinal lymph node dissection or systematic lymph node sampling",
              "Adjuvant Treatment (NSCL-4)",
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins positive",
              "R1; Chemoradiation (sequential or concurrent)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "Yes, for patients with resected stage IIIA (T1–2, N2) NSCLC and positive margins (R1), adjuvant chemoradiation is indicated irrespective of whether mediastinal lymph node dissection was performed during surgery, as positive margins represent a high-risk feature necessitating additional local and systemic control.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_9636488feb36",
      "question": "A 55-year-old recreational tennis player presents with persistent lateral elbow pain and swelling that have failed to improve with physical therapy over several months. His physician prescribes an oral medication that acts by reversibly inhibiting a key enzyme involved in the conversion of arachidonic acid to pro-inflammatory mediators. Which specific molecular target is responsible for the anti-inflammatory effect of this medication in the management of his chronic tendon condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Tendinopathy"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1568272",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0021246",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase (Cyclooxygenase, COX-1/COX-2)",
      "reasoning_path": "Chronic tendinopathy causes inflammation → NSAIDs prescribed → NSAIDs inhibit cyclooxygenase (prostaglandin G/H synthase) → decreased prostaglandin synthesis → reduced inflammation and pain.",
      "umls_path": [
        "Tendinopathy",
        "may_be_treated_by",
        "Indomethacin",
        "has_target",
        "Prostaglandin G/H Synthase 1"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient is experiencing chronic tendinopathy, a condition characterized by persistent pain and inflammation of a tendon, often resulting from repetitive overuse. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to manage pain and inflammation in such cases. NSAIDs, such as indomethacin, exert their therapeutic effects by inhibiting the activity of cyclooxygenase (COX) enzymes, also known as prostaglandin G/H synthases (COX-1 and COX-2). These enzymes are responsible for converting arachidonic acid into prostaglandin H2, a precursor to various pro-inflammatory prostaglandins. By inhibiting COX activity, NSAIDs reduce the synthesis of these mediators, thereby decreasing inflammation and providing symptomatic relief. The inhibition of prostaglandin G/H synthase is therefore the direct molecular mechanism underlying the anti-inflammatory effects of NSAIDs in chronic tendinopathy.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_75f84d613283",
      "question": "In a patient with stage IIIA non-small cell lung cancer characterized by resectable T4 tumor extension (N0-N1), is the recommendation for surgical resection predicated on the absence of distant metastases as confirmed by preoperative FDG-PET/CT and brain MRI?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Trachea/carina or mediastinum",
              "Treatment (NSCL-7)",
              "Chest wall, trachea/carina, or mediastinum; T3 invasion, N0–1; resectable T4 extension, N0–1; Stage IIIA (T4, N0–1) resectable",
              "Surgery (preferred)",
              "Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "Yes, offering surgery as the preferred treatment for resectable stage IIIA (T4, N0–1) non-small cell lung cancer is contingent upon thorough preoperative staging—including FDG-PET/CT and brain MRI—to exclude the presence of distant metastases, ensuring the disease is truly resectable and localized.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_48e10f2533c7",
      "question": "In a patient with stage IIIB non-small cell lung cancer (T1–2, N3), if pathologic confirmation of N3 disease has not been obtained due to inaccessible lymph nodes, is it appropriate to proceed directly with systemic therapy as for metastatic disease?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "N3 nodes positive, M0",
              "Stage IIIB or Stage IIIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "PS 0–2",
              "Multiple lesions",
              "Systemic Therapy for Metastatic Disease (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, initiating systemic therapy for metastatic disease without pathologic confirmation of N3 status is not appropriate. Pathologic confirmation of mediastinal or supraclavicular lymph node involvement is a required step before classifying disease as stage IIIB requiring systemic treatment, to avoid misclassification and ensure accurate staging.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_5e583c5d6121",
      "question": "Which diseases are associated with the target ERBB2 (Ensembl ID ENSG00000141736) in OpenTargets with a minimum relevance score of 0.5?",
      "tool_calls": [
        {
          "tool": "opentargets.search",
          "params": {
            "target_id": "ENSG00000141736",
            "min_score": 0.5
          }
        }
      ],
      "answer": [
        {
          "disease_id": "EFO_0003060",
          "disease_name": "non-small cell lung carcinoma",
          "score": 0.7568236425360201
        },
        {
          "disease_id": "MONDO_0004992",
          "disease_name": "cancer",
          "score": 0.731730988769789
        },
        {
          "disease_id": "EFO_0000305",
          "disease_name": "breast carcinoma",
          "score": 0.6987266920956966
        },
        {
          "disease_id": "EFO_0000616",
          "disease_name": "neoplasm",
          "score": 0.6754639215719295
        },
        {
          "disease_id": "MONDO_0001056",
          "disease_name": "gastric cancer",
          "score": 0.665616672410976
        },
        {
          "disease_id": "EFO_0000304",
          "disease_name": "breast adenocarcinoma",
          "score": 0.635676781867804
        },
        {
          "disease_id": "MONDO_0007254",
          "disease_name": "breast cancer",
          "score": 0.633744733345256
        },
        {
          "disease_id": "EFO_0000571",
          "disease_name": "lung adenocarcinoma",
          "score": 0.624937726916147
        },
        {
          "disease_id": "MONDO_0004986",
          "disease_name": "urinary bladder carcinoma",
          "score": 0.6107553898692176
        },
        {
          "disease_id": "EFO_0003869",
          "disease_name": "breast neoplasm",
          "score": 0.6106814456287735
        },
        {
          "disease_id": "MONDO_0008903",
          "disease_name": "lung cancer",
          "score": 0.6000233791803498
        },
        {
          "disease_id": "EFO_1000294",
          "disease_name": "HER2 Positive Breast Carcinoma",
          "score": 0.5833744232129816
        },
        {
          "disease_id": "EFO_0000503",
          "disease_name": "gastric adenocarcinoma",
          "score": 0.5646081597999976
        },
        {
          "disease_id": "EFO_0005208",
          "disease_name": "glomerular filtration rate",
          "score": 0.5565147382111423
        },
        {
          "disease_id": "MONDO_0001187",
          "disease_name": "urinary bladder cancer",
          "score": 0.5399840248584121
        },
        {
          "disease_id": "MONDO_0008170",
          "disease_name": "ovarian cancer",
          "score": 0.5317537382127806
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "path_e232f491da85",
      "question": "In a patient with newly diagnosed stage IVA, metastatic (M1b) non-squamous non-small cell lung cancer whose tumor tests negative for actionable molecular biomarkers and has a PD-L1 expression less than 1%, can initial systemic immunotherapy monotherapy with a PD-1/PD-L1 inhibitor alone be considered adequate, or is platinum-based chemotherapy a necessary component of first-line treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "PD-L1 <1% and negative for actionable molecular biomarkers above",
              "PD-L1 <1%",
              "INITIAL SYSTEMIC THERAPY",
              "PS 0–2",
              "Systemic therapy • Adenocarcinoma, Large Cell, NSCLC NOS (NSCL-K 1 of 5) • Squamous Cell Carcinoma (NSCL-K 2 of 5)",
              "Tumor response evaluation",
              "Progression",
              "PS 0–2",
              "Systemic therapy, Subsequent (NSCL-K 4 of 5)",
              "Systemic therapy, Progression (NSCL-K 4 of 5)"
            ]
          }
        }
      ],
      "answer": "When actionable molecular alterations are absent and PD-L1 expression is below 1% in advanced non-squamous NSCLC, initial systemic therapy should include platinum-based chemotherapy, rather than immunotherapy monotherapy; immunotherapy alone is not considered adequate due to poor efficacy in this biomarker-defined subgroup.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_20be97c23913",
      "question": "In a patient with mediastinal lymph node recurrence of non-small cell lung cancer who has not received prior thoracic radiotherapy, is it appropriate to prioritize concurrent chemoradiation over immediate systemic therapy, assuming no evidence of disseminated disease?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Yes, in patients with mediastinal lymph node recurrence of NSCLC who have not previously received thoracic radiotherapy and lack evidence of distant metastases, concurrent chemoradiation is the preferred treatment over immediate systemic therapy, as it offers superior local control and potential survival benefit in this locoregional setting.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_ae2f6f49c421",
      "question": "A 2-week-old infant presents with vomiting, poor feeding, and ambiguous genitalia. Laboratory tests reveal hyponatremia, hyperkalemia, and elevated 17-hydroxyprogesterone, leading to a diagnosis of a congenital enzyme deficiency affecting adrenal steroid synthesis. The neonate is started on a medication that both corrects hormone imbalance and exerts anti-inflammatory effects by reducing leukotriene production through inhibition of a key enzyme in the arachidonic acid metabolic pathway. Which enzyme class is directly targeted to achieve this anti-inflammatory effect?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Congenital Adrenal Hyperplasia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001627",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0352536",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lipoxygenase inhibitors",
      "reasoning_path": "Congenital adrenal hyperplasia → corticosteroid therapy → anti-inflammatory effect → inhibition of arachidonic acid pathway → decreased leukotriene synthesis → lipoxygenase is the enzyme inhibited.",
      "umls_path": [
        "Congenital Adrenal Hyperplasia",
        "may_be_treated_by",
        "Hydrocortisone Butyrate",
        "has_mechanism_of_action",
        "Lipoxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This neonate has congenital adrenal hyperplasia (CAH), typically due to 21-hydroxylase deficiency, requiring corticosteroid therapy to suppress excess ACTH and restore hormonal balance. Besides their endocrine actions, some corticosteroids also exhibit anti-inflammatory effects by interfering with eicosanoid synthesis. The arachidonic acid pathway leads to the production of pro-inflammatory mediators like prostaglandins and leukotrienes. While corticosteroids mainly inhibit phospholipase A2, thereby upstream reducing substrate availability, certain anti-inflammatory drugs specifically block the lipoxygenase enzyme class. Lipoxygenases convert arachidonic acid into leukotrienes, which mediate inflammation. By inhibiting lipoxygenase, leukotriene synthesis is decreased, thereby reducing inflammation. Thus, the enzyme class whose inhibition underlies this anti-inflammatory mechanism is lipoxygenase.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_b29c61738cc8",
      "question": "For a patient with stage IIIA (T1–2, N2) non-small cell lung cancer who did not previously receive concurrent chemoradiation and now presents with symptomatic superior vena cava (SVC) obstruction, is the use of an SVC stent with external-beam radiotherapy appropriate regardless of pulmonary function status?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IA (peripheral T1abc, N0)",
              "Pulmonary function tests (PFTs) (if not previously done)\nBronchoscopy (intraoperative preferred)\nConsider pathologic mediastinal lymph node evaluation\nFDG-PET/CT scank (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8) or Stage IIIB/IIIC (NSCL-13)",
              "Stage IIIA (T1–2, N2); Stage IIIB (T3, N2)",
              "Evaluate for perioperative therapy; PFTs (if not previously done); Bronchoscopy; Pathologic mediastinal lymph node evaluation; FDG-PET/CT scan (if not previously done); Brain MRI with contrast",
              "Metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, the use of external-beam radiotherapy in symptomatic SVC obstruction requires consideration of the patient’s pulmonary function status. In cases of severely compromised pulmonary function, radiotherapy may pose excessive risk, and SVC stenting alone becomes the preferred initial intervention to promptly relieve obstruction.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_0601b76289fa",
      "question": "A 68-year-old man with a history of chronic hypertension and coronary artery disease presents with worsening shortness of breath, orthopnea, and lower extremity edema. Echocardiography reveals a reduced ejection fraction, and he is diagnosed with systolic heart failure. He is started on a medication that directly stimulates cardiac contractility and increases renal blood flow by activating a specific class of G protein-coupled receptors. Which pharmacological class does this agent belong to, and what is the mechanism by which it provides symptomatic relief in heart failure?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Congestive heart failure, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0018802",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0938482",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Dopamine agonists—these drugs stimulate dopamine receptors to enhance cardiac contractility and improve renal perfusion.",
      "reasoning_path": "Heart failure symptoms are treated with drugs like ibopamine, which act as dopamine receptor agonists to increase cardiac contractility and renal perfusion, alleviating congestion.",
      "umls_path": [
        "Congestive heart failure, unspecified",
        "may_be_treated_by",
        "Ibopamine hydrochloride",
        "has_mechanism_of_action",
        "Dopamine Agonists"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In patients with systolic heart failure, clinical symptoms arise due to reduced cardiac output and fluid overload. Certain drugs, such as ibopamine, act as dopamine receptor agonists. By stimulating dopamine receptors, particularly in the kidneys and heart, these agents increase myocardial contractility (positive inotropy) and promote vasodilation of renal blood vessels. This dual effect helps to improve forward cardiac output and enhance renal perfusion, facilitating diuresis and fluid removal. The net result is symptomatic improvement, including relief from congestion and edema. Dopamine agonists are classified pharmacologically by their ability to bind and activate dopamine receptors, distinguishing them from other inotropic or vasodilator agents. Thus, the therapeutic action in heart failure is mediated by dopamine receptor stimulation.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_006f938c2394",
      "question": "A 62-year-old woman with chronic knee pain and morning stiffness is diagnosed with osteoarthritis. After trying acetaminophen and NSAIDs with limited relief, her physician recommends a supplement derived from animal cartilage that consists of glycosaminoglycans and is believed to help maintain cartilage structure and function by modulating macromolecular processes within the extracellular matrix. Which type of pharmacological activity best explains the therapeutic mechanism of this agent in her joint disorder?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Cartilage disorder"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0007302",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3473003",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Biological macromolecular activity",
      "reasoning_path": "Osteoarthritis involves cartilage degeneration; chondroitin sulfate sodium exerts its effect by modulating biological macromolecular processes in cartilage, supporting matrix structure and integrity.",
      "umls_path": [
        "Cartilage disorder",
        "may_be_treated_by",
        "CHONDROITIN SULFATE SODIUM (PORCINE)",
        "has_mechanism_of_action",
        "Biological Macromolecular Activity"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with osteoarthritis is prescribed chondroitin sulfate sodium, a glycosaminoglycan supplement sourced from animal cartilage. Chondroitin sulfate is incorporated into the cartilage extracellular matrix, where it interacts with other matrix components such as collagen and proteoglycans. Its therapeutic effect is thought to arise from its ability to influence biological macromolecular processes: it may inhibit degradative enzymes, promote water retention, and support cartilage resilience. Unlike traditional small-molecule drugs that target specific receptors or enzymes, chondroitin sulfate works primarily through its role as a structural macromolecule, impacting the overall metabolism and integrity of cartilage tissue. This type of pharmacological activity—acting at the level of large biological molecules and matrix interactions—underpins its use in the management of cartilage disorders like osteoarthritis, where preservation of cartilage structure and function is key.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_3ab4e501058b",
      "question": "A 47-year-old woman presents to the emergency department with severe headache, visual disturbances, and a blood pressure of 230/130 mmHg. Fundoscopic examination reveals papilledema, and laboratory studies show acute kidney injury. She is diagnosed with a life-threatening elevation in blood pressure and is started on an intravenous antihypertensive agent that rapidly lowers systemic vascular resistance by direct vasodilation of arterioles. Despite its clinical effectiveness, the exact cellular or molecular mechanism by which this agent induces vasodilation remains incompletely understood. Which best describes the mechanistic classification of this therapy?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Malignant Hypertension"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020540",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0282198",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Malignant hypertension → acute antihypertensive therapy → hydralazine use → direct vasodilation → mechanism not definitively established; classified as unknown cellular or molecular interaction.",
      "umls_path": [
        "Malignant Hypertension",
        "may_be_treated_by",
        "Hydralazine Hydrochloride",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient is experiencing hypertensive emergency (malignant hypertension), requiring immediate blood pressure reduction to prevent further end-organ damage. Hydralazine is a direct-acting vasodilator frequently used in such situations. While it is known to relax arteriolar smooth muscle and thereby reduce systemic vascular resistance, the precise cellular or molecular mechanism remains unclear. Proposed mechanisms include interference with intracellular calcium metabolism and stimulation of nitric oxide production, but none have been definitively established. Therefore, the mechanistic classification for hydralazine remains 'unknown cellular or molecular interaction,' reflecting the incomplete understanding of its direct molecular target or pathway.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_7a3041b58347",
      "question": "For a patient with stage II non-small cell lung cancer (T2b, N0), who also has severely reduced pulmonary function on pulmonary function tests (PFTs), is surgical resection still an appropriate first-line treatment option?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Stage IIIB (T1–2, N3) Stage IIIC (T3, N3)",
              "PFTs (if not previously done) FDG-PET/CT scank (if not previously done) Brain MRI with contrastq Pathologic confirmation of N3 disease by: Mediastinoscopy Supraclavicular lymph node biopsy Thoracoscopy Needle biopsy Mediastinotomy EUS biopsy EBUS biopsy",
              "Metastatic disease",
              "Treatment for Metastasis limited sites (NSCL-15) or distant disease (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Severe hemoptysis",
              "Any combination of the following: External-beam RT or brachytherapym; Laser or photodynamic therapy or embolization; Surgery",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "No, severely reduced pulmonary function on PFTs contraindicates surgical resection as first-line therapy in stage II NSCLC. In this context, alternative treatments such as definitive radiotherapy should be prioritized due to high perioperative risk with surgery.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_58f5d003f86b",
      "question": "For patients with stage I–II non–small cell lung cancer who received primary treatment with radiation therapy rather than surgery, is it appropriate to use the same surveillance interval and modality as for those who underwent surgical resection with or without chemotherapy during the first 2–3 years post-treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T1abc–T2a, N1); Stage IIB (T3, N0; T2b, N1); Margins positive",
              "R2; Resection + systemic therapy or Concurrent chemoradiation",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Locoregional recurrence",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Locoregional recurrence or symptomatic local disease",
              "Superior vena cava (SVC) obstruction",
              "Concurrent chemoradiation (if not previously given) ± SVC stent; External-beam RT ± SVC stent; SVC stent",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "No evidence of disseminated disease",
              "Observation or Systemic therapy (category 2B)"
            ]
          }
        }
      ],
      "answer": "No, patients receiving primary radiation therapy require more frequent surveillance—history and physical examination plus chest CT with or without contrast every 3–6 months for 3 years—while those treated surgically (with or without chemotherapy) are monitored every 6 months during the first 2–3 years. This distinction reflects higher recurrence risk and monitoring needs in patients treated with radiation.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_c481c0eefa96",
      "question": "In a patient with stage II non-small cell lung cancer (NSCLC) who presents with N1 nodal involvement and a separate pulmonary nodule in the same lobe, is brain MRI with contrast considered a mandatory staging investigation prior to treatment selection?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IB (peripheral T2a, N0) Stage I (central T1abc–T2a, N0) Stage II (T1abc–2ab, N1; T2b, N0) Stage IIB (T3, N0) Stage IIIA (T3, N1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, FDG-PET/CT scan (if not previously done), Brain MRI with contrast (Stage II, IIIA) (Stage IB [optional])",
              "N1 or N2 disease",
              "Stage IIB (NSCL-8), Stage IIA/IIB (NSCL-8) or Stage IIB/IIC (NSCL-13)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Extrathoracic metastatic disease",
              "Treatment for Metastasis limited sites or distant disease",
              "Locoregional recurrence or symptomatic local disease",
              "Mediastinal lymph node recurrence",
              "No prior RT",
              "Concurrent chemoradiation",
              "Chest CT with contrast Brain MRI with contrast FDG-PET/CT",
              "Evidence of disseminated disease",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Yes; for stage II NSCLC (including N1 disease), brain MRI with contrast is recommended as a mandatory staging assessment to screen for occult brain metastases, as it directly impacts therapeutic planning and eligibility for curative-intent local treatment.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_b8ed7aa17b87",
      "question": "For a patient with non-small cell lung cancer (NSCLC) who has separate pulmonary nodules located in the same lobe (T3, N0) and negative surgical margins (R0) after planned preoperative systemic therapy and surgery, is adjuvant systemic therapy universally indicated, or are there clinical scenarios within this setting where surveillance alone would be appropriate?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Positive mediastinal nodes",
              "Stage IIIA/IIIB (NSCL-8)",
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1) or ipsilateral non-primary lobe (T4, N0–1)",
              "Treatment",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
              "Surgery after preoperative systemic therapy, if planned",
              "N2",
              "Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E) or Sequential chemotherapy + Consider RT",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "In patients with NSCLC, T3N0 with separate pulmonary nodules in the same lobe and R0 resection after preoperative systemic therapy and surgery, adjuvant systemic therapy is generally indicated due to stage IIb/III risk. However, surveillance alone may be considered only if significant contraindications to systemic therapy exist, as per standard practice adjuvant therapy is preferred.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_56037079db2a",
      "question": "A 45-year-old man is diagnosed with hypereosinophilic syndrome after months of unexplained fatigue, recurrent fevers, and marked eosinophilia. He is started on a targeted oral agent that inhibits a specific tyrosine kinase implicated in his disease pathology. At his next visit, the physician reviews his medication list and cautions him about possible increased effects of some antidepressants and beta-blockers when taken concomitantly. What hepatic enzyme system is primarily implicated in these potential drug-drug interactions due to the mechanism of his new therapy?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Hypereosinophilic syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C1540912",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0935989",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cytochrome P450 2D6 (CYP2D6)",
      "reasoning_path": "Imatinib (a tyrosine kinase inhibitor) treats hypereosinophilic syndrome and inhibits CYP2D6, affecting the metabolism of drugs processed by this enzyme.",
      "umls_path": [
        "Hypereosinophilic syndrome",
        "may_be_treated_by",
        "Imatinib",
        "has_mechanism_of_action",
        "Cytochrome P450 2D6 Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Imatinib, a tyrosine kinase inhibitor, is frequently used to treat hypereosinophilic syndrome due to its activity against the FIP1L1-PDGFRA fusion protein. Beyond its primary target, imatinib also inhibits several hepatic cytochrome P450 enzymes, most notably CYP2D6. CYP2D6 is responsible for the metabolism of numerous medications, including many antidepressants, antipsychotics, and beta-blockers. When imatinib inhibits CYP2D6, plasma concentrations of drugs metabolized by this pathway can rise, increasing the risk of adverse effects or toxicity. Therefore, clinicians must monitor for drug-drug interactions and may need to adjust dosages of co-administered agents that are CYP2D6 substrates. The awareness of CYP2D6 inhibition is critical for safely initiating and managing imatinib therapy in patients with complex medication regimens.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_e5590777d83e",
      "question": "In a patient with advanced non-small cell lung cancer (NSCLC) of adenocarcinoma histology, if ALK rearrangement is detected after initiation of first-line systemic therapy, is it standard to continue the current regimen until completion or is it justified to interrupt and switch to crizotinib immediately?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "ALK rearrangement positive",
              "ALK rearrangement",
              "ALK rearrangement discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by crizotinib",
              "Progression",
              "Subsequent Therapy (NSCL-29)"
            ]
          }
        }
      ],
      "answer": "If an ALK rearrangement is discovered during first-line systemic therapy for advanced NSCLC, it is acceptable to either complete the planned systemic regimen, including maintenance, or to interrupt and promptly switch to crizotinib. Both options are endorsed by current guidelines.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_8e88bb29b781",
      "question": "What is the PMID of the article titled “Hepatology in the Digital Era: A Review of Telehealth Care for Liver Disease,” authored by Bloomberg L and published in Current Gastroenterology Reports in 2025?",
      "tool_calls": [
        {
          "tool": "pubmed.search",
          "params": {
            "term": "\"Hepatology in the Digital Era\"[ti] AND Bloomberg L[au] AND 2025[dp]",
            "retmax": 1
          }
        }
      ],
      "answer": [
        "40153166"
      ],
      "type": "retrieval"
    },
    {
      "id": "path_2e04418e5450",
      "question": "For a patient with unresectable stage IIIA non-small cell lung cancer (T4, N0–1) and an EGFR exon 19 deletion, should definitive concurrent chemoradiation be followed by durvalumab or osimertinib as adjuvant therapy, and how should the preferred choice be determined?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIB (T3 invasion, N0) Stage IIIA (T4 extension, N0–1; T3, N1; T4, N0–1)",
              "Evaluate for perioperative therapy, PFTs (if not previously done), Bronchoscopy, Pathologic mediastinal lymph node evaluation, Brain MRI with contrast, MRI with contrast of spine + thoracic inlet for superior sulcus lesions abutting the spine, subclavian vessels, or brachial plexus, FDG-PET/CT scan (if not previously done)",
              "Unresectable disease",
              "Treatment (NSCL-7)",
              "Stage IIIA (T4, N0–1) unresectable",
              "Definitive concurrent chemoradiation (category 1)",
              "Durvalumab (category 1) or Osimertinib (category 1) (if EGFR exon 19 deletion or L858R)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)"
            ]
          }
        }
      ],
      "answer": "In unresectable stage IIIA NSCLC with an EGFR exon 19 deletion, adjuvant osimertinib is preferred after definitive concurrent chemoradiation, as targeted therapy offers greater efficacy for EGFR-mutant tumors. Durvalumab is standard for EGFR wild-type, but osimertinib is prioritized in EGFR-mutant cases due to superior outcomes in this molecular subgroup.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_c186cecf1288",
      "question": "A 7-year-old girl presents with abdominal discomfort and a recent history of passing large, motile worms in her stool. Physical examination is unremarkable, and laboratory findings confirm an intestinal nematode infection. She is prescribed a medication that induces spastic paralysis in the parasite, facilitating its expulsion from the gastrointestinal tract. The drug achieves this effect by causing persistent depolarization of the worm's neuromuscular junctions. Through which molecular mechanism does this medication primarily exert its antiparasitic action?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Ascariasis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0003950",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0034238",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cholinesterase inhibition—by inhibiting cholinesterase, the drug causes sustained acetylcholine activity at the neuromuscular junction, resulting in paralysis of the nematode.",
      "reasoning_path": "Nematode infection → pyrantel therapy → cholinesterase inhibition → sustained acetylcholine activity → worm paralysis → expulsion.",
      "umls_path": [
        "Ascariasis",
        "may_be_treated_by",
        "Pyrantel tartrate",
        "has_mechanism_of_action",
        "Cholinesterase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient is diagnosed with an intestinal nematode infection, such as ascariasis. A common treatment for this condition is pyrantel pamoate (or tartrate), which exerts its antiparasitic effects by inducing neuromuscular paralysis in susceptible helminths. The drug acts as a cholinesterase inhibitor, preventing the breakdown of acetylcholine at the parasite's neuromuscular junction. This leads to continuous stimulation and depolarization of the muscle membrane, causing spastic paralysis. The immobilized worms are then expelled from the host's gastrointestinal tract by normal peristaltic action. This mechanism is selective for nematodes due to differences in their neuromuscular physiology compared to humans. Other antiparasitic agents may use different mechanisms, but paralysis via cholinesterase inhibition is characteristic of pyrantel, making this the key pharmacologic target in this therapeutic context.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_09a09f21e7b9",
      "question": "A 68-year-old woman presents with tense blisters on her lower abdomen and thighs, accompanied by pruritus. Skin biopsy reveals subepidermal blistering with linear deposition of IgG and C3 along the basement membrane zone. She is diagnosed with an autoimmune blistering disorder and is started on an oral medication commonly used for its immunomodulatory properties in dermatologic diseases. This drug exerts its primary effect by inhibiting the incorporation of para-aminobenzoic acid in folate synthesis pathways. Which drug mechanism best explains its therapeutic benefit in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Pemphigoid"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0030805",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0038710",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Para-aminobenzoic acid (PABA) inhibition, interfering with folate synthesis",
      "reasoning_path": "Bullous pemphigoid is treated with sulfapyridine; the drug acts as a PABA inhibitor, blocking folate synthesis, which underlies both its antimicrobial and immunomodulatory effects.",
      "umls_path": [
        "Pemphigoid",
        "may_be_treated_by",
        "Sulfapyridine",
        "has_mechanism_of_action",
        "Para-Aminobenzoic Acid Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has bullous pemphigoid, an autoimmune blistering disease characterized by subepidermal blisters and immune deposition along the basement membrane. Sulfapyridine is used off-label for its immunomodulatory and anti-inflammatory properties in such conditions. The drug is a sulfonamide, which acts as a structural analog of para-aminobenzoic acid (PABA). By competitively inhibiting the enzyme dihydropteroate synthase, sulfapyridine blocks incorporation of PABA into dihydropteroic acid, a precursor in bacterial folate synthesis. While this mechanism is classically antibacterial, sulfonamides also reduce neutrophil chemotaxis and have additional immunomodulatory effects, contributing to their benefit in autoimmune diseases like pemphigoid. Thus, the therapeutic effect in this setting is primarily attributed to sulfapyridine's action as a PABA inhibitor, disrupting folate synthesis pathways and modulating immune responses.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_d7b687e49b96",
      "question": "A 34-year-old woman presents with several rough, hyperkeratotic papules on her fingers that have been slowly enlarging over the past six months. She is diagnosed with common warts and chooses a topical treatment frequently used for lesion ablation in clinical practice. The clinician notes that, despite its widespread use, the exact cellular and molecular mechanism by which this agent achieves therapeutic effects in wart removal is not well defined. Which best describes the mechanism-of-action category for this topical therapy in this scenario?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Verruca vulgaris"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C3665596",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0949307",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Unknown cellular or molecular interaction",
      "reasoning_path": "Formalin is used to treat verruca vulgaris, but its exact cellular or molecular mechanism of action in wart ablation has not been established.",
      "umls_path": [
        "Verruca vulgaris",
        "may_be_treated_by",
        "formalin",
        "has_mechanism_of_action",
        "Unknown Cellular or Molecular Interaction"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "Common warts (verruca vulgaris) are often managed using topical formalin, a chemical cauterant. While formalin is effective in ablating wart tissue, the precise molecular or cellular mechanism underlying its action remains unclear. Unlike agents with well-characterized targets (e.g., salicylic acid disrupting keratinocytes or imiquimod stimulating local immune responses), formalin's therapeutic effect is attributed to its general protein-denaturing and tissue-fixation properties. However, how these effects translate into selective viral eradication or specific wart resolution at the cellular level has not been elucidated. Therefore, when classifying this agent's mechanism of action, it is most accurate to state that the cellular or molecular pathway responsible for its therapeutic benefit in verruca vulgaris is unknown.",
      "type": "kg_reasoning"
    },
    {
      "id": "ret_3c98c188fa77",
      "question": "In ClinicalTrials.gov, which completed interventional studies for Beta-Thalassemia using LentiGlobin BB305 Drug Product started in June 2017 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "overallStatus=COMPLETED;conditions=Beta-Thalassemia;interventions.name=LentiGlobin BB305 Drug Product;startDateFrom=2017-06-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT03207009"
      ],
      "type": "retrieval"
    },
    {
      "id": "ret_c7a67aa6e0e8",
      "question": "In ClinicalTrials.gov, which completed interventional phase 3 studies for Myelodysplastic Syndromes involving Azacitidine started in November 2003 in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "overallStatus=COMPLETED;phases=PHASE3;conditions=Myelodysplastic Syndromes;interventions.name=Azacitidine;startDateFrom=2003-11-01;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00071799"
      ],
      "type": "retrieval"
    },
    {
      "id": "ret_32f0a70c2da6",
      "question": "In ClinicalTrials.gov, which completed interventional studies that started in April 1998 investigated Atorvastatin for Cardiovascular Disease, Cerebrovascular Accident, or Coronary Heart Disease in the United States?",
      "tool_calls": [
        {
          "tool": "ctgov_search",
          "params": {
            "filter_expr": "overallStatus=COMPLETED;startDateFrom=1998-04-01;conditions=Cardiovascular Disease,Cerebrovascular Accident,Coronary Heart Disease;interventions.name=Atorvastatin;locations.country=United States",
            "page_size": 100
          }
        }
      ],
      "answer": [
        "NCT00327691"
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_535863b8fad9",
      "question": "A 27-year-old woman presents with several days of bilateral ocular itching, tearing, and mild redness, worsened in the spring. She has a history of seasonal allergies but no recent illness. On exam, her conjunctivae are injected with scant watery discharge, and no preauricular lymphadenopathy is noted. Her physician prescribes topical drops that stabilize a specific immune cell membrane, preventing release of inflammatory mediators in response to allergens. Which class of mechanism-of-action best describes how this therapy mediates its immunomodulatory effects in allergic conjunctivitis?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Conjunctivitis, unspecified"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0009763",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0086073",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Biological Response Modifiers",
      "reasoning_path": "Clinical signs suggest allergic conjunctivitis. Cromolyn stabilizes mast cells, preventing mediator release. This immunomodulatory effect classifies it as a biological response modifier.",
      "umls_path": [
        "Conjunctivitis, unspecified",
        "may_be_treated_by",
        "Cromolyn-containing product",
        "has_mechanism_of_action",
        "Biological Response Modifiers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient’s symptoms and history are consistent with allergic conjunctivitis, an IgE-mediated hypersensitivity reaction. The prescribed cromolyn-containing ophthalmic preparation acts by stabilizing mast cell membranes, thereby inhibiting degranulation and release of pro-inflammatory mediators such as histamine. This mechanism does not directly antagonize histamine receptors or suppress the immune system globally, but instead modulates the cellular response to allergens. This targeted modulation of immune cell function classifies cromolyn as a biological response modifier. By preventing mast cell activation, cromolyn reduces allergic inflammation at the conjunctival surface, alleviating symptoms without significant systemic effects. Thus, its mechanism of action is best described as biological response modification.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_fa08f5a64530",
      "question": "In patients with a separate pulmonary nodule located in an ipsilateral non-primary lobe, staged as T4 N0–1, and who achieve a complete (R0) resection following preoperative systemic therapy, is adjuvant systemic therapy with or without radiation still indicated even if the patient is over 80 years old with well-compensated comorbidities?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treatment",
              "Separate pulmonary nodule(s), same lobe (T3, N0–1), or ipsilateral non-primary lobe (T4, N0–1)",
              "Surgery after preoperative systemic therapy, if planned",
              "N2",
              "Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E) or Sequential chemotherapy + Consider RT",
              "Surveillance (NSCL-17)"
            ]
          }
        }
      ],
      "answer": "Yes, adjuvant systemic therapy, with or without radiation, remains indicated for patients with completely resected T4 N0–1 non-small cell lung cancer following preoperative systemic therapy, regardless of age, provided comorbidities are well-compensated and the patient can tolerate further treatment.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_126f78e0200c",
      "question": "In the OpenTargets platform, what tractability information is available for the target with Ensembl ID ENSG00000149295 and approved symbol DRD2, where the value is True?",
      "tool_calls": [
        {
          "tool": "opentargets.tractability",
          "params": {
            "target_id": "ENSG00000149295",
            "value": true
          }
        }
      ],
      "answer": [
        {
          "modality": "SM",
          "label": "Approved Drug"
        },
        {
          "modality": "SM",
          "label": "Structure with Ligand"
        },
        {
          "modality": "SM",
          "label": "High-Quality Ligand"
        },
        {
          "modality": "SM",
          "label": "Druggable Family"
        },
        {
          "modality": "AB",
          "label": "UniProt loc high conf"
        },
        {
          "modality": "AB",
          "label": "GO CC high conf"
        },
        {
          "modality": "AB",
          "label": "UniProt SigP or TMHMM"
        },
        {
          "modality": "PR",
          "label": "Small Molecule Binder"
        },
        {
          "modality": "OC",
          "label": "Approved Drug"
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_11ef3b5e521f",
      "question": "A 42-year-old woman presents with fatigue, pallor, and jaundice. Laboratory studies reveal anemia, elevated reticulocyte count, elevated lactate dehydrogenase, and a positive direct antiglobulin (Coombs) test. She is diagnosed with autoimmune hemolytic anemia and started on a corticosteroid. Over several weeks, her hemoglobin improves and jaundice resolves. The prescribed medication is known to suppress immune-mediated red blood cell destruction by inhibiting the synthesis of certain pro-inflammatory mediators derived from arachidonic acid. Which class of enzyme inhibitors is most directly responsible for this therapeutic effect in the context of her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Hemolytic Anemia"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0002878",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0138273",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Lipoxygenase inhibitors",
      "reasoning_path": "Autoimmune hemolytic anemia → immune destruction of RBCs → corticosteroid therapy → downregulation of lipoxygenase → reduced leukotriene synthesis → decreased inflammation and RBC destruction.",
      "umls_path": [
        "Hemolytic Anemia",
        "may_be_treated_by",
        "Prednisolone Sodium Phosphate",
        "has_mechanism_of_action",
        "Lipoxygenase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "In autoimmune hemolytic anemia, antibodies target red blood cells, leading to their premature destruction. Corticosteroids such as prednisolone are first-line therapy because they suppress the immune response and decrease inflammation. One of their molecular actions is the inhibition of enzymes involved in the production of pro-inflammatory mediators from arachidonic acid. While corticosteroids broadly inhibit phospholipase A2, they also downregulate the expression of inflammatory enzymes including lipoxygenases. Lipoxygenases convert arachidonic acid into leukotrienes, which contribute to immune cell recruitment and inflammation. Inhibition of lipoxygenase activity by corticosteroids decreases leukotriene synthesis, thus reducing immune-mediated destruction of red blood cells. This anti-inflammatory effect, alongside other immunosuppressive actions, is central to the clinical improvement seen in autoimmune hemolytic anemia.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_b8460b2d62bc",
      "question": "In a patient with advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology, whose tumor harbors an ALK rearrangement identified via molecular testing prior to any systemic therapy, and who concurrently has significant hepatic impairment, is first-line use of ceritinib still an appropriate choice?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "ALK rearrangement positive",
              "ALK rearrangement",
              "ALK rearrangement discovered prior to first-line systemic therapy",
              "Other Recommended Ceritinibr (category 1)",
              "Progression",
              "Subsequent Therapy (NSCL-28)"
            ]
          }
        }
      ],
      "answer": "Ceritinib, while a recommended first-line therapy for ALK-rearranged advanced NSCLC, is associated with a risk of hepatotoxicity and requires dose adjustment or may be contraindicated in patients with significant hepatic impairment. In such cases, alternative ALK inhibitors with more favorable hepatic safety profiles, such as alectinib, should be prioritized.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_cc9a79c8a0fb",
      "question": "In a patient with advanced squamous cell carcinoma of the lung and confirmed bone metastases, if there is a significant risk of pathological fracture, should orthopedic stabilization always be prioritized before administering palliative external-beam radiotherapy?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Distant metastases",
              "Bone metastases",
              "If risk of fracture, orthopedic stabilization + palliative external-beam RT; Consider bisphosphonate therapy or denosumab",
              "Systemic therapy (NSCL-19)",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results (NSCL-20)"
            ]
          }
        }
      ],
      "answer": "Yes, orthopedic stabilization should be prioritized before palliative external-beam radiotherapy when there is a significant risk of pathological fracture in patients with bone metastases from advanced squamous cell carcinoma, as surgical stabilization prevents imminent fractures and facilitates safer radiotherapy delivery and rehabilitation.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "path_88816f93e22b",
      "question": "For a patient with stage IIIA (T1–2, N2) non–small cell lung cancer who underwent surgery with negative margins (R0) and completed adjuvant systemic therapy, what is the recommended surveillance imaging frequency during the first three years post-treatment, and does this differ from surveillance following definitive chemoradiation in stage III disease?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IIIA (T1–2, N2; T3, N1); Stage IIIB (T3, N2); Margins negative (R0)",
              "Adjuvant Systemic Therapy (NSCL-E)",
              "Surveillance (NSCL-17)",
              "No evidence of clinical/radiographic disease • Stage I–II (primary treatment included surgery ± chemotherapy)  H&P and chest CTj ± contrast every 6 mo for 2–3 y, then H&P and a low-dose non–contrast-enhanced chest CT annually • Stage I–II (primary treatment included RT) or stage III or stage IV (oligometastatic with all sites treated with definitive intent)  H&P and chest CTj ± contrast every 3–6 mo for 3 y, then H&P and chest CT ± contrast every 6 mo for 2 y, then H&P and a low-dose non–contrast-enhanced chest CT annually  Residual or new radiographic abnormalities may require more frequent imaging • Smoking cessation advice, counseling, and pharmacotherapy • FDG-PET/CTkk or brain MRI is not routinely indicated • Cancer Survivorship Care (NSCL-G)",
              "Recurrence • FDG-PET/CT • Brain MRI with contrastq",
              "Distant metastases",
              "Therapy for Recurrence and Metastasis (NSCL-18)",
              "Distant metastases",
              "Localized symptoms",
              "Palliative external-beam RT",
              "Systemic therapy (NSCL-19)"
            ]
          }
        }
      ],
      "answer": "Following surgery with negative margins and adjuvant systemic therapy for stage IIIA (T1–2, N2) non–small cell lung cancer, surveillance imaging with history & physical examination and chest CT (with or without contrast) should be performed every 3–6 months for the first 3 years. This schedule is the same as for patients who received definitive chemoradiation in stage III disease; both require more frequent imaging compared to stage I–II post-surgical cases.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_66767bf1eff3",
      "question": "A 54-year-old woman presents with enlarged hands, coarsened facial features, and joint pain. Laboratory workup reveals elevated insulin-like growth factor-1 (IGF-1) and persistently high serum growth hormone (GH) levels following an oral glucose tolerance test. MRI demonstrates a pituitary adenoma. She is started on a long-acting injectable medication that mimics an endogenous inhibitory hormone, acting on a specific G-protein coupled receptor subtype to suppress GH secretion from somatotrophs in the anterior pituitary. Through which molecular target does this medication primarily exert its therapeutic effect to lower GH levels in this patient?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Acromegaly"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001206",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0771414",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Somatostatin receptor type 5 (SSTR5)",
      "reasoning_path": "Acromegaly → excess GH, pituitary adenoma → treated with lanreotide (somatostatin analogue) → binds SSTR5 on somatotrophs → inhibits GH secretion.",
      "umls_path": [
        "Acromegaly",
        "may_be_treated_by",
        "Lanreotide Acetate",
        "has_target",
        "Somatostatin Receptor Type 5"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "This patient has acromegaly due to a GH-secreting pituitary adenoma, as evidenced by her clinical features and biochemical findings. Somatostatin analogues, such as lanreotide acetate, are used to decrease excess GH secretion. Lanreotide is designed to mimic the action of endogenous somatostatin, an inhibitory hormone that binds to somatostatin receptors on pituitary somatotroph cells. Among the five known somatostatin receptor subtypes, lanreotide has high affinity for somatostatin receptor type 5 (SSTR5), which is particularly important in mediating the inhibition of GH release from these cells. By activating SSTR5, lanreotide suppresses intracellular cAMP production and calcium influx, resulting in reduced GH secretion and, ultimately, lower IGF-1 levels. This mechanism is central to its therapeutic effect in acromegaly management.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_74a46d0d8aab",
      "question": "In patients with advanced or metastatic lung adenocarcinoma and confirmed ALK rearrangement who have already begun first-line systemic therapy without prior ALK testing, if the ALK rearrangement is identified during this initial therapy, is it appropriate to interrupt the ongoing regimen and initiate crizotinib, or should the patient complete the originally planned systemic therapy including maintenance phase before switching to crizotinib?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Adenocarcinoma, Large cell, NSCLC not otherwise specified (NOS)",
              "Molecular testing, including: EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo Programmed death ligand 1 (PD-L1) testing (category 1)",
              "Testing Results",
              "ALK rearrangement positive",
              "ALK rearrangement",
              "ALK rearrangement discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by crizotinib",
              "Progression",
              "Subsequent Therapy (NSCL-29)"
            ]
          }
        }
      ],
      "answer": "If an ALK rearrangement is identified during the course of first-line systemic therapy for advanced or metastatic lung adenocarcinoma, it is appropriate either to interrupt the current regimen and initiate crizotinib or to complete the planned systemic therapy, including the maintenance phase, before transitioning to crizotinib. Both approaches are considered acceptable.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "kg_9afbfcf02a2b",
      "question": "A 28-year-old woman presents to her primary care clinic reporting monthly episodes of lower abdominal cramping, headache, and breast tenderness that begin in the days leading up to her menstrual period. She finds these symptoms disruptive to her daily activities. After evaluation, her physician recommends an over-the-counter medication that provides significant relief. This medication acts by reversibly inhibiting a key enzyme in the prostaglandin synthesis pathway. Which molecular target is most directly responsible for the therapeutic benefit she experiences?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Premenstrual syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0033046",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020740",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 1 (COX-1)",
      "reasoning_path": "PMS symptoms are mediated by prostaglandins. Ibuprofen, an NSAID, is recommended and works by inhibiting COX-1, reducing prostaglandin synthesis and thus alleviating pain and inflammation.",
      "umls_path": [
        "Premenstrual syndrome",
        "may_be_treated_by",
        "Ibuprofen",
        "has_target",
        "Prostaglandin G/H Synthase 1"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "The patient is experiencing premenstrual syndrome (PMS) symptoms, which are often mediated by increased prostaglandin production leading to pain and inflammation. Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), is frequently used to manage these symptoms. Its primary mechanism involves the reversible inhibition of cyclooxygenase enzymes, specifically Prostaglandin G/H Synthase 1 (COX-1) and COX-2. By inhibiting COX-1, ibuprofen decreases the conversion of arachidonic acid to prostaglandins, thereby reducing the inflammatory response and alleviating pain and other PMS-related symptoms. Although ibuprofen also inhibits COX-2, the relief of PMS symptoms is most directly linked to reduction in prostaglandin synthesis via COX-1 inhibition. This mechanism underlies the rapid improvement in abdominal cramping and other discomforts associated with PMS following ibuprofen use.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_07ee1151947e",
      "question": "A 25-year-old woman with a recent diagnosis of infectious mononucleosis presents with severe pharyngitis, lymphadenopathy, and malaise. Laboratory tests confirm Epstein-Barr virus infection. Her clinician initiates antiviral therapy with a drug that requires phosphorylation by viral thymidine kinase and subsequently inhibits viral DNA synthesis by targeting a specific viral enzyme. Which class of medications shares this primary mechanism of action with the prescribed agent in the treatment of her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Epstein-Barr virus disease"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0149678",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0164815",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "DNA polymerase inhibitors",
      "reasoning_path": "Epstein-Barr virus infection → penciclovir (nucleoside analog) given → activated by viral thymidine kinase → inhibits viral DNA polymerase → other drugs with same mechanism are DNA polymerase inhibitors.",
      "umls_path": [
        "Epstein-Barr virus disease",
        "may_be_treated_by",
        "Penciclovir",
        "has_mechanism_of_action",
        "DNA Polymerase Inhibitors"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "The patient is being treated for Epstein-Barr virus infection with penciclovir, which is a guanosine analog antiviral. Once inside infected cells, penciclovir is phosphorylated by viral thymidine kinase to its active triphosphate form. This active metabolite inhibits viral DNA polymerase, the enzyme responsible for viral DNA replication, thus limiting viral proliferation. Other antiviral agents, such as acyclovir and ganciclovir, share this mechanism—they also require initial phosphorylation and subsequently inhibit viral DNA polymerase. The shared drug class is DNA polymerase inhibitors, and their efficacy against herpesviruses (including EBV) depends on this mechanism. Understanding this pathway is crucial for selecting appropriate antiviral therapy and anticipating resistance patterns.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_6f061c3fe8ed",
      "question": "A 43-year-old woman with a history of insomnia and intermittent limb discomfort is diagnosed with restless legs syndrome. Her symptoms persist despite lifestyle modifications, so her physician initiates pharmacologic therapy. Several weeks later, she reports new breakthrough spotting while taking her combined oral contraceptive pills, which she has used reliably for years. Further review reveals her new medication increases hepatic enzyme activity, accelerating the metabolism of certain drugs. Which molecular mechanism best explains the decreased contraceptive efficacy in this scenario?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "restless legs syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0035258",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0006949",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Induction of cytochrome P450 3A4 (CYP3A4)",
      "reasoning_path": "Restless legs syndrome treated with carbamazepine → carbamazepine induces CYP3A4 → increased metabolism of oral contraceptives → reduced efficacy and breakthrough bleeding.",
      "umls_path": [
        "restless legs syndrome",
        "may_be_treated_by",
        "Carbamazepine",
        "has_mechanism_of_action",
        "Cytochrome P450 3A4 Inducers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient with restless legs syndrome was prescribed a medication that induces hepatic enzymes, specifically cytochrome P450 3A4 (CYP3A4). Drugs like carbamazepine, sometimes used for restless legs syndrome, are potent inducers of CYP3A4. This induction increases the hepatic metabolism of co-administered medications, including the estrogen and progestin components of combined oral contraceptives. Enhanced metabolism reduces plasma concentrations of contraceptive hormones, leading to decreased contraceptive efficacy and breakthrough bleeding. Recognizing drug-drug interactions mediated by cytochrome P450 enzymes is crucial in pharmacologic management, especially when prescribing medications with a narrow therapeutic window or those critical for patient safety, such as oral contraceptives.",
      "type": "kg_reasoning"
    },
    {
      "id": "kg_8c991cbed2f0",
      "question": "A 38-year-old immigrant from rural Central America presents with new-onset seizures and headaches. Brain MRI reveals multiple ring-enhancing cystic lesions with surrounding edema. Serology confirms a neuroparasitic infection. He is started on an oral antiparasitic agent that undergoes hepatic metabolism to its active form. The clinical team is concerned about potential drug interactions that could decrease the efficacy of this medication by accelerating its metabolism. Which enzymatic pathway is most likely responsible for such drug interactions, and why is it clinically important to monitor co-administered medications in this scenario?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Cerebral cysticercosis"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0338437",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0001911",
            "rela": "has_mechanism_of_action"
          }
        }
      ],
      "answer": "Cytochrome P450 1A (CYP1A) inducers",
      "reasoning_path": "Neurocysticercosis requires albendazole, which is activated in the liver by CYP1A enzymes. CYP1A inducers speed up this metabolism, lowering active drug levels and reducing efficacy; thus, these interactions must be considered in therapy.",
      "umls_path": [
        "Cerebral cysticercosis",
        "may_be_treated_by",
        "Albendazole",
        "has_mechanism_of_action",
        "Cytochrome P450 1A Inducers"
      ],
      "template_id": "Disease_Drug_moA",
      "reasoning": "This patient has neurocysticercosis, a CNS infection commonly treated with albendazole. Albendazole is a prodrug that requires hepatic biotransformation, primarily via the CYP1A subfamily of cytochrome P450 enzymes, to form its active metabolite, albendazole sulfoxide. Inducers of cytochrome P450 1A, such as certain antiepileptics (e.g., carbamazepine, phenytoin) or rifampin, can increase the metabolism of albendazole, leading to lower plasma concentrations of the active drug. This can decrease therapeutic effectiveness, potentially resulting in treatment failure. Therefore, it is crucial to avoid or monitor concurrent use of CYP1A inducers in patients being treated for CNS parasitic infections with albendazole.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_2955bb0f7a39",
      "question": "In a patient with advanced or metastatic squamous cell lung carcinoma (stage IVA, M1b) who is found to have an ALK rearrangement during the course of ongoing first-line systemic therapy, is it appropriate to interrupt the current systemic therapy and switch to crizotinib based solely on the new molecular finding, or should the initial therapy be completed prior to initiation of targeted treatment?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Stage IVA, M1b",
              "Biomarker testing (NSCL-19) If not previously done • Brain MRI with contrast • FDG-PET/CT scan • Pathologic confirmation of metastatic lesion, if possible",
              "Advanced or metastatic disease",
              "Establish histologic subtypea with adequate tissue for molecular testing (consider rebiopsymm or plasma testing if appropriate) Smoking cessation counseling Integrate palliative carec (NCCN Guidelines for Palliative Care)",
              "Squamous cell carcinoma",
              "Consider molecular testing, including:pp EGFR mutation, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2) Testing should be conducted as part of broad molecular profilingoo PD-L1 testing (category 1)",
              "Testing Results",
              "ALK rearrangement positive",
              "ALK rearrangement",
              "ALK rearrangement discovered during first-line systemic therapy",
              "Complete planned systemic therapy, including maintenance therapy, or interrupt, followed by crizotinib",
              "Progression",
              "Subsequent Therapy (NSCL-29)"
            ]
          }
        }
      ],
      "answer": "If an ALK rearrangement is discovered during first-line systemic therapy in advanced squamous cell lung carcinoma, either completing the planned systemic therapy (including maintenance) or interrupting it to start crizotinib are considered appropriate; the decision depends on clinical judgment, disease response, and tolerance, as both approaches are supported based on the new actionable molecular finding.",
      "type": "diagnostic_pathway"
    },
    {
      "id": "ret_abba18e9ac6b",
      "question": "What diseases are associated with the target ENSG00000015413, also known as DPEP1, with a minimum relevance score of 0.5 in OpenTargets?",
      "tool_calls": [
        {
          "tool": "opentargets.search",
          "params": {
            "target_id": "ENSG00000015413",
            "min_score": 0.5
          }
        }
      ],
      "answer": [
        {
          "disease_id": "EFO_0000544",
          "disease_name": "infection",
          "score": 0.5789958838284464
        },
        {
          "disease_id": "EFO_0003103",
          "disease_name": "urinary tract infection",
          "score": 0.5718469327945962
        },
        {
          "disease_id": "EFO_0004339",
          "disease_name": "body height",
          "score": 0.5694777363303315
        },
        {
          "disease_id": "HP_0100806",
          "disease_name": "Sepsis",
          "score": 0.5663742317859913
        },
        {
          "disease_id": "EFO_0003106",
          "disease_name": "pneumonia",
          "score": 0.5645044200773564
        },
        {
          "disease_id": "EFO_0006336",
          "disease_name": "diastolic blood pressure",
          "score": 0.5628826953113624
        },
        {
          "disease_id": "EFO_0000465",
          "disease_name": "endocarditis",
          "score": 0.5587297348479079
        },
        {
          "disease_id": "EFO_0800133",
          "disease_name": "cysteinylglycine measurement",
          "score": 0.5569275888622791
        },
        {
          "disease_id": "EFO_0800122",
          "disease_name": "cys-gly, oxidized measurement",
          "score": 0.5530844182262401
        },
        {
          "disease_id": "EFO_0800049",
          "disease_name": "cysteinylglycine disulfide measurement",
          "score": 0.5449055245140587
        },
        {
          "disease_id": "MONDO_0005178",
          "disease_name": "osteoarthritis",
          "score": 0.5221747115743878
        }
      ],
      "type": "retrieval"
    },
    {
      "id": "kg_e1d88498f8f3",
      "question": "A 27-year-old woman presents with recurrent monthly episodes of lower abdominal cramping, headache, and breast tenderness occurring in the week prior to her periods. These symptoms resolve with the onset of menstruation. After evaluation, her clinician recommends a commonly used over-the-counter analgesic that provides symptom relief by inhibiting an enzyme involved in the biosynthesis of inflammatory mediators from arachidonic acid. What is the primary molecular target responsible for the therapeutic effects of this medication in her condition?",
      "tool_calls": [
        {
          "tool": "umls.concept_lookup",
          "params": {
            "name": "Premenstrual syndrome"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0033046",
            "rela": "may_be_treated_by"
          }
        },
        {
          "tool": "umls.get_related",
          "params": {
            "from_cui": "C0020740",
            "rela": "has_target"
          }
        }
      ],
      "answer": "Prostaglandin G/H Synthase 2 (COX-2)",
      "reasoning_path": "PMS symptoms driven by prostaglandin production → NSAIDs inhibit prostaglandin synthesis → NSAIDs target COX-2 (Prostaglandin G/H Synthase 2) → symptom relief.",
      "umls_path": [
        "Premenstrual syndrome",
        "may_be_treated_by",
        "Ibuprofen",
        "has_target",
        "Prostaglandin G/H Synthase 2"
      ],
      "template_id": "Disease_Drug_Target",
      "reasoning": "Premenstrual syndrome (PMS) often involves symptoms such as pain, bloating, and breast tenderness, which are linked to increased production of prostaglandins—lipid mediators that contribute to inflammation and heightened pain sensitivity. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, are commonly used to alleviate these symptoms. Their primary mechanism of action is the reversible inhibition of cyclooxygenase enzymes (COX-1 and COX-2), also known as prostaglandin G/H synthases. Of these, COX-2 (Prostaglandin G/H Synthase 2) is particularly important in the context of inflammation and pain, as it is inducible at sites of inflammation and leads to increased synthesis of prostaglandins. By inhibiting COX-2, NSAIDs reduce prostaglandin production, thereby decreasing uterine contractions, lowering pain signaling, and improving premenstrual symptoms. This molecular inhibition explains the efficacy of NSAIDs for PMS symptom relief.",
      "type": "kg_reasoning"
    },
    {
      "id": "path_90bcb3e1c3ce",
      "question": "In a patient diagnosed with a solitary nodule in the contralateral lung and classified as Stage IVA (N0, M1a) non-small cell lung cancer, if both pulmonary lesions are judged to be technically resectable with curative intent, does this scenario imply these should be managed as two primary lung tumors rather than metastatic disease?",
      "tool_calls": [
        {
          "tool": "oncology.path_query",
          "params": {
            "nodes": [
              "Separate pulmonary nodule(s) (Stage IIB, IIIA, IV)",
              "Evaluate for perioperative therapy\nPFTs (if not previously done)\nBronchoscopy\nPathologic mediastinal lymph node evaluation\nFDG-PET/CT scan (if not previously done)",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treatment",
              "Stage IVA (N0, M1a): Contralateral lung (solitary nodule)",
              "Treat as two primary lung tumors if both curable; see Initial Evaluation (NSCL-1)",
              "Pathologic Diagnosis of NSCLC",
              "Initial Evaluation",
              "Pathology review"
            ]
          }
        }
      ],
      "answer": "Yes. In cases where a solitary contralateral lung nodule (N0, M1a) is present and both lesions are amenable to curative resection, they should be managed as synchronous primary lung tumors instead of metastatic disease, guiding treatment toward potentially curative strategies for each lesion.",
      "type": "diagnostic_pathway"
    }
  ]
}